01570000000000565000450099100020000070000020000270600020000470100020000609100090
00081300035000171510020000520350010000724800022000820300021001049300004001251170
00600129085000300135935001000138031000300148032000200151036000600153042000200159
20000020016106500090016312200030017204800140017504800140018904800240020304900360
02270490035002630490036002980490036003340490042003700490037004120490028004490490
02500477049003200502049003400534049003300568049003000601049002500631049002500656
04900300068104900310071104900290074204900260077104300700079704300690086704300680
0936#1#0#i#1#20110405#Revista Brasileira de Reumatologia#Rev. Bras. Reumatol#048
2-5004#Elsevier Editora Ltda#Rev. Bras. Reumatol.#RBR#other#nd#0482-5004#44#2#20
042#1#0#20040400#14#^les^hSumario#^lpt^hSumário#^len^hTable of Contents#^lpt^cRB
R030^tPausa entre Consultas#^len^cRBR030^tBetween Appointments#^lpt^cRBR040^tVin
heta Imagenológica#^len^cRBR040^tImagenologic Vignette#^lpt^cRBR050^tAtualização
 em Reumatologia#^len^cRBR050^tUpdate in Rheumatology#^lpt^cRBR060^tEspaço Image
m#^len^cRBR060^tImage Site#^lpt^cRBR080^tComunicação Breve#^len^cRBR080^tBrief C
ommunication#^lpt^cRBR100^tArtigos de Revisão#^len^cRBR100^tReview Articles#^lpt
^cRBR110^tEditoriais#^len^cRBR110^tEditorials#^lpt^cRBR160^tArtigo Original#^len
^cRBR160^tOriginal Article#^lpt^cRBR260^tRelato de Caso#^len^cRBR260^tCase Repor
t#^les^tRev. Bras. Reumatol.^vvol.44^nno.2^cSão Paulo^mmarzo/abr.^a2004#^lpt^tRe
v. Bras. Reumatol.^vvol.44^nno.2^cSão Paulo^mmar./abr.^a2004#^len^tRev. Bras. Re
umatol.^vvol.44^nno.2^cSão Paulo^mMar/Apr.^a2004##
00270000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00300097#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#o#1#1#text#1#201
10406#085241#v44n2a01.htm#70##
00840000000000421000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030002100102
03100030012303200020012606500090012801400100013703500100014712300020015701200210
01590100043001800700057002230700050002800700009003300700058003391170006003970720
00200403002001300405#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#h#2#
1#text#1#ed#pt#br1.1#1#4.0#ND#01#RBR110#nd#Rev. Bras. Reumatol.#44#2#20040400#^f
VII^lIX#0482-5004#1#Bioética clínica^lpt#^rND^1A01 A02 A03 A04^nJosé^sMarques Fi
lho#Conselho Regional de Medicinado Estado de São Paulo^iA01#SBR^iA02^1Comissão 
de Ética e Defesa Profissional#SPR^iA03#Conselho Regional de Medicina do Estado 
de São Paulo^iA04#other#8#v44n2a01.htm##
00847000000000421000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030002100102
03100030012303200020012606500090012801400100013703500100014712300020015701200280
01590100043001870700057002300700050002870700009003370700058003461170006004040720
00200410002001300412#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#f#3#
1#text#1#ed#pt#br1.1#1#4.0#ND#01#RBR110#nd#Rev. Bras. Reumatol.#44#2#20040400#^f
VII^lIX#0482-5004#1#<b>Bioética clínica</b>^lpt#^rND^1A01 A02 A03 A04^nJosé^sMar
ques Filho#Conselho Regional de Medicinado Estado de São Paulo^iA01#SBR^iA02^1Co
missão de Ética e Defesa Profissional#SPR^iA03#Conselho Regional de Medicina do 
Estado de São Paulo^iA04#other#8#v44n2a01.htm##
00963000000000433000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100121000300104049000700107158000300114030002000117
03100030013703200020014006500090014201400100015103500100016112300020017101200210
01730100043001940700059002370700052002960700011003480700060003591170006004190720
00200425002001300427008008900440#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a0
1.htm#S#l#4#1#text#1#^mmar./abr.^a2004#ed#pt#br1.1#1#4.0#01#RBR110#nd#Rev. Bras.
 Reumatol#44#2#20040400#^fVII^lIX#0482-5004#1#Bioética clínica^lpt#^rND^1A01 A02
 A03 A04^nJosé^sMarques Filho#^iA01^1Conselho Regional de Medicinado Estado de S
ão Paulo#^iA02^1SBR^2Comissão de Ética e Defesa Profissional#^iA03^1SPR#^iA04^1C
onselho Regional de Medicina do Estado de São Paulo#other#8#v44n2a01.htm#Interne
t^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-5004200400020000
1##
00341000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704011300069002001300182#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#5#1#text#58#<p align="right"><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>EDITORIAL</b></font></p>  
   ^cY#v44n2a01.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#6#2#text#58#<p>&nbsp;</p>     ^cY#v44n
2a01.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704012000069002001300189#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#7#3#text#58#<p><font size="4" face="Ve
rdana, Arial, Helvetica, sans-serif"><b>Bio&eacute;tica cl&iacute;nica</b></font
></p>     ^cY#v44n2a01.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#8#4#text#58#<p>&nbsp;</p>     ^cY#v44n
2a01.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#9#5#text#58#<p>&nbsp;</p>     ^cY#v44n
2a01.htm##
00588000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704035900070002001300429#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#10#6#text#58#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">Comiss&atilde;o Nacional de Resid&ecirc;nc
ia M&eacute;dica (CNRM), atrav&eacute;s da Resolu&ccedil;&atilde;o n.º4, de 23 d
e dezembro de 2003<sup>(1)</sup>, tornou obrigat&oacute;ria a abordagem te&oacut
e;rica da bio&eacute;tica nos programas de resid&ecirc;ncia m&eacute;dica.</font
></p>     ^cY#v44n2a01.htm##
00456000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704022700070002001300297#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#11#7#text#58#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"> O artigo 9.º dessa resolu&ccedil;&atilde;
o disp&otilde;e sobre as atividades de treinamento em servi&ccedil;o e as ativid
ades te&oacute;ricas: </font></p>     ^cY#v44n2a01.htm##
00549000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704032000070002001300390#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#12#8#text#58#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">Art. 9.º - Os Programas de Resid&ecirc;nci
a M&eacute;dica ser&atilde;o desenvolvidos com 80% a 90% da carga hor&aacute;ria
 sob forma de treinamento em servi&ccedil;o, destinando-se 10% a 20% para ativid
ades te&oacute;rico-complementares.</font></p>     ^cY#v44n2a01.htm##
00612000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704038300070002001300453#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#13#9#text#58#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">&#167;1.º - Entendem-se como atividades te
&oacute;rico-complementares: sess&otilde;es an&aacute;tomo-cl&iacute;nicas, disc
uss&atilde;o de artigos cient&iacute;ficos, sess&otilde;es cl&iacute;nico-radiol
&oacute;gicas, sess&otilde;es cl&iacute;nico-laboratoriais, cursos, palestras e 
semin&aacute;rios.</font></p>     ^cY#v44n2a01.htm##
00691000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704046100071002001300532#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#14#10#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">&#167;2.º - Nas atividades te&oacute;rico
-complementares devem constar, obrigatoriamente, temas relacionados com bio&eacu
te;tica, &eacute;tica m&eacute;dica, metodologia cient&iacute;fica, epidemiologi
a e bioestat&iacute;stica. Recomenda-se a participa&ccedil;&atilde;o do m&eacute
;dico residente em atividades relacionadas ao controle das infec&ccedil;&otilde;
es hospitalares. </font></p>     ^cY#v44n2a01.htm##
00664000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704043400071002001300505#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#15#11#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">&Eacute; desnecess&aacute;rio enfatizar a
 import&acirc;ncia das referidas atividades te&oacute;rico-complementares na for
ma&ccedil;&atilde;o do especialista em reumatologia, por&eacute;m, a obrigatorie
dade da abordagem da bio&eacute;tica e da &eacute;tica m&eacute;dica nos program
as de resid&ecirc;ncia m&eacute;dica merece ser destacada e elogiada. </font></p
>     ^cY#v44n2a01.htm##
00638000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704040800071002001300479#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#16#12#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A resolu&ccedil;&atilde;o n.º 4/2003 da C
NRM, ao reconhecer a fundamental import&acirc;ncia da discuss&atilde;o bio&eacut
e;tica na forma&ccedil;&atilde;o do jovem m&eacute;dico, denota a aten&ccedil;&a
tilde;o e determina&ccedil;&atilde;o de seus membros em resposta &agrave;s deman
das atuais da pr&aacute;tica m&eacute;dica. </font></p>     ^cY#v44n2a01.htm##
00660000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704043000071002001300501#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#17#13#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">O livro <i>Bioethics: A Bridge to the Fut
ure</i>, de 1971, de autoria do oncologista norte-americano Van Rensselaer Potte
r<sup>(2)</sup>, &eacute; a refer&ecirc;ncia hist&oacute;rica dessa &aacute;rea 
do conhecimento humano. Na totalidade do contexto cient&iacute;fico e tecnol&oac
ute;gico, poucas &aacute;reas evolu&iacute;ram com tanta rapidez. </font></p>   
  ^cY#v44n2a01.htm##
00796000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704056600071002001300637#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#18#14#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Potter concebia originalmente a bio&eacut
e;tica como um compromisso global com o equil&iacute;brio e preserva&ccedil;&ati
lde;o da rela&ccedil;&atilde;o dos seres humanos com o ecossistema e com a pr&oa
cute;pria sobreviv&ecirc;ncia no planeta. N&atilde;o foi esta vis&atilde;o, por&
eacute;m, que se difundiu nos meios cient&iacute;ficos, mas sim a linha de pensa
mento delineada na obra <i>Principles of Biomedical Ethics</i>, escrita por Beau
champ e Childress, em 1979<sup>(3)</sup>. </font></p>     ^cY#v44n2a01.htm##
01097000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704086700071002001300938#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#19#15#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Esta obra, a b&iacute;blia dos bioeticist
as das d&eacute;cadas oitenta e noventa do s&eacute;culo passado, apresentou uma
 nova linha de racioc&iacute;nio, conhecida como principialismo. A abordagem das
 quest&otilde;es de natureza &eacute;tica passou a ser feita a partir de quatro 
princ&iacute;pios b&aacute;sicos: dois de car&aacute;ter deontol&oacute;gico (n&
atilde;o malefic&ecirc;ncia e justi&ccedil;a) e dois de car&aacute;ter teleol&oa
cute;gico (benefic&ecirc;ncia e autonomia). Embora tais princ&iacute;pios n&atil
de;o apresentem filosoficamente car&aacute;ter absoluto, o fato &eacute; que for
am rapidamente aceitos como "ferramentas" b&aacute;sicas na elabora&ccedil;&atil
de;o de discuss&otilde;es e decis&otilde;es de conflitos emergentes na &aacute;r
ea de bio&eacute;tica. </font></p>     ^cY#v44n2a01.htm##
00647000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704041700071002001300488#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#20#16#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">O principialismo mant&eacute;m-se como um
a linha fundamental no ju&iacute;zo de quest&otilde;es bio&eacute;ticas, mas n&a
tilde;o &eacute;, absolutamente, a &uacute;nica utilizada. Diversas outras linha
s ou "dialetos" assumiram importante papel nas &uacute;ltimas d&eacute;cadas, co
mo o contextualismo, o naturalismo, o feminismo etc. </font></p>     ^cY#v44n2a0
1.htm##
00601000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704037100071002001300442#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#21#17#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Historicamente deve ser lembrado que o fi
l&oacute;sofo Tom Beauchamp e o te&oacute;logo James Childress idealizaram o liv
ro a partir do Relat&oacute;rio Belmont, assim denominado por ter sido conclu&ia
cute;do no Centro de Conven&ccedil;&otilde;es Belmont, em Maryland, EUA<sup>(4)<
/sup>. </font></p>     ^cY#v44n2a01.htm##
00802000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704057200071002001300643#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#22#18#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Este relat&oacute;rio foi resultado dos t
rabalhos da Comiss&atilde;o Nacional para Prote&ccedil;&atilde;o dos Seres Human
os em Pesquisa Biom&eacute;dica e Comportamental, que contou com a participa&cce
dil;&atilde;o de profissionais de diferentes &aacute;reas de atividade, incluind
o pesquisadores, m&eacute;dicos, fil&oacute;sofos, te&oacute;logos etc., que con
tribu&iacute;ram para a tarefa de identificar os princ&iacute;pios &eacute;ticos
 b&aacute;sicos nas pesquisas em seres humanos. </font></p>     ^cY#v44n2a01.htm
##
00726000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704049600071002001300567#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#23#19#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Beauchamp e Childress, integrantes da com
iss&atilde;o, aplicaram o "sistema de princ&iacute;pios" &agrave; &aacute;rea cl
&iacute;nico-assistencial, criando uma maneira inteiramente nova de ju&iacute;zo
 de quest&otilde;es &eacute;ticas, diferentemente do ultrapassado enfoque pr&oac
ute;prio e caracter&iacute;stico dos c&oacute;digos e juramentos, muito limitado
s e mais ligados &agrave; moral que a &eacute;tica. </font></p>     ^cY#v44n2a01
.htm##
01118000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704088800071002001300959#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#24#20#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Marco Segre, bioeticista brasileiro<sup>(
5)</sup>, define bio&eacute;tica como sendo "parte da &eacute;tica, ramo da filo
sofia, que enfoca as quest&otilde;es referentes &agrave; vida humana (e, portant
o &agrave; sa&uacute;de). A bio&eacute;tica, tendo a vida como objeto de estudo,
 trata tamb&eacute;m da morte (inerente &agrave; vida)". Este autor defende que 
a bio&eacute;tica deva ser o mais aut&ocirc;noma poss&iacute;vel para cada ser h
umano, buscando sempre uma vis&atilde;o te&oacute;rica de descentralismo, com cl
ara rela&ccedil;&atilde;o com o movimento iluminista do s&eacute;culo XVIII. Na 
vis&atilde;o deste autor a autonomia &eacute; o princ&iacute;pio b&aacute;sico e
 central. Esta "<i>self</i>-&eacute;tica" definida por Segre pode tamb&eacute;m 
ser chamada de "&eacute;tica da liberdade". </font></p>     ^cY#v44n2a01.htm##
00612000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704038200071002001300453#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#25#21#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">O discurso pluralista da bio&eacute;tica 
mant&eacute;m-se em evid&ecirc;ncia, &eacute; a sua pr&oacute;pria alma, devendo
 nele estar presentes a filosofia, a teologia, o direito, a sociologia, a psicol
ogia, a antropologia e demais &aacute;reas relacionadas com o estudo do ser huma
no<sup>(3)</sup>. </font></p>     ^cY#v44n2a01.htm##
00666000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704043600071002001300507#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#26#22#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o &agrave; pr&aac
ute;tica m&eacute;dica, &eacute; n&iacute;tido o crescimento progressivo dos dil
emas &eacute;ticos, presentes cada vez mais no dia-adia, tornando obrigat&oacute
;ria a aten&ccedil;&atilde;o de todos os profissionais da sa&uacute;de para a di
scuss&atilde;o e atualiza&ccedil;&atilde;o de seus temas<sup>(6)</sup>. </font><
/p>     ^cY#v44n2a01.htm##
00696000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704046600071002001300537#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#27#23#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A bio&eacute;tica cl&iacute;nica &eacute;
 um dos ramos mais complexos e desafiadores da bio&eacute;tica. Requer conhecime
ntos tanto da arte m&eacute;dica, quanto de conceitos jur&iacute;dicos e cient&i
acute;ficos. O r&aacute;pido progresso cient&iacute;fico e tecnol&oacute;gico to
rnou esta intera&ccedil;&atilde;o indispens&aacute;vel ao exerc&iacute;cio da me
dicina<sup>(7)</sup>. </font></p>     ^cY#v44n2a01.htm##
00621000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704039100071002001300462#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#28#24#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A bio&eacute;tica cl&iacute;nica &eacute;
, sem d&uacute;vida, o ramo mais importante na forma&ccedil;&atilde;o do jovem m
&eacute;dico, sendo a resid&ecirc;ncia a &eacute;poca ideal para se abordar os c
onceitos te&oacute;ricos integrando-os com a forma&ccedil;&atilde;o pr&aacute;ti
ca do futuro especialista. </font></p>     ^cY#v44n2a01.htm##
00625000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704039500071002001300466#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#29#25#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">O conceito de bio&eacute;tica cl&iacute;n
ica &eacute; amplo e de dif&iacute;cil delimita&ccedil;&atilde;o. A defini&ccedi
l;&atilde;o que considero mais adequada &eacute; a de Levi e Lemos de Barros, no
 livro <i>Inicia&ccedil;&atilde;o &agrave; Bio&eacute;tica</i><sup>(8)</sup>, do
 conselho Federal de Medicina: </font></p>     ^cY#v44n2a01.htm##
00845000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704061500071002001300686#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#30#26#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">"Trata a &eacute;tica cl&iacute;nica das 
condutas desej&aacute;veis no &acirc;mbito da rela&ccedil;&atilde;o que se forma
 entre o profissional da &aacute;rea da sa&uacute;de e seus pacientes, criando-s
e, com isso, condi&ccedil;&otilde;es para que, por um lado, os valores pessoais 
dos seres humanos envolvidos sejam preservados e respeitados e, por outro, a pre
sta&ccedil;&atilde;o de servi&ccedil;o que constitui o objeto especial dessa rel
a&ccedil;&atilde;o possa alcan&ccedil;ar a m&aacute;xima efic&aacute;cia poss&ia
cute;vel." </font></p>     ^cY#v44n2a01.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704011500071002001300186#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#31#27#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Continuam os referidos autores: </font></
p>     ^cY#v44n2a01.htm##
00988000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704075800071002001300829#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#32#28#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">"A rela&ccedil;&atilde;o entre o profissi
onal e seu paciente se d&aacute; dentro de riqu&iacute;ssima e variada gama de m
atizes comportamentais que tornam essa situa&ccedil;&atilde;o &uacute;nica e ini
gual&aacute;vel. H&aacute;, todavia, m&uacute;ltiplos aspectos dessa rela&ccedil
;&atilde;o que podem ser classificados, a fim de se buscar par&acirc;metros &eac
ute;ticos que permitam sejam reguladas situa&ccedil;&otilde;es an&aacute;logas. 
Dois desses aspectos assumem particular&iacute;ssima import&acirc;ncia para a hi
gidez da rela&ccedil;&atilde;o profissional: a informa&ccedil;&atilde;o que &eac
ute; devida ao paciente e a preserva&ccedil;&atilde;o de sua intimidade." </font
></p>     ^cY#v44n2a01.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010100071002001300172#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#33#29#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Conceituam ainda: </font></p>     ^cY#v44
n2a01.htm##
01051000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704082100071002001300892#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#34#30#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">"Quando se cuida da informa&ccedil;&atild
e;o a que tem direito o paciente, trata-se de garantir a ele o poder de decidir 
sobre o pr&oacute;prio destino, permitindo, ou n&atilde;o, que o profissional da
 sa&uacute;de realize em seu favor determinado procedimento (exercendo o pacient
e o que se convencionou chamar de <i>consentimento informado</i>); para que poss
a tomar essa decis&atilde;o necessita o paciente de informa&ccedil;&atilde;o por
menorizada sobre as hip&oacute;teses diagn&oacute;sticas de seu problema, bem co
mo acerca dos procedimentos destinados a complementa&ccedil;&atilde;o ou confirm
a&ccedil;&atilde;o desses diagn&oacute;sticos, os tratamentos poss&iacute;veis (
e suas conseq&uuml;&ecirc;ncias) e o progn&oacute;stico. </font></p>     ^cY#v44
n2a01.htm##
00833000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704060300071002001300674#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#35#31#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A preserva&ccedil;&atilde;o da privacidad
e do paciente, por seu turno, est&aacute; vinculada ao princ&iacute;pio de que t
udo o que diz respeito &agrave; sua intimidade lhe pertence, e somente ele poder
&aacute; dispor; a prote&ccedil;&atilde;o dessa intimidade se d&aacute; por meio
 da ado&ccedil;&atilde;o do <i>sigilo</i>, que torna a circula&ccedil;&atilde;o 
de informa&ccedil;&otilde;es relacionadas &agrave; intimidade do paciente restri
ta apenas ao c&iacute;rculo integrante da rela&ccedil;&atilde;o profissional." <
/font></p>     ^cY#v44n2a01.htm##
00916000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704068600071002001300757#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#36#32#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Estes conceitos e outros relacionados com
 a bio&eacute;tica cl&iacute;nica s&atilde;o fundamentais na forma&ccedil;&atild
e;o do jovem profissional. Os avan&ccedil;os cient&iacute;ficos e tecnol&oacute;
gicos das &uacute;ltimas d&eacute;cadas v&ecirc;m acompanhados de crescentes e d
if&iacute;ceis dilemas &eacute;ticos que devem ser enfrentados e discutidos nest
a importante fase da forma&ccedil;&atilde;o profissional. Exemplos destes dilema
s s&atilde;o a reprodu&ccedil;&atilde;o assistida, o projeto genoma humano e a m
edicina preditiva, os transplantes, a eutan&aacute;sia e o prolongamento da vida
. </font></p>     ^cY#v44n2a01.htm##
00755000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704052500071002001300596#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#37#33#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Deve tamb&eacute;m ser destacada a fundam
ental import&acirc;ncia dos aspectos normativos relacionados com a &eacute;tica 
em pesquisa e principalmente o detalhado conhecimento da resolu&ccedil;&atilde;o
 n.o 196/96 do Conselho Nacional de Sa&uacute;de (CNS), que cria a Comiss&atilde
;o Nacional de &Eacute;tica em Pesquisa (CONEP) e os Comit&ecirc;s de &Eacute;ti
ca em Pesquisa (CEPs) e baliza as normas de pesquisa em seres humanos no Brasil.
 </font></p>     ^cY#v44n2a01.htm##
00864000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704063400071002001300705#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#38#34#text#58#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A ado&ccedil;&atilde;o das medidas necess
&aacute;rias &agrave; implanta&ccedil;&atilde;o efetiva da Resolu&ccedil;&atilde
;o n.º 4/2003 da CNRM &eacute; dever dos respons&aacute;veis pelos programas de 
resid&ecirc;ncia m&eacute;dica em nossa especialidade, devendo merecer especial 
aten&ccedil;&atilde;o a implanta&ccedil;&atilde;o da abordagem bio&eacute;tica n
a forma&ccedil;&atilde;o do futuro especialista em reumatologia, especialidade e
m que a rela&ccedil;&atilde;o m&eacute;dico-paciente ocupa especial destaque na 
pr&aacute;tica di&aacute;ria. </font></p>     ^cY#v44n2a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#39#35#text#58#<p>&nbsp;</p>     ^cY#v4
4n2a01.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704011000071002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#40#36#text#58#<p align="right"><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">JOS&Eacute; MARQUES FILHO  
  ^cY#v44n2a01.htm##
00288000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704005800071002001300129#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#41#37#text#58#<br>  Conselheiro do Con
selho Regional de Medicina    ^cY#v44n2a01.htm##
00283000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704005300071002001300124#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#42#38#text#58#<br>  do Estado de S&ati
lde;o Paulo (CREMESP)    ^cY#v44n2a01.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009000071002001300161#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#43#39#text#58#<br>  Membro da Comiss&a
tilde;o de &Eacute;tica e Defesa Profissional da SBR e SPR    ^cY#v44n2a01.htm##
00316000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704008600071002001300157#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#44#40#text#58#<br>  Conselho Regional 
de Medicina do Estado de S&atilde;o Paulo </font></p>     ^cY#v44n2a01.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#45#41#text#58#<p>&nbsp;</p>     ^cY#v4
4n2a01.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010700071002001300178#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#46#42#text#58#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>     ^
cY#v44n2a01.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704022300073002001300296#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#47#43#text#58#1#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">1. Comiss&atilde;o Nacional
 de Resid&ecirc;ncia M&eacute;dica: Resolu&ccedil;&atilde;o n.º 4, de 23 de deze
mbro de 2003, Bras&iacute;lia, DOU 252, 2003.    ^cY#v44n2a01.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#48#44#text#58# </font></p>     ^cY#v44
n2a01.htm##
00399000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704015500073002001300228#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#49#45#text#58#2#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">2. Potter VR: Bioethics: A 
bridge to the future, New Jersey, englewood Cliffs, 1971.    ^cY#v44n2a01.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#50#46#text#58# </font></p>     ^cY#v44
n2a01.htm##
00415000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704017100073002001300244#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#51#47#text#58#3#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">3. Beauchamp TL, Childress 
JF: Principles of biomedics ethics, 3.ª ed, New York, Oxford Press, 1989.    ^cY
#v44n2a01.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#52#48#text#58# </font></p>     ^cY#v44
n2a01.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704023800073002001300311#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#53#49#text#58#4#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">4. The National Comission f
or the Protection of Human Subjects of Biomedical and Behavioral Research: The B
elmont Report, Washington, Government Printing Office, 1979.    ^cY#v44n2a01.htm
##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#54#50#text#58# </font></p>     ^cY#v44
n2a01.htm##
00526000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704028200073002001300355#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#55#51#text#58#5#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">5. Segre M: Defini&ccedil;&
atilde;o de Bio&eacute;tica e sua Rela&ccedil;&atilde;o com a &Eacute;tica, Deon
tologia e Diceologia. In Segre M, Cohen C (eds): Bio&eacute;tica, 3.ª ed. S&atil
de;o Paulo, Edusp, 2002.    ^cY#v44n2a01.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#56#52#text#58#</font></p>     ^cY#v44n
2a01.htm##
00389000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704014500073002001300218#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#57#53#text#58#6#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">6. Reich WT: Encyclopedia o
f bioethics, New York, Ed The Free Press, 1978.    ^cY#v44n2a01.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#58#54#text#58# </font></p>     ^cY#v44
n2a01.htm##
00395000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704015100073002001300224#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#59#55#text#58#7#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">7. Urban CA: Bio&eacute;tic
a Cl&iacute;nica, Rio de Janeiro, Ed. Revinter, 2003.    ^cY#v44n2a01.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#60#56#text#58#</font></p>     ^cY#v44n
2a01.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704026600073002001300339#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#61#57#text#58#8#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">8. Levi GC, Leme de barros 
AO: &Eacute;tica Cl&iacute;nica: a AIDS como paradigma. In Costa SIF, Oselka G, 
Garrafa V: Inicia&ccedil;&atilde;o &agrave; Bio&eacute;tica, Bras&iacute;lia, CF
M, 1978.    ^cY#v44n2a01.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a01.htm#S#p#62#58#text#58#</font></p>     ^cY#v44n
2a01.htm##
00440000000000229000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690170039000710180047001100660
00900157061000800166065000900174064000500183865000900188002001300197#v44n2#V:\Sc
iELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#c#63#1#text#8#1#Comissão Nacional de
 Residência Médica#Resolução n.º 4, de 23 de dezembro de 2003^lpt#Brasília#DOU 2
52#20030000#2003#20040400#v44n2a01.htm##
00409000000000217000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690160017000710180038000880660
02900126065000900155064000500164865000900169002001300178#v44n2#V:\SciELO\serial\
rbr\v44n2\markup\v44n2a01.htm#S#c#64#2#text#8#2#^rND^sPotter^nVR#Bioethics: A br
idge to the future^len#englewood Cliffs^eNew Jersey#19710000#1971#20040400#v44n2
a01.htm##
00460000000000253000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690160020000710160020000910180
03500111063000200146066000900148062001300157065000900170064000500179865000900184
002001300193#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#c#65#3#text#
8#3#^rND^sBeauchamp^nTL#^rND^sChildress^nJF#Principles of biomedics ethics^len#3
#New York#Oxford Press#19890000#1989#20040400#v44n2a01.htm##
00485000000000217000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690180122000710660011001930620
02700204065000900231064000500240865000900245002001300254#v44n2#V:\SciELO\serial\
rbr\v44n2\markup\v44n2a01.htm#S#c#66#4#text#8#4#The National Comission for the P
rotection of Human Subjects of Biomedical and Behavioral Research: The Belmont R
eport^len#Washington#Government Printing Office#19790000#1979#20040400#v44n2a01.
htm##
00539000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100015000710120078000860160
01500164016001500179018001300194063000200207066001000209062000600219065000900225
064000500234865000900239002001300248#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a01.htm#S#c#67#5#text#8#5#^rND^sSegre^nM#Definição de Bioética e sua Relação c
om a Ética, Deontologia e Diceologia^lpt#^rED^sSegre^nM#^rED^sCohen^nC#Bioética^
lpt#3#São Paulo#Edusp#20020000#2002#20040400#v44n2a01.htm##
00410000000000229000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690160016000710180030000870660
00900117062001800126065000900144064000500153865000900158002001300167#v44n2#V:\Sc
iELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#c#68#6#text#8#6#^rND^sReich^nWT#Ency
clopedia of bioethics^len#New York#Ed The Free Press#19780000#1978#20040400#v44n
2a01.htm##
00402000000000229000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690160016000710180021000870660
01500108062001300123065000900136064000500145865000900150002001300159#v44n2#V:\Sc
iELO\serial\rbr\v44n2\markup\v44n2a01.htm#S#c#69#7#text#8#7#^rND^sUrban^nCA#Bioé
tica Clínica^lpt#Rio de Janeiro#Ed. Revinter#20030000#2003#20040400#v44n2a01.htm
##
00566000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100015000710100025000860120
04100111016001700152016001600169016001700185018002500202066000900227062000400236
065000900240064000500249865000900254002001300263#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a01.htm#S#c#70#8#text#8#8#^rND^sLevi^nGC#^rND^sLeme de barros^nAO#
Ética Clínica: a AIDS como paradigma^lpt#^rND^sCosta^nSIF#^rND^sOselka^nG#^rND^s
Garrafa^nV#Iniciação à Bioética^lpt#Brasília#CFM#19780000#1978#20040400#v44n2a01
.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#o#1#1#article#1#
20110406#085306#v44n2a02.htm#136##
05176000000000613000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701201260
01670120118002930100028004110100031004390100043004700700074005130700050005870831
92700637085000802564085004002572085001702612085002802629083171602657085000804373
08500410438108500360442208500200445808500220447811700060450007200030450611200090
4509111001104518114000904529113001104538002001304549#v44n2#V:\SciELO\serial\rbr\
v44n2\markup\v44n2a02.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#02#RBR160
#nd#Rev. Bras. Reumatol.#44#2#20040400#^f109^l114#0482-5004#Avaliação do índice 
de danos permanentes através do SLICC/ACR-DI em pacientes brasileiros com lúpus 
eritematoso sistêmico^lpt#Cumulative organ damage evaluation using the SLICC/ACR
-DI in brazilian patients with systemic lupus erythematosus^len#^rND^1A01^nJulia
na^sGuarize#^rND^1A02^nSimone^sAppenzeller#^rND^1A01^nLilian Tereza Lavras^sCost
allat#Universidade Estadual de Campinas^iA01^1Faculdade de Ciências Médicas^sSP#
Unicamp^iA02^1FCM^2departamento de clínica médica#^lpt^aOBJETIVO: avaliar a freq
üência e os tipos de danos permanentes com relação ao tempo da doença em pacient
es brasileiros com lúpus eritematoso sistêmico (LES) de um hospital universitári
o, através da aplicação do índice de dano do Systemic Lupus International Collab
orating Clinics/American College of Rheumatology (SLICC/ACR/DI). MÉTODOS: foram 
incluídos 60 pacientes neste estudo. Os dados utilizados, extraídos dos prontuár
ios dos pacientes, foram obtidos através de anamnese, exame físico e exames comp
lementares. A freqüência e os tipos de danos permanentes foram avaliados através
 do SLICC/ACR/DI. A estatística foi realizada através do teste quiquadrado e tes
te t. Regressão multivariada foi utilizada para correlacionar o dano com o tempo
 de doença. RESULTADOS: entre os 60 pacientes, 41 (68,3%) apresentaram algum tip
o de dano. Houve tendência, entre os pacientes não caucasóides e com maior tempo
 de doença, a apresentarem mais danos (p=0,058). Os sistemas mais acometidos for
am: pele (35,0%); neuropsiquiátrica (18,3%); ocular (15,0%); vascularização peri
férica (16,6%); e cardiovascular (10,0%). Com o aumento do tempo de doença (supe
rior a 60 meses), houve maior tendência a danos oculares, neuropsiquiátricos, re
nais, musculoesquelético e da pele. Com evolução superior a 120 meses houve aume
nto dos danos pulmonares, cardiovasculares e aqueles relacionados com a vascular
ização periférica. CONCLUSÕES: observou-se 68,3% de dano permanente, havendo mai
or freqüência de danos relacionados com acometimentos neuropsiquiátricos, ocular
es, da vascularização periférica e da pele. Não se observou importante acometime
nto renal e gonadal, ao contrário do descrito anteriormente. Pacientes não cauca
sóides apresentaram tendência a maiores escores de dano. No entanto, outros estu
dos são necessários para se comprovar o envolvimento de fatores étnicos e/ou fat
ores sócioeconômicos nesse processo de dano irreversível#^dnd^i1#^tm^lpt^klúpus 
eritematoso sistêmico^i1#^tm^lpt^kdano^i1#^tm^lpt^ktempo de doença^i1#^len^aOBJE
CTIVE: to evaluate the frequency and the different types of organ damage in rela
tion to disease duration in Brazilian patients with SLE followed in a tertiary r
eference center through the application of the SLICC/ACR-DI. METHODS: sixty SLE 
patients were enrolled in this study, and relevant data were obtained through me
dical history, physical and laboratory examinations reviewing the hospital recor
ds. The frequency and different types of organ damage were determined using the 
SLICC/ACR-DI. Statistics were performed through qui-square and t-tests. Multivar
iate regression was used to correlate damage with disease duration. RESULTS: for
ty-one patients (68.3%) presented some cumulative organ damage. Non-caucasoid pa
tients and patients with longer disease duration had a slight tendency to have m
ore damage (p = 0.058). Skin (35.0%), neuropsychiatric (18.3%), ocular (15.0%), 
peripheral vascularization (16.6%) and cardiovascular (10.0%) systems were more 
frequently affected. Patients with more than 60 months of disease had a slight t
endency to present greater ocular, neuropsychiatric, renal, skin and musculoskel
etal damage than patients with shorter disease duration. Patients with more than
 120 months of disease had greater pulmonary, cardiovascular and peripheral vasc
ular damage. CONCLUSIONS: in this study, 68.3% of permanent damage was observed.
 Skin, neuropsychiatric, ocular, peripheral vascularization and cardiovascular s
ystems were more frequently affected. Renal and gonadal involvement was not as f
requent as previously described. Non-caucasoid patients had a tendency to presen
t higher scores, but more studies are necessary to determinate if ethnic or econ
omic factors are involved#^dnd^i2#^tm^len^ksystemic lupus erythematosus^i2#^tm^l
en^kcumulative organ damage^i2#^tm^len^koutcome^i2#^tm^len^kprognosis^i2#other#1
5#20030224#24/02/2003#20040311#11/03/2004#v44n2a02.htm##
05246000000000613000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701201330
01670120125003000100028004250100031004530100043004840700074005270700050006010831
95500651085000802606085004002614085001702654085002802671083174402699085000804443
08500410445108500360449208500200452808500220454811700060457007200030457611200090
4579111001104588114000904599113001104608002001304619#v44n2#V:\SciELO\serial\rbr\
v44n2\markup\v44n2a02.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#02#RBR160
#nd#Rev. Bras. Reumatol.#44#2#20040400#^f109^l114#0482-5004#<b>Avaliação do índi
ce de danos permanentes através do SLICC/ACR-DI em pacientes brasileiros com lúp
us eritematoso sistêmico</b>^lpt#<b>Cumulative organ damage evaluation using the
 SLICC/ACR-DI in brazilian patients with systemic lupus erythematosus</b>^len#^r
ND^1A01^nJuliana^sGuarize#^rND^1A02^nSimone^sAppenzeller#^rND^1A01^nLilian Terez
a Lavras^sCostallat#Universidade Estadual de Campinas^iA01^1Faculdade de Ciência
s Médicas^sSP#Unicamp^iA02^1FCM^2departamento de clínica médica#^lpt^a<b>OBJETIV
O:</b> avaliar a freqüência e os tipos de danos permanentes com relação ao tempo
 da doença em pacientes brasileiros com lúpus eritematoso sistêmico (LES) de um 
hospital universitário, através da aplicação do índice de dano do Systemic Lupus
 International Collaborating Clinics/American College of Rheumatology (SLICC/ACR
/DI). <b>MÉTODOS:</b> foram incluídos 60 pacientes neste estudo. Os dados utiliz
ados, extraídos dos prontuários dos pacientes, foram obtidos através de anamnese
, exame físico e exames complementares. A freqüência e os tipos de danos permane
ntes foram avaliados através do SLICC/ACR/DI. A estatística foi realizada atravé
s do teste quiquadrado e teste t. Regressão multivariada foi utilizada para corr
elacionar o dano com o tempo de doença. <b>RESULTADOS:</b> entre os 60 pacientes
, 41 (68,3%) apresentaram algum tipo de dano. Houve tendência, entre os paciente
s não caucasóides e com maior tempo de doença, a apresentarem mais danos (p=0,05
8). Os sistemas mais acometidos foram: pele (35,0%); neuropsiquiátrica (18,3%); 
ocular (15,0%); vascularização periférica (16,6%); e cardiovascular (10,0%). Com
 o aumento do tempo de doença (superior a 60 meses), houve maior tendência a dan
os oculares, neuropsiquiátricos, renais, musculoesquelético e da pele. Com evolu
ção superior a 120 meses houve aumento dos danos pulmonares, cardiovasculares e 
aqueles relacionados com a vascularização periférica. <b>CONCLUSÕES:</b> observo
u-se 68,3% de dano permanente, havendo maior freqüência de danos relacionados co
m acometimentos neuropsiquiátricos, oculares, da vascularização periférica e da 
pele. Não se observou importante acometimento renal e gonadal, ao contrário do d
escrito anteriormente. Pacientes não caucasóides apresentaram tendência a maiore
s escores de dano. No entanto, outros estudos são necessários para se comprovar 
o envolvimento de fatores étnicos e/ou fatores sócioeconômicos nesse processo de
 dano irreversível#^dnd^i1#^tm^lpt^klúpus eritematoso sistêmico^i1#^tm^lpt^kdano
^i1#^tm^lpt^ktempo de doença^i1#^len^a<b>OBJECTIVE:</b> to evaluate the frequenc
y and the different types of organ damage in relation to disease duration in Bra
zilian patients with SLE followed in a tertiary reference center through the app
lication of the SLICC/ACR-DI. <b>METHODS:</b> sixty SLE patients were enrolled i
n this study, and relevant data were obtained through medical history, physical 
and laboratory examinations reviewing the hospital records. The frequency and di
fferent types of organ damage were determined using the SLICC/ACR-DI. Statistics
 were performed through qui-square and t-tests. Multivariate regression was used
 to correlate damage with disease duration. <b>RESULTS:</b> forty-one patients (
68.3%) presented some cumulative organ damage. Non-caucasoid patients and patien
ts with longer disease duration had a slight tendency to have more damage (p = 0
.058). Skin (35.0%), neuropsychiatric (18.3%), ocular (15.0%), peripheral vascul
arization (16.6%) and cardiovascular (10.0%) systems were more frequently affect
ed. Patients with more than 60 months of disease had a slight tendency to presen
t greater ocular, neuropsychiatric, renal, skin and musculoskeletal damage than 
patients with shorter disease duration. Patients with more than 120 months of di
sease had greater pulmonary, cardiovascular and peripheral vascular damage. <b>C
ONCLUSIONS:</b> in this study, 68.3% of permanent damage was observed. Skin, neu
ropsychiatric, ocular, peripheral vascularization and cardiovascular systems wer
e more frequently affected. Renal and gonadal involvement was not as frequent as
 previously described. Non-caucasoid patients had a tendency to present higher s
cores, but more studies are necessary to determinate if ethnic or economic facto
rs are involved#^dnd^i2#^tm^len^ksystemic lupus erythematosus^i2#^tm^len^kcumula
tive organ damage^i2#^tm^len^koutcome^i2#^tm^len^kprognosis^i2#other#15#20030224
#24/02/2003#20040311#11/03/2004#v44n2a02.htm##
05422000000000637000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000200012903100030014903200020015206500090015401400110016303500100
01740120126001840120118003100100028004280100031004560100043004870700076005300700
05200606083199000658085000802648085004002656085001702696085002802713083176502741
08500080450608500410451408500360455508500200459108500220461111700060463307200030
4639112000904642111001104651114000904662113001104671002001304682008008904695#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#l#4#1#article#1#^mmar./abr.^
a2004#oa#pt#br1.1#1#4.0#ilus#tab#02#RBR160#nd#Rev. Bras. Reumatol#44#2#20040400#
^f109^l114#0482-5004#Avaliação do índice de danos permanentes através do SLICC/A
CR-DI em pacientes brasileiros com lúpus eritematoso sistêmico^lpt#Cumulative or
gan damage evaluation using the SLICC/ACR-DI in brazilian patients with systemic
 lupus erythematosus^len#^rND^1A01^nJuliana^sGuarize#^rND^1A02^nSimone^sAppenzel
ler#^rND^1A01^nLilian Tereza Lavras^sCostallat#^iA01^1Universidade Estadual de C
ampinas^2Faculdade de Ciências Médicas^sSP#^iA02^1Unicamp^2FCM^3departamento de 
clínica médica#^lpt^aOBJETIVO: avaliar a freqüência e os tipos de danos permanen
tes com relação ao tempo da doença em pacientes brasileiros com lúpus eritematos
o sistêmico (LES) de um hospital universitário, através da aplicação do índice d
e dano do Systemic Lupus International Collaborating Clinics/American College of
 Rheumatology (SLICC/ACR/DI). MÉTODOS: foram incluídos 60 pacientes neste estudo
. Os dados utilizados, extraídos dos prontuários dos pacientes, foram obtidos at
ravés de anamnese, exame físico e exames complementares. A freqüência e os tipos
 de danos permanentes foram avaliados através do SLICC/ACR/DI. A estatística foi
 realizada através do teste quiquadrado e teste t. Regressão multivariada foi ut
ilizada para correlacionar o dano com o tempo de doença. RESULTADOS: entre os 60
 pacientes, 41 (68,3 por cento) apresentaram algum tipo de dano. Houve tendência
, entre os pacientes não caucasóides e com maior tempo de doença, a apresentarem
 mais danos (p=0,058). Os sistemas mais acometidos foram: pele (35,0 por cento);
 neuropsiquiátrica (18,3 por cento); ocular (15,0 por cento); vascularização per
iférica (16,6 por cento); e cardiovascular (10,0 por cento). Com o aumento do te
mpo de doença (superior a 60 meses), houve maior tendência a danos oculares, neu
ropsiquiátricos, renais, musculoesquelético e da pele. Com evolução superior a 1
20 meses houve aumento dos danos pulmonares, cardiovasculares e aqueles relacion
ados com a vascularização periférica. CONCLUSÕES: observou-se 68,3 por cento de 
dano permanente, havendo maior freqüência de danos relacionados com acometimento
s neuropsiquiátricos, oculares, da vascularização periférica e da pele. Não se o
bservou importante acometimento renal e gonadal, ao contrário do descrito anteri
ormente. Pacientes não caucasóides apresentaram tendência a maiores escores de d
ano. No entanto, outros estudos são necessários para se comprovar o envolvimento
 de fatores étnicos e/ou fatores sócioeconômicos nesse processo de dano irrevers
ível#^dnd^i1#^tm^lpt^klúpus eritematoso sistêmico^i1#^tm^lpt^kdano^i1#^tm^lpt^kt
empo de doença^i1#^len^aOBJECTIVE: to evaluate the frequency and the different t
ypes of organ damage in relation to disease duration in Brazilian patients with 
SLE followed in a tertiary reference center through the application of the SLICC
/ACR-DI. METHODS: sixty SLE patients were enrolled in this study, and relevant d
ata were obtained through medical history, physical and laboratory examinations 
reviewing the hospital records. The frequency and different types of organ damag
e were determined using the SLICC/ACR-DI. Statistics were performed through qui-
square and t-tests. Multivariate regression was used to correlate damage with di
sease duration. RESULTS: forty-one patients (68.3 percent) presented some cumula
tive organ damage. Non-caucasoid patients and patients with longer disease durat
ion had a slight tendency to have more damage (p = 0.058). Skin (35.0 percent), 
neuropsychiatric (18.3 percent), ocular (15.0 percent), peripheral vascularizati
on (16.6 percent) and cardiovascular (10.0 percent) systems were more frequently
 affected. Patients with more than 60 months of disease had a slight tendency to
 present greater ocular, neuropsychiatric, renal, skin and musculoskeletal damag
e than patients with shorter disease duration. Patients with more than 120 month
s of disease had greater pulmonary, cardiovascular and peripheral vascular damag
e. CONCLUSIONS: in this study, 68.3 percent of permanent damage was observed. Sk
in, neuropsychiatric, ocular, peripheral vascularization and cardiovascular syst
ems were more frequently affected. Renal and gonadal involvement was not as freq
uent as previously described. Non-caucasoid patients had a tendency to present h
igher scores, but more studies are necessary to determinate if ethnic or economi
c factors are involved#^dnd^i2#^tm^len^ksystemic lupus erythematosus^i2#^tm^len^
kcumulative organ damage^i2#^tm^len^koutcome^i2#^tm^len^kprognosis^i2#other#15#2
0030224#24/02/2003#20040311#11/03/2004#v44n2a02.htm#Internet^ihttp://www.scielo.
br/scielo.php?script=sci_arttext&pid=S0482-50042004000200002##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#5#1#article#117#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v44n2a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#6#2#article#117#<p>&nbsp;</p>     ^cY#
v44n2a02.htm##
00567000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704033500073002001300408#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#7#3#article#117#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="linkinicio"></a><b>Avalia&cced
il;&atilde;o do &iacute;ndice de danos permanentes atrav&eacute;s do SLICC/ACR-D
I em pacientes brasileiros com l&uacute;pus eritematoso sist&ecirc;mico<sup>(</s
up><a href="#link01"><sup>*</sup></a><sup>)</sup></b></font></p>     ^cY#v44n2a0
2.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#8#4#article#117#<p>&nbsp;</p>     ^cY#
v44n2a02.htm##
00438000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704020600073002001300279#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#9#5#article#117#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><b>Cumulative organ damage evaluation u
sing the SLICC/ACR-DI in brazilian    patients with systemic lupus erythematosus
</b></font></p>     ^cY#v44n2a02.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#10#6#article#117#<p>&nbsp;</p>     ^cY
#v44n2a02.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#11#7#article#117#<p>&nbsp;</p>     ^cY
#v44n2a02.htm##
00429000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704019600074002001300270#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#12#8#article#117#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Juliana Guarize<sup>I</sup>; Simone
 Appenzeller<sup>II</sup>; Lilian Tereza Lavras Costallat<sup>III</sup></b></fon
t></p>     ^cY#v44n2a02.htm##
00439000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704020600074002001300280#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#13#9#article#117#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Sextanista de medicina da 
Faculdade de Ci&ecirc;ncias M&eacute;dicas da Universidade Estadual de Campinas 
(FCM/Unicamp), SP    ^cY#v44n2a02.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010900075002001300184#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#14#10#article#117#<br> <sup>II</sup>P&
oacute;s-graduanda do departamento de cl&iacute;nica m&eacute;dica da FCM/Unicam
p    ^cY#v44n2a02.htm##
00336000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010200075002001300177#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#15#11#article#117#<br> <sup>III</sup>P
rofessora titular da disciplina de reumatologia da FCM/Unicamp</font></p>     ^c
Y#v44n2a02.htm##
00386000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015200075002001300227#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#16#12#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#linkcorresp">Endere&ccedil;
o para correspond&ecirc;ncia</a></font></p>     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#17#13#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#18#14#article#117#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v44n2a02.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#19#15#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v44n
2a02.htm##
00720000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048600075002001300561#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#20#16#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OBJETIVO:</b> avaliar a freq&uuml;
&ecirc;ncia e os tipos de danos permanentes com rela&ccedil;&atilde;o ao tempo d
a doen&ccedil;a em pacientes brasileiros com l&uacute;pus eritematoso sist&ecirc
;mico (LES) de um hospital universit&aacute;rio, atrav&eacute;s da aplica&ccedil
;&atilde;o do &iacute;ndice de dano do Systemic Lupus International Collaboratin
g Clinics/American College of Rheumatology (SLICC/ACR/DI).    ^cY#v44n2a02.htm##
00769000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053500075002001300610#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#21#17#article#117#<br>  <b>M&Eacute;TO
DOS:</b> foram inclu&iacute;dos 60 pacientes neste estudo. Os dados utilizados, 
extra&iacute;dos dos prontu&aacute;rios dos pacientes, foram obtidos atrav&eacut
e;s de anamnese, exame f&iacute;sico e exames complementares. A freq&uuml;&ecirc
;ncia e os tipos de danos permanentes foram avaliados atrav&eacute;s do SLICC/AC
R/DI. A estat&iacute;stica foi realizada atrav&eacute;s do teste quiquadrado e t
este t. Regress&atilde;o multivariada foi utilizada para correlacionar o dano co
m o tempo de doen&ccedil;a.    ^cY#v44n2a02.htm##
01019000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704078500075002001300860#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#22#18#article#117#<br>  <b>RESULTADOS:
</b> entre os 60 pacientes, 41 (68,3%) apresentaram algum tipo de dano. Houve te
nd&ecirc;ncia, entre os pacientes n&atilde;o caucas&oacute;ides e com maior temp
o de doen&ccedil;a, a apresentarem mais danos (p=0,058). Os sistemas mais acomet
idos foram: pele (35,0%); neuropsiqui&aacute;trica (18,3%); ocular (15,0%); vasc
ulariza&ccedil;&atilde;o perif&eacute;rica (16,6%); e cardiovascular (10,0%). Co
m o aumento do tempo de doen&ccedil;a (superior a 60 meses), houve maior tend&ec
irc;ncia a danos oculares, neuropsiqui&aacute;tricos, renais, musculoesquel&eacu
te;tico e da pele. Com evolu&ccedil;&atilde;o superior a 120 meses houve aumento
 dos danos pulmonares, cardiovasculares e aqueles relacionados com a vasculariza
&ccedil;&atilde;o perif&eacute;rica.     ^cY#v44n2a02.htm##
00905000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067100075002001300746#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#23#19#article#117#<br> <b>CONCLUS&Otil
de;ES:</b> observou-se 68,3% de dano permanente, havendo maior freq&uuml;&ecirc;
ncia de danos relacionados com acometimentos neuropsiqui&aacute;tricos, oculares
, da vasculariza&ccedil;&atilde;o perif&eacute;rica e da pele. N&atilde;o se obs
ervou importante acometimento renal e gonadal, ao contr&aacute;rio do descrito a
nteriormente. Pacientes n&atilde;o caucas&oacute;ides apresentaram tend&ecirc;nc
ia a maiores escores de dano. No entanto, outros estudos s&atilde;o necess&aacut
e;rios para se comprovar o envolvimento de fatores &eacute;tnicos e/ou fatores s
&oacute;cioecon&ocirc;micos nesse processo de dano irrevers&iacute;vel.</font></
p>     ^cY#v44n2a02.htm##
00433000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019900075002001300274#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#24#20#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> l&uacute;pus e
ritematoso sist&ecirc;mico, dano, tempo de doen&ccedil;a.</font></p> <hr size="1
" noshade>     ^cY#v44n2a02.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009800075002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#25#21#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v4
4n2a02.htm##
00536000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030200075002001300377#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#26#22#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVE:</b> to evaluate the fre
quency and the different types of organ damage in relation to disease duration i
n Brazilian patients with SLE followed in a tertiary reference center through th
e application of the SLICC/ACR-DI.    ^cY#v44n2a02.htm##
00661000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042700075002001300502#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#27#23#article#117#<br>  <b>METHODS:</b
> sixty SLE patients were enrolled in this study, and relevant data were obtaine
d through medical history, physical and laboratory examinations reviewing the ho
spital records. The frequency and different types of organ damage were determine
d using the SLICC/ACR-DI. Statistics were performed through qui-square and t-tes
ts. Multivariate regression was used to correlate damage with disease duration. 
   ^cY#v44n2a02.htm##
00919000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704068500075002001300760#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#28#24#article#117#<br>  <b>RESULTS:</b
> forty-one patients (68.3%) presented some cumulative organ damage. Non-caucaso
id patients and patients with longer disease duration had a slight tendency to h
ave more damage (p = 0.058). Skin (35.0%), neuropsychiatric (18.3%), ocular (15.
0%), peripheral vascularization (16.6%) and cardiovascular (10.0%) systems were 
more frequently affected. Patients with more than 60 months of disease had a sli
ght tendency to present greater ocular, neuropsychiatric, renal, skin and muscul
oskeletal damage than patients with shorter disease duration. Patients with more
 than 120 months of disease had greater pulmonary, cardiovascular and peripheral
 vascular damage.    ^cY#v44n2a02.htm##
00680000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044600075002001300521#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#29#25#article#117#<br>  <b>CONCLUSIONS
:</b> in this study, 68.3% of permanent damage was observed. Skin, neuropsychiat
ric, ocular, peripheral vascularization and cardiovascular systems were more fre
quently affected. Renal and gonadal involvement was not as frequent as previousl
y described. Non-caucasoid patients had a tendency to present higher scores, but
 more studies are necessary to determinate if ethnic or economic factors are inv
olved.</font></p>     ^cY#v44n2a02.htm##
00431000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019700075002001300272#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#30#26#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> systemic lupus eryth
ematosus, cumulative organ  damage, outcome, prognosis.</font></p> <hr size="1" 
noshade>     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#31#27#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#32#28#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#33#29#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v44n2a02.htm##
01955000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704172100075002001301796#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#34#30#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O l&uacute;pus eritematoso sist&ecirc
;mico (LES) foi tradicionalmente considerado uma doen&ccedil;a cr&ocirc;nica, po
tencialmente fatal e com alta taxa de mortalidade<sup>(1-3)</sup>. Com o aumento
 da sobrevida, a morbidade secund&aacute;ria &agrave; doen&ccedil;a e as poss&ia
cute;veis complica&ccedil;&otilde;es da terapia passaram a despertar maior inter
esse<sup>(4)</sup>. Os danos permanentes no LES podem ser decorrentes da pr&oacu
te;pria doen&ccedil;a (como, por exemplo, nefrite evoluindo para insufici&ecirc;
ncia renal; pneumonite evoluindo para fibrose pulmonar) ou do tratamento emprega
do, pois uma parcela significativa de pacientes recebe corticoster&oacute;ides d
urante meses, anos ou a vida toda<sup>(1-3)</sup>. Os efeitos dos corticoster&oa
cute;ides nos ossos podem levar &agrave; osteoporose e osteonecrose; no sistema 
cardiovascular, &agrave; hipertens&atilde;o arterial sist&ecirc;mica e ateroscle
rose, sendo importantes causas de morbi-mortalidade no LES<sup>(4)</sup>. Outros
 imunossupressores, como a azatioprina e a ciclofosfamida, freq&uuml;entemente e
mpregados no LES, est&atilde;o associados ao aumento de infec&ccedil;&otilde;es,
 infertilidade e ao aparecimento de neoplasias anos ap&oacute;s o in&iacute;cio 
de seu uso<sup>(4)</sup>. A cloroquina, freq&uuml;entemente utilizada para manif
esta&ccedil;&otilde;es cut&acirc;neas, pode causar uma maculopatia por impregna&
ccedil;&atilde;o da droga na retina e, se n&atilde;o reconhecida a tempo, pode s
er respons&aacute;vel por altera&ccedil;&otilde;es debilitantes na vis&atilde;o,
 como vis&atilde;o anormal para cores e emba&ccedil;amento visual<sup>(4)</sup>.
 </font></p>     ^cY#v44n2a02.htm##
00816000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058200075002001300657#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#35#31#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com a maior sobrevida dos pacientes c
om LES, observou-se o aparecimento de co-morbidades como o diabetes melito e a h
ipertens&atilde;o arterial<sup>(1,4)</sup>. Ambos podem ser induzidos por cortic
oster&oacute;ides, pela obesidade, mas tamb&eacute;m apresentam associa&ccedil;&
atilde;o gen&eacute;tica importante. A presen&ccedil;a destas co-morbidades tamb
&eacute;m aumenta a freq&uuml;&ecirc;ncia de danos permanentes, especialmente os
 relacionados com os sistemas cardiovasculares<sup>(4)</sup>. </font></p>     ^c
Y#v44n2a02.htm##
00839000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060500075002001300680#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#36#32#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Para avaliar o impacto destes tipos d
e dano, acumulados durante a evolu&ccedil;&atilde;o do LES, desde o seu in&iacut
e;cio, foi desenvolvido o &iacute;ndice de dano do Systemic Lupus International 
Collaborating Clinics/American College of Rheumatology (SLICC/ACR/DI)<sup>(5)</s
up>. Este &iacute;ndice foi primeiramente aplicado em caucasianos, hisp&acirc;ni
cos, afro-americanos, asi&aacute;ticos e afro-caribenhos. Entre os pa&iacute;ses
 latino-americanos, foi primeiramente aplicado em pacientes mexicanos<sup>(6)</s
up>. </font></p>     ^cY#v44n2a02.htm##
00619000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038500075002001300460#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#37#33#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O objetivo deste trabalho foi avaliar
 a freq&uuml;&ecirc;ncia e os tipos de dano permanentes em pacientes l&uacute;pi
cos brasileiros seguidos em um hospital universit&aacute;rio. Avaliou-se tamb&ea
cute;m a rela&ccedil;&atilde;o entre os diferentes tipos de danos permanentes e 
o tempo de doen&ccedil;a.</font></p>     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#38#34#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00350000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011600075002001300191#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#39#35#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES E M&Eacute;TODOS</b></fo
nt></p>     ^cY#v44n2a02.htm##
00792000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055800075002001300633#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#40#36#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram estudados 60 pacientes que pree
nchiam quatro ou mais crit&eacute;rios para LES<sup>(7)</sup>, acompanhados no a
mbulat&oacute;rio de reumatologia do HC-Unicamp. Os pacientes foram selecionados
 aleatoriamente, n&atilde;o tendo havido qualquer sele&ccedil;&atilde;o pr&eacut
e;via quanto &agrave;s suas caracter&iacute;sticas demogr&aacute;ficas, manifest
a&ccedil;&otilde;es cl&iacute;nicas, laboratoriais ou tratamento, no per&iacute;
odo entre janeiro e dezembro de 2001. </font></p>     ^cY#v44n2a02.htm##
00538000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030400075002001300379#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#41#37#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quanto &agrave; dura&ccedil;&atilde;o
 da doen&ccedil;a, considerada a partir da data do diagn&oacute;stico de LES, os
 pacientes foram previamente selecionados e divididos em 3 grupos, cada grupo co
nstando de 20 pacientes:</font></p>     ^cY#v44n2a02.htm##
00396000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016200075002001300237#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#42#38#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Grupo 1: tempo de evolu&ccedil;&atild
e;o da doen&ccedil;a inferior a 60 meses; </font></p>     ^cY#v44n2a02.htm##
00397000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016300075002001300238#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#43#39#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Grupo 2: tempo de evolu&ccedil;&atild
e;o da doen&ccedil;a entre 60 e 120 meses; </font></p>     ^cY#v44n2a02.htm##
00397000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016300075002001300238#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#44#40#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Grupo 3: tempo de evolu&ccedil;&atild
e;o da doen&ccedil;a superior a 120 meses. </font></p>     ^cY#v44n2a02.htm##
00835000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060100075002001300676#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#45#41#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As caracter&iacute;sticas cl&iacute;n
icas e laboratoriais, bem como os dados demogr&aacute;ficos destes pacientes, fo
ram obtidas a partir de seus prontu&aacute;rios. As medica&ccedil;&otilde;es mai
s freq&uuml;entemente utilizadas no tratamento da doen&ccedil;a e consideradas n
este trabalho foram corticoster&oacute;ides (oral &#91;CE&#93; e endovenoso &#91
;PCE&#93;); antimal&aacute;ricos (DCQ); e citost&aacute;ticos (Azatioprina &#91;
AZA&#93;; Ciclofosfamida oral &#91;CFM&#93; e pulsos endovenosos &#91;PCFM&#93;)
.</font></p>     ^cY#v44n2a02.htm##
00393000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015900075002001300234#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#46#42#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>Caracteriza&ccedil;&atilde;o e 
avalia&ccedil;&atilde;o do dano</b></i></font></p>     ^cY#v44n2a02.htm##
00894000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704066000075002001300735#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#47#43#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o do dano foi
 realizada de acordo com o SLICC/ACR/DI, que avalia 12 itens de danos irrevers&i
acute;veis ocorridos desde o diagn&oacute;stico da doen&ccedil;a, independenteme
nte de serem advindos do LES, da terap&ecirc;utica utilizada no tratamento ou de
 co-morbidades. Os danos foram considerados quando presentes les&otilde;es irrev
ers&iacute;veis h&aacute; no m&iacute;nimo seis meses, n&atilde;o relacionadas c
om inflama&ccedil;&atilde;o ativa e que ocorreram ap&oacute;s o diagn&oacute;sti
co do LES, conforme previamente estabelecido<sup>(5)</sup>. </font></p>     ^cY#
v44n2a02.htm##
00552000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031800075002001300393#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#48#44#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Para cada les&atilde;o observada foi 
somado um ponto, sendo que les&otilde;es repetidas somaram dois pontos, e a mesm
a les&atilde;o n&atilde;o p&ocirc;de ser somada mais de uma vez. O somat&oacute;
rio de pontos definiu o escore obtido.</font></p>     ^cY#v44n2a02.htm##
00745000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051100075002001300586#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#49#45#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O diagn&oacute;stico destas les&otild
e;es foi feito atrav&eacute;s de exames rotineiramente empregados no HC-Unicamp,
 de acordo com as queixas cl&iacute;nicas e os exame f&iacute;sico destes pacien
tes. A avalia&ccedil;&atilde;o dos dist&uacute;rbios cognitivos foi realizada at
rav&eacute;s do exame do estado mental cognitivo<sup>(8)</sup> e de um teste de 
mem&oacute;ria l&oacute;gica como anteriormente descrito<sup>(9)</sup>.</font></
p>     ^cY#v44n2a02.htm##
00365000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013100075002001300206#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#50#46#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>An&aacute;lise estat&iacute;sti
cas</b></i></font></p>     ^cY#v44n2a02.htm##
00743000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050900075002001300584#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#51#47#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os pontos do SLICC/ACR/DI foram anali
sados pela normalidade, e os pacientes foram classificados em portadores ou n&at
ilde;o de danos e suas caracter&iacute;sticas examinadas, usando-se o teste qui-
quadrado e o teste t de Student. Foi considerado o valor de 95% de signific&acir
c;ncia. Para verificar associa&ccedil;&atilde;o do dano com o tempo de doen&cced
il;a foi elaborado um modelo de regress&atilde;o de Cox multivariado.</font></p>
     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#52#48#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#53#49#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v44n2a02.htm##
00373000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013900075002001300214#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#54#50#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>Caracter&iacute;sticas demogr&a
acute;ficas</b></i></font></p>     ^cY#v44n2a02.htm##
01185000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704095100075002001301026#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#55#51#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A maioria dos pacientes estudados foi
 do sexo feminino (96,7%). A m&eacute;dia de idade foi de 38,46 anos (desvio pad
r&atilde;o &#91;DP&#93; de 12,5). Houve maior freq&uuml;&ecirc;ncia de pacientes
 caucas&oacute;ides (75%) com rela&ccedil;&atilde;o &agrave; n&atilde;o caucas&o
acute;ides (25%). O tempo m&eacute;dio de doen&ccedil;a foi de 80 meses (DP=23,2
) e o tempo m&eacute;dio de acompanhamento de 75 meses (DP=25,8). Neste trabalho
 n&atilde;o se observou diferen&ccedil;a significativa entre as vari&aacute;veis
 demogr&aacute;ficas e a ocorr&ecirc;ncia de dano permanente, no entanto, notou-
se tend&ecirc;ncia a maior escore de dano entre os pacientes n&atilde;o caucas&o
acute;ides (p=0,058), sendo a m&eacute;dia do escore de dano entre os pacientes 
n&atilde;o caucas&oacute;ides de 2,133 (DP=0,568) e entre os pacientes caucas&oa
cute;ides de 1,467 (DP= 0,292).</font></p>     ^cY#v44n2a02.htm##
00502000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026800075002001300343#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#56#52#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">N&atilde;o houve diferen&ccedil;a est
at&iacute;stica entre outras vari&aacute;veis demogr&aacute;ficas nos grupos est
udados, divididos em fun&ccedil;&atilde;o do tempo da doen&ccedil;a.</font></p> 
    ^cY#v44n2a02.htm##
00410000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017600075002001300251#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#57#53#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>Manifesta&ccedil;&otilde;es cl&
iacute;nicas e medica&ccedil;&atilde;o utilizada</b></i></font></p>     ^cY#v44n
2a02.htm##
01313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704107900075002001301154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#58#54#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o &agrave;s d
oen&ccedil;as associadas, observou-se aumento significativo da preval&ecirc;ncia
 de hipertens&atilde;o arterial sist&ecirc;mica (p&lt;0,05) nos pacientes do gru
po 3, comparativamente aos pacientes dos grupos 1 e 2. N&atilde;o se observou di
feren&ccedil;a com rela&ccedil;&atilde;o &agrave;s demais doen&ccedil;as, inclui
ndo diabetes melito, s&iacute;ndrome de Sj&ouml;gren, hiper ou hipotireoidismo e
 manifesta&ccedil;&otilde;es neurol&oacute;gicas. Com rela&ccedil;&atilde;o &agr
ave;s medica&ccedil;&otilde;es utilizadas, observou-se maior utiliza&ccedil;&ati
lde;o de ciclofosfamida e pulsos de ciclofosfamida nos pacientes do grupo 3 (p&l
t;0,05) (<a href="#tab01">Tabela 1</a>). Apesar de n&atilde;o ser estatisticamen
te significante, o uso de difosfato de cloroquina foi mais empregado no grupo 2.
 N&atilde;o houve associa&ccedil;&atilde;o estat&iacute;stica entre os tipos de 
dano (<a href="#tab02">Tabela 2</a>) com as medica&ccedil;&otilde;es estudadas.<
/font></p>     ^cY#v44n2a02.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#59#55#article#117#<p><a name="tab01"><
/a></p>     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#60#56#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#61#57#article#117#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a02tab01.jpg"></p>     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#62#58#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#63#59#article#117#<p><a name="tab02"><
/a></p>     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#64#60#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#65#61#article#117#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a02tab02.jpg"></p>     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#66#62#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00393000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015900075002001300234#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#67#63#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>Caracteriza&ccedil;&atilde;o e 
avalia&ccedil;&atilde;o do dano</b></i></font></p>     ^cY#v44n2a02.htm##
00891000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704065700075002001300732#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#68#64#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Num total de 60 pacientes estudados, 
41 (68,3%) apresentaram algum tipo de dano permanente. Observou-se a seguinte di
stribui&ccedil;&atilde;o de freq&uuml;&ecirc;ncia por sistemas acometidos: ocula
r em 9 pacientes (15%); neuropsiqui&aacute;trico em 11 (18,3%); renal em 14 (23,
3%); pulmonar em 5 (8,3%); cardiovascular em 6 (10%); vasculariza&ccedil;&atilde
;o perif&eacute;rica em 10 (16,6%); gastrointestinal em 2 (3,3%); musculoesquel&
eacute;tico em 5 (8,3%); pele em 21 (35%); insufici&ecirc;ncia gonadal em 1 (1,7
%); diabetes melito em 1 (1,7%); e neoplasia em 1 (1,7%).</font></p>     ^cY#v44
n2a02.htm##
00951000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704071700075002001300792#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#69#65#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Entre os danos encontrados na pele, o
 acometimento com cicatriz extensa foi o mais freq&uuml;ente, ocorrendo em 19 de
 21 pacientes. Entre os danos neurol&oacute;gicos o mais prevalente foi a altera
&ccedil;&atilde;o cognitiva, encontrada em 10 de 11 pacientes; trombose venosa, 
ulcera&ccedil;&atilde;o e estase foram as mais prevalentes com rela&ccedil;&atil
de;o ao dano na vasculariza&ccedil;&atilde;o perif&eacute;rica, encontrada em 6 
de 10 pacientes; entre os danos oculares, o mais freq&uuml;ente foi altera&ccedi
l;&atilde;o da retina, em 5 de 9 pacientes, seguido de catarata, em 4 de 9 pacie
ntes (<a href="#tab02">Tabela 2</a>).</font></p>     ^cY#v44n2a02.htm##
01206000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704097200075002001301047#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#70#66#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quando a ocorr&ecirc;ncia de dano &ea
cute; analisada com rela&ccedil;&atilde;o ao tempo da doen&ccedil;a (<a href="/i
mg/revistas/rbr/v44n2/a02fig01.jpg">Figura 1</a>), observa-se que nos pacientes 
com at&eacute; 60 meses de doen&ccedil;a houve 65% de dano, sendo os mais freq&u
uml;entes aqueles referentes &agrave; pele, &agrave; vasculariza&ccedil;&atilde;
o perif&eacute;rica e ao envolvimento neuropsiqui&aacute;trico. Dos pacientes co
m tempo de doen&ccedil;a entre 60 e 120 meses, 75% tinham algum tipo de dano, pr
incipalmente relativos &agrave; pele, ao envolvimento neuropsiqui&aacute;trico, 
ao renal e ao ocular. Dos pacientes com mais de 120 meses de doen&ccedil;a, 65% 
tinham algum tipo de dano, destacando-se os danos da pele e dos sistemas cardiov
ascular, da vasculariza&ccedil;&atilde;o perif&eacute;rica e pulmonar (<a href="
/img/revistas/rbr/v44n2/a02fig01.jpg">Figura 1</a>).</font></p>     ^cY#v44n2a02
.htm##
00607000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037300075002001300448#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#71#67#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nesta casu&iacute;stica observou-se q
ue dois (3,3%) pacientes morreram antes de dez anos de doen&ccedil;a, os quais t
inham escores do SLICC/ACR-DI diferentes de zero. As causas da morte foram fal&e
circ;ncia renal e infec&ccedil;&atilde;o, com respectivamente 10 e 65 meses de d
oen&ccedil;a.</font></p>     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#72#68#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#73#69#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v44n2a02.htm##
01443000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704120900075002001301284#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#74#70#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nas &uacute;ltimas quatro d&eacute;ca
das, com o aumento na expectativa de vida dos pacientes com LES, tornou-se neces
s&aacute;rio avaliar a ocorr&ecirc;ncia de danos irrevers&iacute;veis nos difere
ntes &oacute;rg&atilde;os e sistemas, independente da natureza dos danos<sup>(4,
5)</sup>. O SLICC/ACR/DI<sup>(5)</sup> elaborou um instrumento, separando os con
ceitos de dano e atividade da doen&ccedil;a. Este &iacute;ndice foi desenvolvido
 especificamente para danos ou les&otilde;es acumulados ao longo da evolu&ccedil
;&atilde;o da doen&ccedil;a, oriundos diretamente do pr&oacute;prio LES, de doen
&ccedil;as concomitantes e do seu tratamento<sup>(5)</sup>. At&eacute; o momento
, este &eacute; o primeiro estudo que utiliza o SLICC/ACR-DI em uma popula&ccedi
l;&atilde;o brasileira, tendo sido observada elevada freq&uuml;&ecirc;ncia de da
nos permanentes, ocorrendo em 68,3% dos pacientes estudados. Os danos mais obser
vados foram aqueles referentes &agrave; pele (35%), ao envolvimento neuropsiqui&
aacute;trico (18,3%), ao ocular (15%), &agrave; vasculariza&ccedil;&atilde;o per
if&eacute;rica (16,6%) e ao cardiovascular (10%).</font></p>     ^cY#v44n2a02.ht
m##
01356000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704112200075002001301197#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#75#71#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Estudos<sup>(6,10-14)</sup> mostram q
ue a freq&uuml;&ecirc;ncia de cada dano permanente est&aacute; diretamente assoc
iada ao tempo da doen&ccedil;a. Danos precoces, encontrados logo no in&iacute;ci
o da doen&ccedil;a, s&atilde;o causados diretamente pelo processo inflamat&oacut
e;rio do LES<sup>(4,10)</sup>, enquanto as morbidades tardias sofrem um grande i
mpacto da medica&ccedil;&atilde;o empregada e de doen&ccedil;as concomitantes<su
p>(4,11-14)</sup>. A mortalidade parece estar diretamente associada &agrave; oco
rr&ecirc;ncia de dano, sendo que 25% dos pacientes com dano morrem antes de comp
letar dez anos de doen&ccedil;a<sup>(10)</sup>. Os fatores de risco associados &
agrave; ocorr&ecirc;ncia de dano permanente incluem: idade avan&ccedil;ada ao di
agn&oacute;stico<sup>(6,10)</sup>; maior dura&ccedil;&atilde;o do LES<sup>(11)</
sup>; etnia afro-caribenha ou asi&aacute;tica<sup>(15)</sup>; elevados &iacute;n
dices de atividade da doen&ccedil;a ao diagn&oacute;stico<sup>(6,10)</sup> e no 
decorrer da doen&ccedil;a<sup>(12)</sup>. </font></p>     ^cY#v44n2a02.htm##
02646000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704241200075002001302487#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#76#72#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Neste trabalho foi avaliado o dano co
m rela&ccedil;&atilde;o ao tempo da doen&ccedil;a. Sobre os demais fatores de ri
sco, n&atilde;o se observou diferen&ccedil;a significativa neste grupo de pacien
tes, exceto com rela&ccedil;&atilde;o &agrave; ra&ccedil;a. Embora n&atilde;o es
tatisticamente significativo, notou-se tend&ecirc;ncia a maiores valores de esco
re de dano permanente entre os pacientes n&atilde;o caucas&oacute;ides, n&atilde
;o sendo poss&iacute;vel, contudo, estabelecer quais fatores &eacute;tnicos esta
riam envolvidos nesta tend&ecirc;ncia ou tamb&eacute;m se h&aacute; influ&ecirc;
ncia de fatores s&oacute;cio-econ&ocirc;micos. Com o aumento do tempo da doen&cc
edil;a (superior a 60 meses), houve maior tend&ecirc;ncia a danos oculares, neur
opsiqui&aacute;tricos, renais, musculoesquel&eacute;ticos e cut&acirc;neos. Nos 
pacientes com evolu&ccedil;&atilde;o superior a 120 meses houve aumento dos dano
s pulmonares, cardiovasculares e da vasculariza&ccedil;&atilde;o perif&eacute;ri
ca. Ao contr&aacute;rio do que foi relatado previamente<sup>(13)</sup>, observou
-se envolvimento menor dos sistemas renal e gonadal nestes pacientes. Insufici&e
circ;ncia gonadal prematura (antes dos 40 anos de idade) ocorreu numa preval&eci
rc;ncia de 5%, sendo semelhante &agrave;s casu&iacute;sticas anteriores de pacie
ntes n&atilde;o hisp&acirc;nicos<sup>(14)</sup>. A maior incid&ecirc;ncia de fal
&ecirc;ncia gonadal foi associada aos pulsos endovenosos de ciclofosfamida para 
tratamento de nefrite. O sistema neuropsiqui&aacute;trico foi o segundo mais afe
tado, como descrito anteriormente<sup>(5)</sup>, ocorrendo, principalmente, dist
&uacute;rbios cognitivos e neuropatia perif&eacute;rica. Nesta casu&iacute;stica
 observou-se o grande acometimento da pele, com cicatriz extensa, causado pelo p
rocesso inflamat&oacute;rio da doen&ccedil;a ou secund&aacute;rio &agrave; infec
&ccedil;&atilde;o cut&acirc;nea, como, por exemplo, herpes Zoster, n&atilde;o se
ndo relatada esta freq&uuml;&ecirc;ncia em trabalhos anteriores. A possibilidade
 de a maior exposi&ccedil;&atilde;o solar a que est&atilde;o sujeitas as pacient
es brasileiras (n&atilde;o obstante a recomenda&ccedil;&atilde;o de uso de fotop
rotetores) potencializar o processo inflamat&oacute;rio &eacute; hip&oacute;tese
 que pode ser levantada, mas n&atilde;o comprovada. </font></p>     ^cY#v44n2a02
.htm##
01356000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704112200075002001301197#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#77#73#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A terapia a longo prazo com prednison
a aumenta o risco de morbidade e danos permanentes<sup>(13,14)</sup>. A dose acu
mulada elevada de prednisona est&aacute; associada &agrave; fraturas por osteopo
rose, doen&ccedil;a coronariana sintom&aacute;tica (angina) e catarata. Exposi&c
cedil;&atilde;o a altas doses de prednisona por mais de dois meses subseq&uuml;e
ntes associa-se &agrave; necrose avascular e &agrave; acidente vascular cerebral
 hemorr&aacute;gico; pulsos de corticoster&oacute;ides parecem estar associados 
&agrave; disfun&ccedil;&atilde;o cognitiva<sup>(4,13,14)</sup>. Nesta casu&iacut
e;stica n&atilde;o foi encontrado, no entanto, fratura decorrente de osteoporose
. Observou-se, por&eacute;m, necrose avascular &uacute;nica e recorrente (ambas 
em articula&ccedil;&atilde;o coxo-femural) em pacientes expostos &agrave; terapi
a com altas doses de prednisona (via oral) por mais de dois meses subseq&uuml;en
tes. N&atilde;o houve associa&ccedil;&atilde;o entre medica&ccedil;&otilde;es ut
ilizadas e escores de dano mais elevados. </font></p>     ^cY#v44n2a02.htm##
01176000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704094200075002001301017#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#78#74#article#117#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em conclus&atilde;o, nesta casu&iacut
e;stica de 60 pacientes brasileiros houve 68,3% de dano permanente, acometendo p
rincipalmente a pele (35%), o sistema neuropsiqui&aacute;trico (18,3%), ocular (
15%), vasculariza&ccedil;&atilde;o perif&eacute;rica (16,6%) e cardiovascular (1
0%). Ao longo da doen&ccedil;a, houve tend&ecirc;ncia a maior dano do sistema pu
lmonar, cardiovascular e vasculariza&ccedil;&atilde;o perif&eacute;rica. N&atild
e;o se observou importante acometimento renal e gonadal, ao contr&aacute;rio do 
descrito anteriormente. Pacientes n&atilde;o caucas&oacute;ides tiveram tend&eci
rc;ncia a apresentar maiores escores de dano, no entanto, outros estudos s&atild
e;o necess&aacute;rios para se comprovar a participa&ccedil;&atilde;o de fatores
 &eacute;tnicos e/ou fatores s&oacute;cio-econ&ocirc;micos nesse processo de dan
o irrevers&iacute;vel.</font></p>     ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#79#75#article#117#<p>&nbsp;</p>     ^c
Y#v44n2a02.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#80#76#article#117#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v44n2a02.htm##
00559000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704031100077002001300388#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#81#77#article#117#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. 	Cervera R, Khamasht
a MA, Font J, et al: Morbidity and mortality in systemic lupus erythematosus dur
ing a 10-year period: a comparison of early and late manifestations in a cohort 
of 1,000 patients. Medicine (Baltimore) 82:299-308, 2003.    ^cY#v44n2a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#82#78#article#117#</font></p>     ^cY#
v44n2a02.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026600077002001300343#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#83#79#article#117#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. 	Moss KE, Ioannou Y,
 Sultan SM, et al: Outcome of a cohort of 300 patients with systemic lupus eryth
ematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 61:  4
09-13, 2002.    ^cY#v44n2a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#84#80#article#117#</font></p>     ^cY#
v44n2a02.htm##
00441000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704019300077002001300270#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#85#81#article#117#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Trager J, Ward MM: M
ortality and causes of death in systemic lupus  erythematosus. Curr Opin Rheumat
ol 13:345-51, 2001.    ^cY#v44n2a02.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#86#82#article#117# </font></p>     ^cY
#v44n2a02.htm##
00395000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704014700077002001300224#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#87#83#article#117#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Petri M: Hopkins Lup
us Cohort. Rheum Dis Clin North Am 26: 199-213, 2000.    ^cY#v44n2a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#88#84#article#117#</font></p>     ^cY#
v44n2a02.htm##
00575000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704032700077002001300404#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#89#85#article#117#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Gladman D, Glinzler 
E, Goldsmith C, et al: The development and initial validation of the Systemic lu
pus International Collaborating Clinics/American College of Rheumatology damage 
index for systemic lupus erythematosus. Arthritis Rheum 39: 363-78, 1996.    ^cY
#v44n2a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#90#86#article#117#</font></p>     ^cY#
v44n2a02.htm##
00513000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026500077002001300342#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#91#87#article#117#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Zonana-Nacach A, Cam
argo-Coronel A, Yanez P, et al: Measurement of damage in 210 mexican patients wi
th systemic lupus erythematosus: relationship with disease duration. Lupus 7: 11
9-23, 1998.    ^cY#v44n2a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#92#88#article#117#</font></p>     ^cY#
v44n2a02.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704022400077002001300301#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#93#89#article#117#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Tan EM, Cohen AS, Fr
ies JF, et al: The 1982 revised criteria for the classification of systemic lupu
s erythematosus. Arthritis Rheum 25: 1271-7, 1982.    ^cY#v44n2a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#94#90#article#117#</font></p>     ^cY#
v44n2a02.htm##
00495000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704024700077002001300324#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#95#91#article#117#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Folstein MF, Folstei
n SE, Folstein PR: "Mini mental state" A practical method for grading the cognit
ive state of patient for the clinician. J Psychiatr Res 12: 189-98, 1975.    ^cY
#v44n2a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#96#92#article#117#</font></p>     ^cY#
v44n2a02.htm##
00471000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704022300077002001300300#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#97#93#article#117#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Appenzeller S, Fujis
awa G, Costallat LTL: Dist&uacute;rbios cognitivos no l&uacute;pus eritematoso s
ist&ecirc;mico. Rev Bras Reumatol 39: 12-8, 1999.    ^cY#v44n2a02.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#98#94#article#117#</font></p>     ^cY#
v44n2a02.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704025300078002001300331#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#99#95#article#117#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Rahman P, Glagman 
DD, Urowitz MB, et al: Early damage as measured by the SLICC/ACR damage index is
 a predictor of mortality in systemic lupus erythematosus. Lupus 10: 93-6, 2001.
    ^cY#v44n2a02.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002000076002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#100#96#article#117#</font></p>     ^cY
#v44n2a02.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704026400079002001300343#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#101#97#article#117#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Stoll T, Seifert 
B, Isenberg DA: SLICC/ACR damage index is valid, and renal and pulmonary organ s
cores are predictors of severe outcome in patients with SLE. Br J Rheumatol 35: 
248-5, 1996.    ^cY#v44n2a02.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002000076002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#102#98#article#117#</font></p>     ^cY
#v44n2a02.htm##
00505000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704025500079002001300334#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#103#99#article#117#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Stoll T, Stucki G
, Malik J, et al: Association of the SLICC/ACR damage index with measures of dis
ease activity and health status in patients with SLE. J Rheumatol 24: 309-13, 19
97.    ^cY#v44n2a02.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#104#100#article#117# </font></p>     ^
cY#v44n2a02.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023300080002001300313#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#105#101#article#117#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Zonana-Nacach A,
 Barr SG, Magder LS, et al: Damage in systemic lupus erythematosus and its assoc
iation with corticosteroids. Arthritis Rheum 43: 1801-8, 2000.    ^cY#v44n2a02.h
tm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#106#102#article#117#</font></p>     ^c
Y#v44n2a02.htm##
00421000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017000080002001300250#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#107#103#article#117#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Gorgos L, Goldma
n D, Petri M: The ACR/SLICC damage index in SLE. Arthritis Rheum 36: S68, 1993. 
   ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#108#104#article#117#</font></p>     ^c
Y#v44n2a02.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#109#105#article#117#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Karlson EW, Dalt
roy LH, Lew RA, et al: The relationship of socioeconomic status, race, and modif
iable risk factor to outcomes in patientes with SLE. Arthritis Rheum 40: 47-56, 
1996.    ^cY#v44n2a02.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#110#106#article#117#</font></p>     ^c
Y#v44n2a02.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#111#107#article#117#<p>&nbsp;</p>     
^cY#v44n2a02.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#112#108#article#117#<p>&nbsp;</p>     
^cY#v44n2a02.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022900077002001300306#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#113#109#article#117#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a href="#linkinicio"><img src="/im
g/revistas/rbr/v44n2/seta.jpg" border="0"></a><a name="linkcorresp"></a> <b>Ende
re&ccedil;o para correspond&ecirc;ncia:</b>    ^cY#v44n2a02.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003200077002001300109#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#114#110#article#117#<br>  Simone Appen
zeller    ^cY#v44n2a02.htm##
00346000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704011000077002001300187#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#115#111#article#117#<br> Departamento 
de cl&iacute;nica m&eacute;dica, Faculdade de Ci&ecirc;ncias M&eacute;dicas, Uni
camp    ^cY#v44n2a02.htm##
00288000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005200077002001300129#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#116#112#article#117#<br> CEP 13081-970
, Campinas, SP</font></p>     ^cY#v44n2a02.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009400077002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#117#113#article#117#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Recebido em 24/02/2003.    ^cY#v44n
2a02.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#118#114#article#117#<br>  Aprovado, ap
&oacute;s revis&atilde;o, em 11/03/2004.</font></p>     ^cY#v44n2a02.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#119#115#article#117#<p>&nbsp;</p>     
^cY#v44n2a02.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#120#116#article#117#<p>&nbsp;</p>     
^cY#v44n2a02.htm##
00606000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704037000077002001300447#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a02.htm#S#p#121#117#article#117#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a name="link01"></a><a href="#link
inicio">*</a> 	Trabalho realizado com bolsa de inicia&ccedil;&atilde;o cient&iac
ute;fica da Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa do Estado de S&at
ilde;o Paulo (Fapesp) e com os Fundos Remanescentes da Sociedade Brasileira de R
eumatologia.</font></p>     ^cY#v44n2a02.htm##
00693000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100020000930100
01400113810000600127012016100133030000900294066001000303031000300313014000800316
065000900324064000500333865000900338002001300347035001000360801000900370#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#c#122#1#article#15#1#^rND^sCerve
ra^nR#^rND^sKhamashta^nMA#^rND^sFont^nJ#et al#Morbidity and mortality in systemi
c lupus erythematosus during a 10-year period: a comparison of early and late ma
nifestations in a cohort of 1,000 patients^len#Medicine#Baltimore#82#299-308#200
30000#2003#20040400#v44n2a02.htm#0025-7974#Medicine##
00641000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100017000910100
01700108810000600125012012400131030001400255031000300269014000700272065000900279
064000500288865000900293002001300302035001000315801001400325#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a02.htm#S#c#123#2#article#15#2#^rND^sMoss^nKE#^rND^sIo
annou^nY#^rND^sSultan^nSM#et al#Outcome of a cohort of 300 patients with systemi
c lupus erythematosus attending a dedicated clinic for over two decades^len#Ann 
Rheum Dis#61#409-13#20020000#2002#20040400#v44n2a02.htm#0003-4967#Ann Rheum Dis#
#
00547000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100015000920120
06600107030002000173031000300193014000700196065000900203064000500212865000900217
002001300226035001000239801002000249#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a02.htm#S#c#124#3#article#15#3#^rND^sTrager^nJ#^rND^sWard^nMM#Mortality and ca
uses of death in systemic lupus erythematosus^len#Curr Opin Rheumatol#13#345-51#
20010000#2001#20040400#v44n2a02.htm#1040-8711#Curr Opin Rheumatol##
00487000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760120025000910300
02400116031000300140014000800143065000900151064000500160865000900165002001300174
035001000187801002400197#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a02.htm#S#
c#125#4#article#15#4#^rND^sPetri^nM#Hopkins Lupus Cohort^len#Rheum Dis Clin Nort
h Am#26#199-213#20000000#2000#20040400#v44n2a02.htm#0889-857X#Rheum Dis Clin Nor
th Am##
00706000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100018000930100
01900111810000600130012018000136030001600316031000300332014000700335065000900342
064000500351865000900356002001300365035001000378801001600388#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a02.htm#S#c#126#5#article#15#5#^rND^sGladman^nD#^rND^s
Glinzler^nE#^rND^sGoldsmith^nC#et al#The development and initial validation of t
he Systemic lupus International Collaborating Clinics/American College of Rheuma
tology damage index for systemic lupus erythematosus^len#Arthritis Rheum#39#363-
78#19960000#1996#20040400#v44n2a02.htm#0004-3591#Arthritis rheum##
00634000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100023000760100025000990100
01500124810000600139012012000145030000600265031000200271014000700273065000900280
064000500289865000900294002001300303035001000316801000600326#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a02.htm#S#c#127#6#article#15#6#^rND^sZonana-Nacach^nA#
^rND^sCamargo-Coronel^nA#^rND^sYanez^nP#et al#Measurement of damage in 210 mexic
an patients with systemic lupus erythematosus: relationship with disease duratio
n^len#Lupus#7#119-23#19980000#1998#20040400#v44n2a02.htm#0961-2033#Lupus##
00603000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760100016000900100
01600106810000600122012008500128030001600213031000300229014000700232065000900239
064000500248865000900253002001300262035001000275801001600285#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a02.htm#S#c#128#7#article#15#7#^rND^sTan^nEM#^rND^sCoh
en^nAS#^rND^sFries^nJF#et al#The 1982 revised criteria for the classification of
 systemic lupus erythematosus^len#Arthritis Rheum#25#1271-7#19820000#1982#200404
00#v44n2a02.htm#0004-3591#Arthritis rheum##
00615000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100019000950100
01900114012010400133030001600237031000300253014000700256065000900263064000500272
865000900277002001300286035001000299801001600309#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a02.htm#S#c#129#8#article#15#8#^rND^sFolstein^nMF#^rND^sFolstein^n
SE#^rND^sFolstein^nPR#"Mini mental state" A practical method for grading the cog
nitive state of patient for the clinician^len#J Psychiatr Res#12#189-98#19750000
#1975#20040400#v44n2a02.htm#0022-3956#J Psychiatr Res##
00535000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100021000760100018000970100
02100115012005700136030001800193710000200211031000300213014000500216065000900221
064000500230865000900235002001300244#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a02.htm#S#c#130#9#article#15#9#^rND^sAppenzeller^nS#^rND^sFujisawa^nG#^rND^sCo
stallat^nLTL#Distúrbios cognitivos no lúpus eritematoso sistêmico^lpt#Rev Bras R
eumatol#2#39#12-8#19990000#1999#20040400#v44n2a02.htm##
00623000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01800112810000600130012011900136030000600255031000300261014000500264065000900269
064000500278865000900283002001300292035001000305801000600315#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a02.htm#S#c#131#10#article#15#10#^rND^sRahman^nP#^rND^
sGlagman^nDD#^rND^sUrowitz^nMB#et al#Early damage as measured by the SLICC/ACR d
amage index is a predictor of mortality in systemic lupus erythematosus^len#Lupu
s#10#93-6#20010000#2001#20040400#v44n2a02.htm#0961-2033#Lupus##
00632000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01900110012012800129030001500257031000300272014000600275065000900281064000500290
865000900295002001300304035001000317801001500327#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a02.htm#S#c#132#11#article#15#11#^rND^sStoll^nT#^rND^sSeifert^nB#^
rND^sIsenberg^nDA#SLICC/ACR damage index is valid, and renal and pulmonary organ
 scores are predictors of severe outcome in patients with SLE^len#Br J Rheumatol
#35#248-5#19960000#1996#20040400#v44n2a02.htm#0263-7103#Br J Rheumatol##
00631000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100016000930100
01500109810000600124012011900130030001200249031000300261014000700264065000900271
064000500280865000900285002001300294035001000307801001200317#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a02.htm#S#c#133#12#article#15#12#^rND^sStoll^nT#^rND^s
Stucki^nG#^rND^sMalik^nJ#et al#Association of the SLICC/ACR damage index with me
asures of disease activity and health status in patients with SLE^len#J Rheumato
l#24#309-13#19970000#1997#20040400#v44n2a02.htm#0315-162X#J Rheumatol##
00463000000000217000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100015001010100
01700116810000600133012008400139865000900223002001300232#v44n2#V:\SciELO\serial\
rbr\v44n2\markup\v44n2a02.htm#S#c#134#13#article#15#13#^rND^sZonana-Nacach^nA#^r
ND^sBarr^nSG#^rND^sMagder^nLS#et al#Damage in systemic lupus erythematosus and i
ts association with corticosteroids^len#20040400#v44n2a02.htm##
00539000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940100
01500111012003800126030001600164031000300180020000400183065000900187064000500196
865000900201002001300210035001000223801001600233#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a02.htm#S#c#135#14#article#15#14#^rND^sGorgos^nL#^rND^sGoldman^nD#
^rND^sPetri^nM#The ACR/SLICC damage index in SLE^len#Arthritis Rheum#36#S68#1997
0000#1993#20040400#v44n2a02.htm#0004-3591#Arthritis rheum##
00636000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01400114810000600128012011300134030001600247031000300263014000600266065000900272
064000500281865000900286002001300295035001000308801001600318#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a02.htm#S#c#136#15#article#15#15#^rND^sKarlson^nEW#^rN
D^sDaltroy^nLH#^rND^sLew^nRA#et al#The relationship of socioeconomic status, rac
e, and modifiable risk factor to outcomes in patientes with SLE^len#Arthritis Rh
eum#40#47-56#19960000#1996#20040400#v44n2a02.htm#0004-3591#Arthritis rheum##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#o#1#1#article#1#
20110406#085347#v44n2a03.htm#228##
06082000000000613000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030002100106
03100030012703200020013006500090013201400110014103500100015201201510016201201280
03130100038004410100030004790700017005090832411005260850008029370850040029450850
02402985085002203009085002703031085002603058083218003084085000805264085004105272
08500220531308500220533508500250535708500260538211700060540807200030541411200090
5417111001005426114000905436113001005445002001305455#v44n2#V:\SciELO\serial\rbr\
v44n2\markup\v44n2a03.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#03#RBR160#nd#R
ev. Bras. Reumatol.#44#2#20040400#^f115^l122#0482-5004#Avaliação do índice de da
nos permanentes através de SLICC/ACR-DI em pacientes com mais de cinco anos de d
iagnóstico de lúpus eritematoso sistêmico^lpt#Cumulative organ damage evaluation
 using SLICC/ACR-DI in patients with more than five years of systemic lupus eryt
hematosus^len#^rND^nElaine Marcelina Claudio^sSella#^rND^1A01^nEmilia Inoue^sSat
o#Unifesp/EPM^iA01#^lpt^aOBJETIVO: avaliar a freqüência dos diferentes tipos de 
lesões irreversíveis que ocorrem em pacientes com lúpus eritematoso sistêmico (L
ES) com mais de cinco anos de doença. MÉTODOS: noventa pacientes do sexo feminin
o com diagnóstico de LES há mais de cinco anos foram avaliadas quanto às lesões 
irreversíveis em órgãos e/ou sistemas, através da aplicação do índice de dano do
 Systemic Lupus International Collaborating Clinics/American College of Rheumato
logy (SLICC/ACR-DI). RESULTADOS: a média de idade das pacientes foi 38 ± 10 anos
 (60% da cor branca) e o tempo de diagnóstico de LES foi 128 ± 59 meses; a média
 do número de critérios do ACR foi 7 ± 1 e a média dos escores do SLICC/ACR-DI f
oi 2 ± 2. Setenta e dois por cento das pacientes apresentaram SLICC/ ACR-DI > 1.
 Houve tendência à associação estatística entre idade atual mais avançada e pres
ença de lesões permanentes (p=0,06). Não observamos associação estatisticamente 
significante entre idade na época do diagnóstico de LES, tempo de doença ou núme
ro de critérios do ACR e presença de danos permanentes (p > 0,05). Foi encontrad
a associação significante entre lesão discóide e presença de dano irreversível (
p=0,049) e entre presença de anticorpos antidsDNA e lesão irreversível (p=0,013)
. Quanto aos tipos de danos permanentes, relatamos alterações cardiovasculares e
m 21%, dermatológicas em 21%, musculoesqueléticas em 17%, gonadais em 16%, neuro
psiquiátricas em 13%, oculares em 12%, renais em 12%, vasculares periféricas em 
10%, pulmonares em 6%, endócrinas em 6% e malignidades em 3% dos casos. Não houv
e associação estatisticamente significante entre tempo de uso de prednisona e pr
esença de alteração irreversível (p=0,725), entretanto, houve associação estatis
ticamente significante entre maior dose cumulativa de prednisona e danos permane
ntes (p=0,013). Houve tendência à associação estatística entre menor tempo de us
o de agentes antimaláricos e danos permanentes (p=0,068). CONCLUSÕES: lesões irr
eversíveis foram encontradas em 72% das pacientes com diagnóstico de LES há mais
 de cinco anos. As lesões mais prevalentes foram os acometimentos cardiovascular
es, dermatológicos, musculoesqueléticos e gonadais. Dose cumulativa total de pre
dnisona foi a variável que apresentou associação significante com presença de le
sões irreversíveis em pacientes com LES, sugerindo a importância de estratégias 
para poupar corticoesteróides#^dnd^i1#^tm^lpt^klúpus eritematoso sistêmico^i1#^t
m^lpt^kprognóstico^i1#^tm^lpt^kmorbidade^i1#^tm^lpt^kíndice de dano^i1#^tm^lpt^k
SLICC^i1^sACR-DI#^len^aOBJECTIVE: to evaluate the frequency of different types o
f irreversible lesions in systemic lupus erythematosus (SLE) patients with more 
than five years of disease. METHODS: ninety female SLE patients with more than f
ive years of disease were evaluated concerning the irreversible damage score usi
ng Systemic Lupus International Collaborating Clinics/American College of Rheuma
tology Damage Index for systemic lupus erythematosus (SLICC/ACR/DI). RESULTS: pa
tients mean age was 38 ± 10 years old (60% white). The average time after diagno
sis was 128 ± 59 months, the mean number of ACR criteria was 7 ± 1, and the mean
 SLICC/ACR-DI score was 2 ± 2. Seventy-two percent of patients presented SLICC/A
CRDI score > 1. We found a tendency to association between actual older age and 
presence of damage (p = 0.06). We did not find association between age at time o
f SLE diagnosis, disease duration or number of ACR criteria and presence of irre
versible damage (p > 0.05), but we found a significant association between disco
id lesion and presence of damage (p = 0.049) as well as between positive double 
strand anti-DNA antibody and damage (p = 0.013). Concerning the type of irrevers
ible lesions, we found cardiovascular damage in 21%, dermatological lesions in 2
1%, musculoskeletal lesions in 17%, gonadal lesions in 16%, neuropsychiatric dam
age in 13%, eye lesions in 12%, renal lesions in 12%, peripheral vascular lesion
s in 10%, pulmonary damage in 6%, endocrinological damage in 6% and malignances 
in 3%. There was no significant association between duration of prednisone use a
nd damage (p = 0.725), however we found a significant association between predni
sone cumulative dose and presence of damage (p = 0.013). We found a tendency to 
association between lower duration of antimalarial drugs and irreversible damage
 (p = 0.068). CONCLUSIONS: irreversible lesions were found in 72% of SLE patient
s with more than five years of disease. The more prevalent lesions were cardiova
scular, dermatological, musculoskeletal and gonadal. The cumulative dose of pred
nisone showed significant association with presence of damage, suggesting the im
portance of spare steroid strategies#^dnd^i2#^tm^len^ksystemic lupus erythematos
us^i2#^tm^len^kprognosis^i2#^tm^len^kmorbidity^i2#^tm^len^kdamage index^i2#^tm^l
en^kSLICC^i2^sACR-DI#other#40#20030423#23/4/2003#20030930#30/9/2003#v44n2a03.htm
##
06178000000000613000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030002100106
03100030012703200020013006500090013201400110014103500100015201201580016201201350
03200100038004550100030004930700017005230832452005400850008029920850040030000850
02403040085002203064085002703086085002603113083222103139085000805360085004105368
08500220540908500220543108500250545308500260547811700060550407200030551011200090
5513111001005522114000905532113001005541002001305551#v44n2#V:\SciELO\serial\rbr\
v44n2\markup\v44n2a03.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#03#RBR160#nd#R
ev. Bras. Reumatol.#44#2#20040400#^f115^l122#0482-5004#<b>Avaliação do índice de
 danos permanentes através de SLICC/ACR-DI em pacientes com mais de cinco anos d
e diagnóstico de lúpus eritematoso sistêmico</b>^lpt#<b>Cumulative organ damage 
evaluation using SLICC/ACR-DI in patients with more than five years of systemic 
lupus erythematosus</b>^len#^rND^nElaine Marcelina Claudio^sSella#^rND^1A01^nEmi
lia Inoue^sSato#Unifesp/EPM^iA01#^lpt^a<b>OBJETIVO:</b> avaliar a freqüência dos
 diferentes tipos de lesões irreversíveis que ocorrem em pacientes com lúpus eri
tematoso sistêmico (LES) com mais de cinco anos de doença. <b>MÉTODOS:</b> noven
ta pacientes do sexo feminino com diagnóstico de LES há mais de cinco anos foram
 avaliadas quanto às lesões irreversíveis em órgãos e/ou sistemas, através da ap
licação do índice de dano do Systemic Lupus International Collaborating Clinics/
American College of Rheumatology (SLICC/ACR-DI). <b>RESULTADOS: </b>a média de i
dade das pacientes foi 38 ± 10 anos (60% da cor branca) e o tempo de diagnóstico
 de LES foi 128 ± 59 meses; a média do número de critérios do ACR foi 7 ± 1 e a 
média dos escores do SLICC/ACR-DI foi 2 ± 2. Setenta e dois por cento das pacien
tes apresentaram SLICC/ ACR-DI <u>&gt;</u> 1. Houve tendência à associação estat
ística entre idade atual mais avançada e presença de lesões permanentes (p=0,06)
. Não observamos associação estatisticamente significante entre idade na época d
o diagnóstico de LES, tempo de doença ou número de critérios do ACR e presença d
e danos permanentes (p &gt; 0,05). Foi encontrada associação significante entre 
lesão discóide e presença de dano irreversível (p=0,049) e entre presença de ant
icorpos antidsDNA e lesão irreversível (p=0,013). Quanto aos tipos de danos perm
anentes, relatamos alterações cardiovasculares em 21%, dermatológicas em 21%, mu
sculoesqueléticas em 17%, gonadais em 16%, neuropsiquiátricas em 13%, oculares e
m 12%, renais em 12%, vasculares periféricas em 10%, pulmonares em 6%, endócrina
s em 6% e malignidades em 3% dos casos. Não houve associação estatisticamente si
gnificante entre tempo de uso de prednisona e presença de alteração irreversível
 (p=0,725), entretanto, houve associação estatisticamente significante entre mai
or dose cumulativa de prednisona e danos permanentes (p=0,013). Houve tendência 
à associação estatística entre menor tempo de uso de agentes antimaláricos e dan
os permanentes (p=0,068). <b>CONCLUSÕES:</b> lesões irreversíveis foram encontra
das em 72% das pacientes com diagnóstico de LES há mais de cinco anos. As lesões
 mais prevalentes foram os acometimentos cardiovasculares, dermatológicos, muscu
loesqueléticos e gonadais. Dose cumulativa total de prednisona foi a variável qu
e apresentou associação significante com presença de lesões irreversíveis em pac
ientes com LES, sugerindo a importância de estratégias para poupar corticoesteró
ides#^dnd^i1#^tm^lpt^klúpus eritematoso sistêmico^i1#^tm^lpt^kprognóstico^i1#^tm
^lpt^kmorbidade^i1#^tm^lpt^kíndice de dano^i1#^tm^lpt^kSLICC^i1^sACR-DI#^len^a<b
>OBJECTIVE:</b> to evaluate the frequency of different types of irreversible les
ions in systemic lupus erythematosus (SLE) patients with more than five years of
 disease. <b>METHODS:</b> ninety female SLE patients with more than five years o
f disease were evaluated concerning the irreversible damage score using Systemic
 Lupus International Collaborating Clinics/American College of Rheumatology Dama
ge Index for systemic lupus erythematosus (SLICC/ACR/DI). <b>RESULTS:</b> patien
ts mean age was 38 ± 10 years old (60% white). The average time after diagnosis 
was 128 ± 59 months, the mean number of ACR criteria was 7 ± 1, and the mean SLI
CC/ACR-DI score was 2 ± 2. Seventy-two percent of patients presented SLICC/ACRDI
 score <u>&gt;</u> 1. We found a tendency to association between actual older ag
e and presence of damage (p = 0.06). We did not find association between age at 
time of SLE diagnosis, disease duration or number of ACR criteria and presence o
f irreversible damage (p &gt; 0.05), but we found a significant association betw
een discoid lesion and presence of damage (p = 0.049) as well as between positiv
e double strand anti-DNA antibody and damage (p = 0.013). Concerning the type of
 irreversible lesions, we found cardiovascular damage in 21%, dermatological les
ions in 21%, musculoskeletal lesions in 17%, gonadal lesions in 16%, neuropsychi
atric damage in 13%, eye lesions in 12%, renal lesions in 12%, peripheral vascul
ar lesions in 10%, pulmonary damage in 6%, endocrinological damage in 6% and mal
ignances in 3%. There was no significant association between duration of prednis
one use and damage (p = 0.725), however we found a significant association betwe
en prednisone cumulative dose and presence of damage (p = 0.013). We found a ten
dency to association between lower duration of antimalarial drugs and irreversib
le damage (p = 0.068). <b>CONCLUSIONS:</b> irreversible lesions were found in 72
% of SLE patients with more than five years of disease. The more prevalent lesio
ns were cardiovascular, dermatological, musculoskeletal and gonadal. The cumulat
ive dose of prednisone showed significant association with presence of damage, s
uggesting the importance of spare steroid strategies#^dnd^i2#^tm^len^ksystemic l
upus erythematosus^i2#^tm^len^kprognosis^i2#^tm^len^kmorbidity^i2#^tm^len^kdamag
e index^i2#^tm^len^kSLICC^i2^sACR-DI#other#40#20030423#23/4/2003#20030930#30/9/2
003#v44n2a03.htm##
06422000000000637000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000400107121000300111049000700114158000300121
03000200012403100030014403200020014706500090014901400110015803500100016901201510
01790120128003300100038004580100030004960700019005260832528005450850008030730850
04003081085002403121085002203145085002703167085002603194083227103220085000805491
08500410549908500220554008500220556208500250558408500260560911700060563507200030
5641112000905644111001005653114000905663113001005672002001305682008008905695#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#l#4#1#article#1#^mmar./abr.^
a2004#oa#pt#br1.1#1#4.0#tab#03#RBR160#nd#Rev. Bras. Reumatol#44#2#20040400#^f115
^l122#0482-5004#Avaliação do índice de danos permanentes através de SLICC/ACR-DI
 em pacientes com mais de cinco anos de diagnóstico de lúpus eritematoso sistêmi
co^lpt#Cumulative organ damage evaluation using SLICC/ACR-DI in patients with mo
re than five years of systemic lupus erythematosus^len#^rND^nElaine Marcelina Cl
audio^sSella#^rND^1A01^nEmilia Inoue^sSato#^iA01^1Unifesp/EPM#^lpt^aOBJETIVO: av
aliar a freqüência dos diferentes tipos de lesões irreversíveis que ocorrem em p
acientes com lúpus eritematoso sistêmico (LES) com mais de cinco anos de doença.
 MÉTODOS: noventa pacientes do sexo feminino com diagnóstico de LES há mais de c
inco anos foram avaliadas quanto às lesões irreversíveis em órgãos e/ou sistemas
, através da aplicação do índice de dano do Systemic Lupus International Collabo
rating Clinics/American College of Rheumatology (SLICC/ACR-DI). RESULTADOS: a mé
dia de idade das pacientes foi 38 ± 10 anos (60 por cento da cor branca) e o tem
po de diagnóstico de LES foi 128 ± 59 meses; a média do número de critérios do A
CR foi 7 ± 1 e a média dos escores do SLICC/ACR-DI foi 2 ± 2. Setenta e dois por
 cento das pacientes apresentaram SLICC/ ACR-DI > 1. Houve tendência à associaçã
o estatística entre idade atual mais avançada e presença de lesões permanentes (
p=0,06). Não observamos associação estatisticamente significante entre idade na 
época do diagnóstico de LES, tempo de doença ou número de critérios do ACR e pre
sença de danos permanentes (p > 0,05). Foi encontrada associação significante en
tre lesão discóide e presença de dano irreversível (p=0,049) e entre presença de
 anticorpos antidsDNA e lesão irreversível (p=0,013). Quanto aos tipos de danos 
permanentes, relatamos alterações cardiovasculares em 21 por cento, dermatológic
as em 21 por cento, musculoesqueléticas em 17 por cento, gonadais em 16 por cent
o, neuropsiquiátricas em 13 por cento, oculares em 12 por cento, renais em 12 po
r cento, vasculares periféricas em 10 por cento, pulmonares em 6 por cento, endó
crinas em 6 por cento e malignidades em 3 por cento dos casos. Não houve associa
ção estatisticamente significante entre tempo de uso de prednisona e presença de
 alteração irreversível (p=0,725), entretanto, houve associação estatisticamente
 significante entre maior dose cumulativa de prednisona e danos permanentes (p=0
,013). Houve tendência à associação estatística entre menor tempo de uso de agen
tes antimaláricos e danos permanentes (p=0,068). CONCLUSÕES: lesões irreversívei
s foram encontradas em 72 por cento das pacientes com diagnóstico de LES há mais
 de cinco anos. As lesões mais prevalentes foram os acometimentos cardiovascular
es, dermatológicos, musculoesqueléticos e gonadais. Dose cumulativa total de pre
dnisona foi a variável que apresentou associação significante com presença de le
sões irreversíveis em pacientes com LES, sugerindo a importância de estratégias 
para poupar corticoesteróides#^dnd^i1#^tm^lpt^klúpus eritematoso sistêmico^i1#^t
m^lpt^kprognóstico^i1#^tm^lpt^kmorbidade^i1#^tm^lpt^kíndice de dano^i1#^tm^lpt^k
SLICC^i1^sACR-DI#^len^aOBJECTIVE: to evaluate the frequency of different types o
f irreversible lesions in systemic lupus erythematosus (SLE) patients with more 
than five years of disease. METHODS: ninety female SLE patients with more than f
ive years of disease were evaluated concerning the irreversible damage score usi
ng Systemic Lupus International Collaborating Clinics/American College of Rheuma
tology Damage Index for systemic lupus erythematosus (SLICC/ACR/DI). RESULTS: pa
tients mean age was 38 ± 10 years old (60 percent white). The average time after
 diagnosis was 128 ± 59 months, the mean number of ACR criteria was 7 ± 1, and t
he mean SLICC/ACR-DI score was 2 ± 2. Seventy-two percent of patients presented 
SLICC/ACRDI score > 1. We found a tendency to association between actual older a
ge and presence of damage (p = 0.06). We did not find association between age at
 time of SLE diagnosis, disease duration or number of ACR criteria and presence 
of irreversible damage (p > 0.05), but we found a significant association betwee
n discoid lesion and presence of damage (p = 0.049) as well as between positive 
double strand anti-DNA antibody and damage (p = 0.013). Concerning the type of i
rreversible lesions, we found cardiovascular damage in 21 percent, dermatologica
l lesions in 21 percent, musculoskeletal lesions in 17 percent, gonadal lesions 
in 16 percent, neuropsychiatric damage in 13 percent, eye lesions in 12 percent,
 renal lesions in 12 percent, peripheral vascular lesions in 10 percent, pulmona
ry damage in 6 percent, endocrinological damage in 6 percent and malignances in 
3 percent. There was no significant association between duration of prednisone u
se and damage (p = 0.725), however we found a significant association between pr
ednisone cumulative dose and presence of damage (p = 0.013). We found a tendency
 to association between lower duration of antimalarial drugs and irreversible da
mage (p = 0.068). CONCLUSIONS: irreversible lesions were found in 72 percent of 
SLE patients with more than five years of disease. The more prevalent lesions we
re cardiovascular, dermatological, musculoskeletal and gonadal. The cumulative d
ose of prednisone showed significant association with presence of damage, sugges
ting the importance of spare steroid strategies#^dnd^i2#^tm^len^ksystemic lupus 
erythematosus^i2#^tm^len^kprognosis^i2#^tm^len^kmorbidity^i2#^tm^len^kdamage ind
ex^i2#^tm^len^kSLICC^i2^sACR-DI#other#40#20030423#23/4/2003#20030930#30/9/2003#v
44n2a03.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S04
82-50042004000200003##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#5#1#article#184#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v44n2a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#6#2#article#184#<p>&nbsp;</p>     ^cY#
v44n2a03.htm##
00599000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704036700073002001300440#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#7#3#article#184#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="linkinicio"></a><b>Avalia&cced
il;&atilde;o do &iacute;ndice de danos permanentes atrav&eacute;s de SLICC/ACR-D
I em pacientes com mais de cinco anos de diagn&oacute;stico de l&uacute;pus erit
ematoso sist&ecirc;mico<sup>(</sup><a href="#link01"><sup>*</sup></a><sup>)</sup
></b></font></p>     ^cY#v44n2a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#8#4#article#184#<p>&nbsp;</p>     ^cY#
v44n2a03.htm##
00448000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704021600073002001300289#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#9#5#article#184#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><b>Cumulative organ damage evaluation u
sing SLICC/ACR-DI in patients with    more than five years of systemic lupus ery
thematosus</b></font></p>     ^cY#v44n2a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#10#6#article#184#<p>&nbsp;</p>     ^cY
#v44n2a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#11#7#article#184#<p>&nbsp;</p>     ^cY
#v44n2a03.htm##
00397000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704016400074002001300238#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#12#8#article#184#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Elaine Marcelina Claudio Sella<sup>
I</sup>; Emilia Inoue Sato<sup>II</sup></b></font></p>     ^cY#v44n2a03.htm##
00355000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704012200074002001300196#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#13#9#article#184#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Mestre em reumatologia pel
a Unifesp/EPM    ^cY#v44n2a03.htm##
00305000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007100075002001300146#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#14#10#article#184#<br> <sup>II</sup>Pr
ofessora titular da Unifesp/EPM</font></p>     ^cY#v44n2a03.htm##
00386000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015200075002001300227#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#15#11#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#linkcorresp">Endere&ccedil;
o para correspond&ecirc;ncia</a></font></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#16#12#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#17#13#article#184#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v44n2a03.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#18#14#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v44n
2a03.htm##
00529000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029500075002001300370#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#19#15#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OBJETIVO:</b> avaliar a freq&uuml;
&ecirc;ncia dos diferentes tipos de les&otilde;es irrevers&iacute;veis que ocorr
em em pacientes com l&uacute;pus eritematoso sist&ecirc;mico (LES) com mais de c
inco anos de doen&ccedil;a.    ^cY#v44n2a03.htm##
00642000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040800075002001300483#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#20#16#article#184#<br>  <b>M&Eacute;TO
DOS:</b> noventa pacientes do sexo feminino com diagn&oacute;stico de LES h&aacu
te; mais de cinco anos foram avaliadas quanto &agrave;s les&otilde;es irrevers&i
acute;veis em &oacute;rg&atilde;os e/ou sistemas, atrav&eacute;s da aplica&ccedi
l;&atilde;o do &iacute;ndice de dano do Systemic Lupus International Collaborati
ng Clinics/American College of Rheumatology (SLICC/ACR-DI).     ^cY#v44n2a03.htm
##
02120000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704188600075002001301961#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#21#17#article#184#<br> <b>RESULTADOS: 
</b>a m&eacute;dia de idade das pacientes foi 38 ± 10 anos (60% da cor branca) e
 o tempo de diagn&oacute;stico de LES foi 128 ± 59 meses; a m&eacute;dia do n&ua
cute;mero de crit&eacute;rios do ACR foi 7 ± 1 e a m&eacute;dia dos escores do S
LICC/ACR-DI foi 2 ± 2. Setenta e dois por cento das pacientes apresentaram SLICC
/ ACR-DI <u>&gt;</u> 1. Houve tend&ecirc;ncia &agrave; associa&ccedil;&atilde;o 
estat&iacute;stica entre idade atual mais avan&ccedil;ada e presen&ccedil;a de l
es&otilde;es permanentes (p=0,06). N&atilde;o observamos associa&ccedil;&atilde;
o estatisticamente significante entre idade na &eacute;poca do diagn&oacute;stic
o de LES, tempo de doen&ccedil;a ou n&uacute;mero de crit&eacute;rios do ACR e p
resen&ccedil;a de danos permanentes (p &gt; 0,05). Foi encontrada associa&ccedil
;&atilde;o significante entre les&atilde;o disc&oacute;ide e presen&ccedil;a de 
dano irrevers&iacute;vel (p=0,049) e entre presen&ccedil;a de anticorpos antidsD
NA e les&atilde;o irrevers&iacute;vel (p=0,013). Quanto aos tipos de danos perma
nentes, relatamos altera&ccedil;&otilde;es cardiovasculares em 21%, dermatol&oac
ute;gicas em 21%, musculoesquel&eacute;ticas em 17%, gonadais em 16%, neuropsiqu
i&aacute;tricas em 13%, oculares em 12%, renais em 12%, vasculares perif&eacute;
ricas em 10%, pulmonares em 6%, end&oacute;crinas em 6% e malignidades em 3% dos
 casos. N&atilde;o houve associa&ccedil;&atilde;o estatisticamente significante 
entre tempo de uso de prednisona e presen&ccedil;a de altera&ccedil;&atilde;o ir
revers&iacute;vel (p=0,725), entretanto, houve associa&ccedil;&atilde;o estatist
icamente significante entre maior dose cumulativa de prednisona e danos permanen
tes (p=0,013). Houve tend&ecirc;ncia &agrave; associa&ccedil;&atilde;o estat&iac
ute;stica entre menor tempo de uso de agentes antimal&aacute;ricos e danos perma
nentes (p=0,068).     ^cY#v44n2a03.htm##
00836000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060200075002001300677#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#22#18#article#184#<br> <b>CONCLUS&Otil
de;ES:</b> les&otilde;es irrevers&iacute;veis foram encontradas em 72% das pacie
ntes com diagn&oacute;stico de LES h&aacute; mais de cinco anos. As les&otilde;e
s mais prevalentes foram os acometimentos cardiovasculares, dermatol&oacute;gico
s, musculoesquel&eacute;ticos e gonadais. Dose cumulativa total de prednisona fo
i a vari&aacute;vel que apresentou associa&ccedil;&atilde;o significante com pre
sen&ccedil;a de les&otilde;es irrevers&iacute;veis em pacientes com LES, sugerin
do a import&acirc;ncia de estrat&eacute;gias para poupar corticoester&oacute;ide
s.</font></p>     ^cY#v44n2a03.htm##
00471000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023700075002001300312#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#23#19#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> l&uacute;pus e
ritematoso sist&ecirc;mico, progn&oacute;stico, morbidade, &iacute;ndice de dano
, SLICC/ACR-DI.</font></p> <hr size="1" noshade>     ^cY#v44n2a03.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009800075002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#24#20#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v4
4n2a03.htm##
00476000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024200075002001300317#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#25#21#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVE:</b> to evaluate the fre
quency of different types of irreversible lesions in systemic lupus erythematosu
s (SLE) patients with more than five years of disease.    ^cY#v44n2a03.htm##
00535000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030100075002001300376#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#26#22#article#184#<br>  <b>METHODS:</b
> ninety female SLE patients with more than five years of disease were evaluated
 concerning the irreversible damage score using Systemic Lupus International Col
laborating Clinics/American College of Rheumatology Damage Index for systemic lu
pus erythematosus (SLICC/ACR/DI).    ^cY#v44n2a03.htm##
01652000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704141800075002001301493#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#27#23#article#184#<br>  <b>RESULTS:</b
> patients mean age was 38 ± 10 years old (60% white). The average time after di
agnosis was 128 ± 59 months, the mean number of ACR criteria was 7 ± 1, and the 
mean SLICC/ACR-DI score was 2 ± 2. Seventy-two percent of patients presented SLI
CC/ACRDI score <u>&gt;</u> 1. We found a tendency to association between actual 
older age and presence of damage (p = 0.06). We did not find association between
 age at time of SLE diagnosis, disease duration or number of ACR criteria and pr
esence of irreversible damage (p &gt; 0.05), but we found a significant associat
ion between discoid lesion and presence of damage (p = 0.049) as well as between
 positive double strand anti-DNA antibody and damage (p = 0.013). Concerning the
 type of irreversible lesions, we found cardiovascular damage in 21%, dermatolog
ical lesions in 21%, musculoskeletal lesions in 17%, gonadal lesions in 16%, neu
ropsychiatric damage in 13%, eye lesions in 12%, renal lesions in 12%, periphera
l vascular lesions in 10%, pulmonary damage in 6%, endocrinological damage in 6%
 and malignances in 3%. There was no significant association between duration of
 prednisone use and damage (p = 0.725), however we found a significant associati
on between prednisone cumulative dose and presence of damage (p = 0.013). We fou
nd a tendency to association between lower duration of antimalarial drugs and ir
reversible damage (p = 0.068).    ^cY#v44n2a03.htm##
00610000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037600075002001300451#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#28#24#article#184#<br>  <b>CONCLUSIONS
:</b> irreversible lesions were found in 72% of SLE patients with more than five
 years of disease. The more prevalent lesions were cardiovascular, dermatologica
l, musculoskeletal and gonadal. The cumulative dose of prednisone showed signifi
cant association with presence of damage, suggesting the importance of spare ste
roid strategies.</font></p>     ^cY#v44n2a03.htm##
00435000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020100075002001300276#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#29#25#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> systemic lupus eryth
ematosus, prognosis, morbidity, damage index, SLICC/ACR-DI.</font></p> <hr size=
"1" noshade>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#30#26#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#31#27#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#32#28#article#184#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v44n2a03.htm##
00597000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036300075002001300438#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#33#29#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em virtude do diagn&oacute;stico prec
oce, do avan&ccedil;o das t&eacute;cnicas laboratoriais e de novas op&ccedil;&ot
ilde;es terap&ecirc;uticas, o progn&oacute;stico de l&uacute;pus eritematoso sis
t&ecirc;mico (LES) tem melhorado nas &uacute;ltimas d&eacute;cadas<sup>(1-5)</su
p>.</font></p>     ^cY#v44n2a03.htm##
01501000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704126700075002001301342#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#34#30#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">V&aacute;rios autores t&ecirc;m avali
ado os poss&iacute;veis fatores relacionados ao progn&oacute;stico dos pacientes
 com LES e os resultados mostramse conflitantes. Muitos foram os fatores associa
dos ao pior progn&oacute;stico, como idade mais avan&ccedil;ada na ocasi&atilde;
o do diagn&oacute;stico de LES<sup>(6,7)</sup>, ra&ccedil;a negra<sup>(6,8,9)</s
up>, sexo masculino<sup>(3,10)</sup>, n&iacute;vel s&oacute;cio-econ&ocirc;mico<
sup>(5,9)</sup>, doen&ccedil;a renal<sup>(3,7,11-13)</sup>, envolvimento pulmona
r<sup>(7,13)</sup>, envolvimento c&aacute;rdio-pulmonar<sup>(13)</sup>, comprome
timento do sistema nervoso central e/ou perif&eacute;rico<sup>(12)</sup>, trombo
citopenia<sup>(3,6,7,11)</sup>, tromboembolismo<sup>(11)</sup>, vasculite digita
l<sup>(12)</sup>, hipertens&atilde;o arterial sist&ecirc;mica (HAS)<sup>(12,14)<
/sup>, maior atividade de doen&ccedil;a pelo escore do <i>disease activity index
 for systemic lupus erythematosus</i> (SLE-DAI)&gt;10<sup>(11)</sup> e SLE-DAI <
u>&gt;</u>20<sup>(7)</sup> na apresenta&ccedil;&atilde;o da doen&ccedil;a e freq
&uuml;&ecirc;ncia de exacerba&ccedil;&otilde;es do LES ap&oacute;s o seu diagn&o
acute;stico<sup>(15)</sup>.</font></p>     ^cY#v44n2a03.htm##
01891000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704165700075002001301732#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#35#31#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Por ser o LES doen&ccedil;a polim&oac
ute;rfica e cr&ocirc;nica, caracterizada por amplo espectro de manifesta&ccedil;
&otilde;es cl&iacute;nicas com per&iacute;odos de remiss&otilde;es e exacerba&cc
edil;&otilde;es, torna-se imprescind&iacute;vel a exist&ecirc;ncia de uma medida
 cl&iacute;nica progn&oacute;stica na evolu&ccedil;&atilde;o da doen&ccedil;a. N
esse sentido, a an&aacute;lise peri&oacute;dica das inj&uacute;rias irrevers&iac
ute;veis decorrentes do LES pode ser avaliada por instrumento validado, atrav&ea
cute;s dos crit&eacute;rios propostos pelo <i>Systemic Lupus International Colla
borating Clinics/American College of Rheumatology damage index for systemic lupu
s erythematosus</i> (SLICC/ACR-DI). Este &iacute;ndice tem valor progn&oacute;st
ico e define os danos permanentes provocados pelo LES <i>per se</i>, pelas medid
as terap&ecirc;uticas e/ou co-morbidades associadas. Por defini&ccedil;&atilde;o
, dano permanente foi considerado como altera&ccedil;&atilde;o n&atilde;o relaci
onada com a inflama&ccedil;&atilde;o ativa no momento e sim aquela presente por,
 no m&iacute;nimo, seis meses. Doze &oacute;rg&atilde;os/sistemas s&atilde;o ava
liados por escores: ocular (0-2), neuropsiqui&aacute;trico (0-6), renal (0-3), p
ulmonar (0-5), cardiovascular (0-6), vascular perif&eacute;rico (0-5), gastroint
estinal (0-6), musculoesquel&eacute;tico (0-7), cut&acirc;neo (0-3), end&oacute;
crino (diabetes melito)(0-1), gonadal (0-1) e malignidades (0-2), no total m&aac
ute;ximo te&oacute;rico de 47 pontos (question&aacute;rio no final do artigo)<su
p>(16-19)</sup>. </font></p>     ^cY#v44n2a03.htm##
00817000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058300075002001300658#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#36#32#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Estudando as causas de hospitaliza&cc
edil;&atilde;o de pacientes com LES em unidade de emerg&ecirc;ncia, maior escore
 de SLICC/ACR-DI foi a vari&aacute;vel associada &agrave; hospitaliza&ccedil;&at
ilde;o<sup>(20)</sup>. Pacientes com danos precoces observados j&aacute; na prim
eira avalia&ccedil;&atilde;o cl&iacute;nica apresentaram menor probabilidade de 
sobrevida ap&oacute;s dez anos de seguimento, quando comparados com pacientes se
m altera&ccedil;&otilde;es permanentes precoces<sup>(21)</sup>.</font></p>     ^
cY#v44n2a03.htm##
01202000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704096800075002001301043#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#37#33#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Maiores &iacute;ndices de SLICC/ACR-D
I foram associados com baixo <i>status </i>s&oacute;cio-econ&ocirc;mico e baixo 
n&iacute;vel educacional<sup>(22)</sup>, idade mais avan&ccedil;ada na &eacute;p
oca do diagn&oacute;stico de LES<sup>(23, 24)</sup>, idade maior que 50 anos<sup
>(25)</sup>, maior dura&ccedil;&atilde;o da doen&ccedil;a<sup>(23,24,26)</sup>, 
maior atividade do LES na &eacute;poca do diagn&oacute;stico<sup>(23,24)</sup> e
 maiores escores de SLE-DAI durante o per&iacute;odo de estudo<sup>(25,27)</sup>
. Houve correla&ccedil;&atilde;o entre altos &iacute;ndices do SLICC/ACR-DI e pe
rsist&ecirc;ncia de atividade de doen&ccedil;a com SLE-DAI&gt;10. A sobrevida fo
i menor em pacientes com escores do SLICC/ ACR-DI&gt;2 e de SLE-DAI&gt;10 na &ua
cute;ltima avalia&ccedil;&atilde;o, confirmando o valor progn&oacute;stico do es
core de danos permanentes do LES<sup>(27)</sup>.</font></p>     ^cY#v44n2a03.htm
##
00781000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704054700075002001300622#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#38#34#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O objetivo do presente estudo foi ava
liar os escores do SLICC/ACR-DI em pacientes com diagn&oacute;stico de LES h&aac
ute; mais de cinco anos e definir a freq&uuml;&ecirc;ncia dos diferentes tipos d
e danos permanentes. Secundariamente, avaliar a poss&iacute;vel associa&ccedil;&
atilde;o entre presen&ccedil;a de les&otilde;es permanentes e idade, crit&eacute
;rios de classifica&ccedil;&atilde;o do ACR e uso de medica&ccedil;&otilde;es co
mo prednisona e cloroquina.</font></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#39#35#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00350000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011600075002001300191#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#40#36#article#184#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES E M&Eacute;TODOS</b></fo
nt></p>     ^cY#v44n2a03.htm##
00687000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045300075002001300528#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#41#37#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No per&iacute;odo entre 2000 e 2001 f
oi realizada revis&atilde;o dos prontu&aacute;rios de pacientes com diagn&oacute
;stico de LES em seguimento regular no ambulat&oacute;rio de doen&ccedil;as reum
&aacute;ticas autoimunes do servi&ccedil;o de reumatologia do Hospital S&atilde;
o Paulo - Universidade Federal de S&atilde;o Paulo/Escola Paulista de Medicina (
Unifesp/EPM).</font></p>     ^cY#v44n2a03.htm##
00751000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051700075002001300592#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#42#38#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram inclu&iacute;dos pacientes com 
quatro ou mais crit&eacute;rios para a classifica&ccedil;&atilde;o de LES, de ac
ordo com o ACR<sup>(28,29)</sup>, do sexo feminino e com tempo de diagn&oacute;s
tico da doen&ccedil;a superior a cinco anos. O projeto de estudo foi aprovado pe
lo Comit&ecirc; de &Eacute;tica e Pesquisa M&eacute;dica da Unifesp/EPM e as pac
ientes assinaram termo de consentimento p&oacute;s-informa&ccedil;&atilde;o. </f
ont></p>     ^cY#v44n2a03.htm##
00725000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049100075002001300566#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#43#39#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As participantes foram submetidas ao 
exame f&iacute;sico completo e os seguintes dados foram obtidos atrav&eacute;s d
os prontu&aacute;rios: tempo de diagn&oacute;stico do LES, crit&eacute;rios diag
n&oacute;sticos e outras manifesta&ccedil;&otilde;es cl&iacute;nicas da doen&cce
dil;a, dados laboratoriais gerais e imunol&oacute;gicos e les&otilde;es irrevers
&iacute;veis em &oacute;rg&atilde;os e/ou sistemas.</font></p>     ^cY#v44n2a03.
htm##
00663000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042900075002001300504#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#44#40#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Para o c&aacute;lculo do tempo de uso
 e dose cumulativa de prednisona e tempo de uso de agentes antimal&aacute;ricos 
foram consideradas apenas as pacientes que tiveram diagn&oacute;stico de LES no 
ambulat&oacute;rio da Unifesp/EPM e permaneceram, desde ent&atilde;o, em acompan
hamento cont&iacute;nuo a intervalos m&aacute;ximos de quatro meses. </font></p>
     ^cY#v44n2a03.htm##
00542000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030800075002001300383#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#45#41#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o psiqui&aacu
te;trica foi obtida pelas informa&ccedil;&otilde;es dos prontu&aacute;rios, n&at
ilde;o sendo aplicado question&aacute;rio espec&iacute;fico para o estudo da fun
&ccedil;&atilde;o cognitiva.</font></p>     ^cY#v44n2a03.htm##
00364000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013000075002001300205#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#46#42#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>An&aacute;lise estat&iacute;sti
ca</b></i></font></p>     ^cY#v44n2a03.htm##
00781000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704054700075002001300622#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#47#43#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os testes de qui-quadrado e qui-quadr
ado de <i>Pearson </i>foram utilizados para verificar a rela&ccedil;&atilde;o de
 depend&ecirc;ncia entre as vari&aacute;veis qualitativas. O teste exato de <i>F
isher </i>foi empregado quando a amostra foi &lt;30 ou as freq&uuml;&ecirc;ncias
 esperadas foram &lt;5. O teste de <i>Mann-Whitney</i> foi usado para comparar o
s subgrupos de pacientes com rela&ccedil;&atilde;o &agrave;s vari&aacute;veis qu
antitativas<sup>(30)</sup>.</font></p>     ^cY#v44n2a03.htm##
00582000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034800075002001300423#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#48#44#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram considerados significantes os r
esultados com n&iacute;vel descritivo (p)&lt;0,05 e que foram assinalados com um
 asterisco (*). A tend&ecirc;ncia &agrave; signific&acirc;ncia estat&iacute;stic
a foi admitida nos casos de valores de p<u>&gt;</u>0,05 e &lt;0,10. </font></p> 
    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#49#45#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#50#46#article#184#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v44n2a03.htm##
00688000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045400075002001300529#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#51#47#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Participaram deste estudo 90 paciente
s com LES, com m&eacute;dia de idade de 38 ± 10 anos, 60% da cor branca, m&eacut
e;dia da idade por ocasi&atilde;o do diagn&oacute;stico do LES de 27 ± 9 anos e 
m&eacute;dia do tempo de diagn&oacute;stico de LES de 128 ± 59 meses (<a href="#
tab01">Tabela 1</a>). O escore do SLICC/ACR-DI foi 2 ± 2, com varia&ccedil;&atil
de;o de 0 a 6.</font></p>     ^cY#v44n2a03.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#52#48#article#184#<p><a name="tab01"><
/a></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#53#49#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#54#50#article#184#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a03tab01.jpg"></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#55#51#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
01118000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704088400075002001300959#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#56#52#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os sintomas constitucionais mais comu
mente relacionados ao LES, ao longo de sua evolu&ccedil;&atilde;o, foram alopeci
a em 79 pacientes (88%), febre em 61 (68%), fadiga em 58 (64%) e perda de peso c
orp&oacute;reo em 49 (54%). O n&uacute;mero de crit&eacute;rios do ACR, na &eacu
te;poca do estudo, foi 7 ± 1 (mediana 7, variando de 4 a 10). As seguintes freq&
uuml;&ecirc;ncias dos crit&eacute;rios do ACR foram observadas: eritema malar em
 91% dos casos, les&atilde;o disc&oacute;ide em 23%, fotossensibilidade em 90%, 
vasculite de mucosa em 38%, acometimento articular em 88%, serosite em 37%, acom
etimento renal em 49%, acometimento neurol&oacute;gico em 11%, acometimento hema
tol&oacute;gico em 87%, altera&ccedil;&otilde;es imunol&oacute;gicas em 82% e an
ticorpos antinucleares em 99% das pacientes.</font></p>     ^cY#v44n2a03.htm##
00739000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050500075002001300580#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#57#53#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Vasculite digital foi descrita em pro
ntu&aacute;rios de 46 pacientes (51%). Outras vasculites, que inclu&iacute;ram &
uacute;lceras n&atilde;o mucosas ou digitais, vasculites viscerais e do sistema 
nervoso central comprovadas por exames subsidi&aacute;rios, foram relatadas em 1
6 (18%). Trombose venosa foi definida em 6 (7%) e trombose arterial em 3 (3%). A
nticorpos anticardiolipina foram positivos em 34 pacientes (38%).</font></p>    
 ^cY#v44n2a03.htm##
00859000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704062500075002001300700#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#58#54#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"></b>Houve tend&ecirc;ncia &agrave; as
socia&ccedil;&atilde;o estat&iacute;stica entre idade atual mais avan&ccedil;ada
 e presen&ccedil;a de danos permanentes (p=0,06). N&atilde;o observamos associa&
ccedil;&atilde;o estatisticamente significante entre idade na &eacute;poca do di
agn&oacute;stico de LES e presen&ccedil;a de les&otilde;es permanentes (p=0,353)
. N&atilde;o houve associa&ccedil;&atilde;o estatisticamente significante entre 
tempo de doen&ccedil;a e presen&ccedil;a de danos permanentes (p= 0,319) (<a hre
f="#tab01">Tabela 1</a>).</font></p>     ^cY#v44n2a03.htm##
00843000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060900075002001300684#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#59#55#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cinq&uuml;enta e duas pacientes (58%)
 tinham diagn&oacute;stico de LES entre 61 e 120 meses, 24 (27%) entre 121 e 180
 meses e 14 (15%) com LES h&aacute; mais de 180 meses. N&atilde;o houve diferen&
ccedil;a estatisticamente significante com rela&ccedil;&atilde;o &agrave; presen
&ccedil;a de inj&uacute;rias permanentes nesses subgrupos de pacientes (p=0,466)
. Vinte e cinco pacientes (28%) n&atilde;o apresentaram les&otilde;es permanente
s e 65 (72%) tinham escores de SLICC/ACR-DI <u>&gt;</u>1 (<a href="#tab02">Tabel
a 2</a>).</font></p>     ^cY#v44n2a03.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#60#56#article#184#<p><a name="tab02"><
/a></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#61#57#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#62#58#article#184#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a03tab02.jpg"></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#63#59#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00885000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704065100075002001300726#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#64#60#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">N&atilde;o foi observada associa&cced
il;&atilde;o estatisticamente significante entre n&uacute;mero de crit&eacute;ri
os do ACR e presen&ccedil;a de danos permanentes (p=0,308). Les&atilde;o disc&oa
cute;ide e anticorpos anti-dsDNA foram os crit&eacute;rios diagn&oacute;sticos q
ue mostraram associa&ccedil;&atilde;o estatisticamente significante com o &iacut
e;ndice de danos permanentes (p=0,049 e 0,013, respectivamente). Houve tend&ecir
c;ncia &agrave; associa&ccedil;&atilde;o estat&iacute;stica entre trombocitopeni
a e presen&ccedil;a de danos permanentes (p=0,07). </font></p>     ^cY#v44n2a03.
htm##
00823000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058900075002001300664#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#65#61#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os danos mais freq&uuml;entemente obs
ervados foram: altera&ccedil;&otilde;es cardiovasculares em 21%, dermatol&oacute
;gicas em 21%, musculoesquel&eacute;ticas em 17%, gonadais em 16%, neuropsiqui&a
acute;tricas em 13%, oculares em 12%, renais em 12%, vasculares perif&eacute;ric
as em 10%, pulmonares em 6%, end&oacute;crinas em 6% e malignidades em 3% dos ca
sos. Os danos permanentes em &oacute;rg&atilde;os e/ou sistemas avaliados pelo S
LICC/ACR-DI s&atilde;o apresentados na <a href="#tab03">Tabela 3</a>.</font></p>
     ^cY#v44n2a03.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#66#62#article#184#<p><a name="tab03"><
/a></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#67#63#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#68#64#article#184#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a03tab03.jpg"></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#69#65#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
01178000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704094400075002001301019#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#70#66#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Quarenta e oito pacientes tiveram seg
uimento cl&iacute;nico cont&iacute;nuo em nosso servi&ccedil;o. Todas as pacient
es, em algum momento ao longo da doen&ccedil;a, receberam ester&oacute;ides e 44
 pacientes fizeram uso de medica&ccedil;&atilde;o antimal&aacute;rica. Houve ten
d&ecirc;ncia &agrave; associa&ccedil;&atilde;o estat&iacute;stica entre menor te
mpo de uso de antimal&aacute;ricos (em meses) e les&otilde;es permanentes (p=0,0
68). Quanto &agrave; corticoterapia, n&atilde;o houve associa&ccedil;&atilde;o e
statisticamente significante entre tempo de uso de prednisona (em meses) e prese
n&ccedil;a de altera&ccedil;&atilde;o irrevers&iacute;vel (p=0,725). Observamos,
 no entanto, associa&ccedil;&atilde;o estatisticamente significante entre maior 
dose cumulativa de prednisona (em gramas) e danos permanentes (p=0,013) (<a href
="#tab04">Tabela 4</a>).</font></p>     ^cY#v44n2a03.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#71#67#article#184#<p><a name="tab04"><
/a></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#72#68#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#73#69#article#184#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a03tab04.jpg"></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#74#70#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#75#71#article#184#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v44n2a03.htm##
00928000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704069400075002001300769#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#76#72#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Como conseq&uuml;&ecirc;ncia da melho
ra da sobrevida, os pacientes com diagn&oacute;stico de LES t&ecirc;m apresentad
o consider&aacute;veis comorbidades e isto se deve &agrave;s seq&uuml;elas de at
ividade da doen&ccedil;a e aos efeitos colaterais do tratamento<sup>(31-33)</sup
>. A introdu&ccedil;&atilde;o dos ester&oacute;ides foi um dos fatores important
es para a melhora da expectativa de vida desses pacientes. No entanto, a cortico
terapia tem sido implicada como fator de risco para doen&ccedil;a vascular atero
scler&oacute;tica, miopatia, osteoporose, osteonecrose e catarata em LES<sup>(31
,34,35)</sup>.</font></p>     ^cY#v44n2a03.htm##
00879000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064500075002001300720#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#77#73#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Observamos que pacientes com diagn&oa
cute;stico de LES h&aacute; mais de cinco anos apresentaram escore de SLICC/ACRD
I 2±2. Rivest <i>et al.</i><sup>(24)</sup> avaliaram pacientes com dura&ccedil;&
atilde;o m&eacute;dia de LES de 3,8 (desvio-padr&atilde;o 2,2) anos e o escore d
e danos permanentes relatado foi 1,5±1,8. Molad <i>et al.</i><sup>(25) </sup>enc
ontraram m&eacute;dia de escore de SLICC/ACR-DI de 0,17±0,64 na primeira avalia&
ccedil;&atilde;o e de 1,64±2,1 ap&oacute;s acompanhamento de 46±37 meses, com di
feren&ccedil;a estatisticamente significante.</font></p>     ^cY#v44n2a03.htm##
00652000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041800075002001300493#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#78#74#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Setenta e dois por cento de nossas pa
cientes apresentaram algum dano irrevers&iacute;vel, maior porcentagem quando co
mparada com relatos de literatura, que t&ecirc;m variado de 9,4% a 56%<sup>(21,2
5-27,36-38)</sup>. Esta diferen&ccedil;a provavelmente devese ao fato de incluir
mos neste estudo pacientes com mais de cinco anos de LES. </font></p>     ^cY#v4
4n2a03.htm##
01036000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080200075002001300877#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#79#75#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Como observado em estudos anteriores<
sup>(27,36)</sup>, n&atilde;o foi encontrada associa&ccedil;&atilde;o entre idad
e por ocasi&atilde;o do estudo ou do diagn&oacute;stico de LES e presen&ccedil;a
 de danos permanentes. Em outro trabalho, idade mais avan&ccedil;ada na &eacute;
poca do diagn&oacute;stico de LES mostrou correla&ccedil;&atilde;o com presen&cc
edil;a de danos cardiovascular, musculoesquel&eacute;tico, gastrointestinal, ocu
lar e pulmonar e maior tempo de diagn&oacute;stico de doen&ccedil;a correlaciono
use com maiores danos renal e cardiovascular. Maior atividade de LES na &eacute;
poca do diagn&oacute;stico correlacionou-se com maiores danos renal, musculoesqu
el&eacute;tico e pulmonar<sup>(24)</sup>. </font></p>     ^cY#v44n2a03.htm##
00689000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045500075002001300530#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#80#76#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Como relatado em estudo anterior<sup>
(36)</sup>, a presen&ccedil;a de les&atilde;o disc&oacute;ide foi preditiva de d
ano irrevers&iacute;vel. No presente estudo houve associa&ccedil;&atilde;o signi
ficante entre presen&ccedil;a de anticorpos anti-dsDNA e &iacute;ndice de danos 
permanentes. Esta associa&ccedil;&atilde;o n&atilde;o havia sido estudada em out
ros trabalhos. </font></p>     ^cY#v44n2a03.htm##
00962000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704072800075002001300803#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#81#77#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Relatamos as maiores freq&uuml;&ecirc
;ncias de danos permanentes cardiovasculares (21%), dermatol&oacute;gicos (21%),
 musculoesquel&eacute;ticos (17%) e gonadal (16%). De um modo geral, estas freq&
uuml;&ecirc;ncias s&atilde;o maiores que as referidas na literatura, que mostra 
altera&ccedil;&otilde;es musculoesquel&eacute;ticas irrevers&iacute;veis em 2,7%
 a 18,5%<sup>(24,25,36)</sup>, danos cardiovasculares em 1,6% a 17,2%, dermatol&
oacute;gicos em 4% a 12,5% e fal&ecirc;ncia gonadal prematura em 2% a 11% dos pa
cientes<sup>(24-26,36)</sup>. Provavelmente isto se deve ao fato de termos estud
ado pacientes com maior tempo de doen&ccedil;a. </font></p>     ^cY#v44n2a03.htm
##
00646000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041200075002001300487#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#82#78#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Inj&uacute;rias neuropsiqui&aacute;tr
icas permanentes foram observadas em 13% das pacientes, porcentagem esta dentro 
da varia&ccedil;&atilde;o referida pela literatura (6,6% a 32,4%)<sup>(24-26,36)
</sup>. Danos oculares estiveram presentes em 12% de nossas pacientes e os autor
es os relatam em 1,1% a 18,5%<sup>(24-26,36)</sup>. </font></p>     ^cY#v44n2a03
.htm##
00859000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704062500075002001300700#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#83#79#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Observamos danos renais em 12%, em co
ncord&acirc;ncia com as freq&uuml;&ecirc;ncias relatadas de 8,2% a 11,9%<sup>(24
-26,36)</sup>. Num estudo, menor idade no diagn&oacute;stico de LES e trombocito
penia foram os fatores de risco independentes para inj&uacute;ria renal<sup>(36)
</sup>. Neste estudo, houve tend&ecirc;ncia &agrave; associa&ccedil;&atilde;o es
tat&iacute;stica entre trombocitopenia e danos permanentes. Em outro estudo, esc
ore de dano renal permanente foi relatado como preditivo de doen&ccedil;a renal 
terminal<sup>(39)</sup>. </font></p>     ^cY#v44n2a03.htm##
00826000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059200075002001300667#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#84#80#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Altera&ccedil;&otilde;es vasculares p
erif&eacute;ricas foram observadas em 10% das pacientes. Outros autores relatara
m freq&uuml;&ecirc;ncias entre 1,1% e 9,3%<sup>(24-26,36)</sup>. Danos permanent
es pulmonares e end&oacute;crinos estiveram presentes em 6% dos casos. H&aacute;
 relatos de altera&ccedil;&otilde;es pulmonares em 1,1% a 12,6% dos pacientes e 
de diabetes melito em 0,5% a 5,3%<sup>(24-26,36)</sup>. Escore de dano pulmonar 
foi definido como preditivo de &oacute;bito em dez anos<sup>(39)</sup>. </font><
/p>     ^cY#v44n2a03.htm##
00461000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022700075002001300302#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#85#81#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Observamos malignidade em 3% das paci
entes, freq&uuml;&ecirc;ncia similar &agrave; relatada previamente (at&eacute; 4
,6%)<sup>(24-26,36)</sup>. </font></p>     ^cY#v44n2a03.htm##
00828000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059400075002001300669#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#86#82#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O tempo de uso de agentes antimal&aac
ute;ricos e de prednisona e a dose cumulativa aproximada de prednisona foram cal
culados apenas para as pacientes com prontu&aacute;rios mais completos e em segu
imento cont&iacute;nuo no nosso servi&ccedil;o desde o diagn&oacute;stico de LES
. A sele&ccedil;&atilde;o de apenas 48 das 90 pacientes para tal avalia&ccedil;&
atilde;o teve por finalidade minimizar os erros inerentes a esses c&aacute;lculo
s atrav&eacute;s da revis&atilde;o dos prontu&aacute;rios m&eacute;dicos. </font
></p>     ^cY#v44n2a03.htm##
00719000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048500075002001300560#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#87#83#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Neste estudo, houve tend&ecirc;ncia &
agrave; associa&ccedil;&atilde;o estat&iacute;stica entre menor tempo de uso de 
antimal&aacute;ricos e presen&ccedil;a de danos permanentes. Molad <i>et al.</i>
<sup>(25)</sup> encontraram associa&ccedil;&atilde;o significante entre terapia 
com hidroxicloroquina e menor escore de SLICC/ACR-DI, demonstrando o efeito prot
etor das drogas antimal&aacute;ricas no LES. </font></p>     ^cY#v44n2a03.htm##
01219000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704098500075002001301060#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#88#84#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Observamos associa&ccedil;&atilde;o e
statisticamente significante entre maior dose cumulativa de prednisona e presen&
ccedil;a de altera&ccedil;&otilde;es permanentes. Os trabalhos da literatura tra
zem dados conflitantes. Molad <i>et al.</i><sup>(25)</sup> relataram associa&cce
dil;&atilde;o estatisticamente significante entre dose di&aacute;ria de predniso
na e maior escore de SLICC/ACR-DI, sugerindo que os efeitos adversos dos ester&o
acute;ides provoquem danos permanentes. Rahman <i>et al.</i><sup>(21)</sup> enco
ntraram maior dose m&eacute;dia cumulativa de corticoester&oacute;ide no primeir
o ano de avalia&ccedil;&atilde;o dos pacientes no subgrupo com danos permanentes
 que nos pacientes sem danos precoces. Por outro lado, Nossent<sup>(27) </sup>n&
atilde;o observou correla&ccedil;&atilde;o entre dosagem di&aacute;ria de ester&
oacute;ide ou dose cumulativa da droga e escore do SLICC/ACR-DI. </font></p>    
 ^cY#v44n2a03.htm##
00822000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058800075002001300663#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#89#85#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">No seguimento cl&iacute;nico dos paci
entes com LES s&atilde;o imperativos o reconhecimento dos per&iacute;odos de exa
cerba&ccedil;&atilde;o e a distin&ccedil;&atilde;o entre atividade de doen&ccedi
l;a e os resultados de efeitos cumulativos de destrui&ccedil;&atilde;o org&acirc
;nica previamente existente<sup>(40)</sup>. Nesse sentido, o SLICC/ACR-DI poderi
a refletir o impacto da persist&ecirc;ncia de atividade de doen&ccedil;a e/ou ex
pressar os efeitos cumulativos de ester&oacute;ides<sup>(18)</sup>. </font></p> 
    ^cY#v44n2a03.htm##
01109000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704087500075002001300950#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#90#86#article#184#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Este estudo mostrou que 72% das pacie
ntes com diagn&oacute;stico de LES h&aacute; mais de cinco anos apresentaram les
&otilde;es irrevers&iacute;veis. As maiores freq&uuml;&ecirc;ncias observadas fo
ram de acometimentos cardiovasculares, dermatol&oacute;gicos, musculoesquel&eacu
te;ticos e gonadais. A dose cumulativa de prednisona foi importante vari&aacute;
vel associada &agrave; presen&ccedil;a de les&otilde;es irrevers&iacute;veis em 
pacientes com LES, sugerindo a relev&acirc;ncia das estrat&eacute;gias para poup
ar corticoester&oacute;ides. Observamos, tamb&eacute;m, tend&ecirc;ncia &agrave;
 associa&ccedil;&atilde;o entre menor tempo de uso de agentes antimal&aacute;ric
os e maior escore do SLICC/ACR-DI, sinalizando um poss&iacute;vel efeito proteto
r das drogas antimal&aacute;ricas. </font></p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#91#87#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00370000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013600075002001300211#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#92#88#article#184#<p align="center"><a
 href="/img/revistas/rbr/v44n2/a03qua01.jpg"><img src="/img/revistas/rbr/v44n2/a
03qua01tumb.jpg" border="0">    ^cY#v44n2a03.htm##
00346000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011200075002001300187#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#93#89#article#184#<br>     <font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">Clique para ampliar</font></a><
/p>     ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#94#90#article#184#<p>&nbsp;</p>     ^c
Y#v44n2a03.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#95#91#article#184#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v44n2a03.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704022600077002001300303#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#96#92#article#184#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Dubois EL, Wierzchow
iecki M, Cox MB, Weiner JM: Duration and death in systemic lupus erythematosus -
 an analysis of 249 cases. JAMA 227: 1399-402, 1974.    ^cY#v44n2a03.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#97#93#article#184#</font></p>     ^cY#
v44n2a03.htm##
00481000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704023300077002001300310#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#98#94#article#184#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Urowitz MB, Bookman 
AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA: The bimodal mortality pattern
 of systemic lupus erythematosus. Am J Med 60: 221-5, 1976.    ^cY#v44n2a03.htm#
#
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#99#95#article#184#</font></p>     ^cY#
v44n2a03.htm##
00483000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704023400078002001300312#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#100#96#article#184#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Pistiner M, Wallace
 DJ, Nessim S, Metzger AL, Klinenberg JR: Lupus erythematosus in the 1980s - a s
urvey of 570 patients. Semin Arthritis Rheum 21: 55-64, 1991.    ^cY#v44n2a03.ht
m##
00255000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002000076002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#101#97#article#184#</font></p>     ^cY
#v44n2a03.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704025300078002001300331#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#102#98#article#184#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Abu-Shakra M, Urowi
tz MB, Gladman DD, Gough J: Mortality studies in systemic lupus erythematosus - 
results from a single center: I. causes of death. J Rheumatol 22: 1259-64, 1995.
    ^cY#v44n2a03.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002000076002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#103#99#article#184#</font></p>     ^cY
#v44n2a03.htm##
00497000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704024700079002001300326#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#104#100#article#184#5#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Ward MM, Pyun E, S
tudenski S: Long-term survival in systemic lupus erythematosus - patient charact
eristics associated with poorer outcomes. Arthritis Rheum 38: 274-83, 1995.    ^
cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#105#101#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00552000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704030200079002001300381#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#106#102#article#184#6#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Reveille JD, Barto
lucci A, Alarc&oacute;n GS: Prognosis in systemic lupus erythematosus - negative
 impact of increasing age at onset, black race, and thrombocytopenia, as well as
 causes of death. Arthritis Rheum 33: 37-48, 1990.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#107#103#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00522000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704027200079002001300351#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#108#104#article#184#7#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Abu-Shakra M, Urow
itz MB, Gladman DD, Gough J: Mortality studies in systemic lupus erythematosus -
 results from a single center: II. predictor variables for mortality. J Rheumato
l 22: 1265-70, 1995.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#109#105#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704026000079002001300339#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#110#106#article#184#8#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Ginzler EM, Diamon
d HS, Weiner M, et al: A multicenter study of outcome in systemic lupus erythema
tosus - I. entry variables as predictors of prognosis. Arthritis Rheum 25: 601-1
1, 1982.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#111#107#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704025700079002001300336#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#112#108#article#184#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Studenski S, Allen
 NB, Caldwell DS, Rice JR, Polisson RP: Survival in systemic lupus erythematosus
 - a multivariate analysis of demographic factors. Arthritis Rheum 30: 1326-32, 
1987.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#113#109#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00498000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024700080002001300327#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#114#110#article#184#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Wallace DJ, Pode
ll T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL: Systemic lupus erythemato
sus - survival pattern: experience with 609 patients. JAMA 245: 934-8, 1981.    
^cY#v44n2a03.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#115#111#article#184# </font></p>     ^
cY#v44n2a03.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025800080002001300338#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#116#112#article#184#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Massardo L, Mart
&iacute;nez ME, Jacobelli S, Villarroel L, Rosenberg H, Rivero S: Survival of ch
ilean patients with systemic lupus erythematosus. Semin Arthritis Rheum 24: 1-11
, 1994.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#117#113#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00475000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022400080002001300304#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#118#114#article#184#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Sato EI, Vieira 
ALS, Pochini AC, et al: Fatores progn&oacute;sticos no l&uacute;pus eritematoso 
sist&ecirc;mico. Rev Bras Reumatol 35: 235-241, 1995.    ^cY#v44n2a03.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#119#115#article#184# </font></p>     ^
cY#v44n2a03.htm##
00545000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029400080002001300374#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#120#116#article#184#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Latorre LC: An&a
acute;lise da sobrevida em pacientes com l&uacute;pus eritematoso sist&ecirc;mic
o. Tese de doutorado. Faculdade de Sa&uacute;de P&uacute;blica da Universidade d
e S&atilde;o Paulo, S&atilde;o Paulo, 1997.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#121#117#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021500080002001300295#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#122#118#article#184#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Seleznick MJ, Fr
ies JF: Variables associated with decreased survival in systemic lupus erythemat
osus. Semin Arthritis Rheum 21: 73-80, 1991.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#123#119#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026300080002001300343#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#124#120#article#184#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Swaak AJG, Nosse
nt JC, Bronsveld W, et al: Systemic lupus erythematosus - I. outcome and surviva
l: dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48: 4
47-54, 1989.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#125#121#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00577000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032600080002001300406#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#126#122#article#184#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Gladman D, Ginzl
er E, Goldsmith C, et al: The development and initial validation of the systemic
 lupus international collaborating clinics/American College of Rheumatology dama
ge index for systemic lupus erythematosus. Arthritis Rheum 39: 363-9, 1996.    ^
cY#v44n2a03.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#127#123#article#184# </font></p>     ^
cY#v44n2a03.htm##
00571000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032000080002001300400#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#128#124#article#184#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Gladman DD, Urow
itz MB, Goldsmith CH, et al: The reliability of the systemic lupus international
 collaborating clinics/American College of Rheumatology damage index in patients
 with systemic lupus erythematosus. Arthritis Rheum 40: 809-13, 1997.    ^cY#v44
n2a03.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#129#125#article#184# </font></p>     ^
cY#v44n2a03.htm##
00445000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019400080002001300274#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#130#126#article#184#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Gladman DD, Urow
itz MB: The SLICC/ACR damage index - progress report and experience in the field
. Lupus 8: 632-7, 1999.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#131#127#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00559000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030800080002001300388#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#132#128#article#184#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Gladman DD, Gold
smith CH, Urowitz MB, et al: The systemic lupus international collaborating clin
ics/American College of Rheumatology damage index for systemic lupus erythematos
us international comparison. J Rheumatol 27: 373-6, 2000.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#133#129#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023100080002001300311#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#134#130#article#184#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Rojas-Serrano J,
 Cardiel MH: Lupus patients in an emergency unit. Causes of consultation, hospit
alization and outcome. A cohort study. Lupus 9: 601-6, 2000.    ^cY#v44n2a03.htm
##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#135#131#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00515000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026400080002001300344#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#136#132#article#184#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Rahman P, Gladma
n DD, Urowitz MB, Hallet D, Tam LS: Early damage as measured by the SLICC/ACR da
mage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10
: 93-6, 2001.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#137#133#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00506000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025500080002001300335#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#138#134#article#184#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Lotstein DS, War
d MM, Bush TM, Lambert E, Van Vollenhoven R, Neuwelt M: Socioeconomic status and
 health in women with systemic lupus erythematosus. J Rheumatology 25: 1720-9, 1
998.    ^cY#v44n2a03.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#139#135#article#184# </font></p>     ^
cY#v44n2a03.htm##
00532000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028100080002001300361#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#140#136#article#184#23#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Karlson EW, Dalt
roy LH, Lew RA, et al: The relationship of socioeconomic status, race, and modif
iable risk factors to outcomes in patients with systemic lupus erythematosus. Ar
thritis Rheum 40: 47-56, 1997.    ^cY#v44n2a03.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#141#137#article#184# </font></p>     ^
cY#v44n2a03.htm##
00517000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026600080002001300346#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#142#138#article#184#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Rivest C, Lew RA
, Welsing PMJ, et al: Association between clinical factors, socieconomic status,
 and organ damage in recent onset systemic lupus erythematosus. J Rheumatology 2
7: 680-4, 2000.    ^cY#v44n2a03.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#143#139#article#184# </font></p>     ^
cY#v44n2a03.htm##
00515000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026400080002001300344#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#144#140#article#184#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Molad Y, Gorshte
in A, Wysenbeek AJ, et al: Protective effect of hydroxychloroquine in systemic l
upus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11: 
356-61, 2002.    ^cY#v44n2a03.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#145#141#article#184# </font></p>     ^
cY#v44n2a03.htm##
00532000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028100080002001300361#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#146#142#article#184#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Zonana-Nacach A,
 Camargo-Coronel A, Y&aacute;&ntilde;ez P, et al: Measurement of damage in 210 M
exican patients with systemic lupus erythematosus - relationship with disease du
ration. Lupus 7: 119-23, 1998.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#147#143#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00540000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028900080002001300369#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#148#144#article#184#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Nossent JC: SLIC
C/ACR damage index in afro-caribbean patients with systemic lupus erythematosus 
- changes in and relationship to disease activity, corticosteroid therapy, and p
rognosis. J Rheumatol 25: 654-9, 1998.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#149#145#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00476000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022500080002001300305#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#150#146#article#184#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Tan EM, Cohen AS
, Fries JF, et al: The 1982 revised criteria for the classification of systemic 
lupus erythematosus. Arthritis Rheum 25: 1271-7, 1982.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#151#147#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00498000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024700080002001300327#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#152#148#article#184#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Hochberg MC: Upd
ating the American College of Rheumatology revised criteria for the classificati
on of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997 (letter).    
^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#153#149#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00427000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017600080002001300256#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#154#150#article#184#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Siegel J: Estat&
iacute;stica n&atilde;o-param&eacute;trica, Brasil, McGraw Hill do Brasil, 350, 
1981.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#155#151#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00432000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018100080002001300261#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#156#152#article#184#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Gladman DD, Urow
itz MB: Morbidity in systemic lupus erythematosus. J Rheumatol 14 (suppl 13): 22
3-6, 1987.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#157#153#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00536000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028500080002001300365#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#158#154#article#184#32#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. American College
 of Rheumatology Ad Hoc Committee on systemic lupus erythematosus Guidelines: Gu
idelines for referral and management of systemic lupus erythematosus in adults. 
Arthritis Rheum 42: 1785-96, 1999.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#159#155#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00445000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019400080002001300274#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#160#156#article#184#33#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Trager J, Ward M
M: Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheu
matol 13: 345-51, 2001.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#161#157#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020100080002001300281#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#162#158#article#184#34#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Maxwell SRJ, Moo
ts RJ, Kendall MJ: Corticosteroids: do they damage the cardiovascular system? Po
stgrad Med J 70: 863-70, 1994.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#163#159#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020100080002001300281#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#164#160#article#184#35#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Urowitz MB, Glad
man DD: How to improve morbidity and mortality in systemic lupus erythematosus. 
Rheumatology 39: 238-44, 2000.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#165#161#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027200080002001300352#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#166#162#article#184#36#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Mok CC, Lee KW, 
Ho CTK, Lau CS, Wong RWS: A prospective study of survival and prognostic indicat
ors of systemic lupus erythematosus in a southern Chinese population. Rheumatolo
gy 39: 399-406, 2000.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#167#163#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023100080002001300311#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#168#164#article#184#37#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Thumboo J, Lee H
Y, Fong KY, et al: Accuracy of medical record scoring of the SLICC/ACR damage in
dex for systemic lupus erythematosus. Lupus 9: 358-62, 2000.    ^cY#v44n2a03.htm
##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#169#165#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00546000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029500080002001300375#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#170#166#article#184#38#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Stoll T, Sutclif
fe N, Klaghofer R, Isenberg DA: Do present damage and health perception in patie
nts with systemic lupus erythematosus predict extent of future damage? - a prosp
ective study. Ann Rheum Dis 59: 832-5, 2000.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#171#167#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00541000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029000080002001300370#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#172#168#article#184#39#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Stoll T, Seifert
 B, Isenberg DA: SLICC/ACR damage index is valid, and renal and pulmonary organ 
scores are predictors of severe outcome in patients with systemic lupus erythema
tosus. Br J Rheumatol 35: 248-54, 1996.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#173#169#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00526000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027500080002001300355#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#174#170#article#184#40#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Corzillius M, Li
ang MH: Monitoring patients with systemic lupus erythematosus. In: Lahita RG - S
ystemic lupus erythematosus, 3.a ed. San Diego, Academic Press (section IV, chap
ter 22), p 467-76, 1999.    ^cY#v44n2a03.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#175#171#article#184#</font></p>     ^c
Y#v44n2a03.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#176#172#article#184#<p>&nbsp;</p>     
^cY#v44n2a03.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#177#173#article#184#<p>&nbsp;</p>     
^cY#v44n2a03.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022900077002001300306#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#178#174#article#184#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a href="#linkinicio"><img src="/im
g/revistas/rbr/v44n2/seta.jpg" border="0"></a><a name="linkcorresp"></a> <b>Ende
re&ccedil;o para correspond&ecirc;ncia:</b>    ^cY#v44n2a03.htm##
00280000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004400077002001300121#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#179#175#article#184#<br>  Elaine Marce
lina Claudio Sella    ^cY#v44n2a03.htm##
00362000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704012600077002001300203#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#180#176#article#184#<br> Disciplina de
 reumatologia da Universidade Federal de S&atilde;o Paulo/ Escola Paulista de Me
dicina (Unifesp/EPM)    ^cY#v44n2a03.htm##
00292000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005600077002001300133#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#181#177#article#184#<br> Rua Botucatu,
 740, 3.º andar, V. Clementino    ^cY#v44n2a03.htm##
00284000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004800077002001300125#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#182#178#article#184#<br> CEP 04023-900
, S&atilde;o Paulo, SP    ^cY#v44n2a03.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010500077002001300182#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#183#179#article#184#<br> E-mail: <a hr
ef="mailto:emiliasato@reumato.epm.br">emiliasato@reumato.epm.br</a></font></p>  
   ^cY#v44n2a03.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009300077002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#184#180#article#184#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Recebido em 23/4/2003.    ^cY#v44n2
a03.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#185#181#article#184#<br>  Aprovado, ap
&oacute;s revis&atilde;o, em 30/9/2003. </font></p>     ^cY#v44n2a03.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#186#182#article#184#<p>&nbsp;</p>     
^cY#v44n2a03.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#187#183#article#184#<p>&nbsp;</p>     
^cY#v44n2a03.htm##
00483000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704024700077002001300324#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a03.htm#S#p#188#184#article#184#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a name="link01"></a><a href="#link
inicio">*</a> 	Disciplina de reumatologia da Universidade Federal de S&atilde;o 
Paulo/Escola Paulista de Medicina (Unifesp/EPM). </font></p>     ^cY#v44n2a03.ht
m##
00600000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100024000930100
01400117010001700131012008100148030000500229031000400234014000900238065000900247
064000500256865000900261002001300270035001000283801000500293#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#189#1#article#40#1#^rND^sDubois^nEL#^rND^s
Wierzchowiecki^nM#^rND^sCox^nMB#^rND^sWeiner^nJM#Duration and death in systemic 
lupus erythematosus: an analysis of 249 cases^len#JAMA#227#1399-402#19740000#197
4#20040400#v44n2a03.htm#0098-7484#JAMA##
00648000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100019000940100
01800113010001700131010001700148010001800165012006600183030000900249031000300258
01400060026106500090026706400050027686500090028100200130029003500100030380100090
0313#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#190#2#article#40#2
#^rND^sUrowitz^nMB#^rND^sBookman^nAAM#^rND^sKoehler^nBE#^rND^sGordon^nDA#^rND^sS
mythe^nHA#^rND^sOgryzlo^nMA#The bimodal mortality pattern of systemic lupus eryt
hematosus^len#Am J Med#60#221-5#19760000#1976#20040400#v44n2a03.htm#0002-9343#Am
 J Med##
00643000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100018000940100
01600112010001800128010002100146012006300167030002200230031000300252014000600255
065000900261064000500270865000900275002001300284035001000297801002200307#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#191#3#article#40#3#^rND^sPisti
ner^nM#^rND^sWallace^nDJ#^rND^sNessim^nS#^rND^sMetzger^nAL#^rND^sKlinenberg^nJR#
Lupus erythematosus in the 1980s: a survey of 570 patients^len#Semin Arthritis R
heum#21#55-64#19910000#1991#20040400#v44n2a03.htm#0049-0172#Semin Arthritis Rheu
m##
00634000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100018000960100
01800114010001500132012010400147030001200251031000300263014000800266065000900274
064000500283865000900288002001300297035001000310801001200320#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#192#4#article#40#4#^rND^sAbu-Shakra^nM#^rN
D^sUrowitz^nMB#^rND^sGladman^nDD#^rND^sGough^nJ#Mortality studies in systemic lu
pus erythematosus: results from a single center: I. causes of death^len#J Rheuma
tol#22#1259-64#19950000#1995#20040400#v44n2a03.htm#0315-162X#J Rheumatol##
00614000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100014000910100
01900105012011200124030001600236031000300252014000700255065000900262064000500271
865000900276002001300285035001000298801001600308#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a03.htm#S#c#193#5#article#40#5#^rND^sWard^nMM#^rND^sPyun^nE#^rND^s
Studenski^nS#Long-term survival in systemic lupus erythematosus: patient charact
eristics associated with poorer outcomes^len#Arthritis Rheum#38#274-83#19950000#
1995#20040400#v44n2a03.htm#0004-3591#Arthritis rheum##
00662000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100020000950100
01800115012015200133030001600285031000300301014000600304065000900310064000500319
865000900324002001300333035001000346801001600356#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a03.htm#S#c#194#6#article#40#6#^rND^sReveille^nJD#^rND^sBartolucci
^nA#^rND^sAlarcón^nGS#Prognosis in systemic lupus erythematosus: negative impact
 of increasing age at onset, black race, and thrombocytopenia, as well as causes
 of death^len#Arthritis Rheum#33#37-48#19900000#1990#20040400#v44n2a03.htm#0004-
3591#Arthritis rheum##
00653000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100018000960100
01800114010001500132012012300147030001200270031000300282014000800285065000900293
064000500302865000900307002001300316035001000329801001200339#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#195#7#article#40#7#^rND^sAbu-Shakra^nM#^rN
D^sUrowitz^nMB#^rND^sGladman^nDD#^rND^sGough^nJ#Mortality studies in systemic lu
pus erythematosus: results from a single center: II. predictor variables for mor
tality^len#J Rheumatol#22#1265-70#19950000#1995#20040400#v44n2a03.htm#0315-162X#
J Rheumatol##
00638000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100018000940100
01600112810000600128012011400134030001600248031000300264014000700267065000900274
064000500283865000900288002001300297035001000310801001600320#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#196#8#article#40#8#^rND^sGinzler^nEM#^rND^
sDiamond^nHS#^rND^sWeiner^nM#et al#A multicenter study of outcome in systemic lu
pus erythematosus: I. entry variables as predictors of prognosis^len#Arthritis R
heum#25#601-11#19820000#1982#20040400#v44n2a03.htm#0004-3591#Arthritis rheum##
00660000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100016000950100
01900111010001500130010001900145012009300164030001600257031000300273014000800276
065000900284064000500293865000900298002001300307035001000320801001600330#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#197#9#article#40#9#^rND^sStude
nski^nS#^rND^sAllen^nNB#^rND^sCaldwell^nDS#^rND^sRice^nJR#^rND^sPolisson^nRP#Sur
vival in systemic lupus erythematosus: a multivariate analysis of demographic fa
ctors^len#Arthritis Rheum#30#1326-32#19870000#1987#20040400#v44n2a03.htm#0004-35
91#Arthritis rheum##
00658000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01600112010002100128010001900149010001700168012008100185030000500266031000400271
01400060027506500090028106400050029086500090029500200130030403500100031780100050
0327#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#198#10#article#40#
10#^rND^sWallace^nDJ#^rND^sPodell^nT#^rND^sWeiner^nJ#^rND^sKlinenberg^nJR#^rND^s
Forouzesh^nS#^rND^sDubois^nEL#Systemic lupus erythematosus: survival pattern: ex
perience with 609 patients^len#JAMA#245#934-8#19810000#1981#20040400#v44n2a03.ht
m#0098-7484#JAMA##
00680000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960100
01900115010002000134010001900154010001600173012006700189030002200256031000300278
01400050028106500090028606400050029586500090030000200130030903500100032280100220
0332#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#199#11#article#40#
11#^rND^sMassardo^nL#^rND^sMartínez^nME#^rND^sJacobelli^nS#^rND^sVillarroel^nL#^
rND^sRosenberg^nH#^rND^sRivero^nS#Survival of chilean patients with systemic lup
us erythematosus^len#Semin Arthritis Rheum#24#1-11#19940000#1994#20040400#v44n2a
03.htm#0049-0172#Semin Arthritis Rheum##
00548000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100018000930100
01800111810000600129012005600135030001800191710000200209031000300211014000800214
065000900222064000500231865000900236002001300245#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a03.htm#S#c#200#12#article#40#12#^rND^sSato^nEI#^rND^sVieira^nALS#
^rND^sPochini^nAC#et al#Fatores prognósticos no lúpus eritematoso sistêmico^lpt#
Rev Bras Reumatol#2#35#235-241#19950000#1995#20040400#v44n2a03.htm##
00518000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160018000780180070000960510
01000166050005400176046001000230045000900240044000500249865000900254002001300263
#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#201#13#article#40#13#^
rND^sLatorre^nLC#Análise da sobrevida em pacientes com lúpus eritematoso sistêmi
co^lpt#doutorado#Universidade de São Paulo^dFaculdade de Saúde Pública#São Paulo
#19970000#1997#20040400#v44n2a03.htm##
00572000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100016000980120
08100114030002200195031000300217014000600220065000900226064000500235865000900240
002001300249035001000262801002200272#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a03.htm#S#c#202#14#article#40#14#^rND^sSeleznick^nMJ#^rND^sFries^nJF#Variables
 associated with decreased survival in systemic lupus erythematosus^len#Semin Ar
thritis Rheum#21#73-80#19910000#1991#20040400#v44n2a03.htm#0049-0172#Semin Arthr
itis Rheum##
00602000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01900113810000600132012011600138030001400254031000300268014000700271865000900278
002001300287035001000300801001400310#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a03.htm#S#c#203#15#article#40#15#^rND^sSwaak^nAJG#^rND^sNossent^nJC#^rND^sBron
sveld^nW#et al#Systemic lupus erythematosus: I. outcome and survival: dutch expe
rience with 110 patients studied prospectively^len#Ann Rheum Dis#48#447-54#20040
400#v44n2a03.htm#0003-4967#Ann Rheum Dis##
00706000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01900112810000600131012018000137030001600317031000300333014000600336065000900342
064000500351865000900356002001300365035001000378801001600388#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#204#16#article#40#16#^rND^sGladman^nD#^rND
^sGinzler^nE#^rND^sGoldsmith^nC#et al#The development and initial validation of 
the systemic lupus international collaborating clinics/American College of Rheum
atology damage index for systemic lupus erythematosus^len#Arthritis Rheum#39#363
-9#19960000#1996#20040400#v44n2a03.htm#0004-3591#Arthritis rheum##
00700000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
02000114810000600134012017000140030001600310031000300326014000700329065000900336
064000500345865000900350002001300359035001000372801001600382#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#205#17#article#40#17#^rND^sGladman^nDD#^rN
D^sUrowitz^nMB#^rND^sGoldsmith^nCH#et al#The reliability of the systemic lupus i
nternational collaborating clinics/American College of Rheumatology damage index
 in patients with systemic lupus erythematosus^len#Arthritis Rheum#40#809-13#199
70000#1997#20040400#v44n2a03.htm#0004-3591#Arthritis rheum##
00534000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960120
07600114030000600190031000200196014000600198065000900204064000500213865000900218
002001300227035001000240801000600250#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a03.htm#S#c#206#18#article#40#18#^rND^sGladman^nDD#^rND^sUrowitz^nMB#The SLICC
/ACR damage index: progress report and experience in the field^len#Lupus#8#632-7
#19990000#1999#20040400#v44n2a03.htm#0961-2033#Lupus##
00684000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100020000960100
01800116810000600134012016300140030001200303031000300315014000600318065000900324
064000500333865000900338002001300347035001000360801001200370#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#207#19#article#40#19#^rND^sGladman^nDD#^rN
D^sGoldsmith^nCH#^rND^sUrowitz^nMB#et al#The systemic lupus international collab
orating clinics/American College of Rheumatology damage index for systemic lupus
 erythematosus international comparison^len#J Rheumatol#27#373-6#20000000#2000#2
0040400#v44n2a03.htm#0315-162X#J Rheumatol##
00572000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100018001010120
10900119030000600228031000200234014000600236065000900242064000500251865000900256
002001300265035001000278801000600288#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a03.htm#S#c#208#20#article#40#20#^rND^sRojas-Serrano^nJ#^rND^sCardiel^nMH#Lupu
s patients in an emergency unit: Causes of consultation, hospitalization and out
come. A cohort study^len#Lupus#9#601-6#20000000#2000#20040400#v44n2a03.htm#0961-
2033#Lupus##
00659000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01800112010001600130010001400146012011900160030000600279031000300285014000500288
065000900293064000500302865000900307002001300316035001000329801000600339#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#209#21#article#40#21#^rND^sRah
man^nP#^rND^sGladman^nDD#^rND^sUrowitz^nMB#^rND^sHallet^nD#^rND^sTam^nLS#Early d
amage as measured by the SLICC/ACR damage index is a predictor of mortality in s
ystemic lupus erythematosus^len#Lupus#10#93-6#20010000#2001#20040400#v44n2a03.ht
m#0961-2033#Lupus##
00642000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01500112010001700127010002500144010001700169012007900186030001500265710000200280
031000300282014000700285065000900292064000500301865000900306002001300315#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#210#22#article#40#22#^rND^sLot
stein^nDS#^rND^sWard^nMM#^rND^sBush^nTM#^rND^sLambert^nE#^rND^sVan Vollenhoven^n
R#^rND^sNeuwelt^nM#Socioeconomic status and health in women with systemic lupus 
erythematosus^len#J Rheumatology#2#25#1720-9#19980000#1998#20040400#v44n2a03.htm
##
00661000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01400114810000600128012013800134030001600272031000300288014000600291065000900297
064000500306865000900311002001300320035001000333801001600343#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#211#23#article#40#23#^rND^sKarlson^nEW#^rN
D^sDaltroy^nLH#^rND^sLew^nRA#et al#The relationship of socioeconomic status, rac
e, and modifiable risk factors to outcomes in patients with systemic lupus eryth
ematosus^len#Arthritis Rheum#40#47-56#19970000#1997#20040400#v44n2a03.htm#0004-3
591#Arthritis rheum##
00610000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100014000940100
01900108810000600127012012500133030001500258710000200273031000300275014000600278
065000900284064000500293865000900298002001300307#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a03.htm#S#c#212#24#article#40#24#^rND^sRivest^nC#^rND^sLew^nRA#^rN
D^sWelsing^nPMJ#et al#Association between clinical factors, socieconomic status,
 and organ damage in recent onset systemic lupus erythematosus^len#J Rheumatolog
y#2#27#680-4#20000000#2000#20040400#v44n2a03.htm##
00634000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100019000930100
02000112810000600132012012600138030000600264031000300270014000700273065000900280
064000500289865000900294002001300303035001000316801000600326#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#213#25#article#40#25#^rND^sMolad^nY#^rND^s
Gorshtein^nA#^rND^sWysenbeek^nAJ#et al#Protective effect of hydroxychloroquine i
n systemic lupus erythematosus: Prospective long-term study of an Israeli cohort
^len#Lupus#11#356-61#20020000#2002#20040400#v44n2a03.htm#0961-2033#Lupus##
00636000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100025001010100
01500126810000600141012012000147030000600267031000200273014000700275065000900282
064000500291865000900296002001300305035001000318801000600328#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#214#26#article#40#26#^rND^sZonana-Nacach^n
A#^rND^sCamargo-Coronel^nA#^rND^sYáñez^nP#et al#Measurement of damage in 210 Mex
ican patients with systemic lupus erythematosus: relationship with disease durat
ion^len#Lupus#7#119-23#19980000#1998#20040400#v44n2a03.htm#0961-2033#Lupus##
00617000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780120176000960300
01200272031000300284014000600287065000900293064000500302865000900307002001300316
035001000329801001200339#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#
c#215#27#article#40#27#^rND^sNossent^nJC#SLICC/ACR damage index in afro-caribbea
n patients with systemic lupus erythematosus: changes in and relationship to dis
ease activity, corticosteroid therapy, and prognosis^len#J Rheumatol#25#654-9#19
980000#1998#20040400#v44n2a03.htm#0315-162X#J Rheumatol##
00605000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100016000920100
01600108810000600124012008500130030001600215031000300231014000700234065000900241
064000500250865000900255002001300264035001000277801001600287#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#216#28#article#40#28#^rND^sTan^nEM#^rND^sC
ohen^nAS#^rND^sFries^nJF#et al#The 1982 revised criteria for the classification 
of systemic lupus erythematosus^len#Arthritis Rheum#25#1271-7#19820000#1982#2004
0400#v44n2a03.htm#0004-3591#Arthritis rheum##
00571000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120122000970300
01600219031000300235061000500238065000900243064000500252865000900257002001300266
035001000279801001600289#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#
c#217#29#article#40#29#^rND^sHochberg^nMC#Updating the American College of Rheum
atology revised criteria for the classification of systemic lupus erythematosus^
len#Arthritis Rheum#40#1725#19970000#1997#20040400#v44n2a03.htm#0004-3591#Arthri
tis rheum##
00437000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160016000780180032000940670
00700126062002200133031000400155065000900159064000500168865000900173002001300182
#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#218#30#article#40#30#^
rND^sSiegel^nJ#Estatística não-paramétrica^lpt#Brasil#McGraw Hill do Brasil#350#
19810000#1981#20040400#v44n2a03.htm##
00534000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960120
04600114030001200160031000300172032000500175014000600180065000900186064000500195
865000900200002001300209035001000222801001200232#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a03.htm#S#c#219#31#article#40#31#^rND^sGladman^nDD#^rND^sUrowitz^n
MB#Morbidity in systemic lupus erythematosus^len#J Rheumatol#14#^s13#223-6#19870
000#1987#20040400#v44n2a03.htm#0315-162X#J Rheumatol##
00600000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750120179000780300016002570310
00300273014000800276065000900284064000500293865000900298002001300307035001000320
801001600330#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a03.htm#S#c#220#32#art
icle#40#32#American College of Rheumatology Ad Hoc Committee on systemic lupus e
rythematosus Guidelines: Guidelines for referral and management of systemic lupu
s erythematosus in adults^len#Arthritis Rheum#42#1785-96#19990000#1999#20040400#
v44n2a03.htm#0004-3591#Arthritis rheum##
00549000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100015000940120
06600109030002000175031000300195014000700198065000900205064000500214865000900219
002001300228035001000241801002000251#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a03.htm#S#c#221#33#article#40#33#^rND^sTrager^nJ#^rND^sWard^nMM#Mortality and 
causes of death in systemic lupus erythematosus^len#Curr Opin Rheumatol#13#345-5
1#20010000#2001#20040400#v44n2a03.htm#1040-8711#Curr Opin Rheumatol##
00570000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100016000970100
01800113012006300131030001500194031000300209014000700212065000900219064000500228
865000900233002001300242035001000255801001500265#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a03.htm#S#c#222#34#article#40#34#^rND^sMaxwell^nSRJ#^rND^sMoots^nR
J#^rND^sKendall^nMJ#Corticosteroids: do they damage the cardiovascular system?^l
en#Postgrad Med J#70#863-70#19940000#1994#20040400#v44n2a03.htm#0032-5473#Postgr
ad Med J##
00549000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960120
07500114030001300189031000300202014000700205065000900212064000500221865000900226
002001300235035001000248801001300258#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a03.htm#S#c#223#35#article#40#35#^rND^sUrowitz^nMB#^rND^sGladman^nDD#How to im
prove morbidity and mortality in systemic lupus erythematosus^len#Rheumatology#3
9#238-44#20000000#2000#20040400#v44n2a03.htm#0080-2727#RHEUMATOLOGY##
00656000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100014000920100
01400106010001400120012013700134030001300271031000300284014000800287065000900295
064000500304865000900309002001300318035001000331801001300341#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#224#36#article#40#36#^rND^sMok^nCC#^rND^sL
ee^nKW#^rND^sHo^nCTK#^rND^sLau^nCS#Wong RWS: A prospective study of survival and
 prognostic indicators of systemic lupus erythematosus in a southern Chinese pop
ulation^len#Rheumatology#39#399-406#20000000#2000#20040400#v44n2a03.htm#0080-272
7#RHEUMATOLOGY##
00601000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100014000950100
01500109810000600124012010200130030000600232031000200238014000700240065000900247
064000500256865000900261002001300270035001000283801000600293#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#225#37#article#40#37#^rND^sThumboo^nJ#^rND
^sLee^nHY#^rND^sFong^nKY#et al#Accuracy of medical record scoring of the SLICC/A
CR damage index for systemic lupus erythematosus^len#Lupus#9#358-62#20000000#200
0#20040400#v44n2a03.htm#0961-2033#Lupus##
00679000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100019000930100
01900112010001900131012014400150030001400294031000300308014000600311065000900317
064000500326865000900331002001300340035001000353801001400363#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#226#38#article#40#38#^rND^sStoll^nT#^rND^s
Sutcliffe^nN#^rND^sKlaghofer^nR#^rND^sIsenberg^nDA#Do present damage and health 
perception in patients with systemic lupus erythematosus predict extent of futur
e damage?: a prospective study^len#Ann Rheum Dis#59#832-5#20000000#2000#20040400
#v44n2a03.htm#0003-4967#Ann Rheum Dis##
00658000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01900110012015300129030001500282031000300297014000700300065000900307064000500316
865000900321002001300330035001000343801001500353#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a03.htm#S#c#227#39#article#40#39#^rND^sStoll^nT#^rND^sSeifert^nB#^
rND^sIsenberg^nDA#SLICC/ACR damage index is valid, and renal and pulmonary organ
 scores are predictors of severe outcome in patients with systemic lupus erythem
atosus^len#Br J Rheumatol#35#248-54#19960000#1996#20040400#v44n2a03.htm#0263-710
3#Br J Rheumatol##
00617000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100016000980120
05800114016001700172018003300189063000200222066001000224062001500234061002300249
014000700272065000900279064000500288865000900293002001300302#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a03.htm#S#c#228#40#article#40#40#^rND^sCorzillius^nM#^
rND^sLiang^nMH#Monitoring patients with systemic lupus erythematosus^len#^rND^sL
ahita^nRG#Systemic lupus erythematosus^len#3#San Diego#Academic Press#section IV
, chapter 22#467-76#19990000#1999#20040400#v44n2a03.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#o#1#1#article#1#
20110406#085416#v44n2a04.htm#189##
06342000000000625000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030002100106
03100030012703200020013006500090013201400110014103500100015201201200016201201060
02820100034003880100046004220100040004680100025005080700011005330832464005440850
00803008085004003016085002603056085002503082085002603107085002303133083238803156
08500080554408500410555208500190559308500260561208500200563811700060565807200030
5664112000905667111000905676114000905685113000905694002001305703#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#04
#RBR160#nd#Rev. Bras. Reumatol.#44#2#20040400#^f123^l128#0482-5004#Contribuição 
da doença e sua terapêutica no índice de dano SLICC/ACR na fase precoce do lúpus
 eritematoso sistêmico^lpt#Contribution of the disease and its therapy on the SL
ICC/ACR-DI in early systemic lupus erythematosus^len#^rND^1A01^nMailze Campos^sB
ezerra#^rND^1A01^nFrancisco Saraiva da^sSilva Júnior#^rND^1A01^nEduardo Ferreira
^sBorba Neto#^rND^1A01^nEloisa^sBonfá#FMUSP^iA01#^lpt^aA maioria das informações
 relativas ao curso da doença de pacientes com lúpus eritematoso sistêmico (LES)
 é restrita aos primeiros cinco anos após o diagnóstico. Entretanto, dados sobre
 a precocidade de instalação dos danos são pouco descritos. OBJETIVO: identifica
r os danos precoces de pacientes com LES de diagnóstico recente e verificar a in
fluência da própria doença ou de sua terapêutica como principal causa para a ins
talação destes danos. MÉTODOS: foram estudados retrospectivamente 82 pacientes c
om LES, cujo diagnóstico foi realizado de 1998 até 1999 em nosso serviço. Em tod
os os pacientes o escore do índice de dano do Systemic Lupus Internacional Colla
borating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR-DI) fo
i avaliado no momento do diagnóstico e anualmente três vezes consecutivas. As ma
nifestações clínicas e o esquema terapêutico foram avaliados nas consultas médic
as. O escore do SLICC/ACR para cada órgão/sistema e a prevalência dos danos foi 
identificado, assim como a sua possível causa (doença ou terapia). RESULTADOS: A
 idade (média) inicial foi de 31,6 anos com predomínio do sexo feminino (94%). A
 maioria dos pacientes (94%) apresentou manifestações cutâneas e articulares, se
guidas pelas renais (40%), pulmonares (28%) e neurológicas (18%). Ao final do es
tudo, 52 pacientes (63,4%) não apresentaram seqüelas (sem pontuação no SLICC). D
os 30 pacientes restantes, 16 tiveram escore = 1 e 14 pacientes apresentaram esc
ore = 2. No total observamos 36 danos, sendo 23 atribuídos à doença e 13 à terap
ia (64% vs 36%, p < 0,05). Os sistemas mais freqüentemente acometidos foram o ar
ticular e o neurológico (27,7%), seguidos pelo renal (13,8%). Todos os pacientes
 com comprometimento neurológico tiveram danos precoces decorrentes da própria d
oença (apesar da terapêutica agressiva) enquanto a terapêutica com corticóide fo
i responsável pelos danos em 7/10 pacientes com dano articular (osteonecrose). O
 dano renal foi observado em 13,8% dos pacientes (nefrite grave não responsiva a
o tratamento). Outros efeitos adversos da terapia foram angina, catarata, diabet
es e menopausa precoce. CONCLUSÕES: este estudo sugere que o dano precoce é aind
a um importante problema no LES. São necessárias estratégias eficazes no sentido
 de minimizar as seqüelas, com destaque para as neurológicas. Redução da morbida
de associada à terapia com corticóide também deve ser considerada utilizando-se 
agentes poupadores de esteróides#^dnd^i1#^tm^lpt^klúpus eritematoso sistêmico^i1
#^tm^lpt^kSLICC^i1^sACR-DI#^tm^lpt^kquestionário^i1#^tm^lpt^kdano tecidual^i1#^t
m^lpt^ktratamento^i1#^len^aThe majority of the information available about the d
isease course of patients with systemic lupus erythematosus (SLE) is restricted 
to the first five years after disease onset. However, data about early damage we
re rarely reported. OBJECTIVE: to describe the early damage outcome of SLE patie
nts in early disease and to discriminate the influence of disease itself or its 
therapy as the main cause of their damage. METHODS: we retrospectively studied 8
2 patients with SLE, diagnosed during the period from 1998 to 1999 in our instit
ution. In all patients the Systemic Lupus International Collaborating Clinics/Am
erican College of Rheumatology Damage Index (SLICC/ACR-DI) was scored at the dia
gnosis and annually for the next three years. Clinical manifestations were evalu
ated at each visit as well as the therapy. The SLICC/ACR-DI scores for each orga
n system and the prevalence of damage within organ systems were assessed, as wel
l as its possible main cause (disease or therapy). RESULTS: the mean age at entr
y was 31.6 years with female predominance of 94%. The majority of the patients (
94%) presented cutaneous and articular involvement, 40% renal, 28% pulmonary, an
d 18% neurological manifestations. At the end of the study, 52 (63.4%) patients 
had no damage to score with SLICC. From the remaining 30 patients, 16 had a scor
e of 1 and 14 had a score = 2. In total, 36 damages occurred, 23 of them attribu
ted to the disease and 13 to the therapy (64% vs. 36%; p < 0.05). The most frequ
ently injured systems were the articular and the neurological (27.7%) ones, foll
owed by the renal (13.8%) system. All patients with neurological involvement hav
e early damage due to the disease itself in spite of the aggressive therapeutic 
whereas from 10 patients with articular damage, 70% (7) were associated with ste
roid therapy (osteonecrosis). In contrast, premature renal injury was observed i
n 13.8%, all of them with unresponsive severe nephritis. Other adverse effect of
 therapy included 1 angina, 2 cataracts, 1 diabetes and 2 premature menopauses. 
CONCLUSIONS: this study suggests that early damage is still a major problem in S
LE that reinforces the need for new strategies in order to minimize injury, part
icularly for neurological manifestations. Moreover, it also seems important to r
educe morbidity induced by corticosteroid therapy with the use of steroid-sparin
g agents#^dnd^i2#^tm^len^ksystemic lupus erythematosus^i2#^tm^len^kdamage^i2#^tm
^len^kSLICC^i2^sACR-DI#^tm^len^ktherapy^i2#other#31#20030605#5/6/2003#20040108#8
/1/2004#v44n2a04.htm##
06418000000000625000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089121000300093049000700096158000300103030002100106
03100030012703200020013006500090013201400110014103500100015201201270016201201130
02890100034004020100046004360100040004820100025005220700011005470832495005580850
00803053085004003061085002603101085002503127085002603152085002303178083241903201
08500080562008500410562808500190566908500260568808500200571411700060573407200030
5740112000905743111000905752114000905761113000905770002001305779#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#04
#RBR160#nd#Rev. Bras. Reumatol.#44#2#20040400#^f123^l128#0482-5004#<b>Contribuiç
ão da doença e sua terapêutica no índice de dano SLICC/ACR na fase precoce do lú
pus eritematoso sistêmico</b>^lpt#<b>Contribution of the disease and its therapy
 on the SLICC/ACR-DI in early systemic lupus erythematosus</b>^len#^rND^1A01^nMa
ilze Campos^sBezerra#^rND^1A01^nFrancisco Saraiva da^sSilva Júnior#^rND^1A01^nEd
uardo Ferreira^sBorba Neto#^rND^1A01^nEloisa^sBonfá#FMUSP^iA01#^lpt^aA maioria d
as informações relativas ao curso da doença de pacientes com lúpus eritematoso s
istêmico (LES) é restrita aos primeiros cinco anos após o diagnóstico. Entretant
o, dados sobre a precocidade de instalação dos danos são pouco descritos. <b>OBJ
ETIVO:</b> identificar os danos precoces de pacientes com LES de diagnóstico rec
ente e verificar a influência da própria doença ou de sua terapêutica como princ
ipal causa para a instalação destes danos. <b>MÉTODOS:</b> foram estudados retro
spectivamente 82 pacientes com LES, cujo diagnóstico foi realizado de 1998 até 1
999 em nosso serviço. Em todos os pacientes o escore do índice de dano do System
ic Lupus Internacional Collaborating Clinics/American College of Rheumatology-Da
mage Index (SLICC/ACR-DI) foi avaliado no momento do diagnóstico e anualmente tr
ês vezes consecutivas. As manifestações clínicas e o esquema terapêutico foram a
valiados nas consultas médicas. O escore do SLICC/ACR para cada órgão/sistema e 
a prevalência dos danos foi identificado, assim como a sua possível causa (doenç
a ou terapia). <b>RESULTADOS:</b> A idade (média) inicial foi de 31,6 anos com p
redomínio do sexo feminino (94%). A maioria dos pacientes (94%) apresentou manif
estações cutâneas e articulares, seguidas pelas renais (40%), pulmonares (28%) e
 neurológicas (18%). Ao final do estudo, 52 pacientes (63,4%) não apresentaram s
eqüelas (sem pontuação no SLICC). Dos 30 pacientes restantes, 16 tiveram escore 
= 1 e 14 pacientes apresentaram escore = 2. No total observamos 36 danos, sendo 
23 atribuídos à doença e 13 à terapia (64% vs 36%, p &lt; 0,05). Os sistemas mai
s freqüentemente acometidos foram o articular e o neurológico (27,7%), seguidos 
pelo renal (13,8%). Todos os pacientes com comprometimento neurológico tiveram d
anos precoces decorrentes da própria doença (apesar da terapêutica agressiva) en
quanto a terapêutica com corticóide foi responsável pelos danos em 7/10 paciente
s com dano articular (osteonecrose). O dano renal foi observado em 13,8% dos pac
ientes (nefrite grave não responsiva ao tratamento). Outros efeitos adversos da 
terapia foram angina, catarata, diabetes e menopausa precoce. <b>CONCLUSÕES:</b>
 este estudo sugere que o dano precoce é ainda um importante problema no LES. Sã
o necessárias estratégias eficazes no sentido de minimizar as seqüelas, com dest
aque para as neurológicas. Redução da morbidade associada à terapia com corticói
de também deve ser considerada utilizando-se agentes poupadores de esteróides#^d
nd^i1#^tm^lpt^klúpus eritematoso sistêmico^i1#^tm^lpt^kSLICC^i1^sACR-DI#^tm^lpt^
kquestionário^i1#^tm^lpt^kdano tecidual^i1#^tm^lpt^ktratamento^i1#^len^aThe majo
rity of the information available about the disease course of patients with syst
emic lupus erythematosus (SLE) is restricted to the first five years after disea
se onset. However, data about early damage were rarely reported. <b>OBJECTIVE:</
b> to describe the early damage outcome of SLE patients in early disease and to 
discriminate the influence of disease itself or its therapy as the main cause of
 their damage. <b>METHODS: </b>we retrospectively studied 82 patients with SLE, 
diagnosed during the period from 1998 to 1999 in our institution. In all patient
s the Systemic Lupus International Collaborating Clinics/American College of Rhe
umatology Damage Index (SLICC/ACR-DI) was scored at the diagnosis and annually f
or the next three years. Clinical manifestations were evaluated at each visit as
 well as the therapy. The SLICC/ACR-DI scores for each organ system and the prev
alence of damage within organ systems were assessed, as well as its possible mai
n cause (disease or therapy). <b>RESULTS:</b> the mean age at entry was 31.6 yea
rs with female predominance of 94%. The majority of the patients (94%) presented
 cutaneous and articular involvement, 40% renal, 28% pulmonary, and 18% neurolog
ical manifestations. At the end of the study, 52 (63.4%) patients had no damage 
to score with SLICC. From the remaining 30 patients, 16 had a score of 1 and 14 
had a score = 2. In total, 36 damages occurred, 23 of them attributed to the dis
ease and 13 to the therapy (64% vs. 36%; p &lt; 0.05). The most frequently injur
ed systems were the articular and the neurological (27.7%) ones, followed by the
 renal (13.8%) system. All patients with neurological involvement have early dam
age due to the disease itself in spite of the aggressive therapeutic whereas fro
m 10 patients with articular damage, 70% (7) were associated with steroid therap
y (osteonecrosis). In contrast, premature renal injury was observed in 13.8%, al
l of them with unresponsive severe nephritis. Other adverse effect of therapy in
cluded 1 angina, 2 cataracts, 1 diabetes and 2 premature menopauses. <b>CONCLUSI
ONS: </b>this study suggests that early damage is still a major problem in SLE t
hat reinforces the need for new strategies in order to minimize injury, particul
arly for neurological manifestations. Moreover, it also seems important to reduc
e morbidity induced by corticosteroid therapy with the use of steroid-sparing ag
ents#^dnd^i2#^tm^len^ksystemic lupus erythematosus^i2#^tm^len^kdamage^i2#^tm^len
^kSLICC^i2^sACR-DI#^tm^len^ktherapy^i2#other#31#20030605#5/6/2003#20040108#8/1/2
004#v44n2a04.htm##
06657000000000649000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000400107121000300111049000700114158000300121
03000200012403100030014403200020014706500090014901400110015803500100016901201200
01790120106002990100034004050100046004390100040004850100025005250700013005500832
56300563085000803126085004003134085002603174085002503200085002603225085002303251
08324720327408500080574608500410575408500190579508500260581408500200584011700060
58600720003058661120009058691110009058781140009058871130009058960020013059050080
08905918#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#l#4#1#article#1#
^mmar./abr.^a2004#oa#pt#br1.1#1#4.0#tab#04#RBR160#nd#Rev. Bras. Reumatol#44#2#20
040400#^f123^l128#0482-5004#Contribuição da doença e sua terapêutica no índice d
e dano SLICC/ACR na fase precoce do lúpus eritematoso sistêmico^lpt#Contribution
 of the disease and its therapy on the SLICC/ACR-DI in early systemic lupus eryt
hematosus^len#^rND^1A01^nMailze Campos^sBezerra#^rND^1A01^nFrancisco Saraiva da^
sSilva Júnior#^rND^1A01^nEduardo Ferreira^sBorba Neto#^rND^1A01^nEloisa^sBonfá#^
iA01^1FMUSP#^lpt^aA maioria das informações relativas ao curso da doença de paci
entes com lúpus eritematoso sistêmico (LES) é restrita aos primeiros cinco anos 
após o diagnóstico. Entretanto, dados sobre a precocidade de instalação dos dano
s são pouco descritos. OBJETIVO: identificar os danos precoces de pacientes com 
LES de diagnóstico recente e verificar a influência da própria doença ou de sua 
terapêutica como principal causa para a instalação destes danos. MÉTODOS: foram 
estudados retrospectivamente 82 pacientes com LES, cujo diagnóstico foi realizad
o de 1998 até 1999 em nosso serviço. Em todos os pacientes o escore do índice de
 dano do Systemic Lupus Internacional Collaborating Clinics/American College of 
Rheumatology-Damage Index (SLICC/ACR-DI) foi avaliado no momento do diagnóstico 
e anualmente três vezes consecutivas. As manifestações clínicas e o esquema tera
pêutico foram avaliados nas consultas médicas. O escore do SLICC/ACR para cada ó
rgão/sistema e a prevalência dos danos foi identificado, assim como a sua possív
el causa (doença ou terapia). RESULTADOS: A idade (média) inicial foi de 31,6 an
os com predomínio do sexo feminino (94 por cento). A maioria dos pacientes (94 p
or cento) apresentou manifestações cutâneas e articulares, seguidas pelas renais
 (40 por cento), pulmonares (28 por cento) e neurológicas (18 por cento). Ao fin
al do estudo, 52 pacientes (63,4 por cento) não apresentaram seqüelas (sem pontu
ação no SLICC). Dos 30 pacientes restantes, 16 tiveram escore = 1 e 14 pacientes
 apresentaram escore = 2. No total observamos 36 danos, sendo 23 atribuídos à do
ença e 13 à terapia (64 por cento vs 36 por cento, p < 0,05). Os sistemas mais f
reqüentemente acometidos foram o articular e o neurológico (27,7 por cento), seg
uidos pelo renal (13,8 por cento). Todos os pacientes com comprometimento neurol
ógico tiveram danos precoces decorrentes da própria doença (apesar da terapêutic
a agressiva) enquanto a terapêutica com corticóide foi responsável pelos danos e
m 7/10 pacientes com dano articular (osteonecrose). O dano renal foi observado e
m 13,8 por cento dos pacientes (nefrite grave não responsiva ao tratamento). Out
ros efeitos adversos da terapia foram angina, catarata, diabetes e menopausa pre
coce. CONCLUSÕES: este estudo sugere que o dano precoce é ainda um importante pr
oblema no LES. São necessárias estratégias eficazes no sentido de minimizar as s
eqüelas, com destaque para as neurológicas. Redução da morbidade associada à ter
apia com corticóide também deve ser considerada utilizando-se agentes poupadores
 de esteróides#^dnd^i1#^tm^lpt^klúpus eritematoso sistêmico^i1#^tm^lpt^kSLICC^i1
^sACR-DI#^tm^lpt^kquestionário^i1#^tm^lpt^kdano tecidual^i1#^tm^lpt^ktratamento^
i1#^len^aThe majority of the information available about the disease course of p
atients with systemic lupus erythematosus (SLE) is restricted to the first five 
years after disease onset. However, data about early damage were rarely reported
. OBJECTIVE: to describe the early damage outcome of SLE patients in early disea
se and to discriminate the influence of disease itself or its therapy as the mai
n cause of their damage. METHODS: we retrospectively studied 82 patients with SL
E, diagnosed during the period from 1998 to 1999 in our institution. In all pati
ents the Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index (SLICC/ACR-DI) was scored at the diagnosis and annuall
y for the next three years. Clinical manifestations were evaluated at each visit
 as well as the therapy. The SLICC/ACR-DI scores for each organ system and the p
revalence of damage within organ systems were assessed, as well as its possible 
main cause (disease or therapy). RESULTS: the mean age at entry was 31.6 years w
ith female predominance of 94 percent. The majority of the patients (94 percent)
 presented cutaneous and articular involvement, 40 percent renal, 28 percent pul
monary, and 18 percent neurological manifestations. At the end of the study, 52 
(63.4 percent) patients had no damage to score with SLICC. From the remaining 30
 patients, 16 had a score of 1 and 14 had a score = 2. In total, 36 damages occu
rred, 23 of them attributed to the disease and 13 to the therapy (64 percent vs.
 36 percent; p < 0.05). The most frequently injured systems were the articular a
nd the neurological (27.7 percent) ones, followed by the renal (13.8 percent) sy
stem. All patients with neurological involvement have early damage due to the di
sease itself in spite of the aggressive therapeutic whereas from 10 patients wit
h articular damage, 70 percent (7) were associated with steroid therapy (osteone
crosis). In contrast, premature renal injury was observed in 13.8 percent, all o
f them with unresponsive severe nephritis. Other adverse effect of therapy inclu
ded 1 angina, 2 cataracts, 1 diabetes and 2 premature menopauses. CONCLUSIONS: t
his study suggests that early damage is still a major problem in SLE that reinfo
rces the need for new strategies in order to minimize injury, particularly for n
eurological manifestations. Moreover, it also seems important to reduce morbidit
y induced by corticosteroid therapy with the use of steroid-sparing agents#^dnd^
i2#^tm^len^ksystemic lupus erythematosus^i2#^tm^len^kdamage^i2#^tm^len^kSLICC^i2
^sACR-DI#^tm^len^ktherapy^i2#other#31#20030605#5/6/2003#20040108#8/1/2004#v44n2a
04.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50
042004000200004##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#5#1#article#154#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v44n2a04.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#6#2#article#154#<p>&nbsp;</p>     ^cY#
v44n2a04.htm##
00570000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704033800073002001300411#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#7#3#article#154#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="linkinicio"></a><b>Contribui&c
cedil;&atilde;o da doen&ccedil;a e sua terap&ecirc;utica no &iacute;ndice de dan
o    SLICC/ACR na fase precoce do l&uacute;pus eritematoso sist&ecirc;mico<sup>(
</sup><a href="#link01"><sup>*</sup></a><sup>)</sup></b></font></p>     ^cY#v44n
2a04.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#8#4#article#154#<p>&nbsp;</p>     ^cY#
v44n2a04.htm##
00427000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704019500073002001300268#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#9#5#article#154#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><b>Contribution of the disease and its 
therapy on the SLICC/ACR-DI    in early systemic lupus erythematosus </b></font>
</p>     ^cY#v44n2a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#10#6#article#154#<p>&nbsp;</p>     ^cY
#v44n2a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#11#7#article#154#<p>&nbsp;</p>     ^cY
#v44n2a04.htm##
00487000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704025400074002001300328#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#12#8#article#154#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Mailze Campos Bezerra<sup>I</sup>; 
Francisco Saraiva da Silva J&uacute;nior<sup>I</sup>; Eduardo Ferreira Borba Net
o<sup>II</sup>; Eloisa Bonf&aacute;<sup>III</sup></b></font></p>     ^cY#v44n2a0
4.htm##
00375000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704014200074002001300216#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#13#9#article#154#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>P&oacute;s-graduando da di
sciplina de reumatologia da FMUSP    ^cY#v44n2a04.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008900075002001300164#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#14#10#article#154#<br> <sup>II</sup>M&
eacute;dico assistente da disciplina de reumatologia da FMUSP    ^cY#v44n2a04.ht
m##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#15#11#article#154#<br> <sup>III</sup>P
rofessora titular da disciplina de reumatologia da FMUSP</font></p>     ^cY#v44n
2a04.htm##
00386000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015200075002001300227#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#16#12#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#linkcorresp">Endere&ccedil;
o para correspond&ecirc;ncia</a></font></p>     ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#17#13#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#18#14#article#154#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v44n2a04.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#19#15#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v44n
2a04.htm##
00881000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064700075002001300722#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#20#16#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A maioria das informa&ccedil;&otilde;
es relativas ao curso da doen&ccedil;a de pacientes com l&uacute;pus eritematoso
 sist&ecirc;mico (LES) &eacute; restrita aos primeiros cinco anos ap&oacute;s o 
diagn&oacute;stico. Entretanto, dados sobre a precocidade de instala&ccedil;&ati
lde;o dos danos s&atilde;o pouco descritos. <b>OBJETIVO:</b> identificar os dano
s precoces de pacientes com LES de diagn&oacute;stico recente e verificar a infl
u&ecirc;ncia da pr&oacute;pria doen&ccedil;a ou de sua terap&ecirc;utica como pr
incipal causa para a instala&ccedil;&atilde;o destes danos.    ^cY#v44n2a04.htm#
#
00975000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074100075002001300816#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#21#17#article#154#<br>  <b>M&Eacute;TO
DOS:</b> foram estudados retrospectivamente 82 pacientes com LES, cujo diagn&oac
ute;stico foi realizado de 1998 at&eacute; 1999 em nosso servi&ccedil;o. Em todo
s os pacientes o escore do &iacute;ndice de dano do Systemic Lupus Internacional
 Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR-
DI) foi avaliado no momento do diagn&oacute;stico e anualmente tr&ecirc;s vezes 
consecutivas. As manifesta&ccedil;&otilde;es cl&iacute;nicas e o esquema terap&e
circ;utico foram avaliados nas consultas m&eacute;dicas. O escore do SLICC/ACR p
ara cada &oacute;rg&atilde;o/sistema e a preval&ecirc;ncia dos danos foi identif
icado, assim como a sua poss&iacute;vel causa (doen&ccedil;a ou terapia).    ^cY
#v44n2a04.htm##
01495000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704126100075002001301336#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#22#18#article#154#<br>  <b>RESULTADOS:
</b> A idade (m&eacute;dia) inicial foi de 31,6 anos com predom&iacute;nio do se
xo feminino (94%). A maioria dos pacientes (94%) apresentou manifesta&ccedil;&ot
ilde;es cut&acirc;neas e articulares, seguidas pelas renais (40%), pulmonares (2
8%) e neurol&oacute;gicas (18%). Ao final do estudo, 52 pacientes (63,4%) n&atil
de;o apresentaram seq&uuml;elas (sem pontua&ccedil;&atilde;o no SLICC). Dos 30 p
acientes restantes, 16 tiveram escore = 1 e 14 pacientes apresentaram escore = 2
. No total observamos 36 danos, sendo 23 atribu&iacute;dos &agrave; doen&ccedil;
a e 13 &agrave; terapia (64% vs 36%, p &lt; 0,05). Os sistemas mais freq&uuml;en
temente acometidos foram o articular e o neurol&oacute;gico (27,7%), seguidos pe
lo renal (13,8%). Todos os pacientes com comprometimento neurol&oacute;gico tive
ram danos precoces decorrentes da pr&oacute;pria doen&ccedil;a (apesar da terap&
ecirc;utica agressiva) enquanto a terap&ecirc;utica com cortic&oacute;ide foi re
spons&aacute;vel pelos danos em 7/10 pacientes com dano articular (osteonecrose)
. O dano renal foi observado em 13,8% dos pacientes (nefrite grave n&atilde;o re
sponsiva ao tratamento). Outros efeitos adversos da terapia foram angina, catara
ta, diabetes e menopausa precoce.    ^cY#v44n2a04.htm##
00685000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045100075002001300526#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#23#19#article#154#<br>  <b>CONCLUS&Oti
lde;ES:</b> este estudo sugere que o dano precoce &eacute; ainda um importante p
roblema no LES. S&atilde;o necess&aacute;rias estrat&eacute;gias eficazes no sen
tido de minimizar as seq&uuml;elas, com destaque para as neurol&oacute;gicas. Re
du&ccedil;&atilde;o da morbidade associada &agrave; terapia com cortic&oacute;id
e tamb&eacute;m deve ser considerada utilizando-se agentes poupadores de ester&o
acute;ides.</font></p>     ^cY#v44n2a04.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023100075002001300306#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#24#20#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> l&uacute;pus e
ritematoso sist&ecirc;mico, SLICC/ACR-DI, question&aacute;rio, dano tecidual, tr
atamento.</font></p> <hr size="1" noshade>     ^cY#v44n2a04.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009800075002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#25#21#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v4
4n2a04.htm##
00537000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030300075002001300378#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#26#22#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The majority of the information avail
able about the disease course of patients with systemic lupus erythematosus (SLE
) is restricted to the first five years after disease onset. However, data about
 early damage were rarely reported.    ^cY#v44n2a04.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020200075002001300277#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#27#23#article#154#<br> <b>OBJECTIVE:</
b> to describe the early damage outcome of SLE patients in early disease and to 
discriminate the influence of disease itself or its therapy as the main cause of
 their damage.    ^cY#v44n2a04.htm##
00822000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058800075002001300663#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#28#24#article#154#<br>  <b>METHODS: </
b>we retrospectively studied 82 patients with SLE, diagnosed during the period f
rom 1998 to 1999 in our institution. In all patients the Systemic Lupus Internat
ional Collaborating Clinics/American College of Rheumatology Damage Index (SLICC
/ACR-DI) was scored at the diagnosis and annually for the next three years. Clin
ical manifestations were evaluated at each visit as well as the therapy. The SLI
CC/ACR-DI scores for each organ system and the prevalence of damage within organ
 systems were assessed, as well as its possible main cause (disease or therapy).
    ^cY#v44n2a04.htm##
01326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704109200075002001301167#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#29#25#article#154#<br>  <b>RESULTS:</b
> the mean age at entry was 31.6 years with female predominance of 94%. The majo
rity of the patients (94%) presented cutaneous and articular involvement, 40% re
nal, 28% pulmonary, and 18% neurological manifestations. At the end of the study
, 52 (63.4%) patients had no damage to score with SLICC. From the remaining 30 p
atients, 16 had a score of 1 and 14 had a score = 2. In total, 36 damages occurr
ed, 23 of them attributed to the disease and 13 to the therapy (64% vs. 36%; p &
lt; 0.05). The most frequently injured systems were the articular and the neurol
ogical (27.7%) ones, followed by the renal (13.8%) system. All patients with neu
rological involvement have early damage due to the disease itself in spite of th
e aggressive therapeutic whereas from 10 patients with articular damage, 70% (7)
 were associated with steroid therapy (osteonecrosis). In contrast, premature re
nal injury was observed in 13.8%, all of them with unresponsive severe nephritis
. Other adverse effect of therapy included 1 angina, 2 cataracts, 1 diabetes and
 2 premature menopauses.    ^cY#v44n2a04.htm##
00596000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036200075002001300437#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#30#26#article#154#<br>  <b>CONCLUSIONS
: </b>this study suggests that early damage is still a major problem in SLE that
 reinforces the need for new strategies in order to minimize injury, particularl
y for neurological manifestations. Moreover, it also seems important to reduce m
orbidity induced by corticosteroid therapy with the use of steroid-sparing agent
s.</font></p>     ^cY#v44n2a04.htm##
00416000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018200075002001300257#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#31#27#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> systemic lupus eryth
ematosus, damage, SLICC/ACR-DI, therapy.</font></p> <hr size="1" noshade>     ^c
Y#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#32#28#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#33#29#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#34#30#article#154#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v44n2a04.htm##
00878000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064400075002001300719#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#35#31#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Grandes resultados no tratamento do l
&uacute;pus eritematoso sist&ecirc;mico (LES) foram obtidos nas &uacute;ltimas d
&eacute;cadas. Podese verificar expressiva diminui&ccedil;&atilde;o da taxa de m
ortalidade dos pacientes, sendo que atualmente a sobrevida em 20 anos &eacute; p
r&oacute;xima de 70%<sup>(1)</sup>. Apesar do gradativo avan&ccedil;o obtido em 
termos de redu&ccedil;&atilde;o da mortalidade, a morbidade decorrente da pr&oac
ute;pria doen&ccedil;a e da terap&ecirc;utica passou a assumir maior import&acir
c;ncia no progn&oacute;stico dos pacientes. </font></p>     ^cY#v44n2a04.htm##
01139000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704090500075002001300980#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#36#32#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ante a necessidade de um instrumento 
padronizado para esta avalia&ccedil;&atilde;o, em 1991 foi desenvolvido o System
ic Lupus Internacional Collaborating Clinics/American College of Rheumatology-Da
mage Index (SLICC/ACR-DI), &iacute;ndice de avalia&ccedil;&atilde;o de danos de 
pacientes com LES<sup>(2)</sup>. Trata-se de um instrumento desenvolvido especif
icamente para quantificar preju&iacute;zos irrevers&iacute;veis no LES<sup>(2-4)
</sup>, que se mostrou reprodut&iacute;vel e validado para esta finalidade<sup>(
2-3)</sup>. Neste sentido, este &iacute;ndice &eacute; utilizado atualmente em e
studos longitudinais e <i>trials </i>terap&ecirc;uticos<sup>(4-7)</sup>, pois me
nsura as seq&uuml;elas resultantes tanto da doen&ccedil;a quanto de seu tratamen
to, de forma cumulativa desde o seu in&iacute;cio<sup>(2)</sup>. </font></p>    
 ^cY#v44n2a04.htm##
00793000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055900075002001300634#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#37#33#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Apesar de seu valor progn&oacute;stic
o e de incluir uma ampla s&eacute;rie de preju&iacute;zos permanentes dos divers
os &oacute;rg&atilde;os e sistemas, este &iacute;ndice n&atilde;o discrimina aqu
eles decorrentes especificamente da doen&ccedil;a e/ou de sua terapia<sup>(2)</s
up>. Neste sentido, este estudo se prop&otilde;e a avaliar as repercuss&otilde;e
s da terapia e da pr&oacute;pria doen&ccedil;a em pacientes com diagn&oacute;sti
co precoce atrav&eacute;s do SLICC/ACR.</font></p>     ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#38#34#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00350000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011600075002001300191#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#39#35#article#154#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES E M&Eacute;TODOS</b></fo
nt></p>     ^cY#v44n2a04.htm##
00800000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056600075002001300641#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#40#36#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foram analisados retrospectivamente o
s prontu&aacute;rios de 82 pacientes com diagn&oacute;stico de LES pelos crit&ea
cute;rios do ACR entre os anos de 1998 e 1999<sup>(8)</sup>, atendidos no ambula
t&oacute;rio da disciplina de reumatologia do Hospital das Cl&iacute;nicas da Fa
culdade de Medicina da Universidade de S&atilde;o Paulo (HC/FMUSP), no per&iacut
e;odo de junho a dezembro de 2001. O protocolo foi aprovado pelo comit&ecirc; de
 &eacute;tica dessa institui&ccedil;&atilde;o.</font></p>     ^cY#v44n2a04.htm##
01101000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704086700075002001300942#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#41#37#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os par&acirc;metros cl&iacute;nicos a
nalisados para o envolvimento sist&ecirc;mico foram os estabelecidos para os cri
t&eacute;rios de classifica&ccedil;&atilde;o do LES<sup>(8)</sup> incluindo artr
algia para o envolvimento articular, les&atilde;o m&aacute;culo-papular eritemat
osa em &aacute;reas expostas ou outra les&atilde;o definida como associada ao l&
uacute;pus e confirmada por bi&oacute;psia para o quadro cut&acirc;neo, pneumoni
te intersticial confirmada por tomografia computadorizada para o envolvimento pu
lmonar, miocardite confirmada por eletrocardiograma (ECG) e ecocardiograma para 
o envolvimento card&iacute;aco. Acidente vascular cerebral, neuropatia perif&eac
ute;rica e mielite transversa, definidos como associados ao l&uacute;pus para o 
quadro neurol&oacute;gico. </font></p>     ^cY#v44n2a04.htm##
00750000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051600075002001300591#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#42#38#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A avalia&ccedil;&atilde;o do &iacute;
ndice de dano SLICC/ACR foi realizada de acordo com os crit&eacute;rios estabele
cidos<sup>(2)</sup> e validados<sup>(3)</sup>. Os dados foram obtidos retrospect
ivamente durante a consulta e atrav&eacute;s de extensa revis&atilde;o dos pront
u&aacute;rios. Estes par&acirc;metros foram definidos para o momento do diagn&oa
cute;stico e anualmente at&eacute; completar tr&ecirc;s anos de seguimento. </fo
nt></p>     ^cY#v44n2a04.htm##
00853000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704061900075002001300694#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#43#39#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os exames complementares avaliados ne
ste trabalho foram os estabelecidos nos crit&eacute;rios de classifica&ccedil;&a
tilde;o do LES<sup>(8) </sup>acrescidos daqueles mencionados acima e dos definid
os para avalia&ccedil;&atilde;o do &iacute;ndice de dano<sup>(2)</sup>, ressalta
ndo-se que a disfun&ccedil;&atilde;o cognitiva foi documentada apenas por exame 
cl&iacute;nico. Todos os soros foram tamb&eacute;m testados para a presen&ccedil
;a de anticorpos anti-cardiolipina da classe IgG e IgM, pelo m&eacute;todo de EL
ISA<sup>(9)</sup>. </font></p>     ^cY#v44n2a04.htm##
00576000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034200075002001300417#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#44#40#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">An&aacute;lise estat&iacute;stica foi
 realizada atrav&eacute;s do teste n&atilde;o param&eacute;trico qui-quadrado pa
ra a compara&ccedil;&atilde;o de propor&ccedil;&otilde;es entre os grupos estuda
dos. O n&iacute;vel de signific&acirc;ncia adotado foi de 5%.s</font></p>     ^c
Y#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#45#41#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#46#42#article#154#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v44n2a04.htm##
00509000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027500075002001300350#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#47#43#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Entre os 82 pacientes analisados houv
e predom&iacute;nio do sexo feminino (77 pacientes, 94%), sendo a m&eacute;dia d
e idade no diagn&oacute;stico de 31,6 anos (variando de 21,3 a 41,9 anos). </fon
t></p>     ^cY#v44n2a04.htm##
00704000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047000075002001300545#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#48#44#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As freq&uuml;&ecirc;ncias de manifest
a&ccedil;&otilde;es cl&iacute;nicas est&atilde;o ilustradas na <a href="#tab01">
Tabela 1</a>. A maioria dos pacientes apresentou quadro articular e cut&acirc;ne
o (94%) e 62% apresentaram envolvimento hematol&oacute;gico. O acometimento rena
l ocorreu em 33 pacientes (40%), enquanto o quadro neurol&oacute;gico s&oacute; 
foi observado em 15 pacientes.</font></p>     ^cY#v44n2a04.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#49#45#article#154#<p><a name="tab01"><
/a></p>     ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#50#46#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#51#47#article#154#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a04tab01.jpg"></p>     ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#52#48#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00850000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704061600075002001300691#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#53#49#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Do total de pacientes analisados, 30 
(37%) apresentaram algum dano no per&iacute;odo de at&eacute; tr&ecirc;s anos de
 observa&ccedil;&atilde;o quando avaliados pelo &iacute;ndice de dano SLICC/ACR,
 num total de 36 eventos, analisados de acordo com sua poss&iacute;vel rela&cced
il;&atilde;o causal, isto &eacute;, associados &agrave; doen&ccedil;a ou conseq&
uuml;entes &agrave; terapia (<a href="#tab02">Tabela 2</a>). Os sistemas mais af
etados por estes danos foram o neurol&oacute;gico e o articular (28%), seguido p
elo renal (14%).</font></p>     ^cY#v44n2a04.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#54#50#article#154#<p><a name="tab02"><
/a></p>     ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#55#51#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#56#52#article#154#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a04tab02.jpg"></p>     ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#57#53#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
01223000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704098900075002001301064#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#58#54#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Das 15 pacientes com envolvimento neu
rol&oacute;gico, 10 apresentaram les&otilde;es permanentes, unicamente associada
s &agrave; atividade da doen&ccedil;a (<a href="#tab02">Tabela 2</a>). Houve pre
dom&iacute;nio das seq&uuml;elas relacionadas com quadros focais, representados 
por cinco casos de neuropatia perif&eacute;rica, quatro casos de acidente vascul
ar cerebral e um caso de mielite transversa. Os cinco casos com quadro neurol&oa
cute;gico difuso n&atilde;o evolu&iacute;ram com danos permanentes (<a href="#ta
b01">Tabela 1</a>). Dois pacientes com quadro de convuls&atilde;o n&atilde;o pon
tuaram pelo &iacute;ndice, pois n&atilde;o necessitaram terapia anticonvulsivant
e por mais de seis meses. Tr&ecirc;s pacientes apresentaram psicose de dura&cced
il;&atilde;o limitada, necessitando terapia por per&iacute;odo muito inferior a 
seis meses. N&atilde;o observamos disfun&ccedil;&atilde;o cognitiva. </font></p>
     ^cY#v44n2a04.htm##
00835000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060100075002001300676#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#59#55#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O envolvimento renal, complica&ccedil
;&atilde;o em 33 pacientes, resultou em les&atilde;o permanente significativa em
 14% dos casos: tr&ecirc;s pacientes com protein&uacute;ria &gt;3,5g/dia, um pac
iente com taxa de filtra&ccedil;&atilde;o glomerular &lt; 50% e um com insufici&
ecirc;ncia renal terminal (<a href="#tab01">Tabelas 1</a> e <a href="#tab02">2</
a>). Os cinco casos de dano renal foram decorrentes de seq&uuml;elas exclusivame
nte relacionadas com atividade de nefrite grave (<a href="#tab02">Tabela 2</a>).
 </font></p>     ^cY#v44n2a04.htm##
01605000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704137100075002001301446#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#60#56#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o ao sistema 
m&uacute;sculoesquel&eacute;tico houve dano em 10/77 casos (12,98%) (<a href="#t
ab01">Tabela 1</a>), sendo relacionado com terapia em 70% dos pacientes (<a href
="#tab02">Tabela 2</a>). Oito pacientes apresentaram osteonecrose, sendo 3 em m&
uacute;ltiplos s&iacute;tios (n&atilde;o foram relatados como mais de um evento)
. Dos 8 pacientes com osteonecrose, 3 ocorreram no primeiro ano, 3 no segundo e 
2 no terceiro ano. Interessante notar que todos estavam sob corticoterapia com d
oses superiores a 30 mg/dia no primeiro ano de seguimento e 5 permaneceram  com 
esta dose tamb&eacute;m no segundo ano. Apenas  um paciente apresentou anticorpo
 anticardiolipina positivo  em t&iacute;tulos baixos no in&iacute;cio e posterio
rmente em altos t&iacute;tulos,  associado &agrave; perda de polpa digital, send
o considerado como s&iacute;ndrome do anticorpo anti-fosfolip&iacute;deo (SAAF),
 sendo que neste caso a osteonecrose foi provavelmente atribu&iacute;da &agrave;
 pr&oacute;pria doen&ccedil;a. Todos os casos de osteonecrose eram sintom&aacute
;ticos e o diagn&oacute;stico inicial foi realizado por radiologia simples. Apes
ar do curto tempo de doen&ccedil;a, de apenas tr&ecirc;s anos, foi observada art
rite deformante redut&iacute;vel em dois pacientes.</font></p>     ^cY#v44n2a04.
htm##
00957000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704072300075002001300798#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#61#57#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outros efeitos adversos atribu&iacute
;dos &agrave; terapia com corticoster&oacute;ide foram catarata (dois casos) e d
iabetes (um caso). Al&eacute;m disso, uma paciente apresentou infarto agudo do m
ioc&aacute;rdio, necessitando revasculariza&ccedil;&atilde;o mioc&aacute;rdica, 
por&eacute;m n&atilde;o possu&iacute;a outros fatores de risco para doen&ccedil;
a coronariana como hipertens&atilde;o arterial, dislipidemia, antifosfol&iacute;
pides (<a href="#tab02">Tabela 2</a>). Duas pacientes apresentaram fal&ecirc;nci
a ovariana prematura (FOP), com idade de 35 e 39 anos, provavelmente relacionada
 com maior tempo de uso de ciclofosfamida. </font></p>     ^cY#v44n2a04.htm##
00619000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038500075002001300460#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#62#58#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o a outros da
nos associados &agrave; doen&ccedil;a observamos um caso de fibrose pulmonar e q
uatro casos associados ao sistema vascular perif&eacute;rico: perda de polpa dig
ital (dois casos), amputa&ccedil;&atilde;o de metatarsos (um caso) e trombose ve
nosa profunda (um caso). </font></p>     ^cY#v44n2a04.htm##
00557000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032300075002001300398#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#63#59#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nenhum paciente apresentou les&otilde
;es permanentes decorrentes do quadro dermatol&oacute;gico ou gastrointestinal, 
bem como n&atilde;o foram diagnosticados casos de malignidade no per&iacute;odo 
do estudo (<a href="#tab02">Tabela 2</a>). </font></p>     ^cY#v44n2a04.htm##
01071000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704083700075002001300912#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#64#60#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Avalia&ccedil;&atilde;o global dos 36
 eventos de danos permanentes mostrou que o dano induzido pela terap&ecirc;utica
 &eacute; significativamente menor que aquele causado pela doen&ccedil;a (<a hre
f="#tab02">Tabela 2</a>). Dos danos, 64% foram atribu&iacute;dos &agrave; ativid
ade da doen&ccedil;a, enquanto 36% foram decorrentes da terapia (p=0,04). &Eacut
e; interessante notar que a maioria das seq&uuml;elas (56%) relacionadas com a a
tividade da doen&ccedil;a foi identificada no momento do diagn&oacute;stico (qua
tro danos) e no fim do primeiro ano da doen&ccedil;a (nove danos). Da mesma form
a, a maioria dos danos por terap&ecirc;utica (77%) ocorreu nos primeiros dois an
os com cinco danos ao final do primeiro ano e cinco no final do segundo ano. </f
ont></p>     ^cY#v44n2a04.htm##
01115000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704088100075002001300956#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#65#61#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise da evolu&ccedil;&ati
lde;o do &iacute;ndice de dano no per&iacute;odo de tr&ecirc;s anos nos 82 pacie
ntes demonstrou que, no momento do diagn&oacute;stico, apenas 7% dos pacientes j
&aacute; apresentavam les&atilde;o permanente, com &iacute;ndice de dano m&eacut
e;dio/paciente de 0,073 (<a href="#tab03">Tabela 3</a>). Houve uma significativa
 progress&atilde;o gradativa de aparecimento de les&otilde;es permanentes no gru
po e de ac&uacute;mulo de danos em pacientes individualmente, resultando no fina
l de tr&ecirc;s anos em mais de um ter&ccedil;o dos pacientes com les&atilde;o p
ermanente (37%). Destes, 17% acumularam mais de um dano. Houve tamb&eacute;m um 
aumento de cerca de oito vezes no &iacute;ndice de dano m&eacute;dio/paciente (0
,6) ao final do per&iacute;odo estudado. </font></p>     ^cY#v44n2a04.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#66#62#article#154#<p><a name="tab03"><
/a></p>     ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#67#63#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#68#64#article#154#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a04tab03.jpg"></p>     ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#69#65#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#70#66#article#154#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v44n2a04.htm##
00747000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051300075002001300588#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#71#67#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Este estudo mostra que, apesar da mai
oria dos casos de dano precoce estar diretamente associada &agrave; atividade da
 doen&ccedil;a (com destaque para o sistema nervoso), mais de um ter&ccedil;o do
s eventos de les&atilde;o permanente s&atilde;o decorrentes da terap&ecirc;utica
. Observamos ainda que a evolu&ccedil;&atilde;o dos danos &eacute; rapidamente p
rogressiva ao longo de tr&ecirc;s anos ap&oacute;s o diagn&oacute;stico. </font>
</p>     ^cY#v44n2a04.htm##
01008000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704077400075002001300849#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#72#68#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O envolvimento focal do sistema nervo
so e o quadro renal foram as principais causas de danos associados &agrave; doen
&ccedil;a. J&aacute; foi demonstrado que manifesta&ccedil;&otilde;es neurol&oacu
te;gicas focais (acidente vascular cerebral, convuls&atilde;o, neuropatia, mieli
te transversa) est&atilde;o relacionadas com um pior progn&oacute;stico, com ele
vada mortalidade em 5, 10 e 20 anos quando comparados com pacientes com sintomas
 neuropsiqui&aacute;tricos difusos (cefal&eacute;ia, s&iacute;ndrome org&acirc;n
ica cerebral, psicose)<sup>(10)</sup>. Dados da literatura mostram que o dano no
 in&iacute;cio da doen&ccedil;a est&aacute; relacionado com maior mortalidade<su
p>(12)</sup>. </font></p>     ^cY#v44n2a04.htm##
01034000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080000075002001300875#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#73#69#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ressalta-se que o dano neurol&oacute;
gico precoce continua sendo um problema significativo no LES, visto que mais da 
metade dos pacientes com acometimento neurol&oacute;gico (66%) evolu&iacute;ram 
com les&atilde;o permanente<sup>(13,14)</sup>. Em contraste, apenas 15% dos caso
s de envolvimento renal apresentaram les&atilde;o permanente, o que estaria de a
cordo com a freq&uuml;&ecirc;ncia de casos refrat&aacute;rios ao tratamento padr
&atilde;o com ciclofosfamida<sup>(15)</sup>, refor&ccedil;ando que, apesar de um
a resposta muito superior que a do quadro neurol&oacute;gico, ainda existe a nec
essidade de se buscar alternativas terap&ecirc;uticas para um subgrupo mais grav
e de les&atilde;o renal<sup>(16)</sup>. </font></p>     ^cY#v44n2a04.htm##
00863000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704062900075002001300704#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#74#70#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outros danos associados &agrave; doen
&ccedil;a foram: o vascular perif&eacute;rico (tr&ecirc;s casos de vasculite pro
vocando perdas menores de subst&acirc;ncias e uma amputa&ccedil;&atilde;o); e um
 caso de trombose venosa profunda associado &agrave; SAAF. A artropatia de Jacco
ud ocorre em 3% a 38% dos casos de LES<sup>(17-21)</sup> e &eacute; considerada 
uma deformidade tardia do envolvimento articular. Dois casos apresentaram o padr
&atilde;o t&iacute;pico com subluxa&ccedil;&otilde;es, sem eros&otilde;es, no pr
imeiro ano de doen&ccedil;a. </font></p>     ^cY#v44n2a04.htm##
00516000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028200075002001300357#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#75#71#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As les&otilde;es permanentes decorren
tes do uso de drogas ocorreram em um n&uacute;mero significativo de pacientes (3
9%), e para a maioria dos casos esteve associada ao uso de corticoster&oacute;id
e.</font></p>     ^cY#v44n2a04.htm##
00755000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052100075002001300596#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#76#72#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Neste aspecto, a principal causa de d
ano para o sistema m&uacute;sculoesquel&eacute;tico esteve relacionada com necro
se ass&eacute;ptica. Este quadro foi inicialmente descrito em 1960 por Dubois e 
Cozen<sup>(22)</sup>, com preval&ecirc;ncia estimada de apenas 5%. Estudos mais 
recentes t&ecirc;m documentado preval&ecirc;ncias variando de 14% a 40%, provave
lmente resultantes de melhores m&eacute;todos diagn&oacute;sticos<sup>(23)</sup>
.</font></p>     ^cY#v44n2a04.htm##
01590000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704135600075002001301431#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#77#73#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A terap&ecirc;utica com corticoster&o
acute;ide tem sido relatada como a principal causa de osteonecrose<sup>(24,25)</
sup>. De fato, foi demonstrado que o uso destas drogas leva a uma redu&ccedil;&a
tilde;o de forma&ccedil;&atilde;o e turnover &oacute;sseo. Adicionalmente foi ob
servado um aumento da apoptose do oste&oacute;cito<sup>(24)</sup>. Outros fatore
s tamb&eacute;m t&ecirc;m sido implicados na patog&ecirc;nese desta complica&cce
dil;&atilde;o, como a SAAF<sup>(26,27)</sup>. Al&eacute;m disso, foi observada a
 associa&ccedil;&atilde;o da presen&ccedil;a de anticorpos anticardiolipina e de
 osteonecrose de f&ecirc;mur n&atilde;o traum&aacute;tica em pacientes sem diagn
&oacute;stico de LES<sup>(28)</sup>. Neste estudo, apenas uma paciente com esta 
complica&ccedil;&atilde;o apresentava anticorpos anticardiolipina. A mesma apres
entou perda de polpa digital atribu&iacute;da &agrave; SAAF, sendo este dano atr
ibu&iacute;do &agrave; doen&ccedil;a. Desta forma, a maioria dos casos de osteon
ecrose identificados em nossa popula&ccedil;&atilde;o parece estar relacionada d
iretamente com a corticoterapia, visto que cinco dos oito pacientes foram mantid
os com altas doses por pelo menos dois anos de seguimento e nenhum deles possu&i
acute;a anticorpos anticardiolipina.</font></p>     ^cY#v44n2a04.htm##
00794000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056000075002001300635#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#78#74#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outros danos associados ao uso de cor
ticoter&oacute;ides foram diabetes, catarata e infarto agudo do mioc&aacute;rdio
. Com rela&ccedil;&atilde;o a esta &uacute;ltima complica&ccedil;&atilde;o, obse
rva-se que a incid&ecirc;ncia de doen&ccedil;a coronariana em LES est&aacute; au
mentando nos &uacute;ltimos anos e estudo epidemiol&oacute;gico recente demonstr
ou que o risco em mulheres jovens com LES &eacute; 50 vezes maior que na popula&
ccedil;&atilde;o normal<sup>(29)</sup>. </font></p>     ^cY#v44n2a04.htm##
00772000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053800075002001300613#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#79#75#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A fal&ecirc;ncia ovariana prematura t
em sido diretamente associada ao uso de alquilantes, particularmente a ciclofosf
amida, estando relacionada com a dose cumulativa, dura&ccedil;&atilde;o da terap
ia e a idade da paciente<sup>(30)</sup>. Neste aspecto, as duas pacientes com es
ta manifesta&ccedil;&atilde;o iniciaram a terapia com ciclofosfamida com 35 e 39
 anos de idade, sendo a FOP provavelmente relacionada com o maior tempo de uso d
a ciclofosfamida. </font></p>     ^cY#v44n2a04.htm##
00755000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052100075002001300596#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#80#76#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A efic&aacute;cia do &iacute;ndice de
 SLICC de detectar mudan&ccedil;as ao longo do tempo j&aacute; foi demonstrada e
m estudo pr&eacute;vio<sup>(31)</sup> e confirmada neste estudo. O aumento do da
no paralelo &agrave; dura&ccedil;&atilde;o da doen&ccedil;a nos primeiros anos a
mplia observa&ccedil;&otilde;es anteriores que ap&oacute;s dez anos da doen&cced
il;a, 70% dos pacientes apresentavam dano avaliado pelo SLICC/ACR<sup>(5)</sup>.
 </font></p>     ^cY#v44n2a04.htm##
00621000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038700075002001300462#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#81#77#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Estudos com acompanhamento deste &iac
ute;ndice nos pacientes em 2 anos, 5-10 anos e mais de 10 anos mostraram que a p
rogress&atilde;o de 2 anos at&eacute; 5-10 anos de doen&ccedil;a &eacute; mais l
enta que o observado neste trabalho com uma m&eacute;dia de progress&atilde;o de
 2,3 vezes<sup>(12)</sup>. </font></p>     ^cY#v44n2a04.htm##
00897000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704066300075002001300738#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#82#78#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Conclu&iacute;mos que o dano &eacute;
 rapidamente progressivo nos primeiros anos da doen&ccedil;a. Enfatizamos que s&
atilde;o necess&aacute;rias novas estrat&eacute;gias terap&ecirc;uticas no senti
do de minimizar as seq&uuml;elas decorrentes da doen&ccedil;a, em particular do 
sistema neurol&oacute;gico. Outro aspecto importante &eacute; a necessidade de s
e reduzir a morbidade induzida pela terap&ecirc;utica, que tem como principal en
foque a avalia&ccedil;&atilde;o do risco/benef&iacute;cio de se utilizar, quando
 poss&iacute;vel, agentes poupadores de corticoster&oacute;ide.</font></p>     ^
cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#83#79#article#154#<p>&nbsp;</p>     ^c
Y#v44n2a04.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#84#80#article#154#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v44n2a04.htm##
00516000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026800077002001300345#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#85#81#article#154#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Abu-Shakra, Urowitz 
MB, Gladman DD, Gough J: Mortality studies in systemic lupus erytematosus. Resul
ts from a single centre. II. Predictor variables for mortality. J Rheumatol 22: 
1265-70, 1995.    ^cY#v44n2a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#86#82#article#154# </font></p>     ^cY
#v44n2a04.htm##
00574000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704032600077002001300403#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#87#83#article#154#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Gladman DD, Ginzler 
E, Goldsmith C, et al: The development and initial validation of the systemic lu
pus international collaborating clinics/American College of Rheumatology damage 
index for systemic lupus erythematosus. Arthritis Rheum 39: 363-9, 1996.    ^cY#
v44n2a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#88#84#article#154# </font></p>     ^cY
#v44n2a04.htm##
00568000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704032000077002001300397#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#89#85#article#154#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Gladmann DD, Urowitz
 MB, Goldsmith CH, et al: The reliability of the systemic lupus international co
llaborating clinics/American College of Rheumatology damage index in patients wi
th systemic lupus erythematosus. Arthritis Rheum 40: 809-13, 1997.    ^cY#v44n2a
04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#90#86#article#154# </font></p>     ^cY
#v44n2a04.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704019200077002001300269#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#91#87#article#154#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Gladman DD, Urowitz 
MB. The SLICC/ACR damage index: progress report and experience in the field. Lup
us 8: 632-7, 1999.    ^cY#v44n2a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#92#88#article#154# </font></p>     ^cY
#v44n2a04.htm##
00512000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026400077002001300341#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#93#89#article#154#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Zonna-Nacach A, Cama
rgo-Coronel A, Yanez P, et al: Measurement of damage in 210 mexican patients wit
h systemic lupus erythematosus: relationship with disease duration. Lupus 7: 119
-23, 1998.    ^cY#v44n2a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#94#90#article#154# </font></p>     ^cY
#v44n2a04.htm##
00534000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704028600077002001300363#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#95#91#article#154#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Nossent JC: SLICC/AC
R damage index in afro-Caribbean patients with systemic lupus erythematosus: cha
nges in and relationship to disease activity, corticosteroid therapy and prognos
is. J Rheumatol 25: 654-9, 1998.    ^cY#v44n2a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#96#92#article#154# </font></p>     ^cY
#v44n2a04.htm##
00601000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704035300077002001300430#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#97#93#article#154#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Stoll T, Stucki G, M
alik J, et al: Association of the systemic lupus international collaborating cli
nics/American College of Rheumatology damage index with measures of disease acti
vity and health status in patients with systemic lupus erythematosus. J Rheumato
l 24: 309-13, 1997.    ^cY#v44n2a04.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#98#94#article#154#</font></p>     ^cY#
v44n2a04.htm##
00471000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704022300077002001300300#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#99#95#article#154#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Tan EM, Chen AS, Fri
es JF, et al: The 1982 revised criteria for the classification of systemic lupus
 erythematosus. Arthritis Rheum 25: 1271-7, 1982.    ^cY#v44n2a04.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002000076002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#100#96#article#154#</font></p>     ^cY
#v44n2a04.htm##
00477000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704022800078002001300306#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#101#97#article#154#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Gharavi AE, Harris 
EM, Asherson RA, Hughes GRV: Anticardiolipin antibodies isotype distribution and
 phospholipid specificity. Ann Rheum Dis 46: 1-6, 1987.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#102#98#article#154# </font></p>     ^c
Y#v44n2a04.htm##
00439000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704018900079002001300268#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#103#99#article#154#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Kovacs JAJ, Urowi
tz MB, Gladman DD: Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am 1
9: 795-813, 1993.    ^cY#v44n2a04.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#104#100#article#154# </font></p>     ^
cY#v44n2a04.htm##
00538000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028700080002001300367#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#105#101#article#154#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Stoll T, Seifert
 B, Isenberg DA: SLICC/ACR damage index is valid and renal e pulmonary organ sco
res are predictors of severe outcome in patients with systemic lupus erythematos
us. Br J Rheumatol 35: 248-54, 1996.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#106#102#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00572000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032100080002001300401#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#107#103#article#154#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Gladman DD, Gold
smith CH, Urowitz MB, et al: The Systemic Lupus International Collaborating Clin
ics / American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lup
us Erytematosus International Comparison. J Rheumatol 27: 373-6, 2000.    ^cY#v4
4n2a04.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#108#104#article#154# </font></p>     ^
cY#v44n2a04.htm##
00447000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019600080002001300276#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#109#105#article#154#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Borba EF, Bonf&a
acute; E: A first step toward solving the neuropsychiatric lupus puzzle. J Clin 
Rheumatol 5: 312-3, 1999.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#110#106#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00445000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019400080002001300274#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#111#107#article#154#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Sanni G, Khamash
ta MA: Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupu
s. Lupus 12: 1-2, 2003.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#112#108#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025800080002001300338#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#113#109#article#154#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Boumpas DT, Aust
in HA, Vaughn EM, et al: Controlled trial of pulse methylprednisolone versus two
 regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-5
, 1992.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#114#110#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00442000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019100080002001300271#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#115#111#article#154#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Gescuk BD, Davis
 JC: Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheuma
tol 14:515-21, 2002.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#116#112#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00480000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022900080002001300309#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#117#113#article#154#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Alarcon-Segovia 
D, Abud-Mendonza C, Diaz-Jouanen E, et al: Deforming arthropathy of the hands in
 systemic lupus erythematosus. J Rheumatol 15: 65-9, 1988.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#118#114#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00429000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017800080002001300258#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#119#115#article#154#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Bleifeld CJ, Ing
lis AE: The hand in systemic lupus erythematosus. J Bone Joint Surg 56A: 1207-15
, 1974.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#120#116#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00459000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020800080002001300288#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#121#117#article#154#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Dreyfus JN, Schn
itzer TJ: Pathogenesis and differential diagnosis of the swan-neck deformity. Se
min Arthritis Rheum 13: 200-11, 1983.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#122#118#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00451000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020000080002001300280#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#123#119#article#154#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Esdaile JM, Dano
ff D, Rosenthal L, et al: Deforming arthritis in systemic lupus erythematosus. A
nn Rheum Dis 40: 124-6, 1981.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#124#120#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00415000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704016400080002001300244#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#125#121#article#154#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Kahn MF: Jaccoud
's syndrome in a rheumatology unit. Clin Rheum Pract Winter: 153-5, 1986.    ^cY
#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#126#122#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00450000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019900080002001300279#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#127#123#article#154#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Dubois EL, Cozen
 L: Avascular (aseptic) bone necrosis associated with lupus erythematosus. J Am 
Med Assoc 174: 966-84, 1960.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#128#124#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022100080002001300301#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#129#125#article#154#23#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Petri M: Musculo
skeletal complications of systemic lupus erythematosus in the Hopkins Lupus Coho
rt: an update. Arthritis Care Res 8: 137-45, 1995.    ^cY#v44n2a04.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#130#126#article#154# </font></p>     ^
cY#v44n2a04.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022100080002001300301#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#131#127#article#154#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Manolagas SC, We
instein RS: New developments in the pathogenesis and treatment of steroid-induce
d osteoporosis. J Bone Miner Res 14: 1061-6, 1999.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#132#128#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00449000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019800080002001300278#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#133#129#article#154#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Cunnane G, Lane 
NE: Steroid-induced osteoporosis in systemic lupus erythematosus. Rheum Dis Clin
 North Am 26: 311-27, 2000.    ^cY#v44n2a04.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#134#130#article#154# </font></p>     ^
cY#v44n2a04.htm##
00483000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023200080002001300312#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#135#131#article#154#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Mont MA, Glueck 
CJ, Pacheco IH, Wang P, Hungerford DS, Petri M: Risk factors for osteonecrosis i
n systemic lupus erythematosus. J Rheumatol 24: 654-62, 1997.    ^cY#v44n2a04.ht
m##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#136#132#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00490000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023900080002001300319#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#137#133#article#154#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Egan RM, Munn RK
: Catastrophic antiphospholipid antibody syndrome presenting with multiple throm
boses and sites of avascular necrosis. J Rheumatol 21: 2376-9, 1994.    ^cY#v44n
2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#138#134#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00485000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023400080002001300314#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#139#135#article#154#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Korompilias AV, 
Gilkeson GC, Ortel TL, Seaber AV, Urbaniak JR: Anticardiolipin antibodies and os
teonecrosis of the femoral head. Clin Orthop 345: 174-80, 1997.    ^cY#v44n2a04.
htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#140#136#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#141#137#article#154#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Manzi S, Meilahn
 EM, Rairie JE, et al: Age-specific incidence rates of myocardial infarction and
 angina in women with systemic lupus erythematosus. Am J Epidemiol 145: 408-15, 
1997.    ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#142#138#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00561000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031000080002001300390#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#143#139#article#154#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Boumpas DT, Aust
in HA 3rd, Vaughan EM, Yarboro CH, Klippel J, Balow JE: Risk for sustained ameno
rrhea in patients with systemic lupus erythematosus receiving intermittent pulse
 cyclophosphamide therapy. Ann Intern Med 119: 366-9, 1993.    ^cY#v44n2a04.htm#
#
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#144#140#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024800080002001300328#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#145#141#article#154#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Bootsma H, Derks
en RHWM, Jaegers SMHJ, et al: Usefulness of the SLICC/ACR damage index in patien
ts with systemic lupus erythematosus. Arthritis Rheum 40(suppl9): S160, 1997.   
 ^cY#v44n2a04.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#146#142#article#154#</font></p>     ^c
Y#v44n2a04.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#147#143#article#154#<p>&nbsp;</p>     
^cY#v44n2a04.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#148#144#article#154#<p>&nbsp;</p>     
^cY#v44n2a04.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022900077002001300306#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#149#145#article#154#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a href="#linkinicio"><img src="/im
g/revistas/rbr/v44n2/seta.jpg" border="0"></a><a name="linkcorresp"></a> <b>Ende
re&ccedil;o para correspond&ecirc;ncia:</b>    ^cY#v44n2a04.htm##
00277000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004100077002001300118#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#150#146#article#154#<br>  Eduardo Ferr
eira Borba Neto    ^cY#v44n2a04.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007000077002001300147#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#151#147#article#154#<br> Av. Dr. Arnal
do, 455, 3.º andar, Reumatologia, sala 3.133    ^cY#v44n2a04.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006800077002001300145#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#152#148#article#154#<br> Cerqueira C&e
acute;sar, S&atilde;o Paulo, CEP 01246-903    ^cY#v44n2a04.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009100077002001300168#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#153#149#article#154#<br> E-mail: <a hr
ef="mailto:reumato@edu.usp.br">reumato@edu.usp.br</a></font></p>     ^cY#v44n2a0
4.htm##
00328000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009200077002001300169#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#154#150#article#154#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Recebido em 5/6/2003.    ^cY#v44n2a
04.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007600077002001300153#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#155#151#article#154#<br>  Aprovado, ap
&oacute;s revis&atilde;o, em 8/1/2004.</font></p>     ^cY#v44n2a04.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#156#152#article#154#<p>&nbsp;</p>     
^cY#v44n2a04.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#157#153#article#154#<p>&nbsp;</p>     
^cY#v44n2a04.htm##
00487000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704025100077002001300328#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a04.htm#S#p#158#154#article#154#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a name="link01"></a><a href="#link
inicio">*</a> 	Trabalho realizado na disciplina de reumatologia da Faculdade de 
Medicina da Universidade de S&atilde;o Paulo (FMUSP).</font></p>     ^cY#v44n2a0
4.htm##
00649000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100018000930100
01800111010001500129012012200144030001200266031000300278014000800281065000900289
064000500298865000900303002001300312035001000325801001200335#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#159#1#article#31#1#^rND^sAbu-Shakra#^rND^s
Urowitz^nMB#^rND^sGladman^nDD#^rND^sGough^nJ#Mortality studies in systemic lupus
 erytematosus: Results from a single centre. II. Predictor variables for mortali
ty^len#J Rheumatol#22#1265-70#19950000#1995#20040400#v44n2a04.htm#0315-162X#J Rh
eumatol##
00705000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940100
01900111810000600130012018000136030001600316031000300332014000600335065000900341
064000500350865000900355002001300364035001000377801001600387#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#160#2#article#31#2#^rND^sGladman^nDD#^rND^
sGinzler^nE#^rND^sGoldsmith^nC#et al#The development and initial validation of t
he systemic lupus international collaborating clinics/American College of Rheuma
tology damage index for systemic lupus erythematosus^len#Arthritis Rheum#39#363-
9#19960000#1996#20040400#v44n2a04.htm#0004-3591#Arthritis rheum##
00699000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100018000950100
02000113810000600133012017000139030001600309031000300325014000700328065000900335
064000500344865000900349002001300358035001000371801001600381#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#161#3#article#31#3#^rND^sGladmann^nDD#^rND
^sUrowitz^nMB#^rND^sGoldsmith^nCH#et al#The reliability of the systemic lupus in
ternational collaborating clinics/American College of Rheumatology damage index 
in patients with systemic lupus erythematosus^len#Arthritis Rheum#40#809-13#1997
0000#1997#20040400#v44n2a04.htm#0004-3591#Arthritis rheum##
00532000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100018000940120
07600112030000600188031000200194014000600196065000900202064000500211865000900216
002001300225035001000238801000600248#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a04.htm#S#c#162#4#article#31#4#^rND^sGladman^nDD#^rND^sUrowitz^nMB#The SLICC/A
CR damage index: progress report and experience in the field^len#Lupus#8#632-7#1
9990000#1999#20040400#v44n2a04.htm#0961-2033#Lupus##
00633000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100022000760100025000980100
01500123810000600138012012000144030000600264031000200270014000700272065000900279
064000500288865000900293002001300302035001000315801000600325#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#163#5#article#31#5#^rND^sZonna-Nacach^nA#^
rND^sCamargo-Coronel^nA#^rND^sYanez^nP#et al#Measurement of damage in 210 mexica
n patients with systemic lupus erythematosus: relationship with disease duration
^len#Lupus#7#119-23#19980000#1998#20040400#v44n2a04.htm#0961-2033#Lupus##
00614000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760120175000940300
01200269031000300281014000600284065000900290064000500299865000900304002001300313
035001000326801001200336#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#
c#164#6#article#31#6#^rND^sNossent^nJC#SLICC/ACR damage index in afro-Caribbean 
patients with systemic lupus erythematosus: changes in and relationship to disea
se activity, corticosteroid therapy and prognosis^len#J Rheumatol#25#654-9#19980
000#1998#20040400#v44n2a04.htm#0315-162X#J Rheumatol##
00728000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100016000910100
01500107810000600122012021800128030001200346031000300358014000700361065000900368
064000500377865000900382002001300391035001000404801001200414#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#165#7#article#31#7#^rND^sStoll^nT#^rND^sSt
ucki^nG#^rND^sMalik^nJ#et al#Association of the systemic lupus international col
laborating clinics/American College of Rheumatology damage index with measures o
f disease activity and health status in patients with systemic lupus erythematos
us^len#J Rheumatol#24#309-13#19970000#1997#20040400#v44n2a04.htm#0315-162X#J Rhe
umatol##
00602000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760100015000900100
01600105810000600121012008500127030001600212031000300228014000700231065000900238
064000500247865000900252002001300261035001000274801001600284#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#166#8#article#31#8#^rND^sTan^nEM#^rND^sChe
n^nAS#^rND^sFries^nJF#et al#The 1982 revised criteria for the classification of 
systemic lupus erythematosus^len#Arthritis Rheum#25#1271-7#19820000#1982#2004040
0#v44n2a04.htm#0004-3591#Arthritis rheum##
00612000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940100
01900111010001800130012008100148030001400229031000300243014000400246065000900250
064000500259865000900264002001300273035001000286801001400296#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#167#9#article#31#9#^rND^sGharavi^nAE#^rND^
sHarris^nEM#^rND^sAsherson^nRA#^rND^sHughes^nGRV#Anticardiolipin antibodies isot
ype distribution and phospholipid specificity^len#Ann Rheum Dis#46#1-6#19870000#
1987#20040400#v44n2a04.htm#0003-4967#Ann Rheum Dis##
00566000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01800114012003900132030002400171031000300195014000800198065000900206064000500215
865000900220002001300229035001000242801002400252#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a04.htm#S#c#168#10#article#31#10#^rND^sKovacs^nJAJ#^rND^sUrowitz^n
MB#^rND^sGladman^nDD#Dilemmas in neuropsychiatric lupus^len#Rheum Dis Clin North
 Am#19#795-813#19930000#1993#20040400#v44n2a04.htm#0889-857X#Rheum Dis Clin Nort
h Am##
00655000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01900110012015000129030001500279031000300294014000700297065000900304064000500313
865000900318002001300327035001000340801001500350#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a04.htm#S#c#169#11#article#31#11#^rND^sStoll^nT#^rND^sSeifert^nB#^
rND^sIsenberg^nDA#SLICC/ACR damage index is valid and renal e pulmonary organ sc
ores are predictors of severe outcome in patients with systemic lupus erythemato
sus^len#Br J Rheumatol#35#248-54#19960000#1996#20040400#v44n2a04.htm#0263-7103#B
r J Rheumatol##
00697000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100020000960100
01800116810000600134012017600140030001200316031000300328014000600331065000900337
064000500346865000900351002001300360035001000373801001200383#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#170#12#article#31#12#^rND^sGladman^nDD#^rN
D^sGoldsmith^nCH#^rND^sUrowitz^nMB#et al#The Systemic Lupus International Collab
orating Clinics / American College of Rheumatology (SLICC/ACR) Damage Index for 
Systemic Lupus Erytematosus International Comparison^len#J Rheumatol#27#373-6#20
000000#2000#20040400#v44n2a04.htm#0315-162X#J Rheumatol##
00504000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100015000940120
06600109030001700175710000200192031000200194014000600196065000900202064000500211
865000900216002001300225#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#
c#171#13#article#31#13#^rND^sBorba^nEF#^rND^sBonfá^nE#A first step toward solvin
g the neuropsychiatric lupus puzzle^len#J Clin Rheumatol#2#5#312-3#19990000#1999
#20040400#v44n2a04.htm##
00535000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100020000930120
07900113030000600192031000300198032000400201065000900205064000500214865000900219
002001300228035001000241801000600251#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a04.htm#S#c#172#14#article#31#14#^rND^sSanni^nG#^rND^sKhamashta^nMA#Low-dose p
ulse cyclophosphamide in the treatment of neuropsychiatric lupus^len#Lupus#12#1-
2#20030000#2003#20040400#v44n2a04.htm#0961-2033#Lupus##
00629000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
01700113810000600130012012100136030000700257031000400264014000600268065000900274
064000500283865000900288002001300297035001000310801000700320#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#173#15#article#31#15#^rND^sBoumpas^nDT#^rN
D^sAustin^nHA#^rND^sVaughn^nEM#et al#Controlled trial of pulse methylprednisolon
e versus two regimens of pulse cyclophosphamide in severe lupus nephritis^len#La
ncet#340#741-5#19920000#1992#20040400#v44n2a04.htm#0099-5355#Lancet##
00547000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950120
06200111030002000173031000300193014000700196065000900203064000500212865000900217
002001300226035001000239801002000249#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a04.htm#S#c#174#16#article#31#16#^rND^sGescuk^nBD#^rND^sDavis^nJC#Novel therap
eutic agents for systemic lupus erythematosus^len#Curr Opin Rheumatol#14#515-21#
20020000#2002#20040400#v44n2a04.htm#1040-8711#Curr Opin Rheumatol##
00605000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100025000780100023001030100
02200126810000600148012007100154030001200225031000300237014000500240065000900245
064000500254865000900259002001300268035001000281801001200291#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#175#17#article#31#17#^rND^sAlarcon-Segovia
^nD#^rND^sAbud-Mendonza^nC#^rND^sDiaz-Jouanen^nE#et al#Deforming arthropathy of 
the hands in systemic lupus erythematosus^len#J Rheumatol#15#65-9#19880000#1988#
20040400#v44n2a04.htm#0315-162X#J Rheumatol##
00493000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100017000970120
04500114030001800159710000200177031000400179014000800183065000900191064000500200
865000900205002001300214#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#
c#176#18#article#31#18#^rND^sBleifeld^nCJ#^rND^sInglis^nAE#The hand in systemic 
lupus erythematosus^len#J Bone Joint Surg#2#56A#1207-15#19740000#1974#20040400#v
44n2a04.htm##
00565000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100020000960120
07100116030002200187031000300209014000700212065000900219064000500228865000900233
002001300242035001000255801002200265#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a04.htm#S#c#177#19#article#31#19#^rND^sDreyfus^nJN#^rND^sSchnitzer^nTJ#Pathoge
nesis and differential diagnosis of the swan-neck deformity^len#Semin Arthritis 
Rheum#13#200-11#19830000#1983#20040400#v44n2a04.htm#0049-0172#Semin Arthritis Rh
eum##
00578000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01900112810000600131012005600137030001400193031000300207014000600210065000900216
064000500225865000900230002001300239035001000252801001400262#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#178#20#article#31#20#^rND^sEsdaile^nJM#^rN
D^sDanoff^nD#^rND^sRosenthal^nL#et al#Deforming arthritis in systemic lupus eryt
hematosus^len#Ann Rheum Dis#40#124-6#19810000#1981#20040400#v44n2a04.htm#0003-49
67#Ann Rheum Dis##
00449000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780120046000930300
02400139710000200163014000600165065000900171064000500180865000900185002001300194
#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#c#179#21#article#31#21#^
rND^sKahn^nMF#Jaccoud's syndrome in a rheumatology unit^len#Clin Rheum Pract Win
ter#2#153-5#19860000#1986#20040400#v44n2a04.htm##
00514000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950120
07400110030001500184710000200199031000400201014000700205065000900212064000500221
865000900226002001300235#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#
c#180#22#article#31#22#^rND^sDubois^nEL#^rND^sCozen^nL#Avascular (aseptic) bone 
necrosis associated with lupus erythematosus^len#J Am Med Assoc#2#174#966-84#196
00000#1960#20040400#v44n2a04.htm##
00557000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780120105000930300
01900198031000200217014000700219065000900226064000500235865000900240002001300249
035001000262801001900272#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#
c#181#23#article#31#23#^rND^sPetri^nM#Musculoskeletal complications of systemic 
lupus erythematosus in the Hopkins Lupus Cohort: an update^len#Arthritis Care Re
s#8#137-45#19950000#1995#20040400#v44n2a04.htm#0893-7524#Arthritis care res##
00573000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100020000980120
08700118030001700205031000300222014000700225065000900232064000500241865000900246
002001300255035001000268801001700278#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a04.htm#S#c#182#24#article#31#24#^rND^sManolagas^nSC#^rND^sWeinstein^nRS#New d
evelopments in the pathogenesis and treatment of steroid-induced osteoporosis^le
n#J Bone Miner Res#14#1061-6#19990000#1999#20040400#v44n2a04.htm#0884-0431#J Bon
e Miner Res##
00557000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950120
06500110030002400175031000300199014000700202065000900209064000500218865000900223
002001300232035001000245801002400255#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a04.htm#S#c#183#25#article#31#25#^rND^sCunnane^nG#^rND^sLane^nNE#Steroid-induc
ed osteoporosis in systemic lupus erythematosus^len#Rheum Dis Clin North Am#26#3
11-27#20000000#2000#20040400#v44n2a04.htm#0889-857X#Rheum Dis Clin North Am##
00651000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01800110010001400128010002100142010001500163012006700178030001200245031000300257
01400070026006500090026706400050027686500090028100200130029003500100030380100120
0313#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#c#184#26#article#31#
26#^rND^sMont^nMA#^rND^sGlueck^nCJ#^rND^sPacheco^nIH#^rND^sWang^nP#^rND^sHungerf
ord^nDS#^rND^sPetri^nM#Risk factors for osteonecrosis in systemic lupus erythema
tosus^len#J Rheumatol#24#654-62#19970000#1997#20040400#v44n2a04.htm#0315-162X#J 
Rheumatol##
00586000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100015000930120
12000108030001200228031000300240014000700243065000900250064000500259865000900264
002001300273035001000286801001200296#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a04.htm#S#c#185#27#article#31#27#^rND^sEgan^nRM#^rND^sMunn^nRK#Catastrophic an
tiphospholipid antibody syndrome presenting with multiple thromboses and sites o
f avascular necrosis^len#J Rheumatol#21#2376-9#19940000#1994#20040400#v44n2a04.h
tm#0315-162X#J Rheumatol##
00635000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780100019001000100
01600119010001700135010001900152012006900171030001200240031000400252014000700256
065000900263064000500272865000900277002001300286035001000299801001200309#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#c#186#28#article#31#28#^rND^sKor
ompilias^nAV#^rND^sGilkeson^nGC#^rND^sOrtel^nTL#^rND^sSeaber^nAV#^rND^sUrbaniak^
nJR#Anticardiolipin antibodies and osteonecrosis of the femoral head^len#Clin Or
thop#345#174-80#19970000#1997#20040400#v44n2a04.htm#0009-921X#Clin Orthop##
00635000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100018000930100
01700111810000600128012011200134030001500246031000400261014000700265065000900272
064000500281865000900286002001300295035001000308801001500318#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a04.htm#S#c#187#29#article#31#29#^rND^sManzi^nS#^rND^s
Meilahn^nEM#^rND^sRairie^nJE#et al#Age-specific incidence rates of myocardial in
farction and angina in women with systemic lupus erythematosus^len#Am J Epidemio
l#145#408-15#19970000#1997#20040400#v44n2a04.htm#0002-9262#Am J Epidemiol##
00732000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100021000960100
01800117010001800135010001700153010001600170012013400186030001500320031000400335
01400060033906500090034506400050035486500090035900200130036803500100038180100150
0391#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#c#188#30#article#31#
30#^rND^sBoumpas^nDT#^rND^sAustin^nHA 3rd#^rND^sVaughan^nEM#^rND^sYarboro^nCH#^r
ND^sKlippel^nJ#^rND^sBalow^nJE#Risk for sustained amenorrhea in patients with sy
stemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
^len#Ann Intern Med#119#366-9#19930000#1993#20040400#v44n2a04.htm#0003-4819#Ann 
Intern Med##
00636000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100020000950100
02000115810000600135012009100141030001600232031000300248032000400251020000500255
065000900260064000500269865000900274002001300283035001000296801001600306#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a04.htm#S#c#189#31#article#31#31#^rND^sBoo
tsma^nH#^rND^sDerksen^nRHWM#^rND^sJaegers^nSMHJ#et al#Usefulness of the SLICC/AC
R damage index in patients with systemic lupus erythematosus^len#Arthritis Rheum
#40#^s9#S160#19970000#1997#20040400#v44n2a04.htm#0004-3591#Arthritis rheum##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#o#1#1#article#1#
20110406#085441#v44n2a05.htm#377##
04209000000000613000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701200740
01670120073002410100072003140100044003860100047004300100042004770100053005190700
10100572083136600673085000802039085004102047085003602088085004002124083124902164
08500080341308500390342108500360346008500400349611700060353607200030354211200090
3545111001003554114000903564113000903573002001303582#v44n2#V:\SciELO\serial\rbr\
v44n2\markup\v44n2a05.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#05#RBR160
#nd#Rev. Bras. Reumatol.#44#2#20040400#^f129^l138#0482-5004#Síndrome de Sjögren 
primária: manifestações exócrinas e não exócrinas^lpt#Primary Sjögren's syndrome
: exocrine and non-exocrine manifestations^len#^rND^1A01^nMaria da Graça Henriqu
es da Conceição Negrão Sequeira^sMuñoz#^rND^1A01^nWalter Carlos Baptista^sCastel
ão#^rND^1A01^nFernando Manuel Diamantino^sSaraiva#^rND^1A01^nJosé Carlos Teixeir
a da^sCosta#^rND^1A01^nMário Fernando Oliveira Viana de^sQueiroz#Hospital de San
ta Maria^iA01^1Serviço de reumatologia e doenças ósseas metabólicas^cLisboa^pPor
tugal#^lpt^aOBJETIVO: caracterizar as manifestações clínicas, exócrinas e não ex
ócrinas, de 74 pacientes com síndrome de Sjögren primária (SSp). MÉTODOS: estudo
 retrospectivo dos pacientes com SSp de acordo com os novos critérios americano-
europeus de 2002, seguidos no serviço de reumatologia e doenças ósseas metabólic
as do Hospital de Santa Maria (HSM) nos últimos 25 anos (média de seguimento de 
7,7 anos). RESULTADOS: todos os pacientes apresentaram doença exócrina dos epité
lios superficiais, com destaque para a xerostomia e a queratoconjuntivite seca. 
Doença exócrina dos órgãos internos foi encontrada em 25 pacientes (33,8%), enqu
anto apenas um paciente (1,4%) desenvolveu doença linfocitária B monoclonal (pse
udolinfoma pulmonar). Do total, 55 pacientes (74,3%) também apresentaram manifes
tações não-exócrinas, com predomínio das induzidas por mediadores da inflamação 
(68,9%). As manifestações vasculares inflamatórias estiveram presentes em 54% do
s pacientes e as vasculares não-inflamatórias em 27%. A tiroidite auto-imune sur
giu em 5 pacientes (6,8%). CONCLUSÕES: os componentes oral e ocular dominam a do
ença, sendo mais limitadas as manifestações orgânicas graves. Este modelo classi
ficativo permite comparar alterações fisiopatológicas entre os pacientes e abre 
uma via de estudo para encontrar marcadores de atividade/cronicidade com estas r
elacionados#^dnd^i1#^tm^lpt^ksíndrome de Sjögren primária^i1#^tm^lpt^kmanifestaç
ões exócrinas^i1#^tm^lpt^kmanifestações não exócrinas^i1#^len^aOBJECTIVE: to cha
racterize the exocrine and non-exocrine clinical disease manifestations of 74 pa
tients with primary Sjögren's Syndrome (pSS). METHODS: retrospective study of pS
S patients according to the new 2002 American-European criteria, followed in the
 Hospital Santa Maria, Rheumatology Outpatient Clinics, in the last 25 years (me
an follow-up of 7.7 years). RESULTS: all patients presented surface exocrine dis
ease, especially xerostomia and keratoconjunctivitis sicca. Internal organ exocr
ine disease was found in 25 patients (33.8%), whilst only one patient (1.4%) dev
eloped monoclonal B lymphocyte disease (pulmonary pseudolymphoma). Fifty-five pa
tients (74.3%) also displayed non-exocrine manifestations, in particular inflamm
atory mediator-induced disease (68.9%). Inflammatory vascular disease was presen
t in 54% of patients and noninflammatory vascular disease in 27%. Autoimmune thy
roiditis was found in 5 patients (6.8%). CONCLUSIONS: the disease is dominated b
y oral and ocular involvement, while severe organic manifestations are less freq
uent. This classification model allows a comparison of patients with physiopatho
logical abnormalities and offers the possibility of finding markers of activity/
cronicity related to them#^dnd^i2#^tm^len^kprimary Sjögren's syndrome^i2#^tm^len
^kexocrine manifestations^i2#^tm^len^knon-exocrine manifestations^i2#other#66#20
030731#31/7/2003#20040301#1/3/2004#v44n2a05.htm##
04293000000000613000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701200880
01670120087002550100072003420100044004140100047004580100042005050100053005470700
10100600083139400701085000802095085004102103085003602144085004002180083127702220
08500080349708500390350508500360354408500400358011700060362007200030362611200090
3629111001003638114000903648113000903657002001303666#v44n2#V:\SciELO\serial\rbr\
v44n2\markup\v44n2a05.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#05#RBR160
#nd#Rev. Bras. Reumatol.#44#2#20040400#^f129^l138#0482-5004#<b>Síndrome de Sjögr
en primária</b>: <b>manifestações exócrinas e não exócrinas</b>^lpt#<b>Primary S
jögren's syndrome</b>: <b>exocrine and non-exocrine manifestations</b>^len#^rND^
1A01^nMaria da Graça Henriques da Conceição Negrão Sequeira^sMuñoz#^rND^1A01^nWa
lter Carlos Baptista^sCastelão#^rND^1A01^nFernando Manuel Diamantino^sSaraiva#^r
ND^1A01^nJosé Carlos Teixeira da^sCosta#^rND^1A01^nMário Fernando Oliveira Viana
 de^sQueiroz#Hospital de Santa Maria^iA01^1Serviço de reumatologia e doenças óss
eas metabólicas^cLisboa^pPortugal#^lpt^a<b>OBJETIVO:</b> caracterizar as manifes
tações clínicas, exócrinas e não exócrinas, de 74 pacientes com síndrome de Sjög
ren primária (SSp). <b>MÉTODOS:</b> estudo retrospectivo dos pacientes com SSp d
e acordo com os novos critérios americano-europeus de 2002, seguidos no serviço 
de reumatologia e doenças ósseas metabólicas do Hospital de Santa Maria (HSM) no
s últimos 25 anos (média de seguimento de 7,7 anos). <b>RESULTADOS:</b> todos os
 pacientes apresentaram doença exócrina dos epitélios superficiais, com destaque
 para a xerostomia e a queratoconjuntivite seca. Doença exócrina dos órgãos inte
rnos foi encontrada em 25 pacientes (33,8%), enquanto apenas um paciente (1,4%) 
desenvolveu doença linfocitária B monoclonal (pseudolinfoma pulmonar). Do total,
 55 pacientes (74,3%) também apresentaram manifestações não-exócrinas, com predo
mínio das induzidas por mediadores da inflamação (68,9%). As manifestações vascu
lares inflamatórias estiveram presentes em 54% dos pacientes e as vasculares não
-inflamatórias em 27%. A tiroidite auto-imune surgiu em 5 pacientes (6,8%). <b>C
ONCLUSÕES:</b> os componentes oral e ocular dominam a doença, sendo mais limitad
as as manifestações orgânicas graves. Este modelo classificativo permite compara
r alterações fisiopatológicas entre os pacientes e abre uma via de estudo para e
ncontrar marcadores de atividade/cronicidade com estas relacionados#^dnd^i1#^tm^
lpt^ksíndrome de Sjögren primária^i1#^tm^lpt^kmanifestações exócrinas^i1#^tm^lpt
^kmanifestações não exócrinas^i1#^len^a<b>OBJECTIVE:</b> to characterize the exo
crine and non-exocrine clinical disease manifestations of 74 patients with prima
ry Sjögren's Syndrome (pSS). <b>METHODS:</b> retrospective study of pSS patients
 according to the new 2002 American-European criteria, followed in the Hospital 
Santa Maria, Rheumatology Outpatient Clinics, in the last 25 years (mean follow-
up of 7.7 years). <b>RESULTS:</b> all patients presented surface exocrine diseas
e, especially xerostomia and keratoconjunctivitis sicca. Internal organ exocrine
 disease was found in 25 patients (33.8%), whilst only one patient (1.4%) develo
ped monoclonal B lymphocyte disease (pulmonary pseudolymphoma). Fifty-five patie
nts (74.3%) also displayed non-exocrine manifestations, in particular inflammato
ry mediator-induced disease (68.9%). Inflammatory vascular disease was present i
n 54% of patients and noninflammatory vascular disease in 27%. Autoimmune thyroi
ditis was found in 5 patients (6.8%). <b>CONCLUSIONS:</b> the disease is dominat
ed by oral and ocular involvement, while severe organic manifestations are less 
frequent. This classification model allows a comparison of patients with physiop
athological abnormalities and offers the possibility of finding markers of activ
ity/cronicity related to them#^dnd^i2#^tm^len^kprimary Sjögren's syndrome^i2#^tm
^len^kexocrine manifestations^i2#^tm^len^knon-exocrine manifestations^i2#other#6
6#20030731#31/7/2003#20040301#1/3/2004#v44n2a05.htm##
04453000000000637000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000200012903100030014903200020015206500090015401400110016303500100
01740120074001840120073002580100072003310100044004030100047004470100042004940100
05300536070010300589083142900692085000802121085004102129085003602170085004002206
08312980224608500080354408500390355208500360359108500400362711700060366707200030
3673112000903676111001003685114000903695113000903704002001303713008008903726#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#l#4#1#article#1#^mmar./abr.^
a2004#oa#pt#br1.1#1#4.0#ilus#tab#05#RBR160#nd#Rev. Bras. Reumatol#44#2#20040400#
^f129^l138#0482-5004#Síndrome de Sjögren primária: manifestações exócrinas e não
 exócrinas^lpt#Primary Sjögren's syndrome: exocrine and non-exocrine manifestati
ons^len#^rND^1A01^nMaria da Graça Henriques da Conceição Negrão Sequeira^sMuñoz#
^rND^1A01^nWalter Carlos Baptista^sCastelão#^rND^1A01^nFernando Manuel Diamantin
o^sSaraiva#^rND^1A01^nJosé Carlos Teixeira da^sCosta#^rND^1A01^nMário Fernando O
liveira Viana de^sQueiroz#^iA01^1Hospital de Santa Maria^2Serviço de reumatologi
a e doenças ósseas metabólicas^cLisboa^pPortugal#^lpt^aOBJETIVO: caracterizar as
 manifestações clínicas, exócrinas e não exócrinas, de 74 pacientes com síndrome
 de Sjögren primária (SSp). MÉTODOS: estudo retrospectivo dos pacientes com SSp 
de acordo com os novos critérios americano-europeus de 2002, seguidos no serviço
 de reumatologia e doenças ósseas metabólicas do Hospital de Santa Maria (HSM) n
os últimos 25 anos (média de seguimento de 7,7 anos). RESULTADOS: todos os pacie
ntes apresentaram doença exócrina dos epitélios superficiais, com destaque para 
a xerostomia e a queratoconjuntivite seca. Doença exócrina dos órgãos internos f
oi encontrada em 25 pacientes (33,8 por cento), enquanto apenas um paciente (1,4
 por cento) desenvolveu doença linfocitária B monoclonal (pseudolinfoma pulmonar
). Do total, 55 pacientes (74,3 por cento) também apresentaram manifestações não
-exócrinas, com predomínio das induzidas por mediadores da inflamação (68,9 por 
cento). As manifestações vasculares inflamatórias estiveram presentes em 54 por 
cento dos pacientes e as vasculares não-inflamatórias em 27 por cento. A tiroidi
te auto-imune surgiu em 5 pacientes (6,8 por cento). CONCLUSÕES: os componentes 
oral e ocular dominam a doença, sendo mais limitadas as manifestações orgânicas 
graves. Este modelo classificativo permite comparar alterações fisiopatológicas 
entre os pacientes e abre uma via de estudo para encontrar marcadores de ativida
de/cronicidade com estas relacionados#^dnd^i1#^tm^lpt^ksíndrome de Sjögren primá
ria^i1#^tm^lpt^kmanifestações exócrinas^i1#^tm^lpt^kmanifestações não exócrinas^
i1#^len^aOBJECTIVE: to characterize the exocrine and non-exocrine clinical disea
se manifestations of 74 patients with primary Sjögren's Syndrome (pSS). METHODS:
 retrospective study of pSS patients according to the new 2002 American-European
 criteria, followed in the Hospital Santa Maria, Rheumatology Outpatient Clinics
, in the last 25 years (mean follow-up of 7.7 years). RESULTS: all patients pres
ented surface exocrine disease, especially xerostomia and keratoconjunctivitis s
icca. Internal organ exocrine disease was found in 25 patients (33.8 percent), w
hilst only one patient (1.4 percent) developed monoclonal B lymphocyte disease (
pulmonary pseudolymphoma). Fifty-five patients (74.3 percent) also displayed non
-exocrine manifestations, in particular inflammatory mediator-induced disease (6
8.9 percent). Inflammatory vascular disease was present in 54 percent of patient
s and noninflammatory vascular disease in 27 percent. Autoimmune thyroiditis was
 found in 5 patients (6.8 percent). CONCLUSIONS: the disease is dominated by ora
l and ocular involvement, while severe organic manifestations are less frequent.
 This classification model allows a comparison of patients with physiopathologic
al abnormalities and offers the possibility of finding markers of activity/croni
city related to them#^dnd^i2#^tm^len^kprimary Sjögren's syndrome^i2#^tm^len^kexo
crine manifestations^i2#^tm^len^knon-exocrine manifestations^i2#other#66#2003073
1#31/7/2003#20040301#1/3/2004#v44n2a05.htm#Internet^ihttp://www.scielo.br/scielo
.php?script=sci_arttext&pid=S0482-50042004000200005##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013600073002001300209#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#5#1#article#307#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO ORIGINAL</b> OR
IGINAL ARTICLE</font></p>     ^cY#v44n2a05.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#6#2#article#307#<p>&nbsp;</p>     ^cY#
v44n2a05.htm##
00531000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704029900073002001300372#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#7#3#article#307#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="linkinicio"></a><b>S&iacute;nd
rome de Sj&ouml;gren prim&aacute;ria:    manifesta&ccedil;&otilde;es ex&oacute;c
rinas e n&atilde;o ex&oacute;crinas<sup>(</sup><a href="#link01"><sup>*</sup></a
><sup>)</sup></b></font></p>     ^cY#v44n2a05.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#8#4#article#307#<p>&nbsp;</p>     ^cY#
v44n2a05.htm##
00395000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704016300073002001300236#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#9#5#article#307#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><b>Primary Sj&ouml;gren's syndrome: exo
crine and non-exocrine manifestations</b></font></p>     ^cY#v44n2a05.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#10#6#article#307#<p>&nbsp;</p>     ^cY
#v44n2a05.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#11#7#article#307#<p>&nbsp;</p>     ^cY
#v44n2a05.htm##
00583000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704035000074002001300424#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#12#8#article#307#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Maria da Gra&ccedil;a Henriques da 
Concei&ccedil;&atilde;o Negr&atilde;o Sequeira Mu&ntilde;oz; Walter Carlos Bapti
sta Castel&atilde;o;    Fernando Manuel Diamantino Saraiva; Jos&eacute; Carlos T
eixeira da Costa; M&aacute;rio Fernando Oliveira Viana de Queiroz</b></font></p>
     ^cY#v44n2a05.htm##
00439000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704020600074002001300280#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#13#9#article#307#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Servi&ccedil;o de reumatologia e doen&
ccedil;as &oacute;sseas metab&oacute;licas, Hospital de Santa Maria, Lisboa, Por
tugal</font></p>     ^cY#v44n2a05.htm##
00386000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015200075002001300227#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#14#10#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#linkcorresp">Endere&ccedil;
o para correspond&ecirc;ncia</a></font></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#15#11#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#16#12#article#307#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v44n2a05.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#17#13#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v44n
2a05.htm##
00505000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027100075002001300346#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#18#14#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OBJETIVO:</b> caracterizar as mani
festa&ccedil;&otilde;es cl&iacute;nicas, ex&oacute;crinas e n&atilde;o ex&oacute
;crinas, de 74 pacientes com s&iacute;ndrome de Sj&ouml;gren prim&aacute;ria (SS
p).    ^cY#v44n2a05.htm##
00576000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034200075002001300417#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#19#15#article#307#<br>  <b>M&Eacute;TO
DOS:</b> estudo retrospectivo dos pacientes com SSp de acordo com os novos crit&
eacute;rios americano-europeus de 2002, seguidos no servi&ccedil;o de reumatolog
ia e doen&ccedil;as &oacute;sseas metab&oacute;licas do Hospital de Santa Maria 
(HSM) nos &uacute;ltimos 25 anos (m&eacute;dia de seguimento de 7,7 anos).    ^c
Y#v44n2a05.htm##
01065000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704083100075002001300906#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#20#16#article#307#<br>  <b>RESULTADOS:
</b> todos os pacientes apresentaram doen&ccedil;a ex&oacute;crina dos epit&eacu
te;lios superficiais, com destaque para a xerostomia e a queratoconjuntivite sec
a. Doen&ccedil;a ex&oacute;crina dos &oacute;rg&atilde;os internos foi encontrad
a em 25 pacientes (33,8%), enquanto apenas um paciente (1,4%) desenvolveu doen&c
cedil;a linfocit&aacute;ria B monoclonal (pseudolinfoma pulmonar). Do total, 55 
pacientes (74,3%) tamb&eacute;m apresentaram manifesta&ccedil;&otilde;es n&atild
e;o-ex&oacute;crinas, com predom&iacute;nio das induzidas por mediadores da infl
ama&ccedil;&atilde;o (68,9%). As manifesta&ccedil;&otilde;es vasculares inflamat
&oacute;rias estiveram presentes em 54% dos pacientes e as vasculares n&atilde;o
-inflamat&oacute;rias em 27%. A tiroidite auto-imune surgiu em 5 pacientes (6,8%
).     ^cY#v44n2a05.htm##
00626000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039200075002001300467#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#21#17#article#307#<br> <b>CONCLUS&Otil
de;ES:</b> os componentes oral e ocular dominam a doen&ccedil;a, sendo mais limi
tadas as manifesta&ccedil;&otilde;es org&acirc;nicas graves. Este modelo classif
icativo permite comparar altera&ccedil;&otilde;es fisiopatol&oacute;gicas entre 
os pacientes e abre uma via de estudo para encontrar marcadores de atividade/cro
nicidade com estas relacionados.</font></p>     ^cY#v44n2a05.htm##
00513000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027900075002001300354#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#22#18#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> s&iacute;ndrom
e de Sj&ouml;gren prim&aacute;ria, manifesta&ccedil;&otilde;es ex&oacute;crinas,
 manifesta&ccedil;&otilde;es n&atilde;o ex&oacute;crinas.</font></p> <hr size="1
" noshade>     ^cY#v44n2a05.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009800075002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#23#19#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v4
4n2a05.htm##
00459000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022500075002001300300#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#24#20#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVE:</b> to characterize the
 exocrine and non-exocrine clinical disease manifestations of 74 patients with p
rimary Sj&ouml;gren's Syndrome (pSS).    ^cY#v44n2a05.htm##
00476000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024200075002001300317#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#25#21#article#307#<br>  <b>METHODS:</b
> retrospective study of pSS patients according to the new 2002 American-Europea
n criteria, followed in the Hospital Santa Maria, Rheumatology Outpatient Clinic
s, in the last 25 years (mean follow-up of 7.7 years).    ^cY#v44n2a05.htm##
00827000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059300075002001300668#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#26#22#article#307#<br>  <b>RESULTS:</b
> all patients presented surface exocrine disease, especially xerostomia and ker
atoconjunctivitis sicca. Internal organ exocrine disease was found in 25 patient
s (33.8%), whilst only one patient (1.4%) developed monoclonal B lymphocyte dise
ase (pulmonary pseudolymphoma). Fifty-five patients (74.3%) also displayed non-e
xocrine manifestations, in particular inflammatory mediator-induced disease (68.
9%). Inflammatory vascular disease was present in 54% of patients and noninflamm
atory vascular disease in 27%. Autoimmune thyroiditis was found in 5 patients (6
.8%).    ^cY#v44n2a05.htm##
00572000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033800075002001300413#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#27#23#article#307#<br>  <b>CONCLUSIONS
:</b> the disease is dominated by oral and ocular involvement, while severe orga
nic manifestations are less frequent. This classification model allows a compari
son of patients with physiopathological abnormalities and offers the possibility
 of finding markers of activity/cronicity related to them.</font></p>     ^cY#v4
4n2a05.htm##
00442000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020800075002001300283#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#28#24#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> primary Sj&ouml;gren
's syndrome, exocrine manifestations, non-exocrine manifestations.</font></p> <h
r size="1" noshade>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#29#25#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#30#26#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#31#27#article#307#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v44n2a05.htm##
00715000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048100075002001300556#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#32#28#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A s&iacute;ndrome de Sj&ouml;gren (SS
) &eacute; uma doen&ccedil;a autoimune inflamat&oacute;ria cr&ocirc;nica de caus
a desconhecida, caracterizada pela infiltra&ccedil;&atilde;o linfocit&aacute;ria
 focal do epit&eacute;lio glandular ex&oacute;crino e de m&uacute;ltiplos &oacut
e;rg&atilde;os, com aparecimento de numerosos sinais e sintomas em diversas loca
liza&ccedil;&otilde;es<sup>(1,2,3)</sup>.</font></p>     ^cY#v44n2a05.htm##
00660000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042600075002001300501#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#33#29#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Divide-se em prim&aacute;ria (SSp) e 
secund&aacute;ria segundo apare&ccedil;a isolada ou associada a outras doen&cced
il;as reum&aacute;ticas autoimunes<sup>(4)</sup>, o que obriga a um importante e
sfor&ccedil;o diagn&oacute;stico. &Eacute; uma doen&ccedil;a que afeta sobretudo
 a mulher na quarta e quinta d&eacute;cadas de vida<sup>(5)</sup>.</font></p>   
  ^cY#v44n2a05.htm##
00701000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046700075002001300542#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#34#30#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Alguns estudos epidemiol&oacute;gicos
, realizados nas &uacute;ltimas d&eacute;cadas, estabelecem uma preval&ecirc;nci
a relativamente elevada da doen&ccedil;a: 0,04% a 4,8%, consoante as s&eacute;ri
es<sup>(6,7)</sup>, embora estes estudos estejam condicionados pelos crit&eacute
;rios de classifica&ccedil;&atilde;o/ diagn&oacute;stico utilizados como base pa
ra selecionar os pacientes.</font></p>     ^cY#v44n2a05.htm##
00634000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040000075002001300475#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#35#31#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os crit&eacute;rios atualmente existe
ntes n&atilde;o t&ecirc;m aceita&ccedil;&atilde;o un&acirc;nime pela comunidade 
cient&iacute;fica, tornando dif&iacute;cil a compara&ccedil;&atilde;o de grupos 
de pacientes, das pr&oacute;prias manifesta&ccedil;&otilde;es da s&iacute;ndrome
 ou da efic&aacute;cia dos tratamentos. </font></p>     ^cY#v44n2a05.htm##
00821000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058700075002001300662#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#36#32#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Especialmente utilizados na Europa, j
untamente com os crit&eacute;rios de Copenhagem<sup>(8)</sup> e da Calif&oacute;
rnia<sup>(9)</sup>, os crit&eacute;rios foram elaborados a partir de um estudo m
ultic&ecirc;ntrico que come&ccedil;ou em 1988, levado a cabo pelo Grupo de Estud
o Europeu para a formula&ccedil;&atilde;o dos crit&eacute;rios de classifica&cce
dil;&atilde;o da SS (crit&eacute;rios europeus), que apareceram em 1993 e foram 
revistos em 1996 (<a href="#tab01">Tabela 1</a>)<sup>(10,11)</sup>.</font></p>  
   ^cY#v44n2a05.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#37#33#article#307#<p><a name="tab01"><
/a></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#38#34#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#39#35#article#307#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a05tab01.jpg"></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#40#36#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00846000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704061200075002001300687#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#41#37#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em junho de 2002 foi publicada a prop
osta de classifica&ccedil;&atilde;o da SS pelo Grupo de Estudo Americano-Europeu
, a qual compreende uma redefini&ccedil;&atilde;o dos crit&eacute;rios europeus,
 restringindo e precisando alguns aspectos, nomeadamente a obrigatoriedade de so
rologia positiva para os autoanticorpos anti-Ro (SS-A) e/ou anti-La (SS-B), ou p
resen&ccedil;a de altera&ccedil;&otilde;es t&iacute;picas da SS na bi&oacute;psi
a das gl&acirc;ndulas salivares <i>minor </i>(<a href="#tab02">Tabela 2</a>)<sup
>(12)</sup>.</font></p>     ^cY#v44n2a05.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#42#38#article#307#<p><a name="tab02"><
/a></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#43#39#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#44#40#article#307#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a05tab02.jpg"></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#45#41#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00954000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704072000075002001300795#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#46#42#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">H&aacute; v&aacute;rias formas de cla
ssificar as manifesta&ccedil;&otilde;es da doen&ccedil;a, sendo a mais cl&aacute
;ssica a divis&atilde;o em glandulares e extraglandulares. Outra, mais recente, 
&eacute; a proposta pela escola escandinava em 1995<sup>(13)</sup>, em que a div
is&atilde;o das manifesta&ccedil;&otilde;es cl&iacute;nicas se baseia no envolvi
mento dos &oacute;rg&atilde;os atingidos pelo infiltrado inflamat&oacute;rio e n
os mecanismos, histopatol&oacute;gico e fisiopatol&oacute;gico, respons&aacute;v
eis pelas mesmas<sup>(6)</sup>, classificandoas em ex&oacute;crinas e n&atilde;o
-ex&oacute;crinas<sup>(13,14,15)</sup>. </font></p>     ^cY#v44n2a05.htm##
00643000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040900075002001300484#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#47#43#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O objetivo deste trabalho consistiu e
m caracterizar a popula&ccedil;&atilde;o de pacientes com SSp seguida no servi&c
cedil;o de reumatologia e doen&ccedil;as &oacute;sseas metab&oacute;licas do Hos
pital de Santa Maria, nomeadamente as suas manifesta&ccedil;&otilde;es cl&iacute
;nicas e altera&ccedil;&otilde;es laboratoriais. </font></p>     ^cY#v44n2a05.ht
m##
00766000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053200075002001300607#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#48#44#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Para tal, optamos pela descri&ccedil;
&atilde;o das manifesta&ccedil;&otilde;es da doen&ccedil;a segundo o modelo mais
 recente (ex&oacute;crinas e n&atilde;oex&oacute;crinas), por estar em sintonia 
com os conceitos emanados do European Rheumatology Research Workshop de 2000, re
alizado em Oxford<sup>(16) </sup>e por considerarmos que se adapta melhor &agrav
e; natureza da doen&ccedil;a (<a href="/img/revistas/rbr/v44n2/a05fig01.jpg">Fig
ura 1</a>). </font></p>     ^cY#v44n2a05.htm##
00522000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028800075002001300363#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#49#45#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Faremos refer&ecirc;ncia, ainda, a du
as condi&ccedil;&otilde;es freq&uuml;entemente associadas ao SSp (fibromialgia e
 depress&atilde;o) e &agrave;s altera&ccedil;&otilde;es imunol&oacute;gicas enco
ntradas.</font></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#50#46#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00350000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011600075002001300191#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#51#47#article#307#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PACIENTES E M&Eacute;TODOS</b></fo
nt></p>     ^cY#v44n2a05.htm##
00800000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056600075002001300641#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#52#48#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De um total de 160 pacientes seguidos
 no servi&ccedil;o de reumatologia e doen&ccedil;as &oacute;sseas metab&oacute;l
icas do Hospital de Santa Maria por S&iacute;ndrome de Sj&ouml;gren prim&aacute;
ria, de acordo com os crit&eacute;rios de Bloch<sup>(17)</sup> e Whaley<sup>(18)
</sup>, nos &uacute;ltimos 25 anos, mediante um estudo retrospectivo, foram sele
cionados os que cumpriam os crit&eacute;rios do Grupo de Estudos da Comunidade E
urop&eacute;ia de 1996, somando 88 pacientes. </font></p>     ^cY#v44n2a05.htm##
00733000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049900075002001300574#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#53#49#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A aplica&ccedil;&atilde;o dos novos c
rit&eacute;rios do Grupo de Consenso Americano-Europeu a este grupo inicial levo
u &agrave; elimina&ccedil;&atilde;o de 14 pacientes, por n&atilde;o apresentarem
 altera&ccedil;&otilde;es na bi&oacute;psia das gl&acirc;ndulas salivares <i>min
or </i>(escore por foco <u>&gt;</u>1) nem sorologia positiva (anti-SSa e/ou anti
-SSB) ficando o grupo constitu&iacute;do por 74 pacientes. </font></p>     ^cY#v
44n2a05.htm##
00982000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074800075002001300823#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#54#50#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Estudamos o processo cl&iacute;nico d
e cada paciente registrando os dados necess&aacute;rios para estabelecer o diagn
&oacute;stico da SSp, segundo os crit&eacute;rios europeus e do consenso America
no-Europeu, excluindo a possibilidade de estar associada a outras doen&ccedil;as
 reum&aacute;ticas com base na freq&uuml;&ecirc;ncia de algumas manifesta&ccedil
;&otilde;es cl&iacute;nicas e de marcadores sorol&oacute;gicos, pela associa&cce
dil;&atilde;o ao sistema HLA, e avaliando as queixas sugestivas de SS bem como a
 sua evolu&ccedil;&atilde;o no decurso da doen&ccedil;a, resultados de exames an
al&iacute;ticos e imag&eacute;ticos e terap&ecirc;uticas efetuadas. </font></p> 
    ^cY#v44n2a05.htm##
00937000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704070300075002001300778#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#55#51#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Assim, para al&eacute;m do registro d
os sintomas de secura oral e ocular, todos os pacientes realizaram dois testes o
bjetivos oculares (teste de Schirmer e Rosa de Bengala) e sorologias de v&aacute
;rios anticorpos, a saber: fator reumat&oacute;ide, determinado por rea&ccedil;&
atilde;o de Waaler-Rose e em l&aacute;tex (RA test), anticorpos antinucleares, a
nti-SSA e anti-SSB, detectados por Enzyme linked immunosorbent assays (ELISA). S
essenta e oito pacientes realizaram bi&oacute;psia das gl&acirc;ndulas salivares
 <i>minor</i> do l&aacute;bio inferior<sup>(19)</sup>, 55 cintigrafia salivar, e
 apenas 2 sialografia. </font></p>     ^cY#v44n2a05.htm##
00619000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038500075002001300460#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#56#52#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os dados histol&oacute;gicos foram cl
assificados segundo a escala de Tarpley<sup>(20,21)</sup>. Consideramos positiva
 a bi&oacute;psia se apresentando um escore por foco <u>&gt;</u>1, circunst&acir
c;ncia em que o an&aacute;tomo-patologista a classificou como grau I (1+) ou sup
erior<sup>(22,23)</sup>. </font></p>     ^cY#v44n2a05.htm##
00494000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026000075002001300335#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#57#53#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os resultados da cintigrafia das gl&a
circ;ndulas salivares foram expressos segundo o modelo de Schall<sup>(24)</sup>,
 sendo consideradas patol&oacute;gicas as classes 2, 3 e 4. </font></p>     ^cY#
v44n2a05.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023100075002001300306#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#58#54#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os resultados da sialografia foram cl
assificados seguindo Rubin e Holt<sup>(25)</sup> em 4 graus, considerando-se an&
ocirc;malos os graus 2, 3 e 4. </font></p>     ^cY#v44n2a05.htm##
00575000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034100075002001300416#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#59#55#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os exames para pesquisa de envolvimen
to sist&ecirc;mico, como endoscopias, manometrias, provas de fun&ccedil;&atilde;
o respirat&oacute;ria, entre outros, foram pedidos somente nos pacientes com sin
tomatologia sugestiva de envolvimento de &oacute;rg&atilde;o.</font></p>     ^cY
#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#60#56#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010000075002001300175#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#61#57#article#307#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESULTADOS</b></font></p>     ^cY#
v44n2a05.htm##
00792000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055800075002001300633#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#62#58#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Dos 74 pacientes selecionados, a maio
ria, ou seja, 72 (97,3%) eram mulheres, sendo a idade m&eacute;dia na &uacute;lt
ima consulta de 58,2 ± 12,6 anos, a idade m&eacute;dia de in&iacute;cio dos sint
omas de 47,5 ± 13,3 anos e a do diagn&oacute;stico de 51,4 ± 12,1 anos. A dura&c
cedil;&atilde;o m&eacute;dia da doen&ccedil;a era de 10,3 ± 7,7 anos e o tempo m
&eacute;dio de seguimento hospitalar de 7,7 ± 5,7 anos (<a href="/img/revistas/r
br/v44n2/a05tab03.jpg">Tabela 3</a>). </font></p>     ^cY#v44n2a05.htm##
00606000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037200075002001300447#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#63#59#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os resultados da bi&oacute;psia das g
l&acirc;ndulas salivares <i>minor</i>, segundo a escala de Tarpley, encontram-se
 na <a href="#tab04">Tabela 4</a> e os da cintigrafia das gl&acirc;ndulas saliva
res, segundo a escala de Schall est&atilde;o discriminados na <a href="#tab05">t
abela 5</a>.</font></p>     ^cY#v44n2a05.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#64#60#article#307#<p><a name="tab04"><
/a></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#65#61#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#66#62#article#307#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a05tab04.jpg"></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#67#63#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#68#64#article#307#<p><a name="tab05"><
/a></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#69#65#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#70#66#article#307#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a05tab05.jpg"></p>     ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#71#67#article#307#<p>&nbsp;</p>     ^c
Y#v44n2a05.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020200075002001300277#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#72#68#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os dois pacientes que realizaram sial
ografia apresentaram grau 3 segundo a classifica&ccedil;&atilde;o de Rubin e Hol
t.</font></p>     ^cY#v44n2a05.htm##
00601000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036700075002001300442#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#73#69#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As manifesta&ccedil;&otilde;es cl&iac
ute;nicas dos 74 pacientes com SSp encontram-se sumarizadas na <a href="/img/rev
istas/rbr/v44n2/a05tab06.jpg">Tabela 6</a>, segundo o esquema de classifica&cced
il;&atilde;o ilustrado na <a href="/img/revistas/rbr/v44n2/a05fig01.jpg">Figura 
1</a>. </font></p>     ^cY#v44n2a05.htm##
00375000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014100075002001300216#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#74#70#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b><i>Manifesta&ccedil;&otilde;es ex&
oacute;crinas</i></b></font></p>     ^cY#v44n2a05.htm##
00371000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013700075002001300212#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#75#71#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Doen&ccedil;a dos epit&eacute;lios
 superficiais</b></font></p>     ^cY#v44n2a05.htm##
01035000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080100075002001300876#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#76#72#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Boca:</i> A xerostomia foi a manif
esta&ccedil;&atilde;o inicial, isolada ou associada a outros sintomas, em 40 (54
,1%) dos 74 pacientes, surgindo no entanto na totalidade dos pacientes ao longo 
da evolu&ccedil;&atilde;o da doen&ccedil;a. Esta sensa&ccedil;&atilde;o de secur
a oral traduziu-se por dificuldade na degluti&ccedil;&atilde;o, fala e numa maio
r ou menor intoler&acirc;ncia a alimentos &aacute;cidos ou condimentados, que co
ndicionaram per&iacute;odos de desconforto consider&aacute;vel. Observou-se muco
sa oral seca em 68 pacientes (91,9%) ao longo da evolu&ccedil;&atilde;o, c&aacut
e;ries dent&aacute;rias em 58 pacientes (78,4%) e sinais de candid&iacute;ase or
al cr&ocirc;nica em 20 pacientes (27,0%).</font></p>     ^cY#v44n2a05.htm##
00662000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042800075002001300503#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#77#73#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A candid&iacute;ase oral recorrente o
u cr&ocirc;nica, caracterizada por hiperemia difusa da mucosa jugal e fissura&cc
edil;&atilde;o da l&iacute;ngua, foi a primeira manifesta&ccedil;&atilde;o da do
en&ccedil;a num caso. Uma estomatite aftosa recidivante e resistente &agrave; te
rap&ecirc;utica foi tamb&eacute;m o quadro inicial noutro paciente. </font></p> 
    ^cY#v44n2a05.htm##
00589000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704035500075002001300430#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#78#74#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Olhos:</i> A xeroftalmia surgiu em
 73 (98,6%) dos 74 pacientes e foi a manifesta&ccedil;&atilde;o inicial em 34 de
les (45,9%). Os pacientes queixaram-se fundamentalmente de sensa&ccedil;&atilde;
o de corpo estranho ocular, vista cansada, prurido ocular e olho vermelho. </fon
t></p>     ^cY#v44n2a05.htm##
00441000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020700075002001300282#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#79#75#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Como complica&ccedil;&atilde;o da xer
oftalmia ocorreram em 4 casos (5,4%) altera&ccedil;&otilde;es graves da c&oacute
;rnea. </font></p>     ^cY#v44n2a05.htm##
00684000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045000075002001300525#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#80#76#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Nariz:</i> A secura nasal foi refe
rida por 29 pacientes (39,2%), traduzida objetivamente em 5 casos (6,8%) por atr
ofia da mucosa nasal com o conseq&uuml;ente aparecimento de falsa sensa&ccedil;&
atilde;o de obstru&ccedil;&atilde;o nasal. Dez pacientes (13,5%) relataram epis&
oacute;dios autolimitados de epistaxe ao longo da evolu&ccedil;&atilde;o da doen
&ccedil;a.</font></p>     ^cY#v44n2a05.htm##
00546000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031200075002001300387#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#81#77#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Gl&acirc;ndulas salivares:</i> Tum
efa&ccedil;&atilde;o parot&iacute;dea uni ou bilateral, epis&oacute;dica ou cr&o
circ;nica, foi detectada em 18 pacientes (24,3%), sendo a manifesta&ccedil;&atil
de;o inicial em 7 deles (9,5%). </font></p>     ^cY#v44n2a05.htm##
00687000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045300075002001300528#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#82#78#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Laringe-traqu&eacute;ia:</i> A xer
otraqu&eacute;ia ocasionou queixas que condicionaram grande desconforto, nomeada
mente tosse seca e irritativa em 6 pacientes (8,1%). Esta secura da mucosa das v
ias a&eacute;reas superiores facilitou o aparecimento de infec&ccedil;&otilde;es
 respirat&oacute;rias de repeti&ccedil;&atilde;o, que foram referidas por 5 paci
entes (6,8%).</font></p>     ^cY#v44n2a05.htm##
00484000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025000075002001300325#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#83#79#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Faringe-es&ocirc;fago:</i> Queixar
am-se de disfagia e odinofagia, que localizavam como tendo origem nesta por&cced
il;&atilde;o da via digestiva, 5 pacientes (6,8%).</font></p>     ^cY#v44n2a05.h
tm##
00556000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032200075002001300397#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#84#80#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Trato genital:</i> Doze mulheres (
16,2%) referiram secura vulvovaginal que levou a importantes manifesta&ccedil;&o
tilde;es de dispareunia, tendo constitu&iacute;do o motivo principal de consulta
 m&eacute;dica inicial em 2 casos (2,7%). </font></p>     ^cY#v44n2a05.htm##
00353000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011900075002001300194#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#85#81#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>&Oacute;rg&atilde;os internos</b><
/font></p>     ^cY#v44n2a05.htm##
00678000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044400075002001300519#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#86#82#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Pulm&atilde;o:</i> Em 2 pacientes 
(2,7%) foi detectada doen&ccedil;a intersticial (fibrose pulmonar), que condicio
nava epis&oacute;dios de dispn&eacute;ia. A dispn&eacute;ia tamb&eacute;m se man
ifestou noutros 3 pacientes (4,1%), dos quais 2 (2,7%) tinham padr&atilde;o vent
ilat&oacute;rio restritivo e 1 (1,4%) padr&atilde;o ventilat&oacute;rio obstruti
vo. </font></p>     ^cY#v44n2a05.htm##
00559000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032500075002001300400#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#87#83#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Gastrointestinal:</i> Queixas suge
stivas de refluxo gastroesof&aacute;gico como pirose e ardor retroesternal foram
 referidas por 4 pacientes (5,4%). Num paciente foi poss&iacute;vel detectar hip
omotilidade esof&aacute;gica por manometria. </font></p>     ^cY#v44n2a05.htm##
00524000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029000075002001300365#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#88#84#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Gastrite cr&ocirc;nica atr&oacute;fic
a com infiltrado linfocit&aacute;rio foi descrita em 10 pacientes (13,5%). Dispe
psia, sem documenta&ccedil;&atilde;o de gastrite, foi manifestada por 6 paciente
s (8,1%). </font></p>     ^cY#v44n2a05.htm##
00522000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028800075002001300363#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#89#85#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>P&acirc;ncreas:</i> Um paciente (1
,4%) teve um epis&oacute;dio de pancreatite aguda e outro desenvolveu pancreatit
e cr&ocirc;nica, com um pseudoquisto pancre&aacute;tico como complica&ccedil;&at
ilde;o. </font></p>     ^cY#v44n2a05.htm##
00503000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026900075002001300344#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#90#86#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>F&iacute;gado:</i> Em dois pacient
es (2,7%) detectou-se hepatomegalia, n&atilde;o se verificando, contudo, altera&
ccedil;&atilde;o das provas de fun&ccedil;&atilde;o hep&aacute;tica. </font></p>
     ^cY#v44n2a05.htm##
00732000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049800075002001300573#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#91#87#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Rim:</i> Encontramos patologia ren
al importante em 2 pacientes (2,7%) por doen&ccedil;a renal n&atilde;o tratada, 
que provocou insufici&ecirc;ncia renal cr&ocirc;nica com padr&atilde;o de infilt
rado linfocit&aacute;rio intersticial. Cinco pacientes (6,8%) apresentaram c&oac
ute;licas renais recorrentes, por acidose tubular renal distal que ocasionou a f
orma&ccedil;&atilde;o de c&aacute;lculos e nefrocalcinose.</font></p>     ^cY#v4
4n2a05.htm##
00538000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030400075002001300379#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#92#88#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cistites recorrentes ocorreram em 3 p
acientes (4,1%), tratadas sistematicamente com antibi&oacute;ticos, embora freq&
uuml;entemente a sua g&ecirc;nese n&atilde;o seja bacteriana, como ser&aacute; d
iscutido posteriormente.</font></p>     ^cY#v44n2a05.htm##
00370000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013600075002001300211#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#93#89#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Doen&ccedil;a linfocit&aacute;ria 
B monoclonal</b></font></p>     ^cY#v44n2a05.htm##
00583000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034900075002001300424#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#94#90#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Registrou-se um &uacute;nico caso de 
doen&ccedil;a linfoproliferativa sob a forma de pseudolinfoma pulmonar, caracter
izado radiologicamente como um n&oacute;dulo parenquimatoso, que mereceu exame h
istol&oacute;gico para confirma&ccedil;&atilde;o diagn&oacute;stica. </font></p>
     ^cY#v44n2a05.htm##
00386000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015200075002001300227#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#95#91#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b><i>Manifesta&ccedil;&otilde;es n&a
tilde;o-ex&oacute;crinas</i></b></font></p>     ^cY#v44n2a05.htm##
00366000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013200075002001300207#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#96#92#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Doen&ccedil;a vascular inflamat&oa
cute;ria</b></font></p>     ^cY#v44n2a05.htm##
00498000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026400075002001300339#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#97#93#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Pele: </i>As altera&ccedil;&otilde
;es cut&acirc;neas mais freq&uuml;entes foram a vasculite que apareceu em 9 paci
entes (12,2%), manifestada como p&uacute;rpura palp&aacute;vel. </font></p>     
^cY#v44n2a05.htm##
00459000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022500075002001300300#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#98#94#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Detectaram-se m&aacute;culas eritemat
osas em 3 casos (4,1%). O eritema nodoso e o livedo-reticularis foram vistos em 
um paciente cada (1,4%). </font></p>     ^cY#v44n2a05.htm##
00680000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044600075002001300521#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#99#95#article#307#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i>Sistema m&uacute;sculo-esquel&eacu
te;tico:</i> 67 pacientes (90,5 %) manifestaram queixas de artralgias ao longo d
a evolu&ccedil;&atilde;o da doen&ccedil;a, embora s&oacute; 32 (43,2%) tenham ti
do epis&oacute;dios de artrite bem identificados. Estes epis&oacute;dios de artr
algias/ artrite precederam de meses a anos os sintomas secos em 25 pacientes (33
,8%). </font></p>     ^cY#v44n2a05.htm##
00557000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704032200076002001300398#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#100#96#article#307#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Destaca-se, ainda, a aus&ecirc;ncia 
de deforma&ccedil;&otilde;es articulares, bem como de altera&ccedil;&otilde;es e
rosivas nos exames radiol&oacute;gicos das articula&ccedil;&otilde;es envolvidas
, ao longo do seguimento da doen&ccedil;a. </font></p>     ^cY#v44n2a05.htm##
00427000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704019200076002001300268#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#101#97#article#307#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Diagnosticaram-se 2 casos de miopati
a proximal, sem qualquer altera&ccedil;&atilde;o nas enzimas musculares. </font>
</p>     ^cY#v44n2a05.htm##
00564000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704032900076002001300405#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#102#98#article#307#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Membranas serosas:</i> Detectou-s
e um &uacute;nico caso de envolvimento das serosas, nomeadamente do peric&aacute
;rdio. Tratou-se duma pericardite, com derrame de pequenas dimens&otilde;es, cuj
a evolu&ccedil;&atilde;o foi francamente benigna. </font></p>     ^cY#v44n2a05.h
tm##
01225000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704099000076002001301066#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#103#99#article#307#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Sistema nervoso central e perif&e
acute;rico:</i> O envolvimento do sistema nervoso perif&eacute;rico foi mais fre
q&uuml;ente que o do sistema nervoso central. As queixas neurol&oacute;gicas mai
s comuns foram as parestesias dos membros, em particular dos superiores, que for
am referidas por 18 pacientes (24,3%), sendo num caso a manifesta&ccedil;&atilde
;o inicial da doen&ccedil;a. As patologias que mais ocorreram foram as s&iacute;
ndromes canaliculares: 12 pacientes (16,2%) com s&iacute;ndrome do canal c&aacut
e;rpico, e 1 (1,4%) com s&iacute;ndrome do canal t&aacute;rsico. Foi descrito, a
inda, um caso de nevralgia do trig&ecirc;meo e outro de polineuropatia sensitiva
 pura. Com rela&ccedil;&atilde;o ao envolvimento do SNC, registraram-se 4 casos 
(5,4%) com s&iacute;ndrome cerebelosa e 1 caso com altera&ccedil;&otilde;es cogn
itivas e estado confusional revers&iacute;vel com a terap&ecirc;utica. </font></
p>     ^cY#v44n2a05.htm##
00379000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704014300077002001300220#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#104#100#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b>Doen&ccedil;a vascular n&atilde;
o-inflamat&oacute;ria</b></font></p>     ^cY#v44n2a05.htm##
00712000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704047600077002001300553#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#105#101#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O fen&ocirc;meno de Raynaud foi uma
 manifesta&ccedil;&atilde;o muito freq&uuml;ente nesta s&eacute;rie, constituind
o a primeira manifesta&ccedil;&atilde;o em 3 casos (4,1%), sendo referida por 20
 pacientes (27%) ao longo da evolu&ccedil;&atilde;o da SS. Em nenhum caso se reg
istrou qualquer seq&uuml;ela, nomeadamente ulcera&ccedil;&otilde;es ou perda de 
subst&acirc;ncia das polpas digitais. </font></p>     ^cY#v44n2a05.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#106#102#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b>Doen&ccedil;a induzida por media
dores da inflama&ccedil;&atilde;o</b></font></p>     ^cY#v44n2a05.htm##
00620000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704038400077002001300461#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#107#103#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Quatro pacientes (5,4%) referiram e
pis&oacute;dios de febr&iacute;cula, astenia e fadiga muscular de dif&iacute;cil
 caracteriza&ccedil;&atilde;o, tendo sido este quadro inespec&iacute;fico o moti
vo inicial que ensejou a investiga&ccedil;&atilde;o cl&iacute;nica que levou ao 
diagn&oacute;stico de SSp.</font></p>     ^cY#v44n2a05.htm##
00385000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704014900077002001300226#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#108#104#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Detectou-se anemia (Hb &lt;12g/dl) 
em 23 dos 74 pacientes (31,1%).</font></p>     ^cY#v44n2a05.htm##
00541000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704030500077002001300382#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#109#105#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A leucopenia (leuc&oacute;citos &lt
;4000/mm<sup>3</sup>) foi igualmente comum, tendo sido registrada em 16 paciente
s (21,6%) e a trombocitopenia (plaquetas &lt;100.000/mm<sup>3</sup>) mais rara, 
ocorreu em 6 casos (8,1%). </font></p>     ^cY#v44n2a05.htm##
00461000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022500077002001300302#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#110#106#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A velocidade de sedimenta&ccedil;&a
tilde;o apareceu elevada (superior a 30 mm/1.ª hora, m&eacute;todo de Westergree
n) em 51 pacientes (68,9%).</font></p>     ^cY#v44n2a05.htm##
00366000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704013000077002001300207#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#111#107#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b>Doen&ccedil;a end&oacute;crina a
utoimune</b></font></p>     ^cY#v44n2a05.htm##
00517000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704028100077002001300358#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#112#108#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A tireoidite autoimune foi diagnost
icada em 5 pacientes (6,8%), com altera&ccedil;&atilde;o das provas de fun&ccedi
l;&atilde;o tiroidiana e n&iacute;veis elevados de autoanticorpos antitireoidian
os.</font></p>     ^cY#v44n2a05.htm##
00367000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704013100077002001300208#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#113#109#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b><i>Outras manifesta&ccedil;&otil
de;es</i></b></font></p>     ^cY#v44n2a05.htm##
00651000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704041500077002001300492#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#114#110#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><i>Psiqui&aacute;tricas:</i> 12 pac
ientes (16,2%) apresentaram ao longo do tempo quadros de depress&atilde;o, de ma
ior ou menor gravidade, que obrigaram a tratamento psiqui&aacute;trico. <i>Fibro
mialgia:</i> foi diagnosticada em 11 pacientes (14,9%), num dos casos tendo cons
titu&iacute;do o modo de in&iacute;cio da doen&ccedil;a. </font></p>     ^cY#v44
n2a05.htm##
00378000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704014200077002001300219#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#115#111#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b><i>Altera&ccedil;&otilde;es imun
ol&oacute;gicas </i></b></font></p>     ^cY#v44n2a05.htm##
00421000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704018500077002001300262#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#116#112#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Registrou-se hiperglobulinemia em 5
 pacientes (6,8%) e hipergamaglobulinemia em 30 pacientes (40,5%). </font></p>  
   ^cY#v44n2a05.htm##
00456000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022000077002001300297#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#117#113#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O fator reumat&oacute;ide IgM foi d
etectado em 40 pacientes (54%) pelo RA test e em 27 (36,5%) pela rea&ccedil;&ati
lde;o de Waaler Rose. </font></p>     ^cY#v44n2a05.htm##
00389000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015300077002001300230#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#118#114#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Os anticorpos antinucleares foram d
etectados em 38 pacientes (51,3%). </font></p>     ^cY#v44n2a05.htm##
00414000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704017800077002001300255#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#119#115#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Os anticorpos anti-dsDNA foram posi
tivos em somente 5 casos (6,8%) e em t&iacute;tulos baixos. </font></p>     ^cY#
v44n2a05.htm##
00435000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704019900077002001300276#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#120#116#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Os anticorpos anti-Ro (SS-A) encont
ravam-se presentes no soro em 24 casos (32,4%) e os anti-La (SS-B) em 23 (31,1%)
.</font></p>     ^cY#v44n2a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#121#117#article#307#<p>&nbsp;</p>     
^cY#v44n2a05.htm##
00342000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010600077002001300183#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#122#118#article#307#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p> 
    ^cY#v44n2a05.htm##
00572000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704033600077002001300413#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#123#119#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A s&iacute;ndrome de Sj&ouml;gren p
rim&aacute;ria caracteriza-se por secura da mucosa oral e ocular em pacientes co
m sialadenite focal, envolvendo grande variedade de outras altera&ccedil;&otilde
;es cl&iacute;nicas e laboratoriais, objeto deste estudo. </font></p>     ^cY#v4
4n2a05.htm##
00601000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704036500077002001300442#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#124#120#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O predom&iacute;nio do sexo feminin
o de 97,3%, a idade m&eacute;dia de in&iacute;cio dos sintomas de 47,5 anos e a 
idade m&eacute;dia de diagn&oacute;stico de 51,5 anos est&atilde;o de acordo com
 a maior parte das s&eacute;ries descritas na literatura<sup>(7,15,26,27,28,29)<
/sup>. </font></p>     ^cY#v44n2a05.htm##
01118000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704088200077002001300959#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#125#121#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A xerostomia e a xeroftalmia, tal c
omo &eacute; caracter&iacute;stico da doen&ccedil;a, foram as formas de apresent
a&ccedil;&atilde;o mais freq&uuml;entes<sup>(15,30,31)</sup>. Outras manifesta&c
cedil;&otilde;es iniciais menos comuns foram as artralgias, artrite, fen&ocirc;m
eno de Raynaud, tumefa&ccedil;&atilde;o parot&iacute;dea e sintomas constitucion
ais, tamb&eacute;m j&aacute; descritos em trabalhos anteriores<sup>(5,29,30)</su
p>. Esta multiplicidade de manifesta&ccedil;&otilde;es e o car&aacute;ter insidi
oso e inespec&iacute;fico, geralmente n&atilde;o valorizado, das queixas secas s
&atilde;o respons&aacute;veis pelo intervalo de meses a anos entre o apareciment
o dos primeiros sintomas e o diagn&oacute;stico<sup>(15,16,30)</sup>, que nesta 
s&eacute;rie foi de aproximadamente 4 anos. </font></p>     ^cY#v44n2a05.htm##
00500000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704026400077002001300341#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#126#122#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A elevada porcentagem de pacientes 
com sintomas oculares, de 98,6% ao longo da evolu&ccedil;&atilde;o da doen&ccedi
l;a, est&aacute; de acordo com a literatura<sup>(15,30,31)</sup>. </font></p>   
  ^cY#v44n2a05.htm##
01108000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704087200077002001300949#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#127#123#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Sabe-se que as manifesta&ccedil;&ot
ilde;es oculares da SS s&atilde;o conseq&uuml;&ecirc;ncia da atrofia e destrui&c
cedil;&atilde;o das gl&acirc;ndulas lacrimais pelos infiltrados linfocit&aacute;
rios e em alguns casos por altera&ccedil;&otilde;es da enerva&ccedil;&atilde;o<s
up>(30)</sup>, que condicionam diminui&ccedil;&atilde;o do componente aquoso da 
l&aacute;grima, rico em imunoglobulinas, lactoferrina e lisozima, condicionando,
 ainda, altera&ccedil;&otilde;es na viscosidade da l&aacute;grima que determinar
&atilde;o uma deficiente drenagem, limpeza e lubrifica&ccedil;&atilde;o oculares
. Daqui resulta a queratoconjuntivite seca, devidamente avaliada pelos testes de
 Schirmer e Rosa de Bengala, realizados em todos os pacientes e com resultados p
ositivos na grande maioria deles. </font></p>     ^cY#v44n2a05.htm##
00496000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704026000077002001300337#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#128#124#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A xerostomia foi observada em 100% 
dos pacientes, porcentagem muito elevada, mas semelhante &agrave;s encontradas n
as diversas s&eacute;ries da literatura<sup>(15,30,31)</sup>. </font></p>     ^c
Y#v44n2a05.htm##
00718000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704048200077002001300559#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#129#125#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">As altera&ccedil;&otilde;es do comp
onente salivar da SS s&atilde;o definidas pelos sintomas subjetivos e pelas anom
alias objetivadas pela cintigrafia e/ou sialografia e pela bi&oacute;psia das gl
&acirc;ndulas salivares <i>minor</i>. Consideramos determinante a bi&oacute;psia
 quando mostrou uma importante sialadenite focal, sendo ent&atilde;o muito espec
&iacute;fica para a SS<sup>(5,32,33)</sup>. </font></p>     ^cY#v44n2a05.htm##
00557000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704032100077002001300398#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#130#126#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Um pouco abaixo das porcentagens de
scritas na literatura<sup>(30,34)</sup> foi a encontrada com rela&ccedil;&atilde
;o &agrave; tumefa&ccedil;&atilde;o das par&oacute;tidas, referida em 24,3% dos 
casos, ao longo da evolu&ccedil;&atilde;o. </font></p>     ^cY#v44n2a05.htm##
01248000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704101200077002001301089#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#131#127#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A cintigrafia salivar, realizada po
r cerca de &frac34; dos pacientes, &eacute; importante pois constitui um m&eacut
e;todo adequado de avalia&ccedil;&atilde;o funcional de todas as gl&acirc;ndulas
 salivares, apresentando uma elevada sensibilidade embora pouca especificidade p
ara a doen&ccedil;a. A sialografia, m&eacute;todo de avalia&ccedil;&atilde;o das
 altera&ccedil;&otilde;es anat&ocirc;micas do sistema ductal parot&iacute;deo, p
arece estar em desuso em nossa pr&aacute;tica cl&iacute;nica, visto s&oacute; te
r sido efetuada por 2 pacientes e apesar de ser considerada t&atilde;o sens&iacu
te;vel e espec&iacute;fica como a bi&oacute;psia das gl&acirc;ndulas salivares <
i>minor</i>, apresenta duas desvantagens, que s&atilde;o o fato de em at&eacute;
 15% dos casos n&atilde;o ser poss&iacute;vel localizar corretamente o canal de 
Stenon e o de ser realizada numa &uacute;nica gl&acirc;ndula parot&iacute;dea<su
p>(35)</sup>. </font></p>     ^cY#v44n2a05.htm##
00901000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704066500077002001300742#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#132#128#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A bi&oacute;psia das gl&acirc;ndula
s salivares major n&atilde;o &eacute; t&atilde;o eficaz nem f&aacute;cil de real
izar e n&atilde;o est&aacute; isenta de riscos<sup>(19)</sup>, pelo que tem sido
 substitu&iacute;da h&aacute; mais de 20 anos pela bi&oacute;psia das gl&acirc;n
dulas salivares <i>minor </i>do l&aacute;bio, realizada pela quase totalidade de
 nossos pacientes, a qual tem mostrado ser mais espec&iacute;fica e mais conveni
ente do ponto de vista t&eacute;cnico, pela facilidade de realiza&ccedil;&atilde
;o e pelo baixo risco de complica&ccedil;&otilde;es<sup>(33)</sup>.</font></p>  
   ^cY#v44n2a05.htm##
00842000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704060600077002001300683#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#133#129#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Como j&aacute; foi comentado, o ach
ado cl&aacute;ssico considerado mais espec&iacute;fico da SS &eacute; a sialaden
ite focal, embora n&atilde;o seja patognom&ocirc;nico<sup>(19,33,36)</sup>. Tant
o os crit&eacute;rios europeus de 1996 como os americano-europeus de 2002 requer
em a quantifica&ccedil;&atilde;o do n&uacute;mero de focos de infiltrados linfoc
it&aacute;rios, pelo que realizamos a correspond&ecirc;ncia dos resultados forne
cidos pelos anatomopatologistas (escala de Tarpley) a este sistema<sup>(21,22,23
)</sup>.</font></p>     ^cY#v44n2a05.htm##
00600000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704036400077002001300441#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#134#130#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A diminui&ccedil;&atilde;o da secre
&ccedil;&atilde;o nasal, far&iacute;ngea e laringo-traqueal ocasionou queixas de
 secura nasal em 39,2% dos pacientes, da garganta em 6,8% e tosse irritativa em 
8,1%, valores semelhantes aos referidos em trabalhos anteriores<sup>(29,30,37)</
sup>. </font></p>     ^cY#v44n2a05.htm##
00903000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704066700077002001300744#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#135#131#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Na origem da disfagia, encontrada n
a quase totalidade dos pacientes, ao longo da evolu&ccedil;&atilde;o da doen&cce
dil;a, em concord&acirc;ncia com os dados da literatura, est&atilde;o implicados
 v&aacute;rios mecanismos, como a diminui&ccedil;&atilde;o da quantidade e quali
dade dos componentes da saliva, a destrui&ccedil;&atilde;o das gl&acirc;ndulas s
ecretoras de muco do 1/3 superior do es&ocirc;fago pelo infiltrado linfocit&aacu
te;rio e as altera&ccedil;&otilde;es musculares e de enerva&ccedil;&atilde;o que
 dificultam a progress&atilde;o do bolo alimentar<sup>(38,39)</sup>. </font></p>
     ^cY#v44n2a05.htm##
00737000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704050100077002001300578#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#136#132#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">As manifesta&ccedil;&otilde;es seca
s vulvovaginais, que provocaram queixas de dispareunia em 16,2% das mulheres, po
rcentagem inferior &agrave; encontrada na literatura, devem-se &agrave; infiltra
&ccedil;&atilde;o linfocit&aacute;ria das gl&acirc;ndulas secretoras dos &oacute
;rg&atilde;os genitais externos com altera&ccedil;&otilde;es qualitativas e quan
titativas das secre&ccedil;&otilde;es vaginais<sup>(40)</sup>. </font></p>     ^
cY#v44n2a05.htm##
00970000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704073400077002001300811#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#137#133#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em 5 (6,8%) pacientes registraram-s
e epis&oacute;dios de dispn&eacute;ia, em 2 casos relacionada com doen&ccedil;a 
intersticial (explicada pela passagem de linf&oacute;citos do espa&ccedil;o peri
br&ocirc;nquico para o espa&ccedil;o intersticial), em 1 caso com padr&atilde;o 
ventilat&oacute;rio obstrutivo (determinado pela invas&atilde;o por c&eacute;lul
as mononucleadas das paredes traqueobr&ocirc;nquicas, com diminui&ccedil;&atilde
;o do l&uacute;men e das secre&ccedil;&otilde;es) e em 2 casos por infiltrado pu
lmonar difuso, condicionando um padr&atilde;o ventilat&oacute;rio restritivo, va
lores de acordo com os da literatura<sup>(41,42)</sup>. </font></p>     ^cY#v44n
2a05.htm##
00913000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704067700077002001300754#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#138#134#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A porcentagem de pacientes com sint
omatologia sugestiva de envolvimento gastroesof&aacute;gico encontrada foi simil
ar &agrave;s das s&eacute;ries publicadas<sup>(17,29,38)</sup>. As queixas de re
fluxo gastroesof&aacute;gico que apareceram em 5,4% dos pacientes devemse a alte
ra&ccedil;&otilde;es nas ondas perist&aacute;lticas secund&aacute;rias respons&a
acute;veis pelo esvaziamento do conte&uacute;do alimentar que reflui para o es&o
circ;fago e a altera&ccedil;&otilde;es do esf&iacute;ncter esof&aacute;gico infe
rior por infiltra&ccedil;&atilde;o celular a esse n&iacute;vel<sup>(38)</sup>. <
/font></p>     ^cY#v44n2a05.htm##
00511000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704027500077002001300352#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#139#135#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">As queixas disp&eacute;pticas (8,1%
 dos pacientes), relacionamse tamb&eacute;m com o envolvimento das gl&acirc;ndul
as ex&oacute;crinas do est&ocirc;mago e p&acirc;ncreas<sup>(30,38,39)</sup>. </f
ont></p>     ^cY#v44n2a05.htm##
00609000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704037300077002001300450#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#140#136#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A gastrite cr&ocirc;nica atr&oacute
;fica, que se documentou por estudo endosc&oacute;pico em 13,5% dos pacientes, d
eve-se a infiltrados linfocit&aacute;rios da mucosa g&aacute;strica, semelhantes
 aos descritos na bi&oacute;psia das gl&acirc;ndulas salivares <i>minor</i><sup>
(43,44)</sup>. </font></p>     ^cY#v44n2a05.htm##
00690000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704045400077002001300531#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#141#137#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O envolvimento significativo das gl
&acirc;ndulas pancre&aacute;ticas ex&oacute;crinas, descrito habitualmente como 
raro, surgiu em apenas 2,7% dos casos e deve-se igualmente ao infiltrado linfoci
t&aacute;rio dos &aacute;cinos e canais pancre&aacute;ticos, provocando altera&c
cedil;&otilde;es na composi&ccedil;&atilde;o dos fermentos e do pH secretado<sup
>(29,30)</sup>. </font></p>     ^cY#v44n2a05.htm##
00598000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704036200077002001300439#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#142#138#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o encontramos doen&ccedil;
a hep&aacute;tica significativa registrando-se 2 casos de hepatomegalia, com tra
nsaminases normais, o que corresponde a uma porcentagem de 2,7%, o que est&aacut
e; abaixo do habitualmente descrito na literatura (entre 18% e 23%)<sup>(45)</su
p>. </font></p>     ^cY#v44n2a05.htm##
00998000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704076200077002001300839#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#143#139#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">O envolvimento renal e das vias uri
n&aacute;rias foi de 12,1%, menos elevado que na maior parte dos trabalhos publi
cados, em que oscila entre 20% e 50%<sup>(29,46)</sup>. As manifesta&ccedil;&oti
lde;es detectadas foram quadros de cistites de repeti&ccedil;&atilde;o em 3 paci
entes, sistematicamente tratadas com antibi&oacute;ticos, embora a g&ecirc;nese,
 regra geral, n&atilde;o seja bacteriana e se deva a dep&oacute;sitos de linf&oa
cute;citos e mast&oacute;citos na mucosa vesical. Os dois casos de doen&ccedil;a
 renal importante que provocaram insufici&ecirc;ncia renal cr&ocirc;nica apresen
taram padr&otilde;es de infiltrado linfocit&aacute;rio intersticial<sup>(47)</su
p>. </font></p>     ^cY#v44n2a05.htm##
00813000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704057700077002001300654#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#144#140#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A &uacute;nica altera&ccedil;&atild
e;o linfoproliferativa encontrada foi um pseudolinfoma pulmonar (prolifera&ccedi
l;&atilde;o linfocit&aacute;ria que ultrapassa os limites ganglionares, mas sem 
car&aacute;ter de malignidade)<sup>(41)</sup>. Nenhum dos pacientes desenvolveu 
linfoma ou outra neoplasia linfoproliferativa maligna. A transforma&ccedil;&atil
de;o maligna &eacute; referida por alguns autores como sendo de 5% e at&eacute; 
de 15% em s&eacute;ries mais antigas<sup>(30,48,49)</sup>. </font></p>     ^cY#v
44n2a05.htm##
00528000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704029200077002001300369#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#145#141#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A p&uacute;rpura, que apareceu em n
ossa casu&iacute;stica em 12,1%, foi a manifesta&ccedil;&atilde;o mais comum de 
vasculite cut&acirc;nea, em concord&acirc;ncia com a maioria dos trabalhos<sup>(
29,30)</sup>. </font></p>     ^cY#v44n2a05.htm##
00536000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704030000077002001300377#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#146#142#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A elevada porcentagem de pacientes 
com artralgias (90,5%) e com artrite (43,2%) coincide com as da literatura, bem 
como o fato de se tratar de uma artrite n&atilde;o deformante e n&atilde;o erosi
va<sup>(50,51)</sup>. </font></p>     ^cY#v44n2a05.htm##
00489000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704025300077002001300330#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#147#143#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Os casos de miopatia proximal (2,7%
), devem-se fundamentalmente &agrave; vasculite e s&atilde;o manifesta&ccedil;&o
tilde;es pouco descritas na literatura<sup>(52)</sup>. </font></p>     ^cY#v44n2
a05.htm##
00687000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704045100077002001300528#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#148#144#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A freq&uuml;&ecirc;ncia de envolvim
ento do sistema nervoso perif&eacute;rico, de 25,6% em nossa s&eacute;rie, est&a
acute; um pouco acima do referido na literatura, onde oscila entre 10% e 18%<sup
>(5,30)</sup>. H&aacute; trabalhos que apontam para uma vasculite necrosante dos
 vasa <i>nervorum</i> como causa da neuropatia perif&eacute;rica na SS<sup>(30,5
3,54)</sup>. </font></p>     ^cY#v44n2a05.htm##
00580000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704034400077002001300421#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#149#145#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A patogenia do envolvimento do SNC,
 que se registrou em 6,8% dos pacientes, permanece incerta, parecendo dever-se a
 uma vasculopatia isqu&ecirc;mica inflamat&oacute;ria, afetando mais comumente o
s pequenos vasos, em particular do sistema venoso<sup>(55)</sup>. </font></p>   
  ^cY#v44n2a05.htm##
00731000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704049500077002001300572#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#150#146#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em nossa s&eacute;rie a porcentagem
 de pacientes com fen&ocirc;meno de Raynaud (27%) &eacute; similar &agrave; refe
rida em trabalhos anteriores, com freq&uuml;&ecirc;ncias que oscilam entre 20% e
 59%<sup>(29,53,56)</sup>. Destaca-se a aus&ecirc;ncia de complica&ccedil;&otild
e;es graves, como ulcera&ccedil;&otilde;es ou perda de subst&acirc;ncia das polp
as digitais, como &eacute; caracter&iacute;stico na SSp. </font></p>     ^cY#v44
n2a05.htm##
00725000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704048900077002001300566#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#151#147#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A citopenia &eacute; descrita na li
teratura em aproximadamente um ter&ccedil;o dos pacientes<sup>(29,57)</sup>; a a
nemia apareceu em 29,7% dos casos, caracter&iacute;stica dos estados inflamat&oa
cute;rios cr&ocirc;nicos e, portanto, de patog&ecirc;nese variada, &eacute; gera
lmente normoc&iacute;tica e normocr&ocirc;mica, podendo por vezes ser microc&iac
ute;tica e hipocr&ocirc;mica<sup>(29,30,31)</sup>. </font></p>     ^cY#v44n2a05.
htm##
00557000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704032100077002001300398#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#152#148#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A leucopenia, que em nossa s&eacute
;rie apareceu em 21,6% dos pacientes, tem sido descrita na SS em porcentagens qu
e oscilam entre 10% e 30%<sup>(5,30)</sup>. O mecanismo tamb&eacute;m complexo, 
permanece indeterminado<sup>(31,58)</sup>. </font></p>     ^cY#v44n2a05.htm##
00426000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704019000077002001300267#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#153#149#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A trombocitopenia, rara na literatu
ra (0%-10%), tamb&eacute;m o foi neste estudo (8,1%)<sup>(29,31)</sup>. </font><
/p>     ^cY#v44n2a05.htm##
00623000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704038700077002001300464#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#154#150#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">As altera&ccedil;&otilde;es tireoid
ianas, acompanhando-se de anticorpos espec&iacute;ficos antitireoidianos e infil
trados inflamat&oacute;rios linfoplasmocit&aacute;rios, detectadas em 6,7% dos p
acientes, est&atilde;o descritas em 5% a 20% dos casos, em diversos estudos da l
iteratura<sup>(29,59)</sup>. </font></p>     ^cY#v44n2a05.htm##
00575000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704033900077002001300416#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#155#151#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A fibromialgia, que se pode conside
rar uma condi&ccedil;&atilde;o freq&uuml;entemente associada &agrave; SSp, diagn
osticada em 14,8% de nossos pacientes, &eacute; de fato um achado comum, descrit
o em at&eacute; 60% em algumas s&eacute;ries<sup>(60)</sup>. </font></p>     ^cY
#v44n2a05.htm##
00738000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704050200077002001300579#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#156#152#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Das manifesta&ccedil;&otilde;es psi
qui&aacute;tricas, que ocasionaram consulta especializada, destaca-se a depress&
atilde;o, que foi de 16,2%, a qual aparece noutros trabalhos em porcentagens sup
eriores, que v&atilde;o at&eacute; 50%, tendo sido ainda relacionada em muitos c
asos com a presen&ccedil;a de fibromialgia. Dos 12 pacientes com depress&atilde;
o, 5 tamb&eacute;m apresentavam fibromialgia<sup>(60,61)</sup>. </font></p>     
^cY#v44n2a05.htm##
00604000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704036800077002001300445#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#157#153#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">No que diz respeito aos par&acirc;m
etros imunol&oacute;gicos, a hipergamaglobulinemia detectada em 40,5% dos casos 
&eacute; uma manifesta&ccedil;&atilde;o caracter&iacute;stica da SS, referida fr
eq&uuml;entemente na literatura em porcentagens que ultrapassam os 50%<sup>(29,3
1)</sup>. </font></p>     ^cY#v44n2a05.htm##
00490000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704025400077002001300331#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#158#154#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Os fatores reumat&oacute;ides, dete
ctados em 54% dos pacientes, t&ecirc;m sido referidos por outros autores com val
ores oscilando entre 52% e 98%<sup>(29,30,31,62)</sup>. </font></p>     ^cY#v44n
2a05.htm##
00531000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704029500077002001300372#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#159#155#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o aos antic
orpos antinucleares, houve concord&acirc;ncia em nossa s&eacute;rie em que se re
gistraram 51,3% dos casos, com os valores referidos na literatura de 40% a 97%<s
up>(30,31)</sup>.</font></p>     ^cY#v44n2a05.htm##
00505000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704026900077002001300346#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#160#156#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Os anticorpos anti-dsDNA, que em no
ssa s&eacute;rie apareceram em apenas 6,7% dos casos e em baixo t&iacute;tulo, t
&ecirc;m preval&ecirc;ncia que oscila entre 9% e 29%<sup>(30,63)</sup>.</font></
p>     ^cY#v44n2a05.htm##
00529000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704029300077002001300370#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#161#157#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Os anticorpos anti-Ro e anti-La, ca
racter&iacute;sticos da doen&ccedil;a, detectados num ter&ccedil;o dos pacientes
, aparecem noutras s&eacute;ries com valores que v&atilde;o de 20% a 80%<sup>(29
,30,63)</sup>. </font></p>     ^cY#v44n2a05.htm##
00502000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704026600077002001300343#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#162#158#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Este aumento da produ&ccedil;&atild
e;o de imunoglobulinas e autoanticorpos deve-se a expans&atilde;o policlonal e a
 hiper-reatividade secretora dos linf&oacute;citos B<sup>(5)</sup>. </font></p> 
    ^cY#v44n2a05.htm##
01055000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704081900077002001300896#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#163#159#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Este estudo mostra que a les&atilde
;o org&acirc;nica mais freq&uuml;ente diz respeito aos componentes oral e ocular
, com poucas altera&ccedil;&otilde;es graves noutros &oacute;rg&atilde;os ou sis
temas, o que constitui uma diferen&ccedil;a significativa relativamente a outras
 doen&ccedil;as reum&aacute;ticas autoimunes. A constata&ccedil;&atilde;o desta 
realidade dever&aacute; condicionar as nossas op&ccedil;&otilde;es terap&ecirc;u
ticas, no sentido de dar prioridade &agrave; preven&ccedil;&atilde;o e tratament
o das manifesta&ccedil;&otilde;es secas, ficando a decis&atilde;o de optar por u
ma terap&ecirc;utica mais agressiva baseada na gravidade das manifesta&ccedil;&o
tilde;es n&atilde;o-ex&oacute;crinas<sup>(5,30,64,65)</sup>. </font></p>     ^cY
#v44n2a05.htm##
00565000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704032900077002001300406#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#164#160#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Um dos pontos mais cr&iacute;ticos 
da SSp &eacute; o aparecimento de linfoma, que apesar de n&atilde;o ter surgido 
em nossa s&eacute;rie, obriga-nos a permanecer alertas ao longo da evolu&ccedil;
&atilde;o da doen&ccedil;a<sup>(5,31,49,66)</sup>. </font></p>     ^cY#v44n2a05.
htm##
00800000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704056400077002001300641#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#165#161#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Consideramos que a classifica&ccedi
l;&atilde;o proposta pela escola escandinava, ao agrupar as manifesta&ccedil;&ot
ilde;es cl&iacute;nicas em fun&ccedil;&atilde;o da fisiopatologia, facilita a co
mpara&ccedil;&atilde;o entre os v&aacute;rios pacientes, permitindo ainda estabe
lecer associa&ccedil;&otilde;es entre as caracter&iacute;sticas an&aacute;tomo-f
isiopatol&oacute;gicas e eventuais marcadores de atividade/cronicidade da doen&c
cedil;a, a aprofundar em estudos posteriores. </font></p>     ^cY#v44n2a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#166#162#article#307#<p>&nbsp;</p>     
^cY#v44n2a05.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010700077002001300184#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#167#163#article#307#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>
     ^cY#v44n2a05.htm##
00432000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704018200079002001300261#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#168#164#article#307#1#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Moutsopoulos HM: S
j&ouml;gren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 72: 16
2-5, 1994.    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#169#165#article#307# </font></p>     ^
cY#v44n2a05.htm##
00444000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704019400079002001300273#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#170#166#article#307#2#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Daniels TE: Sj&oum
l;gren's syndrome: clinical spectrum and current diagnostic controversies. Adv D
ent Res 10: 3-8, 1996.    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#171#167#article#307# </font></p>     ^
cY#v44n2a05.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704021300079002001300292#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#172#168#article#307#3#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Manoussakis MN, Mo
utsopoulos HM: Sj&ouml;gren's syndrome: autoimmune epithelitis. Baillieres Best 
Pract Res Clin Rheumatol 14: 73-95, 2000.    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#173#169#article#307# </font></p>     ^
cY#v44n2a05.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704021500079002001300294#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#174#170#article#307#4#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Moutsopoulos HM, M
ann DL, Johnson AH, et al: Genetic differences between primary and secondary sic
ca syndrome. N Engl J Med 301: 761-3, 1979.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#175#171#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00460000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704021000079002001300289#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#176#172#article#307#5#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Moutsopoulos HM, T
zioufas AG: Rheumatology. Sj&ouml;gren's syndrome, 2.ª ed, London, Mosby, Klippe
l JH, Dieppe PA (eds). 32: 1-12, 1998.    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#177#173#article#307# </font></p>     ^
cY#v44n2a05.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704023400079002001300313#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#178#174#article#307#6#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Manthorpe R, Jacob
sson LT, Kirtava Z, Theander E: Epidemiology of Sj&ouml;gren's syndrome, especia
lly its primary form. Ann Med Interne (Paris) 149: 7-11, 1998.    ^cY#v44n2a05.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#179#175#article#307# </font></p>     ^
cY#v44n2a05.htm##
00505000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704025500079002001300334#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#180#176#article#307#7#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Drosos AA, Antonop
oulos AP, Costopoulos JS, Papadimitriou C, Moutsopoulos HM: Prevalence of primar
y Sj&ouml;gren's syndrome in an elderly population. Br J Rheumatol 27: 123-7, 19
88.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#181#177#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00468000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704021800079002001300297#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#182#178#article#307#8#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Manthorpe R, Oxhol
m P, Prause JU, Schi&oslash;dt M: The Copenhagen criteria for Sj&ouml;gren's syn
drome. Scand J Rheumatol Supl 61: 19-21, 1986.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#183#179#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704021700079002001300296#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#184#180#article#307#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Fox RI, Robinson C
, Curd JG, Kozin F, Howell F: Sj&ouml;gren's syndrome:proposed criteria for clas
sification. Arthritis Rheum 29: 577-85, 1986.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#185#181#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00630000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704037900080002001300459#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#186#182#article#307#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Vitali C, Bombar
dieri S, Jonsson R, et al and the European Study Group on Classification Criteri
a for Sj&ouml;gren's Syndrome: Classification criteria for Sj&ouml;gren's syndro
me: a revised version of the European criteria proposed by the American.european
 Consensus Group. Ann Rheum Dis 61: 554-8, 2002.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#187#183#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00558000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030700080002001300387#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#188#184#article#307#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Vitali C, Bombar
dieri S, Moutsopoulos HM, et al: Preliminary criteria for the classification of 
Sj&ouml;gren's syndrome. Results of a prospective concerted action supported by 
the European Community. Arthritis Rheum 36: 340-7, 1993.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#189#185#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00631000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704038000080002001300460#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#190#186#article#307#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Vitali C, Bombar
dieri S, Jonsson R, et al, and the European Study Group on Classification Criter
ia for Sj&ouml;gren's Syndrome: Classification criteria for Sj&ouml;gren's syndr
ome: a revised version of the European criteria proposed by the American.europea
n Consensus Group. Ann Rheum Dis 61: 554-8, 2002.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#191#187#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00437000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018600080002001300266#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#192#188#article#307#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Oxholm P, Asmuss
en K, Axell T, et al: Sj&ouml;gren's syndrome: terminology. Clin Exp Rheumatol 1
3: 693-6, 1995.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#193#189#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00497000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024600080002001300326#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#194#190#article#307#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Oxholm P, Asmuss
en K: Classification of disease manifestations in primary Sj&ouml;gren's syndrom
e: present status and a new proposal. Clin Rheumatol 14 Suppl 1: 3-7, 1995.    ^
cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#195#191#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00548000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029700080002001300377#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#196#192#article#307#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Asmussen K, Ande
rsen V, Bendixen G, et al: Quantitive assessment of clinical disease status in p
rimary Sj&ouml;gren's syndrome. A cross-sectional study using a new classificati
on model. Scand J Rheumatol 26: 197-205, 1997.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#197#193#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00609000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704035800080002001300438#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#198#194#article#307#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Bowman SJ, Pille
mer S, Jonsson R, et al: Contributors to and participants at the workshop. Revis
iting Sj&ouml;gren's syndrome in the new millennium: perspectives on assessment 
and outcome measures. Report of a workshop held on March 2000 at Oxford, UK. Rhe
umatology 40: 1180-8, 2001.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#199#195#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00491000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024000080002001300320#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#200#196#article#307#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Bloch KJ, Buchan
an WW, Who MJ, Bunim JJ: Sj&ouml;gren's syndrome. A clinical, pathological and s
erological study of 62 cases. Medicine (Baltimore) 44: 187-231, 1965.    ^cY#v44
n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#201#197#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021500080002001300295#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#202#198#article#307#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Whaley K, Willia
mson J, Chisholm DM, Webb J, Mason DK, Buchanan WW: Sj&ouml;gren's syndrome: 1. 
Sicca components. Q J Med 42: 279-304, 1973.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#203#199#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00441000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019000080002001300270#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#204#200#article#307#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Daniels TE: Sali
vary histopathology in diagnosis of Sj&ouml;gren syndrome. Scand J Rheumatol Sup
pl 61: 36-43, 1986.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#205#201#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00503000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025200080002001300332#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#206#202#article#307#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Greenspan JS, Da
niels TE, Talal N, Sylvester RA: The histopathology of Sj&ouml;gren's syndrome i
n labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 37: 217-9, 1974
.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#207#203#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00469000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021800080002001300298#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#208#204#article#307#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Tarpley TM, Ande
rson LG, White CL: Minor salivary gland involvement in Sj&ouml;gren's syndrome. 
Oral Surg Oral Med Oral Pathol 37: 64-74, 1974.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#209#205#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00537000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028600080002001300366#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#210#206#article#307#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Daniels TE, Whit
cher JP: Association of patterns of salivary gland inflammation with keratoconju
nctivitis sicca. Analysis of 618 patients with suspected Sj&ouml;gren's syndrome
. Arthritis Rheum 37: 869-77, 1994.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#211#207#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022300080002001300303#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#212#208#article#307#23#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Vivino FB, Gala 
I, Hermann GA: Change in Final Diagnosis on Second Evaluation of Labial Minor Sa
livary Gland Biopsies. J Rheumatol 29: 938-44, 2002.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#213#209#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00470000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021900080002001300299#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#214#210#article#307#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Schall GL, Ander
son LG, Wolf RO: Xerostomia in Sj&ouml;gren's syndrome: evaluation by sequential
 salivary scintigraphy. JAMA 216: 2109-16, 1971.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#215#211#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018900080002001300269#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#216#212#article#307#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Rubin H, Holt M:
 Secretory sialography in diseases of the major salivary glands. Am J Roentgenol
 77: 575-98, 1957.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#217#213#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00512000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026100080002001300341#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#218#214#article#307#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Jacobsson LTH, A
xell TE, Hansen BU: Dry eyes or mouth - An epidemiological study in Swedish adul
ts, with special reference to primary Sj&ouml;gren's syndrome. J Autoimmun 2: 52
1-7, 1989.    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#219#215#article#307# </font></p>     ^
cY#v44n2a05.htm##
00494000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024300080002001300323#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#220#216#article#307#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. O'Callaghan AS, 
Gil JB, Laque RS, et al: Primary Sj&ouml;gren's syndrome: clinical and immunolog
ical characteristics of 114 patients. Med Clin (Barc) 116:721-725, 2001.    ^cY#
v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#221#217#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00469000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021800080002001300298#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#222#218#article#307#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Carsons S: A rev
iew and update of Sj&ouml;gren's syndrome: manifestations, diagnosis and treatme
nt. Am J Manag Care 7(14 Suppl): S433-43, 2001.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#223#219#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00460000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020900080002001300289#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#224#220#article#307#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Costa JT, Sousa 
MC, Silva MC, et al: S&iacute;ndrome de Sj&ouml;gren Primitivo. Acta Reumatol&oa
cute;gica Portuguesa X: 185-232, 1985.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#225#221#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00508000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025700080002001300337#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#226#222#article#307#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Saraiva F: Reuma
tologia - Cl&iacute;nica e Terap&ecirc;utica das Doen&ccedil;as Reum&aacute;tica
s. Sindroma de Sj&ouml;gren, 1.ª ed, Lisboa , Lidel, Queiroz MV (ed). 2: 137-62,
 2002.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#227#223#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021400080002001300294#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#228#224#article#307#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Oxholm P: Primar
y Sj&ouml;gren's syndrome - Clinical and laboratory markers of disease activity.
 Seminars Arthritis Rheum 22: 114-26, 1992.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#229#225#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021200080002001300292#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#230#226#article#307#32#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Daniels TE, Benn
 DK: Is sialography effective in diagnosing the salivary component of Sj&ouml;gr
en Syndrome? Adv Dent Res 10: 25-8, 1996.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#231#227#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00479000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022800080002001300308#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#232#228#article#307#33#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Daniels TE: Clin
ical assessment and diagnosis of immunologically mediated salivary gland disease
 in Sj&ouml;gren's syndrome. J Autoimmun 2: 529-41, 1989.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#233#229#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022100080002001300301#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#234#230#article#307#34#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Pavlidis N, Kars
h J, Moutsopoulos HM: The clinical Picture of primary Sj&ouml;gren's syndrome: a
 retrospective study. J Rheumatol 9: 685-90, 1982.    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#235#231#article#307# </font></p>     ^
cY#v44n2a05.htm##
00422000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017100080002001300251#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#236#232#article#307#35#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Manthorpe R, Jac
obsson LTH: Sj&ouml;gren's syndrome. Bailliere's Clin Rheumatol 9: 483-96, 1995.
    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#237#233#article#307# </font></p>     ^
cY#v44n2a05.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023300080002001300313#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#238#234#article#307#36#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Daniels TE: Labi
al salivary gland biopsy in Sj&ouml;gren's syndrome. Assessment as a diagnostic 
criterion in 362 suspected cases. Arth Rheum 27: 147-56, 1984.    ^cY#v44n2a05.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#239#235#article#307# </font></p>     ^
cY#v44n2a05.htm##
00431000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018000080002001300260#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#240#236#article#307#37#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Batsakis JG: Lym
phoepithelial lesion and Sj&ouml;gren's syndrome. Ann Otol Rhinol Laryngol 89: 1
35, 1980.    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#241#237#article#307# </font></p>     ^
cY#v44n2a05.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021500080002001300295#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#242#238#article#307#38#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Palma R, Freire 
A, Freitas J, et al: Esophageal motility disorders in patients with Sj&ouml;gren
's syndrome. Dig Dis Sciences 39: 758, 1994.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#243#239#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00442000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019100080002001300271#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#244#240#article#307#39#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Kellen G: Esopha
geal function, radiography and dysphagia in Sj&ouml;gren's syndrome. Dig Dis Sci
ences 31: 225, 1986.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#245#241#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00456000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020500080002001300285#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#246#242#article#307#40#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Moutsopoulos HM,
 Chused TM, Mann DL et al: Sj&ouml;gren's syndrome (sicca syndrome): current iss
ues. Ann Int Med 92: 212-26, 1980.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#247#243#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00460000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020900080002001300289#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#248#244#article#307#41#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">41. Gardiner PH, War
d CH, Allison A, et al: Pleuropulmonary abnormalities in primary Sj&ouml;gren's 
syndrome. J Rheumatol 20: 831-7, 1993.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#249#245#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00485000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023400080002001300314#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#250#246#article#307#42#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">42. Talal N: S&iacut
e;ndrome de Sj&ouml;gren: conceptos actuales, factores immunol&oacute;gicos y v&
iacute;ricos en la etiologia. Rev Esp Reumatol 18: 115-8, 1991.    ^cY#v44n2a05.
htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#251#247#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00456000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020500080002001300285#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#252#248#article#307#43#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">43. Ostuni PA, Germa
na B, DiMario F, et al: Gastric involvement in primary Sj&ouml;gren's syndrome. 
Clin Exp Rheumatol 11: 21-5, 1993.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#253#249#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00527000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027600080002001300356#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#254#250#article#307#44#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">44. Pokorny G, Kar&a
acute;csony G, Lonovics J, Hud&aacute;k J, N&eacute;meth J, Varr&oacute; V: Type
s of atrophic gastritis in patients with primary Sj&ouml;gren's syndrome. Ann Rh
eum Dis 50: 97-100, 1991.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#255#251#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00472000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022100080002001300301#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#256#252#article#307#45#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">45. Barbati K, Galan
opoulou V, Moutsopoulos HM: Liver involvement in primary Sj&ouml;gren's syndrome
. Rev Esp Reumatol 20 Suppl 1 (resumen 432), 1993.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#257#253#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00477000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022600080002001300306#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#258#254#article#307#46#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">46. Hordon LD, Kelly
 CA, Griffiths ID, Bird HA: Renal tubular dysfunction in primary Sj&ouml;gren's 
syndrome. Br J Rheumatol 29 Suppl 1 (resumen 74), 1990.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#259#255#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00439000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018800080002001300268#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#260#256#article#307#47#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">47. Winer RL: Sj&oum
l;gren's syndrome with immune complex tubulointerstitial renal disease. Clin Imm
unol 8:494, 1997.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#261#257#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00561000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031000080002001300390#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#262#258#article#307#48#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">48. Tzioufas AG, Mou
tsopoulos HM, Talal N: Sj&ouml;gren's syndrome: Clinical and immunological aspec
ts. Lymphoid malignancy and monoclonal proteins, 1.ª ed, Berlin, Springer-Verlag
, Talal N, Moutsopoulos HM, Kassan SS (eds), 129-136, 1987.    ^cY#v44n2a05.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#263#259#article#307# </font></p>     ^
cY#v44n2a05.htm##
00446000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019500080002001300275#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#264#260#article#307#49#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">49. Kassan SS, Thoma
s TL, Moutsopoulos HM et al: Increased risk of lymphoma in sicca syndrome. Ann I
nt Med 89: 888-92, 1978.    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#265#261#article#307# </font></p>     ^
cY#v44n2a05.htm##
00517000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026600080002001300346#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#266#262#article#307#50#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">50. Orozco-Barocio G
, Ortiz JD, Romero EA, Torre IG, Guerrero RG, D&iacute;az CI: Muskuloskeletal ma
nifestations in primary Sj&ouml;gren's syndrome. Arthritis Rheum 34 Suppl (resum
en S191), 1991.    ^cY#v44n2a05.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#267#263#article#307# </font></p>     ^
cY#v44n2a05.htm##
00446000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019500080002001300275#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#268#264#article#307#51#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">51. Pease CT, Shattl
es W, Barrett NK, Maini RN: The arthropathy of Sj&ouml;gren's syndrome. Br J Rhe
umatol 32: 609-13, 1993.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#269#265#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00455000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020400080002001300284#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#270#266#article#307#52#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">52. Gran JT, Myklebu
st G: The concomitant occurrence of Sj&ouml;gren's syndrome and polymiositis. Sc
and J Rheumatol 21: 150-54, 1992.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#271#267#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020100080002001300281#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#272#268#article#307#53#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">53. Kaltreider HB, T
alal N: The neuropathy of Sj&ouml;gren's syndrome: trigeminal nerve involvement.
 Ann Int Med 70: 751-62, 1969.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#273#269#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00485000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023400080002001300314#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#274#270#article#307#54#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">54. Kaplan JG, Rosen
berg R, Reinitz E, Buchbinder S, Schaumburg HH: Invited review: peripheral neuro
pathy in Sj&ouml;gren's syndrome. Muscle Nerve 13: 570-9, 1990.    ^cY#v44n2a05.
htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#275#271#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00426000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017500080002001300255#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#276#272#article#307#55#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">55. Alexander EL: Ne
urological complications of primary Sj&ouml;gren's syndrome. Medicine 61: 247, 1
982.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#277#273#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00481000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023000080002001300310#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#278#274#article#307#56#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">56. Youinou P, Penne
c YL, Katsikis P, Jouquan J, Fauquert P, LeGoff P: Raynaud's phenomenon in prima
ry Sj&ouml;gren's syndrome. Br J Rheumatol 29: 205-7, 1990.    ^cY#v44n2a05.htm#
#
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#279#275#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021500080002001300295#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#280#276#article#307#57#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">57. Ichikawa Y, Taka
ya M, Yamauchi K et al: Clinical evaluation of 117 patients with Sj&ouml;gren's 
syndrome. Tokai Exp Clin Med 6: 11-22, 1981.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#281#277#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00461000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021000080002001300290#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#282#278#article#307#58#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">58. Starkebaum G, Da
ncey JT, Arend WP: Chronic neutropenia: possible association with Sj&ouml;gren's
 syndrome. J Rheumatol 8: 679-84, 1981.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#283#279#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025800080002001300338#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#284#280#article#307#59#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">59. Kaplan G: Les Ma
ladies Syst&eacute;miques. Syndrome de Gougerot-Sj&ouml;gren, Paris, Flammarion 
M&eacute;dicine Sciences, Kahn ME, Peltier AP, Meyer O, Piette JC (eds). 499-544
, 1991.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#285#281#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025100080002001300331#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#286#282#article#307#60#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">60. Vitali C, Tavoni
 A, Neri R, Castrogiovanni P, Pasero G, Bombardieri S: Fibromialgia features in 
patients with primary Sj&ouml;gren's syndrome. Scand J Rheumatol 18: 21-7, 1989.
    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#287#283#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00492000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024100080002001300321#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#288#284#article#307#61#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">61. Malinow KL, Moli
na R, Gordon B, Selnes OA, Provost TT, Alexander EL: Neuropsychiatric dysfunctio
n in primary Sj&ouml;gren's syndrome. Ann Intern Med 103: 344-9, 1985.    ^cY#v4
4n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#289#285#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00553000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030200080002001300382#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#290#286#article#307#62#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">62. M&uuml;ller K, O
xholm P, H&oslash;ier-Madsen M et al: Circulating IgA and IgM rheumatoid factors
 in patients with primary Sj&ouml;gren's syndrome. Correlation to extraglandular
 manifestations. Scand J Rheumatol 18: 29-31, 1989.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#291#287#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023100080002001300311#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#292#288#article#307#63#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">63. Valesini G, Prio
ri R, Borsetti A et al: Clinical and serological correlations in the evaluation 
of Sj&ouml;gren's syndrome. Clin Exp Rheum 7: 197-202, 1989.    ^cY#v44n2a05.htm
##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#293#289#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00427000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017600080002001300256#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#294#290#article#307#64#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">64. Fox RI, Stern M,
 Michelson P: Update in Sj&ouml;gren's syndrome. Curr Opin Rheumatol 12: 391-8, 
2000.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#295#291#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00461000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021000080002001300290#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#296#292#article#307#65#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">65. Vlachoyiannopoul
os PG: Therapy of Sj&ouml;gren's syndrome. New aspects and future directions. An
n Med Interne (Paris) 149: 49-53, 1998.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#297#293#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00456000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020500080002001300285#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#298#294#article#307#66#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">66. Bunin JJ, Talal 
N: The association of malignant lymphoma with Sj&ouml;gren's  syndrome. Trans As
soc Am Physicians 76: 45-56, 1963.    ^cY#v44n2a05.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#299#295#article#307#</font></p>     ^c
Y#v44n2a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#300#296#article#307#<p>&nbsp;</p>     
^cY#v44n2a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#301#297#article#307#<p>&nbsp;</p>     
^cY#v44n2a05.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022900077002001300306#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#302#298#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a href="#linkinicio"><img src="/im
g/revistas/rbr/v44n2/seta.jpg" border="0"></a><a name="linkcorresp"></a> <b>Ende
re&ccedil;o para correspond&ecirc;ncia:</b>    ^cY#v44n2a05.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010800077002001300185#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#303#299#article#307#<br>  Maria da Gra
&ccedil;a Henriques da Concei&ccedil;&atilde;o Negr&atilde;o Sequeira Mu&ntilde;
oz    ^cY#v44n2a05.htm##
00287000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005100077002001300128#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#304#300#article#307#<br> Praceta Gil V
icente n.º 2, 6.º direito    ^cY#v44n2a05.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004200077002001300119#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#305#301#article#307#<br> 2790-080, Car
naxide, Portugal    ^cY#v44n2a05.htm##
00336000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010000077002001300177#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#306#302#article#307#<br> E-mail: <a hr
ef="mailto:graca.sequeira@clix.pt">graca.sequeira@clix.pt</a> </font></p>     ^c
Y#v44n2a05.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009300077002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#307#303#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Recebido em 31/7/2003.    ^cY#v44n2
a05.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007600077002001300153#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#308#304#article#307#<br>  Aprovado, ap
&oacute;s revis&atilde;o, em 1/3/2004.</font></p>     ^cY#v44n2a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#309#305#article#307#<p>&nbsp;</p>     
^cY#v44n2a05.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#310#306#article#307#<p>&nbsp;</p>     
^cY#v44n2a05.htm##
00492000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704025600077002001300333#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a05.htm#S#p#311#307#article#307#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a name="link01"></a><a href="#link
inicio">*</a> Servi&ccedil;o de reumatologia e doen&ccedil;as &oacute;sseas meta
b&oacute;licas, Hospital de Santa Maria, Lisboa, Portugal.</font></p>     ^cY#v4
4n2a05.htm##
00519000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100023000760120047000990300
02600146031000300172014000600175065000900181064000500190865000900195002001300204
035001000217801002600227#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#312#1#article#66#1#^rND^sMoutsopoulos^nHM#Sjögren's syndrome: autoimmune epith
elitis^len#Clin Immunol Immunopathol#72#162-5#19940000#1994#20040400#v44n2a05.ht
m#0090-1229#Clin Immunol Immunopathol##
00518000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760120079000940300
01300173031000300186014000400189065000900193064000500202865000900207002001300216
035001000229801001300239#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#313#2#article#66#2#^rND^sDaniels^nTE#Sjögren's syndrome: clinical spectrum and
 current diagnostic controversies^len#Adv Dent Res#10#3-8#19960000#1996#20040400
#v44n2a05.htm#0895-9374#Adv Dent Res##
00522000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100022000760100023000980120
04700121030004100168710000200209031000300211014000600214065000900220064000500229
865000900234002001300243#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#314#3#article#66#3#^rND^sManoussakis^nMN#^rND^sMoutsopoulos^nHM#Sjögren's synd
rome: autoimmune epithelitis^len#Baillieres Best Pract Res Clin Rheumatol#2#14#7
3-95#20000000#2000#20040400#v44n2a05.htm##
00591000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100023000760100015000990100
01800114810000600132012006900138030001300207031000400220014000600224065000900230
064000500239865000900244002001300253035001000266801001300276#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#315#4#article#66#4#^rND^sMoutsopoulos^nHM#
^rND^sMann^nDL#^rND^sJohnson^nAH#et al#Genetic differences between primary and s
econdary sicca syndrome^len#N Engl J Med#301#761-3#19790000#1979#20040400#v44n2a
05.htm#0028-4793#N Engl J Med##
00492000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740160023000760160019000990180
03700118063000200155066000700157062000600164031000300170014000500173065000900178
064000500187865000900192002001300201#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a05.htm#S#c#316#5#article#66#5#^rND^sMoutsopoulos^nHM#^rND^sTzioufas^nAG#Rheum
atology: Sjögren's syndrome^len#2#London#Mosby#32#1-12#19980000#1998#20040400#v4
4n2a05.htm##
00589000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100020000950100
01700115010001800132012006800150030001600218710000200234066000600236031000400242
014000500246065000900251064000500260865000900265002001300274#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#317#6#article#66#6#^rND^sManthorpe^nR#^rND
^sJacobsson^nLT#^rND^sKirtava^nZ#^rND^sTheander^nE#Epidemiology of Sjögren's syn
drome, especially its primary form^len#Ann Med Interne#2#Paris#149#7-11#19980000
#1998#20040400#v44n2a05.htm##
00653000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100023000930100
02200116010002300138010002300161012007000184030001500254031000300269014000600272
065000900278064000500287865000900292002001300301035001000314801001500324#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#318#7#article#66#7#^rND^sDroso
s^nAA#^rND^sAntonopoulos^nAP#^rND^sCostopoulos^nJS#^rND^sPapadimitriou^nC#^rND^s
Moutsopoulos^nHM#Prevalence of primary Sjögren's syndrome in an elderly populati
on^len#Br J Rheumatol#27#123-7#19880000#1988#20040400#v44n2a05.htm#0263-7103#Br 
J Rheumatol##
00591000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100016000950100
01700111010001700128012005100145030001800196032000500214014000600219065000900225
064000500234865000900239002001300248035001000261801001800271#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#319#8#article#66#8#^rND^sManthorpe^nR#^rND
^sOxholm^nP#^rND^sPrause^nJU#^rND^sSchiødt^nM#The Copenhagen criteria for Sjögre
n's syndrome^len#Scand J Rheumatol#^s61#19-21#19860000#1986#20040400#v44n2a05.ht
m#0300-9742#Scand J Rheumatol##
00617000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760100018000900100
01500108010001500123010001600138012006100154030001600215031000300231014000700234
065000900241064000500250865000900255002001300264035001000277801001600287#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#320#9#article#66#9#^rND^sFox^n
RI#^rND^sRobinson^nC#^rND^sCurd^nJG#^rND^sKozin^nF#^rND^sHowell^nF#Sjögren's syn
drome: proposed criteria for classification^len#Arthritis Rheum#29#577-85#198600
00#1986#20040400#v44n2a05.htm#0004-3591#Arthritis rheum##
00744000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100021000940100
01700115810000600132012022100138030001400359031000300373014000600376065000900382
064000500391865000900396002001300405035001000418801001400428#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#321#10#article#66#10#^rND^sVitali^nC#^rND^
sBombardieri^nS#^rND^sJonsson^nR#et al#the European Study Group on Classificatio
n Criteria for Sjögren's Syndrome: Classification criteria for Sjögren's syndrom
e: a revised version of the European criteria proposed by the American.european 
Consensus Group^len#Ann Rheum Dis#61#554-8#20020000#2002#20040400#v44n2a05.htm#0
003-4967#Ann Rheum Dis##
00682000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100021000940100
02300115810000600138012014900144030001600293031000300309014000600312065000900318
064000500327865000900332002001300341035001000354801001600364#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#322#11#article#66#11#^rND^sVitali^nC#^rND^
sBombardieri^nS#^rND^sMoutsopoulos^nHM#et al#Preliminary criteria for the classi
fication of Sjögren's syndrome: Results of a prospective concerted action suppor
ted by the European Community^len#Arthritis Rheum#36#340-7#19930000#1993#2004040
0#v44n2a05.htm#0004-3591#Arthritis rheum##
00744000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100021000940100
01700115810000600132012022100138030001400359031000300373014000600376065000900382
064000500391865000900396002001300405035001000418801001400428#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#323#12#article#66#12#^rND^sVitali^nC#^rND^
sBombardieri^nS#^rND^sJonsson^nR#et al#the European Study Group on Classificatio
n Criteria for Sjögren's Syndrome: Classification criteria for Sjögren's syndrom
e: a revised version of the European criteria proposed by the American.european 
Consensus Group^len#Ann Rheum Dis#61#554-8#20020000#2002#20040400#v44n2a05.htm#0
003-4967#Ann Rheum Dis##
00564000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01500112810000600127012003600133030001900169031000300188014000600191065000900197
064000500206865000900211002001300220035001000233801001900243#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#324#13#article#66#13#^rND^sOxholm^nP#^rND^
sAsmussen^nK#^rND^sAxell^nT#et al#Sjögren's syndrome: terminology^len#Clin Exp R
heumatol#13#693-6#19950000#1995#20040400#v44n2a05.htm#0392-856X#Clin Exp Rheumat
ol##
00586000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940120
11000112030001500222031000300237032000700240065000900247064000500256865000900261
002001300270035001000283801001500293#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a05.htm#S#c#325#14#article#66#14#^rND^sOxholm^nP#^rND^sAsmussen^nK#Classificat
ion of disease manifestations in primary Sjögren's syndrome: present status and 
a new proposal^len#Clin Rheumatol#14#3-7^s1#19950000#1995#20040400#v44n2a05.htm#
0770-3198#Clin Rheumatol##
00674000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01800114810000600132012014100138030001800279031000300297014000800300065000900308
064000500317865000900322002001300331035001000344801001800354#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#326#15#article#66#15#^rND^sAsmussen^nK#^rN
D^sAndersen^nV#^rND^sBendixen^nG#et al#Quantitive assessment of clinical disease
 status in primary Sjögren's syndrome: A cross-sectional study using a new class
ification model^len#Scand J Rheumatol#26#197-205#19970000#1997#20040400#v44n2a05
.htm#0300-9742#Scand J Rheumatol##
00730000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01700113810000600130012021000136030001300346031000300359014000700362065000900369
064000500378865000900383002001300392035001000405801001300415#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#327#16#article#66#16#^rND^sBowman^nSJ#^rND
^sPillemer^nS#^rND^sJonsson^nR#et al#Contributors to and participants at the wor
kshop: Revisiting Sjögren's syndrome in the new millennium: perspectives on asse
ssment and outcome measures. Report of a workshop held on March 2000 at Oxford, 
UK^len#Rheumatology#40#1180-8#20010000#2001#20040400#v44n2a05.htm#0080-2727#RHEU
MATOLOGY##
00625000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100019000940100
01400113010001600127012008300143030000900226066001000235031000300245014000800248
065000900256064000500265865000900270002001300279035001000292801000900302#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#328#17#article#66#17#^rND^sBlo
ch^nKJ#^rND^sBuchanan^nWW#^rND^sWho^nMJ#^rND^sBunim^nJJ#Sjögren's syndrome: A cl
inical, pathological and serological study of 62 cases^len#Medicine#Baltimore#44
#187-231#19650000#1965#20040400#v44n2a05.htm#0025-7974#Medicine##
00625000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100020000940100
01900114010001400133010001600147010001900163012004400182030000800226031000300234
01400080023706500090024506400050025486500090025900200130026803500100028180100080
0291#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#329#18#article#66#
18#^rND^sWhaley^nK#^rND^sWilliamson^nJ#^rND^sChisholm^nDM#^rND^sWebb^nJ#^rND^sMa
son^nDK#^rND^sBuchanan^nWW#Sjögren's syndrome: 1. Sicca components^len#Q J Med#4
2#279-304#19730000#1973#20040400#v44n2a05.htm#0033-5622#Q J Med##
00516000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780120061000960300
01800157032000500175014000600180065000900186064000500195865000900200002001300209
035001000222801001800232#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#330#19#article#66#19#^rND^sDaniels^nTE#Salivary histopathology in diagnosis of
 Sjögren syndrome^len#Scand J Rheumatol#^s61#36-43#19860000#1986#20040400#v44n2a
05.htm#0300-9742#Scand J Rheumatol##
00649000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100018000980100
01500116010002000131012007900151030003100230031000300261014000600264065000900270
064000500279865000900284002001300293035001000306801003100316#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#331#20#article#66#20#^rND^sGreenspan^nJS#^
rND^sDaniels^nTE#^rND^sTalal^nN#^rND^sSylvester^nRA#The histopathology of Sjögre
n's syndrome in labial salivary gland biopsies^len#Oral Surg Oral Med Oral Patho
l#37#217-9#19740000#1974#20040400#v44n2a05.htm#0030-4220#Oral Surg Oral Med Oral
 Pathol##
00597000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960100
01600115012005900131030003100190031000300221014000600224065000900230064000500239
865000900244002001300253035001000266801003100276#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#332#21#article#66#21#^rND^sTarpley^nTM#^rND^sAnderson^
nLG#^rND^sWhite^nCL#Minor salivary gland involvement in Sjögren's syndrome^len#O
ral Surg Oral Med Oral Pathol#37#64-74#19740000#1974#20040400#v44n2a05.htm#0030-
4220#Oral Surg Oral Med Oral Pathol##
00632000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960120
15100115030001600266031000300282014000700285065000900292064000500301865000900306
002001300315035001000328801001600338#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a05.htm#S#c#333#22#article#66#22#^rND^sDaniels^nTE#^rND^sWhitcher^nJP#Associat
ion of patterns of salivary gland inflammation with keratoconjunctivitis sicca: 
Analysis of 618 patients with suspected Sjögren's syndrome^len#Arthritis Rheum#3
7#869-77#19940000#1994#20040400#v44n2a05.htm#0004-3591#Arthritis rheum##
00588000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100014000950100
01800109012009100127030001200218031000300230014000700233065000900240064000500249
865000900254002001300263035001000276801001200286#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#334#23#article#66#23#^rND^sVivino^nFB#^rND^sGala^nI#^r
ND^sHermann^nGA#Change in Final Diagnosis on Second Evaluation of Labial Minor S
alivary Gland Biopsies^len#J Rheumatol#29#938-44#20020000#2002#20040400#v44n2a05
.htm#0315-162X#J Rheumatol##
00572000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100019000950100
01500114012008500129030000500214031000400219014000800223065000900231064000500240
865000900245002001300254035001000267801000500277#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#335#24#article#66#24#^rND^sSchall^nGL#^rND^sAnderson^n
LG#^rND^sWolf^nRO#Xerostomia in Sjögren's syndrome: evaluation by sequential sal
ivary scintigraphy^len#JAMA#216#2109-16#19710000#1971#20040400#v44n2a05.htm#0098
-7484#JAMA##
00540000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100014000930120
06700107030001600174031000300190014000700193065000900200064000500209865000900214
002001300223035001000236801001600246#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a05.htm#S#c#336#25#article#66#25#^rND^sRubin^nH#^rND^sHolt^nM#Secretory sialog
raphy in diseases of the major salivary glands^len#Am J Roentgenol#77#575-98#195
70000#1957#20040400#v44n2a05.htm#0361-803X#Am J Roentgenol##
00620000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100016000990100
01700115012012000132030001200252031000200264014000600266065000900272064000500281
865000900286002001300295035001000308801001200318#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#337#26#article#66#26#^rND^sJacobsson^nLTH#^rND^sAxell^
nTE#^rND^sHansen^nBU#Dry eyes or mouth: An epidemiological study in Swedish adul
ts, with special reference to primary Sjögren's syndrome^len#J Autoimmun#2#521-7
#19590000#1989#20040400#v44n2a05.htm#0896-8411#J Autoimmun##
00576000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780100014001000100
01600114810000600130012009100136030000900227710000200236031000400238014000800242
065000900250064000500259865000900264002001300273#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#338#27#article#66#27#^rND^sO'Callaghan^nAS#^rND^sGil^n
JB#^rND^sLaque^nRS#et al#Primary Sjögren's syndrome: clinical and immunological 
characteristics of 114 patients^len#Med Clin#2#116#721-725#20010000#2001#2004040
0#v44n2a05.htm##
00571000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780120087000950300
01600182031000200198031000300200032000800203014000800211065000900219064000500228
865000900233002001300242035001000255801001600265#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#339#28#article#66#28#^rND^sCarsons^nS#A review and upd
ate of Sjögren's syndrome: manifestations, diagnosis and treatment^len#Am J Mana
g Care#7#14#^sSuppl#S433-43#20010000#2001#20040400#v44n2a05.htm#1096-1860#Am J M
anag Care##
00522000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
01600110810000600126012003400132030003200166710000200198014000800200065000900208
064000500217865000900222002001300231#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a05.htm#S#c#340#29#article#66#29#^rND^sCosta^nJT#^rND^sSousa^nMC#^rND^sSilva^n
MC#et al#Síndrome de Sjögren Primitivo^lpt#Acta Reumatológica Portuguesa X#2#185
-232#19850000#1985#20040400#v44n2a05.htm##
00505000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160017000780180084000950630
00200179066000700181062000600188031000200194014000700196065000900203064000500212
865000900217002001300226#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#341#30#article#66#30#^rND^sSaraiva^nF#Reumatologia: Clínica e Terapêutica das 
Doenças Reumáticas. Sindroma de Sjögren^lpt#1#Lisboa#Lidel#2#137-62#20020000#200
2#20040400#v44n2a05.htm##
00505000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120084000940300
02500178710000200203031000300205014000700208065000900215064000500224865000900229
002001300238#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#342#31#art
icle#66#31#^rND^sOxholm^nP#Primary Sjögren's syndrome: Clinical and laboratory m
arkers of disease activity^len#Seminars Arthritis Rheum#2#22#114-26#19920000#199
2#20040400#v44n2a05.htm##
00556000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100015000960120
08700111030001300198031000300211014000500214065000900219064000500228865000900233
002001300242035001000255801001300265#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a05.htm#S#c#343#32#article#66#32#^rND^sDaniels^nTE#^rND^sBenn^nDK#Is sialograp
hy effective in diagnosing the salivary component of Sjögren Syndrome?^len#Adv D
ent Res#10#25-8#19960000#1996#20040400#v44n2a05.htm#0895-9374#Adv Dent Res##
00552000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780120111000960300
01200207031000200219014000700221065000900228064000500237865000900242002001300251
035001000264801001200274#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#344#33#article#66#33#^rND^sDaniels^nTE#Clinical assessment and diagnosis of im
munologically mediated salivary gland disease in Sjögren's syndrome^len#J Autoim
mun#2#529-41#19890000#1989#20040400#v44n2a05.htm#0896-8411#J Autoimmun##
00581000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100015000960100
02300111012007800134030001200212031000200224014000700226065000900233064000500242
865000900247002001300256035001000269801001200279#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#345#34#article#66#34#^rND^sPavlidis^nN#^rND^sKarsh^nJ#
^rND^sMoutsopoulos^nHM#The clinical Picture of primary Sjögren's syndrome: a ret
rospective study^len#J Rheumatol#9#685-90#19820000#1982#20040400#v44n2a05.htm#03
15-162X#J Rheumatol##
00481000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100021000970120
02300118030002700141710000200168031000200170014000700172065000900179064000500188
865000900193002001300202#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#346#35#article#66#35#^rND^sManthorpe^nR#^rND^sJacobsson^nLTH#Sjögren's syndrom
e^len#Bailliere's Clin Rheumatol#2#9#483-96#19950000#1995#20040400#v44n2a05.htm#
#
00525000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780120116000960300
01100212710000200223031000300225014000700228065000900235064000500244865000900249
002001300258#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#347#36#art
icle#66#36#^rND^sDaniels^nTE#Labial salivary gland biopsy in Sjögren's syndrome:
 Assessment as a diagnostic criterion in 362 suspected cases^len#Arth Rheum#2#27
#147-56#19840000#1984#20040400#v44n2a05.htm##
00517000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120051000970300
02500148031000300173031000400176065000900180064000500189865000900194002001300203
035001000216801002500226#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#348#37#article#66#37#^rND^sBatsakis^nJG#Lymphoepithelial lesion and Sjögren's 
syndrome^len#Ann Otol Rhinol Laryngol#89#135#19800000#1980#20040400#v44n2a05.htm
#0003-4894#Ann Otol Rhinol Laryngol##
00554000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100016000930100
01700109810000600126012007000132030001700202710000200219031000300221020000400224
065000900228064000500237865000900242002001300251#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#349#38#article#66#38#^rND^sPalma^nR#^rND^sFreire^nA#^r
ND^sFreitas^nJ#et al#Esophageal motility disorders in patients with Sjögren's sy
ndrome^len#Dig Dis Sciences#2#39#758#19940000#1994#20040400#v44n2a05.htm##
00483000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120073000940300
01700167710000200184031000300186020000400189065000900193064000500202865000900207
002001300216#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#350#39#art
icle#66#39#^rND^sKellen^nG#Esophageal function, radiography and dysphagia in Sjö
gren's syndrome^len#Dig Dis Sciences#2#31#225#19860000#1986#20040400#v44n2a05.ht
m##
00545000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100017001010100
01500118810000600133012005600139030001200195710000200207031000300209014000700212
065000900219064000500228865000900233002001300242#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#351#40#article#66#40#^rND^sMoutsopoulos^nHM#^rND^sChus
ed^nTM#^rND^sMann^nDL#et al#Sjögren's syndrome (sicca syndrome): current issues^
len#Ann Int Med#2#92#212-26#19800000#1980#20040400#v44n2a05.htm##
00580000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01700112810000600129012006400135030001200199031000300211014000600214065000900220
064000500229865000900234002001300243035001000256801001200266#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#352#41#article#66#41#^rND^sGardiner^nPH#^r
ND^sWard^nCH#^rND^sAllison^nA#et al#Pleuropulmonary abnormalities in primary Sjö
gren's syndrome^len#J Rheumatol#20#831-7#19930000#1993#20040400#v44n2a05.htm#031
5-162X#J Rheumatol##
00542000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780120094000930300
01700187031000300204014000600207065000900213064000500222865000900227002001300236
035001000249801001700259#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#353#42#article#66#42#^rND^sTalal^nN#Síndrome de Sjögren: conceptos actuales, f
actores immunológicos y víricos en la etiologia^les#Rev Esp Reumatol#18#115-8#19
910000#1991#20040400#v44n2a05.htm#0304-4815#Rev Esp Reumatol##
00583000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01700112810000600129012005400135030001900189031000300208014000500211065000900216
064000500225865000900230002001300239035001000252801001900262#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#354#43#article#66#43#^rND^sOstuni^nPA#^rND
^sGermana^nB#^rND^sDiMario^nF#et al#Gastric involvement in primary Sjögren's syn
drome^len#Clin Exp Rheumatol#11#21-5#19930000#1993#20040400#v44n2a05.htm#0392-85
6X#Clin Exp Rheumatol##
00664000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100019000950100
01800114010001500132010001600147010001500163012007600178030001400254031000300268
01400070027106500090027806400050028786500090029200200130030103500100031480100140
0324#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#355#44#article#66#
44#^rND^sPokorny^nG#^rND^sKarácsony^nG#^rND^sLonovics^nJ#^rND^sHudák^nJ#^rND^sNé
meth^nJ#^rND^sVarró^nV#Types of atrophic gastritis in patients with primary Sjög
ren's syndrome^len#Ann Rheum Dis#50#97-100#19910000#1991#20040400#v44n2a05.htm#0
003-4967#Ann Rheum Dis##
00593000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100022000950100
02300117012005200140030001700192031000300209032000400212061001200216065000900228
064000500237865000900242002001300251035001000264801001700274#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#356#45#article#66#45#^rND^sBarbati^nK#^rND
^sGalanopoulou^nV#^rND^sMoutsopoulos^nHM#Liver involvement in primary Sjögren's 
syndrome^len#Rev Esp Reumatol#20#^s1#resumen 432#19930000#1993#20040400#v44n2a05
.htm#0304-4815#Rev Esp Reumatol##
00614000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
02000111010001500131012006000146030001500206031000300221032000400224061001100228
065000900239064000500248865000900253002001300262035001000275801001500285#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#357#46#article#66#46#^rND^sHor
don^nLD#^rND^sKelly^nCA#^rND^sGriffiths^nID#^rND^sBird^nHA#Renal tubular dysfunc
tion in primary Sjögren's syndrome^len#Br J Rheumatol#29#^s1#resumen 74#19900000
#1990#20040400#v44n2a05.htm#0263-7103#Br J Rheumatol##
00481000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120076000940300
01300170710000200183031000200185020000400187065000900191064000500200865000900205
002001300214#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#358#47#art
icle#66#47#^rND^sWiner^nRL#Sjögren's syndrome with immune complex tubulointersti
tial renal disease^len#Clin Immunol#2#8#494#19970000#1997#20040400#v44n2a05.htm#
#
00586000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160019000780160023000970160
01500120018010400135063000200239066000700241062001600248014000800264065000900272
064000500281865000900286002001300295#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a05.htm#S#c#359#48#article#66#48#^rND^sTzioufas^nAG#^rND^sMoutsopoulos^nHM#^rN
D^sTalal^nN#Sjögren's syndrome: Clinical and immunological aspects. Lymphoid mal
ignancy and monoclonal proteins^len#1#Berlin#Springer-Verlag#129-136#19870000#19
87#20040400#v44n2a05.htm##
00540000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
02300112810000600135012004900141030001200190710000200202031000300204014000700207
065000900214064000500223865000900228002001300237#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#360#49#article#66#49#^rND^sKassan^nSS#^rND^sThomas^nTL
#^rND^sMoutsopoulos^nHM#et al#Increased risk of lymphoma in sicca syndrome^len#A
nn Int Med#2#89#888-92#19780000#1978#20040400#v44n2a05.htm##
00690000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100024000780100016001020100
01700118010001600135010001900151010001500170012006500185030001600250031000300266
03200080026906100130027706500090029006400050029986500090030400200130031303500100
0326801001600336#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#361#50
#article#66#50#^rND^sOrozco-Barocio^nG#^rND^sOrtiz^nJD#^rND^sRomero^nEA#^rND^sTo
rre^nIG#^rND^sGuerrero^nRG#^rND^sDíaz^nCI#Muskuloskeletal manifestations in prim
ary Sjögren's syndrome^len#Arthritis Rheum#34#^sSuppl#resumen S191#19910000#1991
#20040400#v44n2a05.htm#0004-3591#Arthritis rheum##
00576000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01800112010001600130012004200146030001500188031000300203014000700206065000900213
064000500222865000900227002001300236035001000249801001500259#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#362#51#article#66#51#^rND^sPease^nCT#^rND^
sShattles^nW#^rND^sBarrett^nNK#^rND^sMaini^nRN#The arthropathy of Sjögren's synd
rome^len#Br J Rheumatol#32#609-13#19930000#1993#20040400#v44n2a05.htm#0263-7103#
Br J Rheumatol##
00552000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100019000930120
07000112030001800182031000300200014000700203065000900210064000500219865000900224
002001300233035001000246801001800256#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a05.htm#S#c#363#52#article#66#52#^rND^sGran^nJT#^rND^sMyklebust^nG#The concomi
tant occurrence of Sjögren's syndrome and polymiositis^len#Scand J Rheumatol#21#
150-54#19920000#1992#20040400#v44n2a05.htm#0300-9742#Scand J Rheumatol##
00511000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100015000990120
07100114030001200185710000200197031000300199014000700202065000900209064000500218
865000900223002001300232#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#364#53#article#66#53#^rND^sKaltreider^nHB#^rND^sTalal^nN#The neuropathy of Sjö
gren's syndrome: trigeminal nerve involvement^len#Ann Int Med#2#70#751-62#196900
00#1969#20040400#v44n2a05.htm##
00631000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100019000950100
01700114010002000131010002100151012006400172030001300236031000300249014000600252
065000900258064000500267865000900272002001300281035001000294801001300304#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#365#54#article#66#54#^rND^sKap
lan^nJG#^rND^sRosenberg^nR#^rND^sReinitz^nE#^rND^sBuchbinder^nS#^rND^sSchaumburg
^nHH#Invited review: peripheral neuropathy in Sjögren's syndrome^len#Muscle Nerv
e#13#570-9#19900000#1990#20040400#v44n2a05.htm#0148-639X#Muscle nerve##
00496000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780120061000980300
00900159031000300168020000400171065000900175064000500184865000900189002001300198
035001000211801000900221#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#366#55#article#66#55#^rND^sAlexander^nEL#Neurological complications of primary
 Sjögren's syndrome^len#Medicine#61#247#19820000#1982#20040400#v44n2a05.htm#0025
-7974#Medicine##
00647000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01800112010001700130010001800147010001600165012005500181030001500236031000300251
01400060025406500090026006400050026986500090027400200130028303500100029680100150
0306#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#367#56#article#66#
56#^rND^sYouinou^nP#^rND^sPennec^nYL#^rND^sKatsikis^nP#^rND^sJouquan^nJ#^rND^sFa
uquert^nP#^rND^sLeGoff^nP#Raynaud's phenomenon in primary Sjögren's syndrome^len
#Br J Rheumatol#29#205-7#19900000#1990#20040400#v44n2a05.htm#0263-7103#Br J Rheu
matol##
00555000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01800112810000600130012006400136030001900200710000200219031000200221014000600223
065000900229064000500238865000900243002001300252#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#368#57#article#66#57#^rND^sIchikawa^nY#^rND^sTakaya^nM
#^rND^sYamauchi^nK#et al#Clinical evaluation of 117 patients with Sjögren's synd
rome^len#Tokai Exp Clin Med#2#6#11-22#19810000#1981#20040400#v44n2a05.htm##
00570000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100017000980100
01600115012007000131030001200201031000200213014000700215065000900222064000500231
865000900236002001300245035001000258801001200268#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#369#58#article#66#58#^rND^sStarkebaum^nG#^rND^sDancey^
nJT#^rND^sArend^nWP#Chronic neutropenia: possible association with Sjögren's syn
drome^len#J Rheumatol#8#679-84#19810000#1981#20040400#v44n2a05.htm#0315-162X#J R
heumatol##
00489000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120029000940180
03300123066000600156062002900162014000800191065000900199064000500208865000900213
002001300222#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#370#59#art
icle#66#59#^rND^sKaplan^nG#Les Maladies Systémiques^lfr#Syndrome de Gougerot-Sjö
gren^lfr#Paris#Flammarion Médicine Sciences#499-544#19910000#1991#20040400#v44n2
a05.htm##
00671000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
01400110010002400124010001600148010002100164012007000185030001800255031000300273
01400050027606500090028106400050029086500090029500200130030403500100031780100180
0327#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#371#60#article#66#
60#^rND^sVitali^nC#^rND^sTavoni^nA#^rND^sNeri^nR#^rND^sCastrogiovanni^nP#^rND^sP
asero^nG#^rND^sBombardieri^nS#Fibromialgia features in patients with primary Sjö
gren's syndrome^len#Scand J Rheumatol#18#21-7#19890000#1989#20040400#v44n2a05.ht
m#0300-9742#Scand J Rheumatol##
00658000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01600112010001700128010001800145010002000163012006300183030001500246031000400261
01400060026506500090027106400050028086500090028500200130029403500100030780100150
0317#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#c#372#61#article#66#
61#^rND^sMalinow^nKL#^rND^sMolina^nR#^rND^sGordon^nB#^rND^sSelnes^nOA#^rND^sProv
ost^nTT#^rND^sAlexander^nEL#Neuropsychiatric dysfunction in primary Sjögren's sy
ndrome^len#Ann Intern Med#103#344-9#19850000#1985#20040400#v44n2a05.htm#0003-481
9#Ann Intern Med##
00668000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
02200110810000600132012013700138030001800275031000300293014000600296065000900302
064000500311865000900316002001300325035001000338801001800348#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a05.htm#S#c#373#62#article#66#62#^rND^sMüller^nK#^rND^
sOxholm^nP#^rND^sHøier-Madsen^nM#et al#Circulating IgA and IgM rheumatoid factor
s in patients with primary Sjögren's syndrome: Correlation to extraglandular man
ifestations^len#Scand J Rheumatol#18#29-31#19890000#1989#20040400#v44n2a05.htm#0
300-9742#Scand J Rheumatol##
00571000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01800112810000600130012008200136030001500218710000200233031000200235014000800237
065000900245064000500254865000900259002001300268#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#374#63#article#66#63#^rND^sValesini^nG#^rND^sPriori^nR
#^rND^sBorsetti^nA#et al#Clinical and serological correlations in the evaluation
 of Sjögren's syndrome^len#Clin Exp Rheum#2#7#197-202#19890000#1989#20040400#v44
n2a05.htm##
00544000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100015000920100
01900107012003300126030002000159031000300179014000600182065000900188064000500197
865000900202002001300211035001000224801002000234#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a05.htm#S#c#375#64#article#66#64#^rND^sFox^nRI#^rND^sStern^nM#^rND
^sMichelson^nP#Update in Sjögren's syndrome^len#Curr Opin Rheumatol#12#391-8#200
00000#2000#20040400#v44n2a05.htm#1040-8711#Curr Opin Rheumatol##
00512000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100029000780120069001070300
01600176710000200192066000600194031000400200014000600204065000900210064000500219
865000900224002001300233#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a05.htm#S#
c#376#65#article#66#65#^rND^sVlachoyiannopoulos^nPG#Therapy of Sjögren's syndrom
e: New aspects and future directions^len#Ann Med Interne#2#Paris#149#49-53#19980
000#1998#20040400#v44n2a05.htm##
00560000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100015000940120
06600109030002600175031000300201014000600204065000900210064000500219865000900224
002001300233035001000246801002600256#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a05.htm#S#c#377#66#article#66#66#^rND^sBunin^nJJ#^rND^sTalal^nN#The associatio
n of malignant lymphoma with Sjögren's syndrome^len#Trans Assoc Am Physicians#76
#45-56#19630000#1963#20040400#v44n2a05.htm#0066-9458#Trans Assoc Am Physicians##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#o#1#1#article#1#
20110406#085531#v44n2a06.htm#460##
03385000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701200750
01670120073002420100027003150100029003420100025003710100038003960100036004340700
05900470070003400529070004900563083089300612085000801505085003401513085003801547
08500390158508500260162408308680165008500080251808500330252608500380255908500380
25970850028026351170006026630720003026691120009026721110010026811140009026911130
01002700002001302710#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#h#2#
1#article#1#ra#pt#br1.1#1#4.0#ILUS#TAB#06#RBR100#nd#Rev. Bras. Reumatol.#44#2#20
040400#^f139^l149#0482-5004#Anticorpos contra beta2-glicoproteína I, autoimunida
de e aterosclerose^lpt#Antibodies to beta2-glycoprotein I, autoimmunity and athe
rosclerosis^len#^rND^1A01^nAline^sRanzolin#^rND^1A01^nAndrei^sLotterman#^rND^1A0
1^nJussara^sBohn#^rND^1A01^nCarlos Alberto^svon Mühlen#^rND^1A02 A03^nHenrique L
uiz^sStaub#PUCRS^iA01^1Faculdade de Medicina^2serviço de reumatologia#PUCRS^iA02
^1Faculdade de Medicina#Universidade Luterana do Brasil^iA03^cCanoas^sRS#^lpt^aA
 beta2-glicoproteína I (beta2-gpI) é um cofator fosfolipídico com propriedades a
nticoagulantes. Inúmeras funções biológicas na via da coagulação são atribuíveis
 a este cofator. Os soros de pacientes com síndrome antifosfolipídica (SAF) freq
üentemente reagem contra beta2-gpI em ensaios imunoenzimáticos. Por vezes, pacie
ntes com diátese trombótica apresentam anticorpos antibeta2-gpI na ausência de o
utros anticorpos anti-fosfolípides (AAF). Mais recentemente, comprovou-se a pres
ença da beta2-gpI na placa aterosclerótica. Nesta revisão, abordamos inicialment
e as funções fisiológicas da beta2-gpI na via da coagulação. A seguir, revisamos
 a importância dos anticorpos anti-beta2-gpI em pacientes com SAF, outras diátes
es trombóticas, lúpus eritematoso sistêmico (LES) e infecções. Por fim, o papel 
dos anticorpos anti-beta2-gpI na aterosclerose coronária e cerebral é também abo
rdado#^dnd^i1#^tm^lpt^kbeta2-glicoproteína I^i1#^tm^lpt^kanticorpos anti-beta2-g
pI^i1#^tm^lpt^ksíndrome antifosfolipídica^i1#^tm^lpt^katerosclerose^i1#^len^aBet
a2-glycoprotein I (beta2-gpI) is a phospholipid cofactor with anticoagulant prop
erties. A number of biological functions in the coagulation cascade have been at
tributed to this cofactor. Sera from patients with antiphospholipid syndrome (AP
S) frequently react to beta2-gpI in immunoassays. Occasionally, patients with th
rombotic diathesis present anti-beta2-gpI antibodies in the absence of other ant
iphospholipid antibodies (APA). More recently, the presence of beta2-gpI in the 
atherosclerotic plaque has been proved. In this article, we initially approach t
he physiological functions of beta2-gpI in the coagulation cascade, and we also 
review the importance of anti-beta2gpI antibodies in patients with APS, systemic
 lupus erythematosus (SLE) and infections. Lastly, we focus the role of anti-bet
a2-gpI antibodies in coronary and cerebral atherosclerosis#^dnd^i2#^tm^len^kbeta
2-glycoprotein I^i2#^tm^len^kanti-beta2-gpI antibodies^i2#^tm^len^kantiphospholi
pid syndrome^i2#^tm^len^katherosclerosis^i2#other#99#20030331#31/3/2003#20030812
#12/8/2003#v44n2a06.htm##
03399000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701200820
01670120080002490100027003290100029003560100025003850100038004100100036004480700
05900484070003400543070004900577083089300626085000801519085003401527085003801561
08500390159908500260163808308680166408500080253208500330254008500380257308500380
26110850028026491170006026770720003026831120009026861110010026951140009027051130
01002714002001302724#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#f#3#
1#article#1#ra#pt#br1.1#1#4.0#ILUS#TAB#06#RBR100#nd#Rev. Bras. Reumatol.#44#2#20
040400#^f139^l149#0482-5004#<b>Anticorpos contra beta2-glicoproteína I, autoimun
idade e aterosclerose</b>^lpt#<b>Antibodies to beta2-glycoprotein I, autoimmunit
y and atherosclerosis</b>^len#^rND^1A01^nAline^sRanzolin#^rND^1A01^nAndrei^sLott
erman#^rND^1A01^nJussara^sBohn#^rND^1A01^nCarlos Alberto^svon Mühlen#^rND^1A02 A
03^nHenrique Luiz^sStaub#PUCRS^iA01^1Faculdade de Medicina^2serviço de reumatolo
gia#PUCRS^iA02^1Faculdade de Medicina#Universidade Luterana do Brasil^iA03^cCano
as^sRS#^lpt^aA beta2-glicoproteína I (beta2-gpI) é um cofator fosfolipídico com 
propriedades anticoagulantes. Inúmeras funções biológicas na via da coagulação s
ão atribuíveis a este cofator. Os soros de pacientes com síndrome antifosfolipíd
ica (SAF) freqüentemente reagem contra beta2-gpI em ensaios imunoenzimáticos. Po
r vezes, pacientes com diátese trombótica apresentam anticorpos antibeta2-gpI na
 ausência de outros anticorpos anti-fosfolípides (AAF). Mais recentemente, compr
ovou-se a presença da beta2-gpI na placa aterosclerótica. Nesta revisão, abordam
os inicialmente as funções fisiológicas da beta2-gpI na via da coagulação. A seg
uir, revisamos a importância dos anticorpos anti-beta2-gpI em pacientes com SAF,
 outras diáteses trombóticas, lúpus eritematoso sistêmico (LES) e infecções. Por
 fim, o papel dos anticorpos anti-beta2-gpI na aterosclerose coronária e cerebra
l é também abordado#^dnd^i1#^tm^lpt^kbeta2-glicoproteína I^i1#^tm^lpt^kanticorpo
s anti-beta2-gpI^i1#^tm^lpt^ksíndrome antifosfolipídica^i1#^tm^lpt^kateroscleros
e^i1#^len^aBeta2-glycoprotein I (beta2-gpI) is a phospholipid cofactor with anti
coagulant properties. A number of biological functions in the coagulation cascad
e have been attributed to this cofactor. Sera from patients with antiphospholipi
d syndrome (APS) frequently react to beta2-gpI in immunoassays. Occasionally, pa
tients with thrombotic diathesis present anti-beta2-gpI antibodies in the absenc
e of other antiphospholipid antibodies (APA). More recently, the presence of bet
a2-gpI in the atherosclerotic plaque has been proved. In this article, we initia
lly approach the physiological functions of beta2-gpI in the coagulation cascade
, and we also review the importance of anti-beta2gpI antibodies in patients with
 APS, systemic lupus erythematosus (SLE) and infections. Lastly, we focus the ro
le of anti-beta2-gpI antibodies in coronary and cerebral atherosclerosis#^dnd^i2
#^tm^len^kbeta2-glycoprotein I^i2#^tm^len^kanti-beta2-gpI antibodies^i2#^tm^len^
kantiphospholipid syndrome^i2#^tm^len^katherosclerosis^i2#other#99#20030331#31/3
/2003#20030812#12/8/2003#v44n2a06.htm##
03521000000000685000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000200012903100030014903200020015206500090015401400110016303500100
01740120075001840120073002590100027003320100029003590100025003880100038004130100
03600451070006100487070003600548070005100584083089300635085000801528085003401536
08500380157008500390160808500260164708308680167308500080254108500330254908500380
25820850038026200850028026581170006026860720003026921120009026951110010027041140
00902714113001002723002001302733008008902746#v44n2#V:\SciELO\serial\rbr\v44n2\ma
rkup\v44n2a06.htm#S#l#4#1#article#1#^mmar./abr.^a2004#ra#pt#br1.1#1#4.0#ilus#tab
#06#RBR100#nd#Rev. Bras. Reumatol#44#2#20040400#^f139^l149#0482-5004#Anticorpos 
contra beta2-glicoproteína I, autoimunidade e aterosclerose^lpt#Antibodies to be
ta2-glycoprotein I, autoimmunity and atherosclerosis^len#^rND^1A01^nAline^sRanzo
lin#^rND^1A01^nAndrei^sLotterman#^rND^1A01^nJussara^sBohn#^rND^1A01^nCarlos Albe
rto^svon Mühlen#^rND^1A02 A03^nHenrique Luiz^sStaub#^iA01^1PUCRS^2Faculdade de M
edicina^3serviço de reumatologia#^iA02^1PUCRS^2Faculdade de Medicina#^iA03^1Univ
ersidade Luterana do Brasil^cCanoas^sRS#^lpt^aA beta2-glicoproteína I (beta2-gpI
) é um cofator fosfolipídico com propriedades anticoagulantes. Inúmeras funções 
biológicas na via da coagulação são atribuíveis a este cofator. Os soros de paci
entes com síndrome antifosfolipídica (SAF) freqüentemente reagem contra beta2-gp
I em ensaios imunoenzimáticos. Por vezes, pacientes com diátese trombótica apres
entam anticorpos antibeta2-gpI na ausência de outros anticorpos anti-fosfolípide
s (AAF). Mais recentemente, comprovou-se a presença da beta2-gpI na placa ateros
clerótica. Nesta revisão, abordamos inicialmente as funções fisiológicas da beta
2-gpI na via da coagulação. A seguir, revisamos a importância dos anticorpos ant
i-beta2-gpI em pacientes com SAF, outras diáteses trombóticas, lúpus eritematoso
 sistêmico (LES) e infecções. Por fim, o papel dos anticorpos anti-beta2-gpI na 
aterosclerose coronária e cerebral é também abordado#^dnd^i1#^tm^lpt^kbeta2-glic
oproteína I^i1#^tm^lpt^kanticorpos anti-beta2-gpI^i1#^tm^lpt^ksíndrome antifosfo
lipídica^i1#^tm^lpt^katerosclerose^i1#^len^aBeta2-glycoprotein I (beta2-gpI) is 
a phospholipid cofactor with anticoagulant properties. A number of biological fu
nctions in the coagulation cascade have been attributed to this cofactor. Sera f
rom patients with antiphospholipid syndrome (APS) frequently react to beta2-gpI 
in immunoassays. Occasionally, patients with thrombotic diathesis present anti-b
eta2-gpI antibodies in the absence of other antiphospholipid antibodies (APA). M
ore recently, the presence of beta2-gpI in the atherosclerotic plaque has been p
roved. In this article, we initially approach the physiological functions of bet
a2-gpI in the coagulation cascade, and we also review the importance of anti-bet
a2gpI antibodies in patients with APS, systemic lupus erythematosus (SLE) and in
fections. Lastly, we focus the role of anti-beta2-gpI antibodies in coronary and
 cerebral atherosclerosis#^dnd^i2#^tm^len^kbeta2-glycoprotein I^i2#^tm^len^kanti
-beta2-gpI antibodies^i2#^tm^len^kantiphospholipid syndrome^i2#^tm^len^katherosc
lerosis^i2#other#99#20030331#31/3/2003#20030812#12/8/2003#v44n2a06.htm#Internet^
ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042004000200006#
#
00375000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704014300073002001300216#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#5#1#article#357#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ARTIGO DE REVIS&Atilde
;O</b> REVIEW ARTICLE</font></p>     ^cY#v44n2a06.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#6#2#article#357#<p>&nbsp;</p>     ^cY#
v44n2a06.htm##
00485000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704025300073002001300326#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#7#3#article#357#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="linkinicio"></a><b>Anticorpos 
contra beta2-glicoprote&iacute;na I,    autoimunidade e aterosclerose<sup>(</sup
><a href="#link01"><sup>*</sup></a><sup>)</sup></b></font></p>     ^cY#v44n2a06.
htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#8#4#article#357#<p>&nbsp;</p>     ^cY#
v44n2a06.htm##
00390000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704015800073002001300231#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#9#5#article#357#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><b>Antibodies to beta2-glycoprotein I, 
autoimmunity and atherosclerosis</b></font></p>     ^cY#v44n2a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#10#6#article#357#<p>&nbsp;</p>     ^cY
#v44n2a06.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#11#7#article#357#<p>&nbsp;</p>     ^cY
#v44n2a06.htm##
00485000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704025200074002001300326#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#12#8#article#357#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Aline Ranzolin<sup>I</sup>; Andrei 
Lotterman<sup>I</sup>; Jussara Bohn<sup>I</sup>; Carlos Alberto von M&uuml;hlen<
sup>II</sup>; Henrique Luiz Staub<sup>III</sup></b></font></p>     ^cY#v44n2a06.
htm##
00393000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704016000074002001300234#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#13#9#article#357#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Residente do servi&ccedil;
o de reumatologia da Faculdade de Medicina da PUCRS    ^cY#v44n2a06.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010900075002001300184#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#14#10#article#357#<br> <sup>II</sup>Do
utor em reumatologia, professor de reumatologia da Faculdade de Medicina da PUCR
S    ^cY#v44n2a06.htm##
00413000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017900075002001300254#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#15#11#article#357#<br> <sup>III</sup>D
outor em reumatologia, professor de reumatologia da Faculdade de Medicina da PUC
RS e da Universidade Luterana do Brasil (ULBRA), Canoas, RS</font></p>     ^cY#v
44n2a06.htm##
00386000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015200075002001300227#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#16#12#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#linkcorresp">Endere&ccedil;
o para correspond&ecirc;ncia</a></font></p>     ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#17#13#article#357#<p>&nbsp;</p>     ^c
Y#v44n2a06.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#18#14#article#357#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v44n2a06.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#19#15#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v44n
2a06.htm##
01459000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704122500075002001301300#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#20#16#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A beta2-glicoprote&iacute;na I (beta2
-gpI) &eacute; um cofator fosfolip&iacute;dico com propriedades anticoagulantes.
 In&uacute;meras fun&ccedil;&otilde;es biol&oacute;gicas na via da coagula&ccedi
l;&atilde;o s&atilde;o atribu&iacute;veis a este cofator. Os soros de pacientes 
com s&iacute;ndrome antifosfolip&iacute;dica (SAF) freq&uuml;entemente reagem co
ntra beta2-gpI em ensaios imunoenzim&aacute;ticos. Por vezes, pacientes com di&a
acute;tese tromb&oacute;tica apresentam anticorpos antibeta2-gpI na aus&ecirc;nc
ia de outros anticorpos anti-fosfol&iacute;pides (AAF). Mais recentemente, compr
ovou-se a presen&ccedil;a da beta2-gpI na placa ateroscler&oacute;tica. Nesta re
vis&atilde;o, abordamos inicialmente as fun&ccedil;&otilde;es fisiol&oacute;gica
s da beta2-gpI na via da coagula&ccedil;&atilde;o. A seguir, revisamos a import&
acirc;ncia dos anticorpos anti-beta2-gpI em pacientes com SAF, outras di&aacute;
teses tromb&oacute;ticas, l&uacute;pus eritematoso sist&ecirc;mico (LES) e infec
&ccedil;&otilde;es. Por fim, o papel dos anticorpos anti-beta2-gpI na ateroscler
ose coron&aacute;ria e cerebral &eacute; tamb&eacute;m abordado. </font></p>    
 ^cY#v44n2a06.htm##
00475000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024100075002001300316#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#21#17#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b>beta2-glicopro
te&iacute;na I, anticorpos anti-beta2-gpI, s&iacute;ndrome antifosfolip&iacute;d
ica, aterosclerose.</font></p> <hr size="1" noshade>     ^cY#v44n2a06.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009800075002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#22#18#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v4
4n2a06.htm##
01179000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704094500075002001301020#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#23#19#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Beta2-glycoprotein I (beta2-gpI) is a
 phospholipid cofactor with anticoagulant properties. A number of biological fun
ctions in the coagulation cascade have been attributed to this cofactor. Sera fr
om patients with antiphospholipid syndrome (APS) frequently react to beta2-gpI i
n immunoassays. Occasionally, patients with thrombotic diathesis present anti-be
ta2-gpI antibodies in the absence of other antiphospholipid antibodies (APA). Mo
re recently, the presence of beta2-gpI in the atherosclerotic plaque has been pr
oved. In this article, we initially approach the physiological functions of beta
2-gpI in the coagulation cascade, and we also review the importance of anti-beta
2gpI antibodies in patients with APS, systemic lupus erythematosus (SLE) and inf
ections. Lastly, we focus the role of anti-beta2-gpI antibodies in coronary and 
cerebral atherosclerosis.</font></p>     ^cY#v44n2a06.htm##
00448000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021400075002001300289#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#24#20#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> beta2-glycoprotein I
, anti-beta2-gpI antibodies, antiphospholipid syndrome, atherosclerosis.</font><
/p> <hr size="1" noshade>     ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#25#21#article#357#<p>&nbsp;</p>     ^c
Y#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#26#22#article#357#<p>&nbsp;</p>     ^c
Y#v44n2a06.htm##
00401000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016700075002001300242#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#27#23#article#357#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ANTICORPOS ANTIFOSFOL&Iacute;PIDES
 E S&Iacute;NDROME ANTIFOSFOLIP&Iacute;DICA</b></font></p>     ^cY#v44n2a06.htm#
#
00728000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049400075002001300569#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#28#24#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os anticorpos antifosfol&iacute;pides
 (AAF) compreendem um grupo de autoanticorpos de grande complexidade e heterogen
eidade<sup>(1)</sup>. Os alvos-chave destes anticorpos s&atilde;o fosfol&iacute;
pides (FL) e cofatores fosfolip&iacute;dicos da cascata da coagula&ccedil;&atild
e;o e das membranas celulares. As superf&iacute;cies plaquet&aacute;ria e endote
lial s&atilde;o alvos conhecidos de AAF<sup>(2)</sup>.</font></p>     ^cY#v44n2a
06.htm##
00831000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059700075002001300672#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#29#25#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os AAF est&atilde;o associados a infe
c&ccedil;&otilde;es, neoplasias, uso de drogas e a uma di&aacute;tese tromb&oacu
te;tica conhecida como s&iacute;ndrome antifosfolip&iacute;dica (SAF)<sup>(2,3)<
/sup>. A SAF &eacute; atualmente tida como a mais comum das di&aacute;teses trom
b&oacute;ticas adquiridas do adulto jovem<sup>(1,3)</sup>. Os mecanismos pelos q
uais os AAF induzem trombofilia em pacientes com SAF s&atilde;o m&uacute;ltiplos
. Estes mecanismos est&atilde;o sumarizados na <a href="#tab01">Tabela 1</a>.</f
ont></p>     ^cY#v44n2a06.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#30#26#article#357#<p><a name="tab01"><
/a></p>     ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#31#27#article#357#<p>&nbsp;</p>     ^c
Y#v44n2a06.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#32#28#article#357#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a06tab01.jpg"></p>     ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#33#29#article#357#<p>&nbsp;</p>     ^c
Y#v44n2a06.htm##
00789000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055500075002001300630#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#34#30#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A caracteriza&ccedil;&atilde;o cl&iac
ute;nico-laboratorial da SAF foi progressivamente aprimorada a partir da descri&
ccedil;&atilde;o original de 1986<sup>(4)</sup>. Os crit&eacute;rios atualmente 
aceitos para classifica&ccedil;&atilde;o da SAF datam  do consenso de Saporo de 
1999<sup>(5)</sup>. Tromboses venosas profundas,  isquemia de art&eacute;rias ce
rebrais e morbidade obst&eacute;trica  s&atilde;o os achados mais freq&uuml;ente
s da doen&ccedil;a<sup>(4-6)</sup>.</font></p>     ^cY#v44n2a06.htm##
00504000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027000075002001300345#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#35#31#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Embora descrita inicialmente em pacie
ntes com l&uacute;pus  eritematoso sist&ecirc;mico (LES)<sup>(4)</sup>, a forma 
prim&aacute;ria da SAF &eacute;  reconhecida desde 1989<sup>(6)</sup>.</font></p
>     ^cY#v44n2a06.htm##
00815000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058100075002001300656#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#36#32#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os crit&eacute;rios laboratoriais par
a o diagn&oacute;stico da SAF, de  acordo com o consenso de 1999, fundamentam-se
 em ensaios  de coagula&ccedil;&atilde;o (anticoagulante l&uacute;pico) e no imu
noensaio  enzim&aacute;tico (ELISA) para anticorpos anticardiolipina (aCL). Enqu
anto a padroniza&ccedil;&atilde;o dos testes para detec&ccedil;&atilde;o do AL &
eacute;  ainda problem&aacute;tica, o ELISA, que detecta anticorpos IgG/IgM aCL,
 &eacute; internacionalmente aceito desde 1987<sup>(7)</sup>.</font></p>     ^cY
#v44n2a06.htm##
00974000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074000075002001300815#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#37#33#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A classifica&ccedil;&atilde;o dos AAF
, no entanto, &eacute; complexa e inclui  uma pletora de anticorpos contra outro
s FL e contra cofatores  fosfolip&iacute;dicos. Estes anticorpos n&atilde;o faze
m parte dos  crit&eacute;rios laboratoriais para SAF(5). Entretanto, s&atilde;o 
eventualmente  encontrados em pacientes com tromboses, associadamente  ou n&atil
de;o aos AAF "cl&aacute;ssicos" (AL e anticorpos aCL)(1-3). Neste contexto, deve
m ser citados os anticorpos contra  outros FL ani&ocirc;nicos, contra o FL neutr
o <i>fosfatidiletanolamina  (FE)</i> e contra os cofatores <i>anexina V, protrom
bina</i>  e <i>beta2-glicoprote&iacute;na I (beta2-gpI)</i>.</font></p>     ^cY#
v44n2a06.htm##
00646000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041200075002001300487#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#38#34#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nesta revis&atilde;o, abordaremos os 
aspectos atinentes aos anticorpos  contra o cofator fosfolip&iacute;dico beta2-g
pI. A import&acirc;ncia  destes anticorpos em pacientes com tromboses &eacute; d
etalhadamente  discutida. O papel dos anticorpos anti-beta2-gpI  no processo ate
roscler&oacute;tico &eacute; tamb&eacute;m abordado.</font></p>     ^cY#v44n2a06
.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#39#35#article#357#<p>&nbsp;</p>     ^c
Y#v44n2a06.htm##
00361000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012700075002001300202#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#40#36#article#357#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>BETA2-GPI E ANTICORPOS ANTI-BETA2-
GPI</b></font></p>     ^cY#v44n2a06.htm##
00381000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014700075002001300222#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#41#37#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b><i>Beta2-gpI. Fun&ccedil;&otilde;e
s biol&oacute;gicas</i></b></font></p>     ^cY#v44n2a06.htm##
00492000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025800075002001300333#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#42#38#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A prote&iacute;na plasm&aacute;tica b
eta2-gpI foi originalmente isolada  em 1961<sup>(8)</sup>. O gene da beta2-gpI h
umana &eacute; codificado no  cromossomo 17<sup>(9)</sup>.</font></p>     ^cY#v4
4n2a06.htm##
00768000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053400075002001300609#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#43#39#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O corrente interesse pelo estudo de a
nticorpos antibeta2-  gpI decorre das seguintes informa&ccedil;&otilde;es: a) be
ta2-gpI  &eacute; alvo de anticorpos aCL<sup>(9-11)</sup>; b) o uso de beta2-gpI
 como  imun&oacute;geno em modelos animais gera anticorpos aCL, anticorpos  anti
-beta2-gpI e SAF(12,13). Recentemente, toler&acirc;ncia  oral com baixas doses d
e beta2-gpI foi obtida em camundongos  BALB/c imunizados com o ant&iacute;geno<s
up>(14)</sup>.</font></p>     ^cY#v44n2a06.htm##
00715000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048100075002001300556#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#44#40#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A beta2-gpI (ou apoliprote&iacute;na 
H) &eacute; cofator fosfolip&iacute;dico  com caracter&iacute;sticas anticoagula
ntes naturais. &Eacute; um polipept&iacute;deo  de 50 kilodaltons (kDa), altamen
te glicosilado. Sua cadeia &uacute;nica cont&eacute;m 326 amino&aacute;cidos. Ci
nco dom&iacute;nios,  de cerca de 60 amino&aacute;cidos cada, podem ser identifi
cados  na mol&eacute;cula<sup>(15)</sup>.</font></p>     ^cY#v44n2a06.htm##
00445000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021100075002001300286#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#45#41#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A <a href="/img/revistas/rbr/v44n2/a0
6fig01.jpg">Figura 1</a> mostra a conforma&ccedil;&atilde;o molecular da beta2-g
pI  bovina.</font></p>     ^cY#v44n2a06.htm##
00639000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040500075002001300480#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#46#42#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A seq&uuml;&ecirc;ncia de amino&aacut
e;cidos CKNKEKKC, localizada no  quinto dom&iacute;nio, &eacute; o s&iacute;tio 
de liga&ccedil;&atilde;o da beta2-gpI com FL  ani&ocirc;nicos. O s&iacute;tio de
 liga&ccedil;&atilde;o de AAF com a beta2-gpI, no  entanto, ainda &eacute; mat&e
acute;ria de discuss&atilde;o<sup>(15)</sup>.</font></p>     ^cY#v44n2a06.htm##
00684000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045000075002001300525#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#47#43#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">&Agrave; beta2-gpI &eacute; atribu&ia
cute;da a&ccedil;&atilde;o inibit&oacute;ria na ativa&ccedil;&atilde;o do fator 
 XII (ativa&ccedil;&atilde;o por contato) na via da coagula&ccedil;&atilde;o. A 
mol&eacute;cula  contribui, em paralelo, para a ativa&ccedil;&atilde;o da prote&
iacute;na C da fibrin&oacute;lise<sup>(15)</sup> e interage com a heparina<sup>(
16)</sup>.</font></p>     ^cY#v44n2a06.htm##
00629000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039500075002001300470#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#48#44#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m disso, a beta2-gpI parece
 inativar o complexo  ativador da protrombina ao interagir com FL de carga negat
iva,  possivelmente na superf&iacute;cie plaquet&aacute;ria. Os efeitos da  beta
2-gpI sobre a cascata da coagula&ccedil;&atilde;o s&atilde;o aparentemente  desr
egulados por AAF<sup>(15,17)</sup>.</font></p>     ^cY#v44n2a06.htm##
00578000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034400075002001300419#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#49#45#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A agrega&ccedil;&atilde;o plaquet&aac
ute;ria e a convers&atilde;o da protrombina em  trombina s&atilde;o tamb&eacute;
m bloqueados na presen&ccedil;a de beta2-gpI<sup>(18)</sup>. A beta2-gpI inibe a
 gera&ccedil;&atilde;o de fator Xa por plaquetas<sup>(19)</sup>.</font></p>     
^cY#v44n2a06.htm##
00657000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042300075002001300498#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#50#46#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Segundo Arnout <i>et al</i>., o efeit
o de AL (aumento dos  tempos de coagula&ccedil;&atilde;o FL-dependentes) atribu&
iacute;do aos anticorpos  anti-beta2-gpI &eacute; dependente da forma&ccedil;&at
ilde;o de complexos  bin&aacute;rios que incluem anticorpos anti-beta2-gpI e  an
t&iacute;geno em superf&iacute;cies contendo FL<sup>(20)</sup>.</font></p>     ^
cY#v44n2a06.htm##
00660000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042600075002001300501#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#51#47#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De interesse, anticorpos anti-beta2-g
pI poderiam se ligar,  <i>in vivo</i>, &agrave; beta2-gpI dispon&iacute;vel na m
embrana de c&eacute;lulas  em apoptose. A opsoniza&ccedil;&atilde;o de c&eacute;
lulas apopt&oacute;ticas por  anticorpos anti-beta2-gpI facilita a fagocitose do
s corpos  apopt&oacute;ticos por macr&oacute;fagos<sup>(21)</sup>.</font></p>   
  ^cY#v44n2a06.htm##
00851000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704061700075002001300692#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#52#48#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O teste do veneno de v&iacute;bora de
 Russel (RVVT) compreende um dos testes de coagula&ccedil;&atilde;o utilizados p
ara confirma&ccedil;&atilde;o de AL. Anticorpos anti-beta2-gpI s&atilde;o respon
s&aacute;veis pelo prolongamento do RVVT em ensaios de coagula&ccedil;&atilde;o.
 De interesse, Galli <i>et al.</i>, al&eacute;m de confirmarem o "perfil RVVT" d
os anticorpos anti-beta2-gpI, reportaram que os mesmos seriam trombog&ecirc;nico
s por induzirem resist&ecirc;ncia ao efeito da prote&iacute;na C sobre o fator V
<sup>(22)</sup>. </font></p>     ^cY#v44n2a06.htm##
00356000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012200075002001300197#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#53#49#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b><i>Anticorpos anti-beta2-gpI</i></
b></font></p>     ^cY#v44n2a06.htm##
00703000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046900075002001300544#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#54#50#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os anticorpos contra beta2-gpI reconh
ecem o alvo fundamentalmente em superf&iacute;cies celulares ou quando o cofator
 est&aacute; ligado a FL. Biasiolo <i>et al.</i> comprovaram estes achados como 
caracter&iacute;sticos de pacientes com SAF. Os complexos imunes anti-beta2-gpI 
de pacientes com outras doen&ccedil;as auto-imunes s&atilde;o detectados livreme
nte no plasma<sup>(23)</sup>.</font></p>     ^cY#v44n2a06.htm##
00676000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044200075002001300517#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#55#51#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De acordo com Mason<i> et al.</i>, so
ros de pacientes com SAF reagiram em ELISA contra beta2-gpI e anticorpos aCL. Os
 soros tamb&eacute;m exibiram reatividade contra um antiidiotipo obtido de uma I
gM monoclonal com atividade aCL. A rea&ccedil;&atilde;o humoral contra este anti
-idiotipo foi caracter&iacute;stica de soros de pacientes com SAF<sup>(24)</sup>
. </font></p>     ^cY#v44n2a06.htm##
00802000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056800075002001300643#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#56#52#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A avidez dos anticorpos de pacientes 
com SAF pela cardiolipina (CL) em placas de ELISA &eacute; consideravelmente mai
or quando diluentes que utilizam soro bovino a 10%, fontes de beta2-gpI, s&atild
e;o utilizados. &Eacute; poss&iacute;vel que a conforma&ccedil;&atilde;o bioqu&i
acute;mica da CL seja modificada pela beta2-gpI, ou que os dois compostos formem
 um complexo antig&ecirc;nico, ou ainda que a beta2-gpI funcione como um ant&iac
ute;geno de forma isolada<sup>(15,16,25)</sup>. </font></p>     ^cY#v44n2a06.htm
##
00503000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026900075002001300344#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#57#53#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Sabidamente, anticorpos aCL policlona
is ligam-se a beta2gpI somente em placas de poliestireno irradiadas, onde epitop
os "cr&iacute;ticos" da beta2-gpI podem ser expostos<sup>(25)</sup>. </font></p>
     ^cY#v44n2a06.htm##
00545000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031100075002001300386#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#58#54#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Nos dias de hoje, admite-se que a int
era&ccedil;&atilde;o de beta2gpI com placas de poliestireno irradiadas, ou com C
L, per-mite a exposi&ccedil;&atilde;o de epitopos fundamentais na mol&eacute;cul
a de beta2-gpI<sup>(26)</sup>. </font></p>     ^cY#v44n2a06.htm##
00687000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045300075002001300528#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#59#55#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os testes de ELISA para detec&ccedil;
&atilde;o de anticorpos anti-beta2gpI utilizam placas irradiadas contendo beta2-
gpI na aus&ecirc;ncia de FL<sup>(27)</sup>. As placas de poliestireno irradiadas
 cont&ecirc;m superf&iacute;cies oxidadas, o que facilita a liga&ccedil;&atilde;
o de anticorpos de baixa afinidade com a mol&eacute;cula nativa de beta2-gpI<sup
>(28)</sup>. </font></p>     ^cY#v44n2a06.htm##
00658000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042400075002001300499#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#60#56#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Uma vez que os anticorpos anti-beta2-
gpI de pacientes com SAF s&atilde;o de baixa afinidade, a alta densidade de ant&
iacute;geno em placas de ELISA &eacute; de crucial import&acirc;ncia no ensaio e
nzim&aacute;tico. A dimeriza&ccedil;&atilde;o da beta2-gpI parece aumentar a cap
acidade de liga&ccedil;&atilde;o dos anticorpos<sup>(29)</sup>. </font></p>     
^cY#v44n2a06.htm##
00508000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027400075002001300349#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#61#57#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Enquanto o ELISA para detec&ccedil;&a
tilde;o de aCL utiliza beta2-gpI bovina, o ensaio enzim&aacute;tico espec&iacute
;fico para anti-beta2-gp1 usa beta2-gpI humana purificada<sup>(30)</sup>. </font
></p>     ^cY#v44n2a06.htm##
00770000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053600075002001300611#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#62#58#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A forma de apresenta&ccedil;&atilde;o
 da beta2-gpI influencia fortemente a liga&ccedil;&atilde;o dos anticorpos, com 
marcadas varia&ccedil;&otilde;es interindividuais. Anticorpos anti-beta2-gpI de 
pacientes com SAF podem reagir particularmente contra o ant&iacute;geno bovino, 
ou contra ambos beta2-gpI bovina e humana. Os soros que se ligam a ambos os ant&
iacute;genos s&atilde;o mais freq&uuml;entemente aCL-positivos do que negativos<
sup>(31)</sup>. </font></p>     ^cY#v44n2a06.htm##
00708000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047400075002001300549#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#63#59#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Segundo Santiago <i>et al.</i><sup>(3
2)</sup>, um n&uacute;mero apreci&aacute;vel de vari&aacute;veis pode interferir
 na acuidade da detec&ccedil;&atilde;o de anticorpos anti-beta2-gpI. As diversas
 t&eacute;cnicas de purifica&ccedil;&atilde;o da beta2-gpI originam diferen&cced
il;as qualitativas no ant&iacute;geno, assim como geram concentra&ccedil;&otilde
;es n&atilde;o uniformes do mesmo.</font></p>     ^cY#v44n2a06.htm##
00612000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037800075002001300453#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#64#60#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Por sua vez, placas de poliestireno d
e origens diversas podem gerar diferen&ccedil;as na ader&ecirc;ncia do ant&iacut
e;geno. Em conseq&uuml;&ecirc;ncia, a concentra&ccedil;&atilde;o final do ant&ia
cute;geno pode n&atilde;o ser homog&ecirc;nea quando se compara diferentes ensai
os<sup>(33)</sup>.</font></p>     ^cY#v44n2a06.htm##
00961000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704072700075002001300802#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#65#61#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A partir de testes realizados em um l
aborat&oacute;rio em San Diego, EUA, iniciativas para padroniza&ccedil;&atilde;o
 do ELISA para detec&ccedil;&atilde;o de anticorpos anti-beta2-gpI foram levadas
 a termo em 1998. Os ensaios para os isotipos IgG/IgM/IgA geraram curvas lineare
s e de boa precis&atilde;o. Duzentos e tr&ecirc;s controles sadios foram utiliza
dos para a gera&ccedil;&atilde;o de intervalos de refer&ecirc;ncia baseados em p
ercentis. Em soros de pacientes com SAF, os tr&ecirc;s ensaios anti-beta2-gpI se
 correlacionaram adequadamente com os respectivos ensaios enzim&aacute;ticos par
a detec&ccedil;&atilde;o de aCL<sup>(34)</sup>.</font></p>     ^cY#v44n2a06.htm#
#
00662000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042800075002001300503#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#66#62#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De forma alternativa, Cucnik <i>et al
.</i> sugeriram, em relato recente, que a determina&ccedil;&atilde;o de anti-bet
a2-gpI em ELISA seja baseada em concentra&ccedil;&otilde;es padronizadas de anti
corpos monoclonais IgG e IgM. Os pontos de corte, no estudo, foram calculados a 
partir de resultados obtidos em 434 controles sadios<sup>(35)</sup>.</font></p> 
    ^cY#v44n2a06.htm##
00748000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051400075002001300589#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#67#63#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Ichikawa <i>et al.</i> produziram uma
 IgG monoclonal quim&eacute;rica contendo uma regi&atilde;o constante gama 1 de 
origem humana. O referido anticorpo reagiu contra CL e beta2-gpI de forma simila
r aos soros-padr&otilde;es aCL e anti-beta2-gpIpositivos. Os autores sugerem que
 o referido anticorpo monoclonal possa ser de utilidade em uma padroniza&ccedil;
&atilde;o internacional do ensaio para IgG anti-beta2-gpI<sup>(36)</sup>. </font
></p>     ^cY#v44n2a06.htm##
00522000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028800075002001300363#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#68#64#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A <a href="#tab02">Tabela 2</a> apres
enta os dados de Roubey <i>et al.</i> acerca da sensibilidade e da especificidad
e de anticorpos IgG antibeta2-gpI e aCL para o diagn&oacute;stico de SAF<sup>(37
)</sup>.</font></p>     ^cY#v44n2a06.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003600075002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#69#65#article#357#<p><a name="tab02"><
/a></p>     ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#70#66#article#357#<p>&nbsp;</p>     ^c
Y#v44n2a06.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#71#67#article#357#<p align="center"><i
mg src="/img/revistas/rbr/v44n2/a06tab02.jpg"></p>     ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#72#68#article#357#<p>&nbsp;</p>     ^c
Y#v44n2a06.htm##
00547000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031300075002001300388#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#73#69#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De acordo com os dados de Roubey <i>e
t al.</i> para pontos de corte de 20 UI, o ensaio para IgG anti-beta2-gpI, embor
a menos sens&iacute;vel, foi mais espec&iacute;fico que IgG aCL para o diagn&oac
ute;stico de SAF<sup>(37)</sup>. </font></p>     ^cY#v44n2a06.htm##
00591000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704035700075002001300432#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#74#70#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Segundo dados de 1995, a soropreval&e
circ;ncia de anticorpos anti-beta2-gpI por ELISA em controles sadios &eacute; de
 0%; em casos de LES sem AAF, &eacute; de 12%; em pacientes com LES e AAF, &eacu
te; de 53%; em casos de SAF prim&aacute;ria, &eacute; de 72%<sup>(38)</sup>. </f
ont></p>     ^cY#v44n2a06.htm##
00951000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704071700075002001300792#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#75#71#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em estudo mais recente<sup>(39)</sup>
, Bruce <i>et al.</i> avaliaram a preval&ecirc;ncia de aCL e IgG/IgM/IgA anti-be
ta2-gpI em 133 indiv&iacute;duos com doen&ccedil;as autoimunes e controles. Anti
corpos anti-beta2-gpI (qualquer isotipo) foram observados em 34,9% dos casos de 
LES isolado, em 40,4% dos casos de SAF associada ao LES e em 3% de controles sad
ios. O valor preditivo positivo (VPP) para SAF foi de 38,8% para anticorpos anti
-beta2 e de 50% para IgG aCL. Os autores conclu&iacute;ram que a testagem de ant
i-beta2-gpI, embora &uacute;til em casos isolados, n&atilde;o aumentou a probabi
lidade do diagn&oacute;stico de SAF. </font></p>     ^cY#v44n2a06.htm##
00857000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704062300075002001300698#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#76#72#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Helbert <i>et al.</i> procederam meta
-an&aacute;lise para avaliar comparativamente tr&ecirc;s ensaios comerciais para
 aCL e um ensaio para anti-beta2-gpI. O estudo confirmou que o ensaio para anti-
beta2-gpI &eacute; mais espec&iacute;fico (embora menos sens&iacute;vel) que aCL
 para o diagn&oacute;stico de SAF. A melhor especificidade do ensaio para anti-b
eta2-gpI esteve fundamentada em sua performance usualmente positiva em pacientes
 ateroscler&oacute;ticos e sua testagem geralmente negativa em infec&ccedil;&oti
lde;es<sup>(40)</sup>. </font></p>     ^cY#v44n2a06.htm##
00538000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030400075002001300379#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#77#73#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outros relatos tamb&eacute;m favorece
m a id&eacute;ia de que anticorpos anti-beta2-gpI humana detectados por ELISA se
jam mais espec&iacute;ficos do que aCL em pacientes com quadro cl&iacute;nico de
 SAF<sup>(41,42)</sup>. </font></p>     ^cY#v44n2a06.htm##
00664000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043000075002001300505#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#78#74#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Diferentemente, n&atilde;o mais que 5
0% dos pacientes com SAF aCL-positivos apresentaram anticorpos anti-beta2-gpI. N
este mesmo estudo<sup>(43)</sup>, uma eventual rea&ccedil;&atilde;o cruzada entr
e anticorpos anti-beta2-gpI e anticorpos contra LDL (<i>low-density lipoprotein<
/i>), previamente sugerida<sup>(44)</sup>, n&atilde;o foi confirmada. </font></p
>     ^cY#v44n2a06.htm##
00710000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047600075002001300551#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#79#75#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Digno de nota, boa parte dos estudos 
sobre anticorpos contra beta2-gpI em ELISA inclu&iacute;ram IgG mas n&atilde;o o
utros isotipos de imunoglobulinas<sup>(41-44)</sup>. Al&eacute;m disso, a falta 
de padroniza&ccedil;&atilde;o dos ensaios de fase s&oacute;lida que detectam ant
icorpos contra beta2-gpI tem sido um obst&aacute;culo na an&aacute;lise cr&iacut
e;tica dos estudos cl&iacute;nicos. </font></p>     ^cY#v44n2a06.htm##
00405000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017100075002001300246#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#80#76#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b><i>Anticorpos anti-beta2-gpI e l&u
acute;pus eritematoso sist&ecirc;mico (LES)</i></b></font></p>     ^cY#v44n2a06.
htm##
00656000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042200075002001300497#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#81#77#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em pacientes com LES, a associa&ccedi
l;&atilde;o de anticorpos antibeta2-gpI com trombose tem sido extensivamente est
udada. Recentemente, Santiago <i>et al.</i> demonstraram aus&ecirc;ncia de assoc
ia&ccedil;&atilde;o entre IgG anti-beta2-gpI e eventos tromb&oacute;ticos ou mor
bidade obst&eacute;trica em pacientes com LES<sup>(32)</sup>. </font></p>     ^c
Y#v44n2a06.htm##
00555000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032100075002001300396#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#82#78#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De interesse, George <i>et al.</i> re
portaram que a presen&ccedil;a de anticorpos anti-beta2-gpI &eacute; &uacute;til
 para definir uma subpopula&ccedil;&atilde;o de pacientes com LES propensa a des
envolver trombocitopenia<sup>(45)</sup>. </font></p>     ^cY#v44n2a06.htm##
00724000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049000075002001300565#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#83#79#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De acordo com um estudo de 1992, anti
corpos antibeta2-gpI e AL ocorreram em 89% de pacientes com LES e trombose, enqu
anto aCL foi visto em 78% destes pacientes. Entre todos os casos aCL-positivos m
as anti-beta2-gp1negativos, somente 6% tiveram tromboses. Assim, anticorpos anti
-beta2-gp1 estiveram mais convincentemente associados &agrave; trombofilia que o
utros AAF nesta casu&iacute;stica<sup>(46)</sup>. </font></p>     ^cY#v44n2a06.h
tm##
00596000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036200075002001300437#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#84#80#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De acordo com Sanfilippo <i>et al.</i
>, anticorpos anti-beta2gpI foram mais prevalentes em pacientes com LES e SAF (6
2%) que nas l&uacute;picas aCL-positivas sem trombose. Os autores sugerem que es
tes auto-anticorpos funcionam como marcadores de tromboses no LES<sup>(47)</sup>
. </font></p>     ^cY#v44n2a06.htm##
00749000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051500075002001300590#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#85#81#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Por outro lado, Tubach <i>et al.</i> 
reportaram que a ocorr&ecirc;ncia de IgG anti-beta2-gpI em 102 casos de LES, qua
se t&atilde;o freq&uuml;ente quanto a de aCL (18,6% e 23% respectivamente), n&at
ilde;o aumentou a chance de diagn&oacute;stico de SAF. Outros isotipos anti-beta
2-gpI n&atilde;o foram estudados. No referido relato, o AL se comportou como o m
elhor teste na identifica&ccedil;&atilde;o de casos de SAF<sup>(48)</sup>. </fon
t></p>     ^cY#v44n2a06.htm##
00586000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704035200075002001300427#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#86#82#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em 76 pacientes com LES, oriundos da 
&Iacute;ndia, Shrivastava <i>et al.</i> reportaram que IgG anti-beta2-gpI, assim
 como aCL, estiveram associados &agrave; presen&ccedil;a de convuls&otilde;es ma
s n&atilde;o a outros eventos compat&iacute;veis com SAF<sup>(49)</sup>.</font><
/p>     ^cY#v44n2a06.htm##
00812000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704057800075002001300653#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#87#83#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Aguirre <i>et al.</i> relatam, em 126
 pacientes chilenos com LES, positividade para aCL (qualquer isotipo) de 30%, en
quanto a positividade para anti-beta2-gpI foi de 10%. Embora houvesse uma boa co
rrela&ccedil;&atilde;o IgG aCL-IgG antibeta2-gpI, um n&uacute;mero n&atilde;o de
sprez&iacute;vel de casos foi positivo para apenas um dos anticorpos. Nesta casu
&iacute;stica, o ensaio para anticorpos anti-beta2-gp foi mais espec&iacute;fico
 que aCL para o diagn&oacute;stico de SAF<sup>(50)</sup>. </font></p>     ^cY#v4
4n2a06.htm##
00942000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704070800075002001300783#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#88#84#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Tamb&eacute;m digno de nota, Inanc <i
>et al.</i> avaliaram longitudinalmente pacientes com LES e SAF; aCL, anti-beta2
-gpI e antiprotrombina foram estudados. A maior parte dos pacientes com trombose
 teve teste positivo para IgG antibeta2-gpI, mas n&atilde;o para anticorpos anti
protrombina. Muitos dos casos positivos para IgG anti-beta2-gpI (predominantemen
te IgG2) foram negativos para aCL. Os n&iacute;veis do ant&iacute;geno beta2-gpI
 foram aumentados em alguns casos de SAF. Os autores inferem que a testagem de a
nti-beta2gpI pode ser &uacute;til na investiga&ccedil;&atilde;o de tromboses em 
casos de LES<sup>(51)</sup>.</font></p>     ^cY#v44n2a06.htm##
00631000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039700075002001300472#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#89#85#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os resultados de Sebastiani <i>et al.
</i> em 574 casos de LES sugerem que a presen&ccedil;a de IgG/IgM anti-beta2-gpI
, ou t&iacute;tulos moderados/altos de IgG aCL, s&atilde;o fatores de risco para
 trombose em LES. Sensibilidade, especificidade e valores preditivos foram simil
ares nos dois ensaios<sup>(52)</sup>.</font></p>     ^cY#v44n2a06.htm##
00986000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704075200075002001300827#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#90#86#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cucurull <i>et al.</i> avaliaram a pr
eval&ecirc;ncia, distribui&ccedil;&atilde;o isot&iacute;pica e associa&ccedil;&o
tilde;es cl&iacute;nicas de anticorpos anti-beta2-gpI e aCL em 160 pacientes da 
Col&ocirc;mbia e em igual n&uacute;mero de pacientes espanh&oacute;is com LES. N
a popula&ccedil;&atilde;o colombiana, anticorpos anti-beta2-gpI e IgG aCL se cor
relacionaram com trombose, perdas fetais e trombocitopenia. Em espanh&oacute;is,
 as associa&ccedil;&otilde;es inclu&iacute;ram livedo reticularis, al&eacute;m d
e tromboses e morbidade gestacional. Nas duas popula&ccedil;&otilde;es, o ensaio
 para anti-beta2-gpI foi mais espec&iacute;fico que aCL<sup>(53)</sup>. </font><
/p>     ^cY#v44n2a06.htm##
00703000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046900075002001300544#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#91#87#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">De forma original, Gomez-Pacheco <i>e
t al.</i> avaliaram anticorpos anti-beta2-gpI e aCL antes, durante e depois do e
pis&oacute;dio tromb&oacute;tico em pacientes com LES. Todos os casos de LES com
 trombose foram positivos para anti-beta2-gpI, e um signicativo decr&eacute;scim
o das titula&ccedil;&otilde;es do anticorpo foi observado durante o epis&oacute;
dio oclusivo<sup>(54)</sup>. </font></p>     ^cY#v44n2a06.htm##
00766000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053200075002001300607#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#92#88#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Com rela&ccedil;&atilde;o ao isotipo 
IgA anti-beta2-gpI, &eacute; digno de nota o estudo de Tsutsumi <i>et al.</i> em
 124 pacientes nip&ocirc;nicos com LES. Positividade para IgA anti-beta2-gpI foi
 vista em 25% dos casos. Houve associa&ccedil;&atilde;o significativa deste isot
ipo com tromboses. Os autores sugerem que IgA anti-beta2gpI seja inclu&iacute;da
 na avalia&ccedil;&atilde;o de risco tromb&oacute;tico em pacientes com LES<sup>
(55)</sup>. </font></p>     ^cY#v44n2a06.htm##
00606000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037200075002001300447#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#93#89#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os mesmos autores relatam, em outro e
studo, uma baixa concord&acirc;ncia IgA anti-beta2-gpI-aCL-IgA comparativamente 
ao paralelismo observado nos isotipos IgG/IgM; o achado sugere que IgA aCL e IgA
 anti-beta2-gpI comp&otilde;em dois grupos de AAF com diferentes afinidades<sup>
(56)</sup>. </font></p>     ^cY#v44n2a06.htm##
00643000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040900075002001300484#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#94#90#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em relato de 2001, Bertolaccini <i>et
 al. </i>avaliaram, transversalmente, a preval&ecirc;ncia de IgG/IgM/IgA anti-be
ta2-gpI, aCL e antiprotrombina em 134 casos de LES/SAF. Os autores conclu&iacute
;ram que a testagem de anti-beta2-gpI e IgA aCL n&atilde;o aumentou a probabilid
ade do diagn&oacute;stico de SAF<sup>(57)</sup>. </font></p>     ^cY#v44n2a06.ht
m##
00735000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050100075002001300576#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#95#91#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Em 100 pacientes de origem africana c
om LES, a preval&ecirc;ncia de aCL e anti-beta2-gpI foi, respectivamente, de 33%
 e 28% (dados de Cucurull <i>et al.</i>). O isotipo IgA foi o mais freq&uuml;ent
e em ambos os ensaios. Uma concord&acirc;ncia entre os ensaios foi mais notada p
ara o isotipo IgA. IgG aCL ocorreu em t&iacute;tulos baixos, o que talvez expliq
ue a baixa freq&uuml;&ecirc;ncia de trombose<sup>(58)</sup>. </font></p>     ^cY
#v44n2a06.htm##
00905000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067100075002001300746#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#96#92#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Outra casu&iacute;stica incluiu 207 p
acientes com LES, com testagem para todos os isotipos aCL e anti-beta2-gpI. Trom
bose arterial foi associada com IgG aCL, e TVP com IgA anti-beta2-gpI em an&aacu
te;lise multivariada. Houve correla&ccedil;&atilde;o entre n&iacute;veis de qual
quer isotipo anti-beta2-gpI com IgG aCL. Uma associa&ccedil;&atilde;o entre t&ia
cute;tulos de IgA anti-beta2gpI com os outros dois isotipos anti-beta2-gpI foi o
bservada. Os autores concluem que IgA anti-beta2-gpI pode ser de utilidade na id
entifica&ccedil;&atilde;o de tromboses em casos de LES<sup>(59)</sup>. </font></
p>     ^cY#v44n2a06.htm##
00749000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051500075002001300590#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#97#93#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Pacientes com LES, com ou sem trombos
es, foram estudados por Lakos <i>et al.</i> quanto &agrave; preval&ecirc;ncia de
 todos os isotipos anti-beta2-gpI. Houve forte associa&ccedil;&atilde;o de IgA a
ntibeta2-gpI com trombose venosa, valvulopatias, trombocitopenia, epilepsia e li
vedo reticularis. O isotipo IgG associou-se com tromboses e AL, enquanto IgM ant
i-beta2-gpI se associou com valvulopatia e trombocitopenia<sup>(60)</sup>. </fon
t></p>     ^cY#v44n2a06.htm##
00629000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039500075002001300470#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#98#94#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O somat&oacute;rio de achados observa
dos nos diversos relatos acerca do bin&ocirc;mio IgA anti-beta2-gpI-tromboses no
 LES &eacute;, no m&iacute;nimo, intrigante. Novos estudos, preferencialmente co
ntrolados e com an&aacute;lise multivariada, poder&atilde;o definir mais clarame
nte esta associa&ccedil;&atilde;o. </font></p>     ^cY#v44n2a06.htm##
01134000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704090000075002001300975#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#99#95#article#357#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Dektov <i>et al.</i> arg&uacute;em so
bre a import&acirc;ncia da testagem de IgG/IgM anti-beta2-gpI para a melhor cara
cteriza&ccedil;&atilde;o da SAF. Quarenta e dois casos de SAF e 32 casos de LES 
sem trombose foram avaliados. Houve correla&ccedil;&atilde;o positiva entre titu
la&ccedil;&otilde;es de aCL e anti-beta2-gpI para ambos os isotipos. A especific
idade para SAF foi de 91% para IgG anti-beta2-gpI e de 75% para IgG aCL. Com rel
a&ccedil;&atilde;o ao isotipo IgM, as especificidades foram de, respectivamente,
 87% e 81%. A presen&ccedil;a de AL concomitante &agrave; aCL e antibeta2-gpI id
entificou um grupo de pacientes com SAF prim&aacute;ria severa. Os autores suger
em que o ensaio para antibeta2-gpI, embora mais espec&iacute;fico do que aCL, n&
atilde;o deveria substituir o &uacute;ltimo<sup>(61)</sup>. </font></p>     ^cY#
v44n2a06.htm##
00659000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704042400076002001300500#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#100#96#article#357#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Tektonidou <i>et al.</i> avaliaram q
uais poss&iacute;veis combina&ccedil;&otilde;es de achados iniciais na SAF teria
m valor progn&oacute;stico em termos de novos eventos tromb&oacute;ticos. Pacien
tes que inicialmente cursaram com hem&oacute;lise e anticorpos anti-beta2gpI for
am os mais propensos &agrave; trombofilia futura<sup>(62)</sup>. </font></p>    
 ^cY#v44n2a06.htm##
00381000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704014600076002001300222#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#101#97#article#357#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b><i>Anticorpos anti-beta2-gpI e mo
rbidade gestacional</i></b></font></p>     ^cY#v44n2a06.htm##
00850000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704061500076002001300691#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#102#98#article#357#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Alguns relatos merecem men&ccedil;&a
tilde;o. De forma prospectiva, Faden <i>et al. </i>acompanharam 510 gestantes qu
anto &agrave; presen&ccedil;a de aCL, anti-beta2-gpI e complica&ccedil;&otilde;e
s obst&eacute;tricas. Anticorpos antibeta2-gpI e aCL foram detectados em 3,9% e 
1,6%, respectivamente. Anticorpos anti-beta2-gpI estiveram associados &agrave; p
reecl&acirc;mpsia/ecl&acirc;mpsia, mesmo na aus&ecirc;ncia de aCL. Os auto-res s
ugerem que anticorpos anti-beta2-gpI sejam testados nestas circunst&acirc;ncias<
sup>(63)</sup>. </font></p>     ^cY#v44n2a06.htm##
00657000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704042200076002001300498#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#103#99#article#357#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Em interessante relato onde 90 mulhe
res com morbidade fetal pr&eacute;via foram avaliadas, Franklin<i> et al.</i> ob
servaram presen&ccedil;a de AAF (aCL ou AL) em metade dos casos. Anticorpos anti
-beta2-gpI foram observados em n&atilde;o mais que 22,2% dos casos AAF-positivos
, e em apenas 2,2% das pacientes AAF-negativas<sup>(64)</sup>. </font></p>     ^
cY#v44n2a06.htm##
00678000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704044200077002001300519#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#104#100#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em estudo de caso controle, Gris <i
>et al.</i> reportaram que a presen&ccedil;a de IgG anti-beta2-gpI, assim como a
 de IgG antianexina V, IgM anti-FE e AL, foram associadas com risco significante
 de perdas fetais em mulheres sem tromboses pr&eacute;vias. Al&eacute;m disso, e
stes marcadores se associaram &agrave; morbidade gestacional futura<sup>(65)</su
p>. </font></p>     ^cY#v44n2a06.htm##
00517000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704028100077002001300358#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#105#101#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em estudo de Lynch <i>et al.</i>, a
nticorpos anti-beta2-gpI, difererentemente de IgG aCL e IgG anti-FS, n&atilde;o 
foram preditivos para perdas fetais em uma coorte de 325 pacientes<sup>(66)</sup
>. </font></p>     ^cY#v44n2a06.htm##
00536000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704030000077002001300377#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#106#102#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">De interesse, IgA anti-beta2-gpI fo
i detectada com mais freq&uuml;&ecirc;ncia em mulheres com abortamentos repetido
s (mesmo naquelas com teste negativo para IgG aCL/AL) que em controles f&eacute;
rteis<sup>(67)</sup>. </font></p>     ^cY#v44n2a06.htm##
00590000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704035400077002001300431#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#107#103#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Os achados de Lee <i>et al.</i> rev
elaram associa&ccedil;&atilde;o de ambos aCL e anti-beta2-gpI com SAF, mas a tes
tagem de anti-beta2gpI n&atilde;o foi vantajosa na identifica&ccedil;&atilde;o d
e pacientes com abortamentos ou perdas fetais aCL-negativos<sup>(68)</sup>. </fo
nt></p>     ^cY#v44n2a06.htm##
00401000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704016500077002001300242#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#108#104#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><i><b>Anticorpos anti-beta2-gpI e o
utras doen&ccedil;as tromb&oacute;ticas</b></i></font></p>     ^cY#v44n2a06.htm#
#
00635000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704039900077002001300476#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#109#105#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em 227 pacientes consecutivos com T
VP ou embolia pulmonar (30% dos quais com AAF), anticorpos anti-beta2gpI foram d
emonstrados em 8,4% dos casos. De interesse, a presen&ccedil;a destes anticorpos
 identificou um subgrupo de pacientes consideravelmente propensos a recorr&ecirc
;ncias tromb&oacute;ticas<sup>(69)</sup>.</font></p>     ^cY#v44n2a06.htm##
00560000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704032400077002001300401#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#110#106#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em pacientes sob hemodi&aacute;lise
 com trombose de acessos vasculares, a freq&uuml;&ecirc;ncia de anticorpos anti-
beta2-gpI, diferentemente do que ocorreu com anticorpos contra o fator V bovino,
 n&atilde;o foi significativa<sup>(70)</sup>. </font></p>     ^cY#v44n2a06.htm##
00690000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704045400077002001300531#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#111#107#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A preval&ecirc;ncia de AAF em 54 pa
cientes com hipertens&atilde;o pulmonar (prim&aacute;ria ou secund&aacute;ria) f
oi recentemente avaliada por Martinuzzo <i>et al. </i>AL, n&iacute;veis moderado
s/altos de aCL e anticorpos anti-beta2-gpI estiveram relevantemente associados a
 uma forma cr&ocirc;nica, tromboemb&oacute;lica, de hipertens&atilde;o pulmonar<
sup>(71)</sup>. </font></p>     ^cY#v44n2a06.htm##
00589000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704035300077002001300430#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#112#108#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Liozon et al. relataram completa au
s&ecirc;ncia de anticorpos anti-beta2-gpI em 45 casos de arterite de c&eacute;lu
las gigantes comprovados por bi&oacute;psia; o achado contrasta com a preval&eci
rc;ncia relevante de aCL (51%) nesta afec&ccedil;&atilde;o<sup>(72)</sup>. </fon
t></p>     ^cY#v44n2a06.htm##
00690000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704045400077002001300531#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#113#109#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Koutroubakis <i>et al.</i> reportar
am ocorr&ecirc;ncia significativa de anticorpos anti-beta2-gpI e de aCL em pacie
ntes com doen&ccedil;a inflamat&oacute;ria intestinal (colite ulcerativa e doen&
ccedil;a de Crohn) com rela&ccedil;&atilde;o aos controles. N&atilde;o houve ass
ocia&ccedil;&atilde;o dos anticorpos com tromboses nestas entidades, entretanto<
sup>(73)</sup>. </font></p>     ^cY#v44n2a06.htm##
00579000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704034300077002001300420#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#114#110#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Anticorpos anti-beta2-gpI n&atilde;
o foram observados em nenhum caso de doen&ccedil;a de Beh&ccedil;et; interessant
emente, 25% dos casos foram aCL-positivos. A presen&ccedil;a de aCL n&atilde;o s
e associou &agrave; trombofilia nestes pacientes<sup>(74)</sup>. </font></p>    
 ^cY#v44n2a06.htm##
00385000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704014900077002001300226#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#115#111#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b><i>Anticorpos anti-beta2-gpI e i
nfec&ccedil;&otilde;es </i></b></font></p>     ^cY#v44n2a06.htm##
00490000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704025400077002001300331#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#116#112#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Embora o soro de pacientes com infe
c&ccedil;&otilde;es geralmente seja desprovido de atividade anti-beta2-gpI<sup>(
21)</sup>, o assunto &eacute; mat&eacute;ria de debate. </font></p>     ^cY#v44n
2a06.htm##
00948000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704071200077002001300789#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#117#113#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Um grupo de autores reportou que so
ros de pacientes com s&iacute;filis, tuberculose e infec&ccedil;&atilde;o por Kl
ebsiella, pass&iacute;veis de apresentarem aCL circulantes respectivamente em 6%
, 5%, e 64% das vezes, geralmente n&atilde;o reagem contra beta2gpI em ELISA. Os
 dados refor&ccedil;am a no&ccedil;&atilde;o de que AAF em doen&ccedil;as infecc
iosas s&atilde;o, via de regra, anticorpos aCL desprovidos de atividade anti-bet
a2-gpI e usualmente n&atilde;o-trombog&ecirc;nicos<sup>(21,96)</sup>. No entanto
, teste positivo para anticorpos anti-beta2-gpI foi rerportado em 7,4% dos pacie
ntes HIVpositivos<sup>(75)</sup>. </font></p>     ^cY#v44n2a06.htm##
00501000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704026500077002001300342#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#118#114#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Digno de nota, Santiago <i>et al. <
/i>recentemente relataram a presen&ccedil;a de anticorpos anti-beta2-gpI em paci
entes com leptospirose, s&iacute;filis e kala-azar<sup>(76)</sup>. </font></p>  
   ^cY#v44n2a06.htm##
00467000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704023100077002001300308#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#119#115#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m disso, 57% dos paciente
s com hansen&iacute;ase reagiram fortemente contra beta2-gpI, com grande predom&
iacute;nio de IgM<sup>(77)</sup>.</font></p>     ^cY#v44n2a06.htm##
00401000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704016500077002001300242#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#120#116#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b><i>Ant&iacute;genos de histocomp
atibilidade e anticorpos anti-beta2-gpI</i></b></font></p>     ^cY#v44n2a06.htm#
#
00723000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704048700077002001300564#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#121#117#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Alguns hapl&oacute;tipos do sistema
 de ant&iacute;genos leucocit&aacute;rios humanos (HLA) parecem predominar em pa
cientes com anticorpos anti-beta2-gpI. Usando tecnologia molecular, Loannidis <i
>et al.</i> reportaram, em 67 pacientes gregos com SAF (54 dos quais com anticor
pos anti-beta2-gpI), uma preval&ecirc;ncia aumentada dos hapl&oacute;tipos HLA D
QA1 03 e HLA DRB1*1302-DQB1*0604<sup>(78)</sup>. </font></p>     ^cY#v44n2a06.ht
m##
00602000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704036600077002001300443#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#122#118#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em uma casu&iacute;stica europ&eacu
te;ia de 577 casos de LES, a presen&ccedil;a de anticorpos anti-beta2-gpI foi as
sociada mais intensamente ao hapl&oacute;tipo HLA DRB1*0402; aCL, al&eacute;m de
 associados a HLA DR4, o foram tamb&eacute;m com o hapl&oacute;tipo DR7<sup>(79)
</sup>. </font></p>     ^cY#v44n2a06.htm##
00713000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704047700077002001300554#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#123#119#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Arnett <i>et al.</i>, por sua vez, 
relataram que o alelo HLA DQB1*0302, tipicamente pesquisado em hapl&oacute;tipos
 DR4, foi associado com a presen&ccedil;a de anticorpos antibeta2-gpI em LES/SAF
, especialmente em indiv&iacute;duos de origem mexicana. HLA DR53 foi visto com 
freq&uuml;&ecirc;ncia aumentada em americanos de origem mexicana, mas n&atilde;o
 em caucas&oacute;ides<sup>(80)</sup>. </font></p>     ^cY#v44n2a06.htm##
00374000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704013800077002001300215#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#124#120#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b><i>Anticorpos anti-beta2-gpI e a
terosclerose</i></b></font></p>     ^cY#v44n2a06.htm##
00590000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704035400077002001300431#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#125#121#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Na aterosclerose, a infiltra&ccedil
;&atilde;o da parede arterial por macr&oacute;fagos e c&eacute;lulas musculares 
lisas &eacute; acompanhada da placa ateromatosa, cujo centro necr&oacute;tico &e
acute; circundado por deposi&ccedil;&atilde;o de colesterol<sup>(81)</sup>. </fo
nt></p>     ^cY#v44n2a06.htm##
00595000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704035900077002001300436#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#126#122#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A aterosclerose deve ser analisada 
em contexto multifatorial. Sua patog&ecirc;nese parece se estender de fatores de
 risco conhecidos (hipertens&atilde;o arterial, diabetes melito, tabagismo, hipe
rcolesterolemia) at&eacute; fen&ocirc;menos de auto-imunidade<sup>(81,82)</sup>.
 </font></p>     ^cY#v44n2a06.htm##
00799000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704056300077002001300640#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#127#123#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A perpetua&ccedil;&atilde;o de fato
res de risco como hipertens&atilde;o arterial sist&ecirc;mica (HAS) e hipercoles
terolemia parece, de fato, induzir fen&ocirc;menos de auto-imunidade. O endot&ea
cute;lio ativado &eacute; capaz de secretar adesinas e prote&iacute;nas de choqu
e t&eacute;rmico (Hsp). A ades&atilde;o de macr&oacute;fagos vacuolizados e a mi
gra&ccedil;&atilde;o de c&eacute;lulas musculares lisas culminam com a forma&cce
dil;&atilde;o de ateromas<sup>(81,82)</sup>. </font></p>     ^cY#v44n2a06.htm##
00788000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704055200077002001300629#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#128#124#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Os relatos que associam beta2-gpI, 
anticorpos anti-beta2gpI, anticorpos contra lipoprote&iacute;nas e aterosclerose
 s&atilde;o dignos de nota. Em 1994, um grupo de autores demonstrou que aCL pode
riam reagir cruzadamente com beta2-gpI e LDL oxidado<sup>(44)</sup>. Estes achad
os n&atilde;o foram confirmados quatro anos depois, quando aus&ecirc;ncia de rea
tividade cruzada entre anticorpos anti-beta2-gpI e anti-LDL oxidado foi reportad
a em casos de SAF<sup>(43)</sup>. </font></p>     ^cY#v44n2a06.htm##
00612000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704037600077002001300453#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#129#125#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Romero et al. estudaram o significa
do da presen&ccedil;a de anticorpos anti-beta2-gpI e anti-LDL oxidado por ELISA 
em l&uacute;picas com ou sem SAF. Anticorpos IgG anti-beta2gpI, mas n&atilde;o a
nti-LDL oxidado, associaram-se &agrave; trombose arterial nesta casu&iacute;stic
a<sup>(83)</sup>. </font></p>     ^cY#v44n2a06.htm##
00738000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704050200077002001300579#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#130#126#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Alternativamente, Amengual <i>et al
.</i> reportaram que anticorpos anti-LDL oxidado ocorreram em 22% de 107 casos d
e SAF, dado significante com rela&ccedil;&atilde;o aos controles. Houve associa&
ccedil;&atilde;o deste marcador com tromboses arteriais, mas n&atilde;o venosas.
 N&atilde;o houve correla&ccedil;&atilde;o entre presen&ccedil;a de anticorpos a
nti-LDL oxidado e anticorpos anti-beta2-gpI/aCL<sup>(84)</sup>. </font></p>     
^cY#v44n2a06.htm##
00887000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704065100077002001300728#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#131#127#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A freq&uuml;&ecirc;ncia de anticorp
os contra uma lipoprote&iacute;na modificada por malondialde&iacute;do (MDA-Lpa)
 foi recentemente investigada por Romero <i>et al.</i> em 104 casos de SAF. A pr
eval&ecirc;ncia deste anticorpo foi de 37%; aCL e anti-beta-2-gpI foram detectad
os, respectivamente, em 64% e 46% dos casos. N&atilde;o houve correla&ccedil;&at
ilde;o entre presen&ccedil;a de anticorpos contra MDA-Lpa e aCL/anti-beta2-gpI. 
A presen&ccedil;a de anti-MDA-Lpa na SAF sugere um papel para fen&ocirc;menos ox
idativos nesta afec&ccedil;&atilde;o<sup>(85)</sup>. </font></p>     ^cY#v44n2a0
6.htm##
00880000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704064400077002001300721#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#132#128#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A rela&ccedil;&atilde;o da beta2-gp
I com aterosclerose &eacute; assunto de grande interesse em anos recentes. Georg
e <i>et al.</i> reportaram presen&ccedil;a abundante de beta2-gpI em placas ater
oscler&oacute;ticas humanas. A transi&ccedil;&atilde;o entre as regi&otilde;es m
&eacute;dia e &iacute;ntima das placas, bem como o subendot&eacute;lio, foram ri
cos na express&atilde;o da mol&eacute;cula. A contiguidade com linf&oacute;citos
 CD4+ sugere que a bete2-gpI pode ser alvo de rea&ccedil;&atilde;o auto-imune na
 placa ateroscler&oacute;tica<sup>(86)</sup>. </font></p>     ^cY#v44n2a06.htm##
00597000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704036100077002001300438#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#133#129#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A indu&ccedil;&atilde;o de ateroscl
erose em camundongos deficientes em receptores de LDL ap&oacute;s imuniza&ccedil
;&atilde;o com beta2-gpI foi recentemente demonstrada. Todos os animais imunizad
os desenvolveram altos t&iacute;tulos de anticorpos anti-beta2-gpI<sup>(87)</sup
>. </font></p>     ^cY#v44n2a06.htm##
00648000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704041200077002001300489#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#134#130#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">De acordo com Afek <i>et al.</i>, c
amundongos deficientes em apoliprote&iacute;na E tiveram o processo ateroscler&o
acute;tico acelerado ap&oacute;s imuniza&ccedil;&atilde;o com beta2-gpI. O efeit
o proaterog&ecirc;nico da imuniza&ccedil;&atilde;o com beta2-gpI foi mantido ind
ependentemente de hipercolesterolemia<sup>(88)</sup>. </font></p>     ^cY#v44n2a
06.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#135#131#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b><i>Anticorpos anti-beta2-gpI e a
terosclerose coron&aacute;ria</i></b></font></p>     ^cY#v44n2a06.htm##
00559000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704032300077002001300400#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#136#132#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A rela&ccedil;&atilde;o entre AAF e
 infarto agudo do mioc&aacute;rdio (IAM) tem sido motivo de intenso debate nos &
uacute;ltimos anos. Estima-se que, entre os pacientes com SAF definida, a freq&u
uml;&ecirc;ncia de IAM seja de 4% a 20%(89). </font></p>     ^cY#v44n2a06.htm##
00785000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704054900077002001300626#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#137#133#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Farsi <i>et al.</i> estudaram o bin
&ocirc;mio cardiopatia isqu&ecirc;micaanticorpos anti-beta2-gpI. Vinte casos de 
angina inst&aacute;vel, 17 casos de angina aos esfor&ccedil;os e 40 controles sa
dios foram avaliados. O isotipos IgG e IgM, mas n&atilde;o IgA anti-beta2gpI, fo
ram testados. Preval&ecirc;ncia e titula&ccedil;&atilde;o dos anticorpos foram m
ais expressivos no grupo com angina inst&aacute;vel que em casos de angina aos e
sfor&ccedil;os<sup>(90)</sup>. </font></p>     ^cY#v44n2a06.htm##
00553000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704031700077002001300394#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#138#134#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em outro estudo, as presen&ccedil;a
s de IgG anti-beta2-gpI e de aCL n&atilde;o conferiram risco de reestenose coron
&aacute;ria ap&oacute;s angioplastia, ao contr&aacute;rio do observado com antic
orpos anti-LDL oxidado<sup>(91)</sup>. </font></p>     ^cY#v44n2a06.htm##
00659000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704042300077002001300500#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#139#135#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Limaye <i>et al.</i> n&atilde;o rel
ataram diferen&ccedil;as nos n&iacute;veis de anticorpos anti-beta2-gpI em pacie
ntes com doen&ccedil;a coronariana comparativamente a controles sadios<sup>(92)<
/sup>. De forma similar, Brey <i>et al.</i> reportaram aus&ecirc;ncia de associa
&ccedil;&atilde;o entre IgG anti-beta2-gpI e IAM<sup>(93)</sup>. </font></p>    
 ^cY#v44n2a06.htm##
00665000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704042900077002001300506#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#140#136#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em recente estudo de caso-controles
, nosso grupo avaliou a hip&oacute;tese de que anticorpos anti-beta2-gpI se comp
ortem como fatores de risco para IAM. Ap&oacute;s an&aacute;lise multivariada, o
s dados indicaram que a presen&ccedil;a de IgA antibeta2-gpI conferiu risco inde
pendente para o desfecho (raz&atilde;o de chances 3,4)<sup>(94)</sup>. </font></
p>     ^cY#v44n2a06.htm##
00413000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704017700077002001300254#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#141#137#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><b><i>Anticorpos anti-beta2-gpI, an
ormalidades neurol&oacute;gicas e isquemia cerebral</i></b></font></p>     ^cY#v
44n2a06.htm##
00870000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704063400077002001300711#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#142#138#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em estudos <i>in vitro</i> ou em mo
delos animais, as altera&ccedil;&otilde;es neurol&oacute;gicas relacionadas com 
anticorpos anti-beta2-gpI s&atilde;o dignas de refer&ecirc;ncia. Segundo Caronti
 <i>et al.</i>, soros de pacientes com SAF positivos para anti-beta2-gpI, assim 
como um anticorpo monoclonal anti-beta2-gpI, exibiram reatividade contra c&eacut
e;lulas neuronais e astr&oacute;citos. A liga&ccedil;&atilde;o dos anticorpos, c
onfirmada em imunofluoresc&ecirc;ncia indireta, ocorreu independentemente da pre
sen&ccedil;a de aCL<sup>(95)</sup>. </font></p>     ^cY#v44n2a06.htm##
00657000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704042100077002001300498#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#143#139#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s imuniza&ccedil;&atilde;
o com um anticorpo monoclonal aCL, camundongos f&ecirc;meas da ra&ccedil;a BALB/
c, al&eacute;m de apresentarem aCL, anticorpos anti-beta2-gpI, trombocitopenia e
 reabsor&ccedil;&atilde;o fetal, cursaram tamb&eacute;m com hiporreflexia, hiper
atividade e incoordena&ccedil;&atilde;o motora<sup>(96)</sup>. </font></p>     ^
cY#v44n2a06.htm##
00619000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704038300077002001300460#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#144#140#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A literatura envolvendo anticorpos 
anti-beta2-gpI e acidente vascular cerebral (AVC) isqu&ecirc;mico &eacute; ainda
 incipiente. De interesse, um anticorpo IgG anti-beta2-gpI (na aus&ecirc;ncia de
 aCL e AL) foi recentemente descrito em um adulto com infarto cerebral de origem
 obscura<sup>(97)</sup>. </font></p>     ^cY#v44n2a06.htm##
00661000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704042500077002001300502#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#145#141#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em um dos raros estudos no assunto,
 a presen&ccedil;a de anticorpos anti-beta2-gpI foi avaliada em 259 pacientes co
m AVC isqu&ecirc;mico. A freq&uuml;&ecirc;ncia de IgG anti-beta2-gpI foi baixa e
m casos (2,2%) e controles (1,9%), o que n&atilde;o sugere um papel etiopatog&ec
irc;nico para estes anticorpos no infarto cerebral<sup>(93)</sup>. </font></p>  
   ^cY#v44n2a06.htm##
00769000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704053300077002001300610#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#146#142#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Tamb&eacute;m em 2001, Heinzlef <i>
et al.</i><sup>(98)</sup> avaliaram a freq&uuml;&ecirc;ncia de IgG anti-beta2-gp
I e de aCL em 242 idosos internados em conseq&uuml;&ecirc;ncia de infarto cerebr
al. Nenhum dos pacientes apresentou teste positivo para IgG anti-beta2-gpI. Outr
os isotipos anti-beta2-gpI n&atilde;o foram testados. Os dados corroboram uma ba
ixa ou nula freq&uuml;&ecirc;ncia de IgG anti-beta2-gpI no infarto cerebral<sup>
(89,98)</sup>. </font></p>     ^cY#v44n2a06.htm##
00798000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704056200077002001300639#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#147#143#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">A possibilidade de que anticorpos a
nti-beta2-gpI confiram risco independente para infarto cerebral na fase aguda fo
i recentemente avaliada<sup>(99)</sup>. A associa&ccedil;&atilde;o do isotipo Ig
A anti-beta2gpI com isquemia cerebral aguda foi consistente em nossa casu&iacute
;stica (raz&atilde;o de chances ajustada de 4,6). Infere-se, a partir deste dado
, que estes anticorpos funcionem como fatores de risco independentes para AVC is
qu&ecirc;mico em fase aguda<sup>(99)</sup>. </font></p>     ^cY#v44n2a06.htm##
00798000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704056200077002001300639#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#148#144#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Em suma, IgA anti-beta-gpI s&atilde
;o anticorpos dirigidos contra mol&eacute;culas presentes na placa ateroscler&oa
cute;tica. Epifen&ocirc;menos ou n&atilde;o, estes anticorpos podem ser represen
tativos do bin&ocirc;mio auto-imunidade/aterosclerose em pacientes com IAM<sup>(
94)</sup> ou AVC isqu&ecirc;mico<sup>(99)</sup>. O acr&eacute;scimo destes marca
dores sorol&oacute;gicos &agrave; rotina laboratorial em pacientes com ateroscle
rose deve ser discutido em estudos futuros. </font></p>     ^cY#v44n2a06.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#149#145#article#357#<p>&nbsp;</p>     
^cY#v44n2a06.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010700077002001300184#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#150#146#article#357#<p><font size="3" 
face="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>
     ^cY#v44n2a06.htm##
00446000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704019600079002001300275#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#151#147#article#357#1#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Harris EN: Antipho
spholipid syndrome. In: Klippel JH, Dieppe P, editors. Rheumatology. 2nd.ed, St.
 Louis:Mosby, 1-6, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#152#148#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00515000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704026500079002001300344#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#153#149#article#357#2#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Love PE, Santoro A
S: Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in s
ystemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 112: 
682-98, 1990.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#154#150#article#357# </font></p>     ^
cY#v44n2a06.htm##
00405000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704015500079002001300234#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#155#151#article#357#3#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Hughes GRV: The an
tiphospholipid syndrome: ten years on. Lancet 342: 341-3, 1993.    ^cY#v44n2a06.
htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#156#152#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00417000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704016700079002001300246#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#157#153#article#357#4#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Hughes GRV, Harris
 EN, Gharavi AE: The anticardiolipin syndrome. J Rheumatol 13: 486-9, 1986.    ^
cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#158#154#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00547000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704029700079002001300376#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#159#155#article#357#5#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Wilson WA, Gharavi
 AE, Koike T, et al: International consensus statement on preliminary classifica
tion criteria for definite antiphospholipid syndrome: report of an international
 workshop. Arthritis Rheum 42: 1309-11, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#160#156#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704022800079002001300307#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#161#157#article#357#6#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Asherson RA, Khama
shta MA, Ordi-Ros J, et al: The "primary" antiphospholipid syndrome: major clini
cal and serological features. Medicine 68: 366-74, 1989.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#162#158#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704022400079002001300303#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#163#159#article#357#7#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Gharavi AE, Harris
 EN, Asherson RA, et al: Anticardiolipin antibodies: isotype distribution and ph
ospholipid specificity. Ann Rheum Dis 46: 1-6, 1987.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#164#160#article#357# </font></p>     ^
cY#v44n2a06.htm##
00527000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704027700079002001300356#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#165#161#article#357#8#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Steinkasserer A, C
ockburn DJ, Black DM, et al: Assignment of apolipoprotein H (beta2-gpI) to human
 chromossome 17g 23-qter determination of the major expression site. Cytogenet C
ell Genet 60: 31-3, 1992.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#166#162#article#357# </font></p>     ^
cY#v44n2a06.htm##
00555000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704030500079002001300384#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#167#163#article#357#9#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. McNeil HP, Simpson
 RJ, Chesterman CN, et al: Antiphospholipid antibodies are directed against a co
mplex antigen that includes a lipid-binding inhibitor of coagulation beta2-gpI (
apoliprotein H). Proc Natl Acad Sci 87: 4120-4, 1990.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#168#164#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00471000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022000080002001300300#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#169#165#article#357#10#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Galli M, Comfuri
ous P, Maassen C: Anticardiolipin antibodies (ACA) directe not to cardiolipin bu
t to a plasma cofactor. Lancet 335: 1544-7, 1990.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#170#166#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00519000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026800080002001300348#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#171#167#article#357#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Hunt JE, McNeil 
HP, Morgan GJ, et al: A phospholipid-beta2-gpI complex is an antigen for anticar
diolipin antibodies occurring in autoimmune disease but not with infection. Lupu
s 1: 75-81, 1992.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#172#168#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00489000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023800080002001300318#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#173#169#article#357#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Gharavi AE, Samm
aritano LR, Wen J, et al: Induction of antiphospholipid antibodies by immunizati
on with beta2-gpI (apoliprotein H). J Clin Invest 90: 1105-9, 1992.    ^cY#v44n2
a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#174#170#article#357# </font></p>     ^
cY#v44n2a06.htm##
00490000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023900080002001300319#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#175#171#article#357#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Gharavi AE, Samm
aritano LR, Borastro JL, et al: Specificities and characteristics of beta2-gpI-i
nduced antiphospholipid antibodies. J Clin Lab Med 125: 775-8, 1995.    ^cY#v44n
2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#176#172#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00487000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023600080002001300316#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#177#173#article#357#14#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Blank M, George 
J, Barak V, et al: Oral tolerance to low dose beta2gpI: immunomodulation of expe
rimental antiphospholipid syndrome. J Immunol 161: 5303-12, 1998.    ^cY#v44n2a0
6.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#178#174#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00381000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704013000080002001300210#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#179#175#article#357#15#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Kandiah DA, Kril
is S: Beta2-gpI. Lupus 3: 207-12, 1994.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#180#176#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00532000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028100080002001300361#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#181#177#article#357#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Polz E: Isolatio
n of a specific lipid-binding protein from human serum by affinity chromatograph
y using heparin-sepharose. In: Peeter H, editor. Protides of biological fluids. 
Oxford:Pergamon, 817-20, 1979.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#182#178#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022300080002001300303#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#183#179#article#357#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. 	Borchman D, Har
ris EN, Pierangeli SS, et al: Interactions and molecular structure of cardiolipi
n and beta-2-gp1. Clin Exp Immunol 102: 373-8, 1995.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#184#180#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00455000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020400080002001300284#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#185#181#article#357#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Schousboe I: Bet
a2-gpI: a plasma inhibitor of the contact activation of the intrinsic blood coag
ulation. Blood 66: 1086-91, 1985.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#186#182#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00547000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029600080002001300376#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#187#183#article#357#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Nomura S, Fukuha
ra S, Komiyama Y, et al: Beta2-gpI and anticardiolipin antibody influence factor
 Xa generation but not factor Xa binding to platelet-derived microparticles &#91
;letter&#93;. Thromb Haemost 71: 526-7, 1994.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#188#184#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00521000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027000080002001300350#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#189#185#article#357#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Arnout J, Wittev
rongel C, Vanrusselt M, et al: Beta2-gpI dependent lupus anticoagulants form sta
ble bivalent antibody-beta2-gpI complexes on phospholipid surfaces. Thromb Haemo
st 79: 79-86, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#190#186#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00528000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027700080002001300357#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#191#187#article#357#21#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Hojnik M, Gilbur
d, Ziporen L, et al: Anticardiolipin antibodies in infectious are heterogeneous 
in their dependency on beta2-gpI: analysis of anticardiolipin antibodies in lepr
osy. Lupus 3: 515-8, 1994.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#192#188#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#193#189#article#357#22#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Galli M, Ruggeri
 L, Barbui T: Differential effects of anti-beta2-gpI and antiprothrombin antibod
ies on the anticoagulant acitivity of activated protein C. Blood 91: 1999-2004, 
1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#194#190#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024900080002001300329#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#195#191#article#357#23#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Biasiolo A, Ramp
azzo P, Brocco T, et al: Anti-beta2-gpI-beta2-gpI immune complexes in patients w
ith antiphospholipid syndrome and other immune diseases. Lupus 8: 121-6, 1999.  
  ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#196#192#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025800080002001300338#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#197#193#article#357#24#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Mason NA, Harmer
 IJ, Mageed RA, et al: The BH1 idiotype defines a population of anticardiolipin 
antibodies closely associated with the antiphospholipid syndrome. Lupus 8: 234-9
, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#198#194#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00521000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027000080002001300350#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#199#195#article#357#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Pengo V, Biasiol
o A, Fior MG: Autoimmune antiphospholipid antibodies are directed against a cryp
tic epitope expressed when beta2gpI is bound to a suitable surface. Thromb Haemo
st 73: 29-34, 1995.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#200#196#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026900080002001300349#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#201#197#article#357#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Matsuura E, Igar
ashi Y, Yasuda T, et al: Anticardiolipin antibodies recognize beta2-gp1 structur
e altered by interacting with an oxygen modified solid phase surface. J Exp Med 
179: 457-62, 1994.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#202#198#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00480000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022900080002001300309#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#203#199#article#357#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Arvieux J, Rouss
el B, Jacob MC, et al: Measurement of antiphospholipid antibodies by ELISA using
 beta2-gpI as antigen. J Immunol Methods 143: 223-9, 1991.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#204#200#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00600000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704034900080002001300429#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#205#201#article#357#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Tincani A, Spato
la L, Prati E, et al: The anti-beta2-gpI activity in human antiphospholipid synd
rome sera is due to monoreactive low affinity autoantibodies directed to epitope
s located on native beta2-gpI and preserved during species evolution. J Immunol 
157: 5732-8, 1996.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#206#202#article#357# </font></p>     ^
cY#v44n2a06.htm##
00598000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704034700080002001300427#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#207#203#article#357#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Sheng Y, Kandiah
 DA, Krilis AS: Anti-beta2-gpI autoantibodies from patients with the "antiphosph
olipid" syndrome bind to beta2gpI with low affinity: dimerization of beta2-gpI i
nduces a significant increase in anti-beta2-gpI antibody affinity. J Immunol 161
: 2038-43, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#208#204#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00449000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019800080002001300278#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#209#205#article#357#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Tincani A, Spato
la L, Cinquini M, et al: Anti-beta2-gp1 antibodies: clinical significance. Lupus
 7(suppl. 2): S107-9, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#210#206#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00477000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022600080002001300306#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#211#207#article#357#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Arvieux J, Regna
ult V, Hachulla E, et al: Heterogeneity and immunochemical properties of anti-be
ta2-gpI autoantibodies. Thromb Haemost 80: 393-8, 1998.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#212#208#article#357# </font></p>     ^
cY#v44n2a06.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023300080002001300313#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#213#209#article#357#32#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Santiago M, Roch
a MC, Souza S, et al: Anticorpos anti-beta2-gp1 em pacientes com l&uacute;pus er
itematoso sist&ecirc;mico. Rev Bras Reumatol 40: 285-90, 2000.    ^cY#v44n2a06.h
tm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#214#210#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00532000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028100080002001300361#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#215#211#article#357#33#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Tsutsumi A, Ichi
kawa K, Matsuura E, et al: Heterogeneous behaviour of anti-beta2gp1 antibodies o
n various commercially available enzyme imunnoassay plates coated with beta2-gp1
. J Rheumatol 27: 391-6, 2000.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#216#212#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00533000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028200080002001300362#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#217#213#article#357#34#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Lewis S, Keil LB
, Binder WL, et al: Standardized measurement of major immunoglobulin class (IgG,
 IgM,IgA) antibodies to beta2-gp I in patients with antiphospholipid syndrome. J
 Clin Lab Anal 12: 293-7, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#218#214#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00569000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031800080002001300398#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#219#215#article#357#35#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Cucnik S, Ambroz
ic A, Bozic B, et al: Anti-beta2-gpI ELISA: methodology, determination of cut-of
f values in 434 healthy Caucasians and evaluation of monoclonal antibodies as po
ssible international standards. Clin Chem Lab Med 38: 777-83, 2000.    ^cY#v44n2
a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#220#216#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00573000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032200080002001300402#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#221#217#article#357#36#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Ichikawa K, Tsut
sumi A, Atsumi T, et al: A chimeric antibody with the human gamma 1 constant reg
ion as a putative standard for assay to detect IgG beta2-gpI-dependent anticardi
olipin and anti-beta2gpI antibodies. Arthritis Rheum 42: 2461-70, 1999.    ^cY#v
44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#222#218#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00521000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027000080002001300350#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#223#219#article#357#37#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Roubey RAS, Mald
onado MA, Byrd SN: Comparison of an enzyme-linked immunosorbent assay for antibo
dies to beta2-gpI and a conventional anticardiolipin immunoassay. Arthritis Rheu
m 39: 1606-7, 1996.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#224#220#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00590000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033900080002001300419#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#225#221#article#357#38#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. McNally T, Macki
e IJ, Machin SJ, et al: Increased levels of beta2gpI antigen and beta2-gpI bindi
ng antibodies are associated with a history of thromboembolic complications in p
atients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 34: 1031-
6, 1995.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#226#222#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00591000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704034000080002001300420#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#227#223#article#357#39#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Bruce IN, Clark-
Soloninka CA, Spitzer KA, et al: Prevalence of antibodies to beta2-gpI in system
ic lupus erythematosus and their association with antiphospholipid antibody synd
rome criteria: a single center study and literature review. J Rheumatol 27: 2833
-7, 2000.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#228#224#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00444000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019300080002001300273#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#229#225#article#357#40#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Helbert M, Bodge
r S, Cavenagh J, et al: Optimising testing for phospholipid antibodies. J Clin P
athol 54: 693-8, 2001.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#230#226#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00447000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019600080002001300276#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#231#227#article#357#41#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">41. Balestrieri G, T
incani A, Spatola L, et al: Anti-beta2-gpI: a marker of antiphospholipid syndrom
e? Lupus 4: 122-30, 1995.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#232#228#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00442000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019100080002001300271#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#233#229#article#357#42#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">42. Arvieux J, Rouss
el B, Colomb MG: Anticorps antiphospholipids et anti-beta2-gpI. Ann Biol Clin Pa
ris 52: 381-5, 1994.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#234#230#article#357# </font></p>     ^
cY#v44n2a06.htm##
00519000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026800080002001300348#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#235#231#article#357#43#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">43. Tinahones FJ, Cu
adrado MJ, Khamasta MA, et al: Lack of cross-reaction between antibodies to beta
2-gp1 and oxidized LDL in patients with antiphospholipid sydrome. Br J Rheumatol
 37: 746-9, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#236#232#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025800080002001300338#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#237#233#article#357#44#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">44. Matsuura E, Kata
hira T, Igarashi Y, et al: Beta2-gpI bound to oxidatively modified lipoproteins 
could be targeted by anticardiolipin antibodies. &#91;abstract&#93; Lupus 3: 314
, 1994.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#238#234#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#239#235#article#357#45#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">45. George G, Gilbur
d B, Langewitz P, et al: Beta2-gpI containing immunocomplexes in lupus patients:
 association with thrombocytopenia and lipoprotein (a) levels. Lupus 8: 116-20, 
1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#240#236#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00486000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023500080002001300315#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#241#237#article#357#46#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">46. Viard JP, Amoura
 Z, Back JF: Association of anti-beta2-gp1 antibodies with lupus-type circulatin
g anticoagulant and thrombosis in SLE. Am J Med 93: 181-6, 1992.    ^cY#v44n2a06
.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#242#238#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00551000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030000080002001300380#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#243#239#article#357#47#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">47. Sanfilippo SS, K
hamashta MA, Atsumi T, et al: Antibodies to beta2gpI: a potential marker for cli
nical features of antiphospholipid antibody syndrome in patients with systemic l
upus erythematosus. J Rheumatol 25: 2131-4, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#244#240#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00545000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029400080002001300374#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#245#241#article#357#48#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">48. Tubach F, Hayem 
G, Marchand JL, et al: IgG anti-beta2-gpI antibodies in adult patients with syst
emic lupus erythematosus: prevalence and diagnostic value for the antiphospholip
id syndrome. J Rheumatol 27: 1437-43, 2000.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#246#242#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00536000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028500080002001300365#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#247#243#article#357#49#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">49. Shrivastava A, D
wivedi S, Aggarwal A, et al: Anticardiolipin and anti-beta2-gpI antibodies in In
dian patients with systemic lupus erythematosus: association with the presence o
f seizures. Lupus 10: 45-50, 2001.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#248#244#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00513000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026200080002001300342#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#249#245#article#357#50#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">50. Aguirre V, Cucha
covich R, Barria L, et al: Prevalence and isotype distribution of antiphospholip
id antibodies in Chilean patients with systemic lupus erythematosus. Lupus 10: 7
5-80, 2001.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#250#246#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00568000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031700080002001300397#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#251#247#article#357#51#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">51. Inanc M, Donohoe
 S, Ravirajan CT, et al: Anti-beta2-gpI, antiprothrombin and anticardiolipin ant
ibodies in a longitudinal study of patients with systemic lupus erythematosus an
d the antiphospholipid syndrome. Br J Rheumatol 37: 1089-94, 1998.    ^cY#v44n2a
06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#252#248#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00620000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704036900080002001300449#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#253#249#article#357#52#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">52. Sebastiani GD, G
aleazzi M, Tincani A, et al: Anticardiolipin and anti-beta2-gpI antibodies in a 
large series of European patients with systemic lupus erythematosus. Prevalence 
and clinical associations. European Concerned Action on the Immunogenetics of SL
E. Scand J Rheumatol 28: 344-51, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#254#250#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00528000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027700080002001300357#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#255#251#article#357#53#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">53. Cucurull E, Espi
noza LR, Mendez E, et al: Anticardiolipin and antibeta2-gpI antibodies in patien
ts with systemic lupus erythematosus: comparisons between Colombians and Spaniar
ds. Lupus 8: 134-41, 1999.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#256#252#article#357# </font></p>     ^
cY#v44n2a06.htm##
00501000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025000080002001300330#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#257#253#article#357#54#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">54. Gomez-Pacheco L,
 Villa AR, Drenkard C, et al: Serum anti-beta2gpI and anticardiolipin antibodies
 during thrombosis in systemic lupus erythematosus. Am J Med 106: 417-23, 1999. 
   ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#258#254#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00468000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021700080002001300297#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#259#255#article#357#55#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">55. Tsutsumi A, Mats
uura E, Ichikawa K, et al: IgA class anti-beta2-gpI in patients with systemic lu
pus erythematosus. J Rheumatol 25: 74-8, 1998.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#260#256#article#357# </font></p>     ^
cY#v44n2a06.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025100080002001300331#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#261#257#article#357#56#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">56. Tsutsumi A, Mats
uura E, Ichikawa K, et al: Antibodies to beta2-gpI and clinical manifestations i
n patients with systemic lupus erythematosus. Arthritis Rheum 39: 1466-74, 1996.
    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#262#258#article#357# </font></p>     ^
cY#v44n2a06.htm##
00539000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028800080002001300368#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#263#259#article#357#57#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">57. Bertolaccini ML,
 Atsumi T, Escudero-Contreras A, et al: The value of IgA antiphospholipid testin
g for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythema
tosus. J Rheumatol 28: 2637-43, 2001.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#264#260#article#357# </font></p>     ^
cY#v44n2a06.htm##
00529000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027800080002001300358#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#265#261#article#357#58#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">58. Cucurull E, Ghar
avi AE, Diri E, et al: IgA anticardiolipin and antibeta2-gpI are the most preval
ent isotypes in African American patients with systemic lupus erythematosus. Am 
J Med Sci 318: 55-60, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#266#262#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024800080002001300328#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#267#263#article#357#59#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">59. Lee SS, Cho ML, 
Joo YS, et al: Isotypes of anti-beta2-gpI antibodies: association with thrombosi
s in patients with systemic lupus erythematosus. J Rheumatol 28: 520-4, 2001.   
 ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#268#264#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00496000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024500080002001300325#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#269#265#article#357#60#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">60. Lakos G, Kiss E,
 Regeczy N, et al: Isotype distribution and clinical relevance of anti-beta2-gpI
 antibodies: importance of IgA isotype. Clin Exp Immunol 117: 547-9, 1999.    ^c
Y#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#270#266#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00486000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023500080002001300315#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#271#267#article#357#61#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">61. Detkov, Gil-Agua
do A, Lavilla P, et al: Do antibodies to beta2-gpI contribute to better characte
rization of the antiphospholipid syndrome? Lupus 8: 430-8, 1999.    ^cY#v44n2a06
.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#272#268#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00486000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023500080002001300315#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#273#269#article#357#62#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">62. Tektonidou MG, I
oannidis JP, Boki KA, et al: Prognostic factors and clustering of serious clinic
al outcomes in antiphospholipid syndromes. QJM 93: 523-30, 2000.    ^cY#v44n2a06
.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#274#270#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00656000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704040500080002001300485#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#275#271#article#357#63#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">63. Faden D, Tincani
 A, Tanzi P, et al: Anti-beta2-gpI antibodies in a general obstetric population:
 preliminary results on the prevalence and correlation with pregnancy outcome. A
nti-beta2-gpI antibodies are associated with some obstetric complications, mainl
y preeclampsiaeclampsia. Eur J Obstet Gynecol Reprod Biol 73: 37-42, 1997.    ^c
Y#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#276#272#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023100080002001300311#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#277#273#article#357#64#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">64. Franklin RD, Hol
lier N, Kutteh WH: Beta2-gpI as a marker of antiphospholipid syndrome in women w
ith recurrent pregnancy loss. Fertil Steril 73: 531-5, 2000.    ^cY#v44n2a06.htm
##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#278#274#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00589000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033800080002001300418#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#279#275#article#357#65#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">65. 	Gris JC, Quere 
I, Sanmarco M, et al: Antiphospholipid and antiprotein syndromes in non-thrombot
ic, non-autoimmune women with unexplained recurrent primary early foetal loss: T
he Nimes Obstetricians and Haematologists Study - NOHA. Thromb Haemos 84: 228-36
, 2000.    ^cY#v44n2a06.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#280#276#article#357# </font></p>     ^
cY#v44n2a06.htm##
00528000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027700080002001300357#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#281#277#article#357#66#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">66. Lynch A, Byers T
, Emlen W, et al: Association of antibodies to beta2gpI with pregnancy loss and 
pregnancy-induced hypertension: a prospective study in low-risk pregnancy. Obste
t Gynecol 93: 193-8, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#282#278#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00532000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028100080002001300361#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#283#279#article#357#67#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">67. Lee RM, Branch D
W, Silver RM: Immunoglobulin A anti-beta2gpI antibodies in women who experience 
unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obs
tet Gynecol 185: 748-53, 2001.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#284#280#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00525000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027400080002001300354#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#285#281#article#357#68#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">68. Lee RM, Emlen E,
 Scott JR, et al: Anti-beta2-gpI antibodies in women with recurrent spontaneous 
abortion, unexplained fetal death, and antiphospholipid syndrome. Am J Obstet Gy
necol 181: 642-8, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#286#282#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00526000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027500080002001300355#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#287#283#article#357#69#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">69. Zanon E, Prandon
i P, Vianello F, et al: Anti-beta2-gpI antibodies in patients with acute venous 
thromboembolism: prevalence and association with recurrent thromboembolism. Thro
mb Res 96: 269-74, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#288#284#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00470000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021900080002001300299#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#289#285#article#357#70#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">70. Sands JJ, Nudo A
S, Moore KD, et al: Antibodies to prothrombin, factor V, and beta2-gpI and vascu
lar access thrombosis. ASAIO J 47: 507-10, 2001.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#290#286#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00550000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029900080002001300379#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#291#287#article#357#71#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">71. Martinuzzo ME, P
ombo G, Forastiero RR, et al: Lupus anticoagulant, high levels of anticardiolipi
n and anti-beta2-gpI antibodies are associated with chronic thromboembolic pulmo
nary hypertension. J Rheumatol 25: 1313-9, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#292#288#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00494000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024300080002001300323#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#293#289#article#357#72#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">72. Liozon E, Rousse
l V, Roblot P, et al: Absence of anti-beta2-gpI antibodies in giant cell arterit
is: a study of 45 biopsy-proven cases. Br J Rheumatol 37: 1129-31, 1998.    ^cY#
v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#294#290#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025100080002001300331#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#295#291#article#357#73#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">73. Koutroubakis IE,
 Petinaki E, Anagnostopoulou E, et al: Anticardiolipin and anti-beta2-gpI antibo
dies in patients with inflammatory bowel disease. Dig Dis Sci 43: 2507-12, 1998.
    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#296#292#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00462000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021100080002001300291#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#297#293#article#357#74#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">74. Kang HJ, Lee YW,
 Han SH, et al: Anticardiolipin and anti-beta2gpI antibodies in Beh&ccedil;et di
sease. J Korean Med Sci 13: 400-4, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#298#294#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00544000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029300080002001300373#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#299#295#article#357#75#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">75. McNally T, Purdy
 G, Mackie IJ, et al: The use of an anti-beta2-gpI assay for discrimination betw
een anticardiolipin antibodies associated with infection and increased risk for 
thrombosis. Br J Haematol 91: 471-3, 1995.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#300#296#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00490000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023900080002001300319#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#301#297#article#357#76#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">76. Santiago MB, Mar
tinelli R, Ko A, et al: Anti-beta2-gpI and anticardiolipin antibodies in leptosp
irosis, syphilis and kala-azar. Clin Exp Rheumatol 19: 425-30, 2001.    ^cY#v44n
2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#302#298#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00496000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024500080002001300325#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#303#299#article#357#77#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">77. De Larranaga GF,
 Forastiero RR, Martinuzzo ME, et al: High prevalence of antiphospholipid antibo
dies in leprosy: evaluation of antigen reactivity. Lupus 9: 594-600, 2000.    ^c
Y#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#304#300#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00549000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029800080002001300378#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#305#301#article#357#78#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">78. Ioannidis JP, Te
ktonidou MG, Vlachoyiannopoulos PG, et al: HLA associations of anti-beta2-gpI re
sponse in a Greek cohort with antiphospholipid syndrome and meta-analysis of fou
r ethnic groups. Hum Immunol 60: 1274-80, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#306#302#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00549000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029800080002001300378#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#307#303#article#357#79#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">79. Galeazzi M, Seba
stiani GD, Tincani A, et al: HLA class II alleles associations of anticardiolipi
n and anti-beta2-gpI antibodies in a large series of European patients with syst
emic lupus erythematosus. Lupus 9: 47-55, 2000.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#308#304#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00475000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022400080002001300304#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#309#305#article#357#80#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">80. Arnett FC, Thiag
arajan P, Ahn C, et al: Associations of anti-beta2gpI with class II alleles in t
hree ethnic groups. Arthritis Rheum 42: 268-74, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#310#306#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00411000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704016000080002001300240#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#311#307#article#357#81#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">81. 	Wick G, Xu Q: A
therosclerosis: an autoimmune disease. Exp Gerontol 34: 559-66, 1999.    ^cY#v44
n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#312#308#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00408000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704015700080002001300237#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#313#309#article#357#82#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">82. 	Ross R: Atheros
clerosis: an inflammatory disease. N Engl J Med 340: 115-26, 1999.    ^cY#v44n2a
06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#314#310#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00572000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032100080002001300401#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#315#311#article#357#83#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">83. Romero FI, Ameng
ual O, Atsumi T, et al: Arterial disease in lupus and secondary antiphospholipid
 syndrome: association with antibeta2-gpI antibodies but not with antibodies aga
inst oxidized low-density lipoprotein. Br J Rheumatol 37: 883-8, 1998.    ^cY#v4
4n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#316#312#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023100080002001300311#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#317#313#article#357#84#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">84. Amengual O, Atsu
mi K, Khamashta MA, et al: Antibodies against oxidized low-density lipoprotein i
n antiphospholipid syndrome. Br J Rheumatol 36: 964-8, 1997.    ^cY#v44n2a06.htm
##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#318#314#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00496000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024500080002001300325#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#319#315#article#357#85#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">85. Romero FI, Atsum
i T, Tinahones FJ, et al: Autoantibodies against malondialdehyde-modified lipopr
otein (a) in antiphospholipid syndrome. Arthritis Rheum 42: 2606-11, 1999.    ^c
Y#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#320#316#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00525000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027400080002001300354#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#321#317#article#357#86#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">86. George J, Harats
 D, Gilburd B, et al: Immunolocalization of beta2gpI (apolipoprotein H) to human
 atherosclerotic plaques: potential implications for lesion progression. Circula
tion 99: 2227-30, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#322#318#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023300080002001300313#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#323#319#article#357#87#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">87. George J, Afek A
, Gilburd B, et al: Induction of early atherosclerosis in LDL-receptor-deficient
 mice immunized with beta2-gpI. Circulation 98: 1108-15, 1998.    ^cY#v44n2a06.h
tm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#324#320#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022700080002001300307#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#325#321#article#357#88#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">88. Afek A, George J
, Shoenfeld Y, et al: Enhancement of atherosclerosis in beta2-gpI-immunized apol
iprotein E-deficient mice. Pathobiology 67: 19-25, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#326#322#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00414000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704016300080002001300243#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#327#323#article#357#89#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">89. O'Vaarala: Antip
hospholipid antibodies and myocardial infarction. Lupus S2 132-34, 1998.    ^cY#
v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#328#324#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00480000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022900080002001300309#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#329#325#article#357#90#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">90. Farsi A, Domeneg
hetti MP, Fedi S, et al: High prevalence of antibeta2-gpI antibodies in patients
 with ischemic heart disease. Autoimmunity 30: 93-8, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#330#326#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00541000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029000080002001300370#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#331#327#article#357#91#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">91. George J, Harats
 D, Bakshi E, et al: Anti-oxidized low density lipoprotein antibody determinatio
n as a predictor of reestenosis following percutaneous transluminal coronary ang
ioplasty. Immunol Lett 68: 263-6, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#332#328#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00538000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028700080002001300367#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#333#329#article#357#92#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">92. Limaye V, Beltra
me J, Cook R, Gillis D, Pile K: Evaluation of antibodies to b2-glycoprotein 1 in
 the causation of coronary atherosclerosis as part of the antiphospholipid syndr
ome. Aust NZ J Med 29: 789-93, 1999.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#334#330#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00508000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025700080002001300337#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#335#331#article#357#93#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">93. Brey RL, Abbott 
RD, Curb D, Sharp DS, Ross GW: b2-glycoprotein 1-dependent anticardiolipin antib
odies and risk of ischemic stroke and myocardial infarction. Stroke 32: 1701-06,
 2001.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#336#332#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027200080002001300352#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#337#333#article#357#94#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">94. Ranzolin A, Norm
an GL, Manenti E, Bodanese LC, Von M&uuml;hlen CA, Staub HL: Antibodies to beta2
-glycooprotein I as risk factors for acute myocardial infarction. Arq Bras Cardi
ol, 2003. (In press).    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#338#334#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026900080002001300349#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#339#335#article#357#95#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">95. Caronti B, Calde
raro C, Alessandri C, et al: Serum anti-beta2-gpI antibodies from patients with 
antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmu
n 11: 425-9, 1998.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#340#336#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#341#337#article#357#96#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">96. Ziporen L, Shoen
feld Y, Levy Y, et al: Neurological dysfunction and hyperactive behaviour associ
ated with antiphospholipid antibodies: a mouse model. J Clin Invest 100: 613-9, 
1997.    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#342#338#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00494000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024300080002001300323#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#343#339#article#357#97#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">97. Chen WH, Liu JS:
 An unusual increase of blood anti-beta2-gpI antibody but not antiphospholipid a
ntibody in cerebral ischemia: a case report. Angiology 52: 149-54, 2001.    ^cY#
v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#344#340#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024900080002001300329#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#345#341#article#357#98#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">98. Heinzlef O, Abua
f N, Cohen A, et al: Recurrent stroke and vascular events in elderly patients wi
th anticardiolipin antibodies: a prospective study. J Neurol 248: 373-9, 2001.  
  ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#346#342#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00537000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028600080002001300366#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#347#343#article#357#99#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">99. Staub HL, Norman
 GL, Crowther T, et al: Antibodies to the atherosclerotic plaque components beta
2-glycoprotein and heat-shock proteins as markers of acute cerebral ischemia. Ar
q Neuropsiquiatr, 2003. (In press).    ^cY#v44n2a06.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#348#344#article#357#</font></p>     ^c
Y#v44n2a06.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#349#345#article#357#<p>&nbsp;</p>     
^cY#v44n2a06.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#350#346#article#357#<p>&nbsp;</p>     
^cY#v44n2a06.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022900077002001300306#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#351#347#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a href="#linkinicio"><img src="/im
g/revistas/rbr/v44n2/seta.jpg" border="0"></a><a name="linkcorresp"></a> <b>Ende
re&ccedil;o para correspond&ecirc;ncia:</b>    ^cY#v44n2a06.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003300077002001300110#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#352#348#article#357#<br>  Henrique Lui
z Staub    ^cY#v44n2a06.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007700077002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#353#349#article#357#<br> Servi&ccedil;
o de reumatologia da Faculdade de Medicina da PUCRS    ^cY#v44n2a06.htm##
00277000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004100077002001300118#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#354#350#article#357#<br>  Av. Ipiranga
 6690, sala 220    ^cY#v44n2a06.htm##
00276000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004000077002001300117#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#355#351#article#357#<br> Porto Alegre,
 CEP 90610-000    ^cY#v44n2a06.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010800077002001300185#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#356#352#article#357#<br> E-mail: <a hr
ef="mailto:henriquestaub@terra.com.br">henriquestaub@terra.com.br</a> </font></p
>     ^cY#v44n2a06.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009300077002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#357#353#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Recebido em 31/3/2003.    ^cY#v44n2
a06.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007700077002001300154#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#358#354#article#357#<br>  Aprovado, ap
&oacute;s revis&atilde;o, em 12/8/2003.</font></p>     ^cY#v44n2a06.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#359#355#article#357#<p>&nbsp;</p>     
^cY#v44n2a06.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#360#356#article#357#<p>&nbsp;</p>     
^cY#v44n2a06.htm##
00522000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704028600077002001300363#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a06.htm#S#p#361#357#article#357#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a name="link01"></a><a href="#link
inicio">*</a> 	Servi&ccedil;o de reumatologia da Faculdade de Medicina da Pontif
&iacute;cia Universidade Cat&oacute;lica do Rio Grande do Sul (PUCRS), Porto Ale
gre, RS.</font></p>     ^cY#v44n2a06.htm##
00522000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760120030000930160
01800123016001600141018001700157063000200174066001000176062000600186014000400192
065000900196064000500205865000900210002001300219#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#362#1#article#99#1#^rND^sHarris^nEN#Antiphospholipid s
yndrome^len#^rED^sKlippel^nJH#^rED^sDieppe^nP#Rheumatology^len#2#St. Louis#Mosby
#1-6#19980000#1998#20040400#v44n2a06.htm##
00614000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100018000910120
14000109030001500249031000400264014000700268065000900275064000500284865000900289
002001300298035001000311801001500321#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a06.htm#S#c#363#2#article#99#2#^rND^sLove^nPE#^rND^sSantoro^nAS#Antiphospholip
id antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus ery
thematosus (SLE) and in non-SLE disorders^len#Ann Intern Med#112#682-98#19900000
#1990#20040400#v44n2a06.htm#0003-4819#Ann Intern Med##
00478000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760120048000940300
00700142031000400149014000600153065000900159064000500168865000900173002001300182
035001000195801000700205#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#
c#364#3#article#99#3#^rND^sHughes^nGRV#The antiphospholipid syndrome: ten years 
on^len#Lancet#342#341-3#19300000#1993#20040400#v44n2a06.htm#0099-5355#Lancet##
00531000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940100
01800111012003300129030001200162031000300174014000600177065000900183064000500192
865000900197002001300206035001000219801001200229#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#365#4#article#99#4#^rND^sHughes^nGRV#^rND^sHarris^nEN#
^rND^sGharavi^nAE#The anticardiolipin syndrome^len#J Rheumatol#13#486-9#19860000
#1986#20040400#v44n2a06.htm#0315-162X#J Rheumatol##
00676000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100018000930100
01500111810000600126012015300132030001600285031000300301014000800304065000900312
064000500321865000900326002001300335035001000348801001600358#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#366#5#article#99#5#^rND^sWilson^nWA#^rND^s
Gharavi^nAE#^rND^sKoike^nT#et al#International consensus statement on preliminar
y classification criteria for definite antiphospholipid syndrome: report of an i
nternational workshop^len#Arthritis Rheum#42#1309-11#19990000#1999#20040400#v44n
2a06.htm#0004-3591#Arthritis rheum##
00600000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100020000950100
01800115810000600133012008500139030000900224031000300233014000700236065000900243
064000500252865000900257002001300266035001000279801000900289#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#367#6#article#99#6#^rND^sAsherson^nRA#^rND
^sKhamashta^nMA#^rND^sOrdi-Ros^nJ#et al#The "primary" antiphospholipid syndrome:
 major clinical and serological features^len#Medicine#68#366-74#19890000#1989#20
040400#v44n2a06.htm#0025-7974#Medicine##
00601000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940100
01900111810000600130012008200136030001400218031000300232014000400235065000900239
064000500248865000900253002001300262035001000275801001400285#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#368#7#article#99#7#^rND^sGharavi^nAE#^rND^
sHarris^nEN#^rND^sAsherson^nRA#et al#Anticardiolipin antibodies: isotype distrib
ution and phospholipid specificity^len#Ann Rheum Dis#46#1-6#19870000#1987#200404
00#v44n2a06.htm#0003-4967#Ann Rheum Dis##
00661000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100023000760100019000990100
01600118810000600134012012300140030002100263031000300284014000500287065000900292
064000500301865000900306002001300315035001000328801002100338#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#369#8#article#99#8#^rND^sSteinkasserer^nA#
^rND^sCockburn^nDJ#^rND^sBlack^nDM#et al#Assignment of apolipoprotein H (beta2-g
pI) to human chromossome 17g 23-qter determination of the major expression site^
len#Cytogenet Cell Genet#60#31-3#19970000#1992#20040400#v44n2a06.htm#0011-4529#C
ytogenet Cell Genet##
00687000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100018000930100
02100111810000600132012015300138030001900291031000300310014000700313065000900320
064000500329865000900334002001300343035001000356801001900366#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#370#9#article#99#9#^rND^sMcNeil^nHP#^rND^s
Simpson^nRJ#^rND^sChesterman^nCN#et al#Antiphospholipid antibodies are directed 
against a complex antigen that includes a lipid-binding inhibitor of coagulation
 beta2-gpI (apoliprotein H)^len#Proc Natl Acad Sci#87#4120-4#19900000#1990#20040
400#v44n2a06.htm#0027-8424#Proc Natl Acad Sci##
00580000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100020000930100
01700113012008900130030000700219031000400226014000700230065000900237064000500246
865000900251002001300260035001000273801000700283#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#371#10#article#99#10#^rND^sGalli^nM#^rND^sComfurious^n
P#^rND^sMaassen^nC#Anticardiolipin antibodies (ACA) directe not to cardiolipin b
ut to a plasma cofactor^len#Lancet#335#1544-7#19900000#1990#20040400#v44n2a06.ht
m#0099-5355#Lancet##
00638000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01700110810000600127012013700133030000600270031000200276014000600278065000900284
064000500293865000900298002001300307035001000320801000600330#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#372#11#article#99#11#^rND^sHunt^nJE#^rND^s
McNeil^nHP#^rND^sMorgan^nGJ#et al#A phospholipid-beta2-gpI complex is an antigen
 for anticardiolipin antibodies occurring in autoimmune disease but not with inf
ection^len#Lupus#1#75-81#19920000#1992#20040400#v44n2a06.htm#0961-2033#Lupus##
00616000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100022000960100
01300118810000600131012009300137030001400230031000300244014000700247065000900254
064000500263865000900268002001300277035001000290801001400300#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#373#12#article#99#12#^rND^sGharavi^nAE#^rN
D^sSammaritano^nLR#^rND^sWen^nJ#et al#Induction of antiphospholipid antibodies b
y immunization with beta2-gpI (apoliprotein H)^len#J Clin Invest#90#1105-9#19920
000#1992#20040400#v44n2a06.htm#0021-9738#J Clin Invest##
00583000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100022000960100
01900118810000600137012008700143030001500230710000200245031000400247014000600251
065000900257064000500266865000900271002001300280#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#374#13#article#99#13#^rND^sGharavi^nAE#^rND^sSammarita
no^nLR#^rND^sBorastro^nJL#et al#Specificities and characteristics of beta2-gpI-i
nduced antiphospholipid antibodies^len#J Clin Lab Med#2#125#775-8#19950000#1995#
20040400#v44n2a06.htm##
00610000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100016000930100
01500109810000600124012010000130030001000230031000400240014000800244065000900252
064000500261865000900266002001300275035001000288801001000298#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#375#14#article#99#14#^rND^sBlank^nM#^rND^s
George^nJ#^rND^sBarak^nV#et al#Oral tolerance to low dose beta2gpI: immunomodula
tion of experimental antiphospholipid syndrome^len#J Immunol#161#5303-12#1998000
0#1998#20040400#v44n2a06.htm#0022-1767#J Immunol##
00471000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960120
01400112030000600126031000200132014000700134065000900141064000500150865000900155
002001300164035001000177801000600187#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a06.htm#S#c#376#15#article#99#15#^rND^sKandiah^nDA#^rND^sKrilis^nS#Beta2-gpI^l
en#Lupus#3#207-12#19940000#1994#20040400#v44n2a06.htm#0961-2033#Lupus##
00585000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780120118000920160
01600210018003400226066000700260062000900267014000700276065000900283064000500292
865000900297002001300306#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#
c#377#16#article#99#16#^rND^sPolz^nE#Isolation of a specific lipid-binding prote
in from human serum by affinity chromatography using heparin-sepharose^len#^rED^
sPeeter^nH#Protides of biological fluids^len#Oxford#Pergamon#817-20#19790000#197
9#20040400#v44n2a06.htm##
00603000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
02100113810000600134012007100140030001700211031000400228014000600232065000900238
064000500247865000900252002001300261035001000274801001700284#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#378#17#article#99#17#^rND^sBorchman^nD#^rN
D^sHarris^nEN#^rND^sPierangeli^nSS#et al#Interactions and molecular structure of
 cardiolipin and beta-2-gp1^len#Clin Exp Immunol#102#373-8#19950000#1995#2004040
0#v44n2a06.htm#0009-9104#Clin Exp Immunol##
00527000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120095000970300
00600192031000300198014000800201065000900209064000500218865000900223002001300232
035001000245801000600255#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#
c#379#18#article#99#18#^rND^sSchousboe^nI#Beta2-gpI: a plasma inhibitor of the c
ontact activation of the intrinsic blood coagulation^len#Blood#66#1086-91#198500
00#1985#20040400#v44n2a06.htm#0006-4971#Blood##
00667000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01800112810000600130012014400136030001500280031000300295014000600298065000900304
064000500313865000900318002001300327035001000340801001500350#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#380#19#article#99#19#^rND^sNomura^nS#^rND^
sFukuhara^nS#^rND^sKomiyama^nY#et al#Beta2-gpI and anticardiolipin antibody infl
uence factor Xa generation but not factor Xa binding to platelet-derived micropa
rticles [letter]^len#Thromb Haemost#71#526-7#19940000#1994#20040400#v44n2a06.htm
#0340-6245#Thromb Haemost##
00649000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100022000940100
02000116810000600136012012000142030001500262031000300277014000600280065000900286
064000500295865000900300002001300309035001000322801001500332#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#381#20#article#99#20#^rND^sArnout^nJ#^rND^
sWittevrongel^nC#^rND^sVanrusselt^nM#et al#Beta2-gpI dependent lupus anticoagula
nts form stable bivalent antibody-beta2-gpI complexes on phospholipid surfaces^l
en#Thromb Haemost#79#79-86#19980000#1998#20040400#v44n2a06.htm#0340-6245#Thromb 
Haemost##
00646000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100014000940100
01700108810000600125012014700131030000600278031000200284014000600286065000900292
064000500301865000900306002001300315035001000328801000600338#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#382#21#article#99#21#^rND^sHojnik^nM#^rND^
sGilburd#^rND^sZiporen^nL#et al#Anticardiolipin antibodies in infectious are het
erogeneous in their dependency on beta2-gpI: analysis of anticardiolipin antibod
ies in leprosy^len#Lupus#3#515-8#19940000#1994#20040400#v44n2a06.htm#0961-2033#L
upus##
00604000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01600110012012800126030000600254031000300260065000900263064001600272865000900288
002001300297035001000310801000600320#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a06.htm#S#c#383#22#article#99#22#^rND^sGalli^nM#^rND^sRuggeri^nL#^rND^sBarbui^
nT#Differential effects of anti-beta2-gpI and antiprothrombin antibodies on the 
anticoagulant acitivity of activated protein C^len#Blood#91#20040000#1999-2004, 
1998#20040400#v44n2a06.htm#0006-4971#Blood##
00619000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01600114810000600130012011500136030000600251031000200257014000600259065000900265
064000500274865000900279002001300288035001000301801000600311#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#384#23#article#99#23#^rND^sBiasiolo^nA#^rN
D^sRampazzo^nP#^rND^sBrocco^nT#et al#Anti-beta2-gpI-beta2-gpI immune complexes i
n patients with antiphospholipid syndrome and other immune diseases^len#Lupus#8#
121-6#19990000#1999#20040400#v44n2a06.htm#0961-2033#Lupus##
00628000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940100
01700111810000600128012012600134030000600260031000200266014000600268065000900274
064000500283865000900288002001300297035001000310801000600320#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#385#24#article#99#24#^rND^sMason^nNA#^rND^
sHarmer^nIJ#^rND^sMageed^nRA#et al#The BH1 idiotype defines a population of anti
cardiolipin antibodies closely associated with the antiphospholipid syndrome^len
#Lupus#8#234-9#19990000#1999#20040400#v44n2a06.htm#0961-2033#Lupus##
00638000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100018000930100
01500111012013700126030001500263031000300278014000600281065000900287064000500296
865000900301002001300310035001000323801001500333#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#386#25#article#99#25#^rND^sPengo^nV#^rND^sBiasiolo^nA#
^rND^sFior^nMG#Autoimmune antiphospholipid antibodies are directed against a cry
ptic epitope expressed when beta2gpI is bound to a suitable surface^len#Thromb H
aemost#73#29-34#19950000#1995#20040400#v44n2a06.htm#0340-6245#Thromb Haemost##
00643000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01600114810000600130012012800136030001000264031000400274014000700278065000900285
064000500294865000900299002001300308035001000321801001000331#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#387#26#article#99#26#^rND^sMatsuura^nE#^rN
D^sIgarashi^nY#^rND^sYasuda^nT#et al#Anticardiolipin antibodies recognize beta2-
gp1 structure altered by interacting with an oxygen modified solid phase surface
^len#J Exp Med#179#457-62#19940000#1994#20040400#v44n2a06.htm#0022-1007#J Exp Me
d##
00611000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01600112810000600128012008300134030001800217031000400235014000600239065000900245
064000500254865000900259002001300268035001000281801001800291#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#388#27#article#99#27#^rND^sArvieux^nJ#^rND
^sRoussel^nB#^rND^sJacob^nMC#et al#Measurement of antiphospholipid antibodies by
 ELISA using beta2-gpI as antigen^len#J Immunol Methods#143#223-9#19910000#1991#
20040400#v44n2a06.htm#0022-1759#J Immunol Methods##
00723000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01500112810000600127012021100133030001000344031000400354014000700358065000900365
064000500374865000900379002001300388035001000401801001000411#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#389#28#article#99#28#^rND^sTincani^nA#^rND
^sSpatola^nL#^rND^sPrati^nE#et al#The anti-beta2-gpI activity in human antiphosp
holipid syndrome sera is due to monoreactive low affinity autoantibodies directe
d to epitopes located on native beta2-gpI and preserved during species evolution
^len#J Immunol#157#5732-8#19960000#1996#20040400#v44n2a06.htm#0022-1767#J Immuno
l##
00710000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100018000930100
01700111012021400128030001000342031000400352014000800356065000900364064000500373
865000900378002001300387035001000400801001000410#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#390#29#article#99#29#^rND^sSheng^nY#^rND^sKandiah^nDA#
^rND^sKrilis^nAS#Anti-beta2-gpI autoantibodies from patients with the "antiphosp
holipid" syndrome bind to beta2gpI with low affinity: dimerization of beta2-gpI 
induces a significant increase in anti-beta2-gpI antibody affinity^len#J Immunol
#161#2038-43#19980000#1998#20040400#v44n2a06.htm#0022-1767#J Immunol##
00574000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01800112810000600130012005300136030000600189031000200195032000400197014000700201
065000900208064000500217865000900222002001300231035001000244801000600254#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#c#391#30#article#99#30#^rND^sTin
cani^nA#^rND^sSpatola^nL#^rND^sCinquini^nM#et al#Anti-beta2-gp1 antibodies: clin
ical significance^len#Lupus#7#^s2#S107-9#19980000#1998#20040400#v44n2a06.htm#096
1-2033#Lupus##
00605000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01800113810000600131012008100137030001500218031000300233014000600236065000900242
064000500251865000900256002001300265035001000278801001500288#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#392#31#article#99#31#^rND^sArvieux^nJ#^rND
^sRegnault^nV#^rND^sHachulla^nE#et al#Heterogeneity and immunochemical propertie
s of anti-beta2-gpI autoantibodies^len#Thromb Haemost#80#393-8#19980000#1998#200
40400#v44n2a06.htm#0340-6245#Thromb Haemost##
00564000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01500112810000600127012007500133030001800208710000200226031000300228014000700231
065000900238064000500247865000900252002001300261#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#393#32#article#99#32#^rND^sSantiago^nM#^rND^sRocha^nMC
#^rND^sSouza^nS#et al#Anticorpos anti-beta2-gp1 em pacientes com lúpus eritemato
so sistêmico^lpt#Rev Bras Reumatol#2#40#285-90#20000000#2000#20040400#v44n2a06.h
tm##
00657000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01800114810000600132012013800138030001200276031000300288014000600291065000900297
064000500306865000900311002001300320035001000333801001200343#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#394#33#article#99#33#^rND^sTsutsumi^nA#^rN
D^sIchikawa^nK#^rND^sMatsuura^nE#et al#Heterogeneous behaviour of anti-beta2gp1 
antibodies on various commercially available enzyme imunnoassay plates coated wi
th beta2-gp1^len#J Rheumatol#27#391-6#20000000#2000#20040400#v44n2a06.htm#0315-1
62X#J Rheumatol##
00662000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100015000930100
01700108810000600125012014200131030001600273031000300289014000600292065000900298
064000500307865000900312002001300321035001000334801001600344#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#395#34#article#99#34#^rND^sLewis^nS#^rND^s
Keil^nLB#^rND^sBinder^nWL#et al#Standardized measurement of major immunoglobulin
 class (IgG, IgM,IgA) antibodies to beta2-gp I in patients with antiphospholipid
 syndrome^len#J Clin Lab Anal#12#293-7#19980000#1998#20040400#v44n2a06.htm#0887-
8013#J Clin Lab Anal##
00700000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01500112810000600127012017300133030001800306031000300324014000700327065000900334
064000500343865000900348002001300357035001000370801001800380#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#396#35#article#99#35#^rND^sCucnik^nS#^rND^
sAmbrozic^nA#^rND^sBozic^nB#et al#Anti-beta2-gpI ELISA: methodology, determinati
on of cut-off values in 434 healthy Caucasians and evaluation of monoclonal anti
bodies as possible international standards^len#Clin Chem Lab Med#38#777-83#20000
000#2000#20040400#v44n2a06.htm#1434-6621#Clin Chem Lab Med##
00702000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01600114810000600130012017500136030001600311031000300327014000800330065000900338
064000500347865000900352002001300361035001000374801001600384#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#397#36#article#99#36#^rND^sIchikawa^nK#^rN
D^sTsutsumi^nA#^rND^sAtsumi^nT#et al#A chimeric antibody with the human gamma 1 
constant region as a putative standard for assay to detect IgG beta2-gpI-depende
nt anticardiolipin and anti-beta2gpI antibodies^len#Arthritis Rheum#42#2461-70#1
9990000#1999#20040400#v44n2a06.htm#0004-3591#Arthritis rheum##
00639000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100020000960100
01500116012013000131030001600261031000300277014000700280065000900287064000500296
865000900301002001300310035001000323801001600333#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#398#37#article#99#37#^rND^sRoubey^nRAS#^rND^sMaldonado
^nMA#^rND^sByrd^nSN#Comparison of an enzyme-linked immunosorbent assay for antib
odies to beta2-gpI and a conventional anticardiolipin immunoassay^len#Arthritis 
Rheum#39#1606-7#19960000#1996#20040400#v44n2a06.htm#0004-3591#Arthritis rheum##
00718000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01700112810000600129012019500135030001500330031000300345014000700348065000900355
064000500364865000900369002001300378035001000391801001500401#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#399#38#article#99#38#^rND^sMcNally^nT#^rND
^sMackie^nIJ#^rND^sMachin^nSJ#et al#Increased levels of beta2gpI antigen and bet
a2-gpI binding antibodies are associated with a history of thromboembolic compli
cations in patients with SLE and primary antiphospholipid syndrome^len#Br J Rheu
matol#34#1031-6#19950000#1995#20040400#v44n2a06.htm#0263-7103#Br J Rheumatol##
00716000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100026000940100
01800120810000600138012019000144030001200334031000300346014000700349065000900356
064000500365865000900370002001300379035001000392801001200402#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#400#39#article#99#39#^rND^sBruce^nIN#^rND^
sClark-Soloninka^nCA#^rND^sSpitzer^nKA#et al#Prevalence of antibodies to beta2-g
pI in systemic lupus erythematosus and their association with antiphospholipid a
ntibody syndrome criteria: a single center study and literature review^len#J Rhe
umatol#27#2833-7#20000000#2000#20040400#v44n2a06.htm#0315-162X#J Rheumatol##
00571000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01800111810000600129012005100135030001400186031000300200014000600203065000900209
064000500218865000900223002001300232035001000245801001400255#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#401#40#article#99#40#^rND^sHelbert^nM#^rND
^sBodger^nS#^rND^sCavenagh^nJ#et al#Optimising testing for phospholipid antibodi
es^len#J Clin Pathol#54#693-8#20010000#2001#20040400#v44n2a06.htm#0021-9746#J Cl
in Pathol##
00567000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100017000990100
01700116810000600133012005900139030000600198031000200204014000700206065000900213
064000500222865000900227002001300236035001000249801000600259#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#402#41#article#99#41#^rND^sBalestrieri^nG#
^rND^sTincani^nA#^rND^sSpatola^nL#et al#Anti-beta2-gpI: a marker of antiphosphol
ipid syndrome?^len#Lupus#4#122-30#19950000#1995#20040400#v44n2a06.htm#0961-2033#
Lupus##
00524000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01700112012005000129030002000179710000200199031000300201014000600204065000900210
064000500219865000900224002001300233#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a06.htm#S#c#403#42#article#99#42#^rND^sArvieux^nJ#^rND^sRoussel^nB#^rND^sColom
b^nMG#Anticorps antiphospholipids et anti-beta2-gpI^len#Ann Biol Clin Paris#2#52
#381-5#19940000#1994#20040400#v44n2a06.htm##
00647000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100019000980100
01900117810000600136012011800142030001500260031000300275014000600278065000900284
064000500293865000900298002001300307035001000320801001500330#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#404#43#article#99#43#^rND^sTinahones^nFJ#^
rND^sCuadrado^nMJ#^rND^sKhamasta^nMA#et al#Lack of cross-reaction between antibo
dies to beta2-gp1 and oxidized LDL in patients with antiphospholipid sydrome^len
#Br J Rheumatol#37#746-9#19980000#1998#20040400#v44n2a06.htm#0263-7103#Br J Rheu
matol##
00621000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01800114810000600132012011700138030000600255031000200261032000400263065000900267
064000500276865000900281002001300290035001000303801000600313#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#405#44#article#99#44#^rND^sMatsuura^nE#^rN
D^sKatahira^nT#^rND^sIgarashi^nY#et al#Beta2-gpI bound to oxidatively modified l
ipoproteins could be targeted by anticardiolipin antibodies: [abstract]^len#Lupu
s#3#314#19940000#1994#20040400#v44n2a06.htm#0961-2033#Lupus##
00626000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940100
01900111810000600130012012100136030000600257031000200263014000700265065000900272
064000500281865000900286002001300295035001000308801000600318#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#406#45#article#99#45#^rND^sGeorge^nG#^rND^
sGilburd^nB#^rND^sLangewitz^nP#et al#Beta2-gpI containing immunocomplexes in lup
us patients: association with thrombocytopenia and lipoprotein (a) levels^len#Lu
pus#8#116-20#19990000#1999#20040400#v44n2a06.htm#0961-2033#Lupus##
00597000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
01500110012010900125030000900234031000300243014000600246065000900252064000500261
865000900266002001300275035001000288801000900298#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#407#46#article#99#46#^rND^sViard^nJP#^rND^sAmoura^nZ#^
rND^sBack^nJF#Association of anti-beta2-gp1 antibodies with lupus-type circulati
ng anticoagulant and thrombosis in SLE^len#Am J Med#93#181-6#19920000#1992#20040
400#v44n2a06.htm#0002-9343#Am J Med##
00676000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100020000990100
01600119810000600135012015300141030001200294031000300306014000700309065000900316
064000500325865000900330002001300339035001000352801001200362#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#408#47#article#99#47#^rND^sSanfilippo^nSS#
^rND^sKhamashta^nMA#^rND^sAtsumi^nT#et al#Antibodies to beta2gpI: a potential ma
rker for clinical features of antiphospholipid antibody syndrome in patients wit
h systemic lupus erythematosus^len#J Rheumatol#25#2131-4#19980000#1998#20040400#
v44n2a06.htm#0315-162X#J Rheumatol##
00670000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100015000940100
01900109810000600128012015300134030001200287031000300299014000800302065000900310
064000500319865000900324002001300333035001000346801001200356#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#409#48#article#99#48#^rND^sTubach^nF#^rND^
sHayem^nG#^rND^sMarchand^nJL#et al#IgG anti-beta2-gpI antibodies in adult patien
ts with systemic lupus erythematosus: prevalence and diagnostic value for the an
tiphospholipid syndrome^len#J Rheumatol#27#1437-43#20000000#2000#20040400#v44n2a
06.htm#0315-162X#J Rheumatol##
00655000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100017000990100
01800116810000600134012014600140030000600286031000300292014000600295065000900301
064000500310865000900315002001300324035001000337801000600347#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#410#49#article#99#49#^rND^sShrivastava^nA#
^rND^sDwivedi^nS#^rND^sAggarwal^nA#et al#Anticardiolipin and anti-beta2-gpI anti
bodies in Indian patients with systemic lupus erythematosus: association with th
e presence of seizures^len#Lupus#10#45-50#20010000#2001#20040400#v44n2a06.htm#09
61-2033#Lupus##
00632000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100021000950100
01600116810000600132012012500138030000600263031000300269014000600272065000900278
064000500287865000900292002001300301035001000314801000600324#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#411#50#article#99#50#^rND^sAguirre^nV#^rND
^sCuchacovich^nR#^rND^sBarria^nL#et al#Prevalence and isotype distribution of an
tiphospholipid antibodies in Chilean patients with systemic lupus erythematosus^
len#Lupus#10#75-80#20010000#2001#20040400#v44n2a06.htm#0961-2033#Lupus##
00696000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
02000110810000600130012017100136030001500307031000300322014000800325065000900333
064000500342865000900347002001300356035001000369801001500379#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#412#51#article#99#51#^rND^sInanc^nM#^rND^s
Donohoe^nS#^rND^sRavirajan^nCT#et al#Anti-beta2-gpI, antiprothrombin and anticar
diolipin antibodies in a longitudinal study of patients with systemic lupus eryt
hematosus and the antiphospholipid syndrome^len#Br J Rheumatol#37#1089-94#199800
00#1998#20040400#v44n2a06.htm#0263-7103#Br J Rheumatol##
00751000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100018000990100
01700117810000600134012021700140030001800357031000300375014000700378065000900385
064000500394865000900399002001300408035001000421801001800431#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#413#52#article#99#52#^rND^sSebastiani^nGD#
^rND^sGaleazzi^nM#^rND^sTincani^nA#et al#Anticardiolipin and anti-beta2-gpI anti
bodies in a large series of European patients with systemic lupus erythematosus:
 Prevalence and clinical associations. European Concerned Action on the Immunoge
netics of SLE^len#Scand J Rheumatol#28#344-51#19990000#1999#20040400#v44n2a06.ht
m#0300-9742#Scand J Rheumatol##
00609000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960100
01600115810000600131012014100137030000600278031000200284014000700286865000900293
002001300302035001000315801000600325#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a06.htm#S#c#414#53#article#99#53#^rND^sCucurull^nE#^rND^sEspinoza^nLR#^rND^sMe
ndez^nE#et al#Anticardiolipin and antibeta2-gpI antibodies in patients with syst
emic lupus erythematosus: comparisons between Colombians and Spaniards^len#Lupus
#8#134-41#20040400#v44n2a06.htm#0961-2033#Lupus##
00623000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100016001010100
01800117810000600135012010500141030000900246031000400255014000700259065000900266
064000500275865000900280002001300289035001000302801000900312#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#415#54#article#99#54#^rND^sGomez-Pacheco^n
L#^rND^sVilla^nAR#^rND^sDrenkard^nC#et al#Serum anti-beta2gpI and anticardiolipi
n antibodies during thrombosis in systemic lupus erythematosus^len#Am J Med#106#
417-23#19990000#1999#20040400#v44n2a06.htm#0002-9343#Am J Med##
00593000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01800114810000600132012007500138030001200213031000300225014000500228065000900233
064000500242865000900247002001300256035001000269801001200279#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#416#55#article#99#55#^rND^sTsutsumi^nA#^rN
D^sMatsuura^nE#^rND^sIchikawa^nK#et al#IgA class anti-beta2-gpI in patients with
 systemic lupus erythematosus^len#J Rheumatol#25#74-8#19980000#1998#20040400#v44
n2a06.htm#0315-162X#J Rheumatol##
00631000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01800114810000600132012010200138030001600240031000300256014000800259065000900267
064000500276865000900281002001300290035001000303801001600313#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#417#56#article#99#56#^rND^sTsutsumi^nA#^rN
D^sMatsuura^nE#^rND^sIchikawa^nK#et al#Antibodies to beta2-gpI and clinical mani
festations in patients with systemic lupus erythematosus^len#Arthritis Rheum#39#
1466-74#19960000#1996#20040400#v44n2a06.htm#0004-3591#Arthritis rheum##
00664000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100016001010100
02800117810000600145012013000151030001200281031000300293014000800296065000900304
064000500313865000900318002001300327035001000340801001200350#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#418#57#article#99#57#^rND^sBertolaccini^nM
L#^rND^sAtsumi^nT#^rND^sEscudero-Contreras^nA#et al#The value of IgA antiphospho
lipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lu
pus erythematosus^len#J Rheumatol#28#2637-43#20010000#2001#20040400#v44n2a06.htm
#0315-162X#J Rheumatol##
00655000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01400114810000600128012013700134030001300271031000400284014000600288065000900294
064000500303865000900308002001300317035001000330801001300340#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#419#58#article#99#58#^rND^sCucurull^nE#^rN
D^sGharavi^nAE#^rND^sDiri^nE#et al#IgA anticardiolipin and antibeta2-gpI are the
 most prevalent isotypes in African American patients with systemic lupus erythe
matosus^len#Am J Med Sci#318#55-60#19990000#1999#20040400#v44n2a06.htm#0002-9629
#Am J Med Sci##
00624000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100014000920100
01400106810000600120012011700126030001200243031000300255014000600258065000900264
064000500273865000900278002001300287035001000300801001200310#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#420#59#article#99#59#^rND^sLee^nSS#^rND^sC
ho^nML#^rND^sJoo^nYS#et al#Isotypes of anti-beta2-gpI antibodies: association wi
th thrombosis in patients with systemic lupus erythematosus^len#J Rheumatol#28#5
20-4#20010000#2001#20040400#v44n2a06.htm#0315-162X#J Rheumatol##
00626000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100014000930100
01700107810000600124012010400130030001700234031000400251014000600255065000900261
064000500270865000900275002001300284035001000297801001700307#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#421#60#article#99#60#^rND^sLakos^nG#^rND^s
Kiss^nE#^rND^sRegeczy^nN#et al#Isotype distribution and clinical relevance of an
ti-beta2-gpI antibodies: importance of IgA isotype^len#Clin Exp Immunol#117#547-
9#19990000#1999#20040400#v44n2a06.htm#0009-9104#Clin Exp Immunol##
00605000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100013000780100020000910100
01700111810000600128012010300134030000600237031000200243014000600245065000900251
064000500260865000900265002001300274035001000287801000600297#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#422#61#article#99#61#^rND^sDetkov#^rND^sGi
l-Aguado^nA#^rND^sLavilla^nP#et al#Do antibodies to beta2-gpI contribute to bett
er characterization of the antiphospholipid syndrome?^len#Lupus#8#430-8#19990000
#1999#20040400#v44n2a06.htm#0961-2033#Lupus##
00603000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100020000990100
01500119810000600134012009700140030000400237031000300241014000700244065000900251
064000500260865000900265002001300274035001000287801000400297#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#423#62#article#99#62#^rND^sTektonidou^nMG#
^rND^sIoannidis^nJP#^rND^sBoki^nKA#et al#Prognostic factors and clustering of se
rious clinical outcomes in antiphospholipid syndromes^len#QJM#93#523-30#20000000
#2000#20040400#v44n2a06.htm#0033-5622#QJM##
00802000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01500110810000600125012024800131030003300379031000300412014000600415065000900421
064000500430865000900435002001300444035001000457801003300467#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#424#63#article#99#63#^rND^sFaden^nD#^rND^s
Tincani^nA#^rND^sTanzi^nP#et al#Anti-beta2-gpI antibodies in a general obstetric
 population: preliminary results on the prevalence and correlation with pregnanc
y outcome. Anti-beta2-gpI antibodies are associated with some obstetric complica
tions, mainly preeclampsiaeclampsia^len#Eur J Obstet Gynecol Reprod Biol#73#37-4
2#19970000#1997#20040400#v44n2a06.htm#0301-2115#Eur J Obstet Gynecol Reprod Biol
##
00598000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100017000970100
01700114012009400131030001400225031000300239014000600242065000900248064000500257
865000900262002001300271035001000284801001400294#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#425#64#article#99#64#^rND^sFranklin^nRD#^rND^sHollier^
nN#^rND^sKutteh^nWH#Beta2-gpI as a marker of antiphospholipid syndrome in women 
with recurrent pregnancy loss^len#Fertil Steril#73#531-5#20000000#2000#20040400#
v44n2a06.htm#0015-0282#Fertil Steril##
00681000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100015000930100
01800108810000600126012019700132030001400329710000200343031000300345014000700348
065000900355064000500364865000900369002001300378#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#426#65#article#99#65#^rND^sGris^nJC#^rND^sQuere^nI#^rN
D^sSanmarco^nM#et al#Antiphospholipid and antiprotein syndromes in non-thromboti
c, non-autoimmune women with unexplained recurrent primary early foetal loss: Th
e Nimes Obstetricians and Haematologists Study - NOHA^len#Thromb Haemos#2#84#228
-36#20000000#2000#20040400#v44n2a06.htm##
00656000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100015000930100
01500108810000600123012014000129030001500269031000300284014000600287065000900293
064000500302865000900307002001300316035001000329801001500339#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#427#66#article#99#66#^rND^sLynch^nA#^rND^s
Byers^nT#^rND^sEmlen^nW#et al#Association of antibodies to beta2gpI with pregnan
cy loss and pregnancy-induced hypertension: a prospective study in low-risk preg
nancy^len#Obstet Gynecol#93#193-8#19990000#1999#20040400#v44n2a06.htm#0029-7844#
Obstet Gynecol##
00654000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100017000920100
01700109012014100126030002000267031000400287014000700291065000900298064000500307
865000900312002001300321035001000334801002000344#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#428#67#article#99#67#^rND^sLee^nRM#^rND^sBranch^nDW#^r
ND^sSilver^nRM#Immunoglobulin A anti-beta2gpI antibodies in women who experience
 unexplained recurrent spontaneous abortion and unexplained fetal death^len#Am J
 Obstet Gynecol#185#748-53#20010000#2001#20040400#v44n2a06.htm#0002-9378#Am J Ob
stet Gynecol##
00658000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100015000920100
01600107810000600123012013100129030002000260031000400280014000600284065000900290
064000500299865000900304002001300313035001000326801002000336#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#429#68#article#99#68#^rND^sLee^nRM#^rND^sE
mlen^nE#^rND^sScott^nJR#et al#Anti-beta2-gpI antibodies in women with recurrent 
spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome^len
#Am J Obstet Gynecol#181#642-8#19990000#1999#20040400#v44n2a06.htm#0002-9378#Am 
J Obstet Gynecol##
00650000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100018000930100
01800111810000600129012013500135030001100270031000300281014000700284065000900291
064000500300865000900305002001300314035001000327801001100337#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#430#69#article#99#69#^rND^sZanon^nE#^rND^s
Prandoni^nP#^rND^sVianello^nF#et al#Anti-beta2-gpI antibodies in patients with a
cute venous thromboembolism: prevalence and association with recurrent thromboem
bolism^len#Thromb Res#96#269-74#19990000#1999#20040400#v44n2a06.htm#0049-3848#Th
romb Res##
00591000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100015000940100
01600109810000600125012008600131030000800217031000300225014000700228065000900235
064000500244865000900249002001300258035001000271801000800281#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#431#70#article#99#70#^rND^sSands^nJJ#^rND^
sNudo^nAS#^rND^sMoore^nKD#et al#Antibodies to prothrombin, factor V, and beta2-g
pI and vascular access thrombosis^len#ASAIO J#47#507-10#20010000#2001#20040400#v
44n2a06.htm#0162-1432#ASAIO J##
00675000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100015000990100
02100114810000600135012015200141030001200293031000300305014000700308065000900315
064000500324865000900329002001300338035001000351801001200361#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#432#71#article#99#71#^rND^sMartinuzzo^nME#
^rND^sPombo^nG#^rND^sForastiero^nRR#et al#Lupus anticoagulant, high levels of an
ticardiolipin and anti-beta2-gpI antibodies are associated with chronic thromboe
mbolic pulmonary hypertension^len#J Rheumatol#25#1313-9#19980000#1998#20040400#v
44n2a06.htm#0315-162X#J Rheumatol##
00622000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940100
01600111810000600127012010000133030001500233062000300248014000800251065000900259
064000500268865000900273002001300282035001000295801001500305#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#433#72#article#99#72#^rND^sLiozon^nE#^rND^
sRoussel^nV#^rND^sRoblot^nP#et al#Absence of anti-beta2-gpI antibodies in giant 
cell arteritis: a study of 45 biopsy-proven cases^len#Br J Rheumatol#37#1129-31#
19980000#1998#20040400#v44n2a06.htm#0263-7103#Br J Rheumatol##
00627000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100018001010100
02500119810000600144012009400150030001200244031000300256014000800259065000900267
064000500276865000900281002001300290035001000303801001200313#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#434#73#article#99#73#^rND^sKoutroubakis^nI
E#^rND^sPetinaki^nE#^rND^sAnagnostopoulou^nE#et al#Anticardiolipin and anti-beta
2-gpI antibodies in patients with inflammatory bowel disease^len#Dig Dis Sci#43#
2507-12#19980000#1998#20040400#v44n2a06.htm#0163-2116#Dig Dis Sci##
00585000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100014000930100
01400107810000600121012006700127030001700194031000300211014000600214065000900220
064000500229865000900234002001300243035001000256801001700266#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#435#74#article#99#74#^rND^sKang^nHJ#^rND^s
Lee^nYW#^rND^sHan^nSH#et al#Anticardiolipin and anti-beta2gpI antibodies in Behç
et disease^len#J Korean Med Sci#13#400-4#19980000#1998#20040400#v44n2a06.htm#101
1-8934#J Korean Med Sci##
00671000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950100
01700110810000600127012015300133030001400286031000300300014000600303065000900309
064000500318865000900323002001300332035001000345801001400355#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#436#75#article#99#75#^rND^sMcNally^nT#^rND
^sPurdy^nG#^rND^sMackie^nIJ#et al#The use of an anti-beta2-gpI assay for discrim
ination between anticardiolipin antibodies associated with infection and increas
ed risk for thrombosis^len#Br J Haematol#91#471-3#19950000#1995#20040400#v44n2a0
6.htm#0007-1048#Br J Haematol##
00622000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100020000970100
01200117810000600129012009100135030001900226031000300245014000700248065000900255
064000500264865000900269002001300278035001000291801001900301#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#437#76#article#99#76#^rND^sSantiago^nMB#^r
ND^sMartinelli^nR#^rND^sKo^nA#et al#Anti-beta2-gpI and anticardiolipin antibodie
s in leptospirosis, syphilis and kala-azar^len#Clin Exp Rheumatol#19#425-30#2001
0000#2001#20040400#v44n2a06.htm#0392-856X#Clin Exp Rheumatol##
00615000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100021001010100
02100122810000600143012009600149030000600245031000200251014000800253065000900261
064000500270865000900275002001300284035001000297801000600307#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#438#77#article#99#77#^rND^sDe Larranaga^nG
F#^rND^sForastiero^nRR#^rND^sMartinuzzo^nME#et al#High prevalence of antiphospho
lipid antibodies in leprosy: evaluation of antigen reactivity^len#Lupus#9#594-60
0#20000000#2000#20040400#v44n2a06.htm#0961-2033#Lupus##
00674000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100021000980100
02900119810000600148012013700154030001200291031000300303014000800306065000900314
064000500323865000900328002001300337035001000350801001200360#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#439#78#article#99#78#^rND^sIoannidis^nJP#^
rND^sTektonidou^nMG#^rND^sVlachoyiannopoulos^nPG#et al#HLA associations of anti-
beta2-gpI response in a Greek cohort with antiphospholipid syndrome and meta-ana
lysis of four ethnic groups^len#Hum Immunol#60#1274-80#19990000#1999#20040400#v4
4n2a06.htm#0198-8859#Hum Immunol##
00668000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100021000960100
01700117810000600134012016000140030000600300031000200306014000600308065000900314
064000500323865000900328002001300337035001000350801000600360#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#440#79#article#99#79#^rND^sGaleazzi^nM#^rN
D^sSebastiani^nGD#^rND^sTincani^nA#et al#HLA class II alleles associations of an
ticardiolipin and anti-beta2-gpI antibodies in a large series of European patien
ts with systemic lupus erythematosus^len#Lupus#9#47-55#20000000#2000#20040400#v4
4n2a06.htm#0961-2033#Lupus##
00604000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100021000950100
01300116810000600129012007900135030001600214031000300230014000700233065000900240
064000500249865000900254002001300263035001000276801001600286#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#441#80#article#99#80#^rND^sArnett^nFC#^rND
^sThiagarajan^nP#^rND^sAhn^nC#et al#Associations of anti-beta2gpI with class II 
alleles in three ethnic groups^len#Arthritis Rheum#42#268-74#19990000#1999#20040
400#v44n2a06.htm#0004-3591#Arthritis rheum##
00507000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100012000920120
04300104030001300147031000300160014000700163065000900170064000500179865000900184
002001300193035001000206801001300216#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a06.htm#S#c#442#81#article#99#81#^rND^sWick^nG#^rND^sXu^nQ#Atherosclerosis: an
 autoimmune disease^len#Exp Gerontol#34#559-66#19990000#1999#20040400#v44n2a06.h
tm#0531-5565#Exp Gerontol##
00486000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780120045000920300
01300137031000400150014000700154065000900161064000500170865000900175002001300184
035001000197801001300207#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#
c#443#82#article#99#82#^rND^sRoss^nR#Atherosclerosis: an inflammatory disease^le
n#N Engl J Med#340#115-26#19990000#1999#20040400#v44n2a06.htm#0028-4793#N Engl J
 Med##
00700000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01600113810000600129012017800135030001500313031000300328014000600331065000900337
064000500346865000900351002001300360035001000373801001500383#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#444#83#article#99#83#^rND^sRomero^nFI#^rND
^sAmengual^nO#^rND^sAtsumi^nT#et al#Arterial disease in lupus and secondary anti
phospholipid syndrome: association with antibeta2-gpI antibodies but not with an
tibodies against oxidized low-density lipoprotein^len#Br J Rheumatol#37#883-8#19
980000#1998#20040400#v44n2a06.htm#0263-7103#Br J Rheumatol##
00610000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
02000112810000600132012008500138030001500223031000300238014000600241065000900247
064000500256865000900261002001300270035001000283801001500293#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#445#84#article#99#84#^rND^sAmengual^nO#^rN
D^sAtsumi^nK#^rND^sKhamashta^nMA#et al#Antibodies against oxidized low-density l
ipoprotein in antiphospholipid syndrome^len#Br J Rheumatol#36#964-8#19970000#199
7#20040400#v44n2a06.htm#0263-7103#Br J Rheumatol##
00625000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
02000111810000600131012009700137030001600234031000300250014000800253065000900261
064000500270865000900275002001300284035001000297801001600307#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#446#85#article#99#85#^rND^sRomero^nFI#^rND
^sAtsumi^nT#^rND^sTinahones^nFJ#et al#Autoantibodies against malondialdehyde-mod
ified lipoprotein (a) in antiphospholipid syndrome^len#Arthritis Rheum#42#2606-1
1#19990000#1999#20040400#v44n2a06.htm#0004-3591#Arthritis rheum##
00650000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
01700110810000600127012013400133030001200267031000300279014000800282065000900290
064000500299865000900304002001300313035001000326801001200336#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#447#86#article#99#86#^rND^sGeorge^nJ#^rND^
sHarats^nD#^rND^sGilburd^nB#et al#Immunolocalization of beta2gpI (apolipoprotein
 H) to human atherosclerotic plaques: potential implications for lesion progress
ion^len#Circulation#99#2227-30#19990000#1999#20040400#v44n2a06.htm#0009-7322#Cir
culation##
00609000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100014000940100
01700108810000600125012009500131030001200226031000300238014000800241065000900249
064000500258865000900263002001300272035001000285801001200295#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#448#87#article#99#87#^rND^sGeorge^nJ#^rND^
sAfek^nA#^rND^sGilburd^nB#et al#Induction of early atherosclerosis in LDL-recept
or-deficient mice immunized with beta2-gpI^len#Circulation#98#1108-15#19980000#1
998#20040400#v44n2a06.htm#0009-7322#Circulation##
00604000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100016000920100
01900108810000600127012008800133030001300221031000300234014000600237065000900243
064000500252865000900257002001300266035001000279801001300289#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#449#88#article#99#88#^rND^sAfek^nA#^rND^sG
eorge^nJ#^rND^sShoenfeld^nY#et al#Enhancement of atherosclerosis in beta2-gpI-im
munized apoliprotein E-deficient mice^len#Pathobiology#67#19-25#19990000#1999#20
040400#v44n2a06.htm#1015-2008#Pathobiology##
00488000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120058000940300
00600152032000500158014000700163065000900170064000500179865000900184002001300193
035001000206801000600216#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#
c#450#89#article#99#89#^rND^sO'Vaarala#Antiphospholipid antibodies and myocardia
l infarction^len#Lupus#^sS2#132-34#19980000#1998#20040400#v44n2a06.htm#0961-2033
#Lupus##
00606000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100023000930100
01400116810000600130012008800136030001300224031000300237014000500240065000900245
064000500254865000900259002001300268035001000281801001300291#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#451#90#article#99#90#^rND^sFarsi^nA#^rND^s
Domeneghetti^nMP#^rND^sFedi^nS#et al#High prevalence of antibeta2-gpI antibodies
 in patients with ischemic heart disease^len#Autoimmunity#30#93-8#19990000#1999#
20040400#v44n2a06.htm#0891-6934#Autoimmunity##
00667000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
01600110810000600126012015200132030001300284031000300297014000600300065000900306
064000500315865000900320002001300329035001000342801001300352#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#452#91#article#99#91#^rND^sGeorge^nJ#^rND^
sHarats^nD#^rND^sBakshi^nE#et al#Anti-oxidized low density lipoprotein antibody 
determination as a predictor of reestenosis following percutaneous transluminal 
coronary angioplasty^len#Immunol Lett#68#263-6#19990000#1999#20040400#v44n2a06.h
tm#0165-2478#Immunol Lett##
00656000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01400112010001600126010001400142012013600156030001400292710000200306031000300308
014000700311065000900318064000500327865000900332002001300341#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#453#92#article#99#92#^rND^sLimaye^nV#^rND^
sBeltrame^nJ#^rND^sCook^nR#^rND^sGillis^nD#^rND^sPile^nK#Evaluation of antibodie
s to b2-glycoprotein 1 in the causation of coronary atherosclerosis as part of t
he antiphospholipid syndrome^len#Aust NZ J Med#2#29#789-93#19990000#1999#2004040
0#v44n2a06.htm##
00653000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01400110010001600124010001500140012011300155030000700268031000300275014000800278
065000900286064000500295865000900300002001300309035001000322801000700332#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#c#454#93#article#99#93#^rND^sBre
y^nRL#^rND^sAbbott^nRD#^rND^sCurb^nD#^rND^sSharp^nDS#^rND^sRoss^nGW#b2-glycoprot
ein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myoca
rdial infarction^len#Stroke#32#1701-06#20010000#2001#20040400#v44n2a06.htm#0039-
2499#Stroke##
00677000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
01700113010001900130010002100149010001600170012008800186030001700274065000900291
064000500300061000900305865000900314002001300323035001000336801001700346#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a06.htm#S#c#455#94#article#99#94#^rND^sRan
zolin^nA#^rND^sNorman^nGL#^rND^sManenti^nE#^rND^sBodanese^nLC#^rND^sVon Mühlen^n
CA#^rND^sStaub^nHL#Antibodies to beta2-glycooprotein I as risk factors for acute
 myocardial infarction^len#Arq Bras Cardiol#20030000#2003#In press#20040400#v44n
2a06.htm#0066-782X#Arq Bras Cardiol##
00645000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100019000950100
02000114810000600134012012400140030001200264031000300276014000600279065000900285
064000500294865000900299002001300308035001000321801001200331#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#456#95#article#99#95#^rND^sCaronti^nB#^rND
^sCalderaro^nC#^rND^sAlessandri^nC#et al#Serum anti-beta2-gpI antibodies from pa
tients with antiphospholipid antibody syndrome bind central nervous system cells
^len#J Autoimmun#11#425-9#19980000#1998#20040400#v44n2a06.htm#0896-8411#J Autoim
mun##
00634000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100019000950100
01400114810000600128012011400134030001400248031000400262014000600266065000900272
064000500281865000900286002001300295035001000308801001400318#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#457#96#article#99#96#^rND^sZiporen^nL#^rND
^sShoenfeld^nY#^rND^sLevy^nY#et al#Neurological dysfunction and hyperactive beha
viour associated with antiphospholipid antibodies: a mouse model^len#J Clin Inve
st#100#613-9#19970000#1997#20040400#v44n2a06.htm#0021-9738#J Clin Invest##
00588000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100014000930120
12700107030001000234031000300244014000700247065000900254064000500263865000900268
002001300277035001000290801001000300#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a06.htm#S#c#458#97#article#99#97#^rND^sChen^nWH#^rND^sLiu^nJS#An unusual incre
ase of blood anti-beta2-gpI antibody but not antiphospholipid antibody in cerebr
al ischemia: a case report^len#Angiology#52#149-54#20010000#2001#20040400#v44n2a
06.htm#0003-3197#Angiology##
00622000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100015000960100
01500111810000600126012011400132030000900246031000400255014000600259065000900265
064000500274865000900279002001300288035001000301801000900311#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a06.htm#S#c#459#98#article#99#98#^rND^sHeinzlef^nO#^rN
D^sAbuaf^nN#^rND^sCohen^nA#et al#Recurrent stroke and vascular events in elderly
 patients with anticardiolipin antibodies: a prospective study^len#J Neurol#248#
373-9#20010000#2001#20040400#v44n2a06.htm#0340-5354#J Neurol##
00655000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940100
01800111810000600129012013700135030001900272065000900291064000500300061000900305
865000900314002001300323035001000336801001900346#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a06.htm#S#c#460#99#article#99#99#^rND^sStaub^nHL#^rND^sNorman^nGL#
^rND^sCrowther^nT#et al#Antibodies to the atherosclerotic plaque components beta
2-glycoprotein and heat-shock proteins as markers of acute cerebral ischemia^len
#Arq Neuropsiquiatr#20030000#2003#In press#20040400#v44n2a06.htm#0004-282X#Arq N
europsiquiatr##
00270000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00300097#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#o#1#1#text#1#201
10406#122103#v44n2a07.htm#53##
00791000000000397000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000700094158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016001200480
0162117000600210072000200216010003100218010003900249070009200288002001300380#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#h#2#1#text#1#oa#pt#br1.1#1#4
.0#ILUS#07#RBR030#nd#Rev. Bras. Reumatol.#44#2#20040400#^f150^l151#0482-5004#1#Ó
rtese de jeans para desvio ulnar dos dedos^lpt#other#5#^rND^1A01^nJohanna^sNoord
ehoek#^rND^1A01^nLuiz Fabio Machado^sBarbosa#Universidade Federal de Minas Gerai
s^iA01^1Departamento de Terapia Ocupacional da Escola de#v44n2a07.htm##
00798000000000397000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000700094158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016001200550
0162117000600217072000200223010003100225010003900256070009200295002001300387#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#f#3#1#text#1#oa#pt#br1.1#1#4
.0#ILUS#07#RBR030#nd#Rev. Bras. Reumatol.#44#2#20040400#^f150^l151#0482-5004#1#<
b>Órtese de jeans para desvio ulnar dos dedos</b>^lpt#other#5#^rND^1A01^nJohanna
^sNoordehoek#^rND^1A01^nLuiz Fabio Machado^sBarbosa#Universidade Federal de Mina
s Gerais^iA01^1Departamento de Terapia Ocupacional da Escola de#v44n2a07.htm##
00923000000000421000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100038000500104121000300109049000700112158000300119
03000200012203100030014203200020014506500090014701400110015603500100016712300020
01770120048001791170006002270720002002330100031002350100039002660700094003050020
01300399008008900412#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#l#4#
1#text#1#^mmar./abr.^a2004#oa#pt#br1.1#1#4.0#ilus#07#RBR030#nd#Rev. Bras. Reumat
ol#44#2#20040400#^f150^l151#0482-5004#1#Órtese de jeans para desvio ulnar dos de
dos^lpt#other#5#^rND^1A01^nJohanna^sNoordehoek#^rND^1A01^nLuiz Fabio Machado^sBa
rbosa#^iA01^1Universidade Federal de Minas Gerais^2Departamento de Terapia Ocupa
cional da Escola de#v44n2a07.htm#Internet^ihttp://www.scielo.br/scielo.php?scrip
t=sci_arttext&pid=S0482-50042004000200007##
00374000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704014600069002001300215#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#5#1#text#44#<p align="right"><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>PAUSA ENTRE CONSULTAS</b> 
BETWEEN APPOINTMENTS</font></p>     ^cY#v44n2a07.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#6#2#text#44#<p>&nbsp;</p>     ^cY#v44n
2a07.htm##
00368000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704014000069002001300209#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#7#3#text#44#<p><font size="4" face="Ve
rdana, Arial, Helvetica, sans-serif"><b>&Oacute;rtese de jeans para desvio ulnar
 dos dedos</b></font></p>     ^cY#v44n2a07.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#8#4#text#44#<p>&nbsp;</p>     ^cY#v44n
2a07.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#9#5#text#44#<p>&nbsp;</p>     ^cY#v44n
2a07.htm##
01889000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704166000070002001301730#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#10#6#text#44#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">A articula&ccedil;&atilde;o metacarpofalan
geana (MCF) &eacute; comumente afetada na artrite reumat&oacute;ide (AR), sendo 
sujeita a grande estresse durante movimentos constantes na fun&ccedil;&atilde;o 
di&aacute;ria, como ao abrir e fechar potes e torneiras e ao picar alimentos uti
lizando-se faca. Com a progress&atilde;o do processo reumat&oacute;ide, o equil&
iacute;brio muscular normal &eacute; perdido e as estruturas do sistema ligament
ar s&atilde;o atingidas, com conseq&uuml;ente desenvolvimento de deformidades ma
nifestadas por aumento do desvio ulnar. Uma vez ocorrido o desvio ulnar, as for&
ccedil;as deformantes, desencadeadas por press&otilde;es externas (manuseio de o
bjetos com movimentos na dire&ccedil;&atilde;o ulnar) e/ou internas (desequil&ia
cute;brio das estruturas articulares e musculares) acentuar&atilde;o a deformida
de. As press&otilde;es que contribuem para padr&otilde;es de deformidade devem s
er evitadas. A &oacute;rtese de desvio ulnar tem como objetivo pro-mover aumento
 da fun&ccedil;&atilde;o e neutralizar a tend&ecirc;ncia das articula&ccedil;&ot
ilde;es MCFs desviarem-se ulnarmente durante a preens&atilde;o, promovendo tamb&
eacute;m estabilidade articular ao compensar parcialmente a frouxid&atilde;o lig
amentar e capsular. A &oacute;rtese promove tracionamento dos dedos para seu ali
nhamento central e assim reduz o desvio ulnar. Em raz&atilde;o da rela&ccedil;&a
tilde;o entre o uso da m&atilde;o e o desenvolvimento dessa deformidade, a &oacu
te;rtese indicada deve ser utilizada durante as atividades di&aacute;rias<sup>(1
,2,3,4)</sup>. </font></p>     ^cY#v44n2a07.htm##
01223000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704099400070002001301064#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#11#7#text#44#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">Os materiais descritos na literatura como 
os mais utilizados atualmente na constru&ccedil;&atilde;o de &oacute;rteses s&at
ilde;o os termopl&aacute;sticos de baixa temperatura<sup>(5)</sup>. Este materia
l &eacute; utilizado nos atendimentos de terapia ocupacional realizados no ambul
at&oacute;rio Bias Fortes, do Hospital das Cl&iacute;nicas da Universidade Feder
al de Minas Gerais, em Belo Horizonte. No entanto, para o tratamento de desvio u
lnar, h&aacute; baixa ades&atilde;o ao aparelho confeccionado com este material,
 pois os pacientes o consideram "duro", inflex&iacute;vel a ponto de restringir 
os movimentos, e que "machuca ao fazer as coisas". A partir desta queixa, os pr&
oacute;prios pacientes, em conjunto com os terapeutas ocupacionais, desenvolvera
m uma &oacute;rtese constru&iacute;da com material alternativo (jeans), com a in
ten&ccedil;&atilde;o de melhorar a ades&atilde;o ao uso do aparelho. </font></p>
     ^cY#v44n2a07.htm##
01035000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704080600070002001300876#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#12#8#text#44#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">Atualmente, quatro pacientes utilizam diar
iamente a &oacute;rtese de jeans, principalmente durante a realiza&ccedil;&atild
e;o de suas atividades dom&eacute;sticas. Os pacientes relatam as vantagens da &
oacute;rtese confeccionada de material alternativo em compara&ccedil;&atilde;o c
om aquela anteriormente usada, comentando que "os movimentos ficam melhores", "o
 aparelho d&aacute; mais firmeza para fazer as coisas", "sinto a m&atilde;o no l
ugar", "o alinhamento dos dedos alivia a dor", "a m&atilde;o chega no lugar". Qu
anto ao material (jeans), os pacientes relatam que "&eacute; &oacute;timo", &eac
ute; lav&aacute;vel, n&atilde;o esquenta muito e permite liberdade de movimentos
, sendo esta vantagem a mais importante. </font></p>     ^cY#v44n2a07.htm##
00829000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704060000070002001300670#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#13#9#text#44#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif">Ao colocar as articula&ccedil;&otilde;es e
m posi&ccedil;&otilde;es adequadas, as &oacute;rteses podem permitir que as m&at
ilde;os consigam movimenta&ccedil;&atilde;o funcional de maneira mais efetiva<su
p>(5)</sup>. A sele&ccedil;&atilde;o dos materiais deve incorporar as prefer&eci
rc;ncias individuais como fator cr&iacute;tico na busca dos objetivos cl&iacute;
nicos<sup>(3)</sup>. P&ocirc;de-se verificar a import&acirc;ncia da participa&cc
edil;&atilde;o do paciente no processo de desenvolvimento da &oacute;rtese.</fon
t></p>     ^cY#v44n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#14#10#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#15#11#text#44#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a07fig01.jpg"></p>     ^cY#v44n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#16#12#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#17#13#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#18#14#text#44#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a07fig02.jpg"></p>     ^cY#v44n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#19#15#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#20#16#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#21#17#text#44#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a07fig03.jpg"></p>     ^cY#v44n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#22#18#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#23#19#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#24#20#text#44#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a07fig04.jpg"></p>     ^cY#v44n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#25#21#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#26#22#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#27#23#text#44#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a07fig05.jpg"></p>     ^cY#v44n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#28#24#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010700071002001300178#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#29#25#text#44#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>     ^
cY#v44n2a07.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704022100073002001300294#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#30#26#text#44#1#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">1. Feinberg JR, Trombly CA:
 Arthritis. In: Trombly CA: Occupational Therapy for physical disfunction. Balti
more: Williams &amp; Wilkins, 815-30, 1995.    ^cY#v44n2a07.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#31#27#text#44#</font></p>     ^cY#v44n
2a07.htm##
00403000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704015900073002001300232#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#32#28#text#44#2#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">2. Gilbert-Lenef L: Soft ul
nar deviation splint. Journal of hand therapy 7: 29-30, 1994.    ^cY#v44n2a07.ht
m##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#33#29#text#44#</font></p>     ^cY#v44n
2a07.htm##
00506000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704026200073002001300335#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#34#30#text#44#3#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">3. Hammond A: Rheumatoid ar
thritis. In: Turner, A. et al. Occupational therapy and physical dysfunction; pr
inciples, skills and practice. 4.a ed, New York: Churchill Livingstone, 760-2, 1
996.    ^cY#v44n2a07.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#35#31#text#44# </font></p>     ^cY#v44
n2a07.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704024000073002001300313#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#36#32#text#44#4#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">4. Swanson AB, Pierc TD, Le
onard J, Swanson GG: Orthoses for the Arthritic Hand and Wrist. In: Atlas of Ort
hoses and Assitive Devices. 3.a ed, Mosby, 320-1, 326-9, 1997.    ^cY#v44n2a07.h
tm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#37#33#text#44#</font></p>     ^cY#v44n
2a07.htm##
00522000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704027800073002001300351#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#38#34#text#44#5#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">5. Fess EE, Kiel JH: Imobil
iza&ccedil;&atilde;o do Membro Superior com Tala. In: Neistadt ME, Crepeau EB: W
illard &amp; Spackman - Terapia Ocupacional. 9.a ed, Rio de Janeiro, Guanabara K
oogan, cap 20, 2002.    ^cY#v44n2a07.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#39#35#text#44#</font></p>     ^cY#v44n
2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#40#36#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010300071002001300174#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#41#37#text#44#<p align="right"><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">JOHANNA NOORDEHOEK    ^cY#v
44n2a07.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004000071002001300111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#42#38#text#44#<br>  LUIZ FABIO MACHADO
 BARBOSA    ^cY#v44n2a07.htm##
00292000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704006200071002001300133#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#43#39#text#44#<br>  Departamento de Te
rapia Ocupacional da Escola de    ^cY#v44n2a07.htm##
00319000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704008900071002001300160#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#44#40#text#44#<br>  Educa&ccedil;&atil
de;o F&iacute;sica, Fisioterapia e Terapia Ocupacional da    ^cY#v44n2a07.htm##
00293000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704006300071002001300134#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#45#41#text#44#<br>  Universidade Feder
al de Minas Gerais </font></p>     ^cY#v44n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#46#42#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#47#43#text#44#<p>&nbsp;</p>     ^cY#v4
4n2a07.htm##
00343000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704011300071002001300184#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a07.htm#S#p#48#44#text#44#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Respons&aacute;vel: Saul Schaf</font></p>
     ^cY#v44n2a07.htm##
00540000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100019000710100018000900120
01400108016001800122018005000140066001000190062001900200014000700219065000900226
064000500235865000900240002001300249#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a07.htm#S#c#49#1#text#5#1#^rND^sFeinberg^nJR#^rND^sTrombly^nCA#Arthritis^len#^
rND^sTrombly^nCA#Occupational Therapy for physical disfunction^len#Baltimore#Wil
liams & Wilkins#815-30#19950000#1995#20040400#v44n2a07.htm##
00494000000000265000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100023000710120032000940300
02400126031000200150014000600152065000900158064000500167865000900172002001300181
035001000194801002400204#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a07.htm#S#
c#50#2#text#5#2#^rND^sGilbert-Lenef^nL#Soft ulnar deviation splint^len#Journal o
f hand therapy#7#29-30#19940000#1994#20040400#v44n2a07.htm#0894-1130#JOURNAL OF 
HAND THERAPY##
00583000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100017000710120025000880160
01600113810000600129018008300135063000200218066000900220062002200229014000600251
065000900257064000500266865000900271002001300280#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a07.htm#S#c#51#3#text#5#3#^rND^sHammond^nA#Rheumatoid arthritis^le
n#^rND^sTurner^nA#et al#Occupational therapy and physical dysfunction; principle
s, skills and practice^len#4#New York#Churchill Livingstone#760-2#19960000#1996#
20040400#v44n2a07.htm##
00576000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100018000710100016000890100
01700105010001800122012004600140018004300186063000200229062000600231014001300237
065000900250064000500259865000900264002001300273#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a07.htm#S#c#52#4#text#5#4#^rND^sSwanson^nAB#^rND^sPierc^nTD#^rND^s
Leonard^nJ#^rND^sSwanson^nGG#Orthoses for the Arthritic Hand and Wrist^len#Atlas
 of Orthoses and Assitive Devices^len#3#Mosby#320-1, 326-9#19970000#1997#2004040
0#v44n2a07.htm##
00606000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100015000710100015000860120
04500101016001900146016001800165018004400183063000200227066001500229062001700244
061000700261065000900268064000500277865000900282002001300291#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a07.htm#S#c#53#5#text#5#5#^rND^sFess^nEE#^rND^sKiel^nJ
H#Imobilização do Membro Superior com Tala^lpt#^rND^sNeistadt^nME#^rND^sCrepeau^
nEB#Willard & Spackman: Terapia Ocupacional^len#9#Rio de Janeiro#Guanabara Kooga
n#cap 20#20020000#2002#20040400#v44n2a07.htm##
00271000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00400097#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a08.htm#S#o#1#1#text#1#201
10406#085705#v44n2a08.htm#166##
00549000000000337000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030002100102
03100030012303200020012606500090012801400110013703500100014812300020015801200380
0160002001300198#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a08.htm#S#h#2#1#te
xt#1#oa#pt#br1.1#1#4.0#ND#08#RBR030#nd#Rev. Bras. Reumatol.#44#2#20040400#^f152^
l154#0482-5004#1#Prova para título de especialista^lpt#v44n2a08.htm##
00556000000000337000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030002100102
03100030012303200020012606500090012801400110013703500100014812300020015801200450
0160002001300205#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a08.htm#S#f#3#1#te
xt#1#oa#pt#br1.1#1#4.0#ND#08#RBR030#nd#Rev. Bras. Reumatol.#44#2#20040400#^f152^
l154#0482-5004#1#<b>Prova para título de especialista</b>^lpt#v44n2a08.htm##
00664000000000349000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100121000300104049000700107158000300114030002000117
03100030013703200020014006500090014201400110015103500100016212300020017201200380
0174002001300212008008900225#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a08.ht
m#S#l#4#1#text#1#^mmar./abr.^a2004#oa#pt#br1.1#1#4.0#08#RBR030#nd#Rev. Bras. Reu
matol#44#2#20040400#^f152^l154#0482-5004#1#Prova para título de especialista^lpt
#v44n2a08.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S
0482-50042004000200008##
00375000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704014600070002001300216#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#5#1#text#162#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>PAUSA ENTRE CONSULTAS</b>
 BETWEEN APPOINTMENTS</font></p>     ^cY#v44n2a08.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#6#2#text#162#<p>&nbsp;</p>     ^cY#v44
n2a08.htm##
00418000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704018900070002001300259#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#7#3#text#162#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="linkinicio"></a><b>Prova para t&i
acute;tulo de especialista<a href="#link01"><sup>*</sup></a></b></font></p>     
^cY#v44n2a08.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#8#4#text#162#<p>&nbsp;</p>     ^cY#v44
n2a08.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000400066704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#9#5#text#162#<p>&nbsp;</p>     ^cY#v44
n2a08.htm##
00389000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704015900071002001300230#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#10#6#text#162#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>26.</b> Ombro almofadado ("shoulder pa
d") &eacute; bastante sugestivo de:</font></p>     ^cY#v44n2a08.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704012800071002001300199#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#11#7#text#162#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">a) Infiltra&ccedil;&atilde;o amil&oacute;
ide;</font></p>     ^cY#v44n2a08.htm##
00361000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704013100071002001300202#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#12#8#text#162#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"> b) Infiltra&ccedil;&atilde;o por hemossi
derina;</font></p>     ^cY#v44n2a08.htm##
00359000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000400067704012900071002001300200#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#13#9#text#162#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"> c) Infiltra&ccedil;&atilde;o lip&iacute;
dica;</font></p>     ^cY#v44n2a08.htm##
00362000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013100072002001300203#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#14#10#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> d) Infiltra&ccedil;&atilde;o ocron&oacu
te;tica;</font></p>     ^cY#v44n2a08.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704009600072002001300168#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#15#11#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Mixedema.</font></p>     ^cY#v44n2a0
8.htm##
00403000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704017200072002001300244#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#16#12#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>27.</b> Na S&iacute;ndrome do T&uacut
e;nel do Tarso, est&aacute; comprometido o nervo:</font></p>     ^cY#v44n2a08.ht
m##
00335000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010400072002001300176#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#17#13#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) Tibial posterior;</font></p>     ^cY
#v44n2a08.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010600072002001300178#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#18#14#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Peroneiro profundo;</font></p>     ^
cY#v44n2a08.htm##
00324000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704009300072002001300165#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#19#15#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) Sural;</font></p>     ^cY#v44n2a08.h
tm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010900072002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#20#16#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> d) Peroneiro superficial;</font></p>   
  ^cY#v44n2a08.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010300072002001300175#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#21#17#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Peroneal comum. </font></p>     ^cY#
v44n2a08.htm##
00535000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704030400072002001300376#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#22#18#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>28.</b> Dentre as S&iacute;ndromes Co
mpartimentais (a n&iacute;vel do punho), a compreens&atilde;o sobre o nervo Ulna
r n&atilde;o &eacute; comum, mas quando ocorre, o paciente habitualmente se quei
xa de Parestesia em: </font></p>     ^cY#v44n2a08.htm##
00349000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011800072002001300190#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#23#19#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">a) Face medial de antebra&ccedil;o;</fon
t></p>     ^cY#v44n2a08.htm##
00359000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012800072002001300200#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#24#20#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Na regi&atilde;o T&ecirc;nar e Hipot
enar;</font></p>     ^cY#v44n2a08.htm##
00354000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012300072002001300195#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#25#21#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) Apenas na regi&atilde;o t&ecirc;nar;
</font></p>     ^cY#v44n2a08.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012000072002001300192#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#26#22#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> d) Nos 1º e 2º Quirod&aacute;ctilos;</f
ont></p>     ^cY#v44n2a08.htm##
00364000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013300072002001300205#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#27#23#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) No 5º Quirod&aacute;ctilo e face med
ial do 4º.</font></p>     ^cY#v44n2a08.htm##
00394000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704016300072002001300235#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#28#24#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>29.</b> A maior press&atilde;o exerci
da na coluna lombar se d&aacute; quando:</font></p>     ^cY#v44n2a08.htm##
00362000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013100072002001300203#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#29#25#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) O indiv&iacute;duo encontra-se de p&
eacute;;</font></p>     ^cY#v44n2a08.htm##
00385000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704015400072002001300226#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#30#26#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) O indiv&iacute;duo encontra-se senta
do, recostado, levantando peso;</font></p>     ^cY#v44n2a08.htm##
00376000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014500072002001300217#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#31#27#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">c) O indiv&iacute;duo encontra-se em dec
&uacute;bito ventral; </font></p>     ^cY#v44n2a08.htm##
00436000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704020500072002001300277#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#32#28#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">d) O indiv&iacute;duo encontra-se em p&e
acute;, tentando tocar os p&eacute;s com as m&atilde;os, sem flexionar os joelho
s;</font></p>     ^cY#v44n2a08.htm##
00399000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704016800072002001300240#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#33#29#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) O indiv&iacute;duo encontra-se senta
do, com o tronco para frente levantando peso.</font></p>     ^cY#v44n2a08.htm##
00373000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014200072002001300214#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#34#30#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>30.</b> A marcha em Trendelemburg pod
e ser observada na:</font></p>     ^cY#v44n2a08.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011000072002001300182#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#35#31#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) Osteoartrite do joelho;</font></p>  
   ^cY#v44n2a08.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011700072002001300189#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#36#32#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Osteoartrite do tornozelo;    </font
></p>     ^cY#v44n2a08.htm##
00346000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011500072002001300187#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#37#33#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">c) Osteoartrite da coxofemural; </font><
/p>     ^cY#v44n2a08.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010800072002001300180#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#38#34#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">d) Osteoartrite do tarso;</font></p>    
 ^cY#v44n2a08.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704009900072002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#39#35#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Polimiosite.</font></p>     ^cY#v44n
2a08.htm##
00362000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013100072002001300203#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#40#36#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>31.</b> A s&iacute;ndrome de Tietze &
eacute;:</font></p>     ^cY#v44n2a08.htm##
00375000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014400072002001300216#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#41#37#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) Um condrossarcoma mal&iacute;gno das
 cartilagens costais;</font></p>     ^cY#v44n2a08.htm##
00361000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013000072002001300202#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#42#38#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) A pericardite da artrite reumat&oacu
te;ide;</font></p>     ^cY#v44n2a08.htm##
00399000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704016800072002001300240#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#43#39#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) Anomalias de condu&ccedil;&atilde;o 
card&iacute;aca na s&iacute;ndrome de Reiter;</font></p>     ^cY#v44n2a08.htm##
00400000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704016900072002001300241#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#44#40#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> d) Uma costocondrite benigna das articu
la&ccedil;&otilde;es costocondrais superiores;</font></p>     ^cY#v44n2a08.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010400072002001300176#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#45#41#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Bursite anserina.</font></p>     ^cY
#v44n2a08.htm##
00369000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013800072002001300210#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#46#42#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>32.</b> O micofenolato mofetil atua, 
principalmente:</font></p>     ^cY#v44n2a08.htm##
00360000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012900072002001300201#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#47#43#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) Inibindo a bioss&iacute;ntese das pu
rinas;</font></p>     ^cY#v44n2a08.htm##
00364000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013300072002001300205#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#48#44#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Inibindo a bioss&iacute;ntese das pi
rimidinas;</font></p>     ^cY#v44n2a08.htm##
00364000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013300072002001300205#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#49#45#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) Tornando an&eacute;rgico o linf&oacu
te;cito B;</font></p>     ^cY#v44n2a08.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011400072002001300186#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#50#46#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> d) Antagonizando a TNF-&#181;;</font></
p>     ^cY#v44n2a08.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010900072002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#51#47#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Inibindo a fagocitose.</font></p>   
  ^cY#v44n2a08.htm##
00366000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013500072002001300207#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#52#48#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>33.</b> Aconselha-se, junto com a cic
lofosfamida:</font></p>     ^cY#v44n2a08.htm##
00371000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014000072002001300212#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#53#49#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) Hidrata&ccedil;&atilde;o, antiem&eac
ute;ticos, MESNA;</font></p>     ^cY#v44n2a08.htm##
00376000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014500072002001300217#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#54#50#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Diur&eacute;ticos, analg&eacute;sico
s, cortic&oacute;ides;</font></p>     ^cY#v44n2a08.htm##
00380000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014900072002001300221#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#55#51#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) Betabloqueadores, antiinflamat&oacut
e;rios, diur&eacute;ticos;</font></p>     ^cY#v44n2a08.htm##
00399000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704016800072002001300240#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#56#52#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> d) Bloqueadores de canal de c&aacute;lc
io, diur&eacute;ticos e, antiem&eacute;ticos;</font></p>     ^cY#v44n2a08.htm##
00374000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014300072002001300215#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#57#53#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Ciclosporina, antimal&aacute;ricos e
 cortic&oacute;ides.</font></p>     ^cY#v44n2a08.htm##
00431000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704020000072002001300272#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#58#54#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>34.</b> A diminui&ccedil;&atilde;o do
 paladar (hipogeusia) &eacute; um efeito colateral comum em pacientes usando:</f
ont></p>     ^cY#v44n2a08.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010800072002001300180#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#59#55#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) Antimal&aacute;ricos;</font></p>    
 ^cY#v44n2a08.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704009800072002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#60#56#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Colchicina;</font></p>     ^cY#v44n2
a08.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010100072002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#61#57#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) Methotrexate; </font></p>     ^cY#v4
4n2a08.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010100072002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#62#58#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">d) D-Penicilamina;</font></p>     ^cY#v4
4n2a08.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010100072002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#63#59#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Indometacina. </font></p>     ^cY#v4
4n2a08.htm##
00381000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704015000072002001300222#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#64#60#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>35.</b> A dose equivalente, para 5 mg
 de prednisona &eacute; de:</font></p>     ^cY#v44n2a08.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012600072002001300198#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#65#61#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) 20 mg de HC; 4 mg de TC; 0,75 mg de 
DX;</font></p>     ^cY#v44n2a08.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012600072002001300198#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#66#62#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) 20 mg de HC; 10 mg de MP; 0,9 mg de 
DX;</font></p>     ^cY#v44n2a08.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012600072002001300198#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#67#63#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) 100 mg de MP; 1 mg de DX; 20 mg de B
M; </font></p>     ^cY#v44n2a08.htm##
00353000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012200072002001300194#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#68#64#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">d) 10 mg de HC; 4 mg de DX; 5 mg de BM;<
/font></p>     ^cY#v44n2a08.htm##
00354000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704012300072002001300195#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#69#65#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) 50 mg de HC, 4 mg de TC, 5 mg de BM 
</font></p>     ^cY#v44n2a08.htm##
00411000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704018000072002001300252#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#70#66#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">HC: Hidrocortisona; TC: Triancinolona; D
X: Dexametasona; BM: Betametasona; MP: Metilprednisolona.</font></p>     ^cY#v44
n2a08.htm##
00399000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704016800072002001300240#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#71#67#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>36.</b> A hiperplasia gengival &eacut
e; um efeito colateral relacionada ao uso de:</font></p>     ^cY#v44n2a08.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010800072002001300180#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#72#68#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) Micofenolato mofetil;</font></p>    
 ^cY#v44n2a08.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704009800072002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#73#69#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Colchicina;</font></p>     ^cY#v44n2
a08.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010000072002001300172#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#74#70#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) Methotrexato;</font></p>     ^cY#v44
n2a08.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704009900072002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#75#71#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">d) Ciclosporina;</font></p>     ^cY#v44n
2a08.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010300072002001300175#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#76#72#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Ciclofosfamida. </font></p>     ^cY#
v44n2a08.htm##
00493000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704026200072002001300334#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#77#73#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>37.</b> Dentre os auto-anticorpos esp
ec&iacute;ficos para a esclerose sist&ecirc;mica, assinale aquele mais associado
 ao acometimento renal (crise renal esclerod&eacute;rmica):</font></p>     ^cY#v
44n2a08.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010900072002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#78#74#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">a) Anti-centr&ocirc;mero; </font></p>   
  ^cY#v44n2a08.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010800072002001300180#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#79#75#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">b) Anti-topoisomerase I; </font></p>    
 ^cY#v44n2a08.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010100072002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#80#76#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">c) Anti-Th To-RNP;</font></p>     ^cY#v4
4n2a08.htm##
00342000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011100072002001300183#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#81#77#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> d) Anti-RNA polimerase III;</font></p> 
    ^cY#v44n2a08.htm##
00336000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010500072002001300177#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#82#78#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Anti-fibrilarina. </font></p>     ^c
Y#v44n2a08.htm##
00635000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704040400072002001300476#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#83#79#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>38.</b> A tomografia computadorizada 
de alta resolu&ccedil;&atilde;o de t&oacute;rax tem auxiliado de maneira importa
nte no diagn&oacute;stico do acometimento pulmonar intersticial na esclerose sis
t&ecirc;mica. Assinale a altera&ccedil;&atilde;o tomogr&aacute;fica mais precoce
 associada ao acometimento intersticial: </font></p>     ^cY#v44n2a08.htm##
00346000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011500072002001300187#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#84#80#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">a) Padr&atilde;o c&iacute;stico;</font><
/p>     ^cY#v44n2a08.htm##
00349000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011800072002001300190#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#85#81#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Padr&atilde;o de "favo de mel";</fon
t></p>     ^cY#v44n2a08.htm##
00342000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011100072002001300183#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#86#82#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) Padr&atilde;o reticular;</font></p> 
    ^cY#v44n2a08.htm##
00349000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011800072002001300190#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#87#83#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> d) Padr&atilde;o de "vidro fosco";</fon
t></p>     ^cY#v44n2a08.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704011400072002001300186#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#88#84#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Padr&atilde;o bronquiolar. </font></
p>     ^cY#v44n2a08.htm##
00430000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704019900072002001300271#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#89#85#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>39.</b> Qual &eacute; a v&iacute;scer
a que mais comumente pode estar acometida nos casos de esclerodermia linear:</fo
nt></p>     ^cY#v44n2a08.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010100072002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#90#86#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> a) Es&ocirc;fago;</font></p>     ^cY#v4
4n2a08.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010900072002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#91#87#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Cora&ccedil;&atilde;o;</font></p>   
  ^cY#v44n2a08.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704010200072002001300174#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#92#88#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> c) Pulm&atilde;o; </font></p>     ^cY#v
44n2a08.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704009600072002001300168#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#93#89#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">d) Intestino;</font></p>     ^cY#v44n2a0
8.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704009200072002001300164#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#94#90#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> e) Rim. </font></p>     ^cY#v44n2a08.ht
m##
00499000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704026800072002001300340#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#95#91#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>40.</b> O prurido intenso que, acomet
e os pacientes com esclerose sist&ecirc;mica difusa na fase inicial de endurecim
ento r&aacute;pido e progressivo da pele, ocorre devido &agrave;:</font></p>    
 ^cY#v44n2a08.htm##
00400000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704016900072002001300241#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#96#92#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">a) Sele&ccedil;&atilde;o de clones de fi
broblastos superprodutores de col&aacute;geno;</font></p>     ^cY#v44n2a08.htm##
00372000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014100072002001300213#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#97#93#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> b) Aumento dos n&iacute;veis tissulares
 da endotelina I; </font></p>     ^cY#v44n2a08.htm##
00374000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704014300072002001300215#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#98#94#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">c) Degranula&ccedil;&atilde;o de mast&oa
cute;citos ativados;</font></p>     ^cY#v44n2a08.htm##
00364000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000400068704013300072002001300205#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#99#95#text#162#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"> d) Ativa&ccedil;&atilde;o plaquet&aacut
e;ria;    </font></p>     ^cY#v44n2a08.htm##
00380000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069704014800073002001300221#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#100#96#text#162#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">e) Produ&ccedil;&atilde;o de auto-antic
orpos espec&iacute;ficos. </font></p>     ^cY#v44n2a08.htm##
00606000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069704037400073002001300447#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#101#97#text#162#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><b>41.</b> Dentre as espondiloartropati
as soronegativas, assinale aquela que apresenta altera&ccedil;&otilde;es radiol&
oacute;gicas axiais sim&eacute;tricas, regulares e bilaterais, acometendo de man
eira homog&ecirc;nea todos os corpos vertebrais nas fases avan&ccedil;adas da do
en&ccedil;a:</font></p>     ^cY#v44n2a08.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069704011200073002001300185#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#102#98#text#162#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">a) Artrite psori&aacute;sica;</font></p
>     ^cY#v44n2a08.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000500064708000400069704011200073002001300185#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#103#99#text#162#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"> b) Espondilite anquilosante;</font></p
>     ^cY#v44n2a08.htm##
00346000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704011300074002001300187#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#104#100#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> c) S&iacute;ndrome de Reiter;</font><
/p>     ^cY#v44n2a08.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704011500074002001300189#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#105#101#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> d) Artrite enterop&aacute;tica;</font
></p>     ^cY#v44n2a08.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704012500074002001300199#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#106#102#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> e) Espondiloartropatias indiferenciad
as. </font></p>     ^cY#v44n2a08.htm##
00435000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704020200074002001300276#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#107#103#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>42.</b> Dentre as cinco formas cl&i
acute;nicas tradicionais da artrite psori&aacute;sica, assinale a mais frequente
:</font></p>     ^cY#v44n2a08.htm##
00354000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704012100074002001300195#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#108#104#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> a) Oligoarticular assim&eacute;trica;
</font></p>     ^cY#v44n2a08.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704011800074002001300192#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#109#105#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> b) Poliarticular sim&eacute;trica;</f
ont></p>     ^cY#v44n2a08.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704010400074002001300178#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#110#106#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> c) Cl&aacute;ssica; </font></p>     ^
cY#v44n2a08.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009600074002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#111#107#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">d) Mutilante;</font></p>     ^cY#v44n2
a08.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704010800074002001300182#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#112#108#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> e) Espondil&iacute;tica.</font></p>  
   ^cY#v44n2a08.htm##
00702000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704046900074002001300543#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#113#109#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>43.</b> Paciente de 75 anos, sexo m
asculino, com hist&oacute;ria de hipertens&atilde;o arterial e hiperuricemia, de
u entrada no prontoatendimento hospitalar com artrite de joelho esquerdo de 48 h
oras de evolu&ccedil;&atilde;o. Ao exame f&iacute;sico encontrava-se levemente p
rostrado, subfebril (37,8 ºC) e hemodinamicamente est&aacute;vel. A primeira con
duta a ser tomada &eacute;: </font></p>     ^cY#v44n2a08.htm##
00450000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704021700074002001300291#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#114#110#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">a) 	Solicitar hemograma e dosagem s&ea
cute;rica de &aacute;cido &uacute;rico com o objetivo de avaliar a necessidade d
e artrocentese; </font></p>     ^cY#v44n2a08.htm##
00396000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704016300074002001300237#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#115#111#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">b) Prescrever colchicina e antiinflama
t&oacute;rio n&atilde;o ester&oacute;ide; </font></p>     ^cY#v44n2a08.htm##
00376000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704014300074002001300217#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#116#112#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">c) Artrocentese e an&aacute;lise do l&
iacute;quido sinovial;</font></p>     ^cY#v44n2a08.htm##
00392000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704015900074002001300233#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#117#113#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> d) Solicitar hemograma, hemocultura e
 dosagem de &aacute;cido &uacute;rico;</font></p>     ^cY#v44n2a08.htm##
00352000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704011900074002001300193#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#118#114#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> e) Prescrever 10 mg de prednisona. </
font></p>     ^cY#v44n2a08.htm##
00411000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704017800074002001300252#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#119#115#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>44.</b> Em rela&ccedil;&atilde;o a 
S&iacute;ndrome da Fibromialgia &eacute; correto afirmar:</font></p>     ^cY#v44
n2a08.htm##
00464000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704023100074002001300305#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#120#116#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> a) A qualidade de vida &eacute; pouco
 afetada apesar das queixas dos pacientes pois estes mant&eacute;m suas atividad
es independentes dos sintomas;</font></p>     ^cY#v44n2a08.htm##
00526000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704029300074002001300367#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#121#117#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> b) H&aacute; uma diferen&ccedil;a sig
nificativa entre a realiza&ccedil;&atilde;o de exerc&iacute;cios aer&oacute;bico
s ou exerc&iacute;cios de alongamento e relaxamento, sendo os primeiros de melho
r resultado;</font></p>     ^cY#v44n2a08.htm##
00473000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704024000074002001300314#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#122#118#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> c) Os estudos mostram que a subst&aci
rc;ncia P est&aacute; aumentada, o que demonstra uma prova de sensibiliza&ccedil
;&atilde;o do Sistema Nervoso Central; </font></p>     ^cY#v44n2a08.htm##
00437000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704020400074002001300278#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#123#119#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">d) 	Est&aacute; comprovado o aumento d
a Interleucina-8, pois esta &eacute; estimulada pelo aumento da subst&acirc;ncia
 P;</font></p>     ^cY#v44n2a08.htm##
00586000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704035300074002001300427#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#124#120#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">e) 	Os crit&eacute;rios para o diagn&o
acute;stico atualmente aceitos s&atilde;o: dor difusa pelo corpo por no m&iacute
;nimo 3 meses de dura&ccedil;&atilde;o, associado a sensibilidade em pelo menos 
11 de 18 pontos dolorosos espec&iacute;ficos e dist&uacute;rbio do sono.</font><
/p>     ^cY#v44n2a08.htm##
00480000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704024700074002001300321#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#125#121#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>45.</b> Quais das manifesta&ccedil;
&otilde;es cl&iacute;nicas, abaixo relacionadas, est&atilde;o associadas &agrave
; S&iacute;ndrome do Anticorpo Anti-sintetase:</font></p>     ^cY#v44n2a08.htm##
00392000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704015900074002001300233#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#126#122#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> a) Fraqueza muscular aguda e grave, e
nvolvimento card&iacute;aco, mialgias;</font></p>     ^cY#v44n2a08.htm##
00417000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704018400074002001300258#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#127#123#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> b) Dermatomiosite cl&aacute;ssica, co
mprometimento cut&acirc;neo em V do decote e em bra&ccedil;os; </font></p>     ^
cY#v44n2a08.htm##
00500000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704026700074002001300341#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#128#124#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">c) 	Doen&ccedil;a Pulmonar Intersticia
l Cr&ocirc;nica, artrite, fen&ocirc;meno de Raynaud, febre e altera&ccedil;&atil
de;o cut&acirc;nea definida como "m&atilde;os de mec&acirc;nico"; </font></p>   
  ^cY#v44n2a08.htm##
00400000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704016700074002001300241#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#129#125#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">d) 	Artrite, hipergamaglobulinemia, si
nal de Gottron, heli&oacute;tropo, calcinose; </font></p>     ^cY#v44n2a08.htm##
00467000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704023400074002001300308#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#130#126#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">e) 	Fraqueza da musculatura da cintura
 p&eacute;lvica e escapular, eleva&ccedil;&atilde;o das enzimas musculares, sina
l de Gottron e heli&oacute;tropo.</font></p>     ^cY#v44n2a08.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704015800074002001300232#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#131#127#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>46.</b> Anticorpos anti-centr&ocirc
;mero est&atilde;o mais associados a:</font></p>     ^cY#v44n2a08.htm##
00324000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009100074002001300165#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#132#128#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> a) LES;</font></p>     ^cY#v44n2a08.h
tm##
00326000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009300074002001300167#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#133#129#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> b) CREST;</font></p>     ^cY#v44n2a08
.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009700074002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#134#130#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> c) PM/DM;    </font></p>     ^cY#v44n
2a08.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009000074002001300164#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#135#131#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">d) AR; </font></p>     ^cY#v44n2a08.ht
m##
00324000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009100074002001300165#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#136#132#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">e) 	OA. </font></p>     ^cY#v44n2a08.h
tm##
00463000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704023000074002001300304#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#137#133#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>47.</b> Qual dos marcadores sorol&o
acute;gicos abaixo tem maior especificidade em rela&ccedil;&atilde;o ao acometim
ento pulmonar na polimiosite?</font></p>     ^cY#v44n2a08.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009600074002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#138#134#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> a) Anti-Mi2;</font></p>     ^cY#v44n2
a08.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009600074002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#139#135#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> b) Anti-Jo1;</font></p>     ^cY#v44n2
a08.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009600074002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#140#136#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> c) Anti-SRP;</font></p>     ^cY#v44n2
a08.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009600074002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#141#137#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> d) Anti-RNP;</font></p>     ^cY#v44n2
a08.htm##
00328000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009500074002001300169#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#142#138#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> e) Anti-Ro.</font></p>     ^cY#v44n2a
08.htm##
00434000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704020100074002001300275#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#143#139#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>48.</b> Paciente de 45 anos com qua
dro de dermatomiosite deve-se, obrigatoriamente, pesquisar a presen&ccedil;a de:
</font></p>     ^cY#v44n2a08.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704010000074002001300174#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#144#140#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> a) Toxoplasmose;</font></p>     ^cY#v
44n2a08.htm##
00370000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704013700074002001300211#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#145#141#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> b) Infec&ccedil;&atilde;o por citomeg
alov&iacute;rus;</font></p>     ^cY#v44n2a08.htm##
00395000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704016200074002001300236#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#146#142#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> c) Infec&ccedil;&atilde;o pelo v&iacu
te;rus da imunodefici&ecirc;ncia humana; </font></p>     ^cY#v44n2a08.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009600074002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#147#143#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">d) Neoplasia;</font></p>     ^cY#v44n2
a08.htm##
00356000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704012300074002001300197#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#148#144#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> e) Infec&ccedil;&atilde;o pelo HTLV-1
. </font></p>     ^cY#v44n2a08.htm##
00382000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704014900074002001300223#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#149#145#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>49.</b> A presen&ccedil;a de vascul
ite &eacute; mais notada na:</font></p>     ^cY#v44n2a08.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704011500074002001300189#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#150#146#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> a) Polimiosite prim&aacute;ria;</font
></p>     ^cY#v44n2a08.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704011800074002001300192#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#151#147#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> b) Dermatomiosite prim&aacute;ria;</f
ont></p>     ^cY#v44n2a08.htm##
00355000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704012200074002001300196#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#152#148#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> c) Polimiosite associada a neoplasias
;</font></p>     ^cY#v44n2a08.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704011100074002001300185#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#153#149#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> d) Dermatomiosite infantil;</font></p
>     ^cY#v44n2a08.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704012500074002001300199#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#154#150#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> e) Dermatomiosite associada a neoplas
ias.</font></p>     ^cY#v44n2a08.htm##
00454000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704022100074002001300295#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#155#151#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>50.</b> O teste da tuberculina deve
 ser sempre realizado em pacientes com artrite reumat&oacute;ide que v&atilde;o 
iniciar terapia com:</font></p>     ^cY#v44n2a08.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009700074002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#156#152#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">a) Cloroquina;</font></p>     ^cY#v44n
2a08.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704011100074002001300185#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#157#153#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> b) Corticoster&oacute;ides;</font></p
>     ^cY#v44n2a08.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009900074002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#158#154#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> c) Metotrexate;</font></p>     ^cY#v4
4n2a08.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704011200074002001300186#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#159#155#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> d) Antagonistas do TNF-alfa;</font></
p>     ^cY#v44n2a08.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704010000074002001300174#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#160#156#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"> e) Ciclosporina.</font></p>     ^cY#v
44n2a08.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704009800074002001300172#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#161#157#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>GABARITO</b></font></p>     ^cY#v44
n2a08.htm##
00441000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704020800074002001300282#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#162#158#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">26A; 27A; 28E; 29E; 30C; 31D; 32A; 33A
; 34D; 35A; 36D; 37B; 38D; 39A; 40C; 41B; 42A; 43C; 44C; 45C; 46B; 47B; 48D; 49D
; 50D. </font></p>     ^cY#v44n2a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#163#159#text#162#<p>&nbsp;</p>     ^cY
#v44n2a08.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#164#160#text#162#<p>&nbsp;</p>     ^cY
#v44n2a08.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704010100074002001300175#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#165#161#text#162#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Respons&aacute;vel: Saul Schaf    ^cY#
v44n2a08.htm##
00739000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000500065708000400070704050600074002001300580#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a08.htm#S#p#166#162#text#162#<br>     <a name="lin
k01"></a><a href="#linkinicio">*</a> 	Exame realizado em 3 de setembro de 2003, 
em Ipojuca, PE, durante a XVII Jornada Brasileira de Reumatologia. As quest&otil
de;es 26 a 50 (de um total de 100) est&atilde;o publicadas nesta edi&ccedil;&ati
lde;o, acompanhadas do respectivo gabarito. As primeiras 25 quest&otilde;es enco
ntram-se publicadas na edi&ccedil;&atilde;o nov./dez. 2003 e as demais ser&atild
e;o publicadas nas duas edi&ccedil;&otilde;es subseq&uuml;entes. </font></p>    
 ^cY#v44n2a08.htm##
00271000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00400097#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#o#1#1#text#1#201
10406#085738#v44n2a09.htm#109##
00942000000000445000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000700094158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016001200510
01620120054002130100033002670100029003000100044003290100025003730700058003980700
01800456117000600474072000300480002001300483#v44n2#V:\SciELO\serial\rbr\v44n2\ma
rkup\v44n2a09.htm#S#h#2#1#text#1#oa#pt#br1.1#1#4.0#ILUS#09#RBR040#nd#Rev. Bras. 
Reumatol.#44#2#20040400#^f155^l159#0482-5004#1#Osteocondrite (osteocondrose) dis
secante (OCD)^lpt#Osteochondritis (osteochondrosis) dissecans (OCD)^lpt#^rND^1A0
1^nFlávia Aiko^sSakamoto#^rND^1A01^nAndré Yui^sAihara#^rND^1A01^nArtur da Rocha 
Corrêa^sFernandes#^rND^1A02^nJamil^sNatour#Unifesp^iA01^1EPM^2Departamento de di
agnóstico por imagem#Unifesp^iA02^1EPM#other#10#v44n2a09.htm##
00956000000000445000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000700094158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016001200580
01620120061002200100033002810100029003140100044003430100025003870700058004120700
01800470117000600488072000300494002001300497#v44n2#V:\SciELO\serial\rbr\v44n2\ma
rkup\v44n2a09.htm#S#f#3#1#text#1#oa#pt#br1.1#1#4.0#ILUS#09#RBR040#nd#Rev. Bras. 
Reumatol.#44#2#20040400#^f155^l159#0482-5004#1#<b>Osteocondrite (osteocondrose) 
dissecante (OCD)</b>^lpt#<b>Osteochondritis (osteochondrosis) dissecans (OCD)</b
>^lpt#^rND^1A01^nFlávia Aiko^sSakamoto#^rND^1A01^nAndré Yui^sAihara#^rND^1A01^nA
rtur da Rocha Corrêa^sFernandes#^rND^1A02^nJamil^sNatour#Unifesp^iA01^1EPM^2Depa
rtamento de diagnóstico por imagem#Unifesp^iA02^1EPM#other#10#v44n2a09.htm##
01076000000000469000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100038000500104121000300109049000700112158000300119
03000200012203100030014203200020014506500090014701400110015603500100016712300020
01770120051001790120054002300100033002840100029003170100044003460100025003900700
06000415070002000475117000600495072000300501002001300504008008900517#v44n2#V:\Sc
iELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#l#4#1#text#1#^mmar./abr.^a2004#oa#pt
#br1.1#1#4.0#ilus#09#RBR040#nd#Rev. Bras. Reumatol#44#2#20040400#^f155^l159#0482
-5004#1#Osteocondrite (osteocondrose) dissecante (OCD)^lpt#Osteochondritis (oste
ochondrosis) dissecans (OCD)^lpt#^rND^1A01^nFlávia Aiko^sSakamoto#^rND^1A01^nAnd
ré Yui^sAihara#^rND^1A01^nArtur da Rocha Corrêa^sFernandes#^rND^1A02^nJamil^sNat
our#^iA01^1Unifesp^2EPM^3Departamento de diagnóstico por imagem#^iA02^1Unifesp^2
EPM#other#10#v44n2a09.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_a
rttext&pid=S0482-50042004000200009##
00382000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704015400069002001300223#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#5#1#text#95#<p align="right"><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>VINHETA IMAGENOL&Oacute;GI
CA</b> IMAGENOLOGIC VIGNETTE</font></p>     ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#6#2#text#95#<p>&nbsp;</p>     ^cY#v44n
2a09.htm##
00447000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704021900069002001300288#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#7#3#text#95#<p><font size="4" face="Ve
rdana, Arial, Helvetica, sans-serif"><a name="linkinicio"></a><b>Osteocondrite (
osteocondrose) dissecante (OCD)<sup>(</sup><a href="#link01"><sup>*</sup></a><su
p>)</sup></b></font></p>     ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#8#4#text#95#<p>&nbsp;</p>     ^cY#v44n
2a09.htm##
00367000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704013900069002001300208#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#9#5#text#95#<p><font size="3" face="Ve
rdana, Arial, Helvetica, sans-serif"><b>Osteochondritis (osteochondrosis) dissec
ans (OCD)</b></font></p>     ^cY#v44n2a09.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#10#6#text#95#<p>&nbsp;</p>     ^cY#v44
n2a09.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#11#7#text#95#<p>&nbsp;</p>     ^cY#v44
n2a09.htm##
00473000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704024400070002001300314#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#12#8#text#95#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"><b>Fl&aacute;via Aiko Sakamoto<sup>I</sup>
; Andr&eacute; Yui Aihara<sup>I</sup>; Artur da Rocha Corr&ecirc;a Fernandes<sup
>I</sup>; Jamil Natour<sup>II</sup></b></font></p>     ^cY#v44n2a09.htm##
00372000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704014300070002001300213#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#13#9#text#95#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"><sup>I</sup>Departamento de diagn&oacute;s
tico por imagem da EPM/Unifesp    ^cY#v44n2a09.htm##
00311000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704008100071002001300152#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#14#10#text#95#<br> <sup>II</sup>Discip
lina de Reumatologia da (EPM/Unifesp)</font></p>     ^cY#v44n2a09.htm##
00382000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704015200071002001300223#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#15#11#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#linkcorresp">Endere&ccedil;o pa
ra correspond&ecirc;ncia</a></font></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#16#12#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#17#13#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704011400071002001300185#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#18#14#text#95#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font></p
>     ^cY#v44n2a09.htm##
02964000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704273400071002001302805#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#19#15#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Osteocondrite dissecante (OCD) &eacute; u
ma condi&ccedil;&atilde;o adquirida de etiologia desconhecida, caracterizada pel
a necrose focal do osso subcondral de articula&ccedil;&otilde;es<sup>(1)</sup>. 
A import&acirc;ncia do diagn&oacute;stico precoce desta entidade deve-se ao pote
ncial de cura espont&acirc;nea num momento inicial. Ocorre geralmente em adolesc
entes e adultos jovens do sexo masculino, sendo o joelho o local mais acometido,
 seguido pelo t&aacute;lus. O termo mais adequado para esta altera&ccedil;&atild
e;o &eacute; osteocondrose dissecante, pois se sabe que n&atilde;o h&aacute; pro
cesso inflamat&oacute;rio local. Existem duas teorias quanto &agrave; etiopatoge
nia, s&atilde;o elas: a teoria traum&aacute;tica/mec&acirc;nica, relacionada com
 o aumento da atividade e microtraumas repetitivos, e a predisposi&ccedil;&atild
e;o familiar/heredit&aacute;ria<sup>(2)</sup>. Entretanto, a correla&ccedil;&ati
lde;o an&aacute;tomopatol&oacute;gica e o curso <i>in vivo</i> da OCD ainda s&at
ilde;o baseados em observa&ccedil;&otilde;es cir&uacute;rgicas e histol&oacute;g
icas, e em estudos experimentais<sup>(2)</sup>. Inicialmente h&aacute; demarca&c
cedil;&atilde;o do osso subcondral com necrose, sem comprometimento macrosc&oacu
te;pico da cartilagem sobrejacente. Posteriormente, adjacente ao osso necr&oacut
e;tico, forma-se uma zona de transi&ccedil;&atilde;o, que &eacute; preenchida po
r tecido de granula&ccedil;&atilde;o, composta por tecido fibrocartilaginoso e c
apilares vasculares. Nesta etapa, a les&atilde;o pode ter cura espont&acirc;nea,
 ou evoluir com separa&ccedil;&atilde;o do fragmento &oacute;sseo com ou sem alt
era&ccedil;&atilde;o cartilaginosa. Por fim, h&aacute; extrus&atilde;o do fragme
nto, com forma&ccedil;&atilde;o de corpo livre intra articular e cratera na supe
rf&iacute;cie &oacute;ssea<sup>(2,3)</sup>. H&aacute; autores que separam a OCD 
em duas entidades, a OCD juvenil e a OCD do adulto, diferenciadas pelo in&iacute
;cio dos sintomas com rela&ccedil;&atilde;o ao fechamento da placa epifis&aacute
;ria. O motivo dessa distin&ccedil;&atilde;o deve-se ao melhor progn&oacute;stic
o das les&otilde;es na forma juvenil<sup>(3)</sup>. Como tamb&eacute;m, a longo 
prazo, a OCD do adulto predisp&otilde;e a altera&ccedil;&otilde;es degenerativas
 secund&aacute;rias, com antecipa&ccedil;&atilde;o dos sintomas em cerca de 10 a
nos quando comparado a indiv&iacute;duos s&atilde;os<sup>(2)</sup>. N&atilde;o d
evemos confundir a OCD com osteonecrose p&oacute;s corticoterapia, hemoglobinopa
tias, doen&ccedil;a de Gaucher, doen&ccedil;a de Caisson's<sup>(2)</sup> ou com 
a "osteonecrose espont&acirc;nea"<sup>(2,4)</sup>.</font></p>     ^cY#v44n2a09.h
tm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#20#16#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704011500071002001300186#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#21#17#text#95#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>LOCALIZA&Ccedil;&Atilde;O</b></font></
p>     ^cY#v44n2a09.htm##
01128000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704089800071002001300969#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#22#18#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">O local mais comumente envolvido &eacute;
 o c&ocirc;ndilo femoral (<a href="#fig01">Figura 1</a>), seguido pelo t&aacute;
lus (<a href="#fig02">Figura 2</a>), o cap&iacute;tulo do &uacute;mero (<a href=
"#fig03">Figura 3</a>) e a superf&iacute;cie superior do quadril. No f&ecirc;mur
, a face lateral do c&ocirc;ndilo medial &eacute; acometida em 85% dos casos e o
 c&ocirc;ndilo lateral em 15%<sup>(1)</sup>. No t&aacute;lus, as superf&iacute;c
ies mais envolvidas s&atilde;o a medial e lateral do d&ocirc;mus, e menos comume
nte a central<sup>(2,1)</sup>. Locais raramente comprometidos s&atilde;o a cabe&
ccedil;a do I metatarso, cabe&ccedil;a umeral, escaf&oacute;ide<sup>(2,1)</sup> 
e a cavidade glen&oacute;ide<sup>(5)</sup>. Pode ser bilateral em cerca de 5% do
s casos (<a href="#fig04">Figura 4</a>)<sup>(2)</sup>.</font></p>     ^cY#v44n2a
09.htm##
00266000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003600071002001300107#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#23#19#text#95#<p><a name="fig01"></a><
/p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#24#20#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#25#21#text#95#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a09fig01.jpg"></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#26#22#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00266000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003600071002001300107#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#27#23#text#95#<p><a name="fig02"></a><
/p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#28#24#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#29#25#text#95#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a09fig02.jpg"></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#30#26#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00266000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003600071002001300107#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#31#27#text#95#<p><a name="fig03"></a><
/p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#32#28#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#33#29#text#95#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a09fig03.jpg"></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#34#30#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00266000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003600071002001300107#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#35#31#text#95#<p><a name="fig04"></a><
/p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#36#32#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#37#33#text#95#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a09fig04.jpg"></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#38#34#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704012800071002001300199#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#39#35#text#95#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>AVALIA&Ccedil;&Atilde;O CL&Iacute;NICA
</b></font></p>     ^cY#v44n2a09.htm##
00971000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704074100071002001300812#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#40#36#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Geralmente acomete indiv&iacute;duos masc
ulinos entre a segunda e quarta d&eacute;cadas. O quadro cl&iacute;nico pode ser
 assintom&aacute;tico, ou determinar sintomas intermitentes como dor em moviment
o dependente ao saltar, agachar ou subir escadas; limita&ccedil;&atilde;o do mov
imento e estalidos. Algumas vezes est&aacute; associada a edema discreto, mas nu
nca a hematoma. Caso haja corpos livres, pode haver travamento do joelho. Em raz
&atilde;o dos sintomas frustros, o diagn&oacute;stico &eacute; feito freq&uuml;e
ntemente ap&oacute;s v&aacute;rios anos do in&iacute;cio do quadro ou de forma i
ncidental em estudos radiol&oacute;gicos<sup>(2,6)</sup>.</font></p>     ^cY#v44
n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#41#37#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010100071002001300172#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#42#38#text#95#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>ARTROSCOPIA</b></font></p>     ^cY#v44
n2a09.htm##
00880000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704065000071002001300721#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#43#39#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Gulh, em 1982, prop&ocirc;s uma classific
a&ccedil;&atilde;o artrosc&oacute;pica das altera&ccedil;&otilde;es morfol&oacut
e;gicas no joelho em quatro est&aacute;gios. No primeiro est&aacute;gio, a carti
lagem est&aacute; intacta, parcialmente amolecida e abaulada. No segundo, notam-
se les&otilde;es/fissuras incipientes na cartilagem. No terceiro, h&aacute; frag
mento &oacute;sseo parcialmente destacado; e no quarto observam-se cratera e cor
po livre. Novos e complexos esquemas foram criados, mas n&atilde;o t&ecirc;m rel
ev&acirc;ncia terap&ecirc;utica<sup>(2)</sup>.</font></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#44#40#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00349000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704011900071002001300190#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#45#41#text#95#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>DIAGN&Oacute;STICO POR IMAGEM</b></fon
t></p>     ^cY#v44n2a09.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704012100071002001300192#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#46#42#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b><i>Radiografia convencional</i></b></f
ont></p>     ^cY#v44n2a09.htm##
01198000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704096800071002001301039#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#47#43#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Os exames radiogr&aacute;ficos geralmente
 estabelecem o diagn&oacute;stico de OCD corretamente. Entretanto, n&atilde;o fo
rnecem dados que determinem uma conduta terap&ecirc;utica apropriada, j&aacute; 
que h&aacute; freq&uuml;ente discrep&acirc;ncia entre os achados radiogr&aacute;
ficos e os cir&uacute;rgicos<sup>(2)</sup>. O achado radiogr&aacute;fico caracte
r&iacute;stico &eacute; o foco radioluzente arredondado ou ovalado do osso subco
ndral, de contornos irregulares, que pode apresentar &aacute;rea de esclerose ce
ntral, relacionada com fragmento &oacute;sseo impactado (<a href="#fig05">Figura
 5</a>). As incid&ecirc;ncias preconizadas para a avalia&ccedil;&atilde;o de OCD
 no joelho s&atilde;o a antero-posterior, lateral e do t&uacute;nel; e as necess
&aacute;rias para estudar o t&aacute;lus s&atilde;o a antero-posterior, obl&iacu
te;qua em 30º e a lateral<sup>(1,2,6)</sup>.</font></p>     ^cY#v44n2a09.htm##
00266000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003600071002001300107#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#48#44#text#95#<p><a name="fig05"></a><
/p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#49#45#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#50#46#text#95#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a09fig05.jpg"></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#51#47#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704012800071002001300199#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#52#48#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><i><b>Tomografia computadorizada (TC)</b>
</i></font></p>     ^cY#v44n2a09.htm##
00705000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704047500071002001300546#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#53#49#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A TC fornece um bom delineamento anat&oci
rc;mico da les&atilde;o osteocondral (<a href="#fig06a">Figuras 6a</a> e <a href
="#fig06b">6b</a>), entretanto n&atilde;o avalia o potencial de cura da les&atil
de;o. Davies e Cassar-Pullicino, em 1989, utilizaram a artrotomografia no tornoz
elo e t&ecirc;m conseguido estabelecer o progn&oacute;stico de les&otilde;es da 
cartilagem talar<sup>(2)</sup>.</font></p>     ^cY#v44n2a09.htm##
00267000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003700071002001300108#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#54#50#text#95#<p><a name="fig06a"></a>
</p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#55#51#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00305000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007500071002001300146#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#56#52#text#95#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a09fig06a.jpg">    ^cY#v44n2a09.htm##
00318000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704008800071002001300159#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#57#53#text#95#<br> <a name="fig06b"></
a><img src="/img/revistas/rbr/v44n2/a09fig06b.jpg"></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#58#54#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704011000071002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#59#55#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b><i>Cintilografia</i></b></font></p>   
  ^cY#v44n2a09.htm##
00553000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704032300071002001300394#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#60#56#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Aceitando a teoria isqu&ecirc;mica, Cahil
l e Berg, em 1983, propuseram a descri&ccedil;&atilde;o e o estagiamento da OCD.
 Eles conclu&iacute;ram que a chance de cura correlacionava-se com a extens&atil
de;o da atividade local<sup>(2)</sup>. </font></p>     ^cY#v44n2a09.htm##
00366000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704013600071002001300207#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#61#57#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b><i>Resson&acirc;ncia magn&eacute;tica 
(RM)</i></b></font></p>     ^cY#v44n2a09.htm##
03459000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704322900071002001303300#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#62#58#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">A RM demonstra as altera&ccedil;&otilde;e
s &oacute;sseas e cartilag&iacute;neas mais precocemente que a radiografia conve
ncional<sup>(1,6)</sup>, e tem acur&aacute;cia semelhante ao exame artrogr&aacut
e;fico<sup>(7,8)</sup>. Fornece dados sobre a extens&atilde;o, morfologia e perf
us&atilde;o da les&atilde;o, al&eacute;m de ser um m&eacute;todo n&atilde;o inva
sivo que avalia a condi&ccedil;&atilde;o local com alta sensibilidade<sup>(4)</s
up>. O aspecto cl&aacute;ssico da OCD &agrave; RM corresponde &agrave; altera&cc
edil;&atilde;o focal do osso subcondral, com forma semi-oval ou semicircular, re
lativamente demarcada, com hipossinal em T1 e hipossinal heterog&ecirc;neo em T2
 (<a href="/img/revistas/rbr/v44n2/a09fig07.jpg">Figura 7</a>). Numa fase inicia
l, em que h&aacute; processo reparativo ativo, e a les&atilde;o est&aacute; quas
e ou completamente vascularizada, observa-se realce difuso ap&oacute;s a inje&cc
edil;&atilde;o endovenosa do meio de contraste paramagn&eacute;tico. A zona de t
ransi&ccedil;&atilde;o, preenchida com tecido de granula&ccedil;&atilde;o, tem h
ipossinal em T1, hipersinal em T2 e realce com contraste. Ap&oacute;s a separa&c
cedil;&atilde;o do fragmento, forma-se um espa&ccedil;o preenchido por l&iacute;
quido que, dependendo da separa&ccedil;&atilde;o ser completa ou parcial, haver&
aacute; l&iacute;quido em todo a periferia do fragmento ou n&atilde;o. &Agrave; 
RM, este fluido apresenta hipossinal em T1, hipersinal em T2 e n&atilde;o tem re
alce ap&oacute;s o contraste (<a href="/img/revistas/rbr/v44n2/a09fig08.jpg">Fig
ura 8</a>). Os sinais que indicam instabilidade do fragmento s&atilde;o hipersin
al ao redor do fragmento em T2; &aacute;reas c&iacute;sticas focais com mais de 
5 mm, localizadas profundamente &agrave; les&atilde;o da OCD; deformidade ou fis
suras da cartilagem sobrejacente; e fluido circundando o fragmento<sup>(2,7,9)</
sup>. A RM tamb&eacute;m avalia as dimens&otilde;es do leito &oacute;sseo e o co
rpo livre. O hipersinal ao redor do fragmento em T2 &eacute; o sinal de instabil
idade mais freq&uuml;entemente observado; os demais, apesar de menos comuns, s&a
tilde;o 100% espec&iacute;ficos<sup>(7)</sup>. Outro par&acirc;metro progn&oacut
e;stico &eacute; a dimens&atilde;o da &aacute;rea da les&atilde;o. Quanto menor 
a &aacute;rea da superf&iacute;cie acometida, melhor ser&aacute; a evolu&ccedil;
&atilde;o<sup>(9)</sup>. Esses sinais de RM foram determinados para a OCD do joe
lho, mas podem ser aplicados para o tornozelo. &Eacute; importante diferenciar a
 OCD da fratura aguda. Esta &uacute;ltima apresenta extenso edema medular &oacut
e;sseo circunjacente<sup>(2)</sup>. Outra condi&ccedil;&atilde;o a ser lembrada 
&eacute; que, na avalia&ccedil;&atilde;o p&oacute;s-cir&uacute;rgica de fixa&cce
dil;&atilde;o do fragmento &oacute;sseo, pode haver o hipersinal em T2 por longo
 per&iacute;odo, atribu&iacute;do ao processo de repara&ccedil;&atilde;o<sup>(2,
10)</sup>. Com o intuito de melhorar a avalia&ccedil;&atilde;o da cartilagem art
icular, podese introduzir solu&ccedil;&atilde;o de contraste paramagn&eacute;tic
o na cavidade articular e realizar estudo com RM<sup>(2,6)</sup>.</font></p>    
 ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#63#59#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010000071002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#64#60#text#95#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>TRATAMENTO</b></font></p>     ^cY#v44n
2a09.htm##
01165000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704093500071002001301006#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#65#61#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Pode ser conservador ou cir&uacute;rgico,
 dependendo da estabilidade do fragmento. Numa les&atilde;o com aspecto est&aacu
te;vel determinado pela RM e/ou pelo estudo artrogr&aacute;fico, preconiza-se te
rap&ecirc;utica conservadora, com retirada de carga do membro afetado por 6 a 12
 meses. Caso persista dor e os achados de RM demonstrem redu&ccedil;&atilde;o do
 processo de repara&ccedil;&atilde;o, &eacute; indicado o tratamento cir&uacute;
rgico. Na OCD inst&aacute;vel, tamb&eacute;m &eacute; recomendada a interven&cce
dil;&atilde;o cir&uacute;rgica. H&aacute; melhor progn&oacute;stico dos paciente
s jovens com placa epifis&aacute;ria aberta, e les&otilde;es que apresentam a ca
rtilagem sobrejacente intacta. Nessas duas condi&ccedil;&otilde;es h&aacute; mai
or incid&ecirc;ncia de evolu&ccedil;&atilde;o para cura espont&acirc;nea<sup>(3,
6,8)</sup>.</font></p>     ^cY#v44n2a09.htm##
01480000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704125000071002001301321#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#66#62#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Concluindo, a osteocondrite (osteocondros
e) dissecante &eacute; uma les&atilde;o primariamente &oacute;ssea com envolvime
nto da cartilagem articular secundariamente. H&aacute; forma&ccedil;&atilde;o de
 uma zona transicional ap&oacute;s necrose &oacute;ssea que tem potencial de cur
a, mas pode evoluir para deformidade &oacute;ssea. Etiologicamente, a teoria mec
&acirc;nica/traum&aacute;tica &eacute; a mais aceita. A predisposi&ccedil;&atild
e;o familiar/heredit&aacute;ria pode ser considerada um fator em alguns paciente
s, particularmente em crian&ccedil;as e adolescentes. &Eacute; grande a diferen&
ccedil;a no curso cl&iacute;nico e no progn&oacute;stico de pacientes com fise a
berta e fechada. A OCD &eacute; geralmente diagnosticada pela radiografia simple
s, que n&atilde;o fornece dados quanto &agrave; instabilidade da les&atilde;o. A
 RM &eacute; o exame de escolha para o diagn&oacute;stico. A RM associada ao qua
dro cl&iacute;nico determina a conduta terap&ecirc;utica da OCD. A RM tamb&eacut
e;m auxilia na indica&ccedil;&atilde;o da realiza&ccedil;&atilde;o de artroscopi
a e/ou artrotomia, bem como no seguimento da cicatriza&ccedil;&atilde;o<sup>(1)<
/sup>.</font></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#67#63#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010700071002001300178#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#68#64#text#95#<p><font size="3" face="
Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>     ^
cY#v44n2a09.htm##
00490000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704024600073002001300319#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#69#65#text#95#1#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">1. Rowe LJ, Yochum TR: Hema
tologic and vascular disorders. In: Essentials of Skeletal Radiology. Yochum TR,
 Rowe LJ: 2.a ed, Baltimore, Williams &amp; Wilkins, 1295-301, 1996.    ^cY#v44n
2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#70#66#text#95#</font></p>     ^cY#v44n
2a09.htm##
00439000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704019500073002001300268#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#71#67#text#95#2#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bohndorf K: Osteochondri
tis (osteochondrosis) dissecans: A review and new MRI classification. Eur Radiol
 8: 103-12, 1998.    ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#72#68#text#95#</font></p>     ^cY#v44n
2a09.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704025600073002001300329#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#73#69#text#95#3#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">3. Hughes JA, Cook JV, Chur
chill MA, et al: Juvenil osteochondritis dissecans: a 5-year review of the natur
al history using clinical and MRI evaluation. Pediatr Radiol 33: 410-17, 2003.  
  ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#74#70#text#95#</font></p>     ^cY#v44n
2a09.htm##
00511000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704026700073002001300340#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#75#71#text#95#4#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">4. Stoller DW, Cannon Jr WD
, Anderson LJ: O joelho. In: Resson&atilde;ncia Magn&eacute;tica em Ortopedia &a
mp; Medicina Desportiva. Stoller DW, 2.a ed, Philadelphia, Lippincott-Raven, 393
-6, 2000.    ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#76#72#text#95#</font></p>     ^cY#v44n
2a09.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704020800073002001300281#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#77#73#text#95#5#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">5. Yu JS, Greenway G, Resni
ck D: Osteocondral defect of the glenoide fossa: cross-sectional imaging feature
s. Radiology 206: 35-40, 1998.    ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#78#74#text#95#</font></p>     ^cY#v44n
2a09.htm##
00497000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704025300073002001300326#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#79#75#text#95#6#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">6. Resnick D, Goergen TG: P
hisical injury: concepts and terminology. In: Diagnosis of bone and joint disord
ers. Resnick D. 4.a ed, Philadelphia, W B Saunders Company, 2689-708, 2002.    ^
cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#80#76#text#95#</font></p>     ^cY#v44n
2a09.htm##
00480000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704023600073002001300309#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#81#77#text#95#7#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">7. De Smet AA, Ilahi AO, Gr
af BK: Reassessment of the MR criteria for stability of osteochondritis dissecan
s in the knee and ankle. Skeletal Radiol 25: 159-63, 1996.    ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#82#78#text#95#</font></p>     ^cY#v44n
2a09.htm##
00552000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704030800073002001300381#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#83#79#text#95#8#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">8. J&uuml;rgensen I, Bachma
nn G, Schleicher I, et al: Arthroscopic versus conservative treatment of osteoco
dritis dissecans of the knee: value of magnetic resonance imaging in therapy pla
nning and follow-up. Arthroscopy 18: 378-86, 2002.    ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#84#80#text#95#</font></p>     ^cY#v44n
2a09.htm##
00508000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704026400073002001300337#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#85#81#text#95#9#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">9. De Smet AA, Ilahi AO, Gr
af BK: Untreated osteochondritis dissecans of the femoral condyles: prediction o
f patient outcome using radiographic and MR findings. Skeletal Radiol 26: 463-7,
 1997.    ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#86#82#text#95#</font></p>     ^cY#v44n
2a09.htm##
00455000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000300071704021000074002001300284#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#87#83#text#95#10#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Boutin RD, Januario JA
, Newberg A, et al: MR imaging features of osteochondritis dissecans of the femo
ral sulcus. AJR 180: 641-5, 2003.    ^cY#v44n2a09.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002000071002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#88#84#text#95#</font></p>     ^cY#v44n
2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#89#85#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#90#86#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00459000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704022900071002001300300#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#91#87#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#linkinicio"><img src="/img/revi
stas/rbr/v44n2/seta.jpg" border="0"></a><a name="linkcorresp"></a> <b>Endere&cce
dil;o para correspond&ecirc;ncia:</b>    ^cY#v44n2a09.htm##
00281000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704005100071002001300122#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#92#88#text#95#<br>  Artur da Rocha Cor
r&ecirc;a Fernandes    ^cY#v44n2a09.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007300071002001300144#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#93#89#text#95#<br> Departamento de dia
gn&oacute;stico por imagem da EPM/Unifesp    ^cY#v44n2a09.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003000071002001300101#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#94#90#text#95#<br> Rua Botucatu, 740  
  ^cY#v44n2a09.htm##
00291000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704006100071002001300132#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#95#91#text#95#<br> CEP 04023-900, S&at
ilde;o Paulo, SP </font></p>     ^cY#v44n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#96#92#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#97#93#text#95#<p>&nbsp;</p>     ^cY#v4
4n2a09.htm##
00374000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704014400071002001300215#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#98#94#text#95#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Respons&aacute;veis: Artur da Rocha Corr&
ecirc;a Fernandes e Jamil Natour    ^cY#v44n2a09.htm##
00413000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704018300071002001300254#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a09.htm#S#p#99#95#text#95#<br>     <a name="link01
"></a><a href="#linkinicio">*</a> Departamento de diagn&oacute;stico por imagem 
da Universidade Federal de S&atilde;o Paulo (EPM/Unifesp). </font></p>     ^cY#v
44n2a09.htm##
00535000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100015000730100017000880120
03900105018003700144063000200181066001000183062001900193014000900212065000900221
064000500230865000900235002001300244#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a09.htm#S#c#100#1#text#10#1#^rND^sRowe^nLJ#^rND^sYochum^nTR#Hematologic and va
scular disorders^len#Essentials of Skeletal Radiology^len#2#Baltimore#Williams &
 Wilkins#1295-301#19960000#1996#20040400#v44n2a09.htm##
00519000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100018000730120085000910300
01100176031000200187014000700189065000900196064000500205865000900210002001300219
035001000232801001100242#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a09.htm#S#
c#101#2#text#10#2#^rND^sBohndorf^nK#Osteochondritis (osteochondrosis) dissecans:
 A review and new MRI classification^len#Eur Radiol#8#103-12#19980000#1998#20040
400#v44n2a09.htm#0938-7994#Eur Radiol##
00631000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100017000730100015000900100
02000105810000600125012011200131030001500243031000300258014000700261065000900268
064000500277865000900282002001300291035001000304801001500314#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a09.htm#S#c#102#3#text#10#3#^rND^sHughes^nJA#^rND^sCoo
k^nJV#^rND^sChurchill^nMA#et al#Juvenil osteochondritis dissecans: a 5-year revi
ew of the natural history using clinical and MRI evaluation^len#Pediatr Radiol#3
3#410-17#20030000#2003#20040400#v44n2a09.htm#0301-0449#Pediatr Radiol##
00568000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100018000730100020000910100
01900111012001300130018006100143063000200204066001300206062001700219014000600236
065000900242064000500251865000900256002001300265#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a09.htm#S#c#103#4#text#10#4#^rND^sStoller^nDW#^rND^sCannon Jr^nWD#
^rND^sAnderson^nLJ#O joelho^lpt#Ressonãncia Magnética em Ortopedia & Medicina De
sportiva^lpt#2#Philadelphia#Lippincott-Raven#393-6#20000000#2000#20040400#v44n2a
09.htm##
00567000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100013000730100018000860100
01700104012008000121030001000201031000400211014000600215065000900221064000500230
865000900235002001300244035001000257801001000267#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a09.htm#S#c#104#5#text#10#5#^rND^sYu^nJS#^rND^sGreenway^nG#^rND^sR
esnick^nD#Osteocondral defect of the glenoide fossa: cross-sectional imaging fea
tures^len#Radiology#206#35-40#19980000#1998#20040400#v44n2a09.htm#0033-8419#Radi
ology##
00584000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100017000730100018000900120
04600108018004200154016001700196063000200213066001300215062002100228014000900249
065000900258064000500267865000900272002001300281#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a09.htm#S#c#105#6#text#10#6#^rND^sResnick^nD#^rND^sGoergen^nTG#Phi
sical injury: concepts and terminology^len#Diagnosis of bone and joint disorders
^len#^rND^sResnick^nD#4#Philadelphia#W B Saunders Company#2689-708#20020000#2002
#20040400#v44n2a09.htm##
00601000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100018000730100016000910100
01500107012010100122030001600223031000300239014000700242065000900249064000500258
865000900263002001300272035001000285801001600295#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a09.htm#S#c#106#7#text#10#7#^rND^sDe Smet^nAA#^rND^sIlahi^nAO#^rND
^sGraf^nBK#Reassessment of the MR criteria for stability of osteochondritis diss
ecans in the knee and ankle^len#Skeletal Radiol#25#159-63#19960000#1996#20040400
#v44n2a09.htm#0364-2348#Skeletal Radiol##
00604000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100019000730100018000920100
02000110810000600130012008600136030001200222031000300234014000700237065000900244
064000500253865000900258002001300267035001000280801001200290#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a09.htm#S#c#107#8#text#10#8#^rND^sJürgensen^nI#^rND^sB
achmann^nG#^rND^sSchleicher^nI#et al#Arthroscopic versus conservative treatment 
of osteocodritis dissecans of the knee^len#Arthroscopy#18#378-86#20020000#2002#2
0040400#v44n2a09.htm#0749-8063#Arthroscopy##
00629000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090005000637080003000681180002000710100018000730100016000910100
01500107012013000122030001600252031000300268014000600271065000900277064000500286
865000900291002001300300035001000313801001600323#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a09.htm#S#c#108#9#text#10#9#^rND^sDe Smet^nAA#^rND^sIlahi^nAO#^rND
^sGraf^nBK#Untreated osteochondritis dissecans of the femoral condyles: predicti
on of patient outcome using radiographic and MR findings^len#Skeletal Radiol#26#
463-7#19970000#1997#20040400#v44n2a09.htm#0364-2348#Skeletal Radiol##
00575000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090005000647080003000691180003000720100017000750100019000920100
01700111810000600128012007500134030000400209031000400213014000600217065000900223
064000500232865000900237002001300246035001000259801000400269#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a09.htm#S#c#109#10#text#10#10#^rND^sBoutin^nRD#^rND^sJ
anuario^nJA#^rND^sNewberg^nA#et al#MR imaging features of osteochondritis dissec
ans of the femoral sulcus^len#AJR#180#641-5#20030000#2003#20040400#v44n2a09.htm#
0361-803X#AJR##
00270000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00300097#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a10.htm#S#o#1#1#text#1#201
10406#085800#v44n2a10.htm#70##
00798000000000373000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030002100102
03100030012303200020012606500090012801400110013703500100014812300020015801200470
0160012005900207010003300266070011200299002001300411#v44n2#V:\SciELO\serial\rbr\
v44n2\markup\v44n2a10.htm#S#h#2#1#text#1#oa#pt#br1.1#1#4.0#ND#10#RBR050#nd#Rev. 
Bras. Reumatol.#44#2#20040400#^f160^l167#0482-5004#1#Envolvimento ocular nas doe
nças reumáticas^lpt#Ocular involvement in patients with rheumatic diseases^len#^
rND^1A01^nIvânio Alves^sPereira#Universidade Federal de Santa Catarina^iA01^1Hos
pital Universitário^2serviço de reumatologia^cFlorianópolis^sSC#v44n2a10.htm##
00812000000000373000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030002100102
03100030012303200020012606500090012801400110013703500100014812300020015801200540
0160012006600214010003300280070011200313002001300425#v44n2#V:\SciELO\serial\rbr\
v44n2\markup\v44n2a10.htm#S#f#3#1#text#1#oa#pt#br1.1#1#4.0#ND#10#RBR050#nd#Rev. 
Bras. Reumatol.#44#2#20040400#^f160^l167#0482-5004#1#<b>Envolvimento ocular nas 
doenças reumáticas</b>^lpt#<b>Ocular involvement in patients with rheumatic dise
ases</b>^len#^rND^1A01^nIvânio Alves^sPereira#Universidade Federal de Santa Cata
rina^iA01^1Hospital Universitário^2serviço de reumatologia^cFlorianópolis^sSC#v4
4n2a10.htm##
00915000000000385000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100121000300104049000700107158000300114030002000117
03100030013703200020014006500090014201400110015103500100016212300020017201200470
0174012005900221010003300280070011400313002001300427008008900440#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#l#4#1#text#1#^mmar./abr.^a2004#oa#pt#br1
.1#1#4.0#10#RBR050#nd#Rev. Bras. Reumatol#44#2#20040400#^f160^l167#0482-5004#1#E
nvolvimento ocular nas doenças reumáticas^lpt#Ocular involvement in patients wit
h rheumatic diseases^len#^rND^1A01^nIvânio Alves^sPereira#^iA01^1Universidade Fe
deral de Santa Catarina^2Hospital Universitário^3serviço de reumatologia^cFloria
nópolis^sSC#v44n2a10.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_ar
ttext&pid=S0482-50042004000200010##
00396000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704016800069002001300237#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#5#1#text#66#<p align="right"><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ATUALIZA&Ccedil;&Atilde;O 
EM REUMATOLOGIA</b> UPDATE IN RHEUMATOLOGY</font></p>     ^cY#v44n2a10.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#6#2#text#66#<p>&nbsp;</p>     ^cY#v44n
2a10.htm##
00374000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704014600069002001300215#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#7#3#text#66#<p><font size="4" face="Ve
rdana, Arial, Helvetica, sans-serif"><b>Envolvimento ocular nas doen&ccedil;as r
eum&aacute;ticas</b></font></p>     ^cY#v44n2a10.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#8#4#text#66#<p>&nbsp;</p>     ^cY#v44n
2a10.htm##
00372000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704014400069002001300213#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#9#5#text#66#<p><font size="3" face="Ve
rdana, Arial, Helvetica, sans-serif"><b>Ocular involvement in patients with rheu
matic diseases</b></font></p>     ^cY#v44n2a10.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#10#6#text#66#<p>&nbsp;</p>     ^cY#v44
n2a10.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#11#7#text#66#<p>&nbsp;</p>     ^cY#v44
n2a10.htm##
00390000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704016100070002001300231#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#12#8#text#66#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"><i><b>Sele&ccedil;&atilde;o de artigos e c
oment&aacute;rios feitos por</b></i></font></p>     ^cY#v44n2a10.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704011600070002001300186#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#13#9#text#66#<p><font size="2" face="V
erdana, Arial, Helvetica, sans-serif"><b>Iv&acirc;nio Alves Pereira</b></font></
p>     ^cY#v44n2a10.htm##
00480000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704025000071002001300321#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#14#10#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">M&eacute;dico assistente do servi&ccedil;
o de reumatologia do Hospital Universit&aacute;rio da Universidade Federal de Sa
nta Catarina (UFSC), Florian&oacute;polis, SC </font></p>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#15#11#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#16#12#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#17#13#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
01240000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704101000071002001301081#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#18#14#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><i>As manifesta&ccedil;&otilde;es oculare
s que podem ocorrer em pacientes com doen&ccedil;as reum&aacute;ticas e algumas 
das op&ccedil;&otilde;es terap&ecirc;uticas atuais t&ecirc;m sido objeto de publ
ica&ccedil;&otilde;es cient&iacute;ficas. Vale lembrar que a incid&ecirc;ncia de
 doen&ccedil;as sist&ecirc;micas em uve&iacute;te chega a 40% e que em grande pa
rte as uve&iacute;tes s&atilde;o causadas pelas doen&ccedil;as reum&aacute;ticas
. Medica&ccedil;&otilde;es que incluem corticoster&oacute;ides, imunossupressore
s e agentes biol&oacute;gicos, utilizadas freq&uuml;entemente em doen&ccedil;a i
nflamat&oacute;ria ocular severa, n&atilde;o s&atilde;o de uso continuado pelos 
servi&ccedil;os de oftalmologia, o que faz com que in&uacute;meras vezes reumato
logistas sejam solicitados para investigar, acompanhar, prescrever medicamentos 
ou orientar condutas em situa&ccedil;&otilde;es de doen&ccedil;a sist&ecirc;mica
. </i></font></p>     ^cY#v44n2a10.htm##
00611000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704038100071002001300452#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#19#15#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Joseph A, Raj D, Dua HS, Powel PT, Lanyon
 PC, Powell RJ: Infliximab in the treatment of refractory posterior uveitis (Inf
liximab no tratamento da uve&iacute;te posterior refrat&aacute;ria). Ophtalmolog
y 110: 1449-53, 2003. Institui&ccedil;&atilde;o: Queen's medical center, Nothing
han, Reino Unido.</font></p>     ^cY#v44n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#20#16#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#21#17#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
01641000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704141100071002001301482#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#22#18#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Os autores analisaram os resultados do us
o do infliximab em 5 pacientes com uve&iacute;te posterior grave e risco de perd
a de vis&atilde;o, refrat&aacute;rios ao uso de outras drogas imunossupressoras.
 Dos 5 pacientes, 3 tinham s&iacute;ndrome de Beh&ccedil;et e 2 tinham uve&iacut
e;te posterior idiop&aacute;tica. A resposta terap&ecirc;utica foi avaliada atra
v&eacute;s do escore de oftalmoscopia indireta binocular, da presen&ccedil;a de 
vasculite de retina e acuidade visual. Ap&oacute;s duas semanas da primeira apli
ca&ccedil;&atilde;o do infliximab, 4 dos 5 pacientes mostraram melhora marcante 
na turva&ccedil;&atilde;o do v&iacute;treo e acuidade visual. Ap&oacute;s um seg
uimento de seis meses, estes 4 pacientes alcan&ccedil;aram remiss&atilde;o da uv
e&iacute;te posterior e puderam ser retirados de qualquer outro tratamento imuno
ssupressor. Tr&ecirc;s pacientes necessitaram novas infus&otilde;es de inflixima
b. Um dos pacientes desenvolveu tuberculose ocular e sist&ecirc;mica, que respon
deu ao tratamento com tuberculost&aacute;ticos. Os autores assim conclu&iacute;r
am que infliximab &eacute; realmente efetivo no tratamento da uve&iacute;te post
erior refrat&aacute;ria, mas que estes pacientes devem ser investigados para tub
erculose antes do tratamento e vigiados ap&oacute;s as infus&otilde;es do medica
mento. </font></p>     ^cY#v44n2a10.htm##
00546000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704031600071002001300387#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#23#19#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Apesar do reduzido n&uacute;mero de pacie
ntes, a gravidade do problema e a &oacute;tima resposta a esta nova terap&ecirc;
utica alertam para a sua utiliza&ccedil;&atilde;o em situa&ccedil;&otilde;es de 
risco de perda de vis&atilde;o. </font></p>     ^cY#v44n2a10.htm##
00562000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704033200071002001300403#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#24#20#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Kidd D, Burton B, Plant GT, Grahan EM: Ch
ronic relapsing inflammatory optic neuropathy ( CRION) (Neuropatia &oacute;ptica
 inflamat&oacute;ria recorrente cr&ocirc;nica). Brain 126: 276-84, 2003. Institu
i&ccedil;&atilde;o: St Thomas Hospital, Londres.</font></p>     ^cY#v44n2a10.htm
##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#25#21#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#26#22#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
02035000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704180500071002001301876#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#27#23#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Os autores descrevem as caracter&iacute;s
ticas cl&iacute;nicas e a hist&oacute;ria natural de uma forma de neuropatia &oa
cute;ptica inflamat&oacute;ria recorrente, freq&uuml;entemente bilateral e dolor
osa, caracterizada por recidivas e remiss&otilde;es. A resson&acirc;ncia magn&ea
cute;tica de cr&acirc;nio  &eacute; normal e a resson&acirc;ncia dos nervos &oac
ute;pticos freq&uuml;entemente  mostram aumento da intensidade de sinal. Os sina
is e sintomas respondem bem aos corticoster&oacute;ides, embora imunossupressore
s a longo prazo freq&uuml;entemente sejam necess&aacute;rios. Os autores assim d
escrevem uma s&eacute;rie de 15 pacientes em 10 anos, com neuropatia &oacute;pti
ca subaguda que responderam imediatamente aos corticoster&oacute;ides, mas recid
ivaram com a sua retirada. O grau de perda de vis&atilde;o nos casos descritos f
oi mais severo que nos casos de neurite &oacute;ptica desmielinizante. O envolvi
mento de ambos os nervos &oacute;pticos foi comum e geralmente seq&uuml;encial. 
O quadro dos pacientes assemelha-se a uma neurosarcoidose localizada, no qual in
existem evid&ecirc;ncias de les&otilde;es granulomatosas disseminadas em outros 
&oacute;rg&atilde;os. &Eacute; importante reconhecer que os casos descritos pelo
s autores tamb&eacute;m diferem das neuropatias &oacute;pticas desmielinizantes,
 j&aacute; que n&atilde;o h&aacute; altera&ccedil;&otilde;es na resson&acirc;nci
a magn&eacute;tica de cr&acirc;nio, tampouco altera&ccedil;&otilde;es na s&iacut
e;ntese de imunoglobulinas intra-tecais. No caso de neuropatia &oacute;ptica inf
lamat&oacute;ria recorrente, imunossupressores foram utilizados em situa&ccedil;
&otilde;es de depend&ecirc;ncia aos corticoster&oacute;ides ou de refratariedade
.</font></p>     ^cY#v44n2a10.htm##
00600000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704037000071002001300441#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#28#24#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Rechia FM, Brown GC: Systemic disorders a
ssociated with retinal vascular occlusion (Doen&ccedil;as sist&ecirc;micas assoc
iadas com oclus&atilde;o vascular da retina). Cur Opin Opthalmol 11: 462-7, 2000
. Institui&ccedil;&atilde;o: Servi&ccedil;o de retina Wills Eye Hospital, Philad
elfia.</font></p>     ^cY#v44n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#29#25#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#30#26#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
03255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704302500071002001303096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#31#27#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Oclus&otilde;es das art&eacute;rias da re
tina e da circula&ccedil;&atilde;o venosa s&atilde;o causas comuns de piora da v
is&atilde;o, podendo acometer todos os grupos et&aacute;rios. Entre os fatores a
ssociados, encontram-se as doen&ccedil;as c&eacute;rebro-vasculares e as doen&cc
edil;as cardiovasculares, que podem, inclusive, requerer tratamento sist&ecirc;m
ico. A obstru&ccedil;&atilde;o venosa da retina pode ser a apresenta&ccedil;&ati
lde;o cl&iacute;nica de hipertens&atilde;o arterial sist&ecirc;mica, diabetes me
lito e doen&ccedil;a cardiovascular. Os autores revisaram as patologias sist&eci
rc;micas associadas &agrave; oclus&atilde;o da art&eacute;ria da retina. As oclu
s&otilde;es da art&eacute;ria central da retina comumente se manifestam por decl
&iacute;nio agudo e irrevers&iacute;vel na acuidade visual. A retina pode ter ap
ar&ecirc;ncia normal, mas comumente est&aacute; p&aacute;lida e edemaciada, com 
aspecto opacificado. &Ecirc;mbolos na retina podem ser vis&iacute;veis e origina
m-se tipicamente de placas ateroscler&oacute;ticas ulceradas, de trombos dentro 
de art&eacute;rias car&oacute;tidas internas ou mesmo de v&aacute;lvulas card&ia
cute;acas. Quase metade dos pacientes com oclus&atilde;o da art&eacute;ria da re
tina demonstram altera&ccedil;&otilde;es no ecocardiograma, que incluem endocard
ite bacteriana, doen&ccedil;a valvular card&iacute;aca, infarto do mioc&aacute;r
dio, pr&oacute;tese valvar, cardiopatia cong&ecirc;nita e fibrila&ccedil;&atilde
;o atrial. Relatos de casos de defici&ecirc;ncia de prote&iacute;nas anticoagula
ntes end&oacute;genas como anti-trombina III, prote&iacute;na C, prote&iacute;na
 S e muta&ccedil;&atilde;o do fator V de Leiden podem estar presentes em pacient
es com oclus&atilde;o da art&eacute;ria ou veia da retina. Da mesma forma, relat
os de s&iacute;ndrome antifosfolip&iacute;dica prim&aacute;ria e oclus&otilde;es
 arteriolares ou venosa da retina bilaterais t&ecirc;m sido publicados. Causas i
nflamat&oacute;rias sist&ecirc;micas de oclus&otilde;es arteriais da retina incl
uem o l&uacute;pus eritematoso sist&ecirc;mico, granulomatose de Wegener e displ
asia fibromuscular. Homociste&iacute;na &eacute; considerado atualmente um fator
 de risco independente para oclus&atilde;o arterial ou venosa da retina. Os auto
res assim discutem que todos os pacientes com oclus&atilde;o da art&eacute;ria c
entral da retina ou ramos da art&eacute;ria da retina devem ser submetidos a eco
cardiografia e ultra-sonografia de car&oacute;tidas. Pacientes com oclus&atilde;
o da veia central da retina ou de ramos venosos da retina devem ser investigados
 para a presen&ccedil;a de hipertens&atilde;o arterial sist&ecirc;mica, diabetes
 melito, anormalidades lip&iacute;dicas e eleva&ccedil;&otilde;es da homociste&i
acute;na. Uma pesquisa para hipercoagulabilidade, incluindo anticorpos antifosfo
lip&iacute;dicos, deve ser realizada nos pacientes com hist&oacute;ria de evento
s tromb&oacute;ticos.</font></p>     ^cY#v44n2a10.htm##
00749000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704051900071002001300590#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#32#28#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Goldstein DA, Fontanilha FA, Kaul S, Sahi
n O, Tessler HH: Long-term follow-up of patients treated with short-term high-do
se chlorambucil for sight-threatening ocular inflammation (Seguimento a longo pr
azo dos pacientes tratados com altas doses de clorambucil por curto prazo, nas i
nflama&ccedil;&otilde;es oculares com risco de perda de vis&atilde;o). Ophthalmo
logy 109: 370-7, 2002. Institui&ccedil;&atilde;o: Universidade de Illinois.</fon
t></p>     ^cY#v44n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#33#29#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#34#30#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
04443000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704421300071002001304284#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#35#31#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Os autores realizaram estudo com o objeti
vo de avaliar  a efic&aacute;cia e os efeitos adversos de altas doses de cloramb
ucil por curto per&iacute;odo em pacientes com uve&iacute;te grave e risco de pe
rda de vis&atilde;o. Foram tratados 53 pacientes na enfermaria de oftalmologia d
a Universidade de Illinois e tamb&eacute;m no  consult&oacute;rio particular de 
um dos autores. O desenho do  estudo foi retrospectivo, n&atilde;o comparativo e
 de interven&ccedil;&atilde;o.  Os pacientes foram avaliados atrav&eacute;s da a
cuidade visual, grau de inflama&ccedil;&atilde;o ocular e o do desenvolvimento d
e efeitos colaterais. A indica&ccedil;&atilde;o para o uso de clorambucil nesta 
s&eacute;rie incluiu uve&iacute;te n&atilde;o infecciosa severa com risco de per
da de vis&atilde;o, e com pobre resposta pr&eacute;via ou efeitos intolerantes a
o uso de corticoster&oacute;ides ou ao uso de outros imunossupressores. Perda de
 vis&atilde;o foi definida pelos autores como envolvimento no segundo olho de um
 paciente que j&aacute; apresentava incapacidade visual no primeiro olho, ou doe
n&ccedil;a que comprometia de forma importante a m&aacute;cula no outro olho, ou
 doen&ccedil;a ocular que causava mau funcionamento dos fotorreceptores difusame
nte. Cinq&uuml;enta e tr&ecirc;s pacientes foram tratados com clorambucil por pe
lo menos tr&ecirc;s semanas, sendo que 39 foram reexaminados e 10 foram incapaze
s de retornar. Nove destes 10 pacientes que n&atilde;o retornaram foram entrevis
tados por telefone e um foi contatado por e-mail. Tr&ecirc;s pacientes foram per
didos de seguimento e 1 faleceu por problema card&iacute;aco tr&ecirc;s meses ap
&oacute;s o tratamento com clorambucil. Os diagn&oacute;sticos mais comuns foram
: doen&ccedil;a de Beh&ccedil;et (32%), oftalmia simp&aacute;tica (15%), escleri
te (11%), iridociclite severa com edema macular cist&oacute;ide (11%), coroidite
 serpiginosa (9%), vasculite da cor&oacute;ide/retina (8%), Vogt-Koyanagi-Harada
 (4%), uve&iacute;te intermedi&aacute;ria (2%), retinocoroidopatia de birdshot (
2%), xantogranuloma juvenil (2%) e retinopatia auto-imune(2%). A dura&ccedil;&at
ilde;o m&eacute;dia do uso do clorambucil foi 16 semanas. A dose m&eacute;dia m&
aacute;xima de clorambucil foi 20mg por dia, com varia&ccedil;&atilde;o de 10mg 
a 30mg . Dos 53 pacientes tratados com clorambucil, 41 (77%) estavam ainda em re
miss&atilde;o, sem recorr&ecirc;ncia da doen&ccedil;a na &uacute;ltima avalia&cc
edil;&atilde;o e sem necessidade de novas medica&ccedil;&otilde;es de uso sist&e
circ;mico, no seguimento m&eacute;dio de 54 meses. Doze pacientes (23%) tiveram 
doen&ccedil;a recorrente, com necessidade de corticoster&oacute;ides orais e/ ou
 outros imunossupressores. Amenorr&eacute;ia secund&aacute;ria desenvolveu em 7 
mulheres (26%), herpes zoster n&atilde;o oft&aacute;lmico ocorreu em 6 pacientes
 e 2 pacientes necessitaram transfus&otilde;es de plaquetas. Nenhum paciente des
envolveu malignidade e 1 paciente foi submetido &agrave; esplenectomia por tromb
ocitopenia recorrente, a qual ocorreu ap&oacute;s o tratamento, mas n&atilde;o f
oi considerada secund&aacute;ria ao uso do clorambucil. Do total de pacientes, 4
7% apresentaram melhora em pelo menos duas linhas na escala de acuidade visual d
e Snellen, sendo que 33% apresentaram melhora em pelo menos tr&ecirc;s linhas. S
eis pacientes (11%) tiveram uma piora da vis&atilde;o apesar do tratamento com c
lorambucil, enquanto 8 pacientes (15%) n&atilde;o tiveram altera&ccedil;&otilde;
es na acuidade visual. Os autores assim prop&otilde;em que, em casos de uve&iacu
te;te severa, os pacientes sejam inicialmente tratados com corticoster&oacute;id
es orais; se estes forem insuficientes, imunossupressores como metotrexate, azat
ioprina ou ciclosporina podem ser ministrados. Em casos de doen&ccedil;a severa 
n&atilde;o responsiva aos corticoster&oacute;ides ou aos agentes poupadores de c
orticoster&oacute;ides, clorambucil deve ser considerado. O seu uso deve ser por
 curta dura&ccedil;&atilde;o, pois comumente leva &agrave; remiss&atilde;o e evi
ta a necessidade de corticoterapia prolongada ou uso prolongado de outro imunoss
upressor.</font></p>     ^cY#v44n2a10.htm##
00723000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704049300071002001300564#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#36#32#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Zierhut M, St&uuml;biger N, Aboalchamat W
, Jandenberger H, Bialasiewicz A, Engelmann K: Immunnosuppressive therapy with m
ycophenolate mofetil (cellcept) in treatment of uveitis (Terapia imunossupressor
a com micofenolato mofetil no tratamento das uve&iacute;tes). Der Ophtalmologe: 
Zeitschrift Der Deutschen Ophtalmologischen Gesellschaft 98: 647-51, 2001. Insti
tui&ccedil;&atilde;o: Universidade T&uuml;bingen.</font></p>     ^cY#v44n2a10.ht
m##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#37#33#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#38#34#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
02825000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704259500071002001302666#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#39#35#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Formas severas de uve&iacute;te comumente
 necessitam ser tratadas com imunossupress&atilde;o sist&ecirc;mica. Todas as dr
ogas imunossupressoras dispon&iacute;veis s&atilde;o conhecidas por sua alta fre
q&uuml;&ecirc;ncia relativa de efeitos adversos. Micofenolato mofetil, uma droga
 imunossupressora nova tem mostrado boa efic&aacute;cia no tratamento dos transp
lantes de &oacute;rg&atilde;os e no tratamento de muitas doen&ccedil;as auto-imu
nes. O uso dessa droga em uve&iacute;te, como monoterapia ou combinado com corti
coster&oacute;ide, tem mostrado menos efeitos adversos. O objetivo deste estudo 
multic&ecirc;ntrico foi investigar se a monoterapia com micofenolato mofetil &ea
cute; efetiva nas v&aacute;rias formas de uve&iacute;te. Foram tratados 10 pacie
ntes, dos quais 3 tinham uve&iacute;te anterior, 2 tinham uve&iacute;te intermed
i&aacute;ria, 4 tinham panuve&iacute;te e 1 vasculite de retina. Os pacientes fo
ram tratados atrav&eacute;s de um protocolo de estudo prospectivo, com um grama 
de micofenolato mofetil, duas vezes ao dia. A imunossupress&atilde;o pr&eacute;v
ia foi descontinuada em conseq&uuml;&ecirc;ncia do aparecimento de efeitos adver
sos ou da inefic&aacute;cia do tratamento. O tempo de seguimento variou de 1 a 1
2 meses (m&eacute;dia de 4,5 meses). Durante o uso de micofenolato mofetil, 5 do
s 10 pacientes utilizaram simultaneamente prednisolona e 1 metotrexate. Dos 10 p
acientes, 8 ficaram livres de recorr&ecirc;ncias da uve&iacute;te. No in&iacute;
cio do tratamento com micofenolato mofetil, 1 paciente em uso de ciclosporina A 
melhorou somente ap&oacute;s a troca da ciclosporina para metotrexate. Um pacien
te com uve&iacute;te bilateral recorrente necessitou de corticoterapia complemen
tar para recorr&ecirc;ncia em um dos olhos. Efeitos adversos foram diarr&eacute;
ia em 1 paciente, e outros sintomas gastrintestinais em outro paciente, provocan
do a interrup&ccedil;&atilde;o do tratamento em ambos. Os autores assim concluem
 que o micofenolato mofetil cessou a atividade inflamat&oacute;ria ocular em 8 d
os 10 pacientes e reduziu de forma dr&aacute;stica a incid&ecirc;ncia de recorr&
ecirc;ncia, posto que n&atilde;o haviam apresentado boa resposta com outros imun
ossupressores. Os efeitos adversos foram toler&aacute;veis, quando comparados co
m outros imunossupressores. Os autores alertam para a necessidade de outros estu
dos com maiores tempo de seguimento e n&uacute;mero de pacientes. Apontam para a
 necessidade de um estudo comparativo com ciclosporina A a longo prazo.</font></
p>     ^cY#v44n2a10.htm##
00746000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704051600071002001300587#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#40#36#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Samson CM, Waheed N, Baltatzis S, Foster 
S: Methotrexate therapy for chronic noninfectious uveitis. Analysis of a case se
ries of 160 patients (Terapia com metotrexate para uve&iacute;te n&atilde;o infe
cciosa cr&ocirc;nica. An&aacute;lise de uma s&eacute;rie de 160 pacientes). Opht
almology 108: 1134-9, 2001. Institui&ccedil;&atilde;o: Massachusetts Eye and Ear
 Infirmary, servi&ccedil;o de imunologia ocular e uve&iacute;te, Boston.</font><
/p>     ^cY#v44n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#41#37#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#42#38#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
03993000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704376300071002001303834#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#43#39#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Os autores avaliaram a evolu&ccedil;&atil
de;o dos pacientes com uve&iacute;te n&atilde;o infecciosa cr&ocirc;nica, n&atil
de;o responsivos ao tratamento com antiinflamat&oacute;rios e tratados com metot
rexate. O estudo incluiu todos os pacientes que usaram metotrexate para uve&iacu
te;te entre 1985 e 1999 naquela institui&ccedil;&atilde;o. Foram avaliados o gra
u de controle da inflama&ccedil;&atilde;o ocular, o efeito poupador de corticost
er&oacute;ide do metotrexate, a acuidade visual e os efeitos adversos do uso do 
metotrexate. Um total de 160 pacientes foram avaliados, sendo que o controle da 
inflama&ccedil;&atilde;o ocular ocorreu em 76,2%, o efeito poupador de corticost
er&oacute;ide ocorreu em 56% e a acuidade visual melhorou ou foi mantida em 90% 
dos pacientes. Efeitos adversos que provocaram a descontinuidade do metotrexate 
ocorreram em 18% dos pacientes, por&eacute;m, havendo efeitos adversos severos e
m apenas 8,1% dos pacientes. N&atilde;o ocorreram morbidade ou mortalidade a lon
go prazo, secund&aacute;rias ao uso do metotrexate. Investiga&ccedil;&atilde;o l
aboratorial foi realizada nos pacientes com hemograma, VDRL, FAN, HLA-B27 e soro
logia para toxoplasmose conforme o quadro cl&iacute;nico individual do paciente.
 A uve&iacute;te foi classificada de acordo com o sistema de classifica&ccedil;&
atilde;o do grupo de estudo de uve&iacute;te internacional. A uve&iacute;te foi 
considerada como n&atilde;o infecciosa na aus&ecirc;ncia de evid&ecirc;ncias de 
infec&ccedil;&atilde;o, ap&oacute;s uma pesquisa diagn&oacute;stica. A uve&iacut
e;te foi classificada como cr&ocirc;nica quando persistente por mais de tr&ecirc
;s meses ou recorrente no per&iacute;odo de tr&ecirc;s meses. Os pacientes usara
m o metotrexate com doses iniciais de 7,5 mg por semana, junto com &aacute;cido 
f&oacute;lico 1 mg ao dia. Alguns pacientes que n&atilde;o apresentaram resposta
 ao metotrexate utilizaram a sua associa&ccedil;&atilde;o com ciclosporina, a um
a dose inicial desta de 2,5 mg kg/dia (geralmente 150 a 200mg/dia). Dos 160 paci
entes estudados, 74% eram mulheres com idade m&eacute;dia de in&iacute;cio da uv
e&iacute;te de 33 anos. A dura&ccedil;&atilde;o m&eacute;dia da uve&iacute;te an
tes do in&iacute;cio do metotrexate foi 5 anos e 3 meses. O tempo m&eacute;dio d
e tratamento com metotrexate foi de 16,4 meses. Com rela&ccedil;&atilde;o ao tip
o de uve&iacute;te, 2/3 tinham uve&iacute;te anterior, 15% dos casos tinham panu
ve&iacute;te e 20% tinham uve&iacute;te intermedi&aacute;ria e/ou posterior. Uma
 doen&ccedil;a sist&ecirc;mica relacionada com a uve&iacute;te estava presente e
m 64% dos pacientes tratados. Entre as causas de uve&iacute;te, 37% apresentavam
 uve&iacute;te HLA-B27 positiva, 21 % artrite reumat&oacute;ide juvenil, 10% sar
coidose, 9% espondiloartropatia soronegativa HLA-B27 negativa e 5% doen&ccedil;a
 inflamat&oacute;ria intestinal, sendo as outras patologias sist&ecirc;micas men
os freq&uuml;entes. A dose do metotrexate variou de 7,5 a 40 mg (12,3 mg/semana 
em m&eacute;dia). Dos 14 pacientes que utilizaram a combina&ccedil;&atilde;o de 
metotrexate e ciclosporina, 11 (71%) melhoraram. Os autores entendem que o metot
rexate pode ser utilizado de forma segura nos pacientes com uve&iacute;te, mas a
lertam que a natureza retrospectiva do estudo atual justifica uma interpreta&cce
dil;&atilde;o ainda cuidadosa dos resultados. Os autores concluem nesta s&eacute
;rie de casos publicada (a maior at&eacute; o momento), que o uso do metotrexate
 em uve&iacute;tes &eacute; efetivo nos pacientes n&atilde;o responsivos ao uso 
de corticoster&oacute;ides e tamb&eacute;m nos pacientes que tiveram efeitos col
aterais com os corticoster&oacute;ides.</font></p>     ^cY#v44n2a10.htm##
00699000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704046900071002001300540#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#44#40#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Sfikakis PP, Kalamanis P, et al: Successf
ul treatment of ocular relapse in patients with Beh&ccedil;et's disease with a s
ingle infusion of the anti-TNF agent Infliximab (Tratamento eficaz das recidivas
 oculares nos pacientes com doen&ccedil;a de Beh&ccedil;et). Arthritis 46: S181,
 Abstract 399, 2002. Institui&ccedil;&atilde;o: Hospital geral da Universidade d
e Athenas, Gr&eacute;cia.</font></p>     ^cY#v44n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#45#41#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#46#42#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
03142000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704291200071002001302983#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#47#43#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Uma infus&atilde;o isolada do anticorpo m
onoclonal anti-TNF infliximab foi dada a 5 pacientes com doen&ccedil;a de Beh&cc
edil;et e panuve&iacute;te grave com risco de perda de vis&atilde;o. A terap&eci
rc;utica imunossupressora anterior foi mantida nas mesmas doses ou foi aumentada
 nos 5 pacientes. Houve melhora, com supress&atilde;o efetiva da inflama&ccedil;
&atilde;o ocular naqueles pacientes, o que foi publicado no <i>Lancet </i>de 200
1. Os autores estenderam esta investiga&ccedil;&atilde;o, agora com 14 pacientes
 com doen&ccedil;a de Beh&ccedil;et, mas com o uso de infliximab como monoterapi
a. Uma infus&atilde;o &uacute;nica de infliximab de 5mg/kg foi administrada a 10
 homens e 4 mulheres, com idades variando entre 21 e 56 anos. Os pacientes tinha
m hist&oacute;ria de m&uacute;ltiplas recorr&ecirc;ncias oculares, tendo a &uacu
te;ltima ocorrido nas &uacute;ltimas 48 horas da administra&ccedil;&atilde;o do 
infliximab. O infliximab foi administrado como tratamento inicial em 11 olhos de
 pacientes n&atilde;o tratados, ou associados ao tratamento anterior em 13 olhos
. Exames foram realizados para avalia&ccedil;&atilde;o no dia 1, 7, 14 e 28 ap&o
acute;s o tratamento. Recorr&ecirc;ncias oculares consistiram de uve&iacute;te a
nterior em 3 olhos, uve&iacute;te posterior em 12 olhos e panuve&iacute;te em 9 
olhos, com ou sem vasculite de retina (17 e 7 olhos, respectivamente). A acuidad
e visual estava reduzida em todos os pacientes, por&eacute;m, no primeiro dia ap
&oacute;s o in&iacute;cio do tratamento, houve melhora significante da acuidade 
visual, forte redu&ccedil;&atilde;o das c&eacute;lulas na c&acirc;mara anterior 
e redu&ccedil;&atilde;o tamb&eacute;m na turva&ccedil;&atilde;o do v&iacute;treo
 (m&eacute;dia 50%). Inflama&ccedil;&atilde;o ocular aguda incluindo vasculite e
 les&otilde;es da retina resolveram completamente em 7 dias (12 olhos, incluindo
 1 com hip&oacute;pio) ou em 14 dias (completamente em 7 olhos e em 80% a 90% em
 5 olhos). A acuidade visual retornou aos n&iacute;veis anteriores ao epis&oacut
e;dio inflamat&oacute;rio atual (&uacute;ltima recidiva) em todos os pacientes. 
Edema macular cist&oacute;ide, presente em 5 pacientes, melhorou de forma signif
icante no dia 28 em 3 olhos e permaneceu est&aacute;vel em 2 olhos. As les&otild
e;es da retina cr&ocirc;nica n&atilde;o sofreram influ&ecirc;ncia do uso do infl
iximab. Os pacientes que tinham oligoartrite ( 5 pacientes ) e os pacientes que 
tinham aftas orais durante o estudo ( 7 pacientes ) tiveram melhora destes sinto
mas em 1 a 4 dias ap&oacute;s a infus&atilde;o. N&atilde;o foram observados efei
tos adversos em qualquer dos pacientes. Os autores assim prop&otilde;em que a ef
ic&aacute;cia de uma &uacute;nica aplica&ccedil;&atilde;o de infliximab constitu
i o tratamento de escolha nesta situa&ccedil;&atilde;o ocular grave.</font></p> 
    ^cY#v44n2a10.htm##
00944000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704071400071002001300785#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#48#44#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Ylmaz O, Fresko I, Yasici H, et al: The r
esponse of treatment resistant uveitis in Beh&ccedil;et's syndrome (BS) to a TNF
-</font>&#945;<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> block
er , etarnecept: A open study (A resposta ao tratamento da uve&iacute;te refrat&
aacute;ria na s&iacute;ndrome de Beh&ccedil;et a um bloqueador do TNF-</font>&#9
45;<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> etanercept: um e
studo aberto). Arthritis 46: S181, Abstract 400, 2002. Institui&ccedil;&atilde;o
: Centro de pesquisa em s&iacute;ndrome de Beh&ccedil;et, Faculdade de Medicina 
Cerrahpasa, Istanbul, Turquia.</font></p>     ^cY#v44n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#49#45#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#50#46#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
02599000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704236900071002001302440#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#51#47#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">O objetivo do estudo foi determinar a res
posta ao tratamento da uve&iacute;te resistente ao tratamento na s&iacute;ndrome
 de Beh&ccedil;et, com o uso do bloqueador do TNF-</font>&#945;<font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"> etanercept. Foram estudados 10 pacie
ntes do sexo masculino, com idade m&eacute;dia de 29,8 anos. Dentre os crit&eacu
te;rios de inclus&atilde;o para o estudo, os autores exigiram que os pacientes t
ivessem tido pelo menos um ataque de panuve&iacute;te durante os &uacute;ltimos 
seis meses, uma acuidade visual de pelo menos 1/10 na escala visual de Snellen p
ara um dos olhos e refratariedade ao tratamento pr&eacute;vio com a combina&cced
il;&atilde;o de corticoster&oacute;ides, ciclosporina e azatioprina. Todos os pa
cientes receberam inje&ccedil;&otilde;es subcut&acirc;neas de 25mg de etanercept
 2 vezes por semana por um per&iacute;odo total de 6 meses, al&eacute;m das medi
ca&ccedil;&otilde;es que os pacientes estavam previamente usando, exceto a ciclo
sporina A, que teve de ser descontinuada. Os pacientes foram, ent&atilde;o, aval
iados com intervalos mensais por um oftalmologista. O per&iacute;odo de seguimen
to p&oacute;s-tratamento foi de 53 meses e foi poss&iacute;vel em todos os pacie
ntes inicialmente tratados. As diferen&ccedil;as da acuidade visual com rela&cce
dil;&atilde;o ao in&iacute;cio do tratamento foram analisadas com teste t paread
o. Os autores tamb&eacute;m avaliaram as doses de corticoster&oacute;ides utiliz
adas, antes, durante e ap&oacute;s o tratamento. A acuidade visual melhorou em 6
 dos 10 pacientes, e permaneceu est&aacute;vel nos outros 4 pacientes. Ap&oacute
;s o t&eacute;rmino da terapia a acuidade visual voltou a piorar em 7 pacientes,
 permaneceu est&aacute;vel em 2 pacientes e melhorou em 1 paciente. Houve redu&c
cedil;&atilde;o das doses de corticoster&oacute;ide em 8 dos 10 pacientes durant
e o tratamento, enquanto o requerimento para corticoster&oacute;ide aumentou ap&
oacute;s o pe-menos manter a acuidade visual em um pequeno grupo de r&iacute;odo
 do tratamento em 7 pacientes. Os autores assim pacientes com doen&ccedil;a de B
eh&ccedil;et, mas este efeito n&atilde;o &eacute; concluem que o efeito do etane
rcept foi ben&eacute;fico em pelo mantido ap&oacute;s o t&eacute;rmino do tratam
ento.</font></p>     ^cY#v44n2a10.htm##
00551000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704032100071002001300392#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#52#48#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Rosenberg AM: Uveitis associated eith chi
ldhood rheumatic diseases (Uve&iacute;te associada com doen&ccedil;as reum&aacut
e;ticas da inf&acirc;ncia). Curr Opin Rheumatol 14: 542-7, 2002. Institui&ccedil
;&atilde;o: Saskatoon, Canad&aacute;.</font></p>     ^cY#v44n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#53#49#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#54#50#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
04842000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704461200071002001304683#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#55#51#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Aproximadamente 30% a 40% das crian&ccedi
l;as com uve&iacute;te t&ecirc;m uve&iacute;te anterior, 40% a 50% t&ecirc;m uve
&iacute;te posterior, 10% a 20% t&ecirc;m uve&iacute;te intermedi&aacute;ria e 5
% a 10% tem panuve&iacute;te. A uve&iacute;te anterior assintom&aacute;tica cr&o
circ;nica est&aacute; nitidamente relacionada com a artrite idiop&aacute;tica ju
venil oligoarticular e representa uma entidade distinta. A preval&ecirc;ncia da 
uve&iacute;te associada &agrave; artrite idiop&aacute;tica juvenil tem sido meno
s freq&uuml;ente atualmente, mas varia entre 6% e 17%. O progn&oacute;stico da u
ve&iacute;te associada &agrave; artrite idiop&aacute;tica juvenil est&aacute; me
lhorando, com menor incid&ecirc;ncia atual de perda de vis&atilde;o ou de outras
 complica&ccedil;&otilde;es oculares, em raz&atilde;o do diagn&oacute;stico prec
oce, monitora&ccedil;&atilde;o mais vigilante da doen&ccedil;a ocular e terapia 
imunossupressora mais agressiva usada no tratamento da doen&ccedil;a articular c
oncomitante. As uve&iacute;tes posteriores, embora bem menos freq&uuml;entes, ta
mb&eacute;m podem ocorrer na inf&acirc;ncia e s&atilde;o caracterizadas pela inf
lama&ccedil;&atilde;o da retina, cor&oacute;ide, v&iacute;treo e corpo ciliar. A
s formas n&atilde;o infecciosas de uve&iacute;te posterior incluem aquelas causa
das pela doen&ccedil;a de Beh&ccedil;et, sarcoidose, Vogt-Koyanagi-Harada, oftal
mia simp&aacute;tica, uve&iacute;te intermedi&aacute;ria e corioretinopatia de b
irshot. Nefrite t&uacute;bulo-intersticial e s&iacute;ndrome da uve&iacute;te, u
ma condi&ccedil;&atilde;o de in&iacute;cio mais freq&uuml;ente na inf&acirc;ncia
 e adolesc&ecirc;ncia, parece ser mais comum atualmente do que se acreditava. A 
uve&iacute;te associada &agrave; nefrite t&uacute;bulo-intersticial geralmente &
eacute; anterior, mas ambas as formas intermedi&aacute;ria e posterior podem oco
rrer. Pars planitis, uma uve&iacute;te intermedi&aacute;ria, representa entre 15
% e 20% das crian&ccedil;as com uve&iacute;te e &eacute; considerada uma doen&cc
edil;a das crian&ccedil;as e adultos jovens. O in&iacute;cio logo na inf&acirc;n
cia parece estar associado a uma acuidade visual pior, tanto no in&iacute;cio qu
anto no seguimento. O tratamento da uve&iacute;te n&atilde;o infecciosa continua
 sendo a corticoterapia t&oacute;pica. Em raz&atilde;o da toxicidade potencial d
o corticoster&oacute;ide a longo prazo, pesquisas continuam para o encontro de t
erapias mais efetivas e op&ccedil;&otilde;es terap&ecirc;uticas mais seguras. Es
tudos iniciais sugeriam o uso do clorambucil no tratamento da uve&iacute;te da a
rtrite idiop&aacute;tica juvenil. A experi&ecirc;ncia com o uso do inibidor do f
ator de necrose tumoral alfa etanercept em 10 pacientes foi relatada no tratamen
to de crian&ccedil;as com uve&iacute;te refrat&aacute;ria a corticoster&oacute;i
de t&oacute;pico, metotrexate e ciclosporina. Sete dos pacientes tinham uve&iacu
te;te associada &agrave; artrite idiop&aacute;tica juvenil e 3 tinham uve&iacute
;te idiop&aacute;tica. Dos 16 olhos avaliados, 10 (63%) mostraram redu&ccedil;&a
tilde;o nos indicadores de inflama&ccedil;&atilde;o ocular. Outro estudo, com in
ibidor de TNF em 16 pacientes, mostrou melhora da doen&ccedil;a ocular em 38%: e
ste grupo incluiu 4 pacientes com uve&iacute;te associada &agrave; artrite idiop
&aacute;tica juvenil. Num estudo prospectivo de 10 anos, Gerloni <i>et al.</i> r
elataram sua experi&ecirc;ncia no tratamento de 34 pacientes com artrite juvenil
 e ciclosporina, sendo que deste total 7 pacientes (21%) tinham uve&iacute;te as
sociada. Dos 12 olhos acometidos, 8 (66%) mostraram melhora nos sinais de inflam
a&ccedil;&atilde;o ocular. A acuidade visual melhorou em 7 dos 12 olhos acometid
os (58%) e uma redu&ccedil;&atilde;o da terapia com corticoster&oacute;ide foi a
ssim poss&iacute;vel. Interven&ccedil;&atilde;o cir&uacute;rgica em alguns foi r
espons&aacute;vel pela melhora do quadro ocular. Seis dos 7 pacientes com uve&ia
cute;te tratados com ciclosporina desenvolveram efeitos adversos, incluindo aume
nto da creatinina (3 pacientes), hipertricose (2 pacientes) e hiperplasia gengiv
al (2 pacientes). Com rela&ccedil;&atilde;o &agrave; terapia ocular futura, o us
o de implante ocular intra-v&iacute;treo poder&aacute; contribuir para a melhora
 do tratamento.Apesar do reduzido n&uacute;mero de pacientes, a gravidade do pro
blema e a &oacute;tima resposta a esta nova terap&ecirc;utica alertam para a sua
 utiliza&ccedil;&atilde;o em situa&ccedil;&otilde;es de risco de perda de vis&at
ilde;o. </font></p>     ^cY#v44n2a10.htm##
00490000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704026000071002001300331#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#56#52#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Ohara K: Ocular sarcoidosis (Sarcoidose o
cular). Nippon Rinsho Japanese Journal of Clinical Medicine 60: 1807-12, 2002. I
nstitui&ccedil;&atilde;o: Escola m&eacute;dica de Nipon.</font></p>     ^cY#v44n
2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#57#53#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#58#54#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
01366000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704113600071002001301207#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#59#55#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">O envolvimento ocular na sarcoidose &eacu
te; freq&uuml;ente e pode ser a manifesta&ccedil;&atilde;o cl&iacute;nica inicia
l da doen&ccedil;a. As les&otilde;es oculares mais comuns incluem uve&iacute;te 
granulomatosa associada  a n&oacute;dulos trabeculares na &iacute;ris, faixas de
 opacidade no v&iacute;treo e perivasculite da retina, principalmente afetando v
eias e exsudatos na retina e cor&oacute;ide. Metade dos pacientes com les&otilde
;es oculares t&iacute;picas sugestivas de sarcoidose n&atilde;o mostraram evid&e
circ;ncias de comprometimento sist&ecirc;mico, permanecendo com quadro de sarcoi
dose prov&aacute;vel. Os riscos de deteriora&ccedil;&atilde;o visual s&atilde;o 
glaucoma secund&aacute;rio, opacidades no v&iacute;treo, edema macular cist&oacu
te;ide e neovasculariza&ccedil;&atilde;o da retina. Do total de pacientes, 34% f
oram tratados com corticoster&oacute;ide sist&ecirc;mico, sendo que alguns deles
 requereram outros tratamentos, tais como o metotrexate. O porcentual dos que ev
olu&iacute;ram com acuidade visual pobre foi de 21%.</font></p>     ^cY#v44n2a10
.htm##
00589000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704035900071002001300430#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#60#56#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Castro ED, Cantalapiedra JMH, Cano CM, Os
&eacute;s S: Ocular sarcoidosis . Retrospective study of 18 cases (Sarcoidose   
 ocular. Estudo retrospectivo de 18 casos). Arch Soc Espanhola de Oftalmol 77: 3
01-8, 2002. Institui&ccedil;&atilde;o: Universidade de Valladolid, Espanha.</fon
t></p>     ^cY#v44n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#61#57#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#62#58#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
02326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704209600071002001302167#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#63#59#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Os autores analisaram as caracter&iacute;
sticas cl&iacute;nicas e epidemiol&oacute;gicas, os m&eacute;todos diagn&oacute;
sticos e o progn&oacute;stico visual final de pacientes com sarcoidose ocular. T
rata-se de um estudo retrospectivo de 18 pacientes, no per&iacute;odo de mar&cce
dil;o de 1989 a maio de 1999. Todos os pacientes tiveram os seguintes dados anal
isados: idade, sexo, bilateralidade, progn&oacute;stico visual inicial e final, 
manifesta&ccedil;&otilde;es ocular e sist&ecirc;mica, est&aacute;gio da radiogra
fia do t&oacute;rax, marcadores laboratoriais, cintilografia com g&aacute;lio, r
esultado da bi&oacute;psia, tratamento cl&iacute;nico e cir&uacute;rgico e compl
ica&ccedil;&otilde;es do tratamento. A idade m&eacute;dia de in&iacute;cio da do
en&ccedil;a foi 49,7 anos, 14 pacientes (77,8%) eram mulheres e 4 (22,2%) eram h
omens. O tempo m&eacute;dio de acompanhamento foi de 40,3 meses. Nove pacientes 
(50%) foram submetidos &agrave; bi&oacute;psia. A presen&ccedil;a de granuloma n
&atilde;o caseoso foi constatada em 7 (77,8%). A cintilografia com g&aacute;lio 
foi positiva em 16 pacientes (88,8%). A manifesta&ccedil;&atilde;o ocular mais c
omumente encontrada foi panuve&iacute;te (40%). Entre os 30 olhos estudados, env
olvimento conjuntival foi encontrado em 10 (33,3%), catarata secund&aacute;ria e
m 9 (30%) e glaucoma secund&aacute;rio em 6 (20%). Onze pacientes (61,1%) foram 
tratados com corticoster&oacute;ide oral e 10 (55,5%) com ciclosporina A. No mom
ento em que a sarcoidose foi diagnosticada, 11 olhos (36,6%) apresentaram acuida
de visual melhor que 0,6, e ao fim do seguimento a acuidade visual foi melhor qu
e 0,6 em 17 olhos (56,6%). Os autores assim concluem que o controle adequado da 
inflama&ccedil;&atilde;o ocular pode melhorar o progn&oacute;stico nos pacientes
 com sarcoidose ocular e relatam que nestes pacientes o envolvimento do segmento
 posterior (uve&iacute;te posterior, edema macular ou membrana epitelial) pode e
star associado a um pior progn&oacute;stico visual. </font></p>     ^cY#v44n2a10
.htm##
00687000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704045700071002001300528#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#64#60#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Kruithof E, Kestelyn P, Elewaut C, et al:
 Successful use of infliximab in a patient with treatment resistant spondyloarth
ropathy related uveitis (Uso eficaz do infliximab em um paciente com uve&iacute;
te associado a espondiloartropatia resistente ao tratamento). Ann Rheum Dis 61: 
470, 2002. Institui&ccedil;&atilde;o: Hospital universit&aacute;rio de Ghent, B&
eacute;lgica.</font></p>     ^cY#v44n2a10.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#65#61#text#66#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#66#62#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
03658000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704342800071002001303499#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#67#63#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Uve&iacute;te anterior e intermedi&aacute
;ria s&atilde;o processos inflamat&oacute;rios de causas diversas, que incluem t
rauma, doen&ccedil;as linfoproliferativas e isquemia. As outras etiologias das u
ve&iacute;tes t&ecirc;m patog&ecirc;nese imune, com um componente autoimune asso
ciado. Uve&iacute;te &eacute; uma manifesta&ccedil;&atilde;o comum no grupo das 
espondiloartropatias e pode ocorrer em 40% dos pacientes. Nestes casos, a uve&ia
cute;te se caracteriza por ser anterior e aguda. Ali&aacute;s, das causas de uve
&iacute;te anterior aguda, as espondiloartropatias soronegativas s&atilde;o as d
oen&ccedil;as sist&ecirc;micas mais comuns. Al&eacute;m disso, como acontece nos
 pacientes com espondiloartropatia soronegativa, a inflama&ccedil;&atilde;o inte
stinal subcl&iacute;nica tamb&eacute;m tem sido encontrado nos pacientes com uve
&iacute;te anterior aguda isolada, mesmo sem evid&ecirc;ncias cl&iacute;nicas de
 espondiloartropatia. Os efeitos ben&eacute;ficos do bloqueio do fator de necros
e tumoral </font>&#945;<font size="2" face="Verdana, Arial, Helvetica, sans-seri
f"> com infliximab est&atilde;o bem estabelecidos na doen&ccedil;a de Crohn e at
ualmente tamb&eacute;m no controle dos sintomas articulares dos pacientes com es
pondiloartropatia. Considerando os aspectos de associa&ccedil;&atilde;o das espo
ndiloartropatias com as uve&iacute;tes e os bons resultados terap&ecirc;uticos d
o bloqueio do TNF neste grupo de doen&ccedil;as, os autores relatam os efeitos d
o bloqueio do TNF infliximab na uve&iacute;te resistente ao tratamento em um pac
iente com espondiloartropatia. Trata-se de um paciente do sexo masculino com esp
ondiloartropatia soronegativa HLA-B27 positiva, que apresenta uve&iacute;te reco
rrente do olho esquerdo e que evoluiu com uve&iacute;te anterior cr&ocirc;nica e
 intermedi&aacute;ria. O paciente n&atilde;o teve resposta com corticoster&oacut
e;ide t&oacute;pico, inje&ccedil;&otilde;es subconjuntivais e corticoster&oacute
;ides sist&ecirc;micos. N&atilde;o houve melhora tamb&eacute;m com sulfassalasin
a e ciclosporina. O paciente foi ent&atilde;o submetido a um esquema de indu&cce
dil;&atilde;o com infliximab 5mg/kg na semana 0, semana 2 e semana 6. Ap&oacute;
s 1 semana da indu&ccedil;&atilde;o, a acuidade visual melhorou de forma marcant
e. Esta melhora foi mantida at&eacute; a semana 14, ou seja, 8 semanas ap&oacute
;s a &uacute;ltima infus&atilde;o, ap&oacute;s a qual o paciente teve recorr&eci
rc;ncia. O retratamento com 5mg/kg na semana 14 foi, contudo, novamente eficaz e
m melhorar a inflama&ccedil;&atilde;o ocular e a acuidade visual. A partir de en
t&atilde;o o paciente foi mantido em tratamento a cada 8 semanas, sendo que a in
flama&ccedil;&atilde;o permaneceu est&aacute;vel. N&atilde;o houve necessidade f
utura de inje&ccedil;&otilde;es subconjuntivais ou de corticoster&oacute;ides si
st&ecirc;micos durante este per&iacute;odo. A dose de corticoster&oacute;ide ora
l foi substancialmente reduzida. Considerando os efeitos ben&eacute;ficos do inf
liximab na doen&ccedil;a de Crohn e nas espondiloartropatias e a observa&ccedil;
&atilde;o da efic&aacute;cia cl&iacute;nica neste paciente com uve&iacute;te rel
acionada com espondiloartropatia, os autores sugerem a explora&ccedil;&atilde;o 
deste potencial terap&ecirc;utico nas uve&iacute;tes relacionadas com espondiloa
rtropatia soronegativa. </font></p>     ^cY#v44n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#68#64#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#69#65#text#66#<p>&nbsp;</p>     ^cY#v4
4n2a10.htm##
00359000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704012900071002001300200#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a10.htm#S#p#70#66#text#66#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Respons&aacute;vel: Iv&acirc;nio Alves Pe
reira</font></p>     ^cY#v44n2a10.htm##
00270000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00300097#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a11.htm#S#o#1#1#text#1#201
10406#085820#v44n2a11.htm#19##
00501000000000325000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000700094158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016000200130
0162#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a11.htm#S#h#2#1#text#1#oa#pt#b
r1.1#1#4.0#ILUS#11#RBR060#nd#Rev. Bras. Reumatol.#44#2#20040400#^f168^l168#0482-
5004#1#v44n2a11.htm##
00501000000000325000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000700094158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016000200130
0162#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a11.htm#S#f#3#1#text#1#oa#pt#b
r1.1#1#4.0#ILUS#11#RBR060#nd#Rev. Bras. Reumatol.#44#2#20040400#^f168^l168#0482-
5004#1#v44n2a11.htm##
00631000000000349000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100038000500104121000300109049000700112158000300119
03000200012203100030014203200020014506500090014701400110015603500100016712300020
0177002001300179008008900192#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a11.ht
m#S#l#4#1#text#1#^mmar./abr.^a2004#oa#pt#br1.1#1#4.0#ilus#11#RBR060#nd#Rev. Bras
. Reumatol#44#2#20040400#^f168^l168#0482-5004#1#v44n2a11.htm#Internet^ihttp://ww
w.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042004000200011##
00363000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704013500069002001300204#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#5#1#text#15#<p align="right"><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ESPA&Ccedil;O IMAGEM</b> I
MAGE SITE</font></p>     ^cY#v44n2a11.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#6#2#text#15#<p>&nbsp;</p>     ^cY#v44n
2a11.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#7#3#text#15#<p>&nbsp;</p>     ^cY#v44n
2a11.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704007900069002001300148#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#8#4#text#15#<p align="center"><img src
="/img/revistas/rbr/v44n2/a11fig01.jpg"></p>     ^cY#v44n2a11.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#9#5#text#15#<p>&nbsp;</p>     ^cY#v44n
2a11.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#10#6#text#15#<p>&nbsp;</p>     ^cY#v44
n2a11.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704007900070002001300149#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#11#7#text#15#<p align="center"><img sr
c="/img/revistas/rbr/v44n2/a11fig02.jpg"></p>     ^cY#v44n2a11.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#12#8#text#15#<p>&nbsp;</p>     ^cY#v44
n2a11.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#13#9#text#15#<p>&nbsp;</p>     ^cY#v44
n2a11.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007900071002001300150#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#14#10#text#15#<p align="center"><img s
rc="/img/revistas/rbr/v44n2/a11fig03.jpg"></p>     ^cY#v44n2a11.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#15#11#text#15#<p>&nbsp;</p>     ^cY#v4
4n2a11.htm##
00452000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704022200071002001300293#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#16#12#text#15#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><i>Servi&ccedil;o de Reumatologia do Hosp
ital das Cl&iacute;nicas da Faculdade de Medicina da Universidade de S&atilde;o 
Paulo (FMUSP).</i></font></p>     ^cY#v44n2a11.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#17#13#text#15#<p>&nbsp;</p>     ^cY#v4
4n2a11.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#18#14#text#15#<p>&nbsp;</p>     ^cY#v4
4n2a11.htm##
00362000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704013200071002001300203#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a11.htm#S#p#19#15#text#15#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif">Respons&aacute;vel: Manoel Barros B&eacut
e;rtolo </font></p>     ^cY#v44n2a11.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#o#1#1#article#1#
20110406#085837#v44n2a12.htm#188##
05025000000000757000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701201630
01670120145003300100038004750100036005130100036005490100032005850100027006170100
03500644010002900679010003000708010003200738070003400770070005600804070005300860
07000230091307000580093608315510099408500080254508500320255308500320258508500280
26170850033026450850027026780831324027050850008040290850033040370850032040700850
03004102085004904132085002504181117000604206072000304212112000904215111001004224
114000904234113001104243002001304254#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#h#2#1#article#1#cr#pt#br1.1#1#4.0#ILUS#TAB#12#RBR260#nd#Rev. Bras. R
eumatol.#44#2#20040400#^f169^l174#0482-5004#Imunossupressão com ciclofosfamida e
 fludarabina, com suporte de células tronco hematopoéticas autólogas CD-34+, par
a tratamento de esclerose sistêmica severa^lpt#Immunosuppression with cyclophosp
hamide and fudarabine, with support of autologous CD-34+ stem cells, in the trea
tment of severe scleroderma^len#^rND^1A01^nCarlos Alberto von^sMühlen#^rND^1A02^
nÉverton Luís^sHinterholz#^rND^1A01 A03^nBernardo^sGaricochea#^rND^1A04 A05^nPed
ro^sWeingrill#^rND^1A01^nCarlos^sBarrios#^rND^1A01^nMário Sérgio^sFernandes#^rND
^1A02^nRosângela^sDahmer#^rND^1A02^nMauro W^sKeiserman#^rND^1A01^nHenrique Luiz^
sStaub#PUCRS^iA01^1Faculdade de Medicina#PUCRS^iA02^1Hospital São Lucas^2serviço
 de reumatologia#PUCRS^iA03^1Hospital São Lucas^2serviço de oncologia#Hospital S
ão José^iA04#Universidade de Joinville^iA05^1Faculdade de Medicina^sSC#^lpt^aEvi
dências recentes mostram a possibilidade de se retardar a evolução da esclerose 
sistêmica (ES), mesmo em suas formas mais graves, com ablação de células T, no m
omento reconhecidas como as principais envolvidas no processo fisiopatogênico. A
ltas doses de quimioterapia com suporte de células tronco hematopoéticas (CTH) -
 às vezes denominado pela literatura de "transplante da medula óssea" - tem-se m
ostrado um meio efetivo de controlar algumas doenças auto-imunes, entre elas a e
sclerose sistêmica. Neste trabalho é relatado o caso de paciente com forma difus
a de esclerose sistêmica, em que se efetuou imunossupressão com ciclofosfamida 0
,5 g/m² e fludarabina e suporte de células CD34+ autólogas sem depleção específi
ca de linfócitos T. O paciente foi avaliado de forma periódica durante 12 meses 
através de testes cutâneos, exames de imagem, exames laboratoriais e questionári
o sobre qualidade de vida. A evolução imediata mostrou melhora importante dos qu
adros cutâneo e gastrointestinal, com melhora da diarréia e síndrome de má-absor
ção, que no entanto não se manteve após seis meses de evolução. O paciente apres
entou reação transfusional passageira, infecção por herpes zoster e bronco-pneum
onia durante o período de observação, evoluindo para óbito 12 meses após o proce
dimento. Este ocorreu por complicações no trato intestinal e broncopneumonia por
 aspiração. Imunossupressão induzida por drogas, e não o transplante autólogo de
 células CD-34+, pode ter sido o mecanismo responsável pela melhora nos primeiro
s meses de observação#^dnd^i1#^tm^lpt^kesclerose sistêmica^i1#^tm^lpt^kdoenças a
uto-imunes^i1#^tm^lpt^kimunossupressão^i1#^tm^lpt^ktransplante autólogo^i1#^tm^l
pt^kcélulas CD-34+^i1#^len^aImmune ablation of T lymphocytes, key players in the
 physiopathogenic processes leading to autoimmune diseases, may arrest scleroder
ma progression even in some severely ill patients. High-dose chemotherapy follow
ed by autologous stem cell reinfusion - sometimes named peripheral blood stem ce
ll transplantation - has been an effective therapy for some autoimmune diseases,
 including scleroderma. In this paper the authors present a patient with the dif
fuse form of scleroderma who received immunosuppression with cyclophosphamide 0.
5 g/m² and fludarabine followed by infusion of autologous CD-34+ cells without T
 lymphocyte purging. This patient was followed up with cutaneous score measures,
 imaging and laboratory tests, as well as a well-being questionnaire. After tran
splantation there were major positive responses on skin and gastrointestinal tra
ct, with cessation of diarrhea and malabsorption syndrome. These clinical improv
ements did not last past 6 months. We observed transitory stem cell transfusion 
reaction and localized herpes zoster. The patient died 12 months after the proce
dure due to aspirative pneumonia and gastrointestinal complications. The immunos
uppressive regimen, and not the autologous stem cell transplantation, could have
 been responsible for the observed transitory patient improvement#^dnd^i2#^tm^le
n^ksystemic scleroderma^i2#^tm^len^kautoimmune diseases^i2#^tm^len^kimmunosuppre
ssion^i2#^tm^len^kautologous stem cell transplantation^i2#^tm^len^kCD-34+ cells^
i2#other#40#20020221#21/2/2002#20031127#27/11/2003#v44n2a12.htm##
05061000000000757000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701201700
01670120152003370100038004890100036005270100036005630100032005990100027006310100
03500658010002900693010003000722010003200752070003400784070005600818070005300874
07000230092707000580095008315620100808500080257008500320257808500320261008500280
26420850033026700850027027030831335027300850008040650850033040730850032041060850
03004138085004904168085002504217117000604242072000304248112000904251111001004260
114000904270113001104279002001304290#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#f#3#1#article#1#cr#pt#br1.1#1#4.0#ILUS#TAB#12#RBR260#nd#Rev. Bras. R
eumatol.#44#2#20040400#^f169^l174#0482-5004#<b>Imunossupressão com ciclofosfamid
a e fludarabina, com suporte de células tronco hematopoéticas autólogas CD-34+, 
para tratamento de esclerose sistêmica severa</b>^lpt#<b>Immunosuppression with 
cyclophosphamide and fudarabine, with support of autologous CD-34+ stem cells, i
n the treatment of severe scleroderma</b>^len#^rND^1A01^nCarlos Alberto von^sMüh
len#^rND^1A02^nÉverton Luís^sHinterholz#^rND^1A01 A03^nBernardo^sGaricochea#^rND
^1A04 A05^nPedro^sWeingrill#^rND^1A01^nCarlos^sBarrios#^rND^1A01^nMário Sérgio^s
Fernandes#^rND^1A02^nRosângela^sDahmer#^rND^1A02^nMauro W^sKeiserman#^rND^1A01^n
Henrique Luiz^sStaub#PUCRS^iA01^1Faculdade de Medicina#PUCRS^iA02^1Hospital São 
Lucas^2serviço de reumatologia#PUCRS^iA03^1Hospital São Lucas^2serviço de oncolo
gia#Hospital São José^iA04#Universidade de Joinville^iA05^1Faculdade de Medicina
^sSC#^lpt^aEvidências recentes mostram a possibilidade de se retardar a evolução
 da esclerose sistêmica (ES), mesmo em suas formas mais graves, com ablação de c
élulas T, no momento reconhecidas como as principais envolvidas no processo fisi
opatogênico. Altas doses de quimioterapia com suporte de células tronco hematopo
éticas (CTH) - às vezes denominado pela literatura de "transplante da medula óss
ea" - tem-se mostrado um meio efetivo de controlar algumas doenças auto-imunes, 
entre elas a esclerose sistêmica. Neste trabalho é relatado o caso de paciente c
om forma difusa de esclerose sistêmica, em que se efetuou imunossupressão com ci
clofosfamida 0,5 g/m<sup>2</sup> e fludarabina e suporte de células CD34+ autólo
gas sem depleção específica de linfócitos T. O paciente foi avaliado de forma pe
riódica durante 12 meses através de testes cutâneos, exames de imagem, exames la
boratoriais e questionário sobre qualidade de vida. A evolução imediata mostrou 
melhora importante dos quadros cutâneo e gastrointestinal, com melhora da diarré
ia e síndrome de má-absorção, que no entanto não se manteve após seis meses de e
volução. O paciente apresentou reação transfusional passageira, infecção por her
pes zoster e bronco-pneumonia durante o período de observação, evoluindo para ób
ito 12 meses após o procedimento. Este ocorreu por complicações no trato intesti
nal e broncopneumonia por aspiração. Imunossupressão induzida por drogas, e não 
o transplante autólogo de células CD-34+, pode ter sido o mecanismo responsável 
pela melhora nos primeiros meses de observação#^dnd^i1#^tm^lpt^kesclerose sistêm
ica^i1#^tm^lpt^kdoenças auto-imunes^i1#^tm^lpt^kimunossupressão^i1#^tm^lpt^ktran
splante autólogo^i1#^tm^lpt^kcélulas CD-34+^i1#^len^aImmune ablation of T lympho
cytes, key players in the physiopathogenic processes leading to autoimmune disea
ses, may arrest scleroderma progression even in some severely ill patients. High
-dose chemotherapy followed by autologous stem cell reinfusion - sometimes named
 peripheral blood stem cell transplantation - has been an effective therapy for 
some autoimmune diseases, including scleroderma. In this paper the authors prese
nt a patient with the diffuse form of scleroderma who received immunosuppression
 with cyclophosphamide 0.5 g/m<sup>2</sup> and fludarabine followed by infusion 
of autologous CD-34+ cells without T lymphocyte purging. This patient was follow
ed up with cutaneous score measures, imaging and laboratory tests, as well as a 
well-being questionnaire. After transplantation there were major positive respon
ses on skin and gastrointestinal tract, with cessation of diarrhea and malabsorp
tion syndrome. These clinical improvements did not last past 6 months. We observ
ed transitory stem cell transfusion reaction and localized herpes zoster. The pa
tient died 12 months after the procedure due to aspirative pneumonia and gastroi
ntestinal complications. The immunosuppressive regimen, and not the autologous s
tem cell transplantation, could have been responsible for the observed transitor
y patient improvement#^dnd^i2#^tm^len^ksystemic scleroderma^i2#^tm^len^kautoimmu
ne diseases^i2#^tm^len^kimmunosuppression^i2#^tm^len^kautologous stem cell trans
plantation^i2#^tm^len^kCD-34+ cells^i2#other#40#20020221#21/2/2002#20031127#27/1
1/2003#v44n2a12.htm##
05165000000000781000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000200012903100030014903200020015206500090015401400110016303500100
01740120163001840120145003470100038004920100036005300100036005660100032006020100
02700634010003500661010002900696010003000725010003200755070003600787070005800823
07000550088107000250093607000600096108315510102108500080257208500320258008500320
26120850028026440850033026720850027027050831324027320850008040560850033040640850
03204097085003004129085004904159085002504208117000604233072000304239112000904242
111001004251114000904261113001104270002001304281008008904294#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#l#4#1#article#1#^mmar./abr.^a2004#cr#pt#br1.
1#1#4.0#ilus#tab#12#RBR260#nd#Rev. Bras. Reumatol#44#2#20040400#^f169^l174#0482-
5004#Imunossupressão com ciclofosfamida e fludarabina, com suporte de células tr
onco hematopoéticas autólogas CD-34+, para tratamento de esclerose sistêmica sev
era^lpt#Immunosuppression with cyclophosphamide and fudarabine, with support of 
autologous CD-34+ stem cells, in the treatment of severe scleroderma^len#^rND^1A
01^nCarlos Alberto von^sMühlen#^rND^1A02^nÉverton Luís^sHinterholz#^rND^1A01 A03
^nBernardo^sGaricochea#^rND^1A04 A05^nPedro^sWeingrill#^rND^1A01^nCarlos^sBarrio
s#^rND^1A01^nMário Sérgio^sFernandes#^rND^1A02^nRosângela^sDahmer#^rND^1A02^nMau
ro W^sKeiserman#^rND^1A01^nHenrique Luiz^sStaub#^iA01^1PUCRS^2Faculdade de Medic
ina#^iA02^1PUCRS^2Hospital São Lucas^3serviço de reumatologia#^iA03^1PUCRS^2Hosp
ital São Lucas^3serviço de oncologia#^iA04^1Hospital São José#^iA05^1Universidad
e de Joinville^2Faculdade de Medicina^sSC#^lpt^aEvidências recentes mostram a po
ssibilidade de se retardar a evolução da esclerose sistêmica (ES), mesmo em suas
 formas mais graves, com ablação de células T, no momento reconhecidas como as p
rincipais envolvidas no processo fisiopatogênico. Altas doses de quimioterapia c
om suporte de células tronco hematopoéticas (CTH) - às vezes denominado pela lit
eratura de "transplante da medula óssea" - tem-se mostrado um meio efetivo de co
ntrolar algumas doenças auto-imunes, entre elas a esclerose sistêmica. Neste tra
balho é relatado o caso de paciente com forma difusa de esclerose sistêmica, em 
que se efetuou imunossupressão com ciclofosfamida 0,5 g/m² e fludarabina e supor
te de células CD34+ autólogas sem depleção específica de linfócitos T. O pacient
e foi avaliado de forma periódica durante 12 meses através de testes cutâneos, e
xames de imagem, exames laboratoriais e questionário sobre qualidade de vida. A 
evolução imediata mostrou melhora importante dos quadros cutâneo e gastrointesti
nal, com melhora da diarréia e síndrome de má-absorção, que no entanto não se ma
nteve após seis meses de evolução. O paciente apresentou reação transfusional pa
ssageira, infecção por herpes zoster e bronco-pneumonia durante o período de obs
ervação, evoluindo para óbito 12 meses após o procedimento. Este ocorreu por com
plicações no trato intestinal e broncopneumonia por aspiração. Imunossupressão i
nduzida por drogas, e não o transplante autólogo de células CD-34+, pode ter sid
o o mecanismo responsável pela melhora nos primeiros meses de observação#^dnd^i1
#^tm^lpt^kesclerose sistêmica^i1#^tm^lpt^kdoenças auto-imunes^i1#^tm^lpt^kimunos
supressão^i1#^tm^lpt^ktransplante autólogo^i1#^tm^lpt^kcélulas CD-34+^i1#^len^aI
mmune ablation of T lymphocytes, key players in the physiopathogenic processes l
eading to autoimmune diseases, may arrest scleroderma progression even in some s
everely ill patients. High-dose chemotherapy followed by autologous stem cell re
infusion - sometimes named peripheral blood stem cell transplantation - has been
 an effective therapy for some autoimmune diseases, including scleroderma. In th
is paper the authors present a patient with the diffuse form of scleroderma who 
received immunosuppression with cyclophosphamide 0.5 g/m² and fludarabine follow
ed by infusion of autologous CD-34+ cells without T lymphocyte purging. This pat
ient was followed up with cutaneous score measures, imaging and laboratory tests
, as well as a well-being questionnaire. After transplantation there were major 
positive responses on skin and gastrointestinal tract, with cessation of diarrhe
a and malabsorption syndrome. These clinical improvements did not last past 6 mo
nths. We observed transitory stem cell transfusion reaction and localized herpes
 zoster. The patient died 12 months after the procedure due to aspirative pneumo
nia and gastrointestinal complications. The immunosuppressive regimen, and not t
he autologous stem cell transplantation, could have been responsible for the obs
erved transitory patient improvement#^dnd^i2#^tm^len^ksystemic scleroderma^i2#^t
m^len^kautoimmune diseases^i2#^tm^len^kimmunosuppression^i2#^tm^len^kautologous 
stem cell transplantation^i2#^tm^len^kCD-34+ cells^i2#other#40#20020221#21/2/200
2#20031127#27/11/2003#v44n2a12.htm#Internet^ihttp://www.scielo.br/scielo.php?scr
ipt=sci_arttext&pid=S0482-50042004000200012##
00362000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704013000073002001300203#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#5#1#article#144#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RELATO DE CASO</b> CAS
E REPORT</font></p>     ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#6#2#article#144#<p>&nbsp;</p>     ^cY#
v44n2a12.htm##
00603000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704037100073002001300444#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#7#3#article#144#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><b><a name="linkinicio"></a>Imunossupre
ss&atilde;o com ciclofosfamida e fludarabina,    com suporte de c&eacute;lulas t
ronco hematopo&eacute;ticas aut&oacute;logas    CD-34+, para tratamento de escle
rose sist&ecirc;mica severa<sup>(</sup><a href="#link01"><sup>*</sup></a><sup>)<
/sup></b></font></p>     ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#8#4#article#144#<p>&nbsp;</p>     ^cY#
v44n2a12.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704023300073002001300306#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#9#5#article#144#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><b>Immunosuppression with cyclophospham
ide and fudarabine, with support    of autologous CD-34+ stem cells, in the trea
tment of severe scleroderma</b></font></p>     ^cY#v44n2a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#10#6#article#144#<p>&nbsp;</p>     ^cY
#v44n2a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#11#7#article#144#<p>&nbsp;</p>     ^cY
#v44n2a12.htm##
00671000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704043800074002001300512#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#12#8#article#144#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Carlos Alberto von M&uuml;hlen<sup>
I</sup>; &Eacute;verton Lu&iacute;s Hinterholz<sup>II</sup>; Bernardo Garicochea
<sup>III</sup>; Pedro Weingrill<sup>IV</sup>; Carlos    Barrios<sup>V</sup>; M&a
acute;rio S&eacute;rgio Fernandes<sup>VI</sup>; Ros&acirc;ngela Dahmer<sup>II</s
up>; Mauro W. Keiserman<sup>VII</sup>; Henrique Luiz Staub<sup>VIII</sup></b></f
ont></p>     ^cY#v44n2a12.htm##
00396000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704016300074002001300237#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#13#9#article#144#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Professor titular de reuma
tologia e imunologia da Faculdade de Medicina da PUCRS    ^cY#v44n2a12.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012400075002001300199#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#14#10#article#144#<br> <sup>II</sup>M&
eacute;dico(a) residente do servi&ccedil;o de reumatologia do Hospital S&atilde;
o Lucas da PUCRS    ^cY#v44n2a12.htm##
00403000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016900075002001300244#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#15#11#article#144#<br> <sup>III</sup>P
rofessor adjunto de hematologia da Faculdade de Medicina da PUCRS, chefe do serv
i&ccedil;o de oncologia do Hospital S&atilde;o Lucas da PUCRS    ^cY#v44n2a12.ht
m##
00406000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017200075002001300247#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#16#12#article#144#<br> <sup>IV</sup>M&
eacute;dico preceptor de reumatologista do Hospital S&atilde;o Jos&eacute; e pro
fessor da Faculdade de Medicina da Universidade de Joinville, SC    ^cY#v44n2a12
.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009200075002001300167#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#17#13#article#144#<br> <sup>V</sup>Pro
fessor assistente de oncologia da Faculdade de Medicina da PUCRS    ^cY#v44n2a12
.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009500075002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#18#14#article#144#<br> <sup>VI</sup>Pr
ofessor assistente de hematologia da Faculdade de Medicina da PUCRS    ^cY#v44n2
a12.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010400075002001300179#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#19#15#article#144#<br> <sup>VII</sup>C
hefe do servi&ccedil;o de reumatologia do Hospital S&atilde;o Lucas da PUCRS    
^cY#v44n2a12.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011000075002001300185#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#20#16#article#144#<br> <sup>VIII</sup>
Professor assistente de reumatologia da Faculdade de Medicina da PUCRS</font></p
>     ^cY#v44n2a12.htm##
00386000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015200075002001300227#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#21#17#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#linkcorresp">Endere&ccedil;
o para correspond&ecirc;ncia</a></font></p>     ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#22#18#article#144#<p>&nbsp;</p>     ^c
Y#v44n2a12.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#23#19#article#144#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v44n2a12.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009600075002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#24#20#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v44n
2a12.htm##
02279000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704204500075002001302120#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#25#21#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Evid&ecirc;ncias recentes mostram a p
ossibilidade de se retardar a evolu&ccedil;&atilde;o da esclerose sist&ecirc;mic
a (ES), mesmo em suas formas mais graves, com abla&ccedil;&atilde;o de c&eacute;
lulas T, no momento reconhecidas como as principais envolvidas no processo fisio
patog&ecirc;nico. Altas doses de quimioterapia com suporte de c&eacute;lulas tro
nco hematopo&eacute;ticas (CTH) - &agrave;s vezes denominado pela literatura de 
"transplante da medula &oacute;ssea" - tem-se mostrado um meio efetivo de contro
lar algumas doen&ccedil;as auto-imunes, entre elas a esclerose sist&ecirc;mica. 
Neste trabalho &eacute; relatado o caso de paciente com forma difusa de escleros
e sist&ecirc;mica, em que se efetuou imunossupress&atilde;o com ciclofosfamida 0
,5 g/m<sup>2</sup> e fludarabina e suporte de c&eacute;lulas CD34+ aut&oacute;lo
gas sem deple&ccedil;&atilde;o espec&iacute;fica de linf&oacute;citos T. O pacie
nte foi avaliado de forma peri&oacute;dica durante 12 meses atrav&eacute;s de te
stes cut&acirc;neos, exames de imagem, exames laboratoriais e question&aacute;ri
o sobre qualidade de vida. A evolu&ccedil;&atilde;o imediata mostrou melhora imp
ortante dos quadros cut&acirc;neo e gastrointestinal, com melhora da diarr&eacut
e;ia e s&iacute;ndrome de m&aacute;-absor&ccedil;&atilde;o, que no entanto n&ati
lde;o se manteve ap&oacute;s seis meses de evolu&ccedil;&atilde;o. O paciente ap
resentou rea&ccedil;&atilde;o transfusional passageira, infec&ccedil;&atilde;o p
or herpes zoster e bronco-pneumonia durante o per&iacute;odo de observa&ccedil;&
atilde;o, evoluindo para &oacute;bito 12 meses ap&oacute;s o procedimento. Este 
ocorreu por complica&ccedil;&otilde;es no trato intestinal e broncopneumonia por
 aspira&ccedil;&atilde;o. Imunossupress&atilde;o induzida por drogas, e n&atilde
;o o transplante aut&oacute;logo de c&eacute;lulas CD-34+, pode ter sido o mecan
ismo respons&aacute;vel pela melhora nos primeiros meses de observa&ccedil;&atil
de;o.</font></p>     ^cY#v44n2a12.htm##
00492000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025800075002001300333#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#26#22#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> esclerose sist
&ecirc;mica, doen&ccedil;as auto-imunes, imunossupress&atilde;o, transplante aut
&oacute;logo, c&eacute;lulas CD-34+.</font></p> <hr size="1" noshade>     ^cY#v4
4n2a12.htm##
00332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009800075002001300173#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#27#23#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v4
4n2a12.htm##
01646000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704141200075002001301487#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#28#24#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Immune ablation of T lymphocytes, key
 players in the physiopathogenic processes leading to autoimmune diseases, may a
rrest scleroderma progression even in some severely ill patients. High-dose chem
otherapy followed by autologous stem cell reinfusion - sometimes named periphera
l blood stem cell transplantation - has been an effective therapy for some autoi
mmune diseases, including scleroderma. In this paper the authors present a patie
nt with the diffuse form of scleroderma who received immunosuppression with cycl
ophosphamide 0.5 g/m<sup>2</sup> and fludarabine followed by infusion of autolog
ous CD-34+ cells without T lymphocyte purging. This patient was followed up with
 cutaneous score measures, imaging and laboratory tests, as well as a well-being
 questionnaire. After transplantation there were major positive responses on ski
n and gastrointestinal tract, with cessation of diarrhea and malabsorption syndr
ome. These clinical improvements did not last past 6 months. We observed transit
ory stem cell transfusion reaction and localized herpes zoster. The patient died
 12 months after the procedure due to aspirative pneumonia and gastrointestinal 
complications. The immunosuppressive regimen, and not the autologous stem cell t
ransplantation, could have been responsible for the observed transitory patient 
improvement.</font></p>     ^cY#v44n2a12.htm##
00469000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023500075002001300310#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#29#25#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> systemic scleroderma
, autoimmune diseases, immunosuppression, autologous stem cell transplantation, 
CD-34+ cells.</font></p> <hr size="1" noshade>     ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#30#26#article#144#<p>&nbsp;</p>     ^c
Y#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#31#27#article#144#<p>&nbsp;</p>     ^c
Y#v44n2a12.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011400075002001300189#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#32#28#article#144#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font
></p>     ^cY#v44n2a12.htm##
01606000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704137200075002001301447#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#33#29#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A esclerose sist&ecirc;mica (ES) em s
ua forma difusa possui pior progn&oacute;stico se comparada &agrave; forma CREST
. Seu tratamento &eacute; motivo de controv&eacute;rsia, principalmente por desc
onhecimento fisiopatog&ecirc;nico. Estudos retrospectivos mostram que a D-Penici
lamina aumenta a sobrevida dos pacientes em cinco anos, quando comparados com in
div&iacute;duos sem tratamento<sup>(1-2)</sup>, com melhora cl&iacute;nica maior
 sendo observada nos acometimentos cut&acirc;neo e pulmonar. In&uacute;meros out
ros f&aacute;rmacos foram propostos, sem no entanto trazer um diferencial import
ante nos resultados de fatores cl&iacute;nicos como medidas do acometimento sist
&ecirc;mico. A exce&ccedil;&atilde;o talvez possa ser creditada &agrave; utiliza
&ccedil;&atilde;o de pulsoterapia mensal com altas doses de ciclofosfamida via p
arenteral<sup>(3)</sup>. Mais recentemente alguns resultados se mostram promisso
res com o uso de imunossupress&atilde;o seguida ou n&atilde;o de suporte com tra
nsplante aut&oacute;logo de c&eacute;lulas hematopo&eacute;ticas pluripotenciais
 (antes chamado "transplante de medula &oacute;ssea"), como tratamento para escl
erodermia e outras doen&ccedil;as auto-imunes de adultos e crian&ccedil;as com g
rave acometimento sist&ecirc;mico<sup>(4-10)</sup>. </font></p>     ^cY#v44n2a12
.htm##
00664000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043000075002001300505#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#34#30#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O objetivo deste trabalho &eacute; o 
de relatar o caso de um paciente com esclerodermia severa que recebeu imunossupr
ess&atilde;o com ciclofosfamida e fludarabina, seguido de suporte com CTH e manu
ten&ccedil;&atilde;o com ciclofosfamida e fludarabina. Trata-se, na medida do no
sso conhecimento, do primeiro caso a receber tal tratamento no Brasil.</font></p
>     ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#35#31#article#144#<p>&nbsp;</p>     ^c
Y#v44n2a12.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010400075002001300179#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#36#32#article#144#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>RELATO DO CASO</b></font></p>     
^cY#v44n2a12.htm##
01201000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704096700075002001301042#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#37#33#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Paciente masculino, branco, 46 anos, 
professor, procedente de Santa Catarina, previamente h&iacute;gido, desde 1993 c
om fen&ocirc;meno de Raynaud, artralgias em m&atilde;os e joelhos, fadiga e espe
ssamento cut&acirc;neo de m&atilde;os e p&eacute;s que em poucos meses evoluiu p
ara face, t&oacute;rax e abdome. O exame f&iacute;sico da &eacute;poca mostrava 
ausculta card&iacute;aca e pulmonar sem anormalidades, diminui&ccedil;&atilde;o 
da elasticidade e pregueamento da pele dos membros superiores, face e tronco com
 &aacute;reas de discromia cut&acirc;nea (hipo e hiperpigmenta&ccedil;&atilde;o)
 e sinais de atrofia cut&acirc;nea nos dedos das m&atilde;os j&aacute; com certo
 grau de ader&ecirc;ncia a planos profundos. O paciente preenchia os crit&eacute
;rios de classifica&ccedil;&atilde;o do Col&eacute;gio Americano de Reumatologia
 para esclerose sist&ecirc;mica<sup>(11)</sup>.</font></p>     ^cY#v44n2a12.htm#
#
00822000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058800075002001300663#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#38#34#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As chapas contrastadas de es&ocirc;fa
go mostravam hipoperistalse esof&aacute;gica, com FAN reagente em t&iacute;tulo 
1:160 de padr&atilde;o pontilhado. Os demais exames - hemograma, creatinina, cre
atinafosfoquinase, comum de urina, radiografias de t&oacute;rax e de m&atilde;os
 - n&atilde;o mostravam anormalidades. Iniciou-se uso de prednisona 10mg/dia, D-
Penicilamina 300mg/dia (atingindo a dose de 900mg/dia em 4 meses), nifedipina 20
mg/dia e ciclofosfamida 1g endovenosa por m&ecirc;s durante 6 meses.</font></p> 
    ^cY#v44n2a12.htm##
00898000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704066400075002001300739#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#39#35#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Houve melhora subjetiva do fen&ocirc;
meno de Raynaud, por&eacute;m persistiu o quadro de espessamento cut&acirc;neo, 
o qual se tornou generalizado. Em 1995 o paciente apresentou epigastralgia, real
izando novos exames laboratoriais e de imagem. A tomografia computadorizada de t
&oacute;rax evidenciou forma&ccedil;&otilde;es bolhosas em &aacute;pices e infil
trado intersticial na base direita. A endoscopia digestiva alta mostrou esofagit
e e pangastrite. Demais exames como hemograma, creatinina, transaminases, comum 
de urina e radiografias do t&oacute;rax foram novamente normais.</font></p>     
^cY#v44n2a12.htm##
01727000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704149300075002001301568#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#40#36#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Foi suspensa a D-Penicilamina em cons
eq&uuml;&ecirc;ncia do quadro digestivo, havendo piora marcada do quadro cut&aci
rc;neo ap&oacute;s alguns poucos meses. Foi reiniciada a ciclofosfamida na dose 
de 600mg endovenosa mensal, por&eacute;m tendo que ser suspensa pois o paciente 
apresentou intensa astenia. Neste per&iacute;odo houve melhora das &uacute;lcera
s digitais. Em 1998 o paciente teve quadro de mialgias, fraqueza muscular, com a
ltera&ccedil;&otilde;es laboratoriais sugestivas de miopatia (CPK = 1717 mg/dl, 
normal at&eacute; 170; e TGO = 120 mg/dl, normal at&eacute; 20), com piora dos s
intomas digestivos: dor epig&aacute;strica, alguns epis&oacute;dios de v&ocirc;m
itos, distens&atilde;o abdominal, altern&acirc;ncia de diarr&eacute;ia (tr&ecirc
;s epis&oacute;dios ao dia) com constipa&ccedil;&atilde;o e marcada perda de pes
o. Neste per&iacute;odo aumentou-se a dose de prednisona para 40mg/dia. Houve bo
a resposta da miopatia com melhora da fraqueza muscular e normaliza&ccedil;&atil
de;o da CPK. Reduziu-se a prednisona de forma gradativa at&eacute; sua suspens&a
tilde;o e iniciou-se com bloqueadores da bomba de pr&oacute;tons, drogas pr&oacu
te;-cin&eacute;ticas e metronidazol 400mg/dia. Houve piora progressiva do quadro
 intestinal, com intensifica&ccedil;&atilde;o da diarr&eacute;ia, dor abdominal 
difusa e emagrecimento de 8 kg em 6 meses, sem melhora com medica&ccedil;&atilde
;o proposta. </font></p>     ^cY#v44n2a12.htm##
02903000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704266900075002001302744#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#41#37#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O paciente foi ent&atilde;o internado
 no Hospital S&atilde;o Lucas da Pontif&iacute;cia Universidade Cat&oacute;lica 
do Rio Grande do Sul (PUCRS), em Porto Alegre, RS, com o objetivo de realizar im
unossupress&atilde;o com ciclofosfamida e fludarabina e suporte de CTH para cont
role de sua doen&ccedil;a. Neste per&iacute;odo apresentava-se emagrecido, desid
ratado, com espessamento cut&acirc;neo generalizado e com vasculite de polpas di
gitais (<a href="/img/revistas/rbr/v44n2/a12fig01.jpg">Figura 1</a>). A ausculta
 pulmonar apresentava ru&iacute;dos bibasais compat&iacute;veis com fibrose pulm
onar, o abdome estava distendido, por&eacute;m sem defesa &agrave; palpa&ccedil;
&atilde;o. O tr&acirc;nsito intestinal visto em chapas radiogr&aacute;ficas most
rava dilata&ccedil;&atilde;o de al&ccedil;as e altera&ccedil;&otilde;es compat&i
acute;veis com m&aacute; absor&ccedil;&atilde;o intestinal. Outros exames realiz
ados nesta fase podem ser vistos na <a href="/img/revistas/rbr/v44n2/a12tab01.jp
g">Tabela 1</a>. Ap&oacute;s estabiliza&ccedil;&atilde;o cl&iacute;nica e consen
timento informado do paciente foi iniciada antibioticoterapia profil&aacute;tica
 com fluconazol, sulfametoxazol com trimetoprim e aciclovir, e realizada a mobil
iza&ccedil;&atilde;o de c&eacute;lulas progenitoras CD34+ com o uso IV de fator 
estimulador de col&ocirc;nia de granul&oacute;citos 300mcg/dia durante 6 dias. A
s c&eacute;lulas foram coletadas durante 3 dias e a contagem celular foi realiza
da por citometria de fluxo at&eacute; que pelo menos 2x10<sup>6</sup> c&eacute;l
ulas CD34+/kg fossem obtidas. N&atilde;o foi efetuada deple&ccedil;&atilde;o de 
c&eacute;lulas T ap&oacute;s coleta para n&atilde;o elevar o custo do procedimen
to e por d&uacute;vidas na literatura a respeito deste tipo de conduta<sup>(12,1
3)</sup>. V&aacute;rios transplantes j&aacute; foram efetuados com sucesso sem d
eple&ccedil;&atilde;o de linf&oacute;citos T<sup>(14,15)</sup>. A embalagem com 
c&eacute;lulas CD34+ foi conservada a -70ºC at&eacute; reinfus&atilde;o. A segui
r o paciente recebeu infus&atilde;o IV de ciclofosfamida 500mg/m<sup>2</sup> e f
ludarabina 35mg/m<sup>2</sup> durante 3 dias consecutivos, seguidos da reinfus&a
tilde;o de c&eacute;lulas progenitoras. Ap&oacute;s, seguiu-se administra&ccedil
;&atilde;o de 300mcg/dia de fator estimulador de col&ocirc;nia de granul&oacute;
citos durante 11 dias. Nova imunossupress&atilde;o com dose total de ciclofosfam
ida 500mg/m<sup>2</sup> e de fludarabina 35mg/m<sup>2</sup> de manuten&ccedil;&a
tilde;o foi realizada 5 meses e 8 meses ap&oacute;s o primeiro ciclo.</font></p>
     ^cY#v44n2a12.htm##
01096000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704086200075002001300937#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#42#38#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O paciente teve alta hospitalar 16 di
as ap&oacute;s o in&iacute;cio da imunossupress&atilde;o sem intercorr&ecirc;nci
as graves. Apresentou durante a reinfus&atilde;o de c&eacute;lulas CD34+ uma rea
&ccedil;&atilde;o tipo dist&uacute;rbio neurovegetativo, com calafrios, sensa&cc
edil;&atilde;o de p&acirc;nico e tremores, que cessaram espontaneamente em cerca
 de 30 minutos. O nadir de leuc&oacute;citos no quarto dia ap&oacute;s a imunoss
upress&atilde;o foi de 5.700/mm<sup>3</sup> e o de linf&oacute;citos de 57/mm<su
p>3</sup>, n&atilde;o se atingindo, portanto, abla&ccedil;&atilde;o total da med
ula &oacute;ssea, o que ocorreu conforme programado. Medidas evolutivas de ativi
dade da doen&ccedil;a podem ser vistas na <a href="/img/revistas/rbr/v44n2/a12ta
b01.jpg">Tabela 1</a>.</font></p>     ^cY#v44n2a12.htm##
01178000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704094400075002001301019#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#43#39#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A tomografia computadorizada de t&oac
ute;rax manteve o mesmo padr&atilde;o de fibrose pulmonar bibasal. A impress&ati
lde;o da abertura palmar n&atilde;o mostrou modifica&ccedil;&otilde;es. Os epis&
oacute;dios de diarr&eacute;ia diminu&iacute;ram para um epis&oacute;dio ao dia 
e as crises de dor e distens&atilde;o abdominal tornaram-se bem mais brandas at&
eacute; cessar. O paciente seguiu com dieta pobre em fibras e rica em carnes bra
ncas. Ap&oacute;s a alta hospitalar seguiu tratamento com pentoxifilina 400mg/di
a, usada pelas vasculites de polpas digitais, vibramicina 200mg/dia (para a s&ia
cute;ndrome de m&aacute;-absor&ccedil;&atilde;o intestinal), omeprazol 20mg/dia 
(como profil&aacute;tico de les&otilde;es gastroduodenais), prednisona 15mg/dia 
e fluoxetina 20mg/dia (para depress&atilde;o, ap&oacute;s avalia&ccedil;&atilde;
o psiqui&aacute;trica). </font></p>     ^cY#v44n2a12.htm##
01203000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704096900075002001301044#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#44#40#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cerca de 3 meses ap&oacute;s o transp
lante aut&oacute;logo o paciente apresentou alguns epis&oacute;dios de crise hip
ertensiva sem perda de fun&ccedil;&atilde;o renal onde foi iniciado o uso de cap
topril 50mg/dia. Neste per&iacute;odo voltaram as crises de dor e distens&atilde
;o abdominal, por&eacute;m de forma mais branda e fugazes, acompanhadas por um e
pis&oacute;dio de fezes amolecidas ao dia. O paciente realizou nova sess&atilde;
o de quimioterapia com 35mg/m<sup>2</sup> de fludarabina e 500mg/m<sup>2</sup> d
e ciclofosfamida 5 e 8 meses ap&oacute;s o transplante. Tr&ecirc;s meses ap&oacu
te;s o &uacute;ltimo ciclo de quimioterapia apresentou infec&ccedil;&atilde;o po
r herpes zoster na regi&atilde;o tor&aacute;cica, foi tratado com antiviral em d
oses usuais evoluindo bem, por&eacute;m apresentou neuropatia p&oacute;sherp&eac
ute;tica com boa resposta &agrave; amitriptilina.</font></p>     ^cY#v44n2a12.ht
m##
01443000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704120900075002001301284#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#45#41#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Um m&ecirc;s ap&oacute;s a infec&cced
il;&atilde;o herp&eacute;tica apresentou quadro de pseudo-obstru&ccedil;&atilde;
o intestinal, provavelmente relacionada com sua doen&ccedil;a de base, associado
 aos efeitos anticolin&eacute;rgicos da amitriptilina. Foi tratado clinicamente 
e colocado em nutri&ccedil;&atilde;o parenteral total, havendo melhora do quadro
 intestinal, evoluindo, por&eacute;m, alguns dias ap&oacute;s com quadro de infe
c&ccedil;&atilde;o respirat&oacute;ria e plaquetopenia severa (contagem de 17.00
0 plaquetas/cm<sup>3</sup>). Foi iniciada antibioticoterapia, aumentada a dose d
e prednisona para 2mg/kg/dia e efetuada infus&atilde;o de imunoglobulinas IV 600
 mg/kg/dia, sem que se obtivesse uma boa resposta da plaquetopenia. Esta apenas 
normalizou ap&oacute;s melhora da infec&ccedil;&atilde;o respirat&oacute;ria e a
 retirada do antibi&oacute;tico. Apresentou ent&atilde;o novo quadro de distens&
atilde;o abdominal com v&ocirc;mitos, tendo aspirado conte&uacute;do g&aacute;st
rico e fazendo broncopneumonia aspirativa. Evoluiu para insufici&ecirc;ncia resp
irat&oacute;ria intrat&aacute;vel e &oacute;bito.</font></p>     ^cY#v44n2a12.ht
m##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#46#42#article#144#<p>&nbsp;</p>     ^c
Y#v44n2a12.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010600075002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#47#43#article#144#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>   
  ^cY#v44n2a12.htm##
02096000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704186200075002001301937#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#48#44#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Os resultados obtidos com o tratament
o imunossupressor seguido de infus&atilde;o de c&eacute;lulas CD34+ aut&oacute;l
ogas mostraram boa recupera&ccedil;&atilde;o do estado geral do paciente, com im
portante melhora das crises abdominais nos primeiros 5 meses de acompanhamento. 
Houve normaliza&ccedil;&atilde;o do teste da D-Xylose, mostrando melhora marcada
 do padr&atilde;o de absor&ccedil;&atilde;o intestinal. A hemossedimenta&ccedil;
&atilde;o caiu &agrave; metade, por&eacute;m sem normaliza&ccedil;&atilde;o (<a 
href="/img/revistas/rbr/v44n2/a12tab01.jpg">Tabela 1</a>). Tamb&eacute;m o hemat
&oacute;crito tendeu &agrave; normaliza&ccedil;&atilde;o ap&oacute;s 5 meses, co
m nova queda aos 8 meses de evolu&ccedil;&atilde;o. Ap&oacute;s melhora inicial 
da mobilidade das m&atilde;os e da pele como um todo, principalmente em termos s
ubjetivos, n&atilde;o houve progress&atilde;o favor&aacute;vel do quadro cut&aci
rc;neo com rela&ccedil;&atilde;o aos achados pr&eacute;-transplante. Objetivamen
te n&atilde;o pudemos demonstrar melhora do escore cut&acirc;neo pela t&eacute;c
nica de Kahaleh <i>et al.</i><sup>(16)</sup>, ou da esclerodactilia pelo "carimb
o" das m&atilde;os espalmadas. Piora progressiva dos sintomas gastrointestinais,
 marcantes neste paciente, ocorreu precocemente ap&oacute;s o transplante. De fa
to, n&atilde;o seria de se esperar revers&atilde;o de les&otilde;es esclerod&eac
ute;rmicas estabelecidas na parede intestinal. O &oacute;bito ap&oacute;s 12 mes
es do procedimento n&atilde;o se deveu a complica&ccedil;&otilde;es atribu&iacut
e;veis diretamente &agrave; imunossupress&atilde;o e reposi&ccedil;&atilde;o de 
c&eacute;lulas tronco CD34+, mas sim &agrave; pneumonia aspirativa e insufici&ec
irc;ncia respirat&oacute;ria complicada pela fibrose pulmonar.</font></p>     ^c
Y#v44n2a12.htm##
00882000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064800075002001300723#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#49#45#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O prop&oacute;sito do transplante aut
&oacute;logo de c&eacute;lulas CD34+ &eacute; permitir intensa imunossupress&ati
lde;o com quase total imunoabla&ccedil;&atilde;o da medula &oacute;ssea. Retiram
-se assim as c&eacute;lulas T respons&aacute;veis potencialmente pela doen&ccedi
l;a do indiv&iacute;duo e se consegue uma reconstitui&ccedil;&atilde;o precoce d
os elementos celulares do sangue, com menor risco ao paciente. As c&eacute;lulas
 pluripotenciais reinfundidas colonizar&atilde;o a medula &oacute;ssea, permitin
do hematopoese precoce e um sistema imune novo. </font></p>     ^cY#v44n2a12.htm
##
02054000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704182000075002001301895#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#50#46#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">H&aacute; na literatura v&aacute;rios
 estudos de pacientes com esclerodermia e outras doen&ccedil;as auto-imunes que 
receberam tratamento com imunossupress&atilde;o e transplante aut&oacute;logo de
 c&eacute;lulas progenitoras da medula &oacute;ssea, em geral num tom positivo<s
up>(17,18)</sup>. Tyndall <i>et al.</i><sup>(19)</sup> realizaram, em 1997, imun
oabla&ccedil;&atilde;o da medula &oacute;ssea com ciclofosfamida seguida do tran
splante aut&oacute;logo de medula &oacute;ssea em uma paciente de 37 anos com es
clerodermia grave, observando melhora no estado geral e redu&ccedil;&atilde;o do
 escore cut&acirc;neo em 6 meses de observa&ccedil;&atilde;o, achado semelhante 
ao de nosso paciente. Martini <i>et al.</i><sup>(20) </sup>observaram melhora su
stentada ap&oacute;s 2 anos de transplante aut&oacute;logo e uso de anticorpo mo
noclonal CAMPATH-1G em jovem de 14 anos com esclerodermia. Em outro estudo, Breb
an <i>et al.</i><sup><sup><i>(</i></sup><sup>21)</sup></sup> utilizaram 4g/m<sup
>2</sup> de ciclofosfamida seguidos da infus&atilde;o de fator estimulador de co
l&ocirc;nia de granul&oacute;citos em 4 pacientes com artrite reumat&oacute;ide 
severa e observaram diminui&ccedil;&atilde;o da atividade da doen&ccedil;a. Burt
 <i>et al.</i><sup>(22)</sup> efetuaram tratamento semelhante em 4 pacientes com
 artrite reumat&oacute;ide refrat&aacute;ria, mostrando boa toler&acirc;ncia e e
fic&aacute;cia cl&iacute;nica em 2 casos, com diminui&ccedil;&atilde;o do n&uacu
te;mero de articula&ccedil;&otilde;es inflamadas ap&oacute;s 6 meses. Resultados
 aparentemente brilhantes tamb&eacute;m t&ecirc;m sido publicados em pacientes c
om l&uacute;pus eritematoso sist&ecirc;mico e grave acometimento sist&ecirc;mico
<sup>(23-29)</sup>. </font></p>     ^cY#v44n2a12.htm##
01530000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704129600075002001301371#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#51#47#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">D&uacute;vidas v&ecirc;m sendo levant
adas na literatura, se os efeitos ben&eacute;ficos do procedimento de transplant
e aut&oacute;logo em doen&ccedil;as auto-imunes n&atilde;o ocorreria em raz&atil
de;o das altas doses de imunossupress&atilde;o utilizadas no regime de condicion
amento. Davis <i>et al.</i><sup>(30)</sup> utilizaram dois grupos de pacientes c
om artrite reumat&oacute;ide severa, que receberam 20mg/m<sup>2 </sup>(n=12) e 3
0mg/m<sup>2</sup> (n=14) de fludarabina por 3 dias consecutivos mensalmente dura
nte seis meses. Ambos os grupos apresentaram melhora cl&iacute;nica ap&oacute;s 
6 meses de tratamento, por&eacute;m v&aacute;rios epis&oacute;dios infecciosos o
correram. Viallard <i>et al.</i><sup>(31)</sup>, em 1999, descreveram paciente c
om l&uacute;pus eritematoso sist&ecirc;mico apresentando poliartrite irresponsiv
a a cortic&oacute;ides que melhorou substancialmente com o uso de 25mg/m<sup>2</
sup> de fludarabina durante 5 dias num total de 6 ciclos da medica&ccedil;&atild
e;o. Profunda e prolongada supress&atilde;o de sub-popula&ccedil;&otilde;es CD4+
/ CD8+ s&atilde;o atingidas com fludarabina, um efeito de dele&ccedil;&atilde;o 
qu&iacute;mica de linf&oacute;citos T patog&ecirc;nicos.</font></p>     ^cY#v44n
2a12.htm##
01952000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704171800075002001301793#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#52#48#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">O uso de imunoabla&ccedil;&atilde;o s
eguido de transplante aut&oacute;logo de medula &oacute;ssea tem se mostrado um 
meio eficaz de tratar doen&ccedil;as auto-imunes, por&eacute;m devemos salientar
 que este procedimento apresenta elevada taxa de mortalidade nos melhores centro
s, exigindo longos per&iacute;odos de interna&ccedil;&atilde;o hospitalar e alto
s custos<sup>(17,32,33)</sup>. Sele&ccedil;&atilde;o correta de pacientes (com c
rit&eacute;rios para identificar precocemente fatores adversos e para estabelece
r as potenciais indica&ccedil;&otilde;es), m&eacute;todos de mobiliza&ccedil;&at
ilde;o de c&eacute;lulas CD-34+, manipula&ccedil;&atilde;o do enxerto (com remo&
ccedil;&atilde;o de c&eacute;lulas patog&ecirc;nicas), natureza e toxicidade do 
condicionamento (ajuste para cada distinta doen&ccedil;a autoimune e complica&cc
edil;&otilde;es secund&aacute;rias a longo prazo), questionamentos bio&eacute;ti
cos em crian&ccedil;as e adultos, e recorr&ecirc;ncia precoce ou persist&ecirc;n
cia da doen&ccedil;a b&aacute;sica ap&oacute;s o transplante s&atilde;o t&oacute
;picos ainda n&atilde;o resolvidos e motivo de intenso debate na literatura mais
 atual<sup>(7,34-37)</sup>. No entanto, casos espor&aacute;dicos e algumas s&eac
ute;ries tentam demonstrar que remiss&atilde;o total pode ser conseguida em indi
v&iacute;duos com doen&ccedil;a resistente &agrave; terap&ecirc;utica e severa a
 ponto de colocar em risco a vida dos pacientes. Assim, os potenciais riscos de 
uma terapia experimental seriam aceit&aacute;veis, com potenciais resultados mui
to favor&aacute;veis, mesmo em se tratando de crian&ccedil;as<sup>(38)</sup>. </
font></p>     ^cY#v44n2a12.htm##
00780000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704054600075002001300621#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#53#49#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Uma alternativa a ser explorada seria
 utilizar quimioterapia n&atilde;o-mieloablativa, mas em doses maiores que as no
rmalmente utilizadas por reumatologistas e sem suporte de CTH. Ciclofosfamida e 
fludarabina, da maneira como utilizamos no presente caso, s&atilde;o f&aacute;rm
acos com efeito sin&eacute;rgico e podem causar remiss&otilde;es sustentadas de 
pacientes com doen&ccedil;as auto-imunes quando utilizados isolada ou conjuntame
nte<sup>(30,39,40)</sup>. </font></p>     ^cY#v44n2a12.htm##
00539000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030500075002001300380#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#54#50#article#144#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">S&atilde;o necess&aacute;rios mais es
tudos utilizando esse grupo de drogas em esclerodermia para melhor avaliar sua e
fic&aacute;cia, em estudos controlados com e sem suporte de c&eacute;lulas tronc
o hematopo&eacute;ticas. </font></p>     ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#55#51#article#144#<p>&nbsp;</p>     ^c
Y#v44n2a12.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#56#52#article#144#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>  
   ^cY#v44n2a12.htm##
00483000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704023500077002001300312#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#57#53#article#144#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Canoso JJ: Systemic 
sclerosis (scleroderma) and related syndromes. In Rheumatology in primary care, 
JJ Canoso Editor, WB Saunders: Philadelphia. p. 104-14, 1997.    ^cY#v44n2a12.ht
m##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#58#54#article#144#</font></p>     ^cY#
v44n2a12.htm##
00497000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704024900077002001300326#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#59#55#article#144#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. White B, Wigley FM, 
Steen VD: Systemic sclerosis and related disorders. In Primer on the Rheumatic D
iseases, HR Schumacher Editor, Arthritis Foundation: Atlanta, 263-75, 1997.    ^
cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#60#56#article#144#</font></p>     ^cY#
v44n2a12.htm##
00488000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704024000077002001300317#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#61#57#article#144#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Akesson A, Scheja A,
 Lundin A, Wollheim FA: Improved Pulmonary Function in Systemic Sclerosis After 
Treatment with Cyclophosphamide. Arthritis Rheum 37: 729-35, 1994.    ^cY#v44n2a
12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#62#58#article#144#</font></p>     ^cY#
v44n2a12.htm##
00459000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021100077002001300288#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#63#59#article#144#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Messner RP: The pote
ntial of bone marrow stem cell transplantation in the treatment of autoimmune di
seases. J Rheumatol 24: 819-21, 1997.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#64#60#article#144#</font></p>     ^cY#
v44n2a12.htm##
00460000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021200077002001300289#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#65#61#article#144#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Burt RK: BMT for sev
ere autoimmune diseases: an idea whose time has come. Oncology (Huntingt) 11: 10
01-14; 1017, discussion 1018-24, 1997.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#66#62#article#144#</font></p>     ^cY#
v44n2a12.htm##
00512000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026400077002001300341#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#67#63#article#144#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Burt RK, Traynor AE,
 Pope R, et al: Treatment of autoimmune disease by intense immunosuppressive con
ditioning and autologous hematopoietic stem cell transplantation. Blood 92: 3505
-14, 1998.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#68#64#article#144#</font></p>     ^cY#
v44n2a12.htm##
00445000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704019700077002001300274#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#69#65#article#144#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Snowden JA, Brooks P
M: Hematopoietic stem cell transplantation in rheumatic diseases. Curr Opin Rheu
matol 11: 167-72, 1999.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#70#66#article#144#</font></p>     ^cY#
v44n2a12.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704023000077002001300307#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#71#67#article#144#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Tyndall A, Passweg J
, Gratwohl A: Haemopoietic stem cell transplantation in the treatment of severe 
autoimmune diseases 2000. Ann Rheum Dis 60: 702-7, 2001.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#72#68#article#144#</font></p>     ^cY#
v44n2a12.htm##
00449000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020100077002001300278#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#73#69#article#144#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Snowden JA, Brooks P
M, Biggs JC: Haemopoietic stem cell transplantation for autoimmune diseases. Br 
J Haematol, 99: 9-22, 1997.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#74#70#article#144#</font></p>     ^cY#
v44n2a12.htm##
00396000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704014700078002001300225#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#75#71#article#144#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Lennard AL, Jackso
n GH: Stem cell transplantation. BMJ 321: 433-7, 2000.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#76#72#article#144#</font></p>     ^cY#
v44n2a12.htm##
00458000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704020900078002001300287#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#77#73#article#144#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Masi AT, et al: Pr
eliminary criteria for the classification of systemic sclerosis (scleroderma). A
rthritis and Rheum 23: 581-90, 1980.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#78#74#article#144#</font></p>     ^cY#
v44n2a12.htm##
00497000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704024800078002001300326#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#79#75#article#144#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Slaper-Cortenbach 
IC, Wijngaarden-du Bois MJ, De Vries-van Rossen A, et al: The depletion of T cel
ls from haematopoietic stem cell transplants. Rheumatology 38: 751-4, 1999.    ^
cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#80#76#article#144#</font></p>     ^cY#
v44n2a12.htm##
00433000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704018400078002001300262#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#81#77#article#144#13#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Bierings M: The ro
le of T-cell depletion of autografts for autoimmune diseases. Rheumatology 38: 7
55-6, 1999.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#82#78#article#144#</font></p>     ^cY#
v44n2a12.htm##
00535000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704028600078002001300364#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#83#79#article#144#14#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Fassas A, Anagnost
opoulos A, Kazis A, et al: Peripheral blood stem cell transplantation in the tre
atment of progressive multiple sclerosis: first results of a pilot study. Bone M
arrow Transplant 20: 631-8, 1997.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#84#80#article#144#</font></p>     ^cY#
v44n2a12.htm##
00493000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704024400078002001300322#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#85#81#article#144#15#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Lim SH, Kell J, Al
-Sabah A, Bashi W, Bailey-Wood R: Peripheral blood stem-cell transplantation for
 refractory autoimmune thrombocytopenic purpura. Lancet 349: 475, 1997.    ^cY#v
44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#86#82#article#144#</font></p>     ^cY#
v44n2a12.htm##
00475000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704022600078002001300304#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#87#83#article#144#16#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Kahaleh MB, Sultan
y GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC: A modified scleroderma sk
in scoring method. Clin Exp Rheumatol 4: 367-9, 1986.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#88#84#article#144#</font></p>     ^cY#
v44n2a12.htm##
00512000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704026300078002001300341#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#89#85#article#144#17#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Jantunen E, Myllyk
angas-Luosujarvi R: Stem cell transplantation for treatment of severe autoimmune
 diseases: current status and future perspectives. Bone Marrow Transplant 25: 35
1-6, 2000.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#90#86#article#144#</font></p>     ^cY#
v44n2a12.htm##
00471000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704022200078002001300300#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#91#87#article#144#18#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Moore J, Tyndall A
, Brooks P: Stem cells in the aetiopathogenesis and therapy of rheumatic disease
. Best Pract Res Clin Rheumatol 15: 711-26, 2001.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#92#88#article#144#</font></p>     ^cY#
v44n2a12.htm##
00470000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704022100078002001300299#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#93#89#article#144#19#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Tyndall A, Black C
, Finke J, et al: Treatment of systemic sclerosis with autologous haemopoietic s
tem cell transplantation. Lancet 349: 254, 1997.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#94#90#article#144#</font></p>     ^cY#
v44n2a12.htm##
00519000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704027000078002001300348#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#95#91#article#144#20#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Martini A, Maccari
o R, Ravelli A, et al: Marked and sustained improvement two years after autologo
us stem cell transplantation in a girl with systemic sclerosis. Arthritis Rheum 
42: 807-11, 1999.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#96#92#article#144#</font></p>     ^cY#
v44n2a12.htm##
00586000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704033700078002001300415#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#97#93#article#144#21#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Breban M, Dougados
 M, Picard F, et al: Intensified-dose (4 gm/m<sup>2</sup>) cyclophosphamide and 
granulocyte colony-stimulating factor administration for hematopoietic stem cell
 mobilization in refractory rheumatoid arthritis. Arthritis Rheum 42: 2275-80, 1
999.    ^cY#v44n2a12.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002000075002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#98#94#article#144#</font></p>     ^cY#
v44n2a12.htm##
00530000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704028100078002001300359#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#99#95#article#144#22#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Burt RK, Georganas
 C, Schroeder J, et al: Autologous hematopoietic stem cell transplantation in re
fractory rheumatoid arthritis: sustained response in two of four patients. Arthr
itis Rheum 42: 2281-5, 1999.    ^cY#v44n2a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002000076002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#100#96#article#144#</font></p>     ^cY
#v44n2a12.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704024900079002001300328#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#101#97#article#144#23#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Marmont AM, Van L
int MT, Gualandi F, Bacigalupo A: Autologous marrow stem cell transplantation fo
r severe systemic lupus erythematosus of long duration. Lupus 6: 545-8, 1997.   
 ^cY#v44n2a12.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002000076002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#102#98#article#144#</font></p>     ^cY
#v44n2a12.htm##
00530000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704028000079002001300359#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#103#99#article#144#24#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Musso M, Porretto
 F, Crescimanno A, et al: Autologous peripheral blood stem and progenitor (CD34+
) cell transplantation for systemic lupus erythematosus complicated by Evans syn
drome. Lupus 7: 492-4, 1998.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#104#100#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00585000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033400080002001300414#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#105#101#article#144#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Fouillard L, Gor
in NC, Laporte JP, Leon A, Brantus JF, Miossec P: Control of severe systemic lup
us erythematosus after high-dose immunusuppressive therapy and transplantation o
f CD34+ purified autologous stem cells from peripheral blood. Lupus 8: 320-3, 19
99.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#106#102#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00458000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020700080002001300287#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#107#103#article#144#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Traynor A, Burt 
RK: Haematopoietic stem cell transplantation for active systemic lupus erythemat
osus. Rheumatology 38: 767-72, 1999.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#108#104#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021500080002001300295#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#109#105#article#144#27#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Marmont AM: Inte
nse immunosuppression and stem cell transplantation or rescue for severe systemi
c lupus erythematosus. Lupus 8: 256-7, 1999.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#110#106#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00529000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027800080002001300358#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#111#107#article#144#28#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Traynor AE, Schr
oeder J, Rosa RM, et al: Treatment of severe systemic lupus erythematosus with h
igh-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I stud
y. Lancet 356: 701-7, 2000.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#112#108#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00493000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024200080002001300322#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#113#109#article#144#29#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Trysberg E, Lind
gren I, Tarkowski A: Autologous stem cell transplantation in a case of treatment
 resistant central nervous system lupus. Ann Rheum Dis 59: 236-8, 2000.    ^cY#v
44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#114#110#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00512000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026100080002001300341#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#115#111#article#144#30#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Davis JC, Fessle
r BJ, Tassiulas IO, et al: High dose versus low dose fludarabine in the treatmen
t of patients with severe refractory rheumatoid arthritis. J Rheumatol 25: 1694-
704, 1998.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#116#112#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00456000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020500080002001300285#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#117#113#article#144#31#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Viallard JF, Mer
ci&eacute; P, Faure I, Pellegrin JL, Leng B: Successful treatment of lupus with 
fludarabine. Lupus 8: 767-9, 1999.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#118#114#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00734000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704048300080002001300563#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#119#115#article#144#32#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Tyndall A, Fassa
s A, Passweg J, et al: Autologous haematopoietic stem cell transplants for autoi
mmune disease--feasibility and transplant-related mortality. Autoimmune Disease 
and Lymphoma Working Parties of the European Group for Blood and Marrow Transpla
ntation, the European League Against Rheumatism and the International Stem Cell 
Project for Autoimmune Disease. Bone Marrow Transplant 24: 729-34, 1999.    ^cY#
v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#120#116#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00530000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027900080002001300359#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#121#117#article#144#33#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Binks M, Passweg
 JR, Furst D, et al: Phase I/II trial of autologous stem cell transplantation in
 systemic sclerosis: procedure related mortality and impact on skin disease. Ann
 Rheum Dis 60: 577-84, 2001.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#122#118#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00503000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025200080002001300332#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#123#119#article#144#34#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Tyndall A: Immun
oablation and haemopoietic stem cell transplantation for severe autoimmune disea
se with special reference to systemic lupus erythematosus. Lupus 10: 214-5, 2001
.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#124#120#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00606000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704035500080002001300435#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#125#121#article#144#35#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Tyndall A, Gratw
ohl A: Blood and marrow stem cell transplants in auto-immune disease: a consensu
s report written on behalf of the European League against Rheumatism (EULAR) and
 the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Tra
nsplant 19: 643-5, 1997.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#126#122#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00505000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025400080002001300334#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#127#123#article#144#36#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Euler HH, Marmon
t AM, Bacigalupo A, et al: Early recurrence or persistence of autoimmune disease
s after unmanipulated autologous stem cell transplantation. Blood 88: 3621-5, 19
96.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#128#124#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00475000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022400080002001300304#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#129#125#article#144#37#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Laxer RM, Harris
on C: Bioethical issues in autologous stem cell transplantation in children and 
adults with arthritis. J Rheumatol 28: 2147-50, 2001.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#130#126#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026900080002001300349#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#131#127#article#144#38#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Niethammer D, Ku
mmerle-Deschner J, Dannecker GE: Side-effects of long-term immunosuppression ver
sus morbidity in autologous stem cell rescue: striking the balance. Rheumatology
 38: 747-50, 1999.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#132#128#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00529000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027800080002001300358#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#133#129#article#144#39#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Frewin R, Turner
 D, Tighe M, Davies S, Rule S, Johnson S: Combination therapy with fludarabine a
nd cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J 
Haematol 104: 612-3., 1999.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#134#130#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00468000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021700080002001300297#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#135#131#article#144#40#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Mittal G, Balakr
ishna C, Mangat G, Joshi VR: 'Sustained remission' in a case of SLE following me
gadose cyclophosphamide. Lupus 8: 77-80, 1999.    ^cY#v44n2a12.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002000077002001300097#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#136#132#article#144#</font></p>     ^c
Y#v44n2a12.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#137#133#article#144#<p>&nbsp;</p>     
^cY#v44n2a12.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#138#134#article#144#<p>&nbsp;</p>     
^cY#v44n2a12.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022900077002001300306#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#139#135#article#144#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a href="#linkinicio"><img src="/im
g/revistas/rbr/v44n2/seta.jpg" border="0"></a><a name="linkcorresp"></a> <b>Ende
re&ccedil;o para correspond&ecirc;ncia:</b>    ^cY#v44n2a12.htm##
00280000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004400077002001300121#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#140#136#article#144#<br>  Carlos Alber
to von M&uuml;hlen    ^cY#v44n2a12.htm##
00283000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004700077002001300124#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#141#137#article#144#<br> R. Cel.Camis&
atilde;o 132, ap. 201    ^cY#v44n2a12.htm##
00280000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004400077002001300121#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#142#138#article#144#<br> Porto Alegre,
 RS, CEP 90540-050    ^cY#v44n2a12.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009400077002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#143#139#article#144#<br> E-mail: <a hr
ef="mailto:cavm@rocketmail.com">cavm@rocketmail.com</a> </font></p>     ^cY#v44n
2a12.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009300077002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#144#140#article#144#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">Recebido em 21/2/2002.    ^cY#v44n2
a12.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#145#141#article#144#<br>  Aprovado, ap
&oacute;s revis&atilde;o, em 27/11/2003.</font></p>     ^cY#v44n2a12.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#146#142#article#144#<p>&nbsp;</p>     
^cY#v44n2a12.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#147#143#article#144#<p>&nbsp;</p>     
^cY#v44n2a12.htm##
00720000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704048400077002001300561#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a12.htm#S#p#148#144#article#144#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a name="link01"></a><a href="#link
inicio">*</a> 	Servi&ccedil;os de reumatologia, oncologia e hematologia do Hospi
tal S&atilde;o Lucas da Faculdade de Medicina da Pontif&iacute;cia Universidade 
Cat&oacute;lica do Rio Grande do Sul (PUCRS), Porto Alegre, RS. Trabalho realiza
do com o apoio do Fundo de Aux&iacute;lio &agrave; Pesquisa e Ensino em Reumatol
ogia da Sociedade Brasileira de Reumatologia. </font></p>     ^cY#v44n2a12.htm##
00536000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760120059000930180
03300152016001700185062001200202066001300214014000700227065000900234064000500243
865000900248002001300257#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#
c#149#1#article#40#1#^rND^sCanoso^nJJ#Systemic sclerosis (scleroderma) and relat
ed syndromes^len#Rheumatology in primary care^len#^rED^nJJ^sCanoso#WB Saunders#P
hiladelphia#104-14#19970000#1997#20040400#v44n2a12.htm##
00589000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100017000910100
01600108012004500124018003700169016002100206062002100227066000800248014000700256
065000900263064000500272865000900277002001300286#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a12.htm#S#c#150#2#article#40#2#^rND^sWhite^nB#^rND^sWigley^nFM#^rN
D^sSteen^nVD#Systemic sclerosis and related disorders^len#Primer on the Rheumati
c Diseases^len#^rED^nHR^sSchumacher#Arthritis Foundation#Atlanta#263-75#19970000
#1997#20040400#v44n2a12.htm##
00626000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100016000930100
01600109010001900125012009200144030001600236031000300252014000700255065000900262
064000500271865000900276002001300285035001000298801001600308#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#151#3#article#40#3#^rND^sAkesson^nA#^rND^s
Scheja^nA#^rND^sLundin^nA#^rND^sWollheim^nFA#Improved Pulmonary Function in Syst
emic Sclerosis After Treatment with Cyclophosphamide^len#Arthritis Rheum#37#729-
35#19940000#1994#20040400#v44n2a12.htm#0004-3591#Arthritis rheum##
00539000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760120099000940300
01200193031000300205014000700208065000900215064000500224865000900229002001300238
035001000251801001200261#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#
c#152#4#article#40#4#^rND^sMessner^nRP#The potential of bone marrow stem cell tr
ansplantation in the treatment of autoimmune diseases^len#J Rheumatol#24#819-21#
19970000#1997#20040400#v44n2a12.htm#0315-162X#J Rheumatol##
00537000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760120068000910300
00900159031000300168014000800171061002500179065000900204064000500213865000900218
002001300227035001000240801000900250#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#c#153#5#article#40#5#^rND^sBurt^nRK#BMT for severe autoimmune diseas
es: an idea whose time has come^len#Oncology#11#1001-14#1017, discussion 1018-24
#19970000#1997#20040400#v44n2a12.htm#0030-2414#Oncology##
00633000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100018000910100
01400109810000600123012013300129030000600262031000300268014000800271065000900279
064000500288865000900293002001300302035001000315801000600325#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#154#6#article#40#6#^rND^sBurt^nRK#^rND^sTr
aynor^nAE#^rND^sPope^nR#et al#Treatment of autoimmune disease by intense immunos
uppressive conditioning and autologous hematopoietic stem cell transplantation^l
en#Blood#92#3505-14#19980000#1998#20040400#v44n2a12.htm#0006-4971#Blood##
00551000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940120
06600111030002000177031000300197014000700200065000900207064000500216865000900221
002001300230035001000243801002000253#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#c#155#7#article#40#7#^rND^sSnowden^nJA#^rND^sBrooks^nPM#Hematopoieti
c stem cell transplantation in rheumatic diseases^len#Curr Opin Rheumatol#11#167
-72#19990000#1999#20040400#v44n2a12.htm#1040-8711#Curr Opin Rheumatol##
00596000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100017000930100
01800110012009500128030001400223031000300237014000600240065000900246064000500255
865000900260002001300269035001000282801001400292#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a12.htm#S#c#156#8#article#40#8#^rND^sTyndall^nA#^rND^sPassweg^nJ#^
rND^sGratwohl^nA#Haemopoietic stem cell transplantation in the treatment of seve
re autoimmune diseases 2000^len#Ann Rheum Dis#60#702-7#20010000#2001#20040400#v4
4n2a12.htm#0003-4967#Ann Rheum Dis##
00566000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940100
01600111012006700127030001400194031000300208014000500211065000900216064000500225
865000900230002001300239035001000252801001400262#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a12.htm#S#c#157#9#article#40#9#^rND^sSnowden^nJA#^rND^sBrooks^nPM#
^rND^sBiggs^nJC#Haemopoietic stem cell transplantation for autoimmune diseases^l
en#Br J Haematol#99#9-22#19970000#1997#20040400#v44n2a12.htm#0007-1048#Br J Haem
atol##
00486000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960120
03000114030000400144031000400148014000600152065000900158064000500167865000900172
002001300181035001000194801000400204#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#c#158#10#article#40#10#^rND^sLennard^nAL#^rND^sJackson^nGH#Stem cell
 transplantation^len#BMJ#321#433-7#20000000#2000#20040400#v44n2a12.htm#0959-8138
#BMJ##
00517000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000788100006000930120
08400099030002000183710000200203031000300205014000700208065000900215064000500224
865000900229002001300238#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#
c#159#11#article#40#11#^rND^sMasi^nAT#et al#Preliminary criteria for the classif
ication of systemic sclerosis (scleroderma)^len#Arthritis and Rheum#2#23#581-90#
19800000#1980#20040400#v44n2a12.htm##
00625000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100028000780100030001060100
02900136810000600165012007100171030001300242031000300255014000600258065000900264
064000500273865000900278002001300287035001000300801001300310#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#160#12#article#40#12#^rND^sSlaper-Cortenba
ch^nIC#^rND^sWijngaarden-du Bois^nMJ#^rND^sDe Vries-van Rossen^nA#et al#The depl
etion of T cells from haematopoietic stem cell transplants^len#Rheumatology#38#7
51-4#19990000#1999#20040400#v44n2a12.htm#0080-2727#RHEUMATOLOGY##
00514000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780120071000960300
01300167031000300180014000600183065000900189064000500198865000900203002001300212
035001000225801001300235#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#
c#161#13#article#40#13#^rND^sBierings^nM#The role of T-cell depletion of autogra
fts for autoimmune diseases^len#Rheumatology#38#755-6#19990000#1999#20040400#v44
n2a12.htm#0080-2727#RHEUMATOLOGY##
00673000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100025000940100
01500119810000600134012013000140030002300270031000300293014000600296065000900302
064000500311865000900316002001300325035001000338801002300348#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#162#14#article#40#14#^rND^sFassas^nA#^rND^
sAnagnostopoulos^nA#^rND^sKazis^nA#et al#Peripheral blood stem cell transplantat
ion in the treatment of progressive multiple sclerosis: first results of a pilot
 study^len#Bone Marrow Transplant#20#631-8#19970000#1997#20040400#v44n2a12.htm#0
268-3369#Bone marrow transplant##
00640000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100014000920100
01800106010001500124010002100139012009800160030000700258031000400265032000400269
065000900273064000500282865000900287002001300296035001000309801000700319#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#c#163#15#article#40#15#^rND^sLim
^nSH#^rND^sKell^nJ#^rND^sAl-Sabah^nA#^rND^sBashi^nW#^rND^sBailey-Wood^nR#Periphe
ral blood stem-cell transplantation for refractory autoimmune thrombocytopenic p
urpura^len#Lancet#349#475#19970000#1997#20040400#v44n2a12.htm#0099-5355#Lancet##
00652000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01600114010002200130010001900152010001600171012004700187030001900234031000200253
01400060025506500090026106400050027086500090027500200130028403500100029780100190
0307#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#c#164#16#article#40#
16#^rND^sKahaleh^nMB#^rND^sSultany^nGL#^rND^sSmith^nEA#^rND^sHuffstutter^nJE#^rN
D^sLoadholt^nCB#^rND^sLeRoy^nEC#A modified scleroderma skin scoring method^len#C
lin Exp Rheumatol#4#367-9#19860000#1986#20040400#v44n2a12.htm#0392-856X#Clin Exp
 Rheumatol##
00621000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100032000960120
11400128030002300242031000300265014000600268065000900274064000500283865000900288
002001300297035001000310801002300320#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#c#165#17#article#40#17#^rND^sJantunen^nE#^rND^sMyllykangas-Luosujarv
i^nR#Stem cell transplantation for treatment of severe autoimmune diseases: curr
ent status and future perspectives^len#Bone Marrow Transplant#25#351-6#20000000#
2000#20040400#v44n2a12.htm#0268-3369#Bone marrow transplant##
00555000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01600110012007300126030003000199710000200229031000300231014000700234065000900241
064000500250865000900255002001300264#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#c#166#18#article#40#18#^rND^sMoore^nJ#^rND^sTyndall^nA#^rND^sBrooks^
nP#Stem cells in the aetiopathogenesis and therapy of rheumatic disease^len#Best
 Pract Res Clin Rheumatol#2#15#711-26#20010000#2001#20040400#v44n2a12.htm##
00592000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950100
01500110810000600125012009100131030000700222031000400229020000400233065000900237
064000500246865000900251002001300260035001000273801000700283#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#167#19#article#40#19#^rND^sTyndall^nA#^rND
^sBlack^nC#^rND^sFinke^nJ#et al#Treatment of systemic sclerosis with autologous 
haemopoietic stem cell transplantation^len#Lancet#349#254#19970000#1997#20040400
#v44n2a12.htm#0099-5355#Lancet##
00650000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01700113810000600130012012400136030001600260031000300276014000700279065000900286
064000500295865000900300002001300309035001000322801001600332#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#168#20#article#40#20#^rND^sMartini^nA#^rND
^sMaccario^nR#^rND^sRavelli^nA#et al#Marked and sustained improvement two years 
after autologous stem cell transplantation in a girl with systemic sclerosis^len
#Arthritis Rheum#42#807-11#19990000#1999#20040400#v44n2a12.htm#0004-3591#Arthrit
is rheum##
00706000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01600112810000600128012018100134030001600315031000300331014000800334065000900342
064000500351865000900356002001300365035001000378801001600388#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#169#21#article#40#21#^rND^sBreban^nM#^rND^
sDougados^nM#^rND^sPicard^nF#et al#Intensified-dose (4 gm/m²) cyclophosphamide a
nd granulocyte colony-stimulating factor administration for hematopoietic stem c
ell mobilization in refractory rheumatoid arthritis^len#Arthritis Rheum#42#2275-
80#19990000#1999#20040400#v44n2a12.htm#0004-3591#Arthritis rheum##
00661000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100019000930100
01900112810000600131012013400137030001600271031000300287014000700290065000900297
064000500306865000900311002001300320035001000333801001600343#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#170#22#article#40#22#^rND^sBurt^nRK#^rND^s
Georganas^nC#^rND^sSchroeder^nJ#et al#Autologous hematopoietic stem cell transpl
antation in refractory rheumatoid arthritis: sustained response in two of four p
atients^len#Arthritis Rheum#42#2281-5#19990000#1999#20040400#v44n2a12.htm#0004-3
591#Arthritis rheum##
00626000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960100
01800115010002000133012010500153030000600258031000200264014000600266065000900272
064000500281865000900286002001300295035001000308801000600318#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#171#23#article#40#23#^rND^sMarmont^nAM#^rN
D^sVan Lint^nMT#^rND^sGualandi^nF#^rND^sBacigalupo^nA#Autologous marrow stem cel
l transplantation for severe systemic lupus erythematosus of long duration^len#L
upus#6#545-8#19970000#1997#20040400#v44n2a12.htm#0961-2033#Lupus##
00650000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100018000930100
02100111810000600132012014400138030000600282031000200288014000600290065000900296
064000500305865000900310002001300319035001000332801000600342#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#172#24#article#40#24#^rND^sMusso^nM#^rND^s
Porretto^nF#^rND^sCrescimanno^nA#et al#Autologous peripheral blood stem and prog
enitor (CD34+) cell transplantation for systemic lupus erythematosus complicated
 by Evans syndrome^len#Lupus#7#492-4#19980000#1998#20040400#v44n2a12.htm#0961-20
33#Lupus##
00747000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100016000970100
01800113010001400131010001800145010001700163012017500180030000600355031000200361
01400060036306500090036906400050037886500090038300200130039203500100040580100060
0415#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#c#173#25#article#40#
25#^rND^sFouillard^nL#^rND^sGorin^nNC#^rND^sLaporte^nJP#^rND^sLeon^nA#^rND^sBran
tus^nJF#^rND^sMiossec^nP#Control of severe systemic lupus erythematosus after hi
gh-dose immunusuppressive therapy and transplantation of CD34+ purified autologo
us stem cells from peripheral blood^len#Lupus#8#320-3#19990000#1999#20040400#v44
n2a12.htm#0961-2033#Lupus##
00555000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950120
08500110030001300195031000300208014000700211065000900218064000500227865000900232
002001300241035001000254801001300264#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#c#174#26#article#40#26#^rND^sTraynor^nA#^rND^sBurt^nRK#Haematopoieti
c stem cell transplantation for active systemic lupus erythematosus^len#Rheumato
logy#38#767-72#19990000#1999#20040400#v44n2a12.htm#0080-2727#RHEUMATOLOGY##
00538000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780120110000960300
00600206031000200212014000600214065000900220064000500229865000900234002001300243
035001000256801000600266#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#
c#175#27#article#40#27#^rND^sMarmont^nAM#Intense immunosuppression and stem cell
 transplantation or rescue for severe systemic lupus erythematosus^len#Lupus#8#2
56-7#19990000#1999#20040400#v44n2a12.htm#0961-2033#Lupus##
00649000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960100
01500115810000600130012014100136030000700277031000400284014000600288065000900294
064000500303865000900308002001300317035001000330801000700340#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#176#28#article#40#28#^rND^sTraynor^nAE#^rN
D^sSchroeder^nJ#^rND^sRosa^nRM#et al#Treatment of severe systemic lupus erythema
tosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a 
phase I study^len#Lancet#356#701-7#20000000#2000#20040400#v44n2a12.htm#0099-5355
#Lancet##
00609000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01900114012010300133030001400236031000300250014000600253065000900259064000500268
865000900273002001300282035001000295801001400305#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a12.htm#S#c#177#29#article#40#29#^rND^sTrysberg^nE#^rND^sLindgren^
nI#^rND^sTarkowski^nA#Autologous stem cell transplantation in a case of treatmen
t resistant central nervous system lupus^len#Ann Rheum Dis#59#236-8#20000000#200
0#20040400#v44n2a12.htm#0003-4967#Ann Rheum Dis##
00637000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
02000112810000600132012011500138030001200253031000300265014000900268065000900277
064000500286865000900291002001300300035001000313801001200323#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#178#30#article#40#30#^rND^sDavis^nJC#^rND^
sFessler^nBJ#^rND^sTassiulas^nIO#et al#High dose versus low dose fludarabine in 
the treatment of patients with severe refractory rheumatoid arthritis^len#J Rheu
matol#25#1694-704#19980000#1998#20040400#v44n2a12.htm#0315-162X#J Rheumatol##
00593000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100016000970100
01500113010002000128010001400148012005100162030000600213031000200219014000600221
065000900227064000500236865000900241002001300250035001000263801000600273#v44n2#V
:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#c#179#31#article#40#31#^rND^sVia
llard^nJF#^rND^sMercié^nP#^rND^sFaure^nI#^rND^sPellegrin^nJL#^rND^sLeng^nB#Succe
ssful treatment of lupus with fludarabine^len#Lupus#8#767-9#19990000#1999#200404
00#v44n2a12.htm#0961-2033#Lupus##
00870000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01700111810000600128012033200134030002300466031000300489014000700492065000900499
064000500508865000900513002001300522035001000535801002300545#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#180#32#article#40#32#^rND^sTyndall^nA#^rND
^sFassas^nA#^rND^sPassweg^nJ#et al#Autologous haematopoietic stem cell transplan
ts for autoimmune disease: feasibility and transplant-related mortality. Autoimm
une Disease and Lymphoma Working Parties of the European Group for Blood and Mar
row Transplantation, the European League Against Rheumatism and the Internationa
l Stem Cell Project for Autoimmune Disease^len#Bone Marrow Transplant#24#729-34#
19990000#1999#20040400#v44n2a12.htm#0268-3369#Bone marrow transplant##
00657000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100018000930100
01500111810000600126012013900132030001400271031000300285014000700288065000900295
064000500304865000900309002001300318035001000331801001400341#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#181#33#article#40#33#^rND^sBinks^nM#^rND^s
Passweg^nJR#^rND^sFurst^nD#et al#Phase I/II trial of autologous stem cell transp
lantation in systemic sclerosis: procedure related mortality and impact on skin 
disease^len#Ann Rheum Dis#60#577-84#20010000#2001#20040400#v44n2a12.htm#0003-496
7#Ann Rheum Dis##
00575000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780120147000950300
00600242031000300248014000600251065000900257064000500266865000900271002001300280
035001000293801000600303#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#
c#182#34#article#40#34#^rND^sTyndall^nA#Immunoablation and haemopoietic stem cel
l transplantation for severe autoimmune disease with special reference to system
ic lupus erythematosus^len#Lupus#10#214-5#20010000#2001#20040400#v44n2a12.htm#09
61-2033#Lupus##
00713000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950120
22100113030002300334031000300357014000600360065000900366064000500375865000900380
002001300389035001000402801002300412#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#c#183#35#article#40#35#^rND^sTyndall^nA#^rND^sGratwohl^nA#Blood and 
marrow stem cell transplants in auto-immune disease: a consensus report written 
on behalf of the European League against Rheumatism (EULAR) and the European Gro
up for Blood and Marrow Transplantation (EBMT)^len#Bone Marrow Transplant#19#643
-5#19970000#1997#20040400#v44n2a12.htm#0268-3369#Bone marrow transplant##
00624000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
02000112810000600132012011600138030000600254031000300260014000700263065000900270
064000500279865000900284002001300293035001000306801000600316#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#184#36#article#40#36#^rND^sEuler^nHH#^rND^
sMarmont^nAM#^rND^sBacigalupo^nA#et al#Early recurrence or persistence of autoim
mune diseases after unmanipulated autologous stem cell transplantation^len#Blood
#88#3621-5#19960000#1996#20040400#v44n2a12.htm#0006-4971#Blood##
00571000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940120
10000112030001200212031000300224014000800227065000900235064000500244865000900249
002001300258035001000271801001200281#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a12.htm#S#c#185#37#article#40#37#^rND^sLaxer^nRM#^rND^sHarrison^nC#Bioethical 
issues in autologous stem cell transplantation in children and adults with arthr
itis^len#J Rheumatol#28#2147-50#20010000#2001#20040400#v44n2a12.htm#0315-162X#J 
Rheumatol##
00635000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100027000980100
02000125012011800145030001300263031000300276014000700279065000900286064000500295
865000900300002001300309035001000322801001300332#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a12.htm#S#c#186#38#article#40#38#^rND^sNiethammer^nD#^rND^sKummerl
e-Deschner^nJ#^rND^sDannecker^nGE#Side-effects of long-term immunosuppression ve
rsus morbidity in autologous stem cell rescue: striking the balance^len#Rheumato
logy#38#747-50#19990000#1999#20040400#v44n2a12.htm#0080-2727#RHEUMATOLOGY##
00698000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
01500110010001600125010001400141010001700155012011600172030001400288031000400302
01400060030606500090031206400050032186500090032600200130033503500100034880100140
0358#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a12.htm#S#c#187#39#article#40#
39#^rND^sFrewin^nR#^rND^sTurner^nD#^rND^sTighe^nM#^rND^sDavies^nS#^rND^sRule^nS#
^rND^sJohnson^nS#Combination therapy with fludarabine and cyclophosphamide as sa
lvage treatment in lymphoproliferative disorders^len#Br J Haematol#104#612-3#199
90000#1999#20040400#v44n2a12.htm#0007-1048#Br J Haematol##
00594000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100021000940100
01600115010001600131012007900147030000600226031000200232014000600234065000900240
064000500249865000900254002001300263035001000276801000600286#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a12.htm#S#c#188#40#article#40#40#^rND^sMittal^nG#^rND^
sBalakrishna^nC#^rND^sMangat^nG#^rND^sJoshi^nVR#'Sustained remission' in a case 
of SLE following megadose cyclophosphamide^len#Lupus#8#77-80#19990000#1999#20040
400#v44n2a12.htm#0961-2033#Lupus##
00273000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00300100#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#o#1#1#article#1#
20110406#085927#v44n2a13.htm#95##
04095000000000637000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089121000300094049000700097158000300104030002100107
03100030012803200020013106500090013301400110014203500100015301200980016301200870
02610100046003480100040003940100047004340100031004810100037005120100035005490100
03800584010004100622070001300663083127400676085000801950085004101958085003001999
08500410202908312200207008500080329008500390329808500330333708500280337011700060
3398072000303404112000903407111000903416114000903425113001003434002001303444#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#h#2#1#article#1#cr#pt#br1.1#
1#4.0#ILUS#13#RBR260#nd#Rev. Bras. Reumatol.#44#2#20040400#^f175^l178#0482-5004#
Síndrome de Sjögren primária com vasculite cutânea manifestada por úlceras em me
mbro inferior^lpt#Primary Sjögren's syndrome with cutaneous vasculitis manifeste
d as leg ulcerations^len#^rND^1A01^nSonia Cristina de Magalhães^sSouza#^rND^1A01
^nKatia Akemi Miyazato^sKuruma#^rND^1A01^nDanieli Castro Oliveira de^sAndrade#^r
ND^1A01^nPedro Ming^sAzevedo#^rND^1A01^nCamille Pinto^sFigueiredo#^rND^1A01^nEdu
ardo Ferreira^sBorba#^rND^1A01^nCélio Rodrigues^sGonçalves#^rND^1A01^nCláudia Te
resa Lobato^sBorges#USP^iA01^1HC#^lpt^aA síndrome de Sjögren (SS) primária é uma
 doença autoimune cujo espectro de manisfestação clínica estende-se desde um aco
metimento órgão-específico (exocrinopatia auto-imune) até um processo sistêmico.
 O envolvimento da pele é bastante comum, e a freqüência de doença vascular infl
amatória é estimada entre 20% e 30%. Duas formas clínicas específicas de vasculi
te cutânea, a púrpura palpável e urticária crônica são predominantes, mas eritem
a multiforme, eritema perstans, eritema nodoso, mácula eritematosa e nódulo subc
utâneo também já foram descritos. Os autores descrevem o caso de uma paciente de
 46 anos, que desenvolveu quadro de síndrome de Sjögren primária, com manifestaç
ões oculares, orais, articulares e alterações laboratoriais (FAN, anti-Ro, fator
 reumatóide positivos, e hipergamaglobulinemia). Após dez anos do diagnóstico, a
presentou úlceras em membro inferior, cuja biópsia confirmou tratar-se de lesão 
tipo vasculítica, com excelente resposta ao tratamento com ciclofosmida endoveno
sa. Foram descritos na literatura apenas dois relatos de caso de pacientes com ú
lceras em membros inferiores, como acometimento cutâneo da SS. Os autores ressal
tam a importância do diferencial de úlceras em membros inferiores como acometime
nto cutâneo da SS primária#^dnd^i1#^tm^lpt^ksíndrome de Sjögren primária^i1#^tm^
lpt^kvasculite cutânea^i1#^tm^lpt^kúlcera de membros inferiores^i1#^len^aPrimary
 Sjögren's Syndrome (pSS) is an autoimmune disease with a large spectrum of clin
ical manifestations extending from an organ-specific involvement to a systemic p
rocess. The skin is affected quite commonly and the estimated frequency of infla
mmatory vascular lesions is from 20% to 30%. Two specific, clinically recognizab
le forms of cutaneous vasculitis predominate, palpable purpura and chronic urtic
aria, but erythema multiforme, erythema perstans, erythema nodosum, erithematous
 macules and subcutaneous nodules have also been described. The authors report t
he case of a 46-year-old female patient, diagnosed as primary SS, who presented 
ocular and oral symptoms, poliarthritis and laboratory alterations (with a posit
ive ANA, anti-SSA, rheumatoid factor, and hypergammaglobulinemia). Ten years aft
er the diagnosis, she presented leg ulcers. The biopsy confirmed the presence of
 vasculitic process, and the ulcers improved rapidly after the treatment with en
dovenous cyclophosphamide. There are only two reports of chronic ulceration of t
he legs as cutaneous manifestation of SS. The authors stress the importance of c
onsidering ulcers in the differential diagnosis of cutaneous involvement of prim
ary SS#^dnd^i2#^tm^len^kprimary Sjögren's syndrome^i2#^tm^len^kcutaneous vasculi
tis^i2#^tm^len^kleg ulcerations^i2#other#11#20030605#5/6/2003#20031106#6/11/2003
#v44n2a13.htm##
04109000000000637000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089121000300094049000700097158000300104030002100107
03100030012803200020013106500090013301400110014203500100015301201050016301200940
02680100046003620100040004080100047004480100031004950100037005260100035005630100
03800598010004100636070001300677083127400690085000801964085004101972085003002013
08500410204308312200208408500080330408500390331208500330335108500280338411700060
3412072000303418112000903421111000903430114000903439113001003448002001303458#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#f#3#1#article#1#cr#pt#br1.1#
1#4.0#ILUS#13#RBR260#nd#Rev. Bras. Reumatol.#44#2#20040400#^f175^l178#0482-5004#
<b>Síndrome de Sjögren primária com vasculite cutânea manifestada por úlceras em
 membro inferior</b>^lpt#<b>Primary Sjögren's syndrome with cutaneous vasculitis
 manifested as leg ulcerations</b>^len#^rND^1A01^nSonia Cristina de Magalhães^sS
ouza#^rND^1A01^nKatia Akemi Miyazato^sKuruma#^rND^1A01^nDanieli Castro Oliveira 
de^sAndrade#^rND^1A01^nPedro Ming^sAzevedo#^rND^1A01^nCamille Pinto^sFigueiredo#
^rND^1A01^nEduardo Ferreira^sBorba#^rND^1A01^nCélio Rodrigues^sGonçalves#^rND^1A
01^nCláudia Teresa Lobato^sBorges#USP^iA01^1HC#^lpt^aA síndrome de Sjögren (SS) 
primária é uma doença autoimune cujo espectro de manisfestação clínica estende-s
e desde um acometimento órgão-específico (exocrinopatia auto-imune) até um proce
sso sistêmico. O envolvimento da pele é bastante comum, e a freqüência de doença
 vascular inflamatória é estimada entre 20% e 30%. Duas formas clínicas específi
cas de vasculite cutânea, a púrpura palpável e urticária crônica são predominant
es, mas eritema multiforme, eritema perstans, eritema nodoso, mácula eritematosa
 e nódulo subcutâneo também já foram descritos. Os autores descrevem o caso de u
ma paciente de 46 anos, que desenvolveu quadro de síndrome de Sjögren primária, 
com manifestações oculares, orais, articulares e alterações laboratoriais (FAN, 
anti-Ro, fator reumatóide positivos, e hipergamaglobulinemia). Após dez anos do 
diagnóstico, apresentou úlceras em membro inferior, cuja biópsia confirmou trata
r-se de lesão tipo vasculítica, com excelente resposta ao tratamento com ciclofo
smida endovenosa. Foram descritos na literatura apenas dois relatos de caso de p
acientes com úlceras em membros inferiores, como acometimento cutâneo da SS. Os 
autores ressaltam a importância do diferencial de úlceras em membros inferiores 
como acometimento cutâneo da SS primária#^dnd^i1#^tm^lpt^ksíndrome de Sjögren pr
imária^i1#^tm^lpt^kvasculite cutânea^i1#^tm^lpt^kúlcera de membros inferiores^i1
#^len^aPrimary Sjögren's Syndrome (pSS) is an autoimmune disease with a large sp
ectrum of clinical manifestations extending from an organ-specific involvement t
o a systemic process. The skin is affected quite commonly and the estimated freq
uency of inflammatory vascular lesions is from 20% to 30%. Two specific, clinica
lly recognizable forms of cutaneous vasculitis predominate, palpable purpura and
 chronic urticaria, but erythema multiforme, erythema perstans, erythema nodosum
, erithematous macules and subcutaneous nodules have also been described. The au
thors report the case of a 46-year-old female patient, diagnosed as primary SS, 
who presented ocular and oral symptoms, poliarthritis and laboratory alterations
 (with a positive ANA, anti-SSA, rheumatoid factor, and hypergammaglobulinemia).
 Ten years after the diagnosis, she presented leg ulcers. The biopsy confirmed t
he presence of vasculitic process, and the ulcers improved rapidly after the tre
atment with endovenous cyclophosphamide. There are only two reports of chronic u
lceration of the legs as cutaneous manifestation of SS. The authors stress the i
mportance of considering ulcers in the differential diagnosis of cutaneous invol
vement of primary SS#^dnd^i2#^tm^len^kprimary Sjögren's syndrome^i2#^tm^len^kcut
aneous vasculitis^i2#^tm^len^kleg ulcerations^i2#other#11#20030605#5/6/2003#2003
1106#6/11/2003#v44n2a13.htm##
04259000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107121000300112049000700115158000300122
03000200012503100030014503200020014806500090015001400110015903500100017001200980
01800120087002780100046003650100040004110100047004510100031004980100037005290100
03500566010003800601010004100639070001500680083129200695085000801987085004101995
08500300203608500410206608312340210708500080334108500390334908500330338808500280
34211170006034490720003034551120009034581110009034671140009034761130010034850020
01303495008008903508#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#l#4#
1#article#1#^mmar./abr.^a2004#cr#pt#br1.1#1#4.0#ilus#13#RBR260#nd#Rev. Bras. Reu
matol#44#2#20040400#^f175^l178#0482-5004#Síndrome de Sjögren primária com vascul
ite cutânea manifestada por úlceras em membro inferior^lpt#Primary Sjögren's syn
drome with cutaneous vasculitis manifested as leg ulcerations^len#^rND^1A01^nSon
ia Cristina de Magalhães^sSouza#^rND^1A01^nKatia Akemi Miyazato^sKuruma#^rND^1A0
1^nDanieli Castro Oliveira de^sAndrade#^rND^1A01^nPedro Ming^sAzevedo#^rND^1A01^
nCamille Pinto^sFigueiredo#^rND^1A01^nEduardo Ferreira^sBorba#^rND^1A01^nCélio R
odrigues^sGonçalves#^rND^1A01^nCláudia Teresa Lobato^sBorges#^iA01^1USP^2HC#^lpt
^aA síndrome de Sjögren (SS) primária é uma doença autoimune cujo espectro de ma
nisfestação clínica estende-se desde um acometimento órgão-específico (exocrinop
atia auto-imune) até um processo sistêmico. O envolvimento da pele é bastante co
mum, e a freqüência de doença vascular inflamatória é estimada entre 20 por cent
o e 30 por cento. Duas formas clínicas específicas de vasculite cutânea, a púrpu
ra palpável e urticária crônica são predominantes, mas eritema multiforme, erite
ma perstans, eritema nodoso, mácula eritematosa e nódulo subcutâneo também já fo
ram descritos. Os autores descrevem o caso de uma paciente de 46 anos, que desen
volveu quadro de síndrome de Sjögren primária, com manifestações oculares, orais
, articulares e alterações laboratoriais (FAN, anti-Ro, fator reumatóide positiv
os, e hipergamaglobulinemia). Após dez anos do diagnóstico, apresentou úlceras e
m membro inferior, cuja biópsia confirmou tratar-se de lesão tipo vasculítica, c
om excelente resposta ao tratamento com ciclofosmida endovenosa. Foram descritos
 na literatura apenas dois relatos de caso de pacientes com úlceras em membros i
nferiores, como acometimento cutâneo da SS. Os autores ressaltam a importância d
o diferencial de úlceras em membros inferiores como acometimento cutâneo da SS p
rimária#^dnd^i1#^tm^lpt^ksíndrome de Sjögren primária^i1#^tm^lpt^kvasculite cutâ
nea^i1#^tm^lpt^kúlcera de membros inferiores^i1#^len^aPrimary Sjögren's Syndrome
 (pSS) is an autoimmune disease with a large spectrum of clinical manifestations
 extending from an organ-specific involvement to a systemic process. The skin is
 affected quite commonly and the estimated frequency of inflammatory vascular le
sions is from 20 percent to 30 percent. Two specific, clinically recognizable fo
rms of cutaneous vasculitis predominate, palpable purpura and chronic urticaria,
 but erythema multiforme, erythema perstans, erythema nodosum, erithematous macu
les and subcutaneous nodules have also been described. The authors report the ca
se of a 46-year-old female patient, diagnosed as primary SS, who presented ocula
r and oral symptoms, poliarthritis and laboratory alterations (with a positive A
NA, anti-SSA, rheumatoid factor, and hypergammaglobulinemia). Ten years after th
e diagnosis, she presented leg ulcers. The biopsy confirmed the presence of vasc
ulitic process, and the ulcers improved rapidly after the treatment with endoven
ous cyclophosphamide. There are only two reports of chronic ulceration of the le
gs as cutaneous manifestation of SS. The authors stress the importance of consid
ering ulcers in the differential diagnosis of cutaneous involvement of primary S
S#^dnd^i2#^tm^len^kprimary Sjögren's syndrome^i2#^tm^len^kcutaneous vasculitis^i
2#^tm^len^kleg ulcerations^i2#other#11#20030605#5/6/2003#20031106#6/11/2003#v44n
2a13.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-
50042004000200013##
00361000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704013000072002001300202#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#5#1#article#80#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RELATO DE CASO</b> CASE
 REPORT</font></p>     ^cY#v44n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#6#2#article#80#<p>&nbsp;</p>     ^cY#v
44n2a13.htm##
00532000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704030100072002001300373#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#7#3#article#80#<p><font size="4" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="linkinicio"></a><b>S&iacute;ndr
ome de Sj&ouml;gren prim&aacute;ria com vasculite cut&acirc;nea    manifestada p
or &uacute;lceras em membro inferior<sup>(</sup><a href="#link01"><sup>*</sup></
a><sup>)</sup></b></font></p>     ^cY#v44n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#8#4#article#80#<p>&nbsp;</p>     ^cY#v
44n2a13.htm##
00411000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704018000072002001300252#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#9#5#article#80#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>Primary Sj&ouml;gren's syndrome with 
cutaneous vasculitis    manifested as leg ulcerations</b></font></p>     ^cY#v44
n2a13.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#10#6#article#80#<p>&nbsp;</p>     ^cY#
v44n2a13.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#11#7#article#80#<p>&nbsp;</p>     ^cY#
v44n2a13.htm##
00685000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704045300073002001300526#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#12#8#article#80#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><b>Sonia Cristina de Magalh&atilde;es S
ouza<sup>I</sup>; Katia Akemi Miyazato Kuruma<sup>II</sup>; Danieli Castro Olive
ira de Andrade<sup>I</sup>;    Pedro Ming Azevedo<sup>I</sup>; Camille Pinto Fig
ueiredo<sup>I</sup>; Eduardo Ferreira Borba<sup>III</sup>;     C&eacute;lio Rodr
igues Gon&ccedil;alves<sup>III</sup>; Cl&aacute;udia Teresa Lobato Borges<sup>II
I</sup></b></font></p>     ^cY#v44n2a13.htm##
00378000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704014600073002001300219#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#13#9#article#80#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>M&eacute;dico residente da 
disciplina de reumatologia do HC-USP    ^cY#v44n2a13.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009000074002001300164#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#14#10#article#80#<br> <sup>II</sup>M&e
acute;dica preceptora da disciplina de reumatologia do HC-USP    ^cY#v44n2a13.ht
m##
00336000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010300074002001300177#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#15#11#article#80#<br> <sup>III</sup>M&
eacute;dico assistente da disciplina de reumatologia do HC-USP</font></p>     ^c
Y#v44n2a13.htm##
00385000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704015200074002001300226#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#16#12#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#linkcorresp">Endere&ccedil;o
 para correspond&ecirc;ncia</a></font></p>     ^cY#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#17#13#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00277000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704004400074002001300118#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#18#14#article#80#<p>&nbsp;</p> <hr siz
e="1" noshade>     ^cY#v44n2a13.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009600074002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#19#15#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v44n2
a13.htm##
01935000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704170200074002001301776#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#20#16#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A s&iacute;ndrome de Sj&ouml;gren (SS)
 prim&aacute;ria &eacute; uma doen&ccedil;a autoimune cujo espectro de manisfest
a&ccedil;&atilde;o cl&iacute;nica estende-se desde um acometimento &oacute;rg&at
ilde;o-espec&iacute;fico (exocrinopatia auto-imune) at&eacute; um processo sist&
ecirc;mico. O envolvimento da pele &eacute; bastante comum, e a freq&uuml;&ecirc
;ncia de doen&ccedil;a vascular inflamat&oacute;ria &eacute; estimada entre 20% 
e 30%. Duas formas cl&iacute;nicas espec&iacute;ficas de vasculite cut&acirc;nea
, a p&uacute;rpura palp&aacute;vel e urtic&aacute;ria cr&ocirc;nica s&atilde;o p
redominantes, mas eritema multiforme, eritema perstans, eritema nodoso, m&aacute
;cula eritematosa e n&oacute;dulo subcut&acirc;neo tamb&eacute;m j&aacute; foram
 descritos. Os autores descrevem o caso de uma paciente de 46 anos, que desenvol
veu quadro de s&iacute;ndrome de Sj&ouml;gren prim&aacute;ria, com manifesta&cce
dil;&otilde;es oculares, orais, articulares e altera&ccedil;&otilde;es laborator
iais (FAN, anti-Ro, fator reumat&oacute;ide positivos, e hipergamaglobulinemia).
 Ap&oacute;s dez anos do diagn&oacute;stico, apresentou &uacute;lceras em membro
 inferior, cuja bi&oacute;psia confirmou tratar-se de les&atilde;o tipo vascul&i
acute;tica, com excelente resposta ao tratamento com ciclofosmida endovenosa. Fo
ram descritos na literatura apenas dois relatos de caso de pacientes com &uacute
;lceras em membros inferiores, como acometimento cut&acirc;neo da SS. Os autores
 ressaltam a import&acirc;ncia do diferencial de &uacute;lceras em membros infer
iores como acometimento cut&acirc;neo da SS prim&aacute;ria. </font></p>     ^cY
#v44n2a13.htm##
00471000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704023800074002001300312#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#21#17#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> s&iacute;ndrome
 de Sj&ouml;gren prim&aacute;ria, vasculite cut&acirc;nea, &uacute;lcera de memb
ros inferiores.</font></p> <hr size="1" noshade>     ^cY#v44n2a13.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009800074002001300172#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#22#18#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v44
n2a13.htm##
01535000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704130200074002001301376#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#23#19#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Primary Sj&ouml;gren's Syndrome (pSS) 
is an autoimmune disease with a large spectrum of clinical manifestations extend
ing from an organ-specific involvement to a systemic process. The skin is affect
ed quite commonly and the estimated frequency of inflammatory vascular lesions i
s from 20% to 30%. Two specific, clinically recognizable forms of cutaneous vasc
ulitis predominate, palpable purpura and chronic urticaria, but erythema multifo
rme, erythema perstans, erythema nodosum, erithematous macules and subcutaneous 
nodules have also been described. The authors report the case of a 46-year-old f
emale patient, diagnosed as primary SS, who presented ocular and oral symptoms, 
poliarthritis and laboratory alterations (with a positive ANA, anti-SSA, rheumat
oid factor, and hypergammaglobulinemia). Ten years after the diagnosis, she pres
ented leg ulcers. The biopsy confirmed the presence of vasculitic process, and t
he ulcers improved rapidly after the treatment with endovenous cyclophosphamide.
 There are only two reports of chronic ulceration of the legs as cutaneous manif
estation of SS. The authors stress the importance of considering ulcers in the d
ifferential diagnosis of cutaneous involvement of primary SS.</font></p>     ^cY
#v44n2a13.htm##
00426000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704019300074002001300267#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#24#20#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> primary Sj&ouml;gren'
s syndrome, cutaneous vasculitis, leg ulcerations.</font></p> <hr size="1" nosha
de>     ^cY#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#25#21#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#26#22#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00347000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704011400074002001300188#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#27#23#article#80#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font>
</p>     ^cY#v44n2a13.htm##
01800000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704156700074002001301641#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#28#24#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A s&iacute;ndrome de Sj&ouml;gren (SS)
 prim&aacute;ria &eacute; uma doen&ccedil;a autoimune que acomete predominanteme
nte as gl&acirc;ndulas ex&oacute;crinas, em especial as gl&acirc;ndulas salivare
s e lacrimais. Afeta 2% a 5% dos adultos, sendo nove vezes mais freq&uuml;ente n
a mulher, e embora ocorra predominantemente entre a quarta e quinta d&eacute;cad
as de vida, parece haver maior freq&uuml;&ecirc;ncia da doen&ccedil;a no idoso<s
up>(1)</sup>. O espectro da mol&eacute;stia estende-se desde o acometimento &oac
ute;rg&atilde;o-espec&iacute;fico (exocrinopatia auto-imune) at&eacute; o proces
so sist&ecirc;mico (envolvendo os sistemas m&uacute;sculo-esquel&eacute;tico, pu
lmonar, g&aacute;strico, hematol&oacute;gico, vascular, dermatol&oacute;gico, re
nal e nervoso). O envolvimento da pele &eacute; bastante comum. Manifesta&ccedil
;&otilde;es cut&acirc;neas relacionadas com defici&ecirc;ncia glandular incluem 
xerose (23% a 67%), hipohidrose e infec&ccedil;&otilde;es por candida albicans<s
up>(2)</sup>. Raynaud e livedo reticular tamb&eacute;m podem ser encontrados<sup
>(3)</sup>. No entanto, as les&otilde;es da pele s&atilde;o em sua maioria por d
oen&ccedil;a vascular inflamat&oacute;ria, e ocorrem em 20% a 30% dos pacientes 
com s&iacute;ndrome de Sj&ouml;gren<sup>(2)</sup>. Essas les&otilde;es manifesta
m-se como vasculites, p&uacute;rpura, urtic&aacute;ria e menos freq&uuml;entemen
te como eritema nodoso e forma&ccedil;&atilde;o de &uacute;lcera<sup>(1,4,5,6)</
sup>. </font></p>     ^cY#v44n2a13.htm##
00675000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704044200074002001300516#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#29#25#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">H&aacute; apenas dois relatos de &uacu
te;lcera como manifesta&ccedil;&atilde;o cut&acirc;nea na SS prim&aacute;ria<sup
>(1,4)</sup>. Neste trabalho descrevemos o caso de uma paciente com s&iacute;ndr
ome de Sj&ouml;gren prim&aacute;ria que apresentou p&uacute;rpura recorrente e e
pis&oacute;dio de forma&ccedil;&atilde;o de &uacute;lceras em membros inferiores
.</font></p>     ^cY#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#30#26#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010400074002001300178#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#31#27#article#80#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>RELATO DO CASO</b></font></p>     ^
cY#v44n2a13.htm##
03932000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704369900074002001303773#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#32#28#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Paciente do sexo feminino, 46 anos, br
anca, natural e residente em S&atilde;o Paulo. Iniciou acompanhamento no Hospita
l das Cl&iacute;nicas da Faculdade de Medicina da Universidade de S&atilde;o Pau
lo (HC-USP) em abril de 1991 com hist&oacute;ria de poliartrite sim&eacute;trica
 envolvendo pequenas e grandes articula&ccedil;&otilde;es, xeroftalmia e xerosto
mia h&aacute; dois anos. Na ocasi&atilde;o, apresentava Schirmer &lt; 5 mm em am
bos os olhos, e Rosa Bengala positivo, al&eacute;m de hipergamaglobulinemia com 
mielograma normal, FAN 1/200 com anti-Ro positivo, FR 320UI/ml (normal at&eacute
; 25UI/ml), WR 1/160 (normal at&eacute; 1/20), CH100 280U/ml (normal de 150-350U
/ml), VHS 40 mm/1.ª hora. Radiografia das m&atilde;os mostrava osteopenia periar
ticular das articula&ccedil;&otilde;es acometidas. Feito diagn&oacute;stico de s
&iacute;ndrome de Sj&ouml;gren prim&aacute;ria de acordo com os crit&eacute;rios
 de classifica&ccedil;&atilde;o do ACR<sup>(7)</sup>. Iniciado tratamento com pr
ednisona 10 mg/dia associado a difosfato de cloroquina e AINH. Entre abril de 19
92 e janeiro de 1997 fez uso de prednisona 10mg/dia, difosfato de cloroquina 250
 mg/dia, al&eacute;m de ter sido associado metotrexate na dose m&eacute;dia de 1
0 mg/semana (dose m&aacute;xima de 12,5mg/ semana) pela persist&ecirc;ncia do qu
adro articular. Em 1997, substitu&iacute;do o difosfato de cloroquina por sulfas
salazina tamb&eacute;m em virtude do quadro articular. Em janeiro de 2000, como 
a paciente mantinha artrite apesar do uso de metotrexate 20mg/semana e sulfassal
azina 2g/dia, a sulfassalazina foi substitu&iacute;da por azatioprina 100 mg/dia
. Em mar&ccedil;o de 2000 a paciente evoluiu com p&uacute;rpura de membros infer
iores. A bi&oacute;psia de pele mostrou vasculite leucocitocl&aacute;stica, pesq
uisa de crioglobulinas negativa, imunocomplexos de 156 mcg/ml (normal at&eacute;
 35mcg/ml); anti HCV, anti-Hbc total e anti-HIV negativos; CH100 280U/ ml (norma
l de 150-350U/ml), gama-globulinas 2,56g/dl (monoclonal) e VHS 85 mm/1.ª hora. I
nstitu&iacute;do tratamento com prednisona 1mg/kg/dia e suspensa azatioprina com
 regress&atilde;o completa das les&otilde;es em um m&ecirc;s. Em dezembro de 200
0 reintroduziu-se sulfassalazina em associa&ccedil;&atilde;o com metotrexate por
 persist&ecirc;ncia da artrite. De dezembro de 2000 a fevereiro de 2002 permanec
eu em uso de metotrexate associado a sulfassalazina e cortic&oacute;ide em dose 
baixa. Em fevereiro de 2002 a paciente apresentou novo epis&oacute;dio de p&uacu
te;rpura em membros inferiores, introduzido prednisona 10mg/dia e azatioprina 10
0mg/dia com suspens&atilde;o do metotrexate. Evoluiu com regress&atilde;o comple
ta da p&uacute;rpura em um m&ecirc;s. Em setembro de 2002 voltou a apresentar p&
uacute;rpura discreta em ter&ccedil;o distal da perna direita, quando foi introd
uzido prednisona 30 mg/dia e aumentada azatioprina para 150 mg/dia. A paciente r
etorna duas semanas ap&oacute;s com cinco &uacute;lceras na perna direita, a mai
or com 10cm de di&acirc;metro com bordas erit&ecirc;mato-viol&aacute;ceas e fund
o necr&oacute;tico com &aacute;reas ainda sem delimita&ccedil;&atilde;o (<a href
="#fig01">Figura 1</a>). Imunocomplexos e CH100 sem altera&ccedil;&otilde;es, AN
CA e crioglobulinas negativas. Bi&oacute;psia da les&atilde;o mostrou vasculite 
hialinizante de pequenos vasos. Aumentado prednisona para 40mg/dia e iniciado pu
lso de ciclofosfamida na dose de 1g mensal. Ap&oacute;s quatro pulsos de ciclofo
sfamida a paciente evoluiu com cicatriza&ccedil;&atilde;o quase completa das les
&otilde;es cut&acirc;neas (<a href="#fig02">Figura 2</a>).</font></p>     ^cY#v4
4n2a13.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003600074002001300110#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#33#29#article#80#<p><a name="fig01"></
a></p>     ^cY#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#34#30#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007900074002001300153#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#35#31#article#80#<p align="center"><im
g src="/img/revistas/rbr/v44n2/a13fig01.jpg"></p>     ^cY#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#36#32#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003600074002001300110#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#37#33#article#80#<p><a name="fig02"></
a></p>     ^cY#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#38#34#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007900074002001300153#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#39#35#article#80#<p align="center"><im
g src="/img/revistas/rbr/v44n2/a13fig02.jpg"></p>     ^cY#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#40#36#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010600074002001300180#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#41#37#article#80#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>    
 ^cY#v44n2a13.htm##
01257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704102400074002001301098#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#42#38#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A freq&uuml;&ecirc;ncia de les&otilde;
es da pele de origem inflamat&oacute;ria vascular na SS &eacute; estimada em 20%
 a 30%<sup>(2)</sup>. Duas formas cl&iacute;nicas espec&iacute;ficas de vasculit
e cut&acirc;nea, a p&uacute;rpura palp&aacute;vel e urtic&aacute;ria cr&ocirc;ni
ca s&atilde;o predominantes<sup>(4,6)</sup>. Dois tipos histol&oacute;gicos de v
asculite cut&acirc;nea foram descritos, um leucocitocl&aacute;stico (ou neutrof&
iacute;lico) e o outro mononuclear. Ambos est&atilde;o associados com o mesmo es
pectro de apresenta&ccedil;&atilde;o cl&iacute;nica cut&acirc;nea, entretanto t&
ecirc;m sido associados a sorologias distintas. A leucocitocl&aacute;stica est&a
acute; associada &agrave; presen&ccedil;a de anticorpos anti-Ro, hipergamaglobul
inemia, fator antin&uacute;cleo e fator reumat&oacute;ide, enquanto essas anorma
lidades sorol&oacute;gicas est&atilde;o normalmente ausentes na variante mononuc
lear<sup>(6,8,9)</sup>.</font></p>     ^cY#v44n2a13.htm##
00850000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704061700074002001300691#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#43#39#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Neste sentido, Elaine L. <i>et al.</i>
<sup>(6)</sup> avaliaram 22 pacientes com diagn&oacute;stico de SS prim&aacute;r
ia com les&otilde;es cut&acirc;neas, realizaram bi&oacute;psias da pele e analis
aram os principais exames laboratoriais. A apresenta&ccedil;&atilde;o cl&iacute;
nica mais comum foi a de p&uacute;rpura em 10 pacientes (45%), seguido de urtic&
aacute;ria cr&ocirc;nica em 7 (32%). Os outros apresentavam eritema multiforme, 
eritemas perstans, eritema nodoso, m&aacute;cula eritematosa, e n&oacute;dulo su
bcut&acirc;neo. </font></p>     ^cY#v44n2a13.htm##
00659000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704042600074002001300500#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#44#40#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Vasculite cut&acirc;nea estava present
e em 19 (86%) bi&oacute;psias, sendo que o achado mais comum foi de vasculite le
ucocitocl&aacute;stica (74%), mais associada &agrave; p&uacute;rpura (80%) que &
agrave; urtic&aacute;ria (71%). Vasculite mononuclear ocorreu em 37%, e a combin
a&ccedil;&atilde;o dos dois aspectos histol&oacute;gicos em 10%. </font></p>    
 ^cY#v44n2a13.htm##
01107000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704087400074002001300948#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#45#41#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Apenas dois relatos de caso foram desc
ritos na literatura mostrando pacientes com &uacute;lcera de membros inferiores 
como acometimento cut&acirc;neo de SS<sup>(1,4)</sup>. Zutniga-Montes e Gonzalez
-Buritic&aacute;<sup>(1)</sup> relatam o primeiro caso de ulcera&ccedil;&atilde;
o cr&ocirc;nica em membros inferiores como manifesta&ccedil;&atilde;o principal 
da SS prim&aacute;ria. Neste caso a paciente apresentava oito anos de hist&oacut
e;ria de p&uacute;rpuras recorrentes em membros inferiores, que coalesciam para 
formar &uacute;lceras. Bi&oacute;psia da les&atilde;o ulcerada revelou vasculite
 leucocitocl&aacute;stica. A paciente em quest&atilde;o apresentava positividade
 de fator antinuclear, anti-Ro, fator reumat&oacute;ide, hipergamaglobulinemia p
oliclonal, e complemento normal. </font></p>     ^cY#v44n2a13.htm##
00492000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704025900074002001300333#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#46#42#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">No relato de Guggisberg <i>et al.</i><
sup>(4)</sup> havia ulcera&ccedil;&otilde;es difusas em membros inferiores, por&
eacute;m essas les&otilde;es n&atilde;o foram biopsiadas. </font></p>     ^cY#v4
4n2a13.htm##
00961000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704072800074002001300802#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#47#43#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">At&eacute; onde sabemos esse &eacute; 
terceiro caso descrito de &uacute;lcera em SS prim&aacute;ria. Assim como a paci
ente descrita por Zutniga-Montes e Gonzalez-Buritic&aacute;<sup>(1)</sup>, a pac
iente descrita neste caso tamb&eacute;m apresentou recorr&ecirc;ncia de p&uacute
;rpura em membros inferiores; al&eacute;m disso, o surgimento das &uacute;lceras
 tamb&eacute;m ocorreu no mesmo local onde se desenvolvia o terceiro epis&oacute
;dio de aparecimento da p&uacute;rpura. Do mesmo modo apresentava positividade d
e fator anti-nuclear, anti-Ro, fator reumat&oacute;ide, hipergamaglobulinemia (p
or&eacute;m monoclonal), e complemento normal. </font></p>     ^cY#v44n2a13.htm#
#
00752000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704051900074002001300593#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#48#44#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A SS prim&aacute;ria tem um amplo espe
ctro de manifesta&ccedil;&otilde;es. Sinais e sintomas extraglandulares podem mu
itas vezes dominar a apresenta&ccedil;&atilde;o inicial, causando extensa invest
iga&ccedil;&atilde;o e consider&aacute;vel atraso diagn&oacute;stico<sup>(2,10,1
1)</sup>. Sugerimos que pacientes com &uacute;lceras recorrentes em membros infe
riores sejam avaliadas para o diagn&oacute;stico dessa afec&ccedil;&atilde;o. </
font></p>     ^cY#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#49#45#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010700074002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#50#46#article#80#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>   
  ^cY#v44n2a13.htm##
00460000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704021300076002001300289#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#51#47#article#80#1#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Zutniga-Montes LR, Go
nzalez-Buritica H: Leg ulcers in a patient with primary Sj&ouml;gren's syndrome.
 Arthritis and Rheum 37: 1335-7, 1994.    ^cY#v44n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#52#48#article#80#</font></p>     ^cY#v
44n2a13.htm##
00451000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704020400076002001300280#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#53#49#article#80#2#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bjerrum K, Prause JU:
 Primary Sj&ouml;gren's syndrome: a subjective description of the disease. Clin 
Exp Rheumatol 8: 283-8, 1990.    ^cY#v44n2a13.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#54#50#article#80# </font></p>     ^cY#
v44n2a13.htm##
00437000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704019000076002001300266#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#55#51#article#80#3#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Mason MAS, Gumpel JM,
 Golding PL: Sj&ouml;gren's syndrome - A clinical review. Semin Arthritis Rheum 
2: 301-4, 1973.    ^cY#v44n2a13.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#56#52#article#80# </font></p>     ^cY#
v44n2a13.htm##
00492000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704024500076002001300321#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#57#53#article#80#4#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Guggisberg D, Perreno
ud D, Frenk E: Severe, chronic anorexia and extensive leg ulcerations as present
ing signs of primary Sj&ouml;gren's syndrome. Dermatol 95: 93-5, 1997.    ^cY#v4
4n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#58#54#article#80#</font></p>     ^cY#v
44n2a13.htm##
00508000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704026100076002001300337#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#59#55#article#80#5#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Sais G, Admella C, Fa
ntova MJ, Montero JC: Lymphocytic autoimmune hidradenitis, cutaneous leucocytocl
astic vasculitis and primary Sj&ouml;gren's syndrome. Br J Dermatol 139: 1073-6,
 1998.    ^cY#v44n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#60#56#article#80#</font></p>     ^cY#v
44n2a13.htm##
00531000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704028400076002001300360#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#61#57#article#80#6#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Elaine L, Alexander M
D, Provost TT: Cutaneous manifestations of primary Sj&ouml;gren's syndrome: a re
flection of vasculitis and association with anti-Ro (SSA) and antibodies. J Inve
st Dermatol 80: 386-91, 1983.    ^cY#v44n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#62#58#article#80#</font></p>     ^cY#v
44n2a13.htm##
00469000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704022200076002001300298#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#63#59#article#80#7#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Vitali C, Bombardieri
 S, Moutsopoulos HN, et al: Preliminary criteria for the classification of Sjogr
en's syndrome. Arthritis Rheum 36: 340-7, 1993.    ^cY#v44n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#64#60#article#80#</font></p>     ^cY#v
44n2a13.htm##
00540000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704029300076002001300369#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#65#61#article#80#8#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Alexander EL, Provost
 TT, Arnett FC, Steven MB: Sj&ouml;gren's syndrome: Association of anti-Ro (SSA)
 antibodies with vasculitis, hematologic abnormalities, and serologic hyperreact
ivity. Ann Intern Med 98: 155-9, 1983.    ^cY#v44n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#66#62#article#80#</font></p>     ^cY#v
44n2a13.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704021800076002001300294#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#67#63#article#80#9#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Molina R, Provost TT,
 Alexander EL: Two types of inflammatory vascular disease in Sj&ouml;gren's synd
rome. Arthritis and Rheum 28: 1251-8, 1985.    ^cY#v44n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#68#64#article#80#</font></p>     ^cY#v
44n2a13.htm##
00448000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000300074704020000077002001300277#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#69#65#article#80#10#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Pavlides NA, Karsh 
J, Moutsopoulos HM: The clinical picture of  primary Sj&ouml;gren's syndrome. J 
Rheumatol 9: 685-90, 1982.    ^cY#v44n2a13.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#70#66#article#80#</font></p>     ^cY#v
44n2a13.htm##
00563000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000300074704031500077002001300392#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#71#67#article#80#11#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Markusse HM, Oudker
k M, Vroom ThM, Breedveld FC: Primary  Sj&ouml;gren's syndrome: clinical present
ation and mode of presentation  based on an analysis of 50 patients selected fro
m a department of  Rheumatology. Neth J Med 40: 125-34, 1992.    ^cY#v44n2a13.ht
m##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#72#68#article#80# </font></p>     ^cY#
v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#73#69#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#74#70#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00462000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704022900074002001300303#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#75#71#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#linkinicio"><img src="/img/r
evistas/rbr/v44n2/seta.jpg" border="0"></a><a name="linkcorresp"></a> <b>Endere&
ccedil;o para correspond&ecirc;ncia:</b>    ^cY#v44n2a13.htm##
00287000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704005400074002001300128#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#76#72#article#80#<br>  Sonia Cristina 
de Magalh&atilde;es Souza    ^cY#v44n2a13.htm##
00299000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704006600074002001300140#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#77#73#article#80#<br> Av. Dr. Arnaldo 
455 sala 3133, Cerqueira C&eacute;sar    ^cY#v44n2a13.htm##
00281000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704004800074002001300122#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#78#74#article#80#<br> S&atilde;o Paulo
, SP, CEP 01246-903    ^cY#v44n2a13.htm##
00322000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704008900074002001300163#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#79#75#article#80#<br> E-mail: <a href=
"mailto:ninha76@ig.com.br">ninha76@ig.com.br</a></font></p>     ^cY#v44n2a13.htm
##
00325000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009200074002001300166#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#80#76#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Recebido em 5/6/2003.    ^cY#v44n2a13.
htm##
00310000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007700074002001300151#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#81#77#article#80#<br>  Aprovado, ap&oa
cute;s revis&atilde;o, em 6/11/2003.</font></p>     ^cY#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#82#78#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#83#79#article#80#<p>&nbsp;</p>     ^cY
#v44n2a13.htm##
00469000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704023600074002001300310#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a13.htm#S#p#84#80#article#80#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="link01"></a><a href="#linkini
cio">*</a> Disciplina de reumatologia do Hospital das Cl&iacute;nicas da Univers
idade de S&atilde;o Paulo (HC-USP).</font></p>     ^cY#v44n2a13.htm##
00521000000000265000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100025000750100027001000120
06000127030002000187710000200207031000300209014000700212065000900219064000500228
865000900233002001300242#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a13.htm#S#
c#85#1#article#11#1#^rND^sZutniga-Montes^nLR#^rND^sGonzalez-Buritica^nH#Leg ulce
rs in a patient with primary Sjögren's syndrome^len#Arthritis and Rheum#2#37#133
5-7#19940000#1994#20040400#v44n2a13.htm##
00551000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100017000750100017000920120
07200109030001900181031000200200014000600202065000900208064000500217865000900222
002001300231035001000244801001900254#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a13.htm#S#c#86#2#article#11#2#^rND^sBjerrum^nK#^rND^sPrause^nJU#Primary Sjögre
n's syndrome: a subjective description of the disease^len#Clin Exp Rheumatol#8#2
83-8#19900000#1990#20040400#v44n2a13.htm#0392-856X#Clin Exp Rheumatol##
00557000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100017000750100017000920100
01800109012004200127030002200169031000200191014000600193065000900199064000500208
865000900213002001300222035001000235801002200245#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a13.htm#S#c#87#3#article#11#3#^rND^sMason^nMAS#^rND^sGumpel^nJM#^r
ND^sGolding^nPL#Sjögren's syndrome: A clinical review^len#Semin Arthritis Rheum#
2#301-4#19730000#1973#20040400#v44n2a13.htm#0049-0172#Semin Arthritis Rheum##
00571000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100020000750100019000950100
01500114012010900129030000900238710000200247031000300249014000500252065000900257
064000500266865000900271002001300280#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a13.htm#S#c#88#4#article#11#4#^rND^sGuggisberg^nD#^rND^sPerrenoud^nD#^rND^sFre
nk^nE#Severe, chronic anorexia and extensive leg ulcerations as presenting signs
 of primary Sjögren's syndrome^len#Dermatol#2#95#93-5#19970000#1997#20040400#v44
n2a13.htm##
00639000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100014000750100017000890100
01800106010001800124012011000142030001400252031000400266014000700270065000900277
064000500286865000900291002001300300035001000313801001400323#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a13.htm#S#c#89#5#article#11#5#^rND^sSais^nG#^rND^sAdme
lla^nC#^rND^sFantova^nMJ#^rND^sMontero^nJC#Lymphocytic autoimmune hidradenitis, 
cutaneous leucocytoclastic vasculitis and primary Sjögren's syndrome^len#Br J De
rmatol#139#1073-6#19980000#1998#20040400#v44n2a13.htm#0007-0963#Br J Dermatol##
00648000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100016000750100020000910100
01800111012013700129030001800266031000300284014000700287065000900294064000500303
865000900308002001300317035001000330801001800340#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a13.htm#S#c#90#6#article#11#6#^rND^sElaine^nL#^rND^sAlexander^nMD#
^rND^sProvost^nTT#Cutaneous manifestations of primary Sjögren's syndrome: a refl
ection of vasculitis and association with anti-Ro (SSA) and antibodies^len#J Inv
est Dermatol#80#386-91#19830000#1983#20040400#v44n2a13.htm#0022-202X#J Invest De
rmatol##
00600000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100016000750100021000910100
02300112810000600135012007000141030001600211031000300227014000600230065000900236
064000500245865000900250002001300259035001000272801001600282#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a13.htm#S#c#91#7#article#11#7#^rND^sVitali^nC#^rND^sBo
mbardieri^nS#^rND^sMoutsopoulos^nHN#et al#Preliminary criteria for the classific
ation of Sjogren's syndrome^len#Arthritis Rheum#36#340-7#19930000#1993#20040400#
v44n2a13.htm#0004-3591#Arthritis rheum##
00672000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100020000750100018000950100
01700113010001700130012013800147030001500285031000300300014000600303065000900309
064000500318865000900323002001300332035001000345801001500355#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a13.htm#S#c#92#8#article#11#8#^rND^sAlexander^nEL#^rND
^sProvost^nTT#^rND^sArnett^nFC#^rND^sSteven^nMB#Sjögren's syndrome: Association 
of anti-Ro (SSA) antibodies with vasculitis, hematologic abnormalities, and sero
logic hyperreactivity^len#Ann Intern Med#98#155-9#19830000#1983#20040400#v44n2a1
3.htm#0003-4819#Ann Intern Med##
00544000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100016000750100018000910100
02000109012006900129030002000198710000200218031000300220014000700223065000900230
064000500239865000900244002001300253#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a13.htm#S#c#93#9#article#11#9#^rND^sMolina^nR#^rND^sProvost^nTT#^rND^sAlexande
r^nEL#Two types of inflammatory vascular disease in Sjögren's syndrome^len#Arthr
itis and Rheum#2#28#1251-8#19850000#1985#20040400#v44n2a13.htm##
00558000000000289000450000400060000070200470000670500020005370600020005570000030
00577010003000607090008000637080003000711180003000740100019000770100015000960100
02300111012005500134030001200189031000200201014000700203065000900210064000500219
865000900224002001300233035001000246801001200256#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a13.htm#S#c#94#10#article#11#10#^rND^sPavlides^nNA#^rND^sKarsh^nJ#
^rND^sMoutsopoulos^nHM#The clinical picture of primary Sjögren's syndrome^len#J 
Rheumatol#9#685-90#19820000#1982#20040400#v44n2a13.htm#0315-162X#J Rheumatol##
00688000000000301000450000400060000070200470000670500020005370600020005570000030
00577010003000607090008000637080003000711180003000740100019000770100017000960100
01700113010002000130012015800150030001100308031000300319014000700322065000900329
064000500338865000900343002001300352035001000365801001100375#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a13.htm#S#c#95#11#article#11#11#^rND^sMarkusse^nHM#^rN
D^sOudkerk^nM#^rND^sVroom^nThM#^rND^sBreedveld^nFC#Primary Sjögren's syndrome: c
linical presentation and mode of presentation based on an analysis of 50 patient
s selected from a department of Rheumatology^len#Neth J Med#40#125-34#19920000#1
992#20040400#v44n2a13.htm#0300-2977#Neth J Med##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#o#1#1#article#1#
20110406#085956#v44n2a14.htm#104##
04886000000000637000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701200500
01670120046002170100035002630100028002980100029003260100034003550100042003890100
03000431010003800461070001800499083185600517085000802373085003802381085003102419
08500430245008315770249308500080407008500350407808500310411308500430414411700060
4187072000304193112000904196111001004205114000904215113001104224002001304235#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#h#2#1#article#1#cr#pt#br1.1#
1#4.0#ILUS#TAB#14#RBR260#nd#Rev. Bras. Reumatol.#44#2#20040400#^f179^l184#0482-5
004#Síndrome de Churg Strauss: uma vasculite rara^lpt#Churg strauss Syndrome: a 
rare vasculitis^len#^rND^1A01^nLuciana Calvo^sMardegan#^rND^1A01^nCinira^sSoleda
de#^rND^1A01^nZoraida^sSachetto#^rND^1A01^nManoel Barros^sBertolo#^rND^1A01^nEli
ane Maria Ingrid^sAmstalden#^rND^1A01^nAdil Muhib^sSâmara#^rND^1A01^nSandra Regi
na M^sFernandes#Unicamp^iA01^1FCM#^lpt^aO objetivo deste trabalho é avaliar as c
aracterísticas demográficas, clínicas, laboratoriais e histopatológica de pacien
tes com diagnóstico de síndrome de Churg Strauss (SCS) acompanhados no ambulatór
io de vasculites do Hospital das Clínicas da Universidade Estadual de Campinas (
HC/Unicamp). Foi realizado estudo retrospectivo dos prontuários dos pacientes co
m vasculite primária, classificados como SCS pelos critérios do American College
 of Rheumathology (ACR). Foram observados cinco pacientes com diagnóstico de SCS
 (M/F:3/2, caucasóides). A média de idade do início da doença foi 46 anos (40-55
). A média de tempo de seguimento foi de 2,37 anos (0,25-6). Sintomas sistêmicos
, asma, neuropatia periférica e lesão cutânea foram observados em todos os pacie
ntes. Envolvimento cardiovascular, renal e de trato gastrintestinal estiveram pr
esentes cada qual em um paciente. Todos os pacientes apresentaram eosinofilia (>
10%),e o p-ANCA foi positivo nos três casos investigados. A radiografia de tórax
 revelou infiltrado pulmonar intersticial em dois casos; em um, associado à derr
ame pleural. Na histopatologia, evidências de eosinófilos extravascular foram en
contradas nas biópsias cutâneas de 3/4 pacientes. Todos os pacientes foram trata
dos com prednisona. Em 3, houve a necessidade de associar-se imunossupressor. Ne
nhum paciente evoluiu a óbito. A SCS é uma patologia rara, com acometimento sist
êmico, sendo a asma uma das principais e mais precoce manifestação. Todos os pac
ientes apresentaram sintomas sistêmicos, acometimento de pele e sistema nervoso 
periférico. Envolvimento renal, cardíaco e gastrointestinal foi observado, cada 
qual em um único paciente, diferindo de outras séries nas quais esses acometimen
tos são mais freqüentes. Embora seja uma patologia grave e de prognóstico reserv
ado, observamos evolução favorável com tratamento#^dnd^i1#^tm^lpt^ksíndrome de C
hurg Strauss^i1#^tm^lpt^kvasculite primária^i1#^tm^lpt^kaspectos clínico-laborat
oriais^i1#^len^aThe aim of this report is to verify the demographic, clinical, l
aboratorial and histopathological findings of patients with CSS followed in a Un
iversity Clinical Hospital. We reviewed the medical records of all patients with
 the diagnosis of CSS. Only patients who fulfilled ACR criteria were included. F
ive Caucasian patients were found, with a sex ratio M/F: 3/2. The mean age at di
sease onset was 46 years old (40 to 55) and the mean time of follow-up was 2.37 
years (0.25 to 6). General symptoms, asthma, peripheral neuropathy and skin lesi
ons were the most common clinical findings in all patients. Cardiovascular, gast
rointestinal and renal involvement was found in one patient each. All patients p
resented hypereosinophilia (> 10%) and p-ANCA was present in 3 patients. The che
st x-ray showed pulmonary parenchymal infiltrate in 2 cases and in 1 of them an 
unilateral pleural effusion. Skin biopsies showed extravascular eosinophylia in 
3 out of 4. All patients were treated with prednisone and in 3 it was added immu
nosuppressive drug. No patient died during the follow-up. CSS is a rare disease 
with a multivisceral involvement and asthma is the main and the earliest symptom
. General symptoms and involvement of skin and peripheral nerves were found in a
ll patients. Renal, cardiovascular and gastrointestinal involvement was rare, di
fferently from the literature series where these findings are more frequent. In 
spite of the CSS being a serious and life-threatening disease, these patients pr
esented adequate response to the treatment and a favorable outcome#^dnd^i2#^tm^l
en^kChurg Strauss syndrome^i2#^tm^len^kprimary vasculitis^i2#^tm^len^kclinical-l
aboratorial findings^i2#other#13#20030925#25/9/2003#20031120#20/11/2003#v44n2a14
.htm##
04920000000000637000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000210011103100030013203200020013506500090013701400110014603500100015701200640
01670120060002310100035002910100028003260100029003540100034003830100042004170100
03000459010003800489070001800527083185900545085000802404085003802412085003102450
08500430248108315800252408500080410408500350411208500310414708500430417811700060
4221072000304227112000904230111001004239114000904249113001104258002001304269#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#f#3#1#article#1#cr#pt#br1.1#
1#4.0#ILUS#TAB#14#RBR260#nd#Rev. Bras. Reumatol.#44#2#20040400#^f179^l184#0482-5
004#<b>Síndrome de Churg Strauss</b>: <b>uma vasculite rara</b>^lpt#<b>Churg str
auss Syndrome</b>: <b>a rare vasculitis</b>^len#^rND^1A01^nLuciana Calvo^sMardeg
an#^rND^1A01^nCinira^sSoledade#^rND^1A01^nZoraida^sSachetto#^rND^1A01^nManoel Ba
rros^sBertolo#^rND^1A01^nEliane Maria Ingrid^sAmstalden#^rND^1A01^nAdil Muhib^sS
âmara#^rND^1A01^nSandra Regina M^sFernandes#Unicamp^iA01^1FCM#^lpt^aO objetivo d
este trabalho é avaliar as características demográficas, clínicas, laboratoriais
 e histopatológica de pacientes com diagnóstico de síndrome de Churg Strauss (SC
S) acompanhados no ambulatório de vasculites do Hospital das Clínicas da Univers
idade Estadual de Campinas (HC/Unicamp). Foi realizado estudo retrospectivo dos 
prontuários dos pacientes com vasculite primária, classificados como SCS pelos c
ritérios do American College of Rheumathology (ACR). Foram observados cinco paci
entes com diagnóstico de SCS (M/F:3/2, caucasóides). A média de idade do início 
da doença foi 46 anos (40-55). A média de tempo de seguimento foi de 2,37 anos (
0,25-6). Sintomas sistêmicos, asma, neuropatia periférica e lesão cutânea foram 
observados em todos os pacientes. Envolvimento cardiovascular, renal e de trato 
gastrintestinal estiveram presentes cada qual em um paciente. Todos os pacientes
 apresentaram eosinofilia (&gt;10%),e o p-ANCA foi positivo nos três casos inves
tigados. A radiografia de tórax revelou infiltrado pulmonar intersticial em dois
 casos; em um, associado à derrame pleural. Na histopatologia, evidências de eos
inófilos extravascular foram encontradas nas biópsias cutâneas de 3/4 pacientes.
 Todos os pacientes foram tratados com prednisona. Em 3, houve a necessidade de 
associar-se imunossupressor. Nenhum paciente evoluiu a óbito. A SCS é uma patolo
gia rara, com acometimento sistêmico, sendo a asma uma das principais e mais pre
coce manifestação. Todos os pacientes apresentaram sintomas sistêmicos, acometim
ento de pele e sistema nervoso periférico. Envolvimento renal, cardíaco e gastro
intestinal foi observado, cada qual em um único paciente, diferindo de outras sé
ries nas quais esses acometimentos são mais freqüentes. Embora seja uma patologi
a grave e de prognóstico reservado, observamos evolução favorável com tratamento
#^dnd^i1#^tm^lpt^ksíndrome de Churg Strauss^i1#^tm^lpt^kvasculite primária^i1#^t
m^lpt^kaspectos clínico-laboratoriais^i1#^len^aThe aim of this report is to veri
fy the demographic, clinical, laboratorial and histopathological findings of pat
ients with CSS followed in a University Clinical Hospital. We reviewed the medic
al records of all patients with the diagnosis of CSS. Only patients who fulfille
d ACR criteria were included. Five Caucasian patients were found, with a sex rat
io M/F: 3/2. The mean age at disease onset was 46 years old (40 to 55) and the m
ean time of follow-up was 2.37 years (0.25 to 6). General symptoms, asthma, peri
pheral neuropathy and skin lesions were the most common clinical findings in all
 patients. Cardiovascular, gastrointestinal and renal involvement was found in o
ne patient each. All patients presented hypereosinophilia (&gt; 10%) and p-ANCA 
was present in 3 patients. The chest x-ray showed pulmonary parenchymal infiltra
te in 2 cases and in 1 of them an unilateral pleural effusion. Skin biopsies sho
wed extravascular eosinophylia in 3 out of 4. All patients were treated with pre
dnisone and in 3 it was added immunosuppressive drug. No patient died during the
 follow-up. CSS is a rare disease with a multivisceral involvement and asthma is
 the main and the earliest symptom. General symptoms and involvement of skin and
 peripheral nerves were found in all patients. Renal, cardiovascular and gastroi
ntestinal involvement was rare, differently from the literature series where the
se findings are more frequent. In spite of the CSS being a serious and life-thre
atening disease, these patients presented adequate response to the treatment and
 a favorable outcome#^dnd^i2#^tm^len^kChurg Strauss syndrome^i2#^tm^len^kprimary
 vasculitis^i2#^tm^len^kclinical-laboratorial findings^i2#other#13#20030925#25/9
/2003#20031120#20/11/2003#v44n2a14.htm##
05034000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000200012903100030014903200020015206500090015401400110016303500100
01740120050001840120046002340100035002800100028003150100029003430100034003720100
04200406010003000448010003800478070002000516083186500536085000802401085003802409
08500310244708500430247808315840252108500080410508500350411308500310414808500430
41791170006042220720003042281120009042311110010042401140009042501130011042590020
01304270008008904283#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#l#4#
1#article#1#^mmar./abr.^a2004#cr#pt#br1.1#1#4.0#ilus#tab#14#RBR260#nd#Rev. Bras.
 Reumatol#44#2#20040400#^f179^l184#0482-5004#Síndrome de Churg Strauss: uma vasc
ulite rara^lpt#Churg strauss Syndrome: a rare vasculitis^len#^rND^1A01^nLuciana 
Calvo^sMardegan#^rND^1A01^nCinira^sSoledade#^rND^1A01^nZoraida^sSachetto#^rND^1A
01^nManoel Barros^sBertolo#^rND^1A01^nEliane Maria Ingrid^sAmstalden#^rND^1A01^n
Adil Muhib^sSâmara#^rND^1A01^nSandra Regina M^sFernandes#^iA01^1Unicamp^2FCM#^lp
t^aO objetivo deste trabalho é avaliar as características demográficas, clínicas
, laboratoriais e histopatológica de pacientes com diagnóstico de síndrome de Ch
urg Strauss (SCS) acompanhados no ambulatório de vasculites do Hospital das Clín
icas da Universidade Estadual de Campinas (HC/Unicamp). Foi realizado estudo ret
rospectivo dos prontuários dos pacientes com vasculite primária, classificados c
omo SCS pelos critérios do American College of Rheumathology (ACR). Foram observ
ados cinco pacientes com diagnóstico de SCS (M/F:3/2, caucasóides). A média de i
dade do início da doença foi 46 anos (40-55). A média de tempo de seguimento foi
 de 2,37 anos (0,25-6). Sintomas sistêmicos, asma, neuropatia periférica e lesão
 cutânea foram observados em todos os pacientes. Envolvimento cardiovascular, re
nal e de trato gastrintestinal estiveram presentes cada qual em um paciente. Tod
os os pacientes apresentaram eosinofilia (>10 por cento),e o p-ANCA foi positivo
 nos três casos investigados. A radiografia de tórax revelou infiltrado pulmonar
 intersticial em dois casos; em um, associado à derrame pleural. Na histopatolog
ia, evidências de eosinófilos extravascular foram encontradas nas biópsias cutân
eas de 3/4 pacientes. Todos os pacientes foram tratados com prednisona. Em 3, ho
uve a necessidade de associar-se imunossupressor. Nenhum paciente evoluiu a óbit
o. A SCS é uma patologia rara, com acometimento sistêmico, sendo a asma uma das 
principais e mais precoce manifestação. Todos os pacientes apresentaram sintomas
 sistêmicos, acometimento de pele e sistema nervoso periférico. Envolvimento ren
al, cardíaco e gastrointestinal foi observado, cada qual em um único paciente, d
iferindo de outras séries nas quais esses acometimentos são mais freqüentes. Emb
ora seja uma patologia grave e de prognóstico reservado, observamos evolução fav
orável com tratamento#^dnd^i1#^tm^lpt^ksíndrome de Churg Strauss^i1#^tm^lpt^kvas
culite primária^i1#^tm^lpt^kaspectos clínico-laboratoriais^i1#^len^aThe aim of t
his report is to verify the demographic, clinical, laboratorial and histopatholo
gical findings of patients with CSS followed in a University Clinical Hospital. 
We reviewed the medical records of all patients with the diagnosis of CSS. Only 
patients who fulfilled ACR criteria were included. Five Caucasian patients were 
found, with a sex ratio M/F: 3/2. The mean age at disease onset was 46 years old
 (40 to 55) and the mean time of follow-up was 2.37 years (0.25 to 6). General s
ymptoms, asthma, peripheral neuropathy and skin lesions were the most common cli
nical findings in all patients. Cardiovascular, gastrointestinal and renal invol
vement was found in one patient each. All patients presented hypereosinophilia (
> 10 percent) and p-ANCA was present in 3 patients. The chest x-ray showed pulmo
nary parenchymal infiltrate in 2 cases and in 1 of them an unilateral pleural ef
fusion. Skin biopsies showed extravascular eosinophylia in 3 out of 4. All patie
nts were treated with prednisone and in 3 it was added immunosuppressive drug. N
o patient died during the follow-up. CSS is a rare disease with a multivisceral 
involvement and asthma is the main and the earliest symptom. General symptoms an
d involvement of skin and peripheral nerves were found in all patients. Renal, c
ardiovascular and gastrointestinal involvement was rare, differently from the li
terature series where these findings are more frequent. In spite of the CSS bein
g a serious and life-threatening disease, these patients presented adequate resp
onse to the treatment and a favorable outcome#^dnd^i2#^tm^len^kChurg Strauss syn
drome^i2#^tm^len^kprimary vasculitis^i2#^tm^len^kclinical-laboratorial findings^
i2#other#13#20030925#25/9/2003#20031120#20/11/2003#v44n2a14.htm#Internet^ihttp:/
/www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042004000200014##
00361000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704013000072002001300202#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#5#1#article#87#<p align="right"><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RELATO DE CASO</b> CASE
 REPORT</font></p>     ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#6#2#article#87#<p>&nbsp;</p>     ^cY#v
44n2a14.htm##
00456000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704022500072002001300297#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#7#3#article#87#<p><font size="4" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="linkinicio"></a><b>S&iacute;ndr
ome de Churg Strauss: uma vasculite rara<sup>(</sup><a href="#link01"><sup>*</su
p></a><sup>)</sup></b></font></p>     ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704002200072002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#8#4#article#87#<p>&nbsp;</p>     ^cY#v
44n2a14.htm##
00362000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000300069704013100072002001300203#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#9#5#article#87#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><b>Churg strauss Syndrome: a rare vascul
itis</b></font></p>     ^cY#v44n2a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#10#6#article#87#<p>&nbsp;</p>     ^cY#
v44n2a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704002200073002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#11#7#article#87#<p>&nbsp;</p>     ^cY#
v44n2a14.htm##
00577000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704034500073002001300418#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#12#8#article#87#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><b>Luciana Calvo Mardegan<sup>I</sup>; 
Cinira Soledade<sup>I</sup>; Zoraida Sachetto<sup>II</sup>; Manoel Barros Bertol
o<sup>III</sup>; Eliane Maria Ingrid Amstalden<sup>IV</sup>; Adil Muhib S&acirc;
mara<sup>III</sup>; Sandra Regina M Fernandes<sup>III</sup></b></font></p>     ^
cY#v44n2a14.htm##
00353000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000300070704012100073002001300194#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#13#9#article#87#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>M&eacute;dico residente da 
FCM-Unicamp    ^cY#v44n2a14.htm##
00298000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704006500074002001300139#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#14#10#article#87#<br> <sup>II</sup>M&e
acute;dico assistente da FCM-Unicamp    ^cY#v44n2a14.htm##
00321000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704008800074002001300162#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#15#11#article#87#<br> <sup>III</sup>Pr
ofessor doutor da disciplina de reumatologia da FCM-Unicamp    ^cY#v44n2a14.htm#
#
00346000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704011300074002001300187#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#16#12#article#87#<br> <sup>IV</sup>Pro
fessor doutor da disciplina de anatomia patol&oacute;gica da FCM-Unicamp</font><
/p>     ^cY#v44n2a14.htm##
00385000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704015200074002001300226#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#17#13#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#linkcorresp">Endere&ccedil;o
 para correspond&ecirc;ncia</a></font></p>     ^cY#v44n2a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#18#14#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00277000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704004400074002001300118#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#19#15#article#87#<p>&nbsp;</p> <hr siz
e="1" noshade>     ^cY#v44n2a14.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009600074002001300170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#20#16#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^cY#v44n2
a14.htm##
02475000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704224200074002001302316#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#21#17#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O objetivo deste trabalho &eacute; ava
liar as caracter&iacute;sticas demogr&aacute;ficas, cl&iacute;nicas, laboratoria
is e histopatol&oacute;gica de pacientes com diagn&oacute;stico de s&iacute;ndro
me de Churg Strauss (SCS) acompanhados no ambulat&oacute;rio de vasculites do Ho
spital das Cl&iacute;nicas da Universidade Estadual de Campinas (HC/Unicamp). Fo
i realizado estudo retrospectivo dos prontu&aacute;rios dos pacientes com vascul
ite prim&aacute;ria, classificados como SCS pelos crit&eacute;rios do American C
ollege of Rheumathology (ACR). Foram observados cinco pacientes com diagn&oacute
;stico de SCS (M/F:3/2, caucas&oacute;ides). A m&eacute;dia de idade do in&iacut
e;cio da doen&ccedil;a foi 46 anos (40-55). A m&eacute;dia de tempo de seguiment
o foi de 2,37 anos (0,25-6). Sintomas sist&ecirc;micos, asma, neuropatia perif&e
acute;rica e les&atilde;o cut&acirc;nea foram observados em todos os pacientes. 
Envolvimento cardiovascular, renal e de trato gastrintestinal estiveram presente
s cada qual em um paciente. Todos os pacientes apresentaram eosinofilia (&gt;10%
),e o p-ANCA foi positivo nos tr&ecirc;s casos investigados. A radiografia de t&
oacute;rax revelou infiltrado pulmonar intersticial em dois casos; em um, associ
ado &agrave; derrame pleural. Na histopatologia, evid&ecirc;ncias de eosin&oacut
e;filos extravascular foram encontradas nas bi&oacute;psias cut&acirc;neas de 3/
4 pacientes. Todos os pacientes foram tratados com prednisona. Em 3, houve a nec
essidade de associar-se imunossupressor. Nenhum paciente evoluiu a &oacute;bito.
 A SCS &eacute; uma patologia rara, com acometimento sist&ecirc;mico, sendo a as
ma uma das principais e mais precoce manifesta&ccedil;&atilde;o. Todos os pacien
tes apresentaram sintomas sist&ecirc;micos, acometimento de pele e sistema nervo
so perif&eacute;rico. Envolvimento renal, card&iacute;aco e gastrointestinal foi
 observado, cada qual em um &uacute;nico paciente, diferindo de outras s&eacute;
ries nas quais esses acometimentos s&atilde;o mais freq&uuml;entes. Embora seja 
uma patologia grave e de progn&oacute;stico reservado, observamos evolu&ccedil;&
atilde;o favor&aacute;vel com tratamento.</font></p>     ^cY#v44n2a14.htm##
00460000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704022700074002001300301#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#22#18#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> s&iacute;ndrome
 de Churg Strauss, vasculite prim&aacute;ria, aspectos cl&iacute;nico-laboratori
ais.</font></p> <hr size="1" noshade>     ^cY#v44n2a14.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009800074002001300172#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#23#19#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v44
n2a14.htm##
01890000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704165700074002001301731#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#24#20#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">The aim of this report is to verify th
e demographic, clinical, laboratorial and histopathological findings of patients
 with CSS followed in a University Clinical Hospital. We reviewed the medical re
cords of all patients with the diagnosis of CSS. Only patients who fulfilled ACR
 criteria were included. Five Caucasian patients were found, with a sex ratio M/
F: 3/2. The mean age at disease onset was 46 years old (40 to 55) and the mean t
ime of follow-up was 2.37 years (0.25 to 6). General symptoms, asthma, periphera
l neuropathy and skin lesions were the most common clinical findings in all pati
ents. Cardiovascular, gastrointestinal and renal involvement was found in one pa
tient each. All patients presented hypereosinophilia (&gt; 10%) and p-ANCA was p
resent in 3 patients. The chest x-ray showed pulmonary parenchymal infiltrate in
 2 cases and in 1 of them an unilateral pleural effusion. Skin biopsies showed e
xtravascular eosinophylia in 3 out of 4. All patients were treated with predniso
ne and in 3 it was added immunosuppressive drug. No patient died during the foll
ow-up. CSS is a rare disease with a multivisceral involvement and asthma is the 
main and the earliest symptom. General symptoms and involvement of skin and peri
pheral nerves were found in all patients. Renal, cardiovascular and gastrointest
inal involvement was rare, differently from the literature series where these fi
ndings are more frequent. In spite of the CSS being a serious and life-threateni
ng disease, these patients presented adequate response to the treatment and a fa
vorable outcome.</font></p>     ^cY#v44n2a14.htm##
00430000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704019700074002001300271#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#25#21#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> Churg Strauss syndrom
e, primary vasculitis, clinical-laboratorial findings.</font></p> <hr size="1" n
oshade>     ^cY#v44n2a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#26#22#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#27#23#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00347000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704011400074002001300188#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#28#24#article#87#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>INTRODU&Ccedil;&Atilde;O</b></font>
</p>     ^cY#v44n2a14.htm##
01738000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704150500074002001301579#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#29#25#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A s&iacute;ndrome de Churg-Strauss (SC
S), descrita pela primeira vez em 1951, &eacute; uma vasculite sist&ecirc;mica p
rim&aacute;ria, rara, caracterizada por afetar vasos de pequeno calibre, pela pr
esen&ccedil;a de granulomas extravasculares e hipereosinofilia. Ocorre freq&uuml
;entemente em indiv&iacute;duos com hist&oacute;ria de asma e/ou rinite al&eacut
e;rgica<sup>(1)</sup>. Acredita-se n&atilde;o haver predomin&acirc;ncia por sexo
, embora algumas s&eacute;ries relatem discreto predom&iacute;nio do sexo mascul
ino<sup>(2)</sup>. Manifesta&ccedil;&otilde;es sist&ecirc;micas incluem mialgia,
 febre, perda de peso, artralgia, altera&ccedil;&otilde;es cut&acirc;neas, neuro
patia perif&eacute;rica, envolvimento pulmonar, de trato gastrintestinal e cardi
omiopatia<sup>(3)</sup>; os demais sistemas s&atilde;o comprometidos raramente. 
Na histopatologia, o granuloma eosinof&iacute;lico &eacute; peri ou extravascula
r, por&eacute;m muitas vezes &eacute; dif&iacute;cil de ser demonstrado, n&atild
e;o sendo patognom&ocirc;nico da SCS<sup>(4)</sup>. Os crit&eacute;rios classifi
cat&oacute;rios do American College of Rheumatology (ACR) 1990 incluem presen&cc
edil;a de asma, anormalidade do s&iacute;nus paranasal, neuropatia perif&eacute;
rica, eosinofilia acima de 10% ou acima de 1500/ul (1,5 x 106/1), infiltrado pul
monar n&atilde;o fixo e infiltrado eosinof&iacute;lico extra-vascular em bi&oacu
te;psias<sup>(5)</sup>. </font></p>     ^cY#v44n2a14.htm##
00691000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704045800074002001300532#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#30#26#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Em raz&atilde;o da raridade da doen&cc
edil;a, n&atilde;o h&aacute; consenso sobre o tratamento. Uma grande propor&cced
il;&atilde;o de pacientes pode ser tratada com glicocortic&oacute;ides como mono
terapia inicial, por&eacute;m, em alguns casos, a associa&ccedil;&atilde;o de ag
entes citot&oacute;xicos &eacute; necess&aacute;ria para controle da doen&ccedil
;a<sup>(6)</sup>.</font></p>     ^cY#v44n2a14.htm##
00575000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704034200074002001300416#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#31#27#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O objetivo deste estudo &eacute; avali
ar as caracter&iacute;sticas cl&iacute;nicas, laboratoriais, histopatol&oacute;g
icas e a evolu&ccedil;&atilde;o dos pacientes com diagn&oacute;stico de SCS acom
panhados no ambulat&oacute;rio de reumatologia do HC-Unicamp.</font></p>     ^cY
#v44n2a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#32#28#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010400074002001300178#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#33#29#article#87#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>RELATO DE CASO</b></font></p>     ^
cY#v44n2a14.htm##
00728000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704049500074002001300569#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#34#30#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Estudo retrospectivo do prontu&aacute;
rio m&eacute;dico dos pacientes com diagn&oacute;stico de SCS de acordo com os c
rit&eacute;rios classificat&oacute;rios do ACR<sup>(5)</sup>, acompanhados no am
bulat&oacute;rio de vasculites, no per&iacute;odo de 1982-2002. Foram avaliadas 
as manifesta&ccedil;&otilde;es cl&iacute;nicas, altera&ccedil;&otilde;es radiol&
oacute;gicas, laboratoriais e histopatol&oacute;gica. </font></p>     ^cY#v44n2a
14.htm##
01864000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704163100074002001301705#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#35#31#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Foram observados cinco pacientes (M/F 
3/2), caucas&oacute;ides, que preencheram os crit&eacute;rios do ACR. A m&eacute
;dia de idade do in&iacute;cio da doen&ccedil;a foi de 46 anos (40-55 anos) e a 
de seguimento foi de 2,37 anos (0,25-6 anos). O tempo decorrido entre o in&iacut
e;cio dos sintomas asmatiformes e o diagn&oacute;stico da SCS foi de 4,8 anos (1
-9 anos). Todos os pacientes estudados apresentaram sintomas sist&ecirc;micos (f
ebre e/ou emagrecimento), asma, neuropatia perif&eacute;rica e les&atilde;o cut&
acirc;nea. As les&otilde;es cut&acirc;neas encontradas foram: p&uacute;rpura pal
p&aacute;vel (2/5), livedo reticular (2/5) e les&atilde;o ulcerada em polpas dig
itais (1/5). Neuropatia perif&eacute;rica esteve presente em todos os casos. Em 
quatro dos cinco casos, apresentouse bilateralmente, acometendo tanto membros su
periores quanto inferiores. Em um caso estava presente apenas em membros inferio
res. O acometimento de trato gastrintestinal e renal foi encontrado cada qual em
 um paciente. A nefropatia apresentou evolu&ccedil;&atilde;o favor&aacute;vel co
m o tratamento sem perda de fun&ccedil;&atilde;o renal. Hipertens&atilde;o arter
ial sist&ecirc;mica e altera&ccedil;&atilde;o de sedimento urin&aacute;rio (repr
esentado por hemat&uacute;ria, protein&uacute;ria n&atilde;o nefr&oacute;tica e 
leucocit&uacute;ria) foram observadas em um paciente, que n&atilde;o evoluiu com
 insufici&ecirc;ncia renal. Um paciente apresentou quadro de abdome agudo com pe
rfura&ccedil;&atilde;o intestinal (ocorrido em outro servi&ccedil;o). </font></p
>     ^cY#v44n2a14.htm##
03333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704310000074002001303174#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#36#32#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Caracter&iacute;sticas cl&iacute;nicas
 e demogr&aacute;ficas na <a href="/img/revistas/rbr/v44n2/a14tab01.jpg">Tabela 
1</a>. Um paciente apresentou acometimento card&iacute;aco, caracterizado por bl
oqueio incompleto de ramo direito, e tamb&eacute;m dilata&ccedil;&atilde;o das v
eias cava e supra-hep&aacute;tica. Todos os pacientes apresentaram eosinofilia (
&gt;10%), 4/5 revelavam leucocitose. Anemia normocr&ocirc;mica e normoc&iacute;t
ica esteve presente em 3/5 dos pacientes e plaquetose em 2/5. A velocidade de he
mossedimenta&ccedil;&atilde;o (VHS) estava acelerada em 3 pacientes durante o in
&iacute;cio do seguimento, normalizando ap&oacute;s o tratamento. O p-ANCA foi p
ositivo nos tr&ecirc;s casos investigados. Sorologias para hepatite B, hepatite 
C e sorologia para HIV foram negativas em todos os pacientes. O fator antin&uacu
te;cleo (FAN) tamb&eacute;m n&atilde;o apresentou positividade em nenhum pacient
e. A pesquisa de fator reumat&oacute;ide mostrou-se positiva, em t&iacute;tulos 
baixos, em 2/5 de nossos pacientes. A dosagem de imunoglobulina E s&eacute;rica 
(Ig E) mostrou-se bastante elevada nos dois casos pesquisados. A radiografia do 
t&oacute;rax revelou infiltrado pulmonar intersticial difuso em dois casos, have
ndo, em um, associa&ccedil;&atilde;o com derrame pleural. A ultra-sonografia de 
abdome realizada em quatro pacientes revelou discreta hepatomegalia em um e sina
is de nefropatia parenquimatosa em outro. Em dois pacientes foi realizado ecocar
diograma, sendo que em um caso havia insufici&ecirc;ncia mitral leve (<a href="/
img/revistas/rbr/v44n2/a14tab02.jpg">Tabela 2</a>). Foi realizada bi&oacute;psia
 cut&acirc;nea em quatro pacientes, sendo que tr&ecirc;s apresentaram vasculite 
e dessas, duas com infiltra&ccedil;&atilde;o de eosin&oacute;filos (<a href="/im
g/revistas/rbr/v44n2/a14fig01.jpg">Figura 1</a>). Foram realizadas tr&ecirc;s bi
&oacute;psias de m&uacute;sculo, n&atilde;o sendo evidenciados sinais de vasculi
te em nenhuma, por&eacute;m atrofia e atividade muscular degenerativa estavam pr
esentes em todos os casos. Na histopatologia das duas bi&oacute;psias de nervos 
realizadas, uma apresentava sinais de vasculite aguda com necrose segmentar de p
erineuro e a outra diminui&ccedil;&atilde;o de ax&ocirc;nios miel&iacute;nicos c
om espessamento de parede de vasos m&eacute;dios e infiltrado linfocit&aacute;ri
o. A &uacute;nica bi&oacute;psia renal realizada revelou glomerulonefrite focal 
segmentar necrosante com presen&ccedil;a de crescentes (<a href="/img/revistas/r
br/v44n2/a14tab03.jpg">Tabela 3</a>). Todos os pacientes foram tratados com pred
nisona oral. Foi associado imunossupressor (ciclofosfamida) para o tratamento de
 tr&ecirc;s casos. A indica&ccedil;&atilde;o da  ciclofosfamida foi a n&atilde;o
 resposta a prednisona em 2 pacientes  e a nefropatia no terceiro. Nenhum pacien
te fez uso de  inibidores de leucotrienos para o controle da asma durante o segu
imento. N&atilde;o houve evolu&ccedil;&atilde;o a &oacute;bito durante o  per&ia
cute;odo do estudo.</font></p>     ^cY#v44n2a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#37#33#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010600074002001300180#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#38#34#article#87#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>DISCUSS&Atilde;O</b></font></p>    
 ^cY#v44n2a14.htm##
03031000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704279800074002001302872#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#39#35#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">A SCS afeta principalmente adultos com
 m&eacute;dia de idade de 40-45 anos. Em s&eacute;ries mais recentes foi estabel
ecida uma m&eacute;dia de 50 anos. A freq&uuml;&ecirc;ncia homem/mulher varia mu
ito, acreditando-se haver discreto predom&iacute;nio masculino<sup>(2)</sup>, da
dos tamb&eacute;m encontrados em nossa casu&iacute;stica. A SCS &eacute; a vascu
lite sist&ecirc;mica prim&aacute;ria mais rara; a asma &eacute; uma das principa
is e mais precoce manifesta&ccedil;&atilde;o. Quando comparada &agrave; asma br&
ocirc;nquica, a asma da SCS &eacute; mais tardia, grave e requer uso mais freq&u
uml;ente de corticoester&oacute;ides. Alguns autores sugerem que a introdu&ccedi
l;&atilde;o de prednisona nesses casos consiga controlar a sintomatologia, masca
rando a SCS e retardando o seu diagn&oacute;stico. Atualmente, com o uso dos ini
bidores de leucotrienos para o controle da asma, o cortic&oacute;ide n&atilde;o 
tem sido mais t&atilde;o utilizado. Algumas vasculites anteriormente controladas
 com o ester&oacute;ide podem agora ser evidenciadas pelo cl&iacute;nico. Nenhum
 de nossos pacientes fazia uso dos inibidores de leucotrienos. A freq&uuml;&ecir
c;ncia de rinite al&eacute;rgica observada em nossa casu&iacute;stica (3/5) foi 
semelhante &agrave; observada em s&eacute;ries j&aacute; publicadas anteriorment
e<sup>(6,7)</sup>. A asma &eacute; acompanhada por infiltrado pulmonar em 2/3 do
s casos<sup>(2,4)</sup> e essa associa&ccedil;&atilde;o, na aus&ecirc;ncia de in
fec&ccedil;&atilde;o, &eacute; bastante sugestiva para o diagn&oacute;stico. Doi
s pacientes apresentaram infiltrado pulmonar nessa s&eacute;rie, sendo um deles,
 tardiamente no curso da doen&ccedil;a e o outro um infiltrado intersticial bila
teral concomitante ao diagn&oacute;stico, que desapareceu ap&oacute;s 20 dias de
 terap&ecirc;utica com prednisona. O infiltrado pulmonar &eacute; geralmente per
if&eacute;rico, reticular, sim&eacute;trico, bilateral e desaparece rapidamente 
ap&oacute;s institui&ccedil;&atilde;o terap&ecirc;utica<sup>(2,4,8)</sup>. Opaci
dades nodulares bilaterais podem estar presentes, mas raramente cavitam, como o 
observado na granulomatose de Wegener. A presen&ccedil;a de infiltrado alveolar 
difuso &eacute; sugestiva de hemorragia pulmonar, achado presente em 4% dos paci
entes de uma s&eacute;rie da literatura<sup>(9)</sup>. Neste estudo esse dado n&
atilde;o foi encontrado, provavelmente em raz&atilde;o do pequeno n&uacute;mero 
de pacientes e da baixa freq&uuml;&ecirc;ncia da hemorragia pulmonar. Derrames p
leurais s&atilde;o pouco comuns na literatura. Apenas um paciente, dos dois com 
imagem de infiltrado pulmonar, apresentou esse achado, superando os aproximadame
nte 8% da literatura<sup>(8,9)</sup>.</font></p>     ^cY#v44n2a14.htm##
01126000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704089300074002001300967#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#40#36#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Artralgia migrat&oacute;ria acometendo
 punhos, joelhos e/ou tornozelos &eacute; relatada em aproximadamente 45% dos pa
cientes, por&eacute;m artrite franca n&atilde;o &eacute; um achado comum<sup>(8,
9)</sup>. Em nossa casu&iacute;stica, tr&ecirc;s apresentaram artralgia migrat&o
acute;ria ou aditiva e nenhum desenvolveu artrite. Todos os nossos pacientes apr
esentaram febre e/ou emagrecimento. Na literatura, essa perda de peso r&aacute;p
ida e significativa foi encontrada em 70,8% dos pacientes, precedendo o diagn&oa
cute;stico de SCS. Na presen&ccedil;a de manifesta&ccedil;&otilde;es sist&ecirc;
micas em pacientes com asma e aus&ecirc;ncia de infec&ccedil;&atilde;o, a SCS de
ve ser sempre investigada, principalmente quando o paciente desenvolve les&otild
e;es cut&acirc;neas e neuropatia perif&eacute;rica. </font></p>     ^cY#v44n2a14
.htm##
01270000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704103700074002001301111#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#41#37#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O acometimento cardiovascular ocorre e
m metade dos pacientes e pode ser a primeira manifesta&ccedil;&atilde;o de SCS. 
As manifesta&ccedil;&otilde;es card&iacute;acas variam desde achados eletrocardi
ogr&aacute;ficos em pacientes assintom&aacute;ticos, at&eacute; insufici&ecirc;n
cia card&iacute;aca grave<sup>(2,8,9)</sup>. Outros envolvimentos card&iacute;ac
os incluem infiltra&ccedil;&atilde;o eosinof&iacute;lica do mioc&aacute;rdio, va
sculite coronariana, hipertens&atilde;o arterial sist&ecirc;mica e pericardite. 
A regurgita&ccedil;&atilde;o mitral foi freq&uuml;ente (50%) em uma s&eacute;rie
 com 12 pacientes avaliados com ecocardiograma<sup>(10)</sup>. Neste estudo o ec
ocardiograma foi realizado em dois pacientes e essa altera&ccedil;&atilde;o foi 
visualizada em um, em associa&ccedil;&atilde;o a discreta efus&atilde;o peric&aa
cute;rdica, que j&aacute; havia sido observada nesse paciente h&aacute; tr&ecirc
;s anos em um outro servi&ccedil;o. </font></p>     ^cY#v44n2a14.htm##
01402000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704116900074002001301243#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#42#38#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O envolvimento neurol&oacute;gico este
ve presente em todos os nossos pacientes, superando os 60% encontrados na litera
tura. Geralmente manifesta-se por neuropatia perif&eacute;rica, sendo que o envo
lvimento de SNC &eacute; menos freq&uuml;ente (25%), e pode variar de dist&uacut
e;rbios psiqui&aacute;tricos a mielite transversa, acidente vascular cerebral, e
pilepsia e coma<sup>(2)</sup>. Uma de nossas pacientes apresentou acidente vascu
lar cerebral isqu&ecirc;mico, sem seq&uuml;ela. Um estudo com 47 pacientes mostr
ou que 53,2% apresentavam neuropatia sendo 68% mononeuropatia m&uacute;ltipla e 
24% polineuropatia distal sim&eacute;trica<sup>(11)</sup>. Guillevin, entretanto
, n&atilde;o encontrou polineuropatia progressiva bilateral em sua s&eacute;rie<
sup>(9)</sup>; em nossa casu&iacute;stica todos os pacientes apresentaram monone
uropatia m&uacute;ltipla, grave, sendo necess&aacute;rio a introdu&ccedil;&atild
e;o de ciclofosfamida em dois casos para controlar os sintomas. Ambos os pacient
es apresentaram boa resposta cl&iacute;nica da neuropatia com a medica&ccedil;&a
tilde;o.</font></p>     ^cY#v44n2a14.htm##
01056000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704082300074002001300897#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#43#39#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O envolvimento renal est&aacute; prese
nte em 16% a 49% dos pacientes, mas, geralmente, &eacute; considerado leve. Pode
m estar presentes hemat&uacute;ria, protein&uacute;ria, hipertens&atilde;o ou ai
nda, mais raramente, perda de fun&ccedil;&atilde;o renal. Guillevin reportou que
 26% dos pacientes de sua casu&iacute;stica apresentavam acometimento renal, e d
esses, 5% desenvolveram insufici&ecirc;ncia renal leve<sup>(9)</sup>. Apenas um 
dos pacientes apresentou hipertens&atilde;o e sedimento urin&aacute;rio alterado
 com hemat&uacute;ria e protein&uacute;ria, sem altera&ccedil;&atilde;o de fun&c
cedil;&atilde;o renal. Esse paciente apresentou boa evolu&ccedil;&atilde;o, com 
melhora do sedimento e fun&ccedil;&atilde;o renal preservada. </font></p>     ^c
Y#v44n2a14.htm##
01176000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704094300074002001301017#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#44#40#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">O trato gastrintestinal pode ser acome
tido em 37% a 62% dos casos<sup>(6)</sup> por vasculite mesent&eacute;rica e/ou 
infiltrado eosinof&iacute;lico na parede intestinal, causando isquemia, perfura&
ccedil;&atilde;o, necrose, f&iacute;stula, hemorragia ou sintomas obstrutivos<su
p>(2)</sup>. A dor abdominal severa, sem causa aparente, &agrave; semelhan&ccedi
l;a da que ocorre na poliarterite nodosa, tamb&eacute;m &eacute; descrita na lit
eratura<sup>(9)</sup>. N&atilde;o h&aacute; consenso se o acometimento de trato 
gastrintestinal &eacute; um crit&eacute;rio de progn&oacute;stico ruim na SSC<su
p>(2,6)</sup>. O &uacute;nico paciente de nossa casu&iacute;stica que apresentou
 perfura&ccedil;&atilde;o intestinal estava internado em outro servi&ccedil;o, r
estando-nos poucos dados; contudo, n&atilde;o evoluiu com seq&uuml;ela ou compli
ca&ccedil;&otilde;es. </font></p>     ^cY#v44n2a14.htm##
01875000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704164200074002001301716#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#45#41#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">As les&otilde;es cut&acirc;neas est&at
ilde;o presentes em quase dois ter&ccedil;os dos pacientes relatados na literatu
ra<sup>(6,9)</sup> e podem ser a manifesta&ccedil;&atilde;o inicial da doen&cced
il;a. P&uacute;rpura palp&aacute;vel e n&oacute;dulos s&atilde;o as les&otilde;e
s mais freq&uuml;entes<sup>(2,6,9)</sup>, por&eacute;m encontramos maior freq&uu
ml;&ecirc;ncia de livedo reticular e p&uacute;rpura palp&aacute;vel. Na histolog
ia de fragmentos da pele, presen&ccedil;a de granuloma eosinof&iacute;lico &eacu
te; rara e n&atilde;o &eacute; patognom&ocirc;nico da SCS<sup>(9)</sup>. Neste e
studo a bi&oacute;psia de pele foi a mais sens&iacute;vel para mostrar a presen&
ccedil;a de vasculite de pequenos vasos (3/4), sendo compat&iacute;vel com a tax
a de 66% encontrada na literatura<sup>(9)</sup>. N&atilde;o foi encontrado granu
loma eosinof&iacute;lico em bi&oacute;psias de pele, apenas infiltrado eosinof&i
acute;lico em 2 casos. A bi&oacute;psia de m&uacute;sculo mostrou muito pouca ut
ilidade para evidenciar presen&ccedil;a de vasculite em nossa casu&iacute;stica;
 n&atilde;o sendo encontrada em nenhum dos tr&ecirc;s casos biopsiados. Nesses t
r&ecirc;s pacientes, o que observamos foi atrofia e denerva&ccedil;&atilde;o (10
0%), achados encontrados em 18% das bi&oacute;psias de m&uacute;sculos descritas
 por Solans<sup>(7)</sup>. Em contrapartida, no estudo de Guillevin <i>et al.</i
><sup>(9)</sup>, envolvendo 48 bi&oacute;psias de m&uacute;sculo, 47% mostravam 
vasculite muscular, duas, atrofia fascicular e o restante, normal<sup>(9)</sup>.
 </font></p>     ^cY#v44n2a14.htm##
01178000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704094500074002001301019#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#46#42#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Das duas bi&oacute;psias de nervos rea
lizadas, apenas uma mostrou sinais de vasculite de pequenos vasos, sendo que na 
literatura essa taxa &eacute; de, aproximadamente, 60%. Em raz&atilde;o do peque
no n&uacute;mero de pacientes, n&atilde;o conseguimos estabelecer a efic&aacute;
cia das bi&oacute;psias nos diversos s&iacute;tios, por&eacute;m ressaltamos que
 a bi&oacute;psia de pele, al&eacute;m de ser a menos agressiva, foi a que apres
entou maior positividade. As les&otilde;es, consideradas t&iacute;picas, descrit
as por Churg e Strauss<sup>(1)</sup> (infiltrado tissular rico em eosin&oacute;f
ilos, vasculite necrosante e granuloma extravascular), n&atilde;o s&atilde;o fre
q&uuml;entemente vistas em bi&oacute;psias<sup>(12)</sup>, n&atilde;o s&atilde;o
 espec&iacute;ficos<sup>(13)</sup> e a sua aus&ecirc;ncia n&atilde;o exclui o di
agn&oacute;stico de SCS.</font></p>     ^cY#v44n2a14.htm##
01022000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704078900074002001300863#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#47#43#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Guillevin, em seu seguimento de 96 pac
ientes, encontrou 24% de &oacute;bitos, sendo que desses 47,8% estavam diretamen
te relacionados com vasculite<sup>(9)</sup>. Em an&aacute;lise multivariada ness
a mesma publica&ccedil;&atilde;o, encontrou-se como fatores de pior progn&oacute
;stico o envolvimento mioc&aacute;rdico e o de trato gastrintestinal, independen
te da terap&ecirc;utica institu&iacute;da. Em uma s&eacute;rie menor de 32 pacie
ntes houve 12,5% de &oacute;bitos e desses, 75% relacionados tamb&eacute;m com v
asculite (vasculite intestinal e disseminada)<sup>(7)</sup>. Apesar desses dados
, o progn&oacute;stico da SCS &eacute; considerado bom, com remiss&atilde;o ocor
rendo na maioria dos casos. </font></p>     ^cY#v44n2a14.htm##
00828000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704059500074002001300669#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#48#44#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Em nossa casu&iacute;stica, embora o n
&uacute;mero de pacientes seja pequeno e o tempo m&eacute;dio de seguimento curt
o (a maioria dos &oacute;bitos descritos como secund&aacute;rios &agrave; doen&c
cedil;a ocorrem nos dois primeiros anos)<sup>(9)</sup>, n&atilde;o houve nenhum 
&oacute;bito. H&aacute; de se considerar que apenas um paciente apresentou vascu
lite intestinal e um outro acometimento card&iacute;aco leve, representado por i
nsufici&ecirc;ncia valvar e n&atilde;o por envolvimento mioc&aacute;rdico.</font
></p>     ^cY#v44n2a14.htm##
01329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704109600074002001301170#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#49#45#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Por ser uma patologia rara, n&atilde;o
 existe consenso sobre a melhor terap&ecirc;utica a ser institu&iacute;da. Atual
mente o cortic&oacute;ide &eacute; a medica&ccedil;&atilde;o de primeira escolha
, na dose de 1mg/kg/dia at&eacute; remiss&atilde;o da doen&ccedil;a, com retirad
a gradual em at&eacute; um ano. A principal discuss&atilde;o &eacute; quando ass
ociar um imunossupressor e quais os riscos e benef&iacute;cios dessa associa&cce
dil;&atilde;o. Segundo Guillevin <i>et al.</i><sup>(9)</sup>, o FFS &eacute; um 
excelente preditor de risco de mortalidade. Com um FFS <u>&gt;</u> 2 o risco de 
&oacute;bito aumenta significativamente e nesse grupo a associa&ccedil;&atilde;o
 de ciclofosfamida deveria ser precoce<sup>(3,9)</sup>. N&atilde;o existe um con
senso sobre a melhor forma de administra&ccedil;&atilde;o da ciclofosfamida. Apa
rentemente a efic&aacute;cia das duas formas de administra&ccedil;&atilde;o &eac
ute; semelhante, entretanto a toxicidade da administra&ccedil;&atilde;o oral &ea
cute; superior.</font></p>     ^cY#v44n2a14.htm##
01208000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704097500074002001301049#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#50#46#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Concluindo, a SCS &eacute; uma patolog
ia rara, com acometimento sist&ecirc;mico, sendo a asma uma das principais e mai
s precoce manifesta&ccedil;&atilde;o. Os achados cl&iacute;nicos e laboratoriais
 foram semelhantes aos de outras s&eacute;ries j&aacute; publicadas, sendo o aco
metimento de pulm&otilde;es, pele e sistema nervoso perif&eacute;rico os mais co
muns. O acometimento renal, card&iacute;aco e de trato gastrintestinal foi obser
vado, cada qual, em um &uacute;nico paciente, diferindo de outras s&eacute;ries 
nas quais esses acometimentos s&atilde;o mais freq&uuml;entes. Embora seja uma p
atologia grave e de progn&oacute;stico reservado, observamos evolu&ccedil;&atild
e;o favor&aacute;vel com o tratamento. Ressaltamos que, em adultos asm&aacute;ti
cos, com sinais e sintomas sist&ecirc;micos, sem foco infeccioso, a SCS deve ser
 sempre considerada no diagn&oacute;stico diferencial.</font></p>     ^cY#v44n2a
14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#51#47#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704010700074002001300181#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#52#48#article#87#<p><font size="3" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>REFER&Ecirc;NCIAS</b></font></p>   
  ^cY#v44n2a14.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704019300076002001300269#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#53#49#article#87#1#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Churg J, Strauss L: A
llergic granulomatosis, allergic angiitis, and periarteritis nodosa.Am J Pathol 
27: 277-301, 1951.    ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#54#50#article#87#</font></p>     ^cY#v
44n2a14.htm##
00392000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704014500076002001300221#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#55#51#article#87#2#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Cottin V, Cordier JF:
 Churg Strauss syndrome. Allergy 54: 535-51, 1999.    ^cY#v44n2a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#56#52#article#87# </font></p>     ^cY#
v44n2a14.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704022700076002001300303#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#57#53#article#87#3#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Lanford CA: Treatment
 of polyarteritis nodosa, microscopic polyangiitis, and churg strauss syndrome: 
where do we stand? Arthritis Rheum 44: 508-12, 2001.    ^cY#v44n2a14.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002100074002001300095#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#58#54#article#87# </font></p>     ^cY#
v44n2a14.htm##
00459000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704021200076002001300288#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#59#55#article#87#4#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Katzenstein ALA. Diag
nostic features and differential diagnosis of churg strauss syndrome in the lung
. Am J Clin Pathol 114: 767-72, 2000.    ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#60#56#article#87#</font></p>     ^cY#v
44n2a14.htm##
00488000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704024100076002001300317#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#61#57#article#87#5#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Masi AT, Hunder GG, L
ie JT, et al: The American College of Rheumatology 1990 criteria for classificat
ion of Churg-Strauss syndrome. Arthritis Rheum 33: 1094-100, 1990.    ^cY#v44n2a
14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#62#58#article#87#</font></p>     ^cY#v
44n2a14.htm##
00448000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704020100076002001300277#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#63#59#article#87#6#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Lhote F, Cohen P, Gui
llevin L: Polyarteritis nodosa, microscopic polyangitis and Churg Strauss syndro
me. Lupus 7: 238-58, 1998.    ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#64#60#article#87#</font></p>     ^cY#v
44n2a14.htm##
00477000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704023000076002001300306#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#65#61#article#87#7#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Solans R, Bosch JA, P
&eacute;rez-Bocanegra C, et al.: Churg Strauss syndrome: outcome and long term f
ollow up of 32 patients. Rheumatology 40: 763-71, 2001.    ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#66#62#article#87#</font></p>     ^cY#v
44n2a14.htm##
00398000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704015100076002001300227#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#67#63#article#87#8#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Leff AR, North I, Str
ek ME: Churg Strauss syndrome. Lancet 361: 587-94, 2003.    ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#68#64#article#87#</font></p>     ^cY#v
44n2a14.htm##
00491000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000200074704024400076002001300320#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#69#65#article#87#9#<p><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Guillevin L, Cohen P,
 Gayraud N, Lhote F, Jarrousse B, Casassus P: Churg Strauss syndrome: clinical s
tudy and long-termfollow-up of 96 patients. Medicine 78: 26-37, 1999.    ^cY#v44
n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#70#66#article#87#</font></p>     ^cY#v
44n2a14.htm##
00458000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000300074704021000077002001300287#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#71#67#article#87#10#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Morgan JM, Raposo L
, Gibson DG: Cardiac involvement em Churg-Strauss syndrome shown by electrocardi
ography. Br Heart J 62: 462-6, 1989.    ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#72#68#article#87#</font></p>     ^cY#v
44n2a14.htm##
00475000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000300074704022700077002001300304#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#73#69#article#87#11#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Nagashima T, Cao B,
 Takeuchi N, et al: Clinicopathological studies of peripheral neuropathy in Chur
g-Strauss syndrome. Neuropathology 22, 299-307, 2002.    ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#74#70#article#87#</font></p>     ^cY#v
44n2a14.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000300074704023000077002001300307#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#75#71#article#87#12#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Lanham JG, Elkon KB
, Pusey CD: Systemic vascultis with asthma and eosinophilia: a clinical approach
 to the Churg Strauss sydrome. Medicine 63: 65-81, 1984.    ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#76#72#article#87#</font></p>     ^cY#v
44n2a14.htm##
00502000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071888000300074704025400077002001300331#v44
n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#77#73#article#87#13#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Guillevin L, Jais P
, Weschesler B: Clinical findings and prognosis of polyarteritis nodosa and Chur
g-Strauss vasculitis: a study of 165 patientes. Br J Rheumatol 27: 258-64, 1988.
    ^cY#v44n2a14.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002000074002001300094#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#78#74#article#87#</font></p>     ^cY#v
44n2a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#79#75#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#80#76#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00462000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704022900074002001300303#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#81#77#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a href="#linkinicio"><img src="/img/r
evistas/rbr/v44n2/seta.jpg" border="0"></a><a name="linkcorresp"></a> <b>Endere&
ccedil;o para correspond&ecirc;ncia:</b>    ^cY#v44n2a14.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704003600074002001300110#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#82#78#article#87#<br>  Luciana Calvo M
ardegan    ^cY#v44n2a14.htm##
00318000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704008500074002001300159#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#83#79#article#87#<br> Hospital Univers
it&aacute;rio. Secretaria de Reumatologia da FCM-Unicamp    ^cY#v44n2a14.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704006100074002001300135#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#84#80#article#87#<br> R. Vital Brasil 
100, Cidade Universit&aacute;ria    ^cY#v44n2a14.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002500074002001300099#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#85#81#article#87#<br> Campinas, SP    
^cY#v44n2a14.htm##
00330000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009700074002001300171#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#86#82#article#87#<br> E-mail: <a href=
"mailto:lumardegan@bol.com.br">lumardegan@bol.com.br</a></font></p>     ^cY#v44n
2a14.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704009300074002001300167#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#87#83#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">Recebido em 25/9/2003.    ^cY#v44n2a14
.htm##
00311000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704007800074002001300152#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#88#84#article#87#<br>  Aprovado, ap&oa
cute;s revis&atilde;o, em 20/11/2003.</font></p>     ^cY#v44n2a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#89#85#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704002200074002001300096#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#90#86#article#87#<p>&nbsp;</p>     ^cY
#v44n2a14.htm##
00491000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000300071704025800074002001300332#v44n2#V:\SciELO
\serial\rbr\v44n2\markup\v44n2a14.htm#S#p#91#87#article#87#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="link01"></a><a href="#linkini
cio">*</a> 	Disciplina de reumatologia da Faculdade de Ci&ecirc;ncias M&eacute;d
icas da Universidade Estadual de Campinas (FCM-Unicamp). </font></p>     ^cY#v44
n2a14.htm##
00539000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100015000750100017000900120
07300107030001200180031000300192014000800195065000900203064000500212865000900217
002001300226035001000239801001200249#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a14.htm#S#c#92#1#article#13#1#^rND^sChurg^nJ#^rND^sStrauss^nL#Allergic granulo
matosis, allergic angiitis, and periarteritis nodosa^len#Am J Pathol#27#277-301#
19510000#1951#20040400#v44n2a14.htm#0002-9440#Am J Pathol##
00486000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100016000750100018000910120
02700109030000800136031000300144014000700147065000900154064000500163865000900168
002001300177035001000190801000800200#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44
n2a14.htm#S#c#93#2#article#13#2#^rND^sCottin^nV#^rND^sCordier^nJF#Churg Strauss 
syndrome^len#Allergy#54#535-51#19990000#1999#20040400#v44n2a14.htm#0105-4538#ALL
ERGY##
00559000000000265000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100018000750120112000930300
01600205031000300221014000700224065000900231064000500240865000900245002001300254
035001000267801001600277#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#
c#94#3#article#13#3#^rND^sLanford^nCA#Treatment of polyarteritis nodosa, microsc
opic polyangiitis, and churg strauss syndrome: where do we stand?^len#Arthritis 
Rheum#44#508-12#20010000#2001#20040400#v44n2a14.htm#0004-3591#Arthritis rheum##
00544000000000265000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100023000750120089000980300
01700187031000400204014000700208065000900215064000500224865000900229002001300238
035001000251801001700261#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#
c#95#4#article#13#4#^rND^sKatzenstein^nALA#Diagnostic features and differential 
diagnosis of churg strauss syndrome in the lung^len#Am J Clin Pathol#114#767-72#
20000000#2000#20040400#v44n2a14.htm#0002-9173#Am J Clin Pathol##
00619000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100015000750100017000900100
01400107810000600121012010000127030001600227031000300243014000900246065000900255
064000500264865000900269002001300278035001000291801001600301#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a14.htm#S#c#96#5#article#13#5#^rND^sMasi^nAT#^rND^sHun
der^nGG#^rND^sLie^nJT#et al#The American College of Rheumatology 1990 criteria f
or classification of Churg-Strauss syndrome^len#Arthritis Rheum#33#1094-100#1990
0000#1990#20040400#v44n2a14.htm#0004-3591#Arthritis rheum##
00558000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100015000750100015000900100
01900105012007700124030000600201031000200207014000700209065000900216064000500225
865000900230002001300239035001000252801000600262#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a14.htm#S#c#97#6#article#13#6#^rND^sLhote^nF#^rND^sCohen^nP#^rND^s
Guillevin^nL#Polyarteritis nodosa, microscopic polyangitis and Churg Strauss syn
drome^len#Lupus#7#238-58#19980000#1998#20040400#v44n2a14.htm#0961-2033#Lupus##
00597000000000301000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100016000750100016000910100
02500107810000600132012007500138030001300213031000300226014000700229065000900236
064000500245865000900250002001300259035001000272801001300282#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a14.htm#S#c#98#7#article#13#7#^rND^sSolans^nR#^rND^sBo
sch^nJA#^rND^sPérez-Bocanegra^nC#et al#Churg Strauss syndrome: outcome and long 
term follow up of 32 patients^len#Rheumatology#40#763-71#20010000#2001#20040400#
v44n2a14.htm#0080-2727#RHEUMATOLOGY##
00509000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090008000627080003000701180002000730100015000750100015000900100
01600105012002700121030000700148031000400155014000700159065000900166064000500175
865000900180002001300189035001000202801000700212#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a14.htm#S#c#99#8#article#13#8#^rND^sLeff^nAR#^rND^sNorth^nI#^rND^s
Strek^nME#Churg Strauss syndrome^len#Lancet#361#587-94#20030000#2003#20040400#v4
4n2a14.htm#0099-5355#Lancet##
00659000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100015000950100
01700110010001500127010001900142010001800161012008100179030000900260031000300269
01400060027206500090027806400050028786500090029200200130030103500100031480100090
0324#v44n2#V:\SciELO\serial\rbr\v44n2\markup\v44n2a14.htm#S#c#100#9#article#13#9
#^rND^sGuillevin^nL#^rND^sCohen^nP#^rND^sGayraud^nN#^rND^sLhote^nF#^rND^sJarrous
se^nB#^rND^sCasassus^nP#Churg Strauss syndrome: clinical study and long-termfoll
ow-up of 96 patients^len#Medicine#78#26-37#19990000#1999#20040400#v44n2a14.htm#0
025-7974#Medicine##
00574000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01700111012007900128030001100207031000300218014000600221065000900227064000500236
865000900241002001300250035001000263801001100273#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a14.htm#S#c#101#10#article#13#10#^rND^sMorgan^nJM#^rND^sRaposo^nL#
^rND^sGibson^nDG#Cardiac involvement em Churg-Strauss syndrome shown by electroc
ardiography^len#Br Heart J#62#462-6#19890000#1989#20040400#v44n2a14.htm#0007-076
9#Br Heart J##
00606000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100013000970100
01800110810000600128012008300134030001500217031000300232014000800235065000900243
064000500252865000900257002001300266035001000279801001500289#v44n2#V:\SciELO\ser
ial\rbr\v44n2\markup\v44n2a14.htm#S#c#102#11#article#13#11#^rND^sNagashima^nT#^r
ND^sCao^nB#^rND^sTakeuchi^nN#et al#Clinicopathological studies of peripheral neu
ropathy in Churg-Strauss syndrome^len#Neuropathology#22#299-307#20020000#2002#20
040400#v44n2a14.htm#0919-6544#NEUROPATHOLOGY##
00592000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01600111012010200127030000900229031000300238014000600241065000900247064000500256
865000900261002001300270035001000283801000900293#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a14.htm#S#c#103#12#article#13#12#^rND^sLanham^nJG#^rND^sElkon^nKB#
^rND^sPusey^nCD#Systemic vascultis with asthma and eosinophilia: a clinical appr
oach to the Churg Strauss sydrome^len#Medicine#63#65-81#19840000#1984#20040400#v
44n2a14.htm#0025-7974#Medicine##
00622000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100014000970100
02000111012011500131030001500246031000300261014000700264065000900271064000500280
865000900285002001300294035001000307801001500317#v44n2#V:\SciELO\serial\rbr\v44n
2\markup\v44n2a14.htm#S#c#104#13#article#13#13#^rND^sGuillevin^nL#^rND^sJais^nP#
^rND^sWeschesler^nB#Clinical findings and prognosis of polyarteritis nodosa and 
Churg-Strauss vasculitis: a study of 165 patientes^len#Br J Rheumatol#27#258-64#
19880000#1988#20040400#v44n2a14.htm#0263-7103#Br J Rheumatol##
